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/ 1018 75 Two Year Follow-Up After Post-PTCA ,&Radiation: A QCA Analysis 
Michel Joyal, David Meerkin, Jacques LespBrance, Guyiaine Lucier, 
Raoul Bonan. Montreal Heart Institute, Montreal, Canada 
Background: Post angioplasty intracoronary radiation therapy has been 
demonstrated to be safe and efficacious for restenosis prevention at 6 
months. The influence of this therapy on vessel repair and physiology 
however mandates a more prolonged and detailed analysis of arterial re- 
sponse. The purpose of this study was to determine the effect of post-PTCA 
,&radiation on the intervened segments as assessed by QCA at two years. 
Methods: Twenty-six patients (pts) included in the Canadian arm of the 
BERT trial underwent PTCA and b-radiation therapy without stent implanta- 
tion. All pts were scheduled for 2 year clinical and angiographic FU. Analysis 
at the intervened site (IS) was performed over 15 mm centered at the original 
lesion. 
Results: Clinically driven FU at 2 years revealed cumulative restenosis 
and target lesion revascularization in 3/26 and 5/26 pts respectively. Two-year 
angiographic FU QCA analysis is complete in 16 pts who had no restenosis 
at 6 months. Results of the total cohort will be presented. 
IS Baseline Post 6 months 2 years 
Ref. diam (mm) 2.87 f 0.40 2.97 -f- 0.40 2.91 i 0.42 2.96 rt 0.47 
MLD (mm) 0.91 * 0.33 1.94 i 0.36* 2.28 i- 0.51”t 2.17 + 0.67’ 
% stenosis 68.59 i 10.64 34.56 f 10.61* 23.02 i lOSi** 27.16 zt 15.48’ 
MVD (mm) 2.07 rt 0.43 2.52 zt 0.38* 2.81 zt 0.41** 2.84 + 0.58** 
MLD = minimal lumen diameter, MVD = mean vess? diameter, ‘P .c 0.05 vs. baseline, 
*p < 0.05 vs. post 
Conclusions: Following a mean increase of vessel dimensions at the 
IS at 6 months, stability of mean vessel dimensions over the a-year follow 
up period was demonstrated with minimal late loss and no further vessel 
expansion as assessed by QCA. 
/ 1018 76 Long-Term Morphological Effects of Post Angioplasty ,&Radiation: An IVUS Study 
David Meerkin, Michel Joyal, Johanne Vincent, Raoul Bonan, 
Jean-Claude Tardif. Montreal Heart Institute, Montreal, Canada 
Background: IVUS analysis of vessel response to post PTCA brachytherapy 
has shown maintenance of vessel lumen and unchanged vessel dimensions 
at 6 months. The long-term effects of this therapy on unstented vessels have 
not been demonstrated, necessitating more prolonged follow-up (FU). 
Methods: Twenty-six patients (pts) included in the Canadian arm of 
the BERT trial underwent PTCA and B-radiation therapy without stent im- 
plantation for restenosis prevention. All pts were scheduled for 2-year IVUS 
reassessment. Two series of measurements for restenosis assessment were 
performed. The cross-sections selected for serial analysis were the ones at 
the PTCA site with the smallest MLD at 6 months (series I), and 2 years 
(series II) respectively. 
Results: Analysis of the first 13 patients has been completed. The MLDs 
of series I and II were separated by a distance of 3.9 i 4.0 mm (range 
0.00-12.50). 
Series Post 6 months 2 years 
MLD (mm) I 2.5 * 0.5 2.5 * 0.4 2.5 * 0.5 
II 2.4 iz 0.4 2.5 * 0.4 2.2 zk 0.4** 
Lumen area (mm*) I 5.6i1.2 5.9 37 2.0 5.8 5 2.2 
II 5.5i1.6 5.7f1.7 4.6 zk 1.5” 
EEM (mm*) I 14.0 * 3.0 14.3 * 3.4 14.8 + 3.6 
II 13.2 i 3.6 13.4 i 3.0 13.6 5 3.0 
Wall Area (mm’) I 8.4 zk 2.8 8.3 3~ 2.2 9.0 * 2.9 
II 7.7 i 3.2 7.7 i 2.0 9.1 f 2.7* 
‘P < 0.05 vs. 6 months *P < 0.03 vs. post 
In series I there was no significant change for any IVUS parameter. In 
series II, a slight increase in wall area, with a slight decrease in lumen 
area and MLD was observed at 2 years. The EEM remained unchanged 
irrespective of the method excluding aneurysm formation. 
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Conclusion: The effects of post PTCA brachytherapy on vessel mor- 
phology are largely maintained over 2 years. Vessel wall thickening without 
negative remodeling was responsible for late loss, where present. 
L 1018 77 Intra-Coronary Radiation Therapy With Liquid Rhenium-186. The RadioCath Trial 
Patrick Coussement, Pieter Stella, Hubert Vanbilloen, Alfons Verbruggen, 
Erik Van Limbergen, Peter van Rijk, Peter de Jaegere, Ivan De Scheerder. 
University Hospital Gasthuisberg, Leuven, Belgium; University Hospital, 
Utrechf, The Netherlands 
Background: Restenosis remains one of the major limitations of percu- 
taneous coronary interventions. Since the introduction of coronary stents, 
anti-restenosis therapies are focusing on the inhibition of neo-intimal prolifer- 
ation. Intra-coronary beta-radiation therapy with catheter-based systems is 
one of the strategies under investigation. 
Methods: The RadioCath trial is a safety and performance study with a 
new device, consisting of a 25 mm-long radiation treatment ballooncatheter 
(RTB), which can be charged with a solution of sodium perrhenate-186, a 
predominant beta-emitter with a half-life of 3.78 days. Between November 
1998 and March 1999, 35 pts. with a de novo lesion in a native coronary 
artery have been enrolled in the trial. The prescribed dose of 20 Gy at 0.5 
mm into the vessel wall was delivered successfully, immediately after the 
angioplasty, in 33 pts (94%). One pt. was excluded because of a severe, 
occlusive dissection after the PTCA, in a second pt. there was a technical 
failure of the inflation system. The average dwell time was 6 min. 58 sec. rt 
1 min. 4 sec. In 26 pts. (79%) this was done in a single inflation cycle. In 5 
pts. (15%) two cycles were required and in 2 pts. (6%) three cycles. After the 
radiation treatment, a stent was implanted at the target lesion site in 72% of 
the pts. 
Results: Angiographic follow-up is completed in 33 pts (94%). Restenosis 
of the target lesion (~50% diameter stenosis) was seen in 13 pts. (39%), 
which required re-intervention in 12 pts. (36%). 6 pts. (18%) were treated 
for progression of disease at a non-target site. 4 pts. (12%) experienced a 
‘late’ (after 1 month) acute stent thrombosis of the target lesion, which was 
successfully treated with thrombolysis in 2 pts. and with re-PTCA in another 
2 pts. 
Conclusions: Intra-coronary radiation with a ballooncatheter, filled with 
liquid rhenium-186, is feasible and safe. To draw conclusions on efficacy of 
this device, a randomized, placebo-controlled trial is mandatory. Prolonged 
aggressive antiplatelet therapy may be required to decrease the risk of 
‘late’ acute stent thrombosis. The final results of the FiadioCath trial will be 
presented at the meeting. 
1018-78 Dosimetry of the RDX Cylindrical Shell P-32 
Balloon Source 
James Whiting, Alex’Li, Jtjrg Hausleiter, Brett Trauthen. Cedars-Sinai 
Medical Center, Los Angeles, CA; Radiance Medical Systems, Irvine, CA, 
USA 
Background: Until recently intravascular radiation sources have all had 
one of only three basic geometries: line sources (e.g. Best and Nucletron 
Ir-192, Novoste SrIY-90, Guidant and NeoCardia P-32 and Schneider Y-90), 
cylindrical volume sources (liquid Re-I 88 bailoon), and radioactive stents 
(e.g. lsostent P-32). A new source consisting of an angioplasty balloon with 
P-32 incorporated in the wall material (RDX, Radiance Medical Systems) 
changes its configuration but continues to deliver as the balloon is periodically 
deflated to allow for perfusion. We report on calculations and measurements 
of the dose distribution for this device in both the inflated and deflated 
configuration. 
Methods: Numerical point dose kernel calculations were performed for 
cylindrical shells with diameters ranging from the vessel diameter down 
to a diameter of 0.5 mm, approximating a fully refolded deflated balloon. 
Transaxial measurements of the inflated and deflated dose distributions 
were performed in a lucite phantom using radiochromic film, with and without 
a 3.0 mm AVE stent. 
Results: The inflated balloon dose rate was found to be approximately 
3.5 Gy/min at the 1 .O mm reference depth for a source activity density of 100 
&i/mm 2, independent of source diameter or length. Agreement between 
calculations and measurements was good. The balloon surface dose when 
inflated was calculated to be 6.1 times greater than that at the reference 
depth, but fell to half the surface dose at only 130 microns depth (the stent 
thickness), similar to other linear P-32 sources. When deflated the reference 
dose rate was reduced by only about 25%, and the artery surface dose was 
reduced by half. Stent attenuation reduced the reference depth dose by less 
than 15%. No discrete shadowing by the stent struts was observered when 
the source was inflated; some minimal shadowing was observered up to 0.5 
mm depth when the source was deflated. 
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Conclusions: The RDX cylindrical P-32 source provides a depth dose 
distribution similar to centered linear P-32 sources, with superior centering 
when inflated. Perhaps surprisingly, the dose rate is only slightly lower when 
the system is deflated, allowing short treatment times even if the balloon 
must be deflated frequently during treatment to allow for perfusion. The 
relatively high balloon surface dose falls off vary rapidly, and is comparable 
to other linear beta sources at a depth of only 100-200 microns, or about the 
thickness of a stent. The system was found to be reliable and easy to use 
during testing, and operator exposure was negligible. 
1 1018-79 1 lntracoronary Brachltherapy for In-Stent 
Restenosis With a ’ sFle Liquid-Filled Balloon 
System. Results From the Pilot Phase of a 
Randomized Trial 
Helmut Schiihlen, Neal L. Eigler’ , James S. Whiting’, Roland Haubner, 
Josef Dirschinger, Markus Schwaiger, Albert Schbmig. Klinikum rechfs der 
Isar; Technische Universit~f, Munich, Germany; ‘Cedars-Sinai Medical 
Center, Los Angeles, CA, USA 
Objective of this trial is to evaluate the effectiveness of a ‘*sRe liquid-filled 
balloon system to prevent recurrent restenosis after PTCA for in-stent reste- 
nosis. The system device allows for safe transfer of the ‘s8Re liquid from the 
nuclear hot lab, secure handling in the cath lab to minimize radiation expose 
and the risk of spillage of ‘ssRe, and provides a simple PTCA-like protocol to 
perform brachytherapy. This abstract summarizes the pilot phase of the trial. 
Methods: The primary endpoint is angiographic lumen loss at 6 months, 
secondary endpoints are additional QCA + IVUS data, and clinical outcome 
after 1, 6 and 12 months. Randomization to brachytherapy or no further 
therapy is done after successful repeat PTCA. The prescribed dose is 28 Gy 
at 0.5 mm depth. Dependent on the activity in the balloon, treatment time is 
typically 4 to 13 min, fractioned into 2-min balloon inflations with max. 3 atm. 
Results: In the pilot phase until l/99, 21 patients with at least a 2nd 
restenosis (average 3.7 previous procedures) have been randomized, 11 to 
radiation. The 4-week clinical follow-up has been uneventful in all patients. 
Six-month follow-up has been completed in all patients. There were no deaths 
or myocardial infarctions in both groups. Angiographic restenosis (~50% 
diameter stenosis of treatment site or adjacent segments) was present in 
3/11 patients with radiation, and in IO/10 without radiation (p < O.Oi), late 
lumen loss was reduced from 1.93 i 0.38 mm to 0.78 i 1.06 mm (p < 0.01). 
Conclusions: lntracoronary brachytherapy with the ‘**Re liquid-filled 
balloon can be safely administered with this system in a simple, PTCA-like 
procedure. These preliminary data from the pilot phase already suggest a 
significant benefit for patients with multiple recurrent restenoses. 
1 1018-80 1 Differential Cytotoxicity of Radiocontrast (RC) 
Agents on Human Umbilical Vein Endothelial Cell 
(HUVEC) Monolayers In Vitro 
Christina Fauser, Christlieb Haller. University of Heidelberg, Heidelberg, 
Germany 
Background: The endothelium plays a central role in the regulation of blood . 
flow and coagulation. During coronary angiography and interventions it is 
directly exposed to intravascular RC agents. Little is known on the interaction 
between endothelial cells and RC. 
Objective: We studied the differential cytotoxicity of ionic and non-ionic 
RC agents with different physicochemical properties on HUVECs in vitro. 
Methods: HUVECs were incubated for 1 to 3 hours with RC concentra- 
tions up to 37 mg iodine/ml in growth medium. Cellular damage/viability was 
assessed by trypan blue exclusion and measurement of lactate dehydro- 
genase (LDH) in the medium, The integrity of the HUVEC monolayers was 
determined by the transmonolayer resistance (TMR). The concentrations of 
the functionally important endothelial effector substances endothelin-I (E), 
von Willebrand factor (vWF), plasminogen activator inhibitor-i (PAI-1) and 
thrombomodulin (T) were measured by specific ELlSAs. 
Results: Diatrizoate induced significant cell death with an increase of 
LDH after 3 hours. The concentration of E was already decreased after 1 
hour, while vWF was increased in the culture media. These findings can 
be attributed to cell damage, since there are no intracellular stores for E, 
whereas stored vWF may be released from injured cells; on the other hand the 
concentrations of PAI-I and T were not significantly affected by diatrizoate. 
The dimeric ionic RC agent ioxaglate was less toxic than diatrizoate and did 
not differ from the non-ionic compounds iohexol and iopamidol. Therefore 
osmolality is more important for endothelial cell toxicity in vitro than ionic 
strength. 
Conclusions: RC agents, in particular the hyperosmolal ionic compound 
diatrizoate, are not biologically inert and have differential cytotoxic effects on 
endothelial cells in vitro. This cytotoxicity is more related to hyperosmolality 
than to ionic strength. Although the RC exposure in clinical settings is usually 
shorter than in this in vitro study, in patients with renal failure prolonged 
exposure may occur which could adversely affect endothelial function and 
contribute to the poor results of PTCA in this patient population. 
L---L-m 1018 81 Absence of Late Coronary Occlusions After Beta Radiation Following a Modified Antiplatelet 
Regimen in 120 Consecutive Patients 
Sigmund Silber, lngeborg Krischke, Norbert Seidel, Armin Schneider, 
Peter von Rottkay. Dr. MiNer Hospital, Munich, Germany 
Currently, beta radiation is being increasingly applied in Europe as clinical 
treatment of in-stent restenosis. Recently, however, there was considerable 
concern regarding the risk of late coronary occlusion after brachytherapy, 
which was reported to occur in up to 7% of the cases. This important side 
effect of intracoronary radiation may be related to delayed endothelialization 
following radiation therapy. It may thus be hypothesized that a prolonged 
(~3 months) prescription of clopidogrel may reduce the risk of late coronary 
occlusion in patients with and without stents after brachytherapy. 
We report our experience in 120 consecutive patients who received in- 
tracoronary brachytherapy with the Novoste” Beta-Cath System for de-novo 
lesions, restenosis without stents and in-stent restenosis. Mean age was 
60.5 & 9 years, LV-EF was 61 & IO%, reference diameter was 3.0 & 0.6 
mm; MLD before and directly after radiation was 0.6 f 0.36 respectively 2.8 
+ 0.4 mm. The dose for coronary vessels with a diameter of 2.7-3.35 mm 
is 14 Gy; for 3.36-4.0 mm is 18 Gy. Mean duration of radiation with 14 Gy 
was 173 ic 8 s (165-l 87 s) and 222 f 12 s (212-240 s) with 18 Gy. The 
5F catheter led neither to dissections nor to clinically relevant myocardial is- 
chemia. Coronary overdosing did not occur, but in two patients the pellets got 
stuck in the guiding catheter for less than IO s. The additional time needed 
for the radiation procedure after PTCA was 18 * 6 min. No acute or subacute 
stent/occlusion occurred; no later coronary occlusions were reported. 
Conclusions: Prolonged application of clopidogrel for at least 3 months 
seems to be necessary to reduce the risk of late coronary occlusion following 
intracoronary brachytherapy. 
I 1018 82 Intravascular Brachytherapy With Rhenium-188 Balloon: RADIANT Pilot Study 
Raj Makkar, James Whiting, Alex Li, Joerg Hausleiter, Adela Robinson, 
Neal Eigler. Cedars-Sinai Medical Center, Los Angeles, California, USA 
Background: RADIANT was a pilot study designed to assess the efficacy 
of brachytherapy with a B-emitting Rhenium-188 balloon after coronary in- 
tervention for de novo or restenotic lesions in native coronaries. Primary 
endpoint of the study is late loss on angiography at 9 months and freedom 
from target lesion revascularization at 4 and 9 months. 
Methods and Results: 13 patients with an average of 1 .I restenosis in 
target vessel previously have been enrolled in the pilot study. Prescribed 
radiation dose was 24 Gy at 0.5 mm depth. Radiation was delivered by 
inflating the balloon to 2 arms for 4-7 mins, with one or more deflations as 
necessary for perfusion. One patient had a minor Re-I 88 leak in vivo resulting 
in total body exposure of 0.12 Gy. Radiation exposure to the operators was 
less than 15 mRems/procedure. No special shielding of the cath lab was 
necessary and the operators stayed with the patients in the room for the 
duration of the procedure. At 4 months, 2/13 patients required target lesion 
revascularization, including one patient with delayed stent thrombosis at 96 
days. Nine month clinical and angiographic data is being collected. 
Conclusion: Brachytherapy with Re-I 88 balloon is feasible in the clinical 
setting. Clinical and angiographic outcomes at 9 months will be presented. 
1018-83 New Dose-Effectiveness Model for lntracoronary 
Brachytherapy Predicts External Beam Irradiation 
Results in the Pig Model 
J&g Hausleiter, Alex Li, Craig Abbey, Raj Makkar, Martin Sebastian, 
Hidehiko Honda, James Whiting, Neal Eigler. Cedars-Sinai Medical Cenfer, 
Los Angeles, CA, USA 
Background: The target tissue for coronary brachytherapy and the rela- 
tionship between dose and effectiveness are not known. We analyzed the 
relationship between dose at different tissue depths and inhibition of neoin- 
tima growth in a retrospective analysis of 11 published brachytherapy studies 
in the pig restenosis model (35 dose protocols). 
Methods: The studies included different isotopes (Irigs, Sr/Ygo, P3*, 
Ret** and Rels6) in centered and non-centered devices. Three statistical 
approaches (Spearman rank correlation, ROC analysis, and error in model 
fit for a new dose-effectiveness model) demonstrated the best agreement 
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between dose and inhibition of neointima growth for a tissue depth between 
0.5 and 0.75 mm from the lumen surface. 
Results: The dose-effectiveness model suggests (1) an increased prolif- 
erative response (“Candy WrappeP) with doses 4 4.5 Gy at 0.75 mm and (2) 
the need of 13.5 Gy at 0.75 mm to achieve a 50% reduction in neointima area 
(Fig. A). When the results of published pig studies using external beam irradi- 
ation were applied to the model, a good agreement with the proposed model 
was obtained (Fig. B). Interestingly, the results of the clinical trials SCRIPPS 
and WRIST agreed similarly well, despite the differences in atherosclerotic 
wall morphology. 
Conclusions: This retrospective analysis identifies the adventitia as the 
target tissue for intracoronary brachytherapy in the pig model of restenosis. 
Experimental studies with external beam radiation further support this con- 
cept. Additional results are needed to demonstrate the clinical validity of the 
proposed model. 
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1019-84 Cost Effectiveness Analysis Between 
Percutaneous Coronarv Interventions Versus 
Coronary Bypass Surgery in Multiple Vessel 
Disease: Long Term Follow Up Results of the 
Argentine Randomized Study (ERACI II) 
Alfred0 Rodriguez, Victor Bernardi, Julio Baldi, Jose Navia, Liliana Grinfeld, 
Carlos Mauvecin, Daniel Vogel, Raul Oliveri, lgor Palacios, William O’Neill, 
William Beaumont. Otamendi Hospital, Buenos Aires, Argentina; Michigan, 
USA 
Background: Percutaneous Transluminal Coronary Revascularization (PTCR) 
and Coronary Artery By Pass Graft (CABG) in patients with multiple vessel 
disease (CAD) has been compared previously in several randomized studies 
using old techniques with PTCR (BARI, RITA, CABRI, EAST, GABI, ERACI). 
Objective: The purpose of the present study was to compare cost effec- 
tiveness of current PTCR devices including free use of stents with conven- 
tional CABG in patients with multiple CAD. 
Methods: 450 patients with multiple CAD were randomized at 7 sites in 
Argentina, 225 were randomized to PTCR with stents and 225 to CABG 
(ERACI II). One of the end point of this study was to compare overall 
cost of both procedures and a cost/benefit analysis. The costs included 
hospital charges, fees, professional fees, stents and drugs utilized during the 
procedures. In PTCR arm, I .4 stent per patient was used as well abciximab 
in bolus and infusion in 28% of them. Overall costs and clinical outcome (19.5 
i 6.4 months) were present. 
Results: Basal characteristics in ERACI II patients at the time of random- 
ization showed that 91.1% had Unstable Angina II, Ill or C; 23% peripheral 
or vascular disease and 39% age z 65 years, 
PTCR (225) CABG (225) P 
30 days cost 
Follow up cost 
Overall cost 
Per patient 
Survival 
Freedom from myocardial infarction 
Repeat PTCWCABG 
U$2.548.615 U$2.451.500 NS 
U$261.000 UL95.500 = 0.04 
U$2.809.615 U$2.511.000 ns 
U812.467 U$11.160 ns 
96.9% 92.5% <0.017 
97.7% 93.7% <0.017 
18.6% 5.3% = 0.002 
PCI would save 44 lives for 1000 patients treated. 
Conclusions: In Argentina current PTCR techniques had similar costs 
than conventional CABG, however used in patients with ERACI II character- 
istics PTCR was more effective. 
Diabetic Patients With Multivessel Disease 
Treated With Percutaneous Coronary 
Revascularization had Similar Outcome Than 
Those Treated With Suraerv: One Year Follow Uo 
Results From Two Argekrie Randomized Studies 
(ERACI-ERACI II) 
Carlos Fernandez Pereira, Victor Bernardi, Jorge Martinez, Julio Baldi, 
Daniel Vogel, Liliana Grinfled, Miguel Russo Felsen, Carlos Mauvecin, 
Eduardo Mele, lgor Palacios, Alfred0 Rodriguez. Otamendi Hospital, 
Buenos Aires, Argentina 
Background: One large randomized study (BARI) demonstrated better sur- 
vival with coronary bypass surgery (CABG) compared with percutaneous 
transluminal coronary revascularization (PTCR) in diabetics patients with 
multivessel disease (CAD). 
The purpose of the present study was to assess late outcome of diabetic 
patients included in two randomized studies. 
Methods: From 577 patients with multivessel CAD randomized either 
to PTCR or CABG included in two Argentine randomized studies (ERACI 
and ERACI II) we identified 90 diabetic patients. From these 46 patients 
were randomized to CABG and 44 patients to PTCR. Major adverse events 
(MACE) were defined as death, myocardial infarction (AMI) and requirement 
of new revascularization procedures. Clinical follow up was available at one 
year in all patients. Coronary stents were used in 86.4% (38/44) of patients 
in PTCR group (100% in ERACI II). 
Results: Basal demographic and angiographic characteristics were sim- 
ilar 82.2% of them had unstable angina at time of randomization whereas 
21% had concomitant peripheral vessel disease. 
One year follow up results 
Death 
AMI 
Death + AMI 
Repeat PTCWCABG 
MACE 
PTCR (44 pts) 
4.5% (2/44) 
0% 
4.5% (2144) 
19% (E/42) 
22.7% (10144) 
CABG (46 pts) P 
6.5% (3/46) ns 
6.5% (3/46) ns 
13% (6/46) ns 
69% (3/43) ns 
19.5% (9/46) “S 
Conclusions: Diabetics patients with multivessel CAD randomized to 
PTCR had similar long term survival and incidence of myocardial infarction 
than those randomized to CABG. 
1019-86 Medical Costs Over 18 Months After Stent 
Implantation With Versus Without Intravascular 
Ultrasound Guidance. Results of the Randomized 
“REStenosis After Intravascular Ultrasound 
STenting” (RESIST) Study 
Francois Schiele, Nicolas Meneveau, Marie France Seronde, 
Patrick Arveux, Bernard Bertrand, Nicolas Danchin, Jean-Pierre Bassand. 
Department of Cardiology; University Hospital Saint-Jacques, Besanpon, 
France 
Background: One hundred and fifty five patients were randomized to rou- 
tine stent deployment with versus without Intravascular Ultrasound (IVUS) 
guidance. At 6 months, a non significant 6.6% difference in n&stenosis was 
observed (22.2% vs. 28.8%, p = 0.18) and at 18 months, the difference in 
event free survival was 12% (p = 0.059). The medical costs (procedural and 
hospitalization) were calculated. 
Methods: Units: 1996 actual prices for balloons, guide wire, guiding 
catheters, stents and intravascular ultrasound (IVUS) catheters as well as 
cost for hospitalization in general wards and intensive care unit were taken 
from Saint Jacques University Hospital, Besancon France. Volumes: pro- 
cedural devices used and hospital stay for stent implantation and for all 
lesion revascularization procedures were recorded over 18 months. Medical 
costs were calculated by multiplying units by volumes and compared using 
Mann Whitney U test. Sensitivity analyses were performed to assess the 
robustness of the results. 
Results: In the group without IVUS guidance, 27/76 required for revas- 
cularization (3 of them needed recurrent revascularization) whereas 19/79 (2 
patients needed for second revascularization) in the group with IVUS guid- 
ance. The difference in number of revascularization procedures per patient 
was significant, 31/76 vs 21/79, p = 0.03. The procedural costs were 17% 
higher at stent implantation in the group with IVUS. The total medical costs 
(procedural + hospitalization) were 6.5% higher in the group with IVUS, 4716 
(median 4030) vs 4627 (median 3620) Euro, p = 0.02. Sensitivity analysis 
showed a consistent overcost, ranging from 1% to 6.5%. 
Conclusions: IVUS guidance for stent implantation allows a trend for 
better clinical outcome, with less need for lesion revascularizations. The 
overcost induced by the use of IVUS is not fully offset during follow-up, 
representing 1 to 6.5% of the medical costs. 
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1_1 1019 87 A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After 
Coronary Stenting 
Christian Miiller, Heinz J. BOttner, Jens Petersen, Helmut Roskamm. 
Her.?Zentrum Bad Krozingen, Germany 
Background: The introduction of an effective antiplatelet therapy with aspirin 
and ticlopidine after the placement of coronary-artery stents has decreased 
the risk of subacute stent thrombosis (SAT) and hemorrhagic complications. 
However, the use of ticlopidine is limited by hematological and gastrointestinal 
adverse effects. The safety and efficacy of clopidogrel after stenting remains 
to be established. 
Methods: After successful coronary stenting during elective or emergency 
PTCA, 700 patients with 899 lesions were randomly assigned to receive a 
four week course of either 500 mg ticlopidine (n = 345) or 75 mg clopidogrel 
(n = 355) in addition to 100 mg aspirin. All clinical events reflecting SAT 
we’re included in the pre-specified primary cardiac endpoint: Cardiac death, 
urgent target vessel revascularization, angiographically documented SAT, or 
nonfatal myocardial infarction within 30 days. The primary non-cardiac end- 
point was defined as non-cardiac death, stroke, severe peripheral vascular 
or hemorrhagic events, or any adverse event resulting in discontinuation of 
study medication. 
Results: Cardiac events occurred in 17 patients: 11 (3.1%) with clopi- 
dogrel and 6 (1.7%) with ticlopidine (p = 0.24). The primary non-cardiac 
endpoint was observed in 16 patients (45%) assigned to receive clopidogrel 
versus 33 patients (9.6%) assigned to receive ticlopidine (p = 0.01). 
Conclusions: After the successful placement of coronary artery stents in 
unselected patients, antiplatelet therapy with aspirin and clopidogrel seems 
to be as safe and effective as aspirin and ticlopidine. Non-cardiac events 
were significantly reduced with clopidogrel. 
1019-88 Predictors of Refractory Stent Restenosis After 
Balloon Angioplasty: Statistical Analysis 
Hiroyoshi Yokoi, Takashi Tamura, Yoshihisa Nakagawa, Naoya Hamasaki, 
Hideyuki Nosaka, Takeshi Kimura, Masakiyo Nobuyoshi. Kokura Memorial 
Hospital, Kitakyushu, Japan 
The long-term effectiveness of coronary stent implantation is diminished 
when repeat balloon angioplasty (BA) procedures are required for recurrent 
stem restenosis (SR). The purpose of the present study was to identify the 
predictors of refractory SR which recurred alter 1 or more prior BA of SR, the 
clinical, procedural and angiographical parameters in refractory SR lesions 
(les) were analyzed. Out of 310 pts with 320 lesions (les) with successful 
first BA for SR undergoing 3-month follow-up (3MFU) quantitative coronary 
angiography @CA), the first recurrent SR (250% diameter stenosis at FU) 
was observed in 164 pts with I 64 les (51%). Among these pts, medical 
therapy was selected in 53 asymptomatic pts. Bypass surgery (CABG) was 
performed in 3 pts and 108 pts had a second BA and 87 pts underwent 
3MFUQCA (FUrate = 81%). Second recurrent SR was observed in 59 pts 
with 59 les (68%). Among these pts, medical therapy was selected in 13 
asymptomatic pts and CABG was performed in 1 pts. Out of 45 pts who 
underwent a third BA procedure, 3MFUQCA was performed in 40 pts (FU- 
rate = 89%). Third recurrent SR was observed in 31 pts with 31 les (78%). 
Univariate analysis revealed 7 angiographical significant factors of refrac- 
tory SR. The angiographical factors were ostial les (P = 0.04), RCA les 
(P = 0.007), RCA ostial les (P = O.OOOl), pattern of SR (diffuse type) (P 
= O.OOOl), minimal lumen diameter (MLD) at FU after stent implantation 
(P = 0.002), late loss after stent implantation (P = 0.003), loss index aider 
stent implantation (P = 0.004). These 7 factors were tested with multivariate 
logistic regression analysis. The only one factor of pattern of SR (diffuse 
type) was identified as the independent predictor of refractory SR after BA 
(P = 0.0001) 
Conclusioni Repetitive BA for refractoy SR was associated with very 
high recurrent restenosis rate rather than first BA for SR. BA in diffuse type 
SR was limited approach associated with a higher frequency of refractory SR 
after BA. The other modalities such as brachytherapy may be necessary to 
overcome some of these limitations. 
III 1019 89 Clinical and Anatomic Predictors of Late 
Angiographic Outcome After High Pressure Stent 
Deployment 
Edgar J. Massabni, David L. Fischman, Sheldon Goldberg, Diane 
E. Rehmann, Masakiyo Nobuyoshi, Ian Penn, Jeffrey Moses, Stephen Ellis, 
John Hirshfeld, Zoltan Turi, Jeffrey Werner, Michael P. Savage. For the 
STRESS 111 Investigators; Jefferson Medical College, Philadelphia, PA, USA 
Background: Early trials of corona’y stent implantation identified numer- 
ous predictive factors associated with in-stent restenosis including presence 
of diabetes, vessel size, and post-procedural lumen diameter. However, it 
remains unknown whether clinical or procedural factors affect the late angio- 
graphic outcome of coronary stents placed with current techniques of high 
pressure inflation and antiplatelet therapy. 
Methods: In the STRESS Ill trial, 240 patients underwent elective Pal- 
maz-Schatz stent placement for new, focal lesions in native coronary arteries 
using high pressure deployment (114 atm) and aspirin-ticlopidine regimen. 
Follow-up angiography was prospectively performed at 6 months and was 
available in 176 patients (78% of patients eligible for follow-up). In this anal- 
ysis, we sought to assess whether late angiographic follow-up (6 month 
minimal lumen diameter) could be predicted by clinical and anatomic vari- 
ables 
Results: For the entire study population, the median minimal lumen 
diameter (MLD) at baseline, immediately post-intervention and at follow-up 
was 0.69 mm, 2.62 mm and 1.70 mm, respectively. By univariate analysis, 
MLD at 6 months was significantly smaller in patients with diabetes (1.26 vs 
1.77 mm, p < 0.001) and with recent MI (1.65 vs. 2.15 mm, p = 0.003). MLD 
was lower in LAD lesions (1.58 vs 1.83 mm, p = 0.016) and in vessels < 3.0 
mm (1.50 vs 1.99 mm, p < 0.001). Follow-up MLD also correlated with MLD 
immediately before and after intervention (both p < 0.01). By multivariate 
analysis, independent predictors of 6 month MLD were diabetes (p < 0.002) 
post-procedural MLD (p = 0.002), Ml within 6 weeks (p = 0.008), and small 
vessels (p = 0.018). 
Conclusions: Late angiographic outcome in this prospective trial was 
determined by the presence of diabetes, recent Ml, vessel size, and the 
initial angiographic result, Thus, the customary predictive factors of long-term 
outcome after coronary stenting have not been altered by the advent of high 
pressure techniques and adjunctive antiplatelet therapy. 
1 1019-90 1 Clinical and Angiographic Predictors of CPK-MB 
Release Following Coronary Stent Implantation 
Saihari Sadanandan, Jacqueline Tamis, Maziar Azadpour, 
Jarkarpun Chaipromprasit, Emad Aziz, Peter Homel, James Slater. St. 
Luke%Roosevelt Hospital Center, Columbia University: New York, USA 
Background: CPK release after PTCA is associated with long term adverse 
outcomes. Little is understood regarding the impact of stenting on CPK 
release. 
Methods: We reviewed 673 consecutive pts undergoing coronary stent 
implantation. Among these, 86 (12.7%) pts had post procedure CPK release 
(CPK-MB positive or if MB negative, total CPK ? 3 times normal) (Group-l). 
This group was compared to 100 pts with no CPK release after stenting 
(Group-2). Pts undergoing primary angioplasty were excluded. 
Clinical characteristics: The mean age of Group-l was 63 & 12 years 
and 71% were males. The mean pre-procedural, 6-8, and 16-24 h post 
procedural CPWCPK-MB% were 106/0.5, 220/5.0 and 302/6.0 respectively. 
Baseline clinical variables, including age, HTN, DM, angina1 class, h/o MI, 
PVD, previous PTCA or CABG were not significantly different between the 
two groups. Group I pts were less likely to be smokers (18% vs. 31% p = 
0.04) and more likely to have a h/o CHF (16% vs. 6% p = 0.03). 
Angiographiccharacteristics: The number of vessels diseased, vessels 
intervened, restenotic lesions, LVEF, and the locations of stent (native or graft) 
were not different between the two groups. Group I pts had more complex 
lesions: Type C (65% vs. 22% p < O.OOl), thrombus (20% vs. 5% p = 
0.007), diffuse luminal irregularities (70% vs. 40% p = 0.007). They were also 
more likely to be treated with Reopro (28% vs. 13% p = 0.01) and to have 
~1 stent implanted (44% vs. 15% p < 0.001). Side branch occlusion was 
more common in Group I (31% vs. 5% p < O.OOl), and most often involved 
<l-mm vessels. The incidence of distal embolism or major dissection was 
not different. By multivariate analysis, Type C lesion (p < 0.0001) and side 
branch occlusion (p = 0.01) independently correlated with CPK release. 
Conclusions: Pts with post- stent CPK release have more diffuse dis- 
ease, complex lesions and were more likely to receive ~1 stent. Our results 
indicate that complexity of lesion and side branch occlusion may be the most 
important predictors of CPK release following stent implantation. 
1019-91 Plaque Substrate and Arterial Damage are 
Predictors of Restenosis After Coronary Stenting 
in Humans 
Andrew Farb, Deena K. Weber, Russ Jones, Renu Virmani. Armed forces 
Institute of Pathology Washington, DC, USA 
Background: Despite the increased use of coronary stents, only limited 
pathologic data on stent restenosis in humans are available. 
Methods: Histology and morphometry were performed on 34 coronary 
stents, implanted 160 days, from 21 patients (mean age 59 & 13 years; 
15 men, 6 women). The mean duration of stent implant was 263 f 223 
days. A histologic success was defined as a stent area stenosis of 550% 
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and restenosis as a stem stenosis of ~50%. In cases with medial rupture, a 
fracture length (FL) was measured. 
Results: 
sent Plaque Lumen Neaintima FL 
(mm’) (mm”) (mm*) (mm’) (mm) 
SUCIXSS 5.5 f 2.3 6.0 i 2.4 3.5+ 1.7 2.Oil.O 0.3 * 0.8 
Restencsis 6.0 + 2.6 5.5 A 3.2 1.4f 1.2 4.6 zt 2.1 1.9 i 2.7 
P NS NS <0.0001 <0.0001 co.02 
Lumen area increased as stem area increased (ra = 0.19, p = 0.01) but 
there was a much stronger correlation between stent area and neointimal 
(NI) area (r’ = 0.7, p < 0.0001). Underlying vessel morphology at the stent 
strut site strongly influenced neointimal growth (FP = fibrous plaque, RC = 
ruptured core, RM = ruptured media): 
FP RC RM P 
NI Thickness (mm) 0.65 + 0.33” 0.95 + 0.40” 0.85 zk 0.25* *<0.03 
NI Neoangrogenesis 0.005 i 0.007^,’ 0.010 i 0.009* 0.019 + 0.013t “<0.07, 
(mm*) t<0.001 
NI Inflammatory 1407 i 1466= 3419 i 2670* 3358 * 3305” “<0.002 
Cell Density 
NI neoangiogenesis and inflammation correlated positively with NI growth 
(ra = 0.11, p < 0.0001). Lipid core penetration by stent struts occurred in 
plaques with larger absolute core size (2.05 mm* vs 0.20 mm* in plaques 
without core penetration, p = 0.0002) and in those plaques in which lipid core 
composed a greater percentage of the plaque (21 f 13% vs 4 f 9%, p = 
0.0004). 
Conclusions: Stenting of lipid-rich plaques induces greater inflamma- 
tion and neoangiogenesis, which are associated with restenosis. Increased 
fracture length of the media is associated with poor outcome indicating the 
limitation of the “bigger is better hypothesis” when applied to stenting. 
1019-92 Increased Risk for Restenosis After 
Stent-Implantation in Patients With Mild to 
Moderate Renal Failure 
Christof Weinbrenner, Jens Tuischer, Frank Edelmann, Ruth H. Strasser. 
Deparfment of Cafdio/ogx University of Heidelberg, Germany 
Background: End stage renal disease in patients with diabetes mellitus has 
been suggested to be an additional risk factor for restenosis after percuta- 
neous transluminal coronary angioplasty (PTCA) in coronary artery disease. 
It is not known, however, if isolated chronic renal insufficiency (CRI) without 
diabetes mellitus may promote an increased risk for restenosis. Therefore, 
we investigated the rate of restenosis in patients with CRI, who underwent a 
follow-up angiogram after combined PTCA and stent implantation. 
Methods: 249 patients after PTCAand stent implantation were included in 
the study. Follow-up angiogram was performed after 4 to 12 months. Patients 
with diabetes meliitus, end stage renal disease, acute intervention because 
of stent-thrombosis, or acute myocardial infarction less than 3 months ago 
were excluded. 
Results: 87 patients had a glomerular filtration rate below 75 mlimin 
(CRI), whereas 162 patients had no signs of renal impairment (controls). The 
two groups had the same demographic characteristics and did not differ in the 
main cardiac risk factors including lipid profile, except for hypertension which 
was more frequent in the CRI group (p < 0.05). On follow-up angiogram 58 
patients with CRI (67%, p < 0.05) showed a significant narrowing of the target 
vessel of more than 50%. In contrast, in the group without CRI restenosis 
occurred significantly less frequent than in the CRI group. 
Conclusion: Compensated CRI-patients per se also in the absence of 
diabetes mellitus are at higher risk for restenosis after stent-implantation. 
As shown here, this increased risk is independent of the lipid profile. The 
molecular mechanisms responsible for this increased risk of restenosis re- 
mains to be elucidated. Moreover, patients with CRI require intensive clinical 
surveillance and a conseauent reduction of cardiac risk factors. 
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/ 1020-l 09 / Intracardiac Echocardiography Permits High 
Spatial Resolutlon for Percutaneous Local 
Myocardial Delivery Using a Needle Injection 
Catheter 
Robert J. Lederman, Mark Richards, Erick Avelar, Hong San, P. 
Michael Grossman, Sanjay Rajagopalan, Maria Palasis’ , James J. Barry’, 
Joan Main’, Mani A. Vannan. Universify of Michigan Health Sysfem, Ann 
Arbor, M/; ‘Boston Scientific Corporation, Natick MA: ‘Acuson Corporation, 
Mountain View, CA, USA 
Background: Transcatheter endomyocardial injection offers a minimally- 
invasive alternative to open-chest injection of emerging therapeutic agents 
including growth factors and genes. We tested the feasibility of precise 
catheter manipulation guided by conventional fluoroscopy and by intracar- 
diac echocardiography (ICE). 
Methods: A novel needle injection catheter (Boston Scientific) was ad- 
vanced via the femoral artery into the left ventricular cavity in four 35-40 
kg pigs under fluoroscopic guidance. Catheter manipulations were observed 
simultaneously using a IO Fr, 5.5-10 MHz phased vector array transducer 
with 4-way steerable ICE (Acuson Corp) placed in the right atrium via the 
jugular vein. Paired injections of 50 ~Lfluorescent microspheres plus 50 FL 
1% indelible dye permitted real-time ICE observation of injections in multiple 
fluoroscopic segments. The distance between endocardial injection points 
was measured from heart explants. The distance between ICE injection sites 
were measured off-line by a blinded observer comparing diastolic frames. 
Results: Dye was localized as predicted to all fluoroscopic segments 
identified. ICE-predicted and postmortem-measured distances between mul- 
tiple injection pairs were only 2.3 f 2.1 mm apart. 
Conclusion: Fluoroscopic guidance permits accurate segmental deliv- 
ery of endomyocardial injectate. ICE permits millimeter-scale targeting of 
intramyocardial injections. 
1020-l 10 Cryoapplication Induces Neovascularization: 
A Novel Approach to Percutaneous Myocardial 
Revascularization 
Paul Khairy, Marc Dubuc, Richard Gallo. Montreal Heart Institute, Montreal, 
PO, Canada 
Percutaneous myocardial revascularization (PMR) is emerging as a thera- 
peutic option in severe angina not treatable by conventional means. While its 
mechanism is poorly understood, neovascularization (angiogenesis/vascu- 
logenesis) is hypothesized to account for the observed beneficial effects. We 
evaluated the feasibility of a new percutaneous cryocatheter as a means of 
PMR by assessing its effects on neovascularization. Cryoinjuries were per- 
formed in ventricles of 15 mongrel dogs at -55.5 i 0.8”C with a deflectable 
catheter (CryoCath Technologies Inc, Montreal). Dogs were sacrificed im- 
mediately, and at 3 and 6 weeks. Acute lesions revealed clear demarcations 
between cryoinjured and normal tissue with preserved myocardial architec- 
ture. Both 3 and 6 weeks lesions showed prominent neovascularization. 
Vessel counts in uninjured myocardium, intralesionally, and in a 1 mm sur- 
rounding border zone were assessed by averaging the number of vessels 
in 5 random sites under high power magnification (250X). Analysis of 3 and 
6 weeks sections revealed greater vessel densities intralesionally (12.8 & 
0.6 vessels/mm*) and in border zones (3.3 f 1 .O vessels/mm’) compared to 
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uninjured myocardium (0.6 & 0.4 vessels/mm*) (p < 0.0001). More vessels 
were noted at 3 weeks (n = 72) compared to 6 weeks (n = 68) (14.3 + 6.3 vs 
11.2 f 4.6/mm2, p = 0.002). However, vessels were larger at 6 weeks than at 
3 weeks (0.022 f 0.015 mm2 vs 0.017 f 0.009 mma, p = 0.04) and showed 
greater anatomical development. 
Conclusions: Lesions created by a new cryocatheter result in prominent 
neovascularization without significantly damaging endocardial ultrastructure 
and may represent a promising alternative for PMR. This model suggests 
that over a 6 weeks period, angiogenic sites progressively evolve to form 
more developed vessels. 
IIII 1020 111 Percutaneous Endocarciial Gene Therapy: 
Patterns of In-Vivo Gene Expression Related to 
Regional Myocardial Delivery 
Ezra Deutsch, Norman Tarazona, Timothy A. Sanborn, Jack L. Martin, 
Leonard Y. Lee, Neil Hackett, Tarek El-Sawy, Irene Blanco, Kenneth 
Ft. Fromkin, Todd K. Rosengatt, Ronald G. Crystal. Weill Medical Co//ege of 
Cornell University New York, New York, USA 
Percutaneous endocardial administration of an adenoviral (Ad) vector cod- 
ing for vascular endothelial growth factor using a catheter-based approach 
may represent a strategy to stimulate new blood vessel growth and improve 
myocardial perfusion to ischemic regions. However, the feasibility of percu- 
taneous regional endocardial gene therapy and the subsequent pattern of 
distribution of gene expression in sites of delivery and in remote regions have 
not been characterized. 
Methods: Regional endocardial delivery of a replication-deficient aden- 
ovirus expressing the gene for ,&galactosidase (Adpgal) was performed in 
5 swine guided by the Biosense NOGA’” system of left ventricular (LV) en- 
docardial mapping. A novel delivery system (27 gauge/4 mm length needle) 
incorporated into the Biosense catheter permitted vector administration to all 
regions of the LV. AdpGal (IO” particle units/l 00 ~1) was delivered in 100 ~1 
injections (avg 7/animal). Endocardial delivery was confirmed byfluoroscopy. 
Animals were sacrificed 48 h after gene transfer, the LV was sectioned into 
16 regions (apex to base; anterior to posterior), and quantitative analysis of 
BGal tissue levels (relative light units[RLU]/mg protein) was performed. 
Results: Mean j3Gal expression was 1.5 x 1 O6 in injected segments, 6.4 
x 1 O4 in adjacent segments, and 3.5 x 1 O3 in remote segments (p = 0.005; 
1 way ANOVA). BGal expression in injected and adjacent sites was each 
significantly greater than in remote regions (p < 0.001). BGal expression 
was equivalent in endocardial and epicardial halves of injected and adjacent 
regions. 
Conclusions: BGal expression was observed in myocardial tissue in 
those regions prospectively targeted for gene transfer, and in adjacent seg- 
ments Regional myocardial delivery of gene products to injected zones 
using a catheter-based endocardial approach is feasible in this model, and 
is accompanied by significant gene product expression in adjacent border 
zones. 
1 1020-i 121 Intracardiac Venous System as a Novel Conduit 
for Local Drug Delivery 
Mehrdad Rezaee, Sidney T. Lo, Lynn Bailey, Takeshi Suzuki, David P. Lee, 
Paul G. Yock, Peter J. Fitzgerald, Alan C. Yeung, Simon Stertzer, 
Andrew Carter. Stanford Cardiovascular Medicine, Stanford, California, USA 
Background: Effective strategies for administering angiogenic factors in- 
volve either multiple myocardial injections or intracoronary delivery into highly 
diseased conduits. Alternatively, access to cardiac venous system through 
the coronary sinus provides an extensive network of vessels for regional 
delivery of angiogenic agents to the distal myocardium. 
Methods: Five swine underwent simultaneous right and left heart car- 
diac catheterization. A 7F balloon tip catheter over a guidewire was used 
to cannulate the anterior interventricular vein (AIV). 15 pm fluorescent mic- 
rospheres were used to determine the territory of myocardium that drains 
into the AIV, and would be potentially available for drug delivery. A differ- 
ent color set of microspheres was used to label the left anterior descending 
artery territory (through subselective engagement of LAD). All injections were 
performed over constant time and pressure. Simultaneous .ventricular end 
diastolic pressure (LVEDP), coronary wedge pressure, and distal venous 
wedge pressure were measured during the balloon inflation. The hearts 
were harvested and a circumferential sample was divided into eight seg- 
ments: each segment was divided further into the epicardial and endocardial 
layers. These samples were processed for microspheres sedimentation, and 
subjected to scanning fluorometery to determine the amount of different color 
microspheres in each region. 
Results: There was no significant increase in the LVEDP, and only tran- 
sient elevation of VWP during the injections (range of 5 to 30 mm Hg). The 
concentration of microspheres in the LAD territory was similar in both LAD 
and AIV injections (93% f 3.5 vs. 81% f 7.0, respectively). 68% of the 
microspheres delivered through the AIV localized to the epicardial layer of 
myocardium vs. 53% delivered through the LAD (endocardial localization 
after AIV and LAD injections were 32% and 47%, respectively). 
Conclusion: These data demonstrate the feasibility of using the cardiac 
venous system for regional myocardial reagent delivery. 
) 1020-i 13 1 Left Anterior Descending Coronary Blood Flow 
is Unaffected by Complete Occlusion of the 
Anterior Interventricular Vein 
Niall A. Herity, Sidney T. Lo, Frederick Oei, David P. Lee, Michael R. Ward, 
Steven D. Filardo, Ali Hassan, Takeshi Suzuki, Alan C. Yeung, Peter 
J. Fitzgerald, Paul G. Yock. Sfanford University, Stanford, CA, USA 
Background: Percutaneous selective catheterization of the coronary venous 
system, a novel potential route for local drug or growth factor delivery to 
chronically ischemic myocardium, requires complete balloon occlusion of the 
coronary vein to maximize the delivered concentration of therapeutic agents. 
The purpose of this study was to measure the impact of occlusion of the 
anterior interventricular vein (AIV), which drains the left anterior descending 
(LAD) territory, on blood flow in the LAD. 
Methods: In 6 anesthetized pigs, baseline and hyperemic (intracoronary 
adenosine, 24 mcg) coronary arterial flow parameters were measured before 
and during complete balloon occlusion of the AIV. Recordings were made in 
the LAD and in the circumflex artery (CX), which served as a control. 
Results: Complete occlusion of the AIV had no significant impact on initial 
or hyperemic flow parameters in either the LAD or CX (table). 
Before AIV occlusion During AIV occlusion 
Initial Hyperemic Hyperemic Initial Hyperemic Hyperemic 
APV APV diameter APV APV diameter 
LAD 12.33 24.33 2.95 14.67 24.33 2.91 
(3.01) (5.68)* (0.42) (3.78) (5.72)* (0.30) 
cx j 6.83 28.00 2.75 16.17 28.00 2.84 
(4.58) (4.24)* (0.57) (5.71) (4.98) (0.62) 
Mean (SD). APV = average peak velocity of blood in cm/set. *P < 0.05 compared with 
initial value 
Conclusion: Major cardiac veins can be completely occluded without 
jeopardizing perfusion of the myocardial territory they drain. These observa- 
tions support the safety of the coronary venous route for targeted local drug 
delivery to ischemic myocardium. 
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1 1021-I 14 1 Are the Intravascular Ultrasound Findings After 
Brachytherapy Treatment of In-Stent Restenosis 
Reproducible? 
Gary S. Mintz, Neil J. Weissman, Balram Barghava, Ron Waksman, Paul 
S. Teirstein, Roxana Mehran, Alexandra J. Lansky, Lowell F. Satler, Martin 
B. Leon. Washington Hospital Center, Washington, DC, USA 
Three randomized trials used post-intervention and follow-up intravascular 
ultrasound (IVUS) analysis to show that brachytherapy with k-192 reduces 
in-stent restenosis. However, protocols varied; and the number of pts in each 
trial was either small or IVUS was only a substudy. Therefore, we compared 
the IVUS analysis in SCRIPPS, WRIST, and Gamma-l to prove the repro- 
ducibility of IVUS endpoints across protocols. All studies were performed with 
Follow-uo 96 months k-192 Placebo 0 
A mean IH area (mm*) 
SCRIPPS (n = 18) 
WRIST (n = 47) 
Gamma-l (n = 28) 
A minimum lumen area (mm’) 
SCRIPPS (n = 18) 
WRIST (n = 51) 
Gamma-l (n = 29) 
0.7 zk 0.9 2.3 zt 2.8 0.0009 
0.2 i 2.8 1.7*3.1 <0.0001 
0.8zt 1.3 1.511.1 0.049 
1.011.9 2.8 i 4.5 0.0057 
0.6 f 2.7 1.9 i 3.5 0.0005 
0.8 zt 1.4 2.3& 1.6 0.002 
JACC February 2000 ABSTRACTS - ACCIS2000 7A 
motorized transducer pullback. Stent, lumen, and intimal hyperplasia (IH = 
stent-lumen) areas were measured every 1 mm of in-stent restenosis length. 
IH area was averaged, minimum lumen area was measured, and differences 
were compared. 
Importantly. there was no statistically significant difference among the 
three studies in assessment of in-stent neointimal hyperplasia accumulation 
(Amean IH) or late lumen loss (Aminimum lumen area) in either the lr-192 
or placebo groups. 
We conclude: Despite small pt numbers, IVUS findings after Ir-192 are 
similar across clinical trials. This substantiates the reproducibility of IVUS 
methodology as an endpoint for assessing efficacy of strategies to treat 
in-stent restnosis. 
L--l 1021 115 Vessel Wall Distance Variation Between Centered and Non-Centered Radiation: 
Cross-Sectional and Longitudinal Analysis by 
Intravascular Ultrasound 
Atsushi Takagi, Yasuhiro Honda, Yoshihiro Morino, Raoul Bonan, 
Ron Waksman, Paul S. Teirstein, Barry Rutherford, Ezra Deutsch, 
Kurt Malphurs, Jeff Werner, Paul G. Yock, Peter J. Fitzgerald. Sent And 
Radiation Therapy (START) Trial Investigators; Stanford University, 
Stanford, CA, USA 
Background: Centering devices have been postulated to improve the dosing 
homogenicity in coronary brachytherapy after balloon angioplasty. However, 
the efficacy of centering is not well studied in the treatment of in-stent 
restenosis. Intravascular ultrasound (IVUS) cases for START (Stents And 
Radiation Therapy) trial which is an on-going randomized study using a 
noncentered beta radiation source (gOSr) were analysed. 
Methods: A total of 710 cross sections, obtained during IVUS pull back in 
39 patients, were analyzed. Vessels were defined as large with a reference 
lumen p 3.35 mm, and as small < 3.35 mm, based on the angiography-guided 
dose prescription. For each cross section, the maximum distance to the 
medial layer within the coronary wail with respect to the catheter (assumed to 
be equivalent to the position of gOSr source: SD), and the distance originating 
from the geometric center of the lumen (equivalent to the centering devices: 
CD) were measured. To assess the longitudinal variance in each target 
vessel, the absolute difference from the mean value of each measurement 
were calculated for both origins located at SD and CD. 
Results: Cross-sectional analysis showed that CD was significantly less 
than SD in small vessel group (2.48 ZIZ 0.50 vs. 2.66 -Jt 0.55 mm, p < 0.001). 
This difference was even more prominent in large vessel group (2.86 & 0.45 
vs. 3.10 i: 0.53 mm, P < 0.001). The longitudinal distance variation along the 
target segment was also significantly less originating in CD than SD (0.28 f 
0.22 vs. 0.37 + 0.31 mm: p < 0.0001). 
Conclusions: In patients with in-stent restenosis undergoing brachyther- 
apy, centering within the lumen appears to minimize the distance variation to 
the vessel wall, not only in the cross-sectional geometry but also along the 
longitudinal axis. 
j-- _ J 1021 116 Angiography Reliably Differentiates In-Stent 
versus Stent Edge Restenosis: An IVUS 
Validation Study From the lsostent Restenosis 
Registry 
Alexandra J. Lansky, Neil J. Weissman, Harish Rudra, Joelle Happi, 
Adrienne Tinana, Hui Bui, Roxana Mehran, Jeffrey Moses, 
Antonio Columbo, Gary S. Mintz, Martin B. Leon. The Washington Hospital 
Center, Washington, DC, USA 
Background: Differentiating in-stent versus stent edge restenosis is an es- 
sential component of quantitative angiography of brachytherapy trials. 
Methods: In order to gain insight into the accuracy of angiography to 
distinguish in-stent from stent edge restenosis, we compared intravascular 
ultrasound (IVUS) to quantitative angiography in 20 consecutive patients 
from the lsostent Restenosis Registry evaluating the p3’ coated BX isostent. 
Angiograms were reviewed independently by a technician blinded to the 
IVUS evaluation. Based on a drawing of the precise stent location performed 
at the time of stent implantation, the location of restenosis by quantitative 
angiography (CMS, MEDIS) was classified as (1) “in-stent” if the maximal 
diameter stenosis (>50%) was confined to the axial length of the stent, (2) 
“outside the stent” if the maximal stenosis was beyond the stent edge, and 
(3) “both” if the maximal stenosis spanned the edge of the stent. A similar 
IVUS classification was based on the location of the smallest luminal area 
and in-stent IH > 50% of the stent area in relation to the stent. 
Results: IVUS was not available in 4 patients because of total or subtotal 
occlusions or disease outside of the stent in 2 patients. Of the remaining 14 
patients, IVUS and angiography were concordent in 12 (85.7%) cases. 
In-Stent Angio Out-of-stent Angio Both Angio 
In-sent IVUS 2 0 0 
Out-of-stent 0 3 i 
IVUS 
Both IVUS 1 0 7 
Conclusions: Angiography can accurately localize restenosis at the stent 
margins in 85.7% of cases when using IVUS as the gold standard, and is 
available in all patients irrespective of total occlusions or disease outside the 
stent. 
1021-I 17 Intravascular Ultrasound Lesion Calcium 
Predicts Adverse Clinical Events After Carotid 
Artery Stenting 
Neil J. Weissman, Gary S. Mintz, George Dangas, Roxana Mehran, 
Michael Canos, Daniel A. Canos, Lee H. Monsein, Emily M. Parsons, John 
R. Laird Jr., Michael R. Jaff, Ann 0. Greenberg, Lowell F. Satler, Martin 
B. Leon. Washington Hospital Center, Washington, DC, USA 
Hypotensive (Hypo) and neurologic events arc reported complications after 
carotid artery stenting. We assessed the intravascular ultrasound (IVUS) 
predictors of these adverse events in 102 pts (69% male, 70 f 9 yrs). 
IVUS (3.5F phased array catheter) was performed before and after stent 
placement. In this cohort, prolonged post-procedural Hypo occurred in 20 
pts, and any neurologic event in 16 pts. (IO transient and 6 permanent). The 
only IVUS predictor of neurologic events was lesion calcium (Ca), present in 
64% of lesions. Ca was assessed quantitatively (arc of Ca) and according to 
location (superficial, present in 77% of calcified lesions, vs deep). Neurologic 
events according to presence and location of Ca were 
Hypo was present in 35% of pts with superficial Ca, half of whom had 
prolonged post-procedural Hypo (p = 0.0279 vs deep Ca or no Ca). The 
arc of Ca was larger in pts with prolonged post-procedural Hypo (110” vs 
66”, p = 0.096). None of the following predicted neurologic or Hypo events: 
vessel size, plaque burden, lesion eccentricity, final stent dimensions, lack 
of stent-vessel wall apposition, or presence of dissections. There were no 
clinical predictors of lesion Ca. 
We conclude: Lesion Ca, especially superficial Ca identified by /V/X, 
predicts major adverse clinical events after carotid stenting. These pts should 
be targeted for strategies to avoid both distal embolization and procedural 
hypotension. 
ORAL 
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I 79-l Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis: Clinical and 
Angiographic Results From a Randomized 
Multicenter Trial (ARTIST Study) 
Juergen vom Dahl, Ulrich Dietz, Sigmund Silber, E. Niccoli, H.J. Buettner, 
Francois Schiele, Marlin Thomas, F. Commeau, T. Ramsdale, 
Ernest0 Garcia, Heinrich G. Klues. On Behalf Of The ARTIST Investigators; 
University Hospital, RWTH Aachen, Germany 
Background: Diffuse in-stent restenosis (ISR) with high recurrence rates 
remains a challenging problem for which the best mechanical treatment is 
not clear. The ARTIST study compared balloon angioplasty alone (PTCA) 
with rotational atherectomy followed by adjunctive low-pressure (56 atm) 
balloon angioplasty (ROTA) in patients with a first ISR of 1 O-50 mm length. 
Methods and Results: 298 symptomatic patients (80.3% male, 61 i 11 
years) were randomized. Baseline demographic, clinical and angiographic 
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parameters did not differ between the groups. Angiographic success (~30% 
diameter stenosis (DS)) with randomized device was 88% (PTCA) and 89% 
(ROTA) with crossovers in 0.7% and 5.9% resp. (p ‘= 0.02). Stenting for a 
suboptimal results was necessary in 8.9% vs. 7.2% (ns). In-hospital com- 
plications (myocardial infarction, reintervention, tamponade, puncture site) 
were slightly higher in the ROTA group (22/152 pts vs. 10/146, p = 0.04). 
There was no in-hospital CABG or death. The achieved angiographic results 
(minimal luminal diameter (MLD), luminal gain, DS) at the end of procedure 
were not different by quantitative analysis (QCA) between the two groups. 
Event free survival at 6 months was 91 .I% (PTCA) and 79.6% (ROTA, p = 
0.005). Angiographic follow-up is available in 259/269 eligible patients. By 
QCA, MLD (1.2 i- 0.6 mm vs. 1.0 f 0.6 mm, p = 0.008), DS (56 f 20% vs. 
64 f 22%, p = 0.005), restenosis (>50% DS) rate (51.2% vs. 64.8%, p = 
0.04) as well as the need for target lesion reintervention (36.2% vs. 47.8%, 
p = 0.06) were in favor for the PTCA group. 
Conclusions: In this angiographically controlled randomized study in 
patients with diffuse ISR balloon angioplasty had a better clinical and an- 
giographic outcome as compared to rotational atherectomy followed by low- 
pressure balloon angioplasty. If rotational atherectomy followed by high- 
pressure balloon angioplasty will have more favorable results needs further 
evaluation. 
I:45 r3.m. 
a 79 2 Argentine Randomized Study Coronary Angioplasty With Stents Versus Coronarv Bvoass Suraerv in 
Multiple Vessel Disease (ER~Ciil). One Y&r hollow 
Up Results 
Alfred0 Rodriguez, Victor Bernardi, Jose Navia, Julio Baldi, Liliana Grinfeld, 
Jorge Martinez, Daniel Vogel, Roberto Grinfeld, Alejandro Delacasa, 
Marcel0 Garrido, Raul Oliveri, Eduardo Mele, lgor Palacios, William Q’Neill. 
On behalf of the ERACI II Investigators; Otamendi Hospital, Buenos Aires, 
Argentina 
Objective: The purpose of the present study was to compare percutaneous 
transluminal coronary revascularization (PTCR) employing stent implantation 
to conventional coronary bypass surgery (CABG) in patients with multiple 
vessel coronary artery disease. 
Background: Previous randomized studies comparing balloon angio- 
plasty vs CABG have demonstrated equivalent safety results however coro- 
nary bypass surgery was associated with significantly fewer repeat revascu- 
larization procedures. 
Methods: A total of 2761 patients with coronaty artery disease were 
screened at seven clinical sites and 450 patients were randomly assigned 
to undergo PTCR (225 patients) or CABG (225 patients). Only patients with 
multivessel disease and indication for revascularization were assigned. The 
primary end point was to compare major adverse events (MACE) with both 
techniques at 30 days, one three and five years of follow up. In PTCR group 
1.4 stents per patients were used a well 28% of a bolus and infusion of 
abxicimab. 
Results: Both groups had similar clinical demographics: unstable angina 
in 91%, 39% were older than 65 years, 23% had a history of peripheral 
vascular disease. During the first 30 days, PTCR patients had lower MACE 
compared with CABG. At 19.5 f 6.4 months of follow up (range 11-35 
months) survival was 96.9% in PTCR vs 92.5% in CABG, p < 0.017. Free- 
dom from myocardial infarction was also better in PTCR compared to CABG 
(97.7% vs 93.4%, p 4 0.017). Requirements for new revascularization pro- 
cedures were higher in PTCR than CABG (18.6% vs 5.3%, p < 0.002). 
However only 6.2% of patients in PTCR cross over to CABG. 
Conclusion: In this selected high risk group of patients with multivessel 
disease, PTCR with stent implantation showed better survival and freedom 
from myocardial infarction than conventional surgery. Repeat revasculariza- 
tion procedures were higher in PTCR group. 
El 
2:00 p.m. 
79 3 Debulking Prior to Stenting Improves Acute 
Outcomes: Early Results From the SPORT Trial 
Maurice Buchbinder, Richard Fortuna, Samin K. Sharma, Theodore Bass, 
Robert Kipperman, Joel D. Greenberg, Martin B. Leon. For the SPORT 
Investigators; Scripps Memorial Hospital, La Jolla, California, USA 
To evaluate the role of debulking vs. balloon predilatation on acute and long 
term results of stent implantation (S), 675 patients (pts) were randomized to 
receive balloon dilatation (PTCA) (n = 342) or rotational ablation (RA) (n = 
328) prior to S. In both groups (PTCA vs. RA) pts. were well matched for age 
(64.4 vs. 63.6), gender (70 vs. 68% males), diabetes (28.1 vs. 24.7%) and 
hyperlipidemia (55.3 vs. 51.2%). Multivessel disease was noted in (44.2 vs. 
45.4%) of pts. Lesion length was (18.4 f 8.3 vs. 18.4 f 8.5 mm). Treatment 
site was in the LAD (49.7 vs. 49.1%), RCA (32.5 vs. 30.5%), CX (15.5 vs. 
18.0%). In both groups pts received equal number of S per lesion (1.3 f 0.6 
vs. 1.3 i 0.6). Average S diameter was (3.2 f 0.4 vs. 3.3 f 0.4 mm) while 
average S length was (19.6 vs. 20.1). In the RA group mean burr to artery 
ratio was 0.7 & 0.1. Post S mean inflation pressure was (15.1 * 4.4 vs. 14.0 
f 4.9 atm). 
Results: 
QCA (100%) PTCAfS 
N=194 
Rota + s 
N = 170 
Ref Vessel, mm 
Pre Rx MLD, mm 
Post Rx MLD, mm 
Anglo Success 
Clinical Success 
MACE (in 
hospital) 
Non Q MI 
&-Intervention 
2.89 i 0.5 
0.92 f 0.43 
2.75 k 0.42 
100% 
89% 
13.7% 
2.3% 
9.9% 
2.89 f 0.4 
0.9 f 0.43 
2.84 f 0.42 (p ; 0.041) 
100% 
64% 
17.1% (p = n/s) 
4.3% (p = n/s) 
11.6% 
Conclusion: Debulking using RA prior to S appears to offer a signif- 
icantly larger final residual lumen without increase in complication rates. 
Angiographic and clincial long term (6 mo) outcomes will be presented. 
2:15 p.m. 
I 79-4 The SISA Study: A Randomized Comparison of Balloon Angioplasty and Stent to Prevent Restenosis 
in Small Arteries 
Serge Doucet, Martin J. Schalig, David Hilton, Mathy Vrolix, Bernard De 
Bruyne, Patrick Chenu, Luc Bilodeau, Wasan Udaychalerm. Montreal Heart 
Instifute, Montreal, Canada; Leiden University Medical Center, Leiden, The 
Netherlands 
Background: The Stenting In Small Arteries (SISA) trial is a randomized, 
multicenter, worldwide study where balloon angioplasty (PTCA) is compared 
to stent in pts with a reference diameter (RD) of 2.3-2.9 mm. Angiographic 
restenosis at 6 months is the primary endpoint. 
Methods: Between October 1997 and July 1999, 352 pts with stable 
angina and one de novo lesion in a native coronary artery were randomized 
to standard PTCAor Medtronic beStent implantation after on-line quantitative 
coronary analysis (QCA) measurement had confirmed RD of 2.3-2.9 mm. 
Results: Clinical results for cumulative adverse events are available for 
325 pts at 30 days and 199 pts at 6 months. 
N 
Death 
Q-wave MI 
Non Q-wave MI 
CABG 
RI?-PTCA 
PfS Wifh events any 
30 days 6 months 
PTCA stent PTCA stent 
171 154 103 96 
0 (0%) 0 (0%) 1 (1%) 1 (1%) 
1 (0.6%) 1 (0.6%) 1 (1%) 1 (1%) 
10 (5.7%) 3 (1.9%) 10 (9.7%) 5 (5.2%) 
1 (0.6%) 1 (0.6%) 2 (1.9%) 3 (3.1%) 
6 (3.5%) 1 (0.6%) 26 (25.2%) 16 (16.6%) 
15 (8.8%) 6 (3.9%) 32 (31.1%) 22 (22.9%) 
Conclusion: There is a trend for less adverse events (including rePTCA) 
at 30 days and 6 months with stent compared to PTCA in vessel of 2.3-2.9 
mm. The restenosis rate for each group will be presented. 
I 
2:30 p.m. 
79-5 Elimination of Restenosis by Stenting After Plaque 
Reduction With Platelet Inhibitor Trial (ESPRIT): 
A Prospective Randomiied Trial 
Etsuo Tsuchikane, Tomoko Kobayashi, Nobuhisa Awata, Motohiro Kirino, 
Satoru Otsuji, Makoto Sakurai, Tohru Kobayashi. Osaka Medical Center for 
Cancer and Cardiovascular Diseases, Osaka, Japan 
Optimal DCA provides a favorable long-term angiographic outcome. How- 
ever, restenosis is observed in some cases even after optimal DCA, which 
results from constrictive remodeling and neointimal proliferation. Stenting in- 
hibits the constrictive remodeling. We reported that cilostazol, an antiplatelet 
agent, controls neointimal proliferation after PTCA. The aim of the present 
study was to evaluate the efficacy of primary stenting after optimal DCA fol- 
lowed by administration of cilostazol. Ninety-six lesions successfully dilated 
by aggressive DCA using IVUS were randomly assigned to the DCA-stent 
group (47 lesions) or the DCA-alone group (49 lesions). Single or multiple 
Multilink stents were implanted in the DCA-stent group. Adjunctive balloon 
angioplasty was performed in the DCA-alone group if necessary. Adminis- 
tration of cilostazol (200 mg/day) without aspirin was commenced after the 
procedure and continued until 6 month (M) follow-up (Fu) in both groups. 
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Ticlopidine (200 mgiday) was added in the DCA-stent group for 1 M. Serial 
QCA and IVUS examinations ware performed at pre- and post-procedure, 
and 3 and 6 M Fu. Acute results ware shown in the table. 
MACE 
Reference (mm) 
Post DCA MLD (mm) 
Final MLD (mm) 
Final DS (%) 
Post DCA LA (mm’) 
Final LA (mm’) 
DCA-stent 
0 
3.33 zt 0.34 
2.84 f 0.36 
3.25 i 0.25 
3.6 i 7.1 
7.9 -I- 1.7 
10.3 + 2.0 
WA-alone 
0 
3.24 & 0.38 
2.85 i 0.34 
2.87 i 0.34 
11.1 * 10.0 
8.1 zt 1.9 
8.3 i 1.8 
P value 
NS 
NS 
<0.0001 
0.0003 
NS 
<0.0001 
Final % plaquk area (%) 41.4 * 7.0 53.2 S 8.4 <0.0001 
(MLD: minimal lumen diameter, DS: diameter stenosis, LA: lumen area, final: post-proce- 
dWl) 
Conclusion: Adjunctive stenting after aggressive DCA provides a larger 
immediate lumen compared to aggressive DCA alone. Follow-up clinical and 
angiographic data will be presented. 
2:45 p.m. 
179-6 1 Local Delivery of Enoxaparin Decreases Restenosis 
Rate After Coronary Stenting (POLONIA Study) 
R. Stefan Kiesz, Pawel Buszman, M. Marius Rozek, Jack L. Martin, 
Ezra Deutsch, Ewa Gaszewska, Marek Rewicki, Piotr Seweryniak, 
Maciej Kosmider, Michal Tendera. UJHSC at San Antonio, TX; Jefferson 
Ha&h System - Main Line, Radnor, PA; Cornell IJniversiN New York, NL: 
USA; Silesian Cardiology Centre, Kafowice; National institute of Cardio/ogx 
Warsaw; infernal Ministry Hospital, Warsaw; Lodz Medical School, Lodz, 
Poland 
Experimental work suggests that low molecular weight heparin, at high con- 
centration, inhibits smooth muscle cell proliferation. We investigated whether 
intramural delivery of Enoxaparin prior to stenting decreases in-stent re- 
stenosis. One hundred pts from 4 centers with single lesion, single vessel 
disease were randomized to local administration of Enoxaparin (LDD) ver- 
sus systemic heparinization (SH). The LDD group received reduced systemic 
heparinization (2,500 U). Ten mg of Enoxaparin was administered locally dur- 
ing predilation with PTCA/drug delivery Transport catheter before stent was 
deployed. All pts were treated with 9 cell 16 mm NIR stents. The primary 
endpoints included late luminal loss and loss index. The secondary endpoints 
included major adverse cardiac events (MACE), target lesion revasculariza- 
tion (TLR) and angiographic restenosis at 6 months. 
Results: Clinical follow up was obtained in all pts, and follow-up angiog- 
raphy at 6 month was performed in all but one pt. ate loss and loss index 
were significantly reduced to 0.76 f 0.42 mm and 0.38 i 0.21, respectively, 
in the LDD group vs 1.07 f 0.49 mm and 0.55 f 0.25 in the SH group, 
(both p < 0.0001). Activated clotting time at by the end of the procedure 
was significantly lower in the LDD group 146.9 f 39.8 set when compared 
with the SH group 381.9 + 182.2 set (p < 0.0001). There were no deaths or 
emergent CABG; one non Q-wave MI due to subacute stent closure occurred 
in the SH group. TLR in the LDD group was 8% vs 22% in the SH group (p 
x 0.05). Angiographic restenosis using binary definition occurred in 10% of 
pts in the LDD group and in 24% of pts in the SH group (p x 0.05). 
Conclusions: Our study demonstrates, for the first time, a significant 
decrease in late lumen loss and angiographic restenosis as a result of local 
delivery of enoxaparin. These data suggest that local drug delivery may 
constitute a viable therapeutic option to prevent restenosis after coronary 
stent implantation 
3:00 p.m. 
El 79-7 Percutaneous Transluminal Coronary Revascularization Versus Coronary Bypass Surgery 
In-Patients With Multiple Vessel Disease and Proximal 
Left Anterior Descending Artery Stenosis: Results 
From the ERACI II Study 
Alfred0 Rodriguez, Sandra Saavedra, Carlos Fernandez, 
Maxim0 Rodriguez Alemparte, Julio Baldi, Liliana Grinfeld, 
Roberto Grinfeld, Jorge Martinez, Miguel Russo Felsen, lgor Palacios, 
William O’Neil. On behatf of ERA0 // Investigators; Otamendi Hospita!. 
Buenos Aires, Argentina 
Background: Previous studies comparing percutaneous transluminal coro- 
nary revascularization (PTCR) with coronary bypass surgery (CABG) in mul- 
tiple vessel disease (CAD) suggested a prognosis advantage with CABG 
when proximal left anterior descending artery (LAD) was affected. 
Methods: From 450 pts included in the Argentine Randomized Study 
(ERACI II) we identified 230 with multiple CAD and severe stenosis involving 
proximal or ostial segment in LAD. 83 pts had two vessels disease and 
147 pts three or more vessels. Major adverse events (MACE) as death, 
myocardial infarction (AMI) and repeat procedures (TVR) were present. In 
PTCR 1.5 stentfpatient was used. 
Results: Basal demographic characteristics were similar. Unstable Angina 
present in 89.6% and treated diabetic in 173%. 
30 days Outcome 
Death 
AMI (0) 
Death + AMI 
NR 
MACE 
Follow up (19.5 + 6.4 months) 
Death 
AMI 
Death + AMI 
TVR 
MACE 
PTCFI (n = 113) 
0% 
0.9% 
0.9% 
1.8% 
2.6% 
0.9% 
2.6% 
3.5% 
19.5% 
23% 
CABG (n = 117) P 
2.5% 
5.1% 
76% 0.036 
0% 
7.6% 
4.3% 
5.1% 
9.4% 
3.4% 0.001 
13% 
Conclusions: Patients with multiple CAD and ostial or proximal LAD 
disease, treated with PTCR had lower acute adverse events compared with 
CABG. At follow up lower requirements of repeat procedures are the only 
advantage observed in CABG over PTCR. 
3:15 p.m. 
El 79 8 A Randomized Comparison Between Balloon Angioplasty and Elective Stent Implantation in 
Venous Bypass Grafts; the Venestent Study 
Clara E.E. Hanekamp, Jacques J. Koolen, Peter Den Heyer, Martin 
J. Schalij, Jan J. Piek, Frits W.H.M. Bar, Hans J.R.M. Bonnier. For the 
Venestent Study Group; Cardiology Catharina Hospital, Eindhoven, The 
Netherlands 
Background: Balloon angioplasty of Saphenous Vein Graft (SVG) lesions 
may be performed with relative high immediate angiographic success rates, 
but is limited by high restenosis rates. Observational studies and one ran- 
domized study suggested a beneficial effect on restenosis of elective stent 
implantation in SVG lesions, compared to balloon angioplasty. To determine 
the benefits of elective stent implantation in de novo lesions in the body of a 
SVG, we compared acute and long term clinical and angiographic outcome 
of balloon angioplasty and Wiktor-I stent implantation in SVG lesions. 
Methods: A total of 150 patients in 9 centers, with a denovo SVG lesion 
were randomly assigned to balloon angioplasty or Wiktor-I stent implantation. 
One month post procedure clinical follow-up was performed, and 6 months 
post procedure clinical follow-up, an exercise test and angiographic follow-up 
were performed. Analysis were performed on an intention to treat basis. The 
primary endpoint of the study was the angiographic binary restenosis rate, 
with restenosis defined as >50% diameter stenosis. Secondary endpoints 
were among others Major Adverse Cardiac Event (MACE) free survival and 
target vessel revascularization rate. MACE is defined as death, myocardial 
infarction, bypass graft surgery or angioplasty of the target vessel. 
Results: See table 
Number of patients 
Angiographic success 
Procedural success 
In-hospital MACE 
6 months target vessel revascularization 
6 months MACE free survival 
6 months angiographic restenosis 
Angioplasty 
72 
97.2% 
88.9% 
9.7% 
25.0% 
63.9% 
35.6% 
stent P 
76 
98.7% NS 
91 .O% NS 
9.0% NS 
11.5% 0.03 
80.5% 0.03 
21.9% 0.09 
Cross-over to stent occurred in 23.6% of the patients randomized to 
balloon angioplasty. Angiographic follow-up could be completed in 82% of 
the patients. 
Conclusion: Stent implantation in SVG lesions results in significantly 
improved MACE free survival, significantly decreased target vessel revas- 
cularization rates, and a strong trend towards reduced restenosis rates, as 
compared to balloon angioplasty. 
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El 83 2 Tissue and Myocarclial Distribution of Intracoronary, Intravenous, Intrapericardial, and lntramyocardial 
1251-Labeled-Basid Fibroblast Growth Factor (bFGF) 
Favor lntramyocardial Delivery 
Roger J. Laham, Mehrdad Rezaee, Lawrence Garcia; Mark Post, Frank 
W. Sellke, Donald S. Bairn, Michael Simons. B/DMC/Harvard Medical 
School, Boston, MA, USA 
Background: Therapeutic angiogenesis trials are ongoing, however, the tis- 
sue and myocardial,distributions of growth factors and gene therapy vectors 
using different delivery modalities have not been defined. 
Methods: Yorkshire pigs (n = 48) underwent ameroid constrictor place- 
ment on the left circumflex artery to induce chronic ischemia. 25 PCi 
lz51-bFGF with 30 mg cold bFGF was administered using intracoronary (IC, 
n = 12), intravenous (IV, n = 12), and percutaneous subxyphoid intraperi- 
cardial (n = 12) injections, and intramyocardial (IM, n = 12) delivery using 
BIOSENSE-guided endocardial delivery (15 injections in the ischemic LCX 
distribution). Tissue and myocardial distribution was determined at 1 and 24 
hours by measuring lz51-bFGF specific activity (TCA precipitation). Organ 
and tissue level autoradiography was performed. 
Results: Data for all animals summarized below 
lr. IV IP IM 
Liver 1 hr (%)** 37.6 * 17.1 42.1 i 17.7 0.41 * 0.3* 1.47io.49* 
Liver24 hrs (%)** 2.8i1.5 1.5 i 0.9 0.38 i o.zEa* 1.1 f 0.47* 
Heart 1 hr(%)** 0.88 f0.89 0.26 zk 0.08 1.45 zt 0.98* 4.31 h 1.67* 
Heart24hr(%)** 0.05 * 0.04 0.04 * 0.01 2.98 rt 2.89' 2.3 i 1.54* 
Normal wall %/g** 0.008 zk 0.008 0.003 i. 0.001 0.01 * 0.02* 0.0009 i o.o* 
lschemic wall %/g 0.009 It 0.007 0.003 i 0.001 0.02 f o.o** 0.03 rt o.o** 
Endo-/Epicardial 1.03 0.88 0.04'y 2.25 
*p < 0.05 compared to IC, **p < 0.05 by ANOVA, ly p < 0.05 vs. IM 
IC and IV delivery have significant systemic recirculation with low car- 
diac deposition and retention (better with C). IP and IM delivery result in 
markedly reduced systemic recirculation and improved cardiac deposition 
and retention. IP delivery is limited to the epicardial layers and requires a 
normal pericardium. Myocardial ischemia enhances myocardial deposition 
and retention. 
Conclusion: IP and IM delivery have a more favorable tissue distribution 
and myocardial deposition than IC or IV delivery. IP delivery is limited by 
poor endocardial distribution and the inapplicability to post-CABG patients. 
IM delivery may emerge as the delivery strategy of choice for therapeutic 
angiogenesis. Clinical investigations are underway. 
4:30 p.m. 
CII 83-3 Carotid Artery Intravascular Ultrasound: Safety and Morphologic Observations During Carotid Stenting in 
102 Pts 
Neil J. Weissman, Michael Canos, Gary S. Mintz, John R. Laird Jr., Lowell 
F. Satler, Daniel Canos, Martin B. Leon. Washington Hospital Center, 
Washington, DC, USA 
To assess the mophology of carotid atherosclerosis, intravascular ultrasound 
(IVUS) was performed in 102 pts undergoing carotid stenting. A 3.5 F phased 
array IVUS catheter was advanced to the distal internal carotid (DIC) and 
slowly withdrawn to image the DIC, lesion, and common carotid (CC) after 
pre-dilation and again after stent placement. There were no adverse events. 
89% of lesions were at the origin of the internal carotid. Most were eccentric 
(max/min plaque thickness = 3.2 f 3.4) with max plaque thickness opposite 
the flow divider separating the external and internal carotid in 69%. Lesion 
calcium (Ca) was common (61%, arc = 145 i 97”); conversely, Ca of the 
DIC or CC was uncommon (arc = 2 f 10” and 7 f I”, respectively). 
DIG Lesion cc 
Arterial area (mm’) 28.4i 10.0 44.5 * 13.7 63.4 zk 14.8 
Lumenarea(mm') 20.9 + 8.0 7.8 f 4.2 36.2i10.9 
Plaque area (mm’) 7.7 * 5.0 26.8 f 12.5 27.1 * 8.6 
Plaque burden (%) 27&11 81 +14 4319 
The lesion/DlC arterial area ratio was attenuated in smokers (p = 0.03) 
suggesting an impact of smoking on arterial remodeling similar to coronary 
arteries. The lumen of the DIC (distal reference) measured 5.4 f 1.0 mm 
(range 3.5-8.0 mm). Final stent area (14.6 f 5.1 mm”) corresponded to an 
area stenosis (vs DIC lumen area) of 19 & 23%; the residual area stenosis 
correlated with the arc of lesion Ca (p = 0.0097). 11 stents were poorly 
apposed; there were 3 edge dissections. 
Conclusion: Carotid IVUS is safe. In pts undergoing carotid stent pro- 
cedures, IVUS provides unique insights into vessel size, plaque morphology 
(especially Ca), and distribution of atherosclerosis. 
4:45 p.m. 
El 83 4 Two Years Follow-up After lntracoronary Gamma 
Radiation Therapy for In-Stent Restenosis: Results 
From a Randomized Clinical Trial 
Ron Waksman, Larry R. White, Roxana Mehran, Alexandra J. Lansky, 
Ann Greenberg, Balram Bhargava, Lowell Satler, Kenneth K. Kent, 
Mandy Murphy, Martin B. Leon. Washington Hospital Center, Washington, 
DC, USA 
Background: The Washington Radiation for In-Stent Restenosis Trial 
(WRIST) is a double-blinded randomized trial assessing the effects of gamma 
radiation therapy (CRT) in pts with in-stent restenosis (ISR). 
Methods: 130 pts with pl episode of ISR (100 native coronary pts and 
30 vein graft pts) underwent PTCA, laser ablation, rotational atherectomy, 
and/or additional stenting (36%). Pts were randomized to achieve either 
192-h radioactive seeds or placebo. The prescribed dose was 15 Gy to a 
2 mm radial distance from the center of the source. Patients were followed 
clinically at 6, 12 and 24 months 
Results: Angiographic restenosis was dramatically reduced at 6 months 
in CRT pts. At 6, 12, and 24-month clinical follow-up, pts receiving CRT 
also had markedly lower target lesion and vessel revascularization (TLR and 
TVR) when compared with controls (see Table). Between 6 and 12 months, 
CRT pts had more late recurrences than placebo (TLR: CRT = ?9.3% vs 
placebo = no change and TVR: CRT = t7.6% vs placebo-no change). 
Two years follow-up was completed on 102/I 30 patients and detected only 
one additional TLR in the irradiated group and one TVR in the placebo 
group. 
Restenosis 
Control(65) 
R-192(65) 
P value 
6 mo Angie TLR TLR TLR 
6 m (%) l*m(%) 24 m (%) 
59% 63.1 63.1 83.1 
19% 13.8 23.1 26.2 
0.001 <0.0001 0.001 0.001 
Conclusions: In WRIST, CRT for pts with in-stent restenosis using an 
192-lr system is associated with a marked reduction in the need for repeat 
target lesion and target vessel revascularization at 6 months. Despite in- 
crease in the late recurrences in the irradiated group between 6-12 months, 
the clinical benefit of radiation for this patient cohort was well maintained at 
two years. 
500 p.m. 
I 83-5 Prevention of Distal Embolization During Interventions in CABG and Native Coronary Lesions 
Using a New Protection Filter Device 
Ulrich Gerckens, Ralf Mueller, Sabine Soblik, Thomas Wollweber, 
Eberhard Grube. Department of Carcfio/ogy/Angio/ogy Heart-Center 
Siegburg, Siegburg, Germany 
Background: Percutaneous interventions of CABGs and native coronary ar- 
teries carry the risk of distal embolization especially in degenerated and 
friable lesions. The AngioGuard’” Emboli Capture system consists of a 
guidewire-based filter device to capture and remove embolic debris with- 
out temporary vessel occlusion. 
Device Description: The AngioGuard’” Capture Guidwire system con- 
sists of a 0.014 PTCA wire with an expandable filter basket at the distal end. 
After crossing the target lesion the basket is expanded and the intervention 
can be performed in a standard manner. Plaque debris is captured within the 
distal basket and can be extracted using the AngioGuard” guidewire. The 
filter membrane allows a normal blood-flow during the procedure. 
Method: To evaluate the safety and efficacy of this new protection device 
we used the AngioGuard’” system in 24 Patients with CABG (n = 10) or 
coronary artery lesions (n = 14). In 23 lesions angioplasty with additional stent 
implantation was performed. Assessment of the TIMI flow was performed pre- 
and postintetventional. Serial CWCKMB values were obtained after 8, 16 and 
24 hrs. 
Results: In 23 of 24 patients (95.8%) the system could be safely placed, 
expanded and extracted. In one patient the device could not cross the target 
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lesion. in one case a pre-dilatation to place the system was necessary. We 
observed no in-hospital major cardiac events (AMI, urgent bypass surgey, 
death). In one patient discrete CK elevation (32/16 up to 102/i 8) occurred 
after the intervention. No postinterventional “no-reflow” was observed espe- 
cially in the CABG lesion group. The average TIMI flow increased from 2.0 to 
2.5. The TIMI flow during the procedures was unchanged except in one pa- 
tient. In this case the plaque material captured within the basket completely 
covered the filter membrane with temporary vessel occlusion. Macroscopi- 
tally visible debris was extracted in 20 cases. Single particles measured up 
to 2 x 2 mm. 
Conclusion: The AngioGuard’” Emboli Capture system can be safely 
used to retrieve plaque debris and prevents distal embolization and “no- 
reflow” phenomenon during interventions in degenerated bypass grafts with- 
out temporary vessel occlusion. Even in PTCAs in native coronaries we could 
demonstrate liberation of plaque material. 
163-6 1 See page 546A 
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/ 1040-75 / In-Hospital Outcomes Following Percutaneous 
Transluminal Coronary Angioplasty Versus Stent 
Placement for Acute Myocardial Infarction: New 
York State Experience 
Babak A. Vakili, David L. Brown. Albert Einstein College of 
Medicine/Montefiore Medical Center, Bronx, New York, USA 
Background: Percutaneous transluminal coronary angioplasty (PTCA) is 
effective treatment for acute myocardial infarction (MI). Although stent place- 
ment offers certain advantages over PTCA in the elective setting, little data 
is available to support the use of routine stent placement in acute Ml. 
Methods: Using the 1995 New York State Angioplasty Database, we 
compared the in-hospital mortality of all patients in New York state undergoing 
primary or rescue PTCA with that of patients treated with stent placement for 
a first Ml within 6 hours of symptom onset. 
Results: A total of 861 patients undergoing primary or rescue PTCA or 
stent placement for acute Ml were identified, of whom 706 (82%) had PTCA 
alone. Stent placement was performed in 155 patients (18%). Mean age 
was 60 years, 26% were female, 14% were diabetic, 48% were hypertensive 
and 29% were current smokers. A history of congestive heart failure (CHF) 
was present in 2%. There was no significant difference between PTCA and 
stent patients with regard to age, gender, hypertension, diabetes, smoking 
or CHF (p = NS for all comparisons). The frequency of left main coronary 
disease and three-vessel coronary disease did not differ between the groups. 
Balloon counterpulsation was required in 11% of PTCA patients and 8% of 
stent patients (p = 0.64). There was a trend toward more shock among 
patients treated with PTCA (7% vs. 3%, p = 0.09). Procedural complications 
including stroke, renal failure, emergency bypass surgery and transmural 
MI did not differ between PTCA and stent patients. In-hospital mortality was 
significantly lower for patients treated with stent placement rather than PTCA 
alone (0.6% vs. 5.2%, p = 0.02). 
Conclusion: Patients undergoing stent implantation for primary or rescue 
treatment of acute MI have significantly reduced in-hospital mortality. 
I 1040 76 Twenty-Year Follow-Up After Percutaneous Transluminal Coronary Angioplasty 
Andrea S. Abizaid, Amanda Sousa, Marinella Centemero, 
Alexandre Abizaid, Aurea Chaves, Luiz F. Tanajura, Ana Cristina Seixas, 
Eduardo Sousa. lnstituto Dante Pazzanese de Cardiologia, Slo Paula, 
Brazil 
We report the 20-year outcomes (death, Ml and target lesion revasculariza- 
tion) from a consecutive series of 180 patients (pts) treated from Decem- 
ber/i 979 to August/1983 with balloon PTCA in native coronary arteries. 
Methods: For all pts the technique used was braquial approach, Stertzer 
guiding catheter with a DG 20-3.0 Gruentzig balloon (a non-steerible sys- 
tem). The mean pressure was 6 atm and the mean inflation time was IO-30 
seconds. 
Results: Important clinical, angiographic and procedural characteristics 
were: median age 51 years, 80% men, 15% diabetes, 77% LAD, 72% prox- 
imal lesion location and all ACC/AHA type A/B1 lesions. By QCA analysis, 
the mean reference vessel diameter was 2.99 f 0.42 mm, the % diameter 
stenosis was reduced from 68.4 i 12.8% to 37.9 + 18.1% and the absolute 
gain was 1.08 rt 0.58 mm. Follow-up was obtained in 134 (87%) pts of 155 
pts treated successfully with balloon PTCA. At 20-year follow-up, 30% died 
(13% cardiac death), 9.7% had Ml (85% not related to the target lesion) 
and 15% had TLR at 4.5 f 2.1 months after PTCA (including 7% CABG 
and 8% re-PTCA). Thus, cardiac death, MI or TLR occurred in 50 (37.7%) 
pts. Non-TLR was required in 26.8% pts, including 17.9% CABG and 8.9% 
re-PTCA (mean = 7.2 years and 6.5 years after first PTCA, respectively). 
The two major causes of non-cardiac death were: cancer (45%) and cerebral 
vascular accident (20%). The probability of event-free survival was 89.6%, 
78% and 65% in 5, IO and 20 years, respectively. 
Conclusions: The long-term follow-up of patients treated with balloon 
PTCA shows low incidence of cardiac death (13%) and Ml (9.7%), mainly in 
the first 5 years. Need of any revascularization is more frequent during the 
first year (restenosis) and after 5 years (progression), probably reflecting the 
natural history of coronary artery disease. 
1 1040-77 1 Long-Term Clinical Outcomes of Percutaneous 
Coronary Intervention in Patients With Severe 
Left Ventricular Dysfunction 
Robert Siegel, Jennifer Vermillion, Ambika Bhaskaran, Barbara Barker, 
Alvin Nuttall, Paul Underwood, Tariq Khalil, Deborah Frazier, 
Stephanie Huemiller. Advanced Cardiac Specialists, Phoenix, Arizona, USA 
Severe left ventricular (LV) dysfunction (global LVEF < 30%) is associated 
with adverse morbidity and mortality outcomes in coronary heart disease 
(CHD). Percutaneous intervention (PTCA) in these subsets has historically 
been associated with low rates of procedural success and a high incidence of 
target lesion revascularization (TLR). We present our registry experience of 
PTCA in patients with hemodynamically significant CHD and severe LV dys- 
function. From 1196 to 7/99, we performed PTCA in 317 patients (23% female; 
mean age 64.9 years; range 25-81). Mean global LVEF at catheterization 
was 23.97%. Thirty six percent were direct infarct interventions and 36.8% 
presented with unstable angina. Comorbidities included prior MI, 43%; age > 
70 years, 37%; prior CABG, 25%; diabetes, 24%; multivessel disease, 21%; 
cardiogenic shock, 14.2%. The LAD was the target vessel distribution in 38%: 
50% lesions were ostial or proximal, subtending large myocardial volume. 
Adjunctive IABP support and appropriate inotropic support were employed 
in 43.5% cases. lntracoronary stents were deployed in 31% patients. 
Results: Procedural success was 93.1%. 
In-hospital events 1 -year Follow-up 
(mean hospital stay days (% complete; mean -months) 
Acute CABG Death Mt?.Xl TLR Death EFS Mean 
closure LVEF PTCAICABG LVEF 
r;.9%) (cl&%) (O.l%) 
‘27.67%’ 
(7!&, (S?i) (8:%) 
38.2%’ 
*p value significant at <O.OOOl; TLR: target lesion revascularization; EFS: event-free 
survival 
Conclusions: (1) Percutaneous coronary intervention can be performed 
safely with a high rate of success in a selected clinical subset of patients with 
hemodynamically significant CHD and severe LV dysfunction. (2) In-hospital 
event rates are tow. (3) At 1 -year follow-up, clinical restenosis rates (death, 
TLR, MI) are low and event-free survival is impressive. (4) There is very 
significant improvemenf in global LV systolic performance at 12-month follow 
up, suggesting that the aggressive treatment strategy for salvage of jeopar- 
dized hibernating myocardium may have contributed to improved acute and 
long-term clinical outcomes. 
1040-78 Mortality Trends in Single Coronary Percutaneous 
Intervention in the Prestent and Strent Eras 
Munir Zaqqa, Lance LaMotte, Willian Vaughn, Paolo Angelini. St Luke’s 
Episcopal Hospital and Bay/or College of Medicine, Houston, USA 
Purpose: In recent years, interventional cardiology has undergone numerous 
changes, the most prominent of which has been the advent of coronary 
stinting. The aim of this study was to assess the impact of current trend 
of stent use on all-cause mortality and on mortality related to intervention 
in the circumflex (Cx), left anterior descending (LAD), and fight coronary 
artery (RCA) vessels after percutaneous coronary intervention (PCI) (balloon 
angioplasty, stenting, or debulking) in single coronary vessel interventions. 
Methods: We retrospectively analyzed our institution’s registry data for all 
patients undergoing single PCI in 1993 (when the stent was bein introduced) 
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and in 1997 (when the use of stent was established with the general policy of 
“stenting when feasible”). Mortality rates were obtained at hospital discharge 
by reviewing medical records. 
Results: Over the period of study, the annual number of PCls increased 
from 1326 to 2181. The rate of coronary stenting increased from 2% (under 
an experimental protocol) to 59%, the rate of balloon angioplasty decreased 
from 94 to 34%, and the rate of debulking increased from 4 to 7%. IVUS was 
used in 3% of interventions in 1997. In the stent era, the all-cause mortality 
at time of discharge was significantly reduced in the whole group and in the 
RCA group (Table). 
Conclusions: There was a significantly decreased all-cause mortality 
between the prestent (1993) and the stent eras (1997) in single vessel PCI. 
The mortality difference was sagnificantly decreased for RCA intervention, 
borderline for LAD intervention, and not significant for Cx interventions. 
CX LAD RCA . All 
YfXir 1993 1997 1993 1997 1993 1997 1993 1997 
Number 329 512 563 917 434 752 1326 2181 
Death Rate 1.8% 2% 2% 0.8% 1 .8%* 0.1% 1.9%* 0.9% 
*P value for the difference between 1993 and 1997 ~0.05 
L-A 1040 79 Predictors for Late Death of Patients With Chronically Occluded Coronary Arteries 
Satoshi Shizuta, Yoshihisa Nakagawa, Takeshi Kimura, Takashi Tamura, 
Masashi Iwabuchi, Hiroyoshi Yokoi, Naoya Hamasaki, Hideyuki Nosaka, 
Masakiyo Nobuyoshi. Kokura Memorial Hospital, Kitakyushu, Japan 
Backgrounds: Despite relatively low primary success rate and high inci- 
dence of restenosis, PTCA of chronic total occlusion (CTO) is widely per- 
formed. However, its beneficial effect on late survival has not been clarified 
in previous reports. The objectives of this study were to determine the pre- 
dictors for late death of patients (pts) with CT0 and evaluate the impact of 
successful recanalization of CT0 on long-term survival outcome. 
Methods: CT0 was defined as follows; 1) TIMI flow = ~1, 2) Duration of 
occlusion >2 weeks, 3) Located in prox. and mid. LAD or in prox. Cx or in 
prox. and mid. RCA. Of 1055 pts with single CTO, 930 pts received PTCA 
of CT0 between Jan. 1989 and Dec. 1995 in Kokura Memorial Hospital, 
with a success rate of 64%. As a result, 597 CTOs were reopened and 458 
remained closed. The mean interval of follow-up was 5.4 + 2.5 years, 
Results: 
Risk factors HR for OD /95%CI) HR for CD 195%CI1 
Age (/year) 1.06 (1.04-l .09)*‘” 1.04 (1.01-l .07)* 
DM 1.90 (I .35-2.68)“” 2.15 (1.37-3.38)“* 
EF < 40% 2.61 (1.74-3.89)*** 3.81 (2.32-6.28)*** 
Creatinine >I .5 3.70 (2.22-6.17)“** 4.92 (2.6%9.22)*** 
WA 2.01 (1.19-3.41)** 2.81 (1.45-5.44)’ 
Unopened CT0 1.89 (1.33-2.67)** 2.02 (1.253.26)* 
HR;Hazard Ratio 0D;Overall Death CD;Cardiac Death. Cl; Confidence Interval * p < 
0.005 ** p < 0.001 *** p < 0.0001 
Conclusions: 1) Independent predictors for late overall and cardiac death 
of pts with CT0 were advancing age, poor LV function, renal dysfunction, 
diabetes mellitus, cerebrovascular disease, and unopened CTO. 2) Success- 
ful PTCA of CT0 improves long-term clinical outcome in terms of reduced 
overall and cardiac mortality. 
1 1040-80 1 Patient Characteristics and In-hospital Outcomes 
Following Angioplasty of the Left Main Coronary 
Artery: New York State Experience 
Michael S. Berlowitz, V.S. Srinivas, Babak A. Vakili, David L. Brown. Albert 
Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, 
USA 
Background: Percutaneous transluminal coronary angioplasty (PTCA) of 
the left main coronary artery (LMCA) is occasionally offered to patients who 
are poor candidates for surgical revascularization. However, little data is 
available regarding outcomes of LMCA PTCA. 
Methods: Using the 1995 New York State Angioplasty Database, we 
identified the characteristics and outcomes of all patients undergoing PTCA 
of the LMCA. Univariate and multivariate analyses were used to determine 
independent predictors of adverse outcomes. 
Results: In 1995, 154 PTCAs of the LMCA were performed. The mean 
age was 65.6 f 11 years; 79% were males, Diabetes was present in 21%, 
hypertension in 62% and a history of congestive heart failure (CHF) in 14%. 
The mean angina class was 3.3 IIZ 0.7 and the mean ejection fraction was 
39% f 20. Only 7% of patients had suffered a myocardial infarction within 
23 hours of the PTCA. CHF was present on admission in 13% of patients. 
Shock or hemodynamic instability was present in 11% of patients. The LMCA 
was unprotected in 53% of patients. The in-hospital mortality associated with 
LMCA PTCA was 7.4%. The incidence of a composite endpoint consisting of 
in-hospital mortality, emergency bypass surgery and stroke was 13%. Hemo- 
dynamic instability was the strongest univariate predictor of in-hospital mor- 
tality. Mortality of patients with hemodynamic instability was 58% compared 
to 7% in stable patients (p x 0.001). Multivariate analysis identified hemo- 
dynamic instability as the only independent predictor of in-hospital mortality 
following PTCAof the LMCA (OR 18.5,95% Cl 4.96-68.86, p < 0.001). 
Conclusion: PTCA of the LMCA in hemodynamically stable patients has 
relatively low mortality, which may be appropriate for certain patients who 
are not candidates for bypass surgery. 
1040-81 Outcome of Patients Undergoing Coronary 
Intervention at the Time of Diagnostic 
Catheterization: A Report From the 1999 Dynamic 
Registry 
Alice K. Jacobs, Warren K. Laskey, Helen Vlachos, Michael J. Cowley, 
David P. Faxon, David 0. Williams, Katherine M. Detre. Boston Medical 
Center Boston, MA, USA 
Percutaneous coronary intervention (PCI) is more’frequently being performed 
at the time of diagnostic catheterization (Ad-Hoc (AH)) PCI. To study the 
characteristics of patients undergoing AH vs scheduled (S) PCI and the 
impact on outcome, we evaluated 1630 patients in Wave 2 of the NHLBI 
Dynamic Registry of whom 983 (60.3%) (range 21.9-88.9%) underwent AH 
PCI in the absence of acute MI. There were no differences in age, gender, risk 
factors and comorbid or multivessel disease between groups. AH patients 
were more likely to have unstable angina (44.4 vs 34.9%, p < O.OOi), undergo 
urgent or emergency procedures (38.8 vs 27.1%, p < 0.001) and receive 
Ilb/llla receptor antagonists (35.7 vs 26.7%, p < 0.001) and were less likely to 
have diffuse disease (49.4 vs 61.8%, p < 0.001)) than S patients. Procedural 
characteristics are shown: 
Lesion Characteristics 
thrombus (%) 
calcified (%) 
o.stial (%) 
tortuousity (%) 
Lesion Success (%) 
stent (%) 
AH S 
n=1376 n = 885 
17.9 13.1 
24.7 30.3 
6.3 8.8 
26.2 30.2 
92.1 92.5 
66.5 67.9 
p value 
<O.Ol 
<O.Ol 
<0.05 
<0.05 
NS 
NS 
Procedural complications and the incidence of MI (2.7 vs 2.9%), emer- 
gency CABG (0.5 vs 0.3%) and death (0.9 vs 1.5%) were similar in AH and 
S patients respectively. Multivariate analysis revealed emergency procedure 
(Odds Ratio (OR) 4.3), operator assessment of high risk (OR 0.4), absence 
of diffuse disease (OR 1.5) and class C lesions (OR 1.6) to be significantly 
associated with AH. These data suggest that AH procedures are performed in 
the majority of patients (although incidence varies among sites) undergoing 
contemporary PCI and that angiographic and procedural differences between 
AH and S patients do not influence acute procedural outcome. The impact of 
this strategy on hospital costs and revascularization decision making needs 
further study. 
1040-82 The Effect of Hospital Volume on Long-Term 
Outcome After Percutaneous Transluminal 
Coronary Angioplasty 
Michel Doucet, Mark J. Eisenberg, Lawrence Joseph, Louise Pilote. 
Montreal General Hospital, McGill University, Montreal, Quebec, Canada 
Background: The effect of hospital volume on long-term outcome after PTCA 
is unknown. We studied the impact of hospital volume of PTCA on repeat 
PTCA, CABG, recurrent AMI and death 6 months after PTCA. 
Methods: We analyzed the physicians’ claims and discharge data of 
6,635 patients who underwent a PTCA after AMI between 1991 and 1995 
in Canada. For each administrative year, hospitals where the PTCA was 
performed were classified into three groups: low volume: <200/year, medium 
volume: 200-400iyear and, high volume >400/year. 
Results: Of 6,635 patients, 5% underwent PTCA in a low volume, 39% in 
a medium volume and 56% in a high volume hospital. Compared with patients 
in high and medium volume hospitals, patients in low volume hospitals were 
older, had a more recent AMI and were less likely to have been transferred 
for a PTCA. After adjustment for baseline differences, patients in the low and 
medium volume groups were more likely to undergo CABG within 6 months 
compared with patients in the high volume group (OR 2.1, 95% Cl 1.3-3.3 
and OR 1.5, 95% Cl 1.2-l .9, respectively). However, patients in the low and 
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medium volume groups were less likely to undergo repeat PTCA within 6 
months compared with patients in the high volume group (OR 0.37, 95% Cl 
0.24-0.58 and OR 0.8, 95% Cl 0.70-0.92, respectively). At 6 months, there 
was no significant difference in adjusted rates of repeat revascularization, 
recurrent MI or death between the three groups. 
Conclusion: We conclude that hospital volume does not affect adverse 
event rates at 6 months after PTCA. The higher rates of CABG in low 
volume hospitals and of repeat PTCA in high volume hospitals may represent 
different physician preferences for the treatment of failed PTCA rather than 
higher complication rates. 
1040-83 Outcome Study of Two Large Populations With 
Different Rates of Cardiac Interventions 
Peter R. Mahrer. Kaiser Permanente Medical Center, Los Angeles, CA, USA 
Background: There is a large variability in the rate of diagnostic cardiac 
catheterizations, catheter-based interventions and coronary bypass surgery 
(CABG) among industrialized nations, between U.S. and Canada and within 
the U.S. Outcomes generally have shown little correlation to the rate. Demon- 
strated differences were criticized because the populations had different ex- 
pectations. We compared a segment of a population in a metropolitan area 
with extensive cardiac resources which was insured with an HMO to the re- 
mainder of the population in terms of frequency of interventions and cardiac 
outcomes. 
Methods: In the Los Angeles Basin with a population of 14.9 million, 1.73 
million receive their care through the Kaiser Permanente Health Plan (K). All 
cardiac interventions are reported to the State of California. Data on cardiac 
mortality, mortality from acute myocardial infarction and hospitalizations for 
cardiac causes, we well as length of stay, are available. We identified the 
K and analyzed these outcomes in comparison to the remaining population 
(W 
Results: In the demographics of these populations there was an excess 
of poor and minorities in the NK cohort. In 1994 and 1995, the rate for 
catheterizations per 100,000 was 250 and 270 for K and 400 and 425 for 
NK. PTCA was 55 and 70 K compared to II 0 and 115 NK and 70 and 78 K 
versus 90 and 100 for NK in CABG. Previous MI mortality (1991-1993) for K 
was identical to risk stratified statewide mortality. In 1994-1995, total cardiac 
mortality was slightly lower for Ko The number of hospitalizations and length 
of stay and mortality from cardiac causes was lower for K than NK. 
Conclusion: Despite a lower rate of cardiac interventions among K, no 
detrimental effects can be seen in cardiac mortality or hospitalizations for 
cardiac causes. The generally better outcomes in K may be due to fewer 
poor or uninsured patients and the expertise of high volume tertiary centers. 
Adherence to ACC guidelines and increased utilization of medical therapy 
explains the lower rate of interventions in K. 
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1041-84 1 Stent Based Sirolimus Delivery Reduces 
’ Neointimal Proliferation in a Porcine Coronary 
Model of Restenosis 
Andrew J. Carter, Lynn Ft. Bailey, Gerard Llanos, Warren Lieuallen, 
Greg Kopia, George Papandreou, Pallassana Narayan, Robert Falotico, 
Steve Adelman, Martin B. Leon. Stanford University Medical Center, 
Stanford, CA: Washington Hospital Center, Washington, DC, USA 
Background: Sirolimus (rapamycin) is a potent anti-rejection agent that 
inhibits vascular smooth muscle cell proliferation by blocking cell cycle pro- 
gression. We hypothesized that local stent-based delivery of sirolimus would 
reduce in-stent neointimal hyperplasia after coronary stenting. 
Methods: Fifteen mm long stainless steel balloon expandable tubular 
slotted stents were coated with a 5 fi thick layer of a synthetic nondegradable 
polymer matrix containing sirolimus (Sir). Fifty-nine stents (bare metal, n = 
12; polymer coated, n = 12; polymer + Sir IX dose, n = 11; polymer + Sir 3X 
dose, n = 12; polymer + Sir 1X dose in asustained release matrix (Sir SR), n 
= 12) were implanted at a stent to artery ratio of 1 .I-1.2 to 1 in the coronary 
arteries of 22 juvenile swine. After 28 days, histologic analysis of the stented 
coronary arteries was completed to determine treatment effects. 
Results: see table 
Conclusion: Stent based delivery of sirolimus via a nondegradable poly- 
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Summary of histologic data 
Neointimal % Inflammation InJury score 
Group Area (mm*) Stenosis Score 
Metal 4.57* 0.46 40*4 0.54 i 0.21 0.76 i0.24 
Polymer 5.02 i 0.62 47 zt6 1.17* 0.37 1.11 i 0.32 
Polymer + Sir 1X 2.84 zt0.31*t 2713t 0.43 * 0.22 0.40f 0.16 
Polymer + Sir 3X 3.06 + 0,17*t 28+2t 0.22& 0.08f 0.33 i 0.10 
Polymer + Sir SR 2.77 i 0.41*t 24i4't 0.35 i- 0.19 0.49 * 0.27 
* p < 0.05 versus bare metal; t P = 0.05 versus Polymer 
mer matrix is feasible and effectively reduces late in-stent neointimal hy- 
perplasia. This novel strategy to prevent in-stent restenosis warrants further 
study to determine dose response kinetics and long-term effects. 
LiO41-85 1 Relation Between Tumor Necrosis Factor (TNF) 
Gene Polymorphisms and Thrombotic Events and 
Restenosis in Patients With Coronary Stenting 
Julinda Mehilli, Adnan Kastrati, Werner Koch, Corinna Bottiger, Nicolas von 
Beckerath, Albert Schomig. Deutscbes Helzzentrum and 1. Med. K/ink, JU 
Monchen, Munich, Germany 
Background: Recent findings suggest an important role for inflammation in 
the process of restenosis after percutaneous coronary interventions. TNFw 
is a proinflammatory cytokine with various biologic effects. AI/A2 and BIIB2 
are the better studied polymorphisms for TNF-or and TNF-b, respectively. 
There are data about the association between TNFA2 or TNFB2 alleles 
and the production of TNF-ol. We assessed whether there is an association 
between these polymorphisms and restenosis after coronary stenting. 
Methods: In 1850 consecutive patients with stenting, clinical and angio- 
graphic outcome measures were evaluated over 1 year after the intervention. 
TNFA and TNFB genotyping was performed based on the polymerase chain 
reaction technique. Six-month angiography was carried out in 84% of pa- 
tients Restenosis was defined as a ~50% diameter stenosis. Major adverse 
events (MACE) were defined as death, Q-wave and non-Q-wave myocardial 
infarction and need for revascularization. 
Results: The allele frequency was 0.16 for TNFA2 and 0.68 for TNFBP. 
Early and l-year clinical outcome as well as angiographic restenosis indexes 
were not significantly dependent on C/T genotype (Table). The rare TNFA2 
homozygotes showed a nonsignificant trend toward a higher incidence of 
restenosis compared to carriers of other genotypes. 
TNFAl/l TNFAlI2 TNFA212 TNFBl/l TNFBl/2 TNFBZ/2 
30.dav MACE. % 
1 -year MACE, % 
5.5 5.0 2.0 5.1 4.7 5.8 
24.5 22.7 29.4 23.0 23.4 25.1 
Restenosis, % 33.6 30.2 43.6 30.3 32.2 34.3 
Lumenloss, mm 1.20i0.85 1.2110.83 1.3610.80 1.1710.76 l.ZOf0.85 1.22+ 0.85 
Conclusions: These findings indicate no significant association between 
TNF-a- and TNF-fi-polymorphisms and thrombotic events or restenosis in 
patients with coronary artery disease treated with stenting. 
1 1041-86 1 Angiotensin Converting Enzyme Gene 
Polymorphism and Restenosis Rate After 
Coronary Stenting 
Markus Ferrari, Harald Mudra, Lars Grip, Vassilis Voudris, Peter de 
Jaegere, Volker Schachinger, Johannes Rieber, Dirk Hausmann, 
Martin Rothman, Dietmar H. Koschyk, Hans R. Figulla. On behalf of the 
OPJlCUS ACE-SUBS JUDV; Clinic of internal Medicine, Univ. of Jena & 
Clinic of Internal Medicine, Univ. of Munich, Germany 
Background: Recent publications have brought up the hypothesis that the 
ACE gene polymorphism may influence the level of late luminal loss after 
coronary stent implantation. 
Methods: As a substudy of the OPTICUS study (optimization with ICUS 
to reduce stent restenosis) we analyzed the ACE serum levels and the ACE 
gene polymorphism in 154 patients from 9 different centers. All patients 
underwent elective coronary stent implantation in a stenosis of a major 
coronary vessel. Balloon inflations were repeated until a satisfying result 
was achieved in online quantitative coronary angiography or intravascular 
ultrasound fulfilling the OPTCUS study criteria. After follow-up of 6 months 
all patients underwent reangiography. A blinded quantitative analysis of the 
initial procedure as well as the follow-up examinations were performed by an 
independent core lab. 
Results: According to the ACE gene polymorphism we formed 3 sub- 
groups: DD genotype (n = 86 patients), ID (n = 45) and II (n = 23). All sub- 
groups were comparable in age, gender, extend of coronary artery disease, 
initial degree of stenosis and degree of stenosis after stent implantation. 39 
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patients (25.3%) had significant restenosis: DD 22 pts. (25.6%), ID 8 pts. 
(17X1%), II 9 pts. (39.1%). The serum levels were: DD 0.39 fimol/l/.s, ID 0.36 
pmolllls, II 0.09 ~mol/l/s. 
Conclusion: In this multi center study we did not fred a higher restenosis 
rate in patients with D allele of the ACE gene. In addition, the ACE serum 
levels did not correlate with the restenosis rate. We conclude that the poly- 
morphism of the ACE gene is not a major factor of restenosis after coronaty 
stem implantation. 
I 1041 87 Polymorphisms of the Angiotensin Converting Enzyme and the Angiotensin II Type 1 Receptor 
Genes in In-Stent Restenosis. Is There a 
Synergism? 
Flavio Ribichini, Valeria Ferrero, Antonello Vado, Giuseppe Matullo’ , 
Paolo Russo, Giuseppe Steffenino, Antonio Dellavalle, Elena Colajanni’, 
Simonetia Guarrera’ , Eugenio Uslenghi. Divisione di Cardiologia, Ospecfale 
Santa Croce di Cuneo; ‘Istituto di Genetica Umana delt’(lniversit~ di Torino, 
ltaly 
Background: Activity of the renin-angiotensin system (RAS) is associated 
with the reparative process that follows vessel injuryein animal models. 
Angiotensin converting enzyme (ACE) and angiotensin II (Ang-II) play a 
role in the proliferative response of the vessel wall after balloon trauma. The 
D allele of the I/D polymorphism (poly) of the ACE gene is a neutral marker 
of enhanced ACE activity, and the C allele of the of the A/C poly of the Ang-II 
Type 1 receptor gene seems to modulate the intracellular signaling of Ang-Il. 
Methods: both poly were assessed in a consecutive cohort of stented pts 
scheduled for angiographic follow-up. Total occlusions (26 pts) and diabetic 
patients (81) were excluded. 
Results: A total of 644 pts were prospectively entered in this assessment 
of in-stent restenosis (R). Angiographic follow-up and genotyping were ob- 
tained in 609 pts (94.5%). The global R rate was 24.4%. R according to the 
I/D and A/C poly was distributed as shown in the table: 
Poly I/D D/D = 25.5% l/D= 17% l/l = 15.6% p < 0.03 
Poly A!c A/A = 17.4% A/c = 22.9% c/c = 18.8% p = ns 
A synergistic effect of the association between alleles encoding an en- 
hanced RAS activity (D and C) was investigated. The restenosis rate in D/D 
pts with or without associated C alleles was as follows: 
Polymorphisms A/A 
D/D (217 pts) 114 
I/D (302 pts) 170 
l/l (90 pts) 44 
%R 
26 (22.6%) 
29 (17.1%) 
2 (4.5%)* 
AK + c/c %R P 
103 29 (28.2%) NS 
132 22 (16.7%) Ns 
46 12 (26.1)%* 0.0004* 
l/l pts carrying at least 1 C allele of the A/C poly had an odds ratio for R = 
7.41 (95%CI: 1.55-35.4), with 2DF. 
Conclusion: No synergism was found between the D and the C allele in 
the occurrence of in-stent R; moreover, the highest R rate was observed in l/l 
pts carrying the C allele, what contrasts the low R rate of these pts. This finding 
indicates that the presence of the C allele in pts with low ACE activity (l/l) pre- 
dispose to R, through Ang-II Type-l receptor-mediated effects, independently 
of the ACE activity. These speculations are consistent with the presence of 
alternative pathways of Angll activation and stimulate further study. 
1 1041-881 Endothelial Nitric Oxide Synthase Gene 
Polymorphism is Positively Associated With 
In-Stent Restenosis 
Tomomichi Suzuki, Takahito Tomita, Hideo Matsui, Yukio Toki, Takayuki Ito, 
Kenji‘Okumura, Takahito Sone, HideyukiTsuboi, Junichiro Kondo, 
Tai Kousokabe. Nagoya University, Nagoya; Ogaki Municipal Hospital, 
Ogaki, Japan 
Background: Reduced or impaired synthesis of nitric oxide promotes the 
proliferation of vascular smooth muscle cells, and thus may induce the 
neointimal formation leading to in-stent restenosis. Recent reports have 
suggested that the Glu-Asp 298 polymorphism in exon 7 of the endothelial 
nitric oxide synthase (eNOS) gene is associated with coronary spasm and 
AMI. In this study, we have examined the implication of this polymorphism 
with regard to coronary restenosis after Palmaz-Schatz stent deployment. 
Methods: Eighty-nine lesions in 85 consecutive patients were treated 
with Palmaz-Schatz stents, and were prospectively allowed up for 6 months. 
Those lesions were classified into restenosis (% diameter stenosis 2 50%) 
group (R) and non-restenosis group (NR). Assessment was made using an 
automated quantitative angiographic system. We performed PCR/restriction 
fragment length polymorphism analysis to detect the missense Glu-Asp 298 
variant in exon 7 of the eNOS gene. 
Restenosis No restenosis 
rl=lS n=73 n 
AHA type 82/C lesions 
Small vessels (~3 mm in diameter) 
Multiple stenting 
Maximal balloon pressure > 16 atm 
Glu-Asp 296 vari&t 
56% 
56% 
44% 
44% 
38% 
48% 
56% 
27% 
27% 
12% 
“S. 
“.S. 
“.S. 
“.S. 
p < 0.05 
Results: Coronary risk factors and angiographic findings of stenotic le- 
sions did not differ between the groups. Univariate analyses showed that the 
missense Glu-Asp 298 variant was the only statistically significant predictor 
of restenosis (odds ratio, 4.27; p = 0.025). In addition, multivariate regression 
analysis revealed the missense Glu-Asp 298 variant as the only independent 
predictor for in-stent restenosis (odds ratio, 3.90; p = 0.036). 
Conclusion: The missense Glu-Asp 298 variant is an independent risk 
factor for in-stent restenosis. 
1 1041-89 ( Non-Invasive Heat-Delivery to Arterial Stented 
Segments In Vivo: Effect of Heat on lntimal 
Hyperplasia 
Christodoulos Stefanadis, Leonidas Diamantopoulos, 
Konstantinos Toutouzas, Eleftherios Tsiamis, Charalambos Vlachopoulos, 
Dorothea Tsekoura, Pavlos Toutouzas. Hippokration Hospital, Athens 
Universify, Greece 
Background: A new approach for the elimination of intimal hyperplasia is 
external non-invasive heat delivery to stented arterial segments. The purpose 
of this study was to evaluate the effect of heat on intimal hyperplasia after 
stent implantation in porcine coronary arteries. 
Methods: Heating of stented arterial segments was induced by a new 
method based on the properties of metals when placed into an alternative 
magnetic field. Accordingly, magnetic flux rapid alteration results in power 
loss to the magnetic circuit appearing as heat on the metallic stent in vivo. 
Thus, six Multilink’” stents were implanted in the LAD and 6 Multilink’” stents 
were placed in the LCx. The LAD stented segments had 15 cm distance from 
the induction coil and the LCx segments had 20 cm distance, respectively. 
The temperature of the itented segments was recorded in vivo by a thermog- 
raphy catheter that was previously validated (Circulation 1999;99:1965-71). 
All animals were sacrificed after 4 weeks and histomorphometty was per- 
formed. 
Results: By regulating the generator’s output power we achieved in-vivo 
heating of LAD stented segments of 55°C. In the LCx stented segments a 
temperature of 45 ‘C was achieved. In the LAD segments histomorphometty 
revealed extensive inflammatory and hyperplastic response. In contrast in 
the LCx segments the intimal hyperplasia was minimal without infiltration of 
inflammatory cells. 
Conclusions: This study demonstrates the effect of non-invasive heat 
delivery on metallic stents in porcine coronary arteries. Thus, external heat- 
ing of stents may reduce the hyperplastic response. However, the optimal 
temperature of stents needs to be determined. 
1041-90 Degradation of Metallic Alloys - A New Principle 
in Stent Technology? 
Bernd Heublein, Roland Rohde, Mathias Niemeyer, Volker Kaese, 
Wolfgang Hartung, Christoph R&ken. Hannover Medical School, Hannover, 
Germany 
Background: Degradable cardiovascular implants promise a reconstitution 
of vascular compliance, growth if necessary and allow steerable local drug 
delivery. Synthetic polymers produce a inflammatory proliferative response 
and contain drawbacks in their mechanical properties. We developed a new 
concept of degradation using magnesium alloys (MA) consisting of primary 
non-toxic components. We tested the in vivo degradation and the local 
response over time of one of the magnesium based alloys after intracoronary 
implantation in domestic pigs. 
Methods: 12 domestic pigs (15-25 kg), pretreated by 250 mg ticlopidine 
(T), 21 stents (S) (prototyp, mesh-design) implanted in LAD (9), Circumflex 
(9) and RCA (2); 250 mg T p.d., explantation after IO days (D) (4 S), 
35 D (7 S), 56 D (6 S). Quantitative angiography and IVUS-analysis at 
the time of explantation; histological analysis (methylacrylate inbedding), 
semi-quantitative corrosion analysis. 
Results: [I] The thrombogenicity was low (no acute, one subacute non- 
occlusive thrombosis). [2] The mechanical stability was to low over time lead- 
ing to some late stent-recoil phenomenon at 5 weeks interval. [3] No vessel 
occlusion over time. [4] Clear correlation between velocity of degradation 
(max. 5 weeks), severity of strut-injury and local inflammatory response. [5] 
Distinct positive remodeling combined with lumen re-enlargement after 8 
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weeks @CA) (mean relative lumen diameter 1 .Ol after 10 D, 0.69 after 35 D 
and0.83a~er56D;p(10Dvs35D~0.01:10Dvs56Dand35vs.56D 
ns.; Mann-Whitney-test). 
Conclusion: The bio-degradation of magnesium-based alloys may be a 
promising new technology to improve cardiovascular implants as temporary 
effective systems. Further improvements with respect to prolongation of 
degradation and the mechanical stability over time are necessary. 
) 1041-91 1 Immobilized Hyaluronic Acid as a 
Thromboresistant Coating for Cardiovascular 
Devices 
Stefan Verheye, Mahomed Y. Salame, Keith A. Robinson’, Barbara Wan’, 
Cindy Nickersona, Kevin Ski nnere, Spencer B. King III, Stephen R. Hanson, 
Nicolas A.F. Chronos’ ‘Aflanta Cardiovascular Research Institute, Atlanta, 
Georgia; “Genzyme Corporation, Cambridge, Massachusetts, USA 
Background: Stainless steel is highly thrombogenic and may lead to in- 
creased closure rate after coronary stenting. Coating stents with a biocom- 
patible and non-thrombogenic material may solve this problem. Hyaluronic 
acid (HA) has been shown to inhibit platelet aggregation and adhesion when 
administered systemically. Since the effect of coating tubes (T) and stents 
(S) with immobilized HA is unknown, we assessed their thrombogenicity and 
compared these results with uncoated controls. 
Methods: Thrombosis was assessed in non-human primates by contin- 
uous “‘In-piatelet imaging using a y-camera over 2 h during exposure of 
coated and uncoated stainless steel T (4 mm diameter, n = 8) and S (3.5 mm, 
8 control, 4 HA-coated) to non-anticoagulated blood (100 ml/min) in exteri- 
orized arteriovenous shunts. Time course of platelet deposition is presented 
ae mean f SD. 
Results: Two-way ANOVA to compare the effect of coating or time found 
that coating T with HA resulted in a significant decrease in platelet deposition 
(p < 0.001). HA-coating of S resulted in a trend towards decreased platelet 
deposition (p = 0.06). 
Conclusions: Immobilized HA significantly reduced local platelet depo- 
sition on stainless steel T and tended to decrease platelet deposition on S 
in the primate ex viva shunt model. Immobilized HA may therefore provide a 
thromboresistant coating material for cardiovascular devices. 
L--L.-R 1041 92 Extent of Late Angiographic Luminal Loss 
Following Carotid Artery Stenting 
Fayaz A. Shawl, Fernando Lapetina, Waleed Y. Kadro, Stephanie Cornell, 
Yan Huang, Kathryn G. Dougherty. Washington Adventist Hospital, Takoma 
Park, Maryland, USA 
Background: Carotid stenting (CS) has been shown to be safe and effective 
in treating severe carotid artery stenosis. Restenosis has been the main com- 
plication of percutaneous angioplasty (PA), even after stenting. Restenosis 
would be a difficult challenge after CS. The angiographic restenosis and late 
luminal loss, however, is unknown. 
Methods and Results: Among 176 consecutive pts who underwent CS 
between 8/95 and 8/98, 163 (93%) pts had angiographic follow-up at ~6 
months (mean 9 f 4 months, range 6-15). There were 135 males and 
the mean age was 72 i IO yrs. Angiographic restenosis (>50% stenosis) 
occurred in 6 pts (3.6%). All were successfully treated with PA (n = 3) and 
stent (n =3). Cummulative frequency distribution for minimal luminal diameter 
before and after CS and at F/U is shown with a late luminal loss of 1.23 f 
0.34 mm. 
Conclusion: The late angiographic luminal loss following CS is favorable 
and the late restenosis rate appears low. 
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/ 1042 109 A Novel Catalytic DNA Molecule Targeting The Transcription Factor Egr-1 Inhibits Neointimal 
Formation Following Rat Carotid Angioplasty 
H.C. Lowe, F.S. Santiago, C.N. Chesterman, L.M. Khachigian. Centre For 
Thrombosis And Vascular Research, The University of New South Wales, 
Sydney, Australia 
Background: In-stent restenosis is the result of neointimal formation, de- 
pendent on medial smooth muscle cell (SMC) migration and proliferation, in 
response to the mechanical vascular injury of angioplasty and stenting. Egr-1 
is a transcription factor recently recognised as playing an important role in 
the regulation of a number of genes involved in vascular injury. We have 
recently developed a novel catalytic DNA molecule, ED5, which selectively 
targets Egr-I mRNA. 
Aim: To determine whether targeting Egr-I mRNA using ED5 would inhibit 
neointimal formation following balloon angioplasty to the rat carotid artery. 
Methods: Adult male Sprague Dawley rats underwent balloon angioplasty 
to the left common carotid artery. The DNA enzyme ED5, its scrambled 
counterpart (ED5 SCR) or vehicle alone (VEH) were delivered adventitially in 
pluronic gel with transfecting agent, 6 hours prior to, and again at the time of 
injury. Neointimal and medial areas were measured at 14 days. In a separate 
group of animals 1 hour following injury and drug delivery, carotid sections 
were examined for Egr-I protein expression by immunohistochemistry In a 
third group of animals, fluorescein isothiocyanate (FITC) tagged versions of 
the same drugs were delivered in an identical manner, and sections imaged 
under confocal microscopy. 
Results: FITC labelled ED5 and ED5 SCR localised within the smooth 
muscle cells in the media. Egr-I protein expression and neointima:media 
ratios were significantly reduced in the ED5 group, compared to the other 
groups. 
Group Neointima:media ratio (n = 5) Egr-1 Expression (n = 2) 
ED5 0.31 (o.ll)* + 
ED5 SCR 0.62 (0.13) +++ 
VEH 0.72 (0.15) +++ 
BALLOON ONLY 0.71 (0.17) +++ *p < 0.05 
Conclusions: The DNA enzyme ED5 is capable of localising to SMCs 
following adventitial delivery. ED5 inhibits Egr-I protein expression and neoin- 
timal formation following balloon angioplasty in the rat. These findings imph- 
cate DNA enzymes as potential inhibitors of restenosis. 
1042-l IO Sustained Expression of Chemokines Monocyte 
Chemoattractant Protein-l And Interleukin-8 
After Stent- But Not Balloon-Induced Arterial 
Injury 
John F. Paolini, Michael A. Kjelsberg, Elazer R. Edelman, Campbell 
D.K. Rogers. Health Science Technology, Harvard/Massachusetts Institute 
of Technology, Cambridge, Massachusetts; and Brigham and Women’s 
Hospital, Boston, Massachusetts, USA 
Background: Experimental and human data implicate early inflammatory 
cell recruitment in intimal thickening after mechanical arterial injury, with 
different responses to different injuries. 
Methods: To identify pro-inflammatory signals in vessels injured by bal- 
loon angioplasty or stenting, New Zealand White rabbits underwent iliac 
artery balloon injury (81) or deeper stent-induced injury (SI). Four or 8 hours, 
or 14 or 28 days after injury arteries were harvested and frozen, and RNA 
was prepared by acid-phenol extraction. MCP-I and IL-8 mRNA levels were 
determined by semi-quantitative reverse-transcriptase PCR, normalized to 
expression of the ribosomal gene 36B4, and compared to uninjured levels. 
Results: After BI, MCP-I mRNA levels peaked at 4 hours (5X control) and 
returned to baseline by 8 hours. IL-8 mRNA levels followed a similar pattern 
with lower magnitude. After SI, MCR-1 mRNA levels were markedly elevated 
at 4 hours (12X control), 8 hours, and even 14 days after injury, returning to 
baseline by 28 days. IL-8 mRNA levels were elevated more transiently. 
Conclusions: 1) Stenting induces a more profound and prolonged in- 
flammatory chemokine response than balloon injury. 2) MCP-I but not IL-8 
mRNA levels remain elevated for weeks after stent implantation. 3) Measur- 
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ing and targeting chemokine expression or action may be valid approaches 
to modulating vascular repair. 
I-I 1042 111 Effect of a Recombinant Soluble P-Selectin Glycoprotein Ligand-1 Chimera on Restenosis 
Follotiing ArterLal Injury by Repeat Angioplasty 
in Pigs 
Jean-Guy Bienvenu, Jean-Francois Tanguay, Jean-Franpois Theoret, 
Anjali Kumar, Robert G. Schaub, Yahye Merhi. Montreal H&-f Insfifute, 
Montreal, Quebec, Canada; Hemostasis/lmmunolog~ Genefics Institute, 
inc., Andover, MA, USA 
Background: P-selectin mediates leukocyte recruitment to activated platelets 
and endothelial cells via its high affinity counter-receptor P-Selectin Glyco- 
protein Ligand-I (PSGL-1). Platelet accumulation, leukocyte activation and 
formation of platelet/leukocyte complexes have been previously reported fol- 
lowing coronary angioplasty and were correlated with the occurrence of late 
clinical events. Selectin antagonism or P-selectin deficiency resulted in a 
smaller percent area stenosis in models of arterial injury or vascular remod- 
eling, rPSGL-lg is a recombinant soluble form of PSGL-1, fused to a human 
IgGt In this study, the effect of rPSGL-Ig on the development of restenosis 
4 weeks following arterial injury by repeat angioplasty was investigated. 
Methods: Balloon angioplasty was performed in both carotid arteries of 
cross-bred pigs. Animals were recovered for 4 weeks during which neointimal 
lesions developed at injury sites. Repeat angioplasty was then performed at 
the same sites 15 minutes following a single i administration of either vehicle 
(formulation buffer) or rPSGL-lg (1 mgfkg IV, half life of 10 days in pigs). 
Animals were sacrificed at 1 hour, 1 week or 4 weeks following the second 
angioplasty. Adhesion of autologous 51 Cr-platelets and “’ lnneutrophils was 
quantified. Morphometric analysis was performed on arterial sections from 
the 4 week group of pigs. 
Results: rP.SGL-lg reduced adhesion of platelets (by 85%) and neu- 
trophils (by 75%) in deeply injured arterial segments 1 week following repeat 
angioplasty, but did not affect the acute adherence of these cells 1 hour 
post-injury. At 4 weeks, the residual lumen in deeply injured segments was 
60% larger in the rPSGL-Ig treated pigs as compared to control (6.1 f 0.6 vs 
3.8 f 0.1 mmp; p < 0.01). This difference was not due to a smaller neointimal 
area (0.5 f 0.1 vs 0.7 f 0.1 mm*). However, the ratio of the external elastic 
lamina surface in deeply injured to uninjured vessel segments was 1.5 f 
0.1 in the rPSGL-lg group vs 0.9 f 0.05 in the control group (p < 0.01) 
suggesting some effect on compensatory remodeling. 
Conclusion: These results suggest that P-selectin antagonism using 
rPSGL-lg may inhibit early platelet/leukocyte adhesion at the site of injury 
and positively impact vascular remodeling, both of which contribute to late 
lumen loss. Hence, rPSGL-Ig may have potential in the management of 
restenosis. 
L--l-l 1042 112 Fucoidan Inhibits Smooth Muscle Cell Proliferation And Migration And is Suitable For 
Coating of Stents 
Ralf KBster, Kai Gutensohn, Jan Diirig, Jan Klhler, Stephan Baldus, 
Thomas Bruhn, Christian W. Hamm, Peter Kiihnl, Thomas Meinertz. 
University Hospital Eppendorf Hamburg, Germany 
Proliferation and migration of smooth muscle cells are mechanisms of reste- 
nosis after coronary intervention. Both processes are stimulated by platelet- 
derived growth factors released from platelets. Fucoidan is a polysaccharide 
with fractions of high molecular weight (HMWF) (IOO-150kD) and low molec- 
ular weight (LMWF) (50kD). We investigated the effects of these fractions 
on smooth muscle cell proliferation and migration, platelet activation and 
aggregation. 
Proliferation of cultured human vascular smooth muscle cells incubated 
with different fucoidan fractions was analyzed by growth assays, migratory 
activity was measured by Boyden chamber assays. Platelet rich plasma was 
incubated with HMWF and LMWF and platelet activation-dependent expres- 
sion of P-selectin and glycoprotein P53 was quantified by flow cytometry 
with CD62p and CD63 antibodies Platelet aggregation was measured by 
turbidimetry. 
Serum-induced proliferation of smooth muscle cells was inhibited by 
HMWF and LMWF (HMWF: 52 f 6%, LMWF: 68 i 6% vs control, P < 
0.01). Platelet-derived growth factor B (PDGF-B) induced proliferation could 
be completely inhibited by HMWF and LMWF (P < 0.01). Migration was 
equally decreased by both fucoidan fractions (maximum inhibition by LMWF: 
59 + 7%, P < 0.05). Platelets were only slightly activated by LMWF and 
HMWF (+I0 + 2% and +12 f 3% CD62p signals; +8 & 1% and +9 f 2% 
CD63 signals, P < 0.05). Platelet aggregation was stimulated by HMWF 
(+45 I 15% increase of light transmission, P < 0.05), whereas LMWF did 
not induce a significant change of platelet aggregation. 
Conclusions: Fucoidans inhibit proliferation and migration of vascular 
smooth muscle cells. The antiproliferative effect may partially be explained 
by the inhibition of PDGF-B action. The low molecular weight fraction may 
be useful for the prevention of restenosis and for coating of stents. 
L-L-i 1042 113 Fludarabine, A Stat-l Inhibitor, Abolishes Smootn Muscle Cell Proliferation In Vitro And 
Prevents Neointimal Formation In Wvo 
Daniele Torella, Ciro Indolfi, Marco Pascotto, Angela Maria Stingone, 
Eugenio Stabile, Cinzia Perrino, Alfonso Pisani, Luigi Cavuto, 
Antonio Curoio, Massimo Chiariello. Division of Cardiology, Federico /I 
Universi@ Naples, Italy 
Background: Vascular smooth muscle cell (VSMC) proliferation is a major 
mechanism of neointimal formation after balloon angioplasty and is the only 
mechanism responsible for restenosis after arterial stenting. JAK-STAT in- 
tracellular signaling enhances VSMC proliferation and its inhibition reduces 
proliferative activity of VSMCs in vitro. Furthermore, previous studies have 
demonstrated that a nucleoside analog, Fludarabine (Fludara), causes a 
specific depletion of STAT-l protein (and mRNA) in human lymphocytes. The 
aim of our study was to assess the effects of Fludara on VSMC proliferation 
in vitro and in vivo. 
Methods: To study the effect of Fludara on VSMC proliferation in vifro, 
smooth muscle cells from rat aortic artery (AIO) were used. Cells were grown 
in the presence of 0.05, 0.5, 5, 50, 500bM Fludara or in the absence of the 
same (control). Cell number in all conditions was assessed every 72 hr for 6 
days. In order to evaluate the in vivo effect of this drug, balloon injury of the 
carotid artery of 20 Wistar male rats (350 g) was induced using a 2F Fogarty 
balloon and Fludara (5 mg) was locally delivered at the time of injury in IO 
rats (Group FLU). In the other IO rats only saline solution was delivered at 
the time of injury (Group CON). 
CON FL” CON PI.” 
Results: Fludara markedly inhibited VSMC proliferation in cell culture in 
a dose dependent manner. Furthermore, Fludara reduced neointimal area 
from 0.195 f 0.016 mm* (CON) to 0.095 i 0.030 mm* (FLU), *p < 0.001 and 
neointimdmedia ratio from 1,467 f 0.099 (CON) to 0.688 & 0.218 (FLU), *p 
<: 0.001 after balloon angioplasty (see figure). 
Conclusion: We demonstrated for the first time that local administration 
of Fludarabine, a specific STAT-l inhibitor, abolishes VSMC proliferation in 
vitro and reduces neointimal formation after balloon injury in viva. These data 
may have a clinical relevance in the prevention of restenosis after stenting 
and perhaps after PTCA. 
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1043-I 14 Predictors of lntimal Hyperplasia After Stenting: 
Serial IVUS Study 
Myeong- Ki Hong, Seong-Wook Park, Cheol Whan Lee, Duk-Hyun Kang, 
Jae-Kwan Song, Jae-Joong Kim, Seung-Jung Park. Department of 
Medicine, University of U/San, Asan Medical Center, Seoul, Korea 
We evaluated the predictors of intimal hyperplasia (IH) after coronary stent- 
ing. Pre- and post-intervention, and follow-up IVUS images were obtained in 
59 patients (pts) with single stent implantation (GFX in 34 pts and NIR in 25 
pts). Eight IVUS image slices were selected with equal distance within stent 
for serial comparisons. Total 472 matching images were obtained. Pre- and 
post-intervention IVUS variables such as EEM, lumen and P+M CSA, plaque 
burden (P+M CSA/EEM CSA), remodeling index (lesion/proximal reference 
EEM CSA at preintervention), vessel stretch{(post-intervention - pre-inter- 
vention) EEM CSA} and % vessel stretch (100x vessel stretch/pre-intervention 
EEM CSA) were entered into multivariate linear regression analysis model 
to predict % IH (100 x IH CSAfstent CSA at follow-up). 
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Conclusions: The independent predictors of % IH were pre-intervention 
plaque burden (r = 0.217, p c 0.001) and vessel stretch (r = 0.129, p < 
0.001). 
/ 1043-115 1 Prognostic Significance of Left Main Disease 
Assessed by 3-Dimensional IVUS 
Kelly M. Choi, John M. Pang, Lynne M. Goodreau, Karen S. Pieper, Charles 
J. Davidson. Northwestern University Medical School, Chicago, IL, USA 
To determine the long-term prognosis of patients with angiographically in- 
significant left main coronary artery (LMCA) disease, 107 consecutive pa- 
tients were evaluated with 2-D and 3-dimensional intravascular ultrasound 
(IVUS). IVUS was performed by automated pullback following left coronary 
artery (LAD 85%, LCX 15%) intervention (stent = 88%, balloon = 6%, and 
atherectomy 6%). 
IVUS images were digitized and 3-dimensional reconstruction was per- 
formed. Minimum and mean lumen area, vessel area, maximum % stenosis 
(plaque area + vessel area), and relative plaque burden (total plaque volume 
f length of LMCA) were assessed for the entire length of the LMCA. LMCA 
angiography was analyzed in the worst view by QCA. 
Long-term follow-up was available in 102 (95%), at a median follow-up of 
31 (range 8 to 53) months. MACE was defined as death (n = 6), MI (n = 3), 
repeat PTCA (n = 13), or CABG (n = 16). 
Results: 
IVUS Mean Chi Square Hazard RatiQ P 
Min. Lumen Area (mm*) 15.6 * 5.6 8.1 0.59 (0.40,0.88) 0.004 
Mean Lumen Area (mm”) 17.6i5.6 7.0 0.62 (0.43,0.90) 0.008 
Area Stenosis (“A) 30.5 5 14.5 0.72 1.1 (0.87,1.4) 0.40 
Relative Plaque Burden 4.9 i3.0 0.01 1 .O (0.56,i.g) 0.90 
Angio 
MLD (mm) 4.3io.9 4.2 0.59 (0.35,l.O) 0.04 
Area Stenosis (%) 17.6 f 9.7 0.02 1.0 (0.67,1.6) 0.90 
In the multivariate stepwise logistic regression model, only minimum Iu- 
men area by IVlJS was predictive of MACE (p = 0.004). 
, E”.nt-Fr** suwivrl au Mi”*n.l L”R*” I,.. ;...-...-- ..__...___.__ --- _______ -_---- ...-.- - _-__-._ -? 
Thus, in pts. undergoing PTCA of the left coronary system, 3-dimensional 
lVUS quantitation of the LMCA provides independent prognostic information 
that is not available from contrast angiography. 
1043-l 16 Diabetes And Ostial Lesion Location Have an 
Additive Effect on Target Lesion 
Revascularization Aft& Stent Implantation 
Gary S. Mintz, Roxana Mehran, Michel Jackson, Alexandra J. Lansky, 
Kenneth M. Kent, Martin B. Leon. Washington Hospital Center, Washington, 
DC, USA 
Both diabetes (DM) and ostial lesion location are reported risk factors for 
in-stent restenosis. To determine whether the combination of these two risk 
factors has an additive effect, we analyzed target lesion revascularizatinon 
(TLR Q lyr) in 2242 patients with 2853 lesions treated with intravascular ul- 
trasound (IVUS)-guided implantation of tubular-slotted or multicellular stents. 
IVUS final lumen areas were smaller in DM vs nonDM patients (7.2 f 2.4 
mm* vs 7.7 It 2.5 mm’, p = O.OOll), but larger in ostial vs nonostial lesions 
(8.5 f3.2 vs 7.5 i 2.3 mm?, p < 0.0001). Thus, the higher TLR in DM 
vs nonDM pts (17.2% vs 10.6%, p < 0.0001) can be explained in par? by 
the smaller final lumen area. However, the higher TLR in ostial vs nonostial 
lesions (17.4% vs 12.0%, p = 0.0231) occurred despite the larger final lu- 
men area. Importantly, ostial lesions in DM patients were associated with the 
highest TLR (p < 0.0001) which did not parallel the variations in IVUS final 
lumen area among the four groups (p < 0.0001): 
We conclude: DM and ostial lesion location had an additive effect on 
TLR that cannot be explained by differences in final lumen areas. This led to 
a strikingly high clinical restenosis rate (24%) suggesting that DM and ostial 
lesion location have a synergistic effect in promoting in-stent neointimal 
hyperplasia. 
/ 1043-l 17 ( Impact of The Vessel Size And Procedural Result 
on The Long Term Outcome Following Coronary 
Stenting 
Khaled M. Ziada, Samir R. Kapadia, Guido Belli, Penny L. Houghtaling, 
Patrick L. Whitlow, Irving France, Stephen G. Ellis, Steven E. Nissen, E. 
Murat Tuzcu. The Cleveland Clinic Foundation, C/eve/and, OH, USA 
Background: The final result of stenting procedures may have an impact 
on long term outcome. The prognostic value of the different quantitative 
measures of the procedural result remains unclear. 
Methods: Successful stenting with adjunctive intravascular ultrasound 
(IVUS) was performed in 234 consecutive pts, including 40 (17%) in vein 
grafts. At a median follow-up of 2.3 years, 48 (20%) patients required repeat 
revascularization (TVR). Quantitative angiography (QCA) was performed on 
pre- and post-stenting angiograms. A final post-stenting IVUS was analyzed. 
Cox logistic regression was used to identify predictors of TVR. Receiver 
operator curves for reference diameter and quantitative measures of the 
procedural result were plotted. 
Results: Reference diameter was 3.0 & 0.5 mm. QCA final minimum 
lumen diameter was 2.9 f 1.9 mm and minimum lumen area by ultrasound 
was 7.2 f 2.4 mm*. SVG and minimum area by ultrasound were the only 
predictors of TVR (relative risk 2.9 [I .5, 5.41 and 0.72 [0.6, 0.81, respectively). 
Areas under the curve (AUC) for quantitative measures were: 
Ultrasound minimum lumen area (mm’) 
QCA reference diameter (mm) 
QCA final minimum lumen diameter (mm) 
Ultrasound stenffdistal reference area (%) 
Ultrasound stentlmean reference area &) 
0.66t 
0.64 t 
0.62 t 
0.56 
0.53 
Larger AUC values indicate better sensitivity & specificity, f P = NS 
\ Conclusions: Minimum lumen area by ultrasound was a better predictor 
of TVR than other quantitative measures of the procedural result. However, 
none of these measures was superior to reference vessel size, emphasiz- 
ing the importance of vessel size in determining the long-term outcome of 
stenting. 
1043-I 18 Time Dependent Morphologic Characteristics in 
Anaioaraohic Chronic Total Coronarv 
Ock~~ok: An Intravascular Ultrasdund Study 
Takeshi Suzuki, Hiroaki Hosokawa, Koichi Yokoya, Takahilo Suzuki. 
Sfanford University, Stanford, California, USA; National Toyohashi Higashi 
Hospital, Toyohashi, Japan 
Background: Chronic total occlusion lesions (CTO) of the coronary artery are 
frequently difficult to cross and are at high risk for acute reocclusion or chronic 
vessel renarrowing. The aim of this study was to evaluate the influence 
of occlusion duration on coronary calcification in CT0 using intravascular 
ultrasound (IVUS). 
Methods: We performed IVUS in 70 CTOs at pre-procedure or after 1.5 
mm balloon dilation. IVUS images were obtained with a motorized pullback 
speed of 0.5 mm/set, and arc and length of calcification in lesions were 
measured. CT0 is defined as lesions occluded for a period of 2 weeks or 
more, and TIMI-O or TIMI-I flow. 
Results: As the figures indicate, old CTOs have considerably more cal- 
cification with a longer length and a larger arc (see figure next page). 
Conclusion: These results suggest that older CTOs have more complex 
plaque components including a large calcific burden. This may explain the 
adverse revascularization profile of older CTOs. 
18A ABSTRACTS - ACCIS2000 
Arc vs Occlusion duration 
N=70. P~0.01 
1043-l 19 Influence of Calcium on Coronary Dissection 
Following Cutting Balloon Angioplasty: 
An Intravascular Ultrasound Study 
Shinichi Shimodozono, Hiroyuki Okura, Motoya Hayase, Hiroaki Hosokawa, 
Takahiko Suzuki, Tetsu Yamaguchi, Paul G. Yock, Peter J. Fitzgerald. For 
the REDUCE Investigators: Stanford University Medical Center, Stanford, 
CA, USA 
Previous intravascular ultrasound (IVUS) studies have demonstrated that the 
presence of calcium within the vessel wall is strongly associated with both 
the location and size of the dissection following balloon angioplasty (BA). 
The Cutting Balloon (CB) has been shown to achieve an efficient lumen gain 
by creating a controlled dissection within the vessel wall. The aim of this 
study was to clarify the size and location of coronary dissection following CB 
in calcified coronary segments. 
Methods: A total of 89 patients (50 CB and 39 BA) from the REstenosis 
ReDUction by Cutting Balloon Evaluation (REDUCE) trial were analyzed 
using IVUS. IVUS images were obtained throughout the tight segment and 
matched to the segment. The presence of intralesional calcium and the 
relative of dissection for each lesion were compared. For each cross section, 
the area of the dissected tissue arm was measured, divided by the neolumen 
cross sectional area, and expressed as a ratio (dissection area index, DAI). 
Results: Target lesion calcification was detected in 17 of 39 (43%) cases 
in the BA group and in 28 of 50 (56%) in the CB group. The percentage of 
these patients in which the dissection was adjacent to the calcific portion of 
the vessel wall trended to be smaller in the CB group compared to the BA 
group (64% vs. 82%, p = 0.19). In the BA group, DAI was significantly larger 
in the calcified vessels than those in the non-calcified vessels (22 & 15% vs. 
12 & 12%, p < 0.05). However, in the CB group, there was no difference in 
DAI between the calcified vessels and the non-calcified vessels (13 i 12% 
vs. 12 f lo%, p = NS). 
Conclusions: Vessel dissection after CB was less dependent upon cal- 
cium deposits compared to conventional BA. The size of dissections with CB 
is less than BA. CB vessel arm is less dependent a calcium deposits. These 
finding suggests that the CB may be preferable for calcified lesion to the 
conventional BA in terms of the risk of large dissection caused by balloon 
inflation. 
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L.l--l 1062 75 Predictors of Late Clinical Outcomes in Patients With Unstable Angina Undergoing Percutaneous 
Coronary Interventions 
Javed M. Ahmed, Roxana Mehran, George Dangas, Mun K. Hong, 
Manuela Negoita, Alexanda J. Lansky, Hassan Faraj, Nasra Hashmi, 
Petros Okubagzi, Navita Modi, Michael Astatkie, Kenneth M. Kent, Neil 
J. Weissman, Bryan Curry, Frank Kiipper, Lowell F. Satler, August0 
D. Pichard, Kenneth M. Kent, Gregg W. Stone, Martin 8. Leon. 
Cardiovascular Research Foundation, Washington, DC, USA 
Background: Patients with unstable angina (UA) have an increased risk of 
restenosis after percutaneous coronary interventions (PCI). However, pre- 
dictors of late events (death, Q-wave MI and any revascularization) and of 
target lesion revascularization (TLR) in these patients are not known. 
Methods: We studied 597 patients with UA who underwent IVUS guided 
PCI. Baseline characteristics included age 69 * 8 years, 65% male, 25% dia- 
betes (11% insulin-treated), 58% hypertension, 36% left anterior descending 
(LAD), and 10% ostial lesions; 54% were treated with stems. 
Results: By quantitative angiography, reference lumen diameter was 3.0 
f 0.53 mm and final diameter stenosis was 13.3 & 15.1%. Final lumen cross- 
sectional area (CSA) by IVUS was 7.3 * 2.5 mm’. At one-year follow-up TLR 
was 24% and major adverse cardiac event (MACE) rate was 28%. Indepen- 
dent predictors of one year TLR and MACE are shown in the table. 
Predictors of TLR OR P Predictors of MACE OR P 
Diabetes 1.99 <O.Ol Diabetes 1.96 co.01 
Final lumen CSA 0.81 <O.Oi Final lumen CSA 0.82 <O.Oi 
LAD 1.54 <O.Ol 
Male gender 1.56 0.01 
Conclusion: The most powerful predictors of late cardiac events and TLR 
in patients with UA are diabetes and final luminal CSA by IVUS. In addition 
TLR is higher in males and in LAD lesions. 
( 1062-76 1 Five-Year Outcome in Patients Treated by PTCA: 
A Comparison of Non-Diabetic Lesions to 
Diabetic Lesions 
Sou Takenaka, Nobuaki Nakamura, Nobuo Shiode, Kinya Shirota, 
Hiromi Suyama, Yasutoshi Goto, Yoshio Nakazawa, Katsumi Inoue, 
Tsutomu Nagamatsu. Matsue Red Cross Hospital, Matsue, Japan 
Backgrounds: Despite the increasing use of percutaneous transluminal 
coronary angioplasty (PTCA) to treat stenotic coronary disease, there are 
few retrospective studies evaluating its long-term results. 
Methods: A total of 104 patients with 183 lesions had no restenosis 
at 3-12 months and undertook coronary angiogram at least 5 years after 
PTCA. Twenty-five patients (24%) were diabetes mellitus (DM). Quantitative 
coronary analyses were performed (1) before and (2) immediately after 
PTCA, (3) during the 3-12 month period and (4) after 5 years had passed. 
Results: 
all tlofl-DM DM 
Lesions (n) 183 138 45 
Late restenosis rate (%) 8.2 6.5 13.3 
Target lesion revascularization (%) 5.5 2.9 13.3 
Total occlusion (%) 2.7 0.7 8.9* 
Stenotic regression (%) 40.4 40.6 40.0 
Stenotic progression (%) 18.6 -16.6 24.4 
(>lO% regression/progression of %DS, comparing 5-years to 3-12 months) 
RD (before PTCA) (mm) 2.57 j: 0.58 2.61 f 0.56 2.48 i 0.57 
MLD (before PTCA) (mm) 0.73 * 0.43 0.74 + 0.42 0.68 f 0.47 
MLD (immediately after PTCA) (mm) 1.98 iz 0.61 2.00 zk 0.58 1.93 zk 0.67 
RD (>&years follow-up) (mm) 2.48 zk 0.60 2.53 i 0.57 2.36 i 0.62 
MLD (>5-years follow-up) (mm) 1.76 i 0.62 1.84 f 0.58 1.54 i 0.68* 
%DS (5.years)-%DS (3-12 months) (%) -2.8 G? 23.2 -5.0 * 19.7 3.5 i30.6* 
*p < 0.05 compared to non-DM lesions, %DS = %diameter stenosis; RD = reference 
diameter; MLD = minimum lumen diameter; 42% of 154 non-diseased vessels at the first 
PTCA had new lesions (%DS > 50%) during the follow-up periods. In DM group, 51% of 
35 non-diseased vessels had new lesions. 
Conclusions: The late restenosis rate was low in the lesions with no 
restenosis during the 3-12 month period, and approximately two-fifths of 
JACC February 2000 ABSTRACTS - ACCIS2000 19A 
these lesions had stenotic regression. Compared with non-diabetic lesions, Conclusions: The Cutting balloon is a good alternate approach com- 
diabetic lesions which underwent PTCA were disposed to have stenotic pared to standard PTCA with a large number of “stent like results”, reducing 
progression and became total occluded. markedly the need for stent implantations following standard PTCA. 
I. 1062 77 Coronary Angioplasty With Provisional Stenting m Dialysis Patients: In-Hospital and 6 Month 
Outcomes 
Farzin Beygui, Jean P. Metzger, Claude Le Feuvre, Gerard Helft, 
Gregoire Dambrin, Andre Vacheron. Adult Cardiology Department, Necker 
Hospital, Paris, France 
Background: Patients undergoing long-term dialysis have high rates of 
coronary artery disease and the outcome of coronary angioplasty (PTCA) in 
such patients is reported to be poor in small series. 
Methods: We studied immediate angiographic results, in-hospital compli- 
cations and 6 month outcome of PTCA, with provisional stenting, performed 
in 119 patients with long-term dialysis. The results were compared to those 
of 1328 non-dialysis patients undergoing PTCA during the same period 
[12/93-12/97]. Indications for stenting were post-PTCA diameter stenosis 
235%, threatening dissection and bail-out after balloon PTCA. All patients 
were followed-up >6 months. 
Results: 
Dialysis Non-dialysis 
n= 119 n= 1328 
Stenting (%) 
Angiographic success (%) 
In-hospital: 
Death (%) 
MI pa) 
Follow-up: 
Angina (%) 
MI (%) 
Death (%) 
Revascularization (%) 
TLR (%) 
MACF 1%) 
38* 
91 
26 
91 
2.5 
3.9’ 1.5 
60t 36 
6 2.4 
2.d 0.2 
48t 33 
32* 22 
52t 37 
*p < 0.05, tp < 0.01, MACE: deathlMI/CABG/PTCA 
Outcomes were comparable between dialysis patients with optimal result 
after balloon PTCA and those with stent implantation. 
Conclusions: Compared to non-dialysis patients, balloon PTCA provides 
more suboptimal angiographic results in dialysis patients, requiring higher 
rates of stenting. Despite comparable final angiographic results, in-hospital 
and 6 month outcomes are poorer in dialysis patients. 
1 1062-79 1 Initial Experience With Angiojet@ Mechanical 
Thrombectomy in the Treatment of Acute 
Myocardial Infarction 
A. DeLago, R. Papaleo, A. Macina, Ft. Chander. Albany Medical Center, 
AlbanK NX USA 
Background: The achievement of TIMI grade 3 flow at discharge is an 
important indicator of in-hospital and long-term survival for patients with 
acute myocardial infarction (MI). While aggressive thrombolysis achieves 
TIMI 3 flow in only 50% of patients, primary intervention has been shown 
to be highly effective in establishing TIMI 3 flow. Angiographic evidence of 
thrombus is associated with an increased incidence of complications, and 
thrombus removal may potentially improve early patency rates and decrease 
complications. We evaluated the efficacy of thrombectomy with the AngioJet 
(AJ) catheter in patients receiving coronary intervention for MI. 
Methods: AJ thrombectomy was performed in 46 patients with 44 native 
coronary lesions and 2 saphenous vein graft lesions, presenting to our center 
between 5198 and 5/99. Four patients had history of prior MI, 2 presented 
in cardiogenic shock, and 45% of interventions were rescue procedures 
for failed thrombolysis. Angiographically evident thrombus was present in 
infarct-related vessels with reference diameter 22.0 mm by visual estimation, 
and the AJ catheter was used at the discretion of the angiographer. In most 
cases, balloon angioplasty and stenting was performed and Ilb/llla inhibitors 
were used. 
Results: Procedure success (final diameter stenosis 150% with final TIMI 
3 flow, in the absence of death, emergency bypass surgery, or stroke during 
the hospital stay) was achieved in 44 of 46 (96%) patients: Pre-treatment 
flow was TIMI 0 in 40 patients, TIMI 1 in 5 patients, and TIMI 2 in 1 patient. 
All patients had final TIMI 3 flow. Balloon angioplasty followed by stenting 
was performed in 89% of patients and Ilb/llla inhibitors were used in 87% 
of patients. The mean AJ operation time was 54.0 sec. Distal embolization 
occurred in 3 cases. Transient heart block and bradycardia were observed 
during AJ treatment, and temporary pacing was used in 2 patients, with 
no subsequent complications. There were 2 deaths, no emergency bypass 
surgeries, and no strokes during the hospital stay. 
Conclusion: AJ thrombectomy can be performed safely and effectively in 
patients undergoing coronary intervention for the treatment of MI. While the 
combination of AJ, stent, and llbillla inhibitors has the potential to provide 
further improvement in clinical outcomes in the setting of Ml, determination of 
the specific benefits of this combination therapy require further clinical study. 
Bernward J. Voigt, Petra Pfitzner, Peter Weismueller, Ullrich Boeck, 
1062-78 
Michael Achtelik, Hans-Joachim Trappe. University /-/ospifa/ Herne, 
Cutting Balloon Angioplasty: An Alternate Way in 
Department of Cardiology and Angiologl: Ruhr-University-Bochum, 
Germany 
the Treatment of Complex Coronary Lesions 
Jassim Al Suwaidi, James L. Velianou, Peter B. Berger, Kirk N. Garratt, Guy 
1062-80 
S. Reeder, Diane E. Grill, David R. Holmes Jr.. Mayo Clinic, Rochesfer, MN, 
Primary PTCA in Patients With Acute Myocardial 
USA 
Infarction and Prior Coronarv Arterv Bvpass - _. 
Grafting 
Background: The cutting balloon (Interventional technologies, Letterkenny, 
Ireland) is a non compliant PTCA-Balloon armed with 3-4 micosurgical 
blades mounted longitudinally on its outer surface. When the balloon is 
inflated the blades are exposed to achieve controlled surgical incisions in the 
stenosis avoiding uncontrolled dissection and reducing elastic recoil facilitat- 
ing maximum dilatation. We investigated wether we could get stent like result 
without need for stentimplantation. 
Methods: 69 patients (pts) with 69 de novo lesions had been chosen for 
cutting balloon angioplasty (CBA). We only used cutting balloons (CB) with 
a length of 10 mm. Procedural success was defined as a residual stenosis 
~30% compared to reference vessel diameter. Lesion location: LAD in 35 pts, 
CX in 22 pts, RCA in 12 pts, 28 lesions located in the proximal segment, 27 
in the mid portion and 14 in the distal. According to AHA-criteria stenosis had 
been defined as type A in 26, type B in 32 and type C in 11 pts. Mean stenosis 
length was 7.9 mm (3-25 mm), mean number of inflations 1,4/stenosis (l-4), 
mean inflation pressure 5.9 bar (4-8). 
Results: Placement of the device had been successful in 67 pts, in 2 pts 
unsuccessful because of severe kinking of the vessel and the relativ rigidity 
of the blade armed balloon. Mean reference vessel diameter was 2.89 f 
1.3, initial minimal lumen diameter (MLD) was 0.57 i 0.46 mm, or 80.3% 
Diameter stenosis, postprocedural MLD was 2.32 rt 1.45 mm or 22.8% 
diameter stenosis. Procedural success was achieved with CB alone in 42 pts 
(60.9%), with adjunctive standard-PTCA (mostly due to primary undersizing 
of the CB) in 13 pts (l&8%), after additional stent-implantation in 14 pts 
(20.3%). Reasons for stentimplantation had been severe dissections in 9 pts 
and in 5 pts (7.23%) residual stenosis >30%. 
Background: The impact of prior coronary bypass surgery (CABG) on clinical 
outcome in patients (pts) undergoing 1” PTCA for acute Ml is unclear. 
Methods: We compared the clinical outcome of 1073 pts with (n = 129) 
and without (n = 944) prior CABG undergoing 1” PTCA for MI at Mayo Clinic 
between 1991 and 1997. Prior CABG pts were divided into those in whom 
a vein graft (n = 63) vs native artery (n = 65) was believed to be the culprit 
vessel. 
Results: Pts with prior CABG were older and more likely to have diabetes, 
hypertension, hyper-cholesterolemia, present with congestive heart failure, 
and have a lower left ventricular ejection fraction. Baseline characteristics of 
prior CABG pts with a vein graft vs native culprit vessels were similar. *MACE 
(Death, MI and target vessel revascularization) 
Procedural success (%) 
SO-days (%) 
Death 
Reinfarction 
CABG 
1 yr (cumulative %) 
Death 
Reinfarction 
CABG 
MACE* 
Prior No prior Vein Native 
CABG CABG P graft vessel P 
78.9 83.9 0.16 71.4 86.2 0.04 
12.5 8.3 0.17 15.9 9.2 0.73 
9.0 4.3 0.05 12.7 7.7 0.96 
13.2 7.1 0.04 6.5 0.0 0.04 
25.8 11.9 0.001 30.2 21.6 0.27 
18.1 9.0 0.02 25.9 11.1 0.04 
10.0 13.7 0.24 14.5 5.8 0.14 
49.2 35.8 0.04 52.4 46.2 0.48 
On multivariate analysis, only a vein culprit vessel (RR 1.46 [Cl 95%: I .05, 
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2.031, p = 0.025) but not a native culprit vessel (RR 0.96 [Cl 95%: 0.66, 
1.381. p = 0.08) or prior CABG (RR 1 .I8 [Cl 95%: 0.91, 1.531, p = 0.20) were 
independently associated with major adverse events. 
Conclusion: 1” PTCA for MI in pts with prior CABG is associated with 
a lower success and higher complication rate primarily because of baseline 
clinical characteristics or if a vein graft is the culprit vessel. 
1 1062-81 1 Predictors of TIMI 5 2 Coronary Flow After 
Primary Angioplasty in Patients With Acute 
Myocardial Infarction 
Fernando A. Cura, Philippe L. L’Allier, Samir R. Kapadia, Linda M. Dipaola, 
Carolyn Apperson-Hansen, Sorin J. Brener, Stephen G. Ellis, Eric J. Topel. 
Far the RAPPORT Investigators; The Cleveland Clime Foundation, 
Cleveland, Ohio, USA 
Background: The goal of angioplasty during acute Ml is the restoration 
of normal flow to achieve myocardial reperfusion. However, non-adequate 
coronary, flow is obtained in IO-20% of patients. This phenomenon is as- 
sociated with poor outcome. Factors associated with TIMI 5 2 after primary 
angioplasty during acute Ml are unknown. 
Methods: Between 11/95 and 2/97, RAPPORT trial randomized 483 pa- 
tients with acute Ml to primary angioplasty with or without adjunctive abcix- 
imab. A multivariate model was used to detect baseline clinical, angiographic 
or therapeutic characteristics associated with TIMI flow grade 52 after angio- 
plasty. TIMI flow grade was classified by an independent core lab. Variables 
with p < 0.15 in the univariate analysis were included in the multivariate 
model. 
Results: The study population comprised of 434 patients (49 pts were 
excluded because no intervention, performed) with a mean age of 60.8 
f 12 years, 71% of male gender, and 36% with anterior wall localization. 
Patients underwent angioplasty within 4.9 f 3.8 hours from the onset of 
chest pain. The incidence of TIMI 3 flow at the end of the intervention was 
84%. Multivariate analysis revealed that patients older than 65 years (OR 
2.6, 95% Cl i&5.0), male gender (OK 2.4 95% Cl 1.1~5.2), baseline TIMI 
O-l flow (OR 2.7, 95% Cl 1.2-5.9) and presence of thrombus at baseLine 
angiogram (OR 2.4 95% Cl 1.2-4.9) were significantly associated with TIMI 
5 2. Interestingly, the time from onset of chest pain to intervention and the 
use of adjunctive abciximab were not associated. 
Conclusion: Angiographic evidence of thrombus and two specific demo- 
graphic characteristic factors such as age and male gender predict lack of 
adequate coronary reperfusion, with resistance to, abciximab effects. New 
strategies are needed to address this important unmet therapeutic goal. 
1062-82 Predictors of Delay From ER to Cath With Primary 
PTCA for Acute Ml 
Daniel E. Simpson, Judith A. Boura, Loreli L. Grines, Cindy L. Grines. 
Brooke Army Medical Center, Fort Sam Houston, TX; William Beaumont 
Hospital, Royal Oak, MI, USA 
Background: The detrimental effect of treatment delay for acute Ml with 
thrombolytics is well validated but it remains controversial with primary PTCA. 
Since time of day is known to influence delay, we sought to define other 
predictors of delay (260 minutes from ER to cath based on the ACC/AHA 
guidelines) utilizing the PAMI databases. 
Methods: Data were available on 2820 patients from 98 sites participating 
in PAMI-2, Stent PAMI and NoSOS. Eighty-nine patients with no time from 
ER to cath due to pre-hospital diagnosis and direct admission to the cath lab 
(European Centers) were excluded. 
Results: The mean time to cath was 103 minutes with 60.3% receiving 
“delayed” treatment. Of 41 variables, 6 were identified as predictors of delay. 
Specifically, a history of hypertension, diabetes, CHF, treatment at non-teach- 
ing centers, larger institutions (>200 beds) and privately funded institutions 
were associated with delay. 
Predictor of Delay 
History of Diabetes 
History of CHF 
Non-Teaching 
Center > 200 Beds 
Private Fundina 
Percent Delayed 
71.1% 
73.0% 
66.5% 
66.7% 
63.8% 
Mean Time with Mean Time without 
Predictor Predictor (p < 0.05) 
118.0 99.6 
121.5 102.6 
113.1 102.7 
111.7 73.9 
105.3 95.0 
Conclusions: The majority of acute Ml patients are not reperfused with 
primary PTCA within the recommended ACC/AHA time constraints. Rapid 
treatment protocols should be developed to identify Ml patients with comorbid 
conditions and to expedite care in large centers. 
1062-83 The Relationship of Primary Angioplasty Volume 
and Survival Among Interventional Hospitals in 
the National Registry of Myocardial Infarction 
John G. Canto, Nathan R. Every, David Magid, William J. Rogers, Judith 
A. Malmgren, Paul D. Frederick, William J. French, Alan J. Tiefenbrunn, 
Vijay K. Misra, Catarina I. Kiefe, Hal V. Barron. For the NRMt Investigators; 
University of Alabama at Birmingham, Birmingham, AL, USA 
Background: Previous studies have documented an inverse relationship 
between provider volume and outcomes in cardiovascular care, such as for 
elective coronary angioplasty (PTCA), stents, and coronary bypass surgery 
(CABG). However, it is unknown whether outcomes may be better among 
centers with higher volumes of primary PTCA for myocardial infarction (Ml). 
Methods: 450 intetventional hospitals (with PTCA and CABG availability) 
were ranked according to primary PTCA volume. Volume was calculated 
by taking the total number of patients who received primary PTCA at each 
hospital divided by the total number of days that a hospital was enrolled 
in the NRMI. Quartiles of volume were then defined. Multivariable logistic 
regression models were developed to ascertain predictors of mortality. Can- 
didate predictors were: primary PTCA volume, age, race, gender, region, 
smoker, diabetes, hypertension, high cholesterol, angina, prior MI, PTCA, 
CABG, heart failure, and stroke. 
Results: 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 
N 2,825 5,245 9,303 19,162 
Volume/year 5-11 12-20 21-33 >33 
Crude Mortality, % 7.7 7.5 7.0 5.7 
OR for in-hospital mortality among Ml patients who received primary PTCA 
Unadjusted OR 95% Cl p value 
Quartile 2 (vs Quartile 1) 0.964 0.812-1.145 0.6779 
Quartile 3 (vs Quartile 1) 0.888 0,757-l .042 0.1456 
Quartile 4 (vs Quartile 1) 0.720 0.619-0.837 <0.0001 
Adjusted 
Quartile 2 (vs Quartile 1) 0.929 0,775-l .114 0.4261 
Quartile 3 (vs Quartile 1) 0.855 0.722-1.012 0.0683 
Quartile 4 (vs Quartile 1) 0.719 0.614-0.843 <0.0001 
Conclusion: Among patients who presented at intetventional hospitals, 
mortality was significantly lower among those who received primary PTCA in 
high volume PTCA hospitals as compared to low volume PTCA hospitals. 
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1063-I 09 Effects of lntracoronary Radiation on Healing 
Dissection and Thrombosis Followina Balloon 
Injury in the Porcine Model 
Yves Cottin, Yoram Vodovotz, Marc Kollum, Han-So0 Kim, Rosanna Chan, 
Balram Bhargava, Ron Waksman. Washington Hospital Center; 
Washington, DC, USA 
Background: lntracoronaty radiation (IR) after balloon injury (BI) has an 
anti-restenotic effect, but can delay healing and increase thrombosis. 
Methods: The effect of IR on dissection repair, thrombus formation, and 
internal elastic lamina (IEL) changes were evaluated. Thirty porcine coronar- 
ies underwent BI followed by either 0 or 18 Gy of gaY prescribed to 1.2 mm 
from the balloon center. The animals were euthanized 14d post-treatment, 
and intimal area (IA), IA corrected for medial fracture length (IA/FL), dissec- 
tion area (DA), dissection rate (DR), and thrombus area were quantified. The 
roughness index (RI) of the IEL was calculated from the surface profile length 
and the straight-line length. 
IAJFL (mm) 
Control (n = 12) 
0.55 * 0.29 
18Gyg0Y(n=17) P value 
0.05 i 0.09 <O.OOl 
DR (%j ’ 77 88 NS 
DACmm2) 0.19f0.28 0.32 i 0.29 <0.05 
Mural TA imm2) 0.29 zt 0.30 0.03i 0.01 <O.OOl 
RI a.75 1.2 20.1 * 3.1 <O.OOl 
JACC February 2000 
Results: IA/FL was reduced following IR. Control and irradiated arteries 
had equal DR. Thecontrol had a smaller DA, with smaller mural thrombi. The 
surface of the IEL was more irregular after IR, as reflected in the RI (Table). 
DA and mural TA correlated positively only in the IR group (Rs = 0.889; p < 
0.001; cza.cs = 1 .OO). When mural thrombi were present, TA and RI correlated 
positively (CX = 0.76, p < 0.01). 
Conclusion: Incomplete healing of dissections may occur after IR at 14d, 
associated with a higher RI and TR. These findings may influence the design 
of IR studies. 
1063-l 10 Brachytherapy Induces Positive Vascular 
Remodeling Using Self-Expanding Stents 
Judah Weinberger, Sean Pinney, Renu Virmani, Frieda Trichter, C-S. Wuu. 
Columbia University: New York, NY; Armed Forces Institute of Pathology, 
Washington DC, USA 
Background: Observations of patients treated with vascular brachytherapy 
suggest that, in addition to inhibition of neointimal hyperplasia at sites of 
balloon angioplasty, but not stents, radiation induces positive remodeling 
leading to an improved late lumen diameter. We sought to test the hypothesis 
that self-expanding stents, by virtue of continued positive radial force on 
the vessel wall, together with brachytherapy would synergistically increase 
favorable arterial remodeling. 
Methods: Nitinol self-expanding stents were implanted in pig iliac arteries 
(n = 12) bilaterally. Nominal stent size was IO-15% oversized, compared to 
the reference vessel diameter, based on IVUS measurements. One of the 
two arteries was randomly selected for vascular brachytherapy using the 
Rhenium188-fiquid-filled balloon to deliver 20 Gy at 0.5 mm into the vessel 
wall. At 4 weeks post implant, all animals underwent repeat angiography, 
and were killed. Pressure fixed distal aorta and iliac arteries were examined 
histologically. 
Results: Self-expanding stents that were radiated immediately after im- 
plantation resulted in a markedly enlarged lumenal diameter (1.18 f 0.17 
[relative units] stentediirradiated vs. 0.81 f 0.35 reference, p = 0.04). Self- 
expanding stents implanted in non-radiated iliac arteries did not significantly 
increase lumenal diameter (MLD: 0.78 f 0.13 stent vs. 0.74 + 0.2 reference 
vessel p = 0.72). Radiated, stented arteries had significantly larger lumens 
at follow-up than did control-stented arteries (p = 0.0009). There was, on 
average, a 35% larger lumen (95% C.I. 28%) in the radiated stent compared 
with controls. Histological results will be presented at the meeting. 
Conclusion: Brachytherapy in conjunction with self-expending stent im- 
plantation produces positive vascular remodeling. 
1063-l 11 Tungsten-l 88 Radioactive Coil Delivered 
lntracoronarv Inhibits Neointima Formation After 
Balloon and Stent Injury of Porcine Coronary 
Arteries 
Ron Waksman, Balram Bhargava, Rosanna Chan, Marc Kollum, 
Yoram Vodovotz, Efi Lavie. Washington Hospital Center, Washington, DC. 
USA; Soreq, NRC, Yavne, Lsrael 
The effectiveness of a new coiled wire of 188-Tungsten (rs8W) a pure /I 
emitter (half-life 69.4 days) was tested. 
Methods: Domestic pigs underwent intervention to their coronary arteries 
either by balloon injury (El) n = 20 or intracoronary stenting n = 20. A 30-mm 
in length radioactive 188-Tungsten coiled-wire 1 -mm in diameter manually 
delivered to cover the angioplasty site in eight of the BI arteries, in 4 arteries 
post stenting and in 6 arteries prior to stenting. A prescribed dose of 15 Gy at 
2 mm from the center of the source required dwell time of IO min. Two weeks 
after BI and four weeks after stenting the animals were killed, the arteries 
were examined by histological and morphometric techniques. The lntimal 
Area (IA), the IA corrected to the degree of injury (IA/FL) and the Injury Score 
(IS) were measured. 
Balloon Ball00n stent stent 
IA (mm”) IAfFL IA (mm*) IS 
Control 1.00 i 0.8 0.52io.32 2.72 i 1.2 1.95 zk 0.7 
Irradiated 0.15 i- 0.9 0.58 i 0.10 0.57 i 0.38 1.77 * 0.7 
P eo.001 NS <O.OOl NS 
Results: Nearly complete inhibition of neointima formation was demon- 
strated in the irradiated arteries with similar IA in arteries irradiated prior 
versus post stenting. There was no excess of fibrin, thrombus, or fibrosis in 
the irradiated arteries compared to control. 
Conclusions: lntracoronaty delivery of the radioactive coiled le8W is fea- 
sible, safe, following balloon and stenting and results in consistent, inhibition 
of neointima formation in the porcine model. 
ABSTRACTS - ACCIS2000 21A 
Device Influence on Outcome in the Treatment of 
In-Stent Restenosis With and Without Radiation. 
A Sub Analysis from the WRIST Study 
Ron Waksman, Marco Zimarino, Roxana Mehran, Alexandra J. Lansky, 
August0 D. Pichard, Balram Bhargava, Lowell Satler, Kenneth Kent, Larry 
R. White, Martin B. Leon. -Washington Hospital Center, Washington, DC, 
USA 
Background: Different devices are available for the treatment of In-Stent 
Restenosis (ISR). Vascular Brachytherapy (VB) has demonstrated effecacy 
prevention recurrent ISR. 
Methods: To determine the optimal device for the treatment of ISR, 
we evaluated 130 patients (pts) from the WRIST study who were random- 
ized to placebo or gamma radiation (lr192) following intervention. Devices 
used included Balloon (POBA), Rotational Atherectomy (RA), Excimer Laser 
(ELCA) and Stent. Six-month angiographic one year clinical outcomes were 
compared among the treatment groups. Baseline clinical characteristics, ref- 
erence vessel size and minimal lumen diameters were similar. 
Results: Selection of device did not influence the acute outcome in 
irradiated and placebo patients. Re stenting was associate with a trend 
of greater late loss (p < 0.05) and higher rates of late thrombosis when 
compared with other devices both for radiation and placebo patients ($ p < 
0.02). 
Length Acute Late Loss Restenosis Late 
mm Gain (mm) Rate ("la) Thrombosis 
Placebo N=56 22&112 1.2 * 0.5 0.8iO.7 34 (61%) 3 (5%) 
POBA N=7 16zk 10 0.7io.5 0.3 zt 0.8 3 (43%) 0 
RA N=18 22zk6 1.2 i 0.4 0.9 * 0.5 14 (78%) 0 
ELCA N=l3 25117 1.3i0.5 0.7 i 0.5 6 (46%) 0 
stent N=18 23i11 1.4 * 0.5 1.0 iO.6* 11 (61%) 3 (5%)* 
Radiation N=59 2Oi10 1.1 * 0.5 0.3 i- 0.7 12 (20.3%) 5 (8%) 
POBA N=5 13*5 0.7 i 0.4 0.04 * 0.4 0 (0.0%) 0 
RA N=l7 2019 1.1 i 0.4 0.2io.5 3 (6%) 0 
ELCA N=14 21f9 1.0 zk 0.5 0.2 * 0.8 4 (29%) 1 (2%) 
stent N=23 21110 1.1 zk 0.5 0.6 zk 0.8* 7(30%) 4 (6%)* 
Conclusions: The overall recurrence of ISR in pts treated with conven- 
tional devices is high (61%). VB reduces the recurrence (to 20.3%) associated 
with a significant reduction in late loss. Device selection does not influence 
late outcomes in both irradiated and non-irradiated group. Re-stenting should 
be used selectively due to higher rates of thrombosis seen in both groups. 
1063-l 13 Safety and Efficacy of Manual Stepping and 
Overlapping of a ,&Emitter for Diffuse In-Stent 
Restenosis Lesions 
Ron Waksman, Balram Bhargava, Rosanna C. Chan, Roxana Mehran, 
Alexandra J. Lansky, Larry R. White, Lowell Satler, Kenneth K. Kent, Martin 
B. Leon. Washington Hospital Center, Washington DC, USA 
Background: lntracoronaty B radiation has demonstrated efficacy for the 
treatment of In Stent Resfenosis (ISR). Longer lesions require stepping of 
short B sources for adequate coverage of the lesion and its margins. 
Methods: The efficacy and safety of manual stepping of 9OY (a pure B 
emitter) was evaluated in 16/50 patients with diffuse ISR in native coronaries 
who were enrolled in the BETA Washington Radiation for In-stent Restenosis 
Trial. Following an angioplasty with balloon, laser angioplasty, rotational 
atherectomy, and/or additional stents a segmented balloon catheter 2.5-4.0 
mm in diameter was positioned at the treatment segment. A 9OY 0.014 wire 
source 29 mm in length was automatically loaded to deliver a dose of 20.6 
Gy prescribed at 1 mm from the surface of the balloon. For lesions ~25 mm 
manual stepping of the radiation catheter with an overlap of up to 3 mm at 
the stented segment was performed and the source delivered again to the 
new positioned. The calculated dose at the overlapped area did not exceed 
70 Gy. 
Results: At 6 months there was no evidence of perforation or aneurysm 
at the overlapped segments. 
Lesion length(mm) 
Late Thrombosis 
Late loss (mm) 
Revascularization (6 m) 
Stepping No stepping 
(n=16) (n = 34) 
22.3+ 11.1 15.3 zk 8.4 
2116 (12.5%) 4134 (11.8%) 
-0.06 zt 0.31 0.26 iO.48 
5116 31.3% 9134 (26.5%) 
P 
0.04 
NS 
0.04 
NS 
Conclusion: Manual stepping and overlapped B-emitters for diffuse ISR 
is safe and may contribute to further reduction of the late loss. 
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lrrl 1063 II 4 Stent and Stent-Edge Remodeling After Conventional and Radioactive Stent Implantation 
I. Patrick Kay, Mane1 Sabate, Marco A. Costa, Ken Kozuma, 
Mariano Albertal, Jurgen M. Ligthart, Veronique L. Coen, Peter 
C. Levendag, Willem G. van der Giessen, Patrick W. Serruys. Thomxcentef 
and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands 
Background: Stent edge restenosis is a recognized complication of radioac- 
tive stent implantation. Little is known of the mechanism by which an ‘edge 
effect occurs’, or indeed whether it develops after conventional stent im- 
plantation. Equally remodeling behind the radioactive stent has not been 
described. 
Aim: To describe remodeling of the stent and at the stent edge after 
conventional (CS) and radioactive stent implantation. 
Method: 18 patients who had undergone stenting using conventional 
stents (Multilink n = 8, NIR n = 10) were compared with patients who had 
undergone radioactive stent (Palmaz Schatz, 6X Isostent) implantation with 
activity levels 0.75-l 5 &i (n = 17) and 6.0-12 &i (n = 12). intravascular 
ultrasound was performed post stent implantation and at 6 month follow-up 
using a motorized pullback device (0.5 mm/s), with subsequent 3-dimensional 
reconstruction and quantification. Measurements were made of the change 
in (A) lumen volume (LV) and total vessel volume (TVV) at the stent edge 
(up to 5 mm proximal and distal to the stent) and TVV, stent volume (SV), 
neointimal hyperplasia (NIH) andplaque volume (behind stent) (BPI). These 
findings were compared post stenting, at follow-up and between treatment 
groups. 
Results: Clinical baseline characteristics, reference vessel size and stent 
length were similar between groups. No change was seen in stent volumes 
between post and follow-up. 
Edae (mm31 ALV ANV APlaCWe 
CS -9.1* -6.46* +I .47 
0.75-l .5 &i -a.49* -11.21* -2.31 
6.0-12 uCi -11.24* -8.68* +3.3 
Stent (mm3) ALV ATVV AABPl NIH 
CS -20.7* +1.14 +1.67 +20.1a 
0.75-l .5 &i -21 .a4* -4.1 -3.94 +16.03 
6.0-12 &Ci -10.7*t -2.77 -0.96 +L3.90* 
*p < 0.05 (baseline vs follow-up), *p < 0.05 (between stent groups). 
Conclusion: Stent edge renarrowing occurs after both conventional and 
radioactive stent implantation and is due to a decrease in the TVV with 
a concordant decrease in LV. Higher-dose radioactive stent implantation 
decreases NIH with no change in TVV or BPI. 
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( 1064-84 ( Angioplasty and Stenting of Extracranial Carotid 
Arteries in High-Risks Patients 
M. Henry, M. Amor, I. Henry, C. Klonaris, I. Masson, E. Leborgne, 
A. Polydorou, M. Hugel. U.C.C.I., Polyclinique, Essey-/es-Nancy, France 
Background: To study the safety and feasibility of percutaneous angioplasty 
and stent placement for atherosclerotic stenosis of the extracranial carotid 
arteries in high risks patients as an alternative to surgical endarterectomy. 
Methods: Carotid angioplasty was attempted in 315 arteries, 290 patients 
M: 213, F: 77, mean age: 70.5 f 9.6 y (40-93 y). Mean lesion length: 
14.7 5 6.7 mm. Mean arterial diameter: 5.3 * 1.1 mm. In 15 patients, the 
contralateral carotid artery was thrombosed. 44% were symptomatic, 56% 
were asymptomatic. 55% had severe coronary artery disease, 34% had 
peripheral vascular disease. Stents deployed in all carotid arteries but 1: 
Palmaz (n = 199), Wallstent (n = 77), other stents (n = 79). 165 arteries were 
treated without cerebral protection (femoral approach: 150, direct puncture: 
13 brachial approach: 2). 142 arteries were treated with cerebral protection 
Three protection techniques used: Theron’s technique (n = 47), PercuSurge 
device (n = 93), and our technique with a new device (n = 10). 
Results: Immediate technical success was 314/315. Mean stenosis 
dropped from 82.3 f 8.7% to 2.9 f 7%. Postoperatively one patient died 
(0.3%), no cases of myocardial infarction were noticed. Also 13 neurological 
complications occurred: 4 TIA, 4 minor and 5 major strokes. 8 appeared 
in patients treated without, cerebral protection (4.8%) and 5 with cerebral 
protection (3.3%) p < 0.02. With cerebral protection 4 events occurred with 
Theron’s technique (8.5%) and one with the PercuSurge device (1.1%) p 
< 0.01, One patient developed a minor stroke on third day due to cerebral 
hemorrhage after treatment with Reopro. Mean follow up was 17.1 * 8.5 
months, (max. 50 m). We observed 1 mild compression of a Palmaz stent 
and 10 restenoses (4%). No ipsilateral neurological complications were seen. 
Primary and secondary patency rates were 96% and 99% at 4 years. 
Conclusion: Carotid angioplasty and stenting seems safe and effective 
procedure. Cerebral protection should decrease the neurologic embolic com- 
plication rate and enlarge its indications. Randomized studies are awaited. 
crl 1064 8.5 Endoluminal Stenting for Abdominal Angina: 
An Alternative to Surgical Revascularization 
Suresh P. Jain, Christopher J. White, Tyrone J. Collins, J. Stephen Jenkins, 
Krishnamoorthy Vivekananthan, Stephen R. Ramee. Ochsner Clinic, New 
Orleans, LA, USA 
To evaluate the clinical efficacy of endoluminal stenting (ES) in the treatment 
of chronic abdominal angina, we analyzed acute and long term outcomes in 
13 pts (6 females, mean age 67 f 8 yrs) who underwent ES. ES deployment 
were performed in celiac artery (n = 9), superior mesenteric artery (n = 6) 
inferior mesenteric artery (n = I), and a vein graft to a superior mesenteric 
artery (n = I). A total of 18 Palmaz medium stents and 1 multilink stent were 
deployed. The average balloon size was 6 i 1 mm and stents were deployed 
at 12 f 2 ATM. Clinical follow up (22 i 16 mth, range 6-55 months) was 
available in all 13 pts. Quantitative angiography was performed using an 
automated edge detection technique. 
Results: Acute clinical success (~20% diameter stenosis accompanied 
by symptomatic relief without emergency surgery or death) was achieved in 
all 13 pts (100%). 
MLD (mm) 
Diameter stenosis (%) 
Acute Gain (mm) 
Baseline 
0.83 f 0.3 
86.19 zk 5.39 
post stent 
6.06 * 1.30 
1.2 * 3.19 
5.23 IL 1.21 
P 
<0.0001 
<0.0001 
<0.0001 
Four pts died during follow up (2 cardiac failures, 1 renal failure, 1 lung 
cancer) and none had recurrence of symptoms till death.. One patient de- 
veloped in-stent restenosis with recurrent symptoms after 6 months and 
was successfully treated with balloon angioplasty, the remaining 8 pts were 
completely asymptomatic. 
Conclusion: Endoluminal stenting of the atherosclerotic mesenteric and 
celiac arteries is a safe and effective modality for chronic abdominal angina 
seconadty to mesenteric ischemia. It is a viable aternative to surgical revas- 
cularization. 
1064-86 Comparison of Early Outcomes in Age and 
Gender Matched Patients Undergoing 
Conventional Open Surgical Repair of Abdominal 
Aneurysms vs Patients Treated Percutneously 
With the AneuRx Stent Graft 
Marcus H. Howell, William K. Vaughn, Rollo P. Villareal, Biswajit Kar, 
Neil Strickman, Charles H. Hallman, Zvonimir Krajcer. The Texas Heart 
Institute, Houston, Texas, USA 
Background: Percutaneous endovascular treatment of infrarenal abdominal 
aortic aneurysms is receiving increasing popularity among physicians and 
patients. The current third generation devices offer the potential to avoid 
the significant morbidity and mortality associated with conventional open 
repair. In an effort to test this potential we compared the early outcomes of 
age and gender matched patients undergoing conventional surgical repair 
versus those treated with the AneuRx stent graft. 
Methods: Between 1993 and 1998 159 patients mean age 71.6 (range 
52-86), 87% males, underwent conventional surgical repair of unruptured 
abdominal aneurysms at The Texas Heattlnstitute. From 1998 until present 
55 patients have been treated with the AneuRx stent graft for abdominal 
aortic aneurysms mean age 71.2 (range 58-88) and 87% males at The 
Texas Heart Institute. One-month follow-up is available in all the surgical 
patients and in 50 of the AneuRx treated patients. In the surgical group: 45% 
had prior Ml; 6.5% had diabetes; 9% had a history of congestive heart failure 
(CHF); 12.2% had stable angina: 36% had chronic obstructive pulmonary 
disease (COPD); and 65.8% had hypertension. ln the AneuRx group: 42% 
had prior MI; 27% had diabetes; 29% had a history of CHF; 38% had stable 
angina; 40% had COPD; 80% had hypertension; 79% were American Society 
of Anesthesiologist grade IV or higher. 
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Results: In the surgical group there were 6 early deaths, average hospital 
stay was 11 & 11.7 days, and less than 1% of patients had major morbidity 
(i.e. MI, stroke, CHF, renal failure, respiratory failure). In the AneuRx group 
there was no one month mortality or major morbidity (Fishers exact test p = 
0.164), the average hospital stay was 2.31 days (range I-8). Average blood 
loss was 432 cc’s and only 7 patients required transfusions, 
Conclusions: Our early results show that infrarenal abdominal aortic 
aneurysms can be safely and successfully treated with the AneuRx stent 
graft when compared with the gold standard open surgical repair. Not only is 
there no increased early morbidity or mortality there is a trend toward less 
morbidity and mortality and significantly lower hospital stay. Longer follow-up 
is required to determine the long-term efficacy of the AneuRx stent graft in 
the prevention of rupture and death due to abdominal aortic aneurysms. 
I 1064 87 Transluminal Endovascular Treatment of Thracic, 
Thoracoabdominal Aortic Aneurysms and 
Dissection With INOUE Stent Graft 
Kenichi Abe, Takeshi Kimura, Arata Tabuchi, Hiroyoshi Yokoi, 
Yoshihisa Nakagawa, Naoya Hamasaki, Hideyuki Nosaka, 
Masakiyo Nobuyoshi, Kanji Inoue. Kokura Memorial Hospita/, Kifakyushu; 
Takeda Hospital, Kyoto, Japan 
Background: Endovascular treatment for Abdominal aortic aneurysm be- 
comes to be popular. But previously reported stent graft technology for 
thracic (TAAs), thoracoabdominal aortic aneurysms (T-A AAs) and dissec- 
tion (DAAs) is limited by involvement of major side-branches. The aim of the 
study was to evaluate safety and efficacy of Transluminal Endovascular Graft 
Placement (TEGP) with INOUE stent graft for TAAs, T-A AAs and DAAs. 
Methods: Since Aug. ‘98 and Aug. ‘99, we performed TEGP with INOUE 
stent graft for TAAs, T-A AAs and DAAs in 13 patients (pts.) 14 lesion (ies.) 
(10 men and 3 women; mean age 69 f 11 years). The les. consists of 4 TAAs, 
3 T-A AAs and 7 DAAs (3B). Mean maximum diameter of the aneurysms was 
63 mm (range, 42-118 mm). Eight (61.5%) of the pts. had medical conditions 
that excluded them from open repair, 2 high age more than 79 years, 4 sever 
pulmonary dysfunction, 1 sever renal dysfunction and 1 impossibility to have 
blood transfusion for his faith. INOUE stent graft was inserted through 20-24 
Fr. sheath via a femoral artery under local anesthesia and was fabricated 
as self-expandable with adjunctive balloon expanding. Seven (50.0%) of 
les. had a single brunch graft, 1 (7.1%) had a dual brunch graft, 1 (7.1%) 
had a three brunches graft and 5 (35.7%) had a straight graft. In 5 les. of 
DAAs, INOUE stent graft was used to close the entry site and to protect left 
subclavian artery by its brunch. In 4 les. of TAAs involving main brunches of 
arch, the stent graft was planed to keep the blood flow of the brunches. After 
INOUE stent graft was brought to the intended sites, brunches of INOUE 
stent graft were pulled into major branches of aorlic arch by hauling into 
traction wire with Goose-neck snare wire. 
Results: In all cases, stent graft were implanted successfully to the 
intended sites and brunches had good patency. Mean procedure time was 
3.08 f 1.23 hours. One pt. (7.7%) undergoing TEGP for T-A AA had transient 
spinal artery syndrome. The mean follow-up was 6 months (range, I-13 
months). Only one pt. (7.7%) has minor residual leakage up to now. There 
have been no death, no aneurysm ruptures, no surgical conversions to open 
repair and no late development of endoleakage. 
Conclusion: TEGP with lnoue stent graft for TAAs, T-A AAs and DAAs 
is less invasive and effective especially for high risk pts. lnoue stent can be 
used in TAA, DAA involving major branches of aortic arch. TEGP with lnoue 
stent graft is new useful strategy for TAAs, T-A AAs and DAAs. 
1 1064-88 1 Comparison of Abdominal Aortic Aneurysm 
Repair by Percutaneous Implantation of 
Uncovered Wire Mesh Stents and Coil 
Embolization of the Aneurysm Cavity in Patients 
With and Without Pre-Existent Thrombus 
Ali E. De&as, Alan M. Cohen, Carlos Cafri, Abid Assali, Stefano Sringola, 
Michael A. Rhiner, Nabil F. Maklad, Bharat Raval, George Schroth, 
H.V. Anderson, Oscar R. Resales, Berdardo de la Guardia, Richard 
W. Smalling. University of Texas Medical School and Hermann Hospital, 
Houston, Texas, USA 
Background: We have previously demonstrated the feasibility of percu- 
taneous placement of uncovered wire mesh stents with trans-stent coil 
embolization of the aneurysm cavity for the treatment of abdominal aortic 
aneurysm. Whether pre-existing thrombus in the AAA cavity provided an 
advantage or disadvantage in this setting was unclear. 
Methods: Sixteen patients (pts) (mean age 76 + 6, 69% males,) with a 
mean maximum AAA diameter of 52.7 + 10.3 mm were treated. Maximum 
sheath size was 12 Fr. Wallstents (3.8 i 1.2 per patient, size: 24 x 7.5 
and 4.5 mm (aorta) and 16 x 9 mm (iliac), mean total length: 25.0 i- 8.8 
mm). Fluoroscopy time was 53.4 + 24.6 minutes and total procedure time 
was 168.8 i 46.2 minutes. Total hospitalization time was 23.7 & 10.5 hours. 
Coiling of the AAA cavity was required in 9 pts. (Mean 30.7 * 15 coils) The 
follow-up was done using bi-monthly abdominal duplex ultrasound and yearly 
Computerized Tomography (CT). (Mean follow-up: 192 f 187 days (range 
42-720 days)) 
Results: The success rate of the procedure was 15116 (94%). There was 
no thirty-day mortality. Four patients required additional coil placement due to 
low levels of flow outside the stent determined by ultrasound. No flow outside 
the stent was found in patients with previously thrombosed aneurysms. 
One-year or greater CT follow-up was available for 5 pts. (3 non-thrombosed, 
2 thrombosed). The overall pro and post stenting diameters were 43.6 + 5.4 
mm, and 43.1 f 7.1 mm respectively. No patients have died secondary to 
aneurysm rupture. The results in pts. with thrombosed vs. non-thrombosed 
aneurysms are given in the table. 
Non-Thrombosed 
Thrombosed 
Size before stenting 
42.97 i 4.16 mm 
44.50 * a.77 mm 
Size 1 y after stenting 
43.13 * 8.31 mm 
43.10 * 8.06 mm 
Conclusion: Patients with abdominal aortic aneurysms with intralumi- 
nal thrombus not requiring coil embolization after treatment with uncovered 
wire-mesh stents demonstrated markedly less peri-stent flow at ultrasound 
follow-up and a greater tendency for aneurysm shrinkage one year post- 
implant. 
L--l- 1064 89 Necrotic Vascular Graft-Covered Stents Inhibit 
Smooth Muscle Migration: A Possible Mechanism 
of Reducing lntimal Hyperplasia 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, 
Sophia Vaina, Dorothea Tsekoura, Pavlos Toutouzas. Hippokration 
Hospital, Athens Universi& Greece 
Background: Restenosis after stent implantation is characterized by smooth 
muscle cell (SMC) migration from the arterial media towards the intimal layer 
and their subsequent proliferation. The aim of this study was to determine 
whether the extent of intimal hyperplasia after stenting can be reduced by 
inhibiting SMC migration. 
Methods: A 3-4 cm graft was harvested from the right femoral artery of 
12 swines (20-25 kg). The boundary tissues of the graft were removed and 
it was embedded in 100% pure ethanol solution (Merck KGaA, Germany) for 
30 min. After the achievement of cellular desiccation the necrotic arterial graft 
was washed by Ringer’s lactate solution and was stabilised on the external 
surface of a Multilink’” stent with 3 sutures (Prolene 7.0) at each end of the 
stent. Covering of stents by this necrotic graft aimed to inhibit SMC migration 
from the arterial media (figure). Twelve covered stents (group A) and 12 
conventional Multilink’” stents (group B) were implanted in the fight and left 
iliac artery of 12 swines alternatively. Two months after the procedure the 
animals were sacrificed for histologic evaluation. 
Results: Under light microscopy, only rare SMCs were observed in the 
neointima layer of group A segments, in contrast to numerous SMCs in group 
B. Both maximal intimal thickness (0.20 f 0.11 vs. 0.32 & 0.14 mm, P < 
0.01) and media thickness (0.12 i: 0.003 vs. 0.17 f 0.005 mm, P x 0.02) 
were less in group A compared to group B. 
Conclusions: The development of intimal hyperplasia may be reduced 
by the inhibition of SMC migration from the arterial media towards the intima 
resulting in atrophy of the media. This may be the target of future interventions 
to prevent restenosis. 
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/ 1064 90 Transluminal Endovascular Graft Placement With INOUE Stent Graft is Effective for Many Types of 
Aneurysms 
Kenichi Abe, Takeshi Kimura, Arata Tabuchi, Hiroyoshi Yokoi, 
Yoshihisa Nakagawa, Naoya Hamasaki, Hideyuki Nosaka, 
Masakiyo Nobuyoshi, Kanji moue. Kokura Memofiaial Hospit& Kifakyusbu; 
Takeda Hospital, Kyoto, Japan 
The feasibility and efficacy of Transluminal Endovascular Graft Placement 
(TEGP) with INOUE stent graft for treatment of many types of aneurysms 
was investigated. Since Aug. ‘97 and Aug. ‘99, We performed TEGP with 
INOUE stent graft in 34 patients (pts.) 35 lesion (les.) (27 men and 7 women; 
mean age 73 * 9 years). The les. consists of 20 infrarenal Abdominal Aortic 
Aneurysms (AAAs), 4 Thoracic Aortic Aneurysms (TAAs), 7 Dissecting Aortic 
Aneurysms (DAAs) (36) 3 Thoraco-abdominal Aortic Aneurysms (AAs) and 
1 Common iliac AA. Twenty (58.8%) of the pts. had medical conditions 
that excluded them from open repair, 10 high age more than 79 years, 1 
Aortic stenosis, 5 sever pulmonary dysfunction, 1 sever renal dysfunc-tion, 
1 Hepatic cell carcinoma, 1 paralysis due to prior cerebral infarction and 1 
impossibility to have blood transfusion for his faith. INOUE stem graft was 
inserted through 20-24 Fr. sheath via a femoral artery under local anesthesia 
and was fabricated as self-expandable with adjunctive balloon expanding. 
Eighteen (51.4%) of les. had a bifurcated stent graft, 7 (20.0%) had straight 
graft, 8 (22.9%) had single brunch graft, 1 (2.9%) had dual brunch graft 
and 1 (2.9%) had three brunches stent graft. In all cases, stent graft were 
implanted successfully to the intended sites. Mean procedure time was 2.92 
f 1.25 hours. One pt. (2.9%) died due to shower embolism at 5 days after 
TEGP for AAA. One pt.(2.9%) undergoing TEGP for Thoraco-abdominal AA 
had transient paraplegia. Nine pts. (26.5%) required transfusion The mean 
follow-up was 9 months (range, 1-25 months). One pt. (2.9%) had surgery 
at 67 days because of graft dislodgement and severe leakage. Only one 
pt. (2.9%) has minor residual leakage up to now and 1 pt. (2.9%) has late 
development of endoleakage. Among 23 pts. more than 3 month after TEGP, 
the maximum diameter of aneurysms decreased in 11 (47.8%) pts. and 
increased in one (4.3%) pt. 
Conclusion: TEGP with lnoue stent graft 1) is less invasive and at least 
as effective as surgery, 2) is especially useful for high risk pts, and 3) can be 
used in many types of aneurysms not only AAA, but also TAA, DAA involving 
major branches of aortic arch. This advantage is due to its high flexibility and 
side branch availability. 
1064-91 Descending Thoracic Aorta Disease Treated by 
Percutaneous Endoprosthesis: A Brazilian 
Experience 
J. Honorio Palma, Jose A.M. Souza, Claudia MR. Alves, Dirceu 
R. Almeida, Jo&o L.V. Herrmann, Antonio C. Carvalho, Enio Buffolo. 
UNIFESP-EPM, S3o Paulu, ST, Brazil 
Purpose: Surgical treatment of diseases of the descending thoracic aorta 
still carries high morbidity and mortality. We report our experience with the 
use of a percutaneous Braile’” stent-graft endoprosthesis as an alternative to 
surgery in complicated type B aortic dissection (AD - 17 pts), tree descending 
aortic aneurysm (7 pts) and aortic atherosclerotic penetrating ulcer (AAPU - 
6 pts), and 2 pseudoaneurysms. The device is self-expandable and covered 
with a polyester mesh with a final diameter after expansion varying from 
20-24 Fr and delivered by transfemoral approach. 
Methods: From Dee/96 to Aug/99 32 pts (ages 18-80, mean 60.7 years 
old) were treated with stent-graft endoprosthesis. All pts were treated for 
recurrent pain, expansion or signs of rupture. The procedure was done at 
the cath lab and the device deployed under angiographic and TEE guidance. 
General anesthesia was used in most cases (30/32 pts). All pts underwent 
CT or MRI evaluation 3 to 5 days after the procedure and at 6 months of 
follow up. 
Results: The procedure was successful in 27 patients (84.4%) as the 
device properly sealed the false lumen, the ulcer or the aneurysm lumen 
as documented by angiography or TEE. The in-hospital mortality was 6.2% 
(2/32 - both of multiple organ failure), and elective surgical correction was 
necessary in 2 pts (a pseudo coarctation as the stent-graft “kinked” and one 
pt with persistent severe leaking). The mean ICU and hospital length of stay 
after the procedure was of 3 and 5 days respectively, and blood transfusion 
was required in 5 pts averaging 0.2 pack of red blood cell/pt. At a mean 
follow-up of 9.7 months 28 pts are alive (survival rate of 87.5%): One late 
death was due to an acute myocardial infarction and a sudden death was 
diagnosed as an aortic rupture at necropsy. Reopening of false lumen was 
detected in 2 pt and one required surgical correction, Of pts with successful 
procedure at hospital discharge 88.8% are free of events (death, surgery, 
and any leak) at follow-up. 
Conclusion: Percutaneous treatment of selected cases of AD, true 
aneurysms of descending aorta and AAPU with the use of an endopros- 
thesis is feasible with a high success rate, low mortality, shorter hospital stay 
and less blood utilization. At a mean follow up of 9.7 months results are 
maintained with a small attrition rate: however, a longer follow-up is needed. 
1 1064-92 1 The Kit Carson Approach to Chronic Total 
Occlusions of the SFA 
G. Biamino, J. Margolis, A. Hedrick, J. Neet, N. Morris. Clinical Research & 
Education, Miami Heart Institute, Miami Beach, FL, USA 
Background: Long superficial femoral artery (SFA) occlusions have a rel- 
atively low success rate because of the tendency for guidewires to take a 
subintimal course. Consequently, patients with long SFA occlusions are usu- 
ally referred for surgical revascularization. If one could have a scout looking 
ahead of the guidewire to warn of impending sub-intimal passage, it should 
be possible to cross long SFA occlusions on a consistent basis. A new 
Guidewire System (Safe-Steei”, IntraLuminal Therapeutics, Carlsbad, Cali- 
fornia), that uses Optical Coherence Reflectometry (OCR), makes it possible 
to navigate such lesions. We have used this approach in conjunction with 
Excimer laser angioplasty to treat successfully a 20 cm SFA occlusion. 
Description of Device: This new technology is based on the variable 
absorption and scattering of near-infrared light by substances such as plaque, 
blood, tissue and thrombus. Algorithms have been devised based on variable 
absorption rates and different scattering coefficients as a light beam of known 
intensity is introduced through the guidewire and illuminates adjacent to the 
tip. 
Procedure: A 20 cm occlusion of the (SFA), was treated with a 2.2 
mm Spectranetics’” Excimer laser catheter using the step-by-step technique. 
To avoid misdirection of the laser catheter, the Safe-Steer’” Guidewire was 
substituted for the usual guidewire. Using the Safe-Steei” Guidewire as a 
“scout” to warn of impending sub-intimal passage, the occlusion was crossed 
quickly and accurately. When laser catheter and guidewire approached arte- 
rial wall, real-time feedback from the Safe-Steep Guidewire made it possible 
to redirect the laser catheter, thus avoiding dissection or perforation. 
Results: This technique of leading with the guidewire to assure intralu- 
minal maintenance and following with the therapeutic catheter allowed us to 
successfully traverse the CT0 while minimizing the risk of arterial wall per- 
foration. Complete recanalization of the vessel was achieved and enhanced 
with balloon angioplasty achieving a residual stenosis of 10%. 
Conclusion: In this first experience, the Safe-Steei” Guidewire System 
was a safe and efficacious complement to standard technique. Real-time 
feedback allowed for immediate catheter redirection of the laser catheter and 
confidence that lasing was occurring within the true lumen. Additional studies 
will need to be undertaken to further support this finding. 
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1065-l 15 Percutaneous Transluminal Coronary 
Anoioplastv Results in Stimulation of Monocvte- 
bucNot Eo&nophil-Specific Chemotaxis 
Emanuel V. Economou, Anastasia A. Katinioti, Christodoulos I. Stefanadis, 
Christos P. Pitsavos, Athanasios G. Trikas, Marina G. Toutouza, Pavlos 
K. Toutouzas. Dept, Cardiology, Univ. Athens, Hippokration Hospital, 
Athens, Greece 
Background: Percutaneous transluminal coronary angioplasty (PTCA) leads 
to the release of inflammatory mediators, including chemokines, as a result 
of plaque rupture and endothelial injury. Monocyte chemoattractant pro- 
tein-l (MCP-I) and eotaxin (EOX) are monocyte- and eosinophil-specific 
chemokines, respectively, involved in the migration across and the initial 
adhesion of these cell types to the inflammatory site(s) of endothelium. Aim 
of this study was to evaluate the significance of circulating soluble forms 
of MCP-1 and EOX in patients (pts) with coronary artery disease (CAD) 
undergoing PTCA in a three months follow-up. 
Methods: Twenty nine consecutive pts with CAD referred for an ini- 
tial elective PTCA and obtained primary success (<IO% residual diameter 
stenosis). Twenty CAD pts who underwent elective coronary angiography 
without PTCA (CA) and 20 healthy subjects (HS) sewed as controls. Periph- 
eral blood was sampled on the morning of PTCA or CA and at 24 hours (h) 
as well as 3 months (m) after PTCA or CA and was evaluated for plasma 
levels of MCP-1 and EOX (both measured by ELISA). In CAD pts undergoing 
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PTCA, before the procedure, MCP-1 plasma levels (579 f 97 pg/mL) were 
similar to those of CA pts (549 f 87 pg/mL) but significantly higher compared 
to those of HS (97 & 12 pg/mL, p < 0.001). These levels rose significantly to 
618 i 76 pg/mL after 24 h and to 676 f 78 pg/mL after 3 m (p < 0.03 and 
p < 0.001, respectively, in comparison to values before PTCA). However, in 
CA pts, MCP-1 plasma levels rose to 589 i 72 pg/mL after 24 h (p < 0.002, 
in comparison to the respective levels before CA) and declined after 3 m to 
values similar to those before the procedure (532 i 76 pg/mL, p < 0.006 in 
comparison to the respective levels after 24 h). EOX plasma levels, before 
PTCA, were (159 i 22 pg/mL) similar to those of CA pts (146 i: 28 pg/mL) 
before the respective procedure but significantly higher compared to those 
of HS (91 i 15 pg/mL, p < 0.002). These levels rose significantly to 210 + 
27 pg/mL (p < 0.004 in comparison to the respective levels before PTCA) 
and declined after 3 m to values similar to those before the procedure (172 
f 32 pg/mL, p < 0.007 in comparison to the respective levels after 24 h). 
Similarly, in CA pts, EOX plasma levels rose significantly to 191 f 34 pg/mL 
after 24 h (p < 0.03 in comparison to the respective levels before CA) and 
declined after 3 m to values (152 f 28 pg/mL, p < 0.01 in comparison to the 
respective levels after 24 h) similar to those before the procedure. 
Conclusions: These data indicate that chemokine-induced monocyte- 
and eosinophil-specific chemoattraction are both stimulated in CAD pts, prob- 
ably due to the disease-related endothelial damage. PTCA triggers preferably 
chemokine-induced monocyte-specific chemoattraction. Since monocytes, in 
contrast to eosinophils, can form foam cells, this may contribute to the pro- 
gression of CAD, possibly not only at the site of PTCA-induced endothelial 
damage. 
L---L-m 1065 116 Exochelin Prevents Neointima Formation After Coronary Artery Balloon Injury in a Porcine 
Model 
Eli A. Rosenthal, Teresa J. Bohlmeyer, Alastair D. Robertson, 
Catriona MacPhail, Eric Monnet, Lawrence D. Horwitz. University of. 
Coiorado Health Sciences Center, Denver, Colorado, USA 
Background: Vascular smooth muscle cell proliferation is a critical factor 
in the neointima formation that causes restenosis following coronary angio- 
plasty (PTCA). Exochelin (EXO), a highly diffusible lipophilic iron chelator 
secreted by Mycobacterium tuberculosis, inhibits proliferation of vascular 
smooth muscle cells in culture. We hypothesized that treatment with EXO 
would inhibit neointima formation in balloon-injured vessels in viva. 
Methods: Twenty-four pigs were subjected to overstretch coronary artery 
injury with PTCA balloons. With the investigators blinded, the pigs were 
randomized to receive via Infiltrator catheter intramural injections of either 
EXO (n = 14) or saline (control)(n = 10). After euthanasia 30 days later, 
injured coronary segments were excised and the site of maximal neointima 
formation identified. An injury score was assigned, neointima thickness was 
measured, and ratio of neointima area to internal elastic lamina (IEL) area 
(stenosis index) was calculated. 
Results: After adjustment by analysis of covariance for injury score, EXO 
reduced stenosis index by 47% and corrected neointima thickness by 48%. 
Stenosis Index* 
Neointima thickness* 
Control 
0.49 i 0.06 
0.29 f 0.03 
EXO 
0.26 i 0.06 
0.15 * 0.02 
P value 
0.007 
0.003 
Data presented as mean & standard error, “adjusted for grade of injury, Neointima thick- 
ness corrected by IEL area and reported in units l/mm 
Conclusion: EXO substantially reduced neointima formation in this por- 
cine overstretch injury model of restenosis. Therefore, EXO is a candidate 
for prevention of restenosis clinically. 
l--A 1065 117 Non-Invasive Ultrasound Induced Heating of 
Stents: Importance of Stent Composition 
Birendra Lal, Bujin Guo, Morteza Naghavi, James T. Willerson, 
Ward Casscells. University of Texas at Houston, Houston, Texas, USA 
Background: Hyperthermia is known to have anti-proliferative and apop- 
totic effects, which have been investigated extensively in cancer studies. We 
demonstrated gentle heating suppresses pro-inflammatory cytokines and 
promotes macrophage apoptosis, and thus mitigates inflammation in athero- 
sclerotic plaques. We hypothesized that gentle heating can be accomplished 
using ultrasound (US) and a constant temperature can be maintained using 
pulsed US. The heating rate of an object under the same US power and 
frequency is determined primarily by its absorption and reflection rates. 
Methods: To test the hypothesis, we used a phantom of 5.08 cm thick 
layer of pork muscle, in which various annular stent shape materials were 
placed. To monitor the heating multiple hypodermic thermocouples were 
used. The heating was induced using FDA-approved levels of therapeutic 
ultrasound (intensity 0.5-2.5 W/cm’, frequency l-3 MHz) in both pulse and 
continuous modes. It was found that nylon, and some types of PVC, exhibit 
temperature increases that are larger (235’ C) and faster (1.5-15 times) 
than the surrounding tissue, while Lexan, PTFE, Latex, Teflon, Ceramic and 
Delrin do not display selective heating. A modest heating effect (2’C increase 
in 15 minutes) was also found in a metal stent. 
Conclusion: US heating of tissue adjacent to a prosthesis depends on 
stent composition, induction of thermal apoptosis by ultrasound may prove to 
be effective in limiting restenosis in polymeric stents and grafts. Issues that 
need to be addressed include the optimal biocompatible material and design 
of stents and the in-vivo effects of phased-array US on the stented artery 
and its surrounding tissues. We hypothesized that by using fast-heating, 
non-toxic materials, we could devise US-heated stents. 
1 1065-l 18 1 Angiographic and Histologic Effect of 
Endovascular Irradiation on Normal Pig 
Coronary Arteries at 6 Months 
Mahomed Y. Salame’ , Stefan Verheye’ , Nicolas A.F. Chronos’, Stephen 
P. Mulkey’ , Spencer B. King Ill’, Keith A. Robinson*. ‘Emory University 
School of Medicine, Atlanta, Georgia; *Atlanta Cardiovascular Research 
Institute, Atlanta, Georgia, USA 
Background: Endovascular radiation (ER) reduces neointima formation in 
balloon-injured vessels. During ER adjacent normal vessel is often irradiated. 
Since little is known about ER of normal arteries, we studied its effects in pig 
coronaries. 
Methods: Normal right coronary arteries of adult mini-pigs received ER 
(0,7, 14,21,28 Gy at 2 mm) and animals were given aspirin daily. Reference 
(ref LD), minimum and maximum lumen diameters were measured by QCA 
at 6 months and histopathology performed. 
Results: On QCA, control sham-irradiated vessels were seen to have 
a % diameter stenosis of 3.7 & 5.8. Normal vessels exposed to ER (7, 14 
or 21-28 Gy at 2 mm) showed segmental heterogeneity in lumen diameter. 
Increased % stenosis occurred in ER compared to controls; stenotic areas 
were associated with a combination of mural thrombus and fibrous neointima. 
Additionally, focal enlargement (>25% of refLD on QCA) did not occur in the 
control or 7 Gy groups but tended to occur in vessels receiving 14 or 21-28 
Gy (x2: p = 0.11). These enlarged segments showed medial atrophy, little 
neointima and occasional small thrombi. 
Group A:0 Gy Group B:7 Gy Group C:14 Gy Group D:21-28 Gy 
% Stenosis 3.7 * 5.8 39.4 f 0.4* 28.0 * 9 4* 41.3 + 5.3’ 
n Enlargement 014 o/2 2/3 213 
(~25%) 
tp = 0.001; @p = 0.008; *p = 0.0003 compared to control (Group A) 
Conclusions: Normal non balloon-injured pig coronary arteries treated 
with ER at low and high doses are associated with 1) increased diameter 
stenosis related to a combination of thrombosis and neointima formation and 
2) a trend towards vessel enlargement for 14-28 Gy. Further study using a 
more potent antiplatelet agent is needed. 
1065-l 19 Tranilast Reduces Arterial Wall Cell Proliferation 
After Balloon Angioplasty in Pig Coronary 
Arteries 
Stefan Verheye’ , Mahomed Y. Salame’, Sugao Ishiwata’ , Hector De 
Leon’, Spencer B. King Ill’, Keith A. Robinsor?, Nicolas A.F. Chronos’. 
‘Emory University School of Medicine, Atlanta, Georgia; ‘Atlanta 
Cardiovascular Research Institute, Atlanta, Georgia, USA 
Background: Tranilast (T), an anti-keloid and anti-allergic drug, has been 
shown to reduce restenosis after PTCA in human coronary arteries and 
inhibit neointima formation in ballooned pig coronary arteries. We therefore 
investigated whether this result was associated with an antiproliferative effect 
of T. 
Methods: Eighteen pigs were randomized to receive T orally (4 g/d) 
or placebo. PTCA of the LAD and LCX was performed in all pigs; T was 
started 3 days prior to PTCA and continued until euthanasia at 3, 7, and 
14 days. Bromodeoxyuridine (BrdU) was given 24 h before euthanasia in 
all pigs. Sections were prepared for BrdU-staining. Proliferating cells in 5 
vessel regions (I: media at tear, II: media away from tear, Ill: adventitia at 
tear, IV: adventitia away from tear, V: neointima) of 3 sections per vessel 
were counted and expressed as a % of the total cell count in each region. 
Results: T reduced proliferation at 3 days in regions I (17.3 vs 27.7, p < 
0.05) and IV (13 vs 28.6, p < 0.05), at 7 days in regions I (9.8 vs 25.4, p < 
O.Ol), Ill (8.1 vs 36.7, p < 0.001) and V (40 vs 60.5, p < 0.05). By 14 days 
the % of proliferating cells was relatively low in the C group and T did not 
reduce it further (p = ns in all regions). 
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Conclusions: The inhibitory effect of T on neointima formation after PTCA 
in pig coronary arteries is associated with an antiproliferative effect, which 
occurs within the first week after PTCA. 
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El 825 1 A Multicenter Registry of the JoStent@ PTFE Stent Graft for the Treatment of Arterial Perforations 
Complicating Percutaneous Coronary Interventions 
Alexandra J. Lansky, Gregg W. Stone, Eberhard Grube, Brian Proctor, 
Victoria Curling, Abdel Brahimi, Mina Nakbeen, Adrian Danchenko, Hui Bui, 
Martin B. Leon. The Washington’Hospital Center; Washington, D.C., USA 
Background: The incidence of perforations complicating coronary inter- 
ventions with new devices ranges from 0.15% to 2.5%, accounting for an 
estimated 4000 cases in the United States annually. Free flowing perforations 
are associated with an in-hospital MACE rate ranging from 40% to 60% and 
a mortality rate of up to 20%. 
Methods: The JoMed@ stent graft, a PTFE stent sandwich ideally suited 
for treatment of coronary perforations, was assessed in a multicenter interna- 
tional registry of 35 patients. Indications for JoStent@ implantation in native 
coronaries (77.8%) and saphenous vein grafts (22.2%) included perforations 
complicating coronary intervention (N = 32), AV fistulae (N = 2), and large 
aneurysm (N = 1). 
Results: The mean patient age was 66 years and 65.7% were male. 
Procedural complications prior to JoStent implantations included pericardial 
effusion in 22% and tamponade treated with pericardiocentesis in 13.9%. 
A single patient had a cardiac arrest and was successfully resuscitated. 
JoStent@ deployment was successful with complete perforation sealing in 
100% of cases. A total of 28 of the 35 cineangiograms were suitable for 
independent angiographic assessment. Grade I perforations (contained) (N 
= 4) were all sealed with a single JoStent@. Grade II perforations (myocardial 
blush without contrast jetting) (N = II), were sealed with a single (N = 9) or 
3 JoStents (N = 1). One additional patient in this group had acute closure 
proximal to the JoStent. Grade Ill perforations (frank perforation with contrast 
jetting) (N = 7) were sealed with a single (N = 4) or 3 JoStents@ (N = 1). 2 
cases in this group had a residual grade I perforation, but remained clinically 
stable. The 2 large AV fistulae and the aneurysm were completely sealed 
with 2 JoStents”. The final JoStent diameter stenosis was 11%. There were 
no procedural or in-hospital deaths, and no patient developed a Q-wave Ml 
or required emergency CABG. 
Conclusion: In hemodynamically compromising perforations complicat- 
ing coronary interventions, PTFE covered stents can be used emergently 
with a high success rate and may be life saving where other conventional 
treatment modalities are associated with high morbidity and mortality rates. 
9:30 a.m. 
825-2 Comparison of Procedural and One-Year Outcome 
With Only Balloon Angioplasty, Covered Stents and 
Non-Covered Stents in Saphenous Vein Grafts 
Aniruddha Dharmadhikari, Carlo Di Mario, Vaios Tzifos, Angelo Anzuini, 
Margaret Puchala-Borowik, Flavio Airoldi, Georgio Gimelli, Mauro Carlino, 
Antonio Colombo. Hospital San Raffaele and Centfo Cuore Columbus, 
Milan, ltaly 
Background: Considering the high incidence of thromboembolic complica- 
tions and restenosis following percutaneous interventions (PCI) on saphe- 
nous vein grafts (SVG), we assessed the utility of covered stents to improve 
the results in these lesion subsets. 
Methods: A retrospective comparison of the procedural and one-year 
follow-up results was made in 186 patients who had undergone a technically 
successful PCI on the SVGs either by only balloon angioplasty (POBA), non- 
covered stents or polytetrafluoethylene (PTFE) covered stents - coronary 
stent graft JoStent (JoMed International AB, Helsingborg, Germany). The 
baseline clinical characteristics in the three groups were comparable. 
Results: There was no statistically significant difference between imme- 
diate results in the three groups. However, at the end of one year follow-up 
period, event-free survival in the covered stent group was significantly better 
than that in the POBA group (p = 0.04). 
Conclusions: There is a definite trend towards lowered incidence of 
in-hospital and follow-up adverse events with the use of covered stents in 
POBA Non-covered 
stents 
Covered P 
stem 
“= 
Mean Graft Age 
In-hoso MACE 
MI 
CABG 
Death 
Follow-up MACE 
MI 
Death 
Revascularization 
Event-Free Survival 
31 125 
116Lk64 106161 
4 (12.9) 11 (8.8) 
2 11 
1 0 
1 0 
12 (41.4) 44 (35.5) 
2 6 
1 3 
9 35 
15 (48.4)) 70 (56) 
30 
120+55 ns 
1 (3.3) “S 
0 
0 
7 (24.1) ns 
0 
22 ($3.3)) 0.04 
Figures in parenthesis indicate percentages; ns = not significant 
diseased SVGs. A large randomized study appears necessary to support the 
preliminary observations. 
9:45 a.m. 
L-i-.-l 825 3 Feasibility, Immediate and Long-Term Results of the Autologous Venous Graft-Covered Stents: 
A Retrospective Comparative Analysis 
Eleftherios Tsiamis, Christodoulos Stefanadis, Konstantinos Toutouzas, 
loannis Kallikazaros, Costas Stratos, Manolis Vavuranakis, 
Konstantinos Tentolouris, Costas Tsioufis, Pavlos Toutouzas. Hippokration 
Hospital, University of Athens, Greece 
Previous experimental studies with the autologous venous graft-covered 
stent (AVGCS) have shown favorable results. The aim of this study was to 
evaluate the feasibility and safety of this new technique in human coronary 
arteries and to compare the long-term outcome with uncovered stents. 
Methods: Conventional stents were covered either completely, both in- 
ternally and externally, or only externally by autologous venous grafts. Fifty- 
eight AVGCSs were implanted in 56 patients. Additionally, in 113 patients 
738 uncovered stents were implanted serving as a control group. 
Results: The procedure was successful in all patients. Acute thrombosis 
was observed in 3 patients of the control group. One patient-with an AVGCS 
presented with subacute thrombosis. The target vessel revascularization rate 
was 12% in the AVGCS group vs 14.5% in the control group (p = NS). The 
restenosis rate was 13.3% in covered stents vs 20.8% (p = NS). The MLD 
had a trend to be greater in the AVGCS group at follow-up (2.22 f 0.9 vs 
2.10 * 0.9 mm, p = 0.07). The event-free survival rate at 4 years was 86% 
in the AVGCS vs 81% in the control group (figure, p = NS). Stents covered 
by thicker venous grafts were associated with improved clinical outcome (p 
< 0.02). 
Control 
Conclusions: Covered stents by autologous venous grafts may be safely 
implanted without procedure-related complications. This technique may be 
successfully used for several indications. 
IO:00 a.m. 
825-4 The JOSTENT’” Coronary Stent Graft - Just Another 
Stent? . . . or How Should it be Implanted? 
Clemens von Birgelen, Michael Haude, Christoph Altmann, Jdrg Herrmann, 
Heinrich Wieneke, Matthias Jasper, Jens Brinkhoff, Dietrich Baumgart, 
Stefan Sack, Raimund Erbel. Universitiy Hospital Essen, Department of 
Cardiology, Essen, Germany 
Background: Recently, the novel JOSTENT’” Coronary Stent Graft (CSG), 
consisting of two thin metal stents that fix a thin flexible polytetrafluoroethy- 
lene (PTFE) membrane in-between, has been introduced. However, knowl- 
edge about the deployment characteristics of this new device are very limited. 
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Methods and Results: Twenty-four CSG were implanted for treatment 
of acute coronary rupture, degenerated vein graft lesions, thrombus-contain- 
ing lesions, lesions with ruptured plaque or adjacent pseudoaneurysm, and 
stents with recurrent in-stent restenosis. All CSG were easily crimped on 
high-pressure balloon catheters and introduced without difficulties through 
mildly curved proximal segments. No CSG was lost and all CSG were suc- 
cessfully implanted at 16 i 2 atm. In 7 CSG, substantial residual diameter 
stenosis (DS) (p = 0.01) triggered post-dilatation (PD) with a larger balloon 
(table). Quantitative angiographic analysis, which included all intermediate 
steps of the procedure, demonstrated in the PD group that the initial balloon 
size matched the diameter of the reference segment only. After PD, the fi- 
nal B/A (balloon-to-artery) ratio of all 24 CSG was 1.21 + 0.20 (at 16 f 3 
atm). Elective CSG implantation was associated with 2 small non-Q-wave 
myocardial infarctions, resulting from unavoidable side branch occlusion by 
the membrane. 
B/A Ratio Post Implantation 
B/A Ratio Final 
DS Post implantation (%) 
PD No PD P 
1 .oo i 0.09 1.24 zkO.18 <O.Ol 
1.15io.15 1.24iO.18 Ns 
25110 8+6 co.005 
DS Final &) 83~5 8*6 NS 
Conclusions: The use of oversized high-pressure balloon catheters is 
mandatory to achieve an adequate expansion of this new CSG. Implantation 
of the device is feasible and safe, but the endoprosthesis should be accurately 
sized and placed to avoid occlusion of side branches originating from the 
target lesion segment. 
IO:15 a.m. 
825-5 Four-Year Follow-Up After Autologous Venous 
Graft-Covered Stent implantation: Impact of Vein 
Thickness in the Long-Term Outcome 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, 
loannis Kallikazaros, Costas Stratos, Manolis Vavuranakis, 
Konstantinos Tentolouris, Pavlos Toutouzas. Hippokration Hospital, 
Universify of Athens, Greece 
Background: The immediate and mid-term results after the implantation of 
the autologous venous graft-covered stent (AVGCS) were favorable. How- 
ever, the long-term outcome remains unknown. 
Methods: Conventional stents were covered by autologous venous grafts 
of different vessel wall thickness. Forty-three grafts were removed from the 
anterobrachial region (thicker veins) and 15 from the deltoideopectoral sul- 
cus (thinner veins). The stents were covered by the graft. Non-premounted 
(Palmaz’“, a Palmaz-Schatz’“) and premounted stems (Mu&link”) were used. 
Fifty-eight AVGCSs were implanted in 56 patients (pts). Follow-up was ob- 
tained in all pts until 41.7 & 12.4 months. 
Results: The procedure of AVGCS preparation and delivery to the target 
vessels was feasible and uncomplicated. Acute thrombosis was not ob- 
served. One patient suffered from subacute thrombosis The angiographic 
restenosis rate was 13.3% and the target lesion revascularization rate was 
12% The event-free survival rate at years was 86%. The event-free survival 
rate was greater in pts with stents covered by thicker venous grafts (94% vs 
68% respectively, p < 0.02, figure). 
1 
20 40 
Conclusions: At near 4-year follow-up after the implantation of AVGCS 
late restenosis was not detected. The clinical outcome is influenced by the 
thickness of the venous graft used for covering the stents. 
IO:30 a.m. 
825-6 Stents Covered by Autologous Arterial Grafts in 
Human Coronary Arteries: Long-Term Angiographic 
and Clinical Follow-up 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, 
loannis Kallikazaros, Costas Stratos, Manolis Vavuranakis, Costas Tsioufis, 
Konstantinos Tentolouris, Pavlos Toutouzas. Hippokrafion Hospitaal, 
University of Athens, Greece 
A renewed interest for radial artery conduits for bypass surgery has been 
emerged during the last years. In order to combine a surgical with a percuta- 
neous technique, stents were covered by autologous radial arterial grafts. We 
evaluated the late outcome of 15 patients (pts) who underwent autologous 
arterial graft-covered stent (AAGCS) implantation. 
Methods: A graft from the radial artery was harvested. Conventional 
stents were covered by the arterial grafts. Fifteen covered stents were im- 
planted in 15 pts (mean age: 56.12 + 7.34 yrs). The AAGCSs were implanted 
in selected lesions, in totally occluded vessels, in ostial lesions, in thrombus- 
containing lesions, in bail-out cases and in saphenous vein grafts, 
Results: Results. The procedure of stent covering was feasible and short 
in duration. Procedural success was 100% with no in-hospital stent throm- 
bosis, Q-wave myocardial infarction or death. In 14 pts (93.3%), including 
pts with clinical restenosis, a repeat angiography was performed after 9.8 f 
2.4 (MLD immediately after: 2.92 f 0.22, follow-up: 2.15 & 0.54 mm). Target 
lesion revascularization was required in 2 pts. The event-free survival rate at 
3.5 years was 87% (figure). 
Conclusions: The clinical experience by using the AAGCS in human 
coronary arteries was encouraging regarding the immediate and follow-up 
results. Since covering of stents by an autologous arterial graft may be 
applied for several indications, the efficacy of this technique needs to be 
further evaluated. 
Conclusions. lntracoronary implantation of stents covered by an autolo- 
gous arterial graft may be performed safely with excellent long-term results. 
A multicenter study is required to assess the efficacy. 
ORAL 
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9:15 a.m. 
826-l One-Year Follow-Up of Endovascular Irradiation in 
Pig Coronary Arteries 
Mahomed Y. Salame’ , Stefan Verheye’ , Stephen P. Mulkey’ , Ian 
R. Cracker’ , Nicolas A.F. Chronos’, Spencer 8. King Ill’, Keith 
A. Robinson’. ‘Emory University School of Medicine, Atlanta, Georgia; 
‘Aflanta Cardiovascular Research Institute, Atlanfa, Georgia, USA 
Background: Previous studies showed vessel enlargement and mural throm- 
bosis resulting in angiographic segmental heterogeneity, in both normal and 
balloon-injured pig coronaries at six months. In the present study we sought to 
determine whether these phenomena were resolved by one-year follow-up. 
Methods: Six adult mini-pigs underwent overstretch balloon coronary 
injury in the LAD and LCX. LAD, LCX, and RCA then received ER (14 or 28 
Gy to 2 mm from source center) or sham treatment (n = 2 pigs per group). 
They were given aspirin 81 mg daily for six months, then were euthanatized 
at one year post-angioplasty for tissue harvest after repeat angiography. 
Results: Angiography of control pigs showed smooth vessel contours 
in both non-injured RCA and ballooned LAD and LCX; ballooned arteries 
showed medial ruptures associated with fibrous neointima under histologic 
examination. However in irradiated coronaries whether ballooned or not 
and especially at 28 Gy, segmental luminal heterogeneity was apparent 
with alternating regions of enlargement and stenosis. Histologic evaluation 
showed stenoses corresponded to regions of mural thrombus; little fibrous 
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neointima formation was observed especially in coronaries treated with 28 
Gy. Ballooned irradiated vessels had smaller lumens and larger neointima 
(composed of poorly organized mural thrombus) than ballooned controls (see 
table). Even non-ballooned vessels showed mural thrombus, and these also 
displayed regions of medial atrophy. 
Histomorphometry of Ballooned Coronaries 
LUmen Vessel lntima IntimaIfracture 
Control 2.27f 1.10 4.13 f 0.72 0.8 * 20.60 0.48 f 0.18 
14Gy 1.16*0.73 3.73% 1.18 1.65 f oe7* 0.79 * 0.17** 
28Gv 1.17zt 0.49" 4.34 + 2.16 2.08 i 2.21 1.07& 1.10 
*P = 0.06 vs. control, ‘*P = 0.02 vs control 
Conclusions: Coronary pathology associated with endovascular irradi-’ 
ation in the presence and absence of balloon overstretch injury in pigs as 
detected at 6 months persists at one year. Longer-term follow-up is needed 
to determine the resolution of these phenomena, and further studies are 
needed to ascertain optimum close and adjunct antiplatelet therapy for clini- 
cal implementation. 
9:30 a.m. 
826-2 Low Versus High Dose Radiation has Divergent 
Effects on SMC Migratory and Adhesive Behavior 
Marvin J. Slepian, Behrooz Dehdashti, Anne Fritz, Keith A. Robinson, 
Luke Whitesell. lnterventional Cardiology, Sarver Heart Center, University of 
Arizona, Tucson, AZ, USA 
Background: Ionizing radiation has been shown to limit neointimal thickening 
following arterial injury. Smooth muscle cell (SMC) migration is a vital step in 
post-injury neointimal thickening. Little is known of the effects of radiation on 
SMC migratory and adhesive behavior. We examined the effect of radiation 
on: 1. post-injury SMC migration 2. integrin-dependent SMC adhesion and 
3. quantitative -1 and 3 integrin expression. 
Methods: Adult rat aortic SMC monolayers were scrape-wounded, im- 
mediately irradiated (Gamma source; 0.1, 1 and IO Gy) and migration at 48 h 
was determined as mean area of SMCs emerging from wound edges. SMC 
monolayers (3 x IO4 cell/mm’) were irradiated (0.1 and IO Gy), incubated 
for 24 h, harvested and resuspended in RPM1 + 0.2% BSA and seeded (IO4 
SMC/cm”) on Fibronectin (FN), Vitronectin (VN) or Collagen I (Col) coated 
dishes. Adherent SMCs/lOOx field were determined 1 h post-plating. -1 and 
3 integrin expression and cell viability were analyzed via flow cytometry on 
identically irradiated and incubated (24 h) SMCs. For all studies identically 
treated non-irradiated SMCs were controls. 
Results: (As % untreated control) Radiation altered SMC migration, with 
increased migration detected at low (0.1 Gy) dose and decreased migration 
at high (10 Gy) dose. (0.1 Gy: 125 i 6%, p < 0.001; 1 Gy: 105 f 3, p = 0.13; 
10 Gy: 80 f 7, p < 0.001). Radiation at low dose decreased SMC adhesion 
to FN (77 f 18%, p < 0.03) VN (40 & 18%, p < 0.001) and Col (75 rt 20%, 
p < 0.03) whereas at high dose it increased adhesion to FN (124 f 16%, p 
< 0.001) and Col (150 f 20%, p < 0.001). -1 and 3 integrin expression and 
cell viability were not altered over the studied radiation dosage range at 24 h. 
Conclusion: Radiation modulates post-injury SMC migration with diver- 
gent effects at low versus high doses. Altered migration involves changes in 
cell adhesive behavior in a manner mechanistically consistent with the na- 
ture of migration alteration, i.e. decreased adhesion in hyper- and increased 
adhesion in hypomigratory states. The divergent effects of radiation on SMC 
migration may contribute to the varying extents of neointimal thickening clin- 
ically detected at different distances from radiation sources. 
9:45 a.m. 
826-3 Effect of Gamma-Irradiation on Hydrated Collagen 
Gel Seeded With Arterial Smooth Muscle Cells 
Pierre-Frederic Keller, Thierry Ziegler, Bernadette Mermillod, 
Patrice Delafontaine, Georges Youri Popowski, Vitali Verin. Universify 
Hospital, Geneva; University Hospital Lausanne, Switzerland 
Background: Vessel wall responses to PTCA include neointimal proliferation 
and adventitial remodeling which involves both smooth muscle cells (SMC) 
and fibroblasts. The contraction of a collagen gel is a good in vitro model of 
wound repair and vascular remodeling. Because irradiation is an important 
new therapeutic modality capable to prevent restenosis the purpose of this 
study was to evaluate the effect of irradiation on the contraction of the 
collagen gel by SMC. 
Methods: We studied the effect of different doses (0 Gray (Gy) control, 6 
Gy, 12 Gy and 18 Gy) of gamma-irradiation on the contraction of a collagen 
gel seeded with SMC (calf carotid arteries) over a period of 15.days. 
Results: The decrease in the diameter of gels was much more important 
in the control than in the irradiated groups reaching 6.8 f 0.5 mm in the 
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control group; 13.7 i 0.8 mm in the 6 Gy group; 15.5 f 0.9 mm in the 12 
Gy group and 16.1 f 0.9 mm in the 18 Gy group at 15 days (p < 0.0001). 
The irradiated gels showed an important dose-dependent reduction in SMC 
proliferation rate (p < 0.0001) and increase in the number of non viable SMC 
(p < 0.002) 15 days after irradiation. 
Conclusion: Gamma-irradiation with single doses ranging from 6 Gy to 
18 Gy produces a significant dose-dependent inhibition of the contraction of 
collagen gels seeded with arterial SMC. This effect of irradiation is related to a 
significant decrease in SMC viability and a decrease in the proliferation rate. 
These findings shed light on mechanisms whereby irradiation may positively 
affect arterial remodeling after PTCA. 
IO:00 a.m. 
El 826 4 Matrix Metalloproteinase Inhibitor GM6001 Selectively Reduce lntimal Hyperplasia and lntima 
Collagen Content in Stented but not Balloon Treated 
Arteries 
Christopher W. Li, Warren J. Cantor, Ranga Robinson, John N. Wylie, Alan 
W. Barolet, Winston Tsui, Louis Fenkell, Bradley H. Strauss. St Michael’s 
Hospital, Univeristy of Toronto, Toronto, Canada 
Background: We have previously shown significant increase in collagen 
content and synthesis after stenting versus balloon angioplasty (BA). To 
investigate the role of matrix metalloproteinases (MMP) in such collagen 
upregulation we studied the effects of a non-specific MMP-inhibitor GM6001 
on stented and balloon treated arteries. 
Methods: In a double-injury rabbit model, adjacent iliac arteries received 
BA (3.0 mm) or stenting (NIR, 3.0 x 16 mm). GM6001 was injected S.C. 
(100 mg/kg/day) x 8 d. At IO wks arteries were removed for biochemical 
studies (n = 25) or perfusion fixed for histomophormetry (n = 17). The intima 
was separated from the medial-adventitial layers. These were incubated 
ex-vivo in “‘C-hydroxyproline for 6 hours. Collagen content and synthesis 
were determined by assays for total hydroxyproline and t4C-hydroxyproline, 
respectively. Perfusion fixed arteries with stents were embedded in plastic 
and cut with a tungsten carbide knife for cross-sectional area measurements. 
Results: GM6001 caused a significant 40% reduction in both intima total 
collagen content and intima cross-sectional area in the stented but not the 
BA treated arteries (diagram) (mean f SEM). Stent intima collagen synthesis 
was 258 f 69 and 163 * 51 (cpmisegment) in the control and GM6001 group 
respectively (p = 0.38). 
12 
N 0.8 
@ 
0.4 
0 
Conclusion: Selective effects of GM6001 on stent intima suggest different 
mechanisms of intimal hyperplasia in stenting versus balloon angioplasty and 
MMP-inhibition as a potential therapeutic target for in-stent restenosis. 
IO:15 a.m. 
826-5 Intravascular Sonotherapy Impacts Neointimal 
Hyperplasia Following Stent Implantation in Swine 
Femoral Arteries 
Peter J. Fitzgerald, M. Pauliina Moore, Motoya Hayase, Atsushi Takagi, 
Frank D. Kolodgie, Doug Corl, Menahem Nassi, Renu Virmani’, Paul 
G. Yock. ‘Armed Force Institute of Pathology Washington, DC; Stanford 
University Stanford, CA, USA 
Catheter based ultrasound therapy has been recently applied to clot lysis 
and plaque ablation. In-vitro studies suggest that the biological effects of 
ultrasound can impact intimal proliferation in both human and animal cell 
cultures. Accordingly, we assessed the effect of intravascular sonotherapy 
(ST) on intimal hyperplasia in a swine stent model. 
Methods: Following balloon injury, biliary stents were implanted in femoral 
arteries of 15 swine. Thirty-six stented sites were randomized to ST or sham 
therapy (SH) using an 8 Fr. catheter and ST system (URX’“, PharmaSonics 
Inc) Ultrasound energy was delivered at 600 KHz for the duration of 300 sec. 
The percentage of proliferating smooth muscle cells was assessed using 
Bromodeoxyuridine histology preparation (%BrdU) at 7 days in 20 stented 
sites. At 28 days, the absolute change in neointimal thickness and the ratio 
of neointimal/stent area (%stenosis) was calculated by histopathologic in 16 
stented sites. 
Results: No vascular complication was observed during the procedures. 
At 7 days, %BrdU was smaller in the ST group treated for 300 set than 
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SHT (24.1 i 7.0 vs. 31.2 * 3.0%, p < 0.05). At the 28 days, %stenosis was 
significantly less in the IST group (36 f 24%) than in the SHT group (44 i 
27%, p < 0.05). In addition, mean neointimal thickness in IST trended less 
(417 =t 461 ym) than in the SHT group (643 * 869 brn, p = 0.26). 
Conclusions: In this swine model, intravascular sonotherapy decelerates 
cellular proliferation which may decrease in-stent hyperplasia. Intravascular 
sonotherapy may be an effective non-ionizing energy source favorably im- 
pacting in-stem restenosis. 
ORAL 
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Monday, March 13, 2000, IO:45 a.m.-12:15 p.m. 
Anaheim Convention Center, Room 21 OA 
IO:45 a.m. 
834-l Predictors of Early Complications and “Optimal” 
Stent Results After Native Vessel Coronary Stenting. 
Is the ACC/AHA Lesion System Useful in Predicting 
Outcomes? 
Jeffrey J. Popma, Kalon Ho, Ross Prpic, Satyendra Giri, Ravi Rao, Donald 
E. Cutlip, Leonid Firer, Alla Lanina, Magdy Badareldin, Richard E. Kuntz. 
Brigham and Women’s Hospital, Boston, MA, USA 
Background: The ACC/AHA lesion classification system was developed to 
identifying patients “at risk” for early procedural failure and complications 
after conventional balloon angioplasty. 
Methods: To determine whether the ACC/AHA criteria predict outcome 
after elective coronary stenting, we reviewed the 30 day clinical events in 
4,202 patients undergoing coronary stent placement in several randomized 
steflt clinical trials. All patients were deemed suitable for placement of one 
or two Palmaz-Schatz coronary stents. 30 day major adverse cardiac events 
(MACE) included death, myocardial infarction, or urgent revascularization 
(TVR) and occurred in 3.4% of patients. Procedure success (PROC) was de- 
fined as ~50% diameter stenosis and no MACE. ACC/AHA lesion complexity 
was determined using standard definitions. “Optimal” stent implantation was 
defined a ~20% residual stenosis and no MACE. 
Results: Lesions were classified as type A lesions in 9.2%, type Bi in 
27.1%, type B2 lesions in 53.2%, and type C lesions in 10.5%. 
30d MACE, % 
PROC,% 
“Optrmal”, % 
30dTVR,% 
A I31 82 c A/B1 BP/C P value 
3.0 2.7 3.4 5.0 2.6 3.6 0.145 
98.1 98.7 97.6 97.3 98.5 97.6 0.046 
91.5 90.6 67.2 73.4 90.8 84.9 0.001 
3.0 2.7 3.5 5.3 2.8 3.8 0.089 
Multivariable regression demonstrated that lesion length 1 O-20 mm (odds 
ratio [OR]: 1.23; p = 0.051), lesion length > 20 mm (OR: 3.04; P < O.OOOl), 
bend > 45-90 degrees (OR: 1.35; p = 0.045) bend > 90 degrees (OR: 2.93; 
p = 0.067), and calcification (OR: 1.26; p = 0.046) predict a “suboptimal” 
stent result. 
We conclude that: 1) procedural success rates are high (>97%) and 
30 day complication rates are low (+O%) in patients undergoing elective 
stent placement, 2) the ACCiAHA criterion still predicts the occurrence of 
procedural success, and 3) the ACCiAHA criterion is a strong predictor of an 
“optimal” stent placement. 
II:00 a.m. 
834-2 Clinical and Angiographic Restenosis After Stenting 
of LAD Lesions: Insights From a Large Database of 
Recent Stent Trials 
Manish S. Chauhan, Kalon K.L. Ho, Donald S. Bairn, Christine Rizzitano, 
Janine Schmidt, Doreen Vovcsko, Richard E. Kuntz, Donald E. Cutlip. Beth 
lsraei Deaconess Medical Center, Boston, MA, USA 
Background: There are limited data on clinical and angiographic restenosis 
rates for stenting of LAD compared to other vessels especially in the era of 
newer stents, high-pressure dilation and anti-platelet regimens. 
Methods: Of 7,171 patients treated in 7 recent multicenter trials of coro- 
nary artery stenting with uniform criteria, 2442 (42%) underwent stenting of 
the LAD. 
Results: Patients undergoing treatment of LAD were more likely to have 
single vessel disease (71 vs. 59%, p = O.OOl), smaller vessels (2.8 vs. 3.1 
mm, p = 0.0001) and heavy calcification (21 vs. 14%, p = 0.001) compared 
to non-LAD. Diabetics were equally distributed. Angiographic and follow-up 
results are shown below. Clinical restenosis (CR, defined as target lesion 
revascularization) was significantly higher for LAD. Angiographic restenosis 
(AR, ~50% diameter stenosis) was not different, although late loss index (LI) 
was higher for LAD. In multivariable models, LAD was not an independent 
predictor of CR or LI after adjusting for vessel size, final lumen diameter 
(MLD),, lesion length and diabetes. 
LAD' Non-LAD P 
Final MLD (mm) 2.68 i 0.41 2.87 zt 0.43 0.0001 
Acute Gain (mm) 1.63i0.48 1.81 io.52 0.0001 
Late Loss(mm) 0.88 h 0.56 0.87 + 0.63 NS 
LI 0.58 i 0.47 0.50 + 0.38 0.003 
AR (%) 20.8 19.3 NS 
CR (%) 12.1 9.6 0.001 
Conclusions: CR and LI were higher for LAD, but these may be explained 
by smaller vessel size and final MLD rather than vessel location per se. 
11:15 a.m. 
l---L-l 834 3 Percutaneous Coronary Revascularization for Multivessel Disease in the Stent Era. Acute and 
Long-Term Outcome 
Francisco Fernanez-Aviles, Joaquin J. Alonso, Juan M. Duran, 
Federico Gimeno, Benign0 Ramos, Albert0 Ortiz, Raquel Palomino, Luis de 
ia Fuente, Olga Sanz, Javier Paniagua. Hospital Universitario, Valladolid, 
Spain 
Background: The objective of this study was to assess the efficacy of 
coronary stenting (CS) in the setting of multivessel disease. 
Methods: We followed 583 consecutive pts (62 i IO yr., 86% male) 
with multivessel coronary disease who underwent CS. Indication for PTCA 
was unstable angina in 63% of pts and 16% were diabetics. Seven percent 
of pts had previous heart failure and 52% previous myocardial infarction. 
Mean ejection fraction was 0.59 f 13 and the mean number of diseased 
vessels was 2.4 I 0.5. Clinical follow-up was completed for 94% of pts 
(mean time of follow-up: 36 & 18 m., 18-78). In 70% of pts revascularization 
was accomplished by means of Stent exclusively, while in the remaining 30% 
the procedure combined CS and balloon. 
Results: Initial clinical success (angiographic success without major com- 
plication) was 87%. The incidence of angiographic restenosis for any of 
treated vessels was 34% (Stented vessels: 31%, ballooned vessel: 45%). 
The long-term evolution is shown in the figure. 
The multivariate analysis (logistic regression) showed that diabetes (OR: 
1.46, 95%CI: 1.13-1.88), the minimal lumen diameter after PTCA and the 
occurrence of AMI during the procedure (OR: 2.2 95%CI: 1.15-3.88) were 
independent predictors of major adverse cardiac events in the long-term 
follow-up. 
Conclusions: Thus, initial outcome and long-term survival and revascu- 
larization free survival are acceptable in pts with multivessel disease treated 
with percutaneous revascularization using Stent. 
11:30 a.m. 
834-4 A New Score System to Predict Major 
Cardiovascular Events During Coronary Stenting. 
Does AHA/ACC Lesion Type Classification Matter? 
David Paniagua, William K. Vaughn, R. David Fish. St Luke’s Episcopal 
Hospital/Texas Hear? lnstitufe and Bay/or College of Medicine, Houston, 
Texas, USA 
Background: Predictors of outcomes after percutaneous coronary proce- 
dures were developed during the angioplasty (PTCA) era and thesevariables 
were extrapolated to the stent population. The best example is the ACCIAHA 
type of lesion classification. We sought to investigate which variables are pre- 
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dictive of major adverse cardiovascular events MACE-death, stroke, acute 
MI, urgent coronary bypass surgery (CABG)- during coronary stenting. 
Methods: We studied 5441 patients who underwent stent deployment at 
St Luke’slTexas Heart Institute in Houston, Texas from January 1994 until 
December 1998. Baseline demographics, comorbid conditions, AHAIACC 
angiographic lesion type, in-hospital outcome were analyzed. A multivariable 
analysis was performed using a logistic regression model. A score system 
was created based on the beta coefficiencies from the logistic model. The 
models were evaluated for predictive accuracy by using receiver operator 
characteristic (ROC) analysis. 
Results: The mean patient age was 62 f 11 years (range 26 to 92), 24% 
women, 22% diabetic, 71% hypertensive, 20% CABG, 51% previous my- 
ocardial infarction, 13% prior coronary interventions, mean ejection fraction 
48% * 13. MACE occurred in 3.5% of the population. The variables that pre- 
dict MACE in the multivariate analysis are previous CABG (OR 0.6, 95%CI 
O&0.9), unstable angina (OR 1.6, 95%CI 1 .I-2.3) urgent procedure (OR 
3.8, 95% Cl 2.6-5.3) congestive failure (OR 3, 95% Cl 2.1-4.4), and shock 
(OR 20, 95%CI 10.3-38.8). No other variable was significant predictor of 
MACE. The model assigned a score of -1 to previous CABG, 1 for unstable 
angina, 2 for urgent procedure and 2 for congestive heart failure. The maxi- 
mal score is 11 and the minimum 0. The in-hospital predictive mortality and 
MACE have a linear correlation with the score system The ROC predictive 
accuracy of the model is 0.75. 
Conclusion: The ACC/AHA lesion type does not predict major cardio- 
vascular events during coronary stent. This new score system is a simple 
prediction rule to risk stratify patients who undergo coronary stenting and 
identifies a group with very high complication rates. 
II:45 a.m. 
1 834-5 1 Risk of Early and Long-Term Events Following 
Coronary Stenting Are Not Predicted by Traditional 
Lesion Classification 
Leslie A. Webb, Eric R. Powers, Ian J. Sarembock, Lawrence W. Gimple, 
Lawrence R. Burwell, Michael Ragosta. University of Virginia He&h 
System, Charlottesville, VA, USA 
Background: The procedural success and risk of balloon angioplasty can be 
estimated prior to intervention by classification of the lesion using AHA/ACC 
criteria (Type A, B,, BP, and C). The ability of this classification system to pre- 
dict acute events or target vessel revascularization (TVR) following coronary 
stenting is unknown. We hypothesized that traditional lesion characterization 
does not predict acute or long-term outcome after stenting. 
Methods: Clinical variables were gathered in 327 consecutive patients 
(227 males, 100 females) undergoing successful coronary artery stent pro- 
cedures on 349 lesions. Coronary angiograms were reviewed and lesions 
classified as Type A, BI, 82 or C using AHA/ACC criteria; the presence of 
specific undesirable features for each lesion was documented. The type, di- 
ameter, length and number of stents were noted. The incidence of subacute 
thrombosis (SAT) at 30 days and TVR at 6 months were determined. 
Results: The 349 lesions consisted predominantly of type B lesions: A 
(n = 45) Br (n = 101) 8s (n = 176) and C (n = 27). Stents were placed 
to reduce restenosis (n = 229), to treat dissection after balloon angioplasty 
(n = 91), for abrupt vessel closure (n = 12) or for poor angiographic result 
(n = 17). SAT at 30 days was observed in 6 patients (1.7%) and TVR at 
6 months observed in 60 (18.2%). Lesion classification was not associated 
with SAT (A = 2.2%, BI = 1.0%, 8s = 2.2% and C = 0%; p = ns) or TVR (A 
= 9.1%, Bt = 20.4%, Bz = 19.2% and C = 20%, p = ns). None of the clinical 
or angiographic variables assessed predicted SAT. TVR at 6 months was 
associated with stent type (Gianturco-Roubin II = 32.5%, Palmaz-Schatz = 
11.2%, ACS Multilink = 11.0% and Paragon =‘4.3%, p = O.OOi), stent length 
(~20 mm = 10.7% vs >20 mm = 24.4%, p = 0.0015) and the presence of a 
bifurcation stenosis (16.8% no bifurcation vs 40% for bifurcation, p < 0.02). 
Conclusion: SAT and TVR after coronary stenting are not predicted by 
lesion characteristics associated with high event rates after balloon angio- 
plasty. Stent design, stent length and bifurcation stenoses are important 
predictors of TVR. Thus, traditional lesion classification schemes provide 
no guidance in identifying patients at increased risk for SAT or TVR after 
coronary stenting. 
Noon 
I 834 6 Unrestricted Availability of Coronary Stents 
Correlates With Decreased Risk of Mortality and 
Major Adverse Clinical Events 
W. Warren Suh, Diane E. Grill, Charanjit S. Rihal, Malcolm R. Bell, David 
R. Holmes Jr., Kirk N. Garratt. Mayo Clinic and Foundation, Rochester, MN, 
USA 
Background: Unrestricted stent availability is associated with decreased 
abrupt vascular closure rates and improved early adverse events, but whether 
it is associated with improved late clinical outcomes is unknown. 
Methods: A series of consecutive patients was identified retrospectively 
from our coronary intervention registry. Two cohorts were analyzed: patients 
treated between 1988 and 1992 (n = 3049) when stents were not generally 
available and patients treated between 1994 and 1997 (n = 3958) when 
stents were available on an unrestricted basis. 
Results: The late cohort patients consisted of more females, had more 
comorbidity (diabetes, hypertension, hypercholesterolemia, and history of 
prior coronary bypass surgery), and were more likely to present with acute 
myocardial infarction and congestive heart failure prior to procedure. 
The unadjusted l-year survival probabilities for the early and late cohorts 
were 0.961 and 0.964 (p = 0.1704) while major adverse clinical (death, 
Q wave myocardial infarction, repeat angioplasty or emergency coronary 
bypass surgery) event-free probabilities were 0.682 vs. 0.710 (p = 0.0015), 
respectively. 
After performing a multivariate Cox modelling to adjust for the other 
potential confounding variables, the late cohort had a significantly lower risk 
of mortality (RR = 0.82, 95% Cl = 0.69-0.98; p = 0.0311) and major adverse 
clinical endpoint (RR = 0.88, 95% Cl = 0.81-0.95; p = 0.0017) relative to the 
early cohort. 
Conclusions: The late time period with unrestricted stent availability 
was associated with decreased adjusted mortality and major adverse clinical 
event risks. This study suggests that benefits observed with the introduction 
of coronary stents into clinical practice with respect to reduced abrupt clo- 
sure rates and improved early adverse clinical endpoints remain unchanged 
resulting in improvements in important late clinical outcomes. 
ORAL 
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835-l Procedural Strategies and Outcomes of 
Percutaneous Coronary Intervention in 1999: 
Results of the Dynamic Registry 
David 0. Williams, Helen Vlachos, Sheyl F. Kelsey, Katherine M. Detre, 
Michael J. Cowley, David P. Faxon, James Slater, Spencer B. King. Rhode 
Island Hospital and Brown University School of Medicine, Providence, RI, 
USA 
Background: The Dynamic Registry is designed to identify changes in per- 
cutaneous coronary interventions (PCI) that occur over time. Two sequential 
waves of PCI patients (pts) were enrolled from 15 clinical centers in 1997-98, 
Wave 1 (WI) n = 2526, and in 1999, Wave 2 (W2) n = 1791. 
Purpose: Compare the pt characteristics, procedural strategies and in- 
hospital outcomes of WI and W2. 
Results: Pts in WI and W2 did not differ in age or gender or in history 
of diabetes, smoking, hx of CHF, hypercholesterolemia, prior PCI or CABG. 
Fewer W2 pts had prior Ml (W1:39.3% vs. W2:34.6%, p < 0.01) but more 
were hypertensive (59.4% vs. 64.8%, p < 0.001). Wl and W2 pts were similar 
in number of diseased vessels and significant lesions and in the indication 
for PCI. Less than 2.5% of PCI were non-femoral approaches. The radial 
artery was used for 1.9% of W2 pts. There was no difference in the site of 
attempted lesions or in lesion severity although in W2 more lesions had a 
prior stent (5.2% vs. 7.3%, p < 0.001) a smaller reference diameter (3.08 
mm vs. 2.99 mm, p < O.Ol), were longer (12.4 mm vs. 13.0 mm, p < 0.01) 
but were less often calcified (29.7% vs. 26.3%, p < 0.01) or ostial (8.6% vs. 
7.1%, p < 0.05) or total occlusions (14.4% vs. 11.6%, p < 0.001). Lesions 
in W2 were more often treated by stents (59.0% vs. 70.2%, p < 0.01) and 
less often by rotational atherectomy (10.7% vs. 5.9%, p < 0.001). Use of 
any balloon declined from 97.0% to 89.4%, p < 0.001. Multiple stents were 
used with the Duet (32.9%) the NIR (18.8%), the GFX (9.6%) being most 
common. Beta- and gamma-radiation were the most common investigational 
devices in W2. Abrupt closure was less common in W2 than WI (2.0% vs. 
l.O%, p < 0.01). In W2 AMI (2.8%) emergency CABG (0.4%), and death 
(1.4%) were not different than WI although angiographic success was less 
common in W2 (96.0% vs. 92.2%, p < 0.001). 
Conclusions: In 1999, PCI was more commonly attempted in lesions 
with prior stents, longer lesions and those in smaller arteries. Use of stents 
increased further, abrupt closure was less common and the rate of adverse 
events remained low. A further increase in lesion success rate was not 
observed. 
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835-2 Longterm Survival Following Surgical Versus 
Percutaneous Coronary Revascularization in 
Patients With Low and Preserved Ejection Fractions 
David Malenka, Gerald O’Connor, Hebe Quinton, Matthew Watkins, 
Lawrence Dacey, Samuel Shubrooks, David Charlesworth, John Robb, 
William Bradley. John O’Meara for the Northern New England 
Cardiovascular Disease Study Group, Lebanon, New Hampshire, USA 
Background: Compared to medical management, coronary artery bypass 
surgery (CABG) provides better sutvival for patients with multi-vessel coro- 
nary artery disease (mCAD) and a low ejection fraction (EF). We examined 
how survival following percutaneous coronary interventions (PCI) compared 
to CABG for this patient population. 
Methods: Data from 15,678 consecutive revascularizations on patients 
with mCAD and a measured EF (CABG = 11,804; PTCA = 3,874) performed 
in Northern New England (NNE) from 1990-1996 were linked to the National 
Death Index to determine survival. Cox proportional hazard regression ad- 
justing for age, sex, diabetes, prior revascularization, priority, and 3-vessel 
disease was used to compare survival by procedure and EF (~40% v >40%). 
Results: There were a total of I,61 8 deaths during 39,679 person-years 
of followup. An EF < 40% was present in 13.8% of PCI and 15.4% of CABG 
patients. Adjusted survival by procedure and EF is shown below. 
Conclusions: In NNE, patients with mCAD and an EF < 40% who 
undergo CABG have better longterm survival than patients who undergo 
PCI. Survival for patients with mCAD and an EF z 40% who undergo PCI 
have a longterm survival similar to patients undergoing CABG. 
11:30 a.m. 
/ 835 3 Modeling the Risk of Major In-Hospital 
Complications Following Percutaneous Coronary 
Intervention 
Frederic S. Resnic, Lucila Ohno-Machado, Gavin J. Blake, Jimmy Pavliska, 
Andrew Selwyn, Jeffrey J. Popma. Brigham and Women’s Hospital, Boston, 
MA, USA 
Background: Prior estimates of the risk of major in-hospital complications 
following percutaneous coronary intervention (PCI) may no longer be uni- 
formly applicable. Accordingly, we sought to model the risk of in-hospital 
death and the risk of death, coronary bypass surgery or myocardial infarction 
(DCMI) in the era of stenting and glycoprotein Ilb/llla (GP Ilb/llla) antagonist 
use. 
Methods: We prospectively collected data on 37 clinical and procedural 
variables for 2,804 consecutive cases from l/97 through 2/99. The dataset 
was randomly divided into a training set (1877 cases) and a validation set 
(927 cases). Multiple logistic regression (LR) models were constructed from 
variables selected by stepwise, forward, and backward model building algo- 
rithms. Simplified risk score models were derived from the beta coefficients 
of the LR model. Artificial neural network models (ANN) were also developed 
using all available covariates. Models were assessed by comparing the areas 
under the ROC curves (ROC). 
Results: Independent covariates selected by LR (p < 0.05) included 
age, female gender, occluded vessel, type B2 or C lesion, presenting AMI, 
congestive heart failure, and left main lesion. The use of a GP llbillla an- 
tagonist and coronary stents were associated with a significantly reduced 
risk of death and DCMI. The risk score models performed comparably to the 
complete LR model on the validation set (ROC-death: 0.794 vs. 0.812 for LR; 
ROC-DCMI: 0.730 vs. 0.760 for LR). ANN models performed slightly better 
than LR (ROC-death: 0.821; ROC-DCMI: 0.791). There was no significant 
difference in ROC among LR, ANN and risk score models. Risk scores for 
the entire dataset versus in-hospital mortality is shown in the figure (p-value 
for trend < 0.001). 
In-Hosaltal Mortaliivs. Riik Score 
Conclusion: Risk score models can be used to model the risk of major 
in-hospital complications following PCI with discriminatory power approach- 
ing multiple logistic regression. Such models may provide a sound basis 
for controlling for severity of illness in outcomes studies. Further research 
is warranted to refine the covariates selected, as well as to confirm these 
results in a multicenter study. 
11:45 a.m. 
835-4 It’s Quality Not Quantity That Counts! Operator 
Performance in Coronary Angioplasty - The Utility 
of One-Month Outcomes 
Joseph Lindsay Jr., Ellen E. Pinnow, August0 D. Pichard. Washington 
Hospital Center, Washington, DC, USA 
Background: Institutions must monitor the performance of operators (OP) 
performing coronary angioplasty (CA). In-hospital complications are too in- 
frequent to provide statistical power to identify OP deviating from the insti- 
tutional norm. Reasoning that major adverse cardiac events (MACE) within 
I-mo of CA reflect baseline and procedural factors, and that such events are 
more frequent than in-hospital complications, we tested 1 -mo MACE for their 
statistical power to evaluate individual OP performance. 
Methods: 37 OP performed 1967 CA in our laboratory 4/i/98 through 
g/30/98. The 1882 (95.7%) for whom I-mo follow-up information was ob- 
tained were analyzed. 12 baseline variables were recorded. Multivariate 
modeling demonstrated that renal failure, recent acute MI, cardiogenic shock, 
lesion complexity, and multilesion CA were independent predictors of I-mo 
MACE (death, MI, CABG, repeat CA of target vessel). From this model 
an expected I-mo MACE rate was calculated for each pt and the ob- 
served/expected (O/E) ratio for the set of pts treated by each OP, calculated. 
Results: The overall I-mo MACE rate was 7.0%. Of 20 OP performing 
~30 CA during the 6-mo study period, 5 (25%) had a MACE rate > 2.4 times 
than expected (O/E > 2.4) for their patient set. In 1 the observed MACE rate 
exceeded the upper limit of the 95% confidence interval for his patient set. 
All 17 OP performing 230 CA during the 6-mo had an O/E < 1.9. Three 
had a O/E > 1.5, but in none did the observed rate exceed the upper 95% 
confidence limit. 
Conclusion: 1 -mo MACE can be used to identify individual OP whose 
performance may be substandard and may be useful to laboratory directors 
as a basis for appropriate corrective action. These data also confirm that 
though some low-volume OP have good outcomes with CA, less good results 
are more frequent in that group as a whole. 
Noon 
835-5 Does Therapy With GP llbllla Receptor Antagonists 
Improve Late Clinical Outcome Following 
Percutaneous Coronary Intervention? A Report 
From the NHLBI Dynamic Registry 
Howard A. Cohen, Alice K. Jacobs, Wanlin Yeh, David P. Fexon, David 
0. Williams, David R. Holmes, Richard Shaw, Anil Mehra, Katherine 
M. Detre. University of Pittsburgh, Presbyterian University Hospita/, 
Pittsburgh, PA, USA 
Background: We tested the hypothesis that GP llbllla receptor antago- 
nists (RA) improve late clinical outcome following successful percutaneous 
coronary intervention (PCI). 
Methods: In the 1997-98 first wave of the NHLBI Dynamic Registry, 
23% of the 2252 patients from 13 centers received (RA) prior to or during 
PCI. Since these RA patients (pts) had significantly more risk factors for 
peri-procedural complications, only RA and non-RA treated pts who achieved 
procedural success (~50% residual, no CABG, death or Ml) were compared. 
Results: (table) After adjusting for all significant demographic, clinical, an- 
giographic and procedural inequalities, Ml rate remained twice, CABG/PTCA 
30% and D/MI/CABG 50% higher in RA pts. 95% confidence intervals were 
(1.1, 3.6) (1.0, 1.7) (1.1, 2.1). 
32A ABSTRACTS - ACCIS2000 JACC February 2000 
Clinical Events at One Year 
In Patients with Initial Success 
No Ilb/llla 
Number of patients 1607 453 
Death % 2.7 3.7 
MI %* 2.3 5.2 
CABG %* 5.4 6.6 
Repeat PCI % 14.1 17.3 
Death/Ml %* 4.7 8.8 
Death/MI/CABG %“* 9.5 14.6 
CABG/ReDeat PCI %* 16.1 23.7 
*p < 0.05, **p < 0.01 
Conclusions: We detected no benefit of RA in improving late clinical 
outcome after PCI. 
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I 1085 75 Is it Safe to Perform Coronary Intervention in Patients With Occult Blood in Stool and Stable 
Hemoglobin? 
Gurkan Taviloglu, Daniel Soffer, Gishel New, Peter Baiocco, Ali Aboufares, 
Lynne Glasser, Jusuf Zlatanic, Neil Coplan, Jeffrey Moses, lssam Moussa. 
Lenox Hi// Heart and Vascular Institute, New York, N’r: USA 
Background: The potential clinical sequelae of positive occult blood in stool 
(POBS) of pts undergoing cardiac catheterization (CC) or percutaneous coro- 
nary intervention (PCI) is unknown. We sought to determine the incidence of 
GI bleeding (GIB) in pts with stable hemoglobin (Hb) who had POBS prior to 
coronary intervention. 
Methods: We reviewed the medical records of 164 consecutive pts (91 
male, mean age & SD: 66 i 11 yrs) who were admitted for CC or PCI and 
underwent GI endoscopy. These pts were divided into 3 groups. Group I; 
57 pts who had POBS on admission, Group /I; 30 pts who initially tested 
negative but subsequently had POBS after initiation of iv heparin, and Group 
111; (control group) 77 pts who had negative occult blood stool (NOBS). 
All pts received IV heparin, aspirin and clopidogrel or ticlopidine prior to 
cardiac procedure. The incidence of sig GIB (>2 g fall in Hb, hematemesis or 
melena) and requirement of blood transfusion was determined. The results 
are outlined in the table below. 
Results: 
GI Bleeding 
Transfusion 
Requirement 
Gr I Gr II Gr Ill 
(n = 57) (n = 30) (n = 77) 
13 (23%) 18 (60%) 4 (5%) 
7 (12%) 7 (23%) 1 (1.3%) 
Using a Chi-square analysis, there was a sig difference in GIB between 
all groups (Gr I vs Gr II p < 0.005; Gr I vs Gr Ill p < 0.005; Gr II vs Gr Ill p 
< 0.0001). However, there was a difference in transfusion requirement only 
between Groups I and Ill (p < 0.05) and II and Ill (p < 0.0005). 
Conclusion: Patients with occult blood in stool are at high risk for subse- 
quent GI bleeding following CC or PCI. In particular, those who subsequently 
test positive for occult blood following heparin administration represent the 
highest risk sub-group that require prompt GI investigation, if possible, prior 
to CC or PCI. 
1 1085-76 1 The Incidence, Management and Outcome After 
Coronary Artery Perforation During Percutaneous 
Coronary Intervention: A Single Center 
Experience 
Luis Gruberg, Ellen Pinnow, Roy Flood, Yvonne Bonnet, Mihaela Tebeica, 
Ron Waksman, Kenneth M. Kent, August0 D. Pichard, Lowell F. Satler, 
Martin B. Leon, Joseph Lindsay, Jr.. Washingfon Hospifal Center, 
Washington, D. C., USA 
Background: Coronary artery perforation is a rare but dreaded complication 
during percutaneous coronary intervention (PCI). We have analyzed the 
incidence, management and outcome of these patients. 
Methods: Between June 1990 at-&August 1999, a total of 23,616 pa- 
tients underwent PCI at the Washington Hospital Center. Coronary artery 
perforation was reported in 88 patients (0.37%). Chart review was performed 
in 84 available charts. 
Results: Mean age was 64 f 13 years (range 32-94), 43% were female. 
Lesion locations were right coronary artery in 38%, left circumflex 38% and 
left anterior descending in 24%. Complex B or C type lesions accounted for 
92% of the perforations, including 32% with total occlusions. Severe vessel 
calcification and tortuosity was seen in 38% and 42% respectively. Device 
use was as follows: balloon angioplasty in 32%, rotational atherectomy in 
25%, stenting in 21%, laser angioplasty in 19% and directional atherectomy 
in 9%. The majority of patients underwent emergency bypass surgery and 
pericardiocentesis (43%), whereas 34% were treated with perfusion balloon, 
8% underwent stent deployment, 5% pericardial window, and one patient 
coil embolization. A total of 8 patients (10%) died in-hospital. Other major 
complications included cardiac tamponade in 42% and acute myocardial 
infarction in 39%. Patients who died were older (74 years vs. 63 years, p = 
0.02), developed cardiac tamponade (86% vs. 36%, p = 0.02) and underwent 
emergency coronary bypass surgety (75% vs. 39%, p = 0.06). 
We conc/ude:Although the likelihood of coronary artery perforation after 
PCI is low (0.4%), it is associated with high morbidity and mortality, especially 
elderly patients who develop cardiac tamponade. 
/ 1085 77 Myocardial Rupture After Percutaneous Coronary Interventions 
Andrew Farb, Allen P. Burke, Renu Virmani. Armed Forces lnsfitute of 
Pathology, Washington, DC, USA 
Background: Myocardial rupture (MR) most often occurs 1-4 days after 
spontaneous thrombotic coronary occlusion and acute Ml. However, a series 
of cases of MR as a complication of elective coronary intervention has not 
been reported. 
Methods: From 201 cases of native coronary interventions (PTCA and/or 
stenting) referred to us for consultation, 5 cases were identified with MR 
directly related to the revascularization procedure. 
Results: All 5 cases of MR occurred in women (mean age 77 i 8 years 
old, range 69-89 years) presenting with unstable angina (n = 4) or non-Q 
wave Ml (n = 1). All cases involved left coronary revascularization (LAD n = 
2 with anterior wall MR; LCX n = 3 with lateral wall MR). Acute transmural Ml 
was present in all cases, and hearts otherwise demonstrated either no other 
Ml (n = 3) or a small healed subendocardial Ml (n = 2) related to a non-target 
artery stenosis. Patients had either 1 (n = 2) or 2 (n = 3) vessel disease, and 
4 of 5 were hypertensive. The pre-intervention angiographic stenoses were 
>90% without collateral vessels to the target artery. 
CW? Intervention Pathology Time to MR 
1 LCX stent LCX pate+ LOM thrombus 4 days 
2 LCX PTCA LCX dissection with lumen 47 hrs 
compromise 
3 LAD stent Stent thrombus 28 hours 
4 LAD stent Stat thrombus and dissection <24 hrs 
5 LCX PTCA LCX dissection and thrombus <24 hrs 
Patients were clinically stable at the conclusion of their revascularization 
procedures, and the target vessel had ~10% stenosis in 4/5 cases and. 
Bradycardia preceded cardiac arrest in 4 cases, and 3 patients had chest 
pain. 
Conclusion: Cardiac rupture may occur after initially successful target 
vessel revascularization complicated by sidebranch occlusion, or by target 
vessel dissection or thrombosis. Myocardial rupture tends to occur early after 
infarction post-coronary intervention. Elderly women with hypertension and 
1-2 vessel disease without collaterals appear to be at increased risk for this 
complication. 
1 1085-78 1 Predictors of Radial Artery Thrombosis After 
Transradial Approach: A Multivariate Analysis of a 
Large Series 
G.R. Barbeau, S. Bilodeau, G. Carrier, S. Ferland, L. LBtoumeau, 
L. Lacoursiere, P. LBveillB, S. Simard, J.F. Gobeil, M.-M. LariviBre. lnstifut 
de Cardiologie de QuBbec, Ste-Fey, Canada 
Background: Percutaneous transradial approach (TRA) is a growing new 
technique with advantages (immediate ambulation, low vascular complica- 
tion) and limitations [small catheters, lower success rate, learning curve, 
radial artery thrombosis (RAT)]. Occurrence of RAThas been reported in the 
range of 4-8%, but, except for heparin dosage in univariate analysis in small 
series, no other predictors has been identified. The purpose of this study was 
to evaluate the predictors of RATafter TRA in a large series. 
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Methods: Stepwise logistic regression analysis was performed using 
baseline clinical data (gender, age, weight, height, body mass index) and 
procedural data [Heparin (No heparin, i-75, >75-125 and >I25 u/kg), 
sheath size (4&5, 6 and 788 French)] in a registry of TRA patients (pts). 
Results: From 01-95 to 01-99, of the 7026 procedures attempted, 1564 
pts had 2D echo and doppler evaluation of the ipsilaterai radial artery 6-36 
hours post procedure. RAToccurred in 79 (5%) pts, without clinical sequalae. 
Predictors of RATwere: 
Results: A total of 2604 patients underwent PCI, of which 463 received 
a glycoprotein Ilb/llla inhibitor. In these patients, 124 had femoral arteri- 
otomy closure with the Perclose device. In this subset, 7 (5.6%) patients 
suffered a hemorrhagic complication (4 hematoma, 3 retroperitoneal bleed). 
ACT-guided manual compression was used in the remaining 339 patients, of 
which 3 (1 .O%) suffered hemorraghic complications. 
Variables 
Sheath Size 
Age 
Heparin 
Confidence level (95%) 
Odds ratio L0W?r upper p value 
1.918 1.055 3.486 0.0328 
0.979 0.959 0.999 0.0375 
0.663 0.464 0.945 0.0232 
GP Ilb/llla patients complications % P 
PerClOSe - 1191 17 1.4 
No Perclose - 950 9 0.9 
Pt?ElOX? + 124 7 5.6 0.002* 
No Perclose + 339 3 1.0 
*--vs. No Perclose with GP llb/llla 
Conclusion: RATis rare (5%) after JRA and not associated with clinical 
sequalae. The strongest predictors of RAT after TRA are sheath size, low 
dose of heparin and a younger patient. 
Conclusions: The combination of a vascular closure device and a glyco- 
protein Ilb/llla inhibitor may adversely affect the vascular complication rate 
in patients who undergo elective PCI. 
1085-79 Do Sealing Devices After Vascular Interventions 
Make a Difference in Clinical Practice? 
1085-81 Removal of lntra Aortic Balloon Pump in the 
Cardiac Cath Lab immediately Following 
Supported Intervention Using Perclose Vascular 
Suture Device 
Ali E. Denktas, Caries Cafri, Shafiq T. Mamdani, Oscar R. Resales, 
Kenichi Fujise, George Schroth, H. Vernon Anderson, Richard W. Smalling. 
University of Texas-Houston and Hermann Hospital, Houston, Texas, USA 
Background: Randomized trials have supported that sealing devices after 
vascular interventions are associated with lower complication rates. Whether 
this advantage exists in the setting of unselected patients and multiple 
operators is unclear. 
Kevin M. Rankin, Michael A. Kutcher, Robert J. Applegate, Gregory 
A. Braden. Wake Forest University School of Medicine, Winston-Salem, 
North Carolina, USA 
Methods: 260 patients undergoing coronary and peripheral procedures 
were prospectively analyzed, Angio-Seal@: 86 patients (31%); Perclose@ 
device: 111 patients (41%), manual pressure: 64 patients (23%). Clinical 
characteristics, complication rates and ambulation times were compared. 
Results: No significant baseline demographic or clinical differences were 
observed. Coronary interventions [AS: 90%, PVS: 82%, MP: 69% (p = 0.003)] 
and prolonged ACT [AS 272 set, PVS 256 set, MP 159 set (p < O.OOOl)] 
were more frequent in the groups receiving sealing devices. The group of 
patients who had a venous sheath (p = 0.04), any procedural complication 
(p = 0.03), oozing (p = 0.0002) or in whom a Gp llbllla inhibitor (p cy 0.01) 
was used ambulated late regardless of the sealing device use. The findings 
are summarized in the table. 
Increasingly, high risk pts undergo coronary intervention use lntra Aortic 
balloon pump (IABP) for hemodynamic assistance, however, this generally 
requires transferring these pts to a higher level of care and prolonged hos- 
pitalizations. Additionally, vascular complications from IABP may be related 
to the duration of IABP placement. The Perclose vascular suture (PVS) de- 
vice is useful in removing vascular access sheaths in anticoagulated pts 
undergoing intervention but its use for IABP removal has not previously been 
reported. 
Angioseal’ Perclose@ MSU3. 
Pressure 
p value 
Major bleeding 3.5% 1.8% 4.6% NS 
Any complication 23.3% 23.4% 14.1% NS 
Ambulation < 6 h 34.3% 34.0% 3.4%” 
Ambulation > 6 h 65.7% 66.0% 96.6%* 
*p < 0.0001 (ANOVA, Newman-Keuls test) between Angioseal vs. Manual pressure, and 
Perclose vs. manual pressure. 
Study: we report on 13 consecutive pts who underwent PCI with IABP 
support. In the first 6 pts a long guidewire was inserted through the IABP 
catheter and the IO Fr PVC device was used to close the arteriotomy. 
However, in subsequent 7 pts, after vascular access was initially obtained, the 
arteriotomy was dilated with an 8 Fr dilator and a 8 Fr PVS was deployed, the 
needles removed, but the sutures remained untied. The IABP was placed and 
the PCI procedure performed. At the conclusion, the IABP catheter removed 
and arteriotomy closed by tying Perclose sutures. The PCI vascular access 
sheath was also removed with a PVS device. All pts received Abciximab and 
had ACTS between 200300 sets. All 13 pts had successful vascular closures 
without major complications. All patients were cared for post procedure in 
intermediate care setting and had early ambulation. Mean length of stay post 
procedure for this high risk group was 1.9 & 0.4 days with 7 of 13 discharged 
within 24 hours. 
Conclusions: In everyday practice, sealing devices did not provide an 
advantage over manual pressure in decreasing complication rates afler vas- 
cular interventions. There is a trend towards decrease in major bleeding with 
Perclose@ use. Sealing device use was associated with early ambulation 
despite higher level of anticoagulation. However, the majority of the patients 
ambulated after six hours irrespective of device use. 
Conclusion: Perclose vascular suture device allows for safe removal of 
IABP catheters used for transient hemodynamic support of high risk PCI 
anticoagulated pts. This approach avoids transfer of these pts to the CCU 
while shortening hospital stays and minimizing vascular complications. 
I 1085 82 Femoral Vascular Access Complications 
Following Arteriotomy Closure Devices: 
A Comparison With Manual Compression After 
Percutaneous Coronary Interventions 
1085-80 Vascular Complications in Patients Who Receive 
a Glycoprotein Ilb/llla Inhibitor and Vascular 
Closure With the Perclose Device 
Bonnie L. Hiatt, David P. Lee, Andrew J. Carter, Alan C. Yeung. Stanford 
University, Stanford, CA, USA 
Roxana Mehran, George Dangas, Mun K. Hong, Regina Deible, 
Hassan Faraj, Sayed El Sayyad, Manuela Negoita, Petros Okubagzi, 
Michael Astatkie, August0 D. Pichard, Gregg W. Stone, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
Background: Glycoprotein Ilb/llla inhibitors are increasingly used in per- 
cutaneous coronary interventions (PCI). These agents increase the risk of 
bleeding, most commonly at the local puncture site. Vascular closure de- 
vices, including the Perclose arteriotomy device, have also become more 
frequently used in the catheterization laboratory. These devices may also 
increase the risk of local vascular complications. The relationship between 
glycoprotein llbillla inhibitors and the use of vascular closure devices on the 
vascular complication rate has not yet been defined. 
Background: Femoral arteriotomy closure devices (CD) have become avail- 
able for immediate sheath removal and early ambulation after percutaneous 
coronary interventions (PCI). However, the frequency of vascular access 
complications (VAC) after CD versus manual compression (MC) have not 
been compared yet in real world conditions. 
Methods: A single center retrospective analysis was performed in pa- 
tients admitted for elective PCI who received glycoprotein Ilb/llla inhibitor 
(abciximab or tirofiban) between July 1996 and August 1999. The use of the 
Perclose device in this patient population was also recorded. A significant 
hemorrhagic complication was defined as hematoma requiring a transfusion 
or retroperitoneal bleed. 
Methods: We analyzed the in-hospital complications following femoral 
sheath removal with CD (64% collagen- and 36% suture-based; n = 523,7-8 
F sheaths) versus MC (n = 5,936; 7-9 F sheaths), excluding use of intraaonic 
balloon pump or thrombolytics. Baseline characteristics and platelet Ilb/llla 
inhibitor use was similar between the groups. 
Results: (see table) Frequency (CD, MC) of pseudoanurysm (I%, I%), 
AV fistula (0.6%, 0.9%) and GI bleeding (0.8%, 0.7%) were similar. By 
multivariate analysis, independent predictors of major hematoma were: BSA 
(odds ratio [OR] 0.97, confidence intervals [Cl] 0.96-0.99, p = 0.0004) and 
use of CD (OR 4.3, Cl 2.1-8.9, p < 0.0001) 
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CD MC P 
Body surface area (BSA) 2.0 * 0.2 1.9 * 0.2 0.03 
Hematoma 9.3% 5.1% <0.0001 
Hematocrit drop > 15% 6.2% 3.1% 0.0006 
Major Hem&ma* 2.2% 0.6% <0.0001 
Transfusion need 8% 6% 0.07 
Vascular Surgery 2.5% 1.3% 0.03 
* Major Hematoma = Hematoma plus Hematocrit drop > 15%. 
Conclusions: Despite smaller body size, MC had lower vascular access 
complications after PCI compared to CD. Further CD design is indicated and 
thorough training of operators is warranted to reduce VAC. 
1085-83 Percutaneous Thrombin Injection is an Effective 
Treatment for latrogenic Femoral 
Pseudoaneurysms 
Nigel Jepson, Geoff Parr, Roger Allan, John Frawley, Mark Pitney. 
Departments of Cardiology and Vascular Surgery, Prince of Wales Hospital, 
Sydney; Australia 
Background: Femoral pseudoaneurysms (FPAs) complicating coronary in- 
tervention can be problematic in patients receiving anticoagulant and inten- 
sive antiplatelet therapy. In view of the limitations of prolonged compression, 
we prospectively evaluated percutaneous thrombin injection as an alternative 
method of treating FPAs. 
Methods: 18 patients (IO male), mean age 66 (38-82) years with duplex 
ultrasound confirmed FPAs (3 arising from the common femoral and 15 
from the superficial femoral artery) were assessed. Compression repair was 
unsuccessful in 9 cases. Femoral cannulation occurred 1-14 (mean 5) days 
prior to thrombin injection - 10 had undergone 6 Fr diagnostic angiography 
and 8 percutaneous coronary intervention using 8 Fr catheters (abciximab 
used in 3 cases). Maximal FPA dimension ranged 16-60 (mean 35) mm. 
Treatment was performed in 3 patients on warfarin, 7 on aspirin and ticlopidine 
(or clopidogrel) and 1 on enoxiparin. Under continuous ultrasound imaging a 
fine bore needle (21-23 G) was inserted into the FPA with position confirmed 
by injection of saline microbubbles. Bovine thrombin solution (1000 units/ml) 
was then injected in 0.3-I ml boluses (to a maximum dose of 2 ml). 
Results: Thrombin injection successfully occluded FPAs in all (18/18) 
cases. Thrombosis was immediate (<IO sets) in 14 FPAs after one injection. 
Occlusion was achievedwithin IO rains after a second thrombin dose in the 
remainder. Analgesia was required in only 3 patients. There were no cases 
of FPA recurrence at repeat imaging at 24 hours and in clinical follow-up. 
No patient experienced fever or allergy however partial thrombotic occlusion 
of the superficial femoral artery occurred in one patient (excessive thrombin 
dose administered) necessitating embolectomy. 
Conclusions: Percutaneous thrombin injection appears to be a safe 
and effective method for treating iatrogenic FPAs. The rapid and successful 
resolution in all cases (without prolonged compression) despite antiplatelet or 
anticoagulant therapy represents a significant advantage over conventional 
therapies. 
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1086-84 Inhibition of In-Stent Restenosis by the Quanam 
Drug Delivery Polymer Stent, in Humans Followed 
for up to 8 Months 
Eberhard Grube, Ulrich Gerkens, Stephen Oesterle, Eugene Pomerantsev, 
lrina Pomerantseva, Michael Froix, Robert Eury, Alan Yeung, 
Simon Stertzer. Heart Center Siegburg, Siegborg, Germany; Stanford 
Universifq: Stanford, CA, USA 
Background: The Quanam drug delivery stent (Q-DL) is a non-biodegrad- 
able proprietary polymer, seamlessly ensheathing a Quanam metal stent 
(Q-M), and loaded in its matrix with a slow release microtubule inhibitor. Ki- 
netic studies have shown drug release up to 30 days into subjacent tissues. 
The metal stent scaffold is a specially designed slotted tube stent made of 
316L steel. 
Methods: 16 drug delivery (Q-DL) stents were implanted in a randomized 
pilot trial in 15 patients. 19 control bare metal stents (Q-M) were placed in 
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16 patients. Stent sizes ranged from 3.0-3.5 mm diameter and from 13-17 
mm in length. Patient cohorts and lesions were clinically comparable, 46% 
type A (AHA/ACC), and 54% types B2 and C. All 31 patients were followed 
for 3-8 months clinically, angiographically and by IVUS at the study center. 
QCA and QCU were performed by independent core lab in 25 patients. 
Results: Procedural success 100%; Study Center angiographic (binary) 
restenosis rates (all patients): Q-DL (drug) stent = 0%; Q-M (bare metal) = 
54%. IVUS in all 16 restudied Q-DL patients showed near total absence of 
intimal proliferation within, or at the ends of lesions. Core lab QCA data: 
Group MLD pre 
Q-M(n=12) 1.2 f 0.7 
Q-DL (n = 13) 1.4f0.4 
P NS 
MLD post 
2.9 f 0.4 
2.8 zk 0.5 
NS 
MLD flu 
0.9 * 0.9 
2.2 * 0.4 
0.003 
%D f/u 
64.8 + 34.3 
14.2i22.1 
0.004 
Months 
4.0 rt 1.5 
4.0 Et 0.2 
NS 
Conclusions: These data indicate that drug delivery from a polymer stent 
is safe, and engenders an extremely low amount of in-stent restenosis, thus 
justifying the more extensive randomized trial now in progress. 
1086-85 Intravascular Ultrasound Assessment of a New 
Biodegradable Self-Expanding Coronary Stent in 
Humans 
Hidenori Komori, Takafumi Tsuji, Hideo Tamai, Eisho Kyo, Kunihiko Kosuga, 
Akiyoshi Kawashima, Shigeo Matsui, Tatsuhiko Hata, Seiichiro Motohara, 
Hiromu Uehata. Shiga Medical Center for Ad&s, Moriyama, Japan 
Background: Although metallic stents are effective to prevent acute reoc- 
elusion and to reduce late restenosis following coronary angioplasty, the 
long-term safety remains to be studied. A biodegradable poly-l-lactic acid 
(PLLA) stent is reported to be absorber for over 12 months. We report re- 
suits of intravascular ultrasound (IVUS) assessment following PLLA stent 
implantation in humans. 
Methods: The Igaki-Tamai stent is made of PLLA monopolymer (molec- 
ular mass 183 kD) with 0.17 mm thickness, and has a zigzag helical coil 
design with self-expanding ability. Fifteen patients electively underwent suc- 
cessful PLLA stent implantation for coronary artery stenoses. There were 14 
males, and 25 stents were implanted in 19 lesions (LAD 8, LCX 7, RCA 4). To 
evaluate expanding ability and the efficacy of the PLLA stent, IVUS studies 
were performed immediately after, at 1 day, at 3 months and at 6 months 
using 40 MHz IVUS catheter with motorized pullback system. We measured 
the stent cross-sectional area (CSA), the lumen CSA and the neointimal area 
in all stents. 
Results: There was no significant difference in the stent CSA between 
immediately after and at 1 day (7.42 mm2 vs 7.37 mm’). The stent CSA 
tended to be larger at 3 months than immediately after stenting (8.18 mm2 
vs 7.42 mm2, p = 0.086). There was no difference between stent CSA at 3 
months and at 6 months (8.18 mm* vs 8.13 mm2). Lumen-CSA at 6 months 
was similar to that of at 3 months (5.63 mm” vs 5.67 mms, NS) without 
further increase of neointima (2.51 mm’ to 2.50 mm’, NS). Stent struts still 
remained at 6 months. 
Conclusions: The Igaki-Tamai stents self-expand up to 3 months with 
limited intimal hyperplasia thereafter. This unique feature of the stent may be 
promissing to reduce restenosis after coronary angioplasty. 
1086-86 Antiplatelet Effect of Abciximab, Tirofiban and 
Eptifibatide With Coronary Stent Placement 
Franz-Josef Neumann, Willibald Hochholzer, Gisela Pogatsa-Murray, 
Meinrad Gawaz, Albert Schbmig. Deutsches Herzzentrum und 1. 
Medizinische Klinik der Technischen UniversEit, Munich, Germany 
Background: The GP Ilb/llla antagonists abciximab (A), tirofiban (T) and 
eptifibatide (E) differ in chemical structure, molecular target, and pharma- 
cokinetics. We investigated, whether A, T, and E achieve a comparable 
antiplatelet effect with coronary stenting. 
Methods: Sixty patients undergoing coronary stenting were randomly 
assigned to A (bolus 0.25 mg/kg, infusion 10 pglmin for 12 h), T (bolus 
10 pg/kg, infusion at 0.15 wgikglmin for 72 h), or E (bolus 180 pg/kg, 
infusion 2 bg/kg/min for 72 h). Platelet inhibition was assessed by the rapid 
platelet-function assay (RPFA, Accumetrics). 
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Results: As shown in the figure, A, T and E achieved >80% inhibi- 
tion of platelet aggregation during infusion. Recovery of platelet aggregation 
was delayed after A, but rapid after T and E. Conventional platelet aggre- 
gometry confirmed the results of RPFA. Flow cytometry revealed that A, T 
and E caused a similar inhibition monocyte-platelet interaction and a similar 
increase in P-selectin suface expression. 
Conclusion: A, T and E at currently recommended doses achieved an 
adequate inhibition of platelet aggregation. Prolonged infusions of T and E 
can mimic the tapering antiplatelet effect of A. 
1 1086-87 1 Abciximab Reduces Early Mortality but not Late 
Adverse Outcomes in Unselected Diabetics 
Undergoing Stent Implantation 
James L. Velianou, Verghese Mathew, Stephanie H. Wilson, Gregory 
W. Barsness, Diane E. Grill, David R. Holmes Jr.. Mayo Clinic, Rochester; 
MN, USA 
Background: Percutaneous coronary intervention (PCI) in patients with dia- 
betes mellitus (DM) is associated with higher rates of adverse cardiac events. 
Recent data suggest that target lesion revascularization rates are reduced in 
DM patients treated with combined stent placement and abciximab. 
Methods: We performed an analysis of the Mayo Clinic PCI registry for 
all DM patients (n = 570) who undetwent stent implantation with (n = 157) 
and without (n = 413) abciximab from 1995-98. Patients with acute infarction 
(Ml) were excluded. 
Results: The baseline clinical and angiographic characteristics differed 
between the two groups. The abciximab patients were more likely to be 
male, have prior Ml, lower ejection fraction, prior thrombus, multivessel and 
graft intervention. High rates of bypass graft interventions occurred (15.7%) 
overall. See table for event rates between the groups. 
Events (%) 
Death 
Any MI 
Repeat PCI 
CABG 
Composite 
Abciximab 
30-d 1 -yr 
0.6 8.9 
9.0 13.3 
0 14.7 
0 10.3 
9.6 30.4 
No Abciximab 
30-d 1 -yr 
3.0 8.8 
5.6 11.4 
1.1 15.9 
0.3 6.2 
8.6 26.7 
p-VdW 
30-d 1 -yr 
0.03 0.97 
0.18 0.57 
0.03 0.76 
0.32 0.20 
0.72 0.43 
Conclusion: DM patients with stents who received abciximab had more 
adverse clinical and lesion characteristics than those not receiving abciximab. 
Death and repeat PCI were reduced at 30-days, but there was no difference 
at I-year. Multivariate analysis revealed no associated long-term benefit of 
abciximab in unselected DM patients receiving stents. 
1086-88 Striking Reduction of Mortality and Target Vessel 
Revascularization With Stent-Abciximab in 
Diabetic Women 
Leslie Cho, Steve P. Marso, Deepak L. Bhatt, Eric J. Topol. C/eve/and Clinic 
Foundation, C/eve/and, OH, US.4 
Background: Diabetic women have a particularly higher risk of death and 
nonfatal Ml after percutaneous coronary intervention (PCI). However, there 
have been little data regarding the outcome of diabetic women in the current 
era of PCI with stenting and abciximab. 
Methods: We used the EPlSTENTdatabase which enrolled 2399 patients 
referred for elective or urgent PCI who were suitable candidates for either 
conventional angioplasty or stent implantation with or without abciximab. The 
primary endpoint for the study was a composite of death, Ml or target vessel 
revascularization at 1 year. 
Results: There were 143 diabetic women. Demographics were similar for 
the 3 groups. Results are summarized. 
Table 1 
sent + stent + p-Value* Balloon + P- 
Placebo abciximab abciximab value*’ 
Death/MI/ 34.5% 13.3% 0.02 28.9% 0.04 
NR 
Death 7.7% 0.0% 0.06 4.4% 0.10 
TVR 21.4% 4.5% 0.02 26.7% 0.02 
* p-value for stent-placebo vs. stent-abciximab: *’ p-value for balloon-abciximab vs. 
stent-abciximab 
Conclusion: These data demonstrates dramatic reduction in mortality, 
Ml or TVR at 1 year for diabetic women treated with stent and abciximab 
compared to stent alone or balloon with abciximab. 
I 1086 89 Left Internal Mammary Artery Grafting Comparing to Endoluminal Reconstruction With 
Less-shortening Wallstents in Patients With a 
Diffusely Degenerated Saphenous Vein Graft 
Implanted to the Left Anterior Descending 
Coronary Artery 
RQmi P. Choussat, Alexander J. Black, Irene Bossi, Jean Fajadet, 
Jean Marco. Chique Pasteur, Toulouse, France 
Background: The optimal treatment strategy for patients with diffusely de- 
generated saphenous vein graft (SVG) to the lefl anterior descending coro- 
nary artery (LAD) is controversial. “Endoluminal reconstruction” by stent 
implantation and coronary grafting with the use of the left internal mammary 
artery (LIMA) are two proposed treatments. However, there is no data com- 
paring these two treatments. The aim of our study was therefore to evaluate 
the immediate and long-term clinical results of these two treatments’ strategy. 
Methods: Between May 1995 and September 1998, 72 consecutive 
patients (pts) in our institution with diffusely degenerated SVG to the LAD 
were treated by “Endoluminal reconstruction”, by Wallstent implantation (n = 
44), or by coronary artery grafting with the use of the LIMA (n = 28). End points 
were death, myocardial infarction (Ml), need for additional revascularization 
(target vessel and non-target vessel). 
Results: Follow-up (mean duration 21.6 f 11.3 months) was obtained in 
all patients. There were 4 deaths and 3 Ml in the percutaneous translumi- 
nal coronary angioplasty (PTCA) group comparing to 1 death and 1 Ml in 
the coronary artery bypass surgery (CABG) group (p = 0.22 and p = 0.36 
respectively). Target vessel and nontarget vessel revascularization occurred 
in 13 and 7 pts in the PTCA group comparing to 0 patient in the CABG group 
(p = 0.005 and 0.05 respectively). The combined end-point of death, MI, 
target and non-target vessel revascularization occurred in 19 pts (43.2%) in 
the PTCA group versus 2 pts (7.1%) in the CABG group, p = 0.0001. The 
estimated 3-year event-free survival rates (freedom from death/Ml/target and 
non-target vessel revascularization) were (mean f SEE) 46.5 f 20.3% in 
the PTCA group comparing to 92.9 f 10.5% in the CABG group (p = 0.002). 
Conclusion: Despite the lack of randomization between the two treat- 
ments’ strategy, pts undergoing endoluminal reconstruction of diffusely de- 
generated SVG to the LAD were more likely to undetwent major cardiac 
events than those treated by repeat CABG surgery using LIMA grafting. 
1 1086-90 1 Direct Stenting vs. Stenting With Pre-Dilation in 
Selected Coronary Lesions. Immediate and 
In-Hospital Results of a Multicenter, Prospective 
and Randomized Study. The DIRECT STUDY 
FBbio S. Brito Jr., Adrian0 M. Caixeta, Marco A. Perin, Miguel A.N. Rati, 
Marcel0 Cantarelli, HBlio Castello Jr., Expedito Ribeiro, LBlio A. Silva. Albert 
Einstein Hospital, SPo Paula, SF: Brazil 
Background: Coronary stenting without the conventional pro-dilation is now 
possible with the new low profile stents (ST). This new strategy may reduce 
costs, procedural time and injury to the vessel wall, positively influencing 
acute and late results. 
Purpose: To evaluate the efficacy and safety of the technique of direct 
coronary stenting (direct-ST) in selected eases, and its influence on costs 
and duration of the procedure. 
Methods: Between 2/99 and 8199, 112 lesions (107 patients) were ran- 
domized in 7 hospitals to have direct-ST (60 lesions) or conventional ST 
implantation (52 lesions). Lesions with significant calcification and/or angu- 
lation were excluded from randomization. 
Results: Demographic, clinical and angiographic factors were similar 
in both groups. Stenosis (visual analysis) was 390% in 30 (50%) lesions 
in the direct-ST group and in 23 (44.2%) in the conventional group (p 
= 0.672). Unstable lesions were frequent in both groups (direct-ST: 55% 
vs. pre-dilation: 44.2%; p = 0.342). Direct-ST was successful in 58 of 60 
lesions (96.7%). Two failures (with no ST embolization) occurred because of 
impossibility to cross the lesion with the ST (1 lesion with mild calcification). 
No complications occurred in this group. In the pre-dilation group, all ST were 
successfully implanted, although an acute Ml followed by elective CABG 
occurred after ST thrombosis. Multilink Duet was the most commonly used 
ST in both groups (direct-ST: 58.3% vs. pre-dilation: 57.7%; p = 0.898). 
Fluoroscopy time (direct-ST: 7 i 5.5 min vs. pre-dilation: 7.4 f 4.7 min; p 
= 0.682), contrast volume (114 k 57 ml vs. 130 -I 45 ml; p = 0.106) and 
peak CKMB (13.5 f 7.8 vs. 16.8 It 16.3; p = 0.166) were similar in both 
groups. In the direct-ST group, only 11 PTCA balloons were used, mainly for 
post-dilation, while 55 balloons were used in the conventional group (0.18 
vs. 1.06 balloons/lesion; p 4 0.0001). 
Conclusions. Direct-ST is a feasible and safe technique when used in 
selected coronary lesions, without significant calcification and/or angulation. 
The degree of stenosis is not an important limitation, especially when treat- 
ing unstable lesions, where thrombus plays an important role. Procedural 
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costs are lower with this strategy, because it reduces the use of PTCA bal- 
loons, although it does not seem to significantly reduce the duration of the 
procedure. 
I 1086 91 Vessel Wall Passivation to Platelets and Neutroohils is not Comolete One Month After 
Jean-Franpois Tanguay, Talal Hammoud, Pascale Geoffroy, Yahye Merhi. 
Montreal Heart Institute, Montreal, Canada 
Background: After balloon angioplasty (PTCA) and stenting, complete ves- 
sel wall passivation to platelets (PLT) and neutrophils (PMN) is critical to 
achieve optimal clinical outcome. We have shown that compared to PTCA, 
stented vessels remained significantly more attractive to PMN up to 24 hours. 
In this study we evaluated the in viva vessel wall reactivity at one month in a 
porcine coronary artery model. 
Methods: Each animals (n = 8) was pretreated with ASA and heparin 
before PTCA and stenting of each coronary artery. Animals were euthanized 
at 24 h and one month after the procedure. Adhesion was quantified using 
5’Cr-PLTand “r In-PMN. After in vivofixation, the stented, dilated and normal 
uninjured segments were harvested for gamma counting. 
Results: 
PLTx106cm2 24 h 1 month PMNx103/cmP 24 h 1 month 
PTCA (n) 3.0*1.1 (10) 1.4&0.6(12) PTCA (n) 70f17(14) 64+17(12) 
Stent (n) 6.1 f0.8 (5) 3.9f0.9 (12) Stent (n) 225&44 (7) 194f59 (12) 
0 NS 0.02 0.001 0.04 
Conclusions: Normal uninjured segments were thromboresistant to PLT 
and PMN adhesion. Stented vessels are more attractive to PLT and PMN. 
At one month, vessel wall passivation is not complete compared to PTCA 
and suggest ongoing thrombotic and inflammatory reactions after stenting. 
These findings may have important clinical and therapeutic implications, 
LLA 1086 92 Protection Against Restenosis From an Interleukin-1 Receptor Antagonist Gene 
Polymorphism in Patients Treated With Coronary 
Stenting 
Adnan Kastrati, Werner Koch, Peter B. Berger, Julinda Mehilli, 
Katherine Stephenson, Nicolas von Beckerath, Corinna Bdttiger, 
Albert Schomig, Franc0 diGiovine, Gordon W. Duff. Deufsches 
Herzzentrum, TU Munich, Germany; Div. Molecular & Genetic Medicine, 
University of Sheffield, UK 
Background: Cytokines of the interleukin-I (IL-l) family play a central role 
in regulating inflammatory responses. There is a strong evidence to support 
IL-l regulation of smooth muscle cell mitogenesis and extracellular matrix 
production. IL-l receptor antagonist (IL-lra) counters the proinflammatory 
effects of IL-I. IL-I ra is the product of a polymorphic gene. The rare allele 
2 in its gene (IL-lRN’2) correlates with altered IL-lra protein levels. We 
assessed the association between IL-1 ra polymorphism and restenosis after 
coronary stenting. 
Methods: In 1850 consecutive pts, clinical and angiographic (6-month 
reangiography rate: 84%, restenosis as a ~50% diameter stenosis) outcome 
measures were evaluated over 1 year after the intervention. Genotyping for 
an exon 2 polymorphism (+2018) of IL-IRN (alleles 1 and 2) was based on 
a PCR technique. 
Results: Allele 2 frequency was 0.28. Allele 2 was associated with a 
significant decrease in the risk for restenosis and reintervention (TVR), es- 
pecially in younger pts ~60 yrs (odds ratios in the Figure). The younger 
pts showed a significant gene dose effect, with rates of restenosis and TVR 
decreasing progressively with heterozygosity and homozygosity for allele 2 
(bar graphs on the right). 
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Conclusions: Allele 2 of the IL-lra gene was associated with a lower 
incidence of restenosis after coronary stenting. This may offer the rationale 
for future studies to test recombinant IL-1 ra for prevention of restenosis. 
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I 1087 115 Balloon Dilation of MMP Inhibited Porcine Arteries: The Bigger the Better 
Marion J. Sierevogel, Gerard Pasterkamp, Evelyn Velema, Dominique P. de 
Kleijn, Cornelius Borst. Department of Cardiology University Medical 
Center, Utrecht, The Netherlands 
Background: Late Lumen Loss (LLL) after balloon dilation is the result of 
constrictive remodeling (REM) and intimal hyperplasia (IH). Previously, we 
demonstrated that inhibition of Matrix Metalloproteinases (MMPs) reduces 
LLL after balloon dilation by inhibition of constrictive REM. In the present 
study IH and REM were assessed with and without MMP inhibition and 
related to acute luminal gain (ALG). 
Methods: In 22 pigs, balloon dilation was performed in 41 femoral and 
30 internal lilac arteries. Pigs were randomly divided into 4 groups: a control 
group (n = 22 vessels) and three groups in which Marimastat, an oral MMP 
inhibitor, was administered for 2 weeks (n = 15) 4 weeks (n = 18) or 6 weeks 
(n = 16). Pigs were terminated 42 days after intervention. Intravascular 
ultrasound (IVUS) was performed at all time-points. At 0.5 cm intervals, 
IVUS images of the dilated segment were matched pre-, post intervention 
and at follow-up. For each artery, the location with the smallest lumen at 
follow up was selected for further calculations. REM and IH were plotted 
versus ALG. Data of the three Marimastat groups were pooled because no 
significant differences were observed. 
Results: 
* p = 0.01 
REM (mm’) 
IH (mm’) 
IH “s ALG 
REM “s ALG 
Control 
2.43 z!z 4.19 
2.23 zk 1.59 
y = 0.20x * 1.34, r = 0.44 
Cl slope: 0.01 to 0.38 
y = 0.78X-l .09, r = 0.66 
Cl slooe: 0.36 to 1.18 
Marimastat 
-0.23 f 2.82* 
2.74 zk 1.86 
y = 0.23X + 1.70, r = 0.38 
Cl slope: 0.07 to 0.40 
y = 0.05x-0.47, r = 0 
Cl slooe: -0.22 to 0.32 
Conclusions: Marimastat blocked constrictive REM irrespective of acute 
luminal gain. The impact of luminal gain on IH was relatively small. Thus, 
the motto ‘the bigger the better’ applies to balloon dilation in MMP inhibited 
arteries. 
L--.-IL 1087 116 Intravenous ARC69931 MX, a Novel P2T Platelet Receptor Antagonist, in Patients Undergoing 
Percutaneous Coronary 
Interventions-Preliminary Results from a 
Placebo or Active Controlled Trial 
W. Douglas Weaver, Robert A. Harrington, Cindy L. Grines, Ellen C. Keeley, 
Dean J. Kereiakes, John A. Bittl, Donna R. Grogan, Hakan Emanuelsson. 
Henry Ford Heart and Vascular Institute, Detroit Ml, USA 
Background: We performed a double-blind, placebo-controlled, dose-res- 
ponse trial of ARC69931 MX, an inhibitor of ADP-mediated platelet activation 
and aggregation, in patients undergoing percutaneous coronary intervention 
(PCI) to assess tolerance and safety. 
Methods: Patients were randomized to an 18-24 hour infusion of AR- 
C69931MX (1.0 &kg/min, 2.0 wg/kg/min or 4.0 pg/kg/min) or placebo in 
addition to aspirin and heparin during PCI. Primary endpoints included major 
bleeding and major adverse cardiac events (MACE). 
Results: Baseline demographics and procedural characteristics between 
groups were similar except less unstable angina (29%) and more frequent 
abciximab use (6%) in the 4.0 pg/kg/min group. Mean duration of infusion 
was 20.5 hours. 
Endpoint A (n = 53) 6 (n = 53) 
MACE* 14% 9% 
Bleeding 
TIMI Minor 4% 8% 
TIMI Major 0% 0% 
*Death, infarction or repeat revascularization 
C (n = 52) D(n=51) 
17% 12% 
6% 12% 
0% 2% 
Conclusions: The addition of AR-C69931 MX to aspirin and heparin dur- 
ing PCI was tolerated to a dose of 4.0 pg/kg/min and not associated with 
any significant increase in major bleeding or MACE. An open-label follow-up 
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study comparing the 4 pg/kg/min dose directly with abciximab is presently 
enrolling patients. This class of platelet inhibitors may be important in the 
future treatment of acute coronary syndromes. The unblinded final results 
wili be presented. 
1087-l 17 Quinapril With High Affinity to Tissue 
Angiotensin-Converting Enzyme Inhibitor 
Reduces Restenosis After Percutaneous 
Transcatheter Coronary Revascularzation 
Tomokazu Okimoto, Michinori Imazu, Yasuhiko Hayashi’, Kotaro Sumii, 
Mamoru Toyofuku, Kenji Kajiwara, Yoshito Shimizu, Michio Yamakido. 
Hiroshima Univ. Sch. of Med.: ’ Tsuchiya General Hospital, Hiroshima, 
Japan 
Background: Experimental studies demonstrated that vascular injury re- 
sulted in an induction of vascular angiotensin-converting enzyme (ACE), and 
suggested that inhibition of vascular ACE was important in the prevention 
of restenosis. These results suggest a possible pharmacological effect of 
quinapril, an ACE inhibitor with high affinity to tissue ACE, on restenosis 
after coronary angioplasty. The present study aimed to determine a benefit 
of quinapril on the restenosis. 
Methods: Patients (pts) with ischemic heart disease were enrolled after 
successful percutaneous transiuminal coronary angioplasty or stent implan- 
tation at 7 participating institutions, Two hundred fifty-five pts (acute myocar- 
dial infarction 35%, unstable angina 19%) with 294 lesions were randomly 
assigned to the quinapril (Q) group (IO-20 mgiday) or control (C) group. 
Administration of quinapril was continued for 3-6 months of follow-up (FU). 
Quantitative coronary angiography was performed before and after angio- 
plasty and at FU. 
Results: Eligible FU angiography was performed in 108 pts with 124 
lesions (stent 56%) in Q group and in 107 pts with 130 lesions (stent 53%) 
in C group. The baseline characteristics and results of angioplasty showed 
no significant differences between the two groups. However, minimal lumen 
diameter at FU and net gain were significantly larger (1.62 f 0.72 vs. 1.44 
i 0.70 mm, p < 0.05 and 1.12 * 0.77 vs. 0.87 + 0.81 mm, p < 0.05) in Q 
group. In Q group, restenosis per patient and per lesion was significantly lower 
(34.3% vs. 44.9%, p < 0.05 and 30.6% vs. 43.8%, p < 0.05). Multivariable 
analysis revealed that administration of quinapril independently contributed 
to reducing the restenosis per patient and per lesion (odds ratio = 0.73, p < 
0.05 and odds ratio = 0.75, p < 0.05). 
Conclusions: Quinapril significantly reduces restenosis after coronary 
angioplasty. 
1087-l 18 Intravascular Delivery of Neutrally Charged 
Antisense Phosphorodiamidate 
Compound-Resten-NG inhibits Myointimal 
Hyperplasia Following Balloon Angioplasty 
Patrick Iverson, Victor Skrinska, Eamone Keane, Latha Raja Shankar, 
Jeffrey Moses, Paramjith Chawla, Michael H. Keelan, Nicholas Kipshidze. 
Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin, 
Milwaukee, W/; AVI Biopharma, Corvallis, OR; Lenox Hi// Hospital, Nx NY 
USA 
Background: Myointimal Hyperplasia following percutaneous transluminal 
coronary Angioplasty (PTCA) is a key component of the restenotic process. 
We evaluated the long term impact of local delivery of new neutrally charged 
antisense phosphorodiamidate compound Resten-NG upon myointimal hy- 
perplasia following PTCA in a rabbit model. 
Methods: Twenty four New Zealand white rabbits were anaesthetized, 
transport catheter inserted in the iliac artery and PTCA performed (8 atm for 
30 seconds, three times). The endoluminal delivery of saline (n = 10) or 500 
pg Resten-NG to the PTCA was 2 atm via the outer balloon for two minutes. 
The diet was supplemented with 0.25% cholesterol for ten days before and 
eight weeks following treatment, 
Results: Angiography was performed at the harvest and vessels were 
fixed in formalin, processed and stained with Hematoxylin and Eosin, Movat’s 
and for PCNA. The area of intima and media were determined by planimetry. 
Lumen (mms) 
lntima (mma) 
Control 
0.62 i 0.73 
1.67 + 0.44 
Antisense 
1.89 * 0.35 
0.82 zk 0.32 
P Value 
0.003 
0.002 
Conclusion: Histological analysis revealed that local delivery of Anti- 
sense prevented balloon induced changes. We conclude that local delivery 
of Resten-NG inhibited myointimal Hyperplasia following PTCA in a rabbit 
for up to eight weeks. 
I. 1087 119 Low-Power Red Laser Light Promotes Prohferation of Cardiomyocytes In Vitro 
Nicholas Kipshidze, Ashwani Khanna, Jeffrey Moses. Medical College of 
Wisconsin, Milwaukee, WI; Lenox Hill Hospital, New York, NY; USA 
Background: We previously reported that endoluminal low power Red Laser 
light (LPRLL) promotes post angioplasty wound repair in vitro and in vivo. We 
hypothesized that LPRLL may contribute to tissue repair following myocardial 
injury. Accordingly, we studied the effect of LPRLL irradiation in the fetal 
cardiomyocytes in vitro. 
Methods: All cell cultures were irradiated with a single dose (5 mW) using 
a He-Ne continues wave laser (630 nm) for 5, IO, 15 and 20 min. Assessment 
of effect was performed after 18 hours following irradiation. Effect of LPRLL 
on new DNA synthesis was studied by 3H-Thymdine incorporation assay; 
VEGF and TGF-B expression was studied by RT-PCR. 
5 min 10 min 15 min 20 min 
TGF-fi 0.25iO.25 0.71 i 0.17 0.80 i 0.05 0.38iO.11 
VEGF 0.12 f 0.08 1.10+ 0.12 1.31 * 0.80 0.20 * 0.32 
Results: It was found that (1) increased cardiomyocyte proliferation 
(1 O-60%) can be obtained with LPRLL and this effect is dose dependent; (2) 
there is a significant dose dependent increase in VEGF and TGF-,3 mRNA 
expression.. 
Conclusion: This preliminary data suggests that LPRL induces increased 
proliferation of Cardiomyocytes and increases the production of, VEGF and 
TGF-p in vitro. Further in vivo studies are warranted, hence this data may 
have significant importance leading to the establishment of the new methods 
for myocardial photo-regulation and photo-angiogenesis. 
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LI 088-l 09 1 Design of an Infrared Fiber Catheter for Thermal 
Imaging of Atherosclerotic Plaques 
Bujin Guo, James T. Willerson, Greg Bearman, Janice McNatt, Basit Malik, 
Khawar GUI, Ward Casscells. The University of Texas, Medical School, 
Houston, TX, USA 
Infrared thermal imaging has proven to be very sensitive in measuring small 
temperature differences. We have demonstrated in vitro that heat accurately 
locates inflamed plaques are those significantly warmer than atherosclerotic 
plaques without inflammation. In order to develop a non-surgical method 
of locating these plaques, a novel infrared fiber optic imaging system has 
been developed. The infrared fiber optical imaging bundle consists of an 
array formed with 100 pm individual AS& chalcogenide glass fibers which 
transmit infrared radiation from 0.7 wrn to 7 ym with little energy loss. The 
first prototype consists of a 30 x 30 (6 mm O.D.) square array and the second 
consists of a IO x IO (3 mm O.D.) square array. By combining the infrared 
fiber bundles with a highly sensitive lndium Antimonide (InSb) infrared focal 
plane array (FPA) detector, we are able to obtain in vivo thermal graphic 
images in the aortas of Watanabe hereditable hypercholesterolemic rabbits. 
These images have clearly shown temperature differences over a 2 mm2 
area, with -100 km spatial and better than 0.1 “C thermal resolution. 
We conclude that 1) thermal heterogeneity of atherosclerotic plaques is 
detectable in vivo and 2) an infrared catheter may be useful for studying 
the causes and natural history of heterogeneity of plaque temperature and 
eventually for clinical localization and locally delivered therapy. 
A new design using a “ring type” fiber array to direct the IR fiber towards 
the circumferential of the lumen wall will be presented. Several different 
curvatures have been considered to optimize the photon receiving angle. By 
using microbolometers as IR detectors and new IR fiber, we can extend the 
wavelength range up to 12 Km, which increase sensitivity. 
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I 1088 110 Depth Distortion in Intravascular Ultrasound Tissue Characterization: A Major Pitfall in Gray 
Scale Interpretation 
Atsushi Takagi, Akiko Maehara, Brian K. Courtney, Abel L. Robertson, Paul 
G. Yock, Peter J. Fitzgerald. Stanford Universifx Stanford, CA, USA 
Plaque morphology, as assessed by intravascular ultrasound (IVUS), may 
impact coronary disease management. Conventional approach to tissue 
characterization is based on the gray-scale intensity (GSI) of a plaque. How- 
ever, intensity is modified by time-gain compensation (TGC), and the effect 
of distance between the IVUS catheter and a region of interest (ROI) is not 
well characterized. Accordingly, we assessed the GSI and radio-frequency 
back scatter intensity (BSI) in plaque using a depth-controlled model. 
Methods: Twenty-five non-calcified human coronary plaques were im- 
aged using a 30 MHz IVUS system in a water bath. BSI was measured in a 
ROI, changing the depth of 1.5, 2.5 and 3.5 mm from catheter. Images were 
digitized, and the GSI in the-R01 was measured in each identical sequence. 
Fibro-fatty plaques (n = 8) were compared to fibrous plaque (n = 18) as 
reference at a given depth. Each plaque was classified histo-pathologically. 
Results: The GSI values of fibro-fatty plaques were significantly lower 
at the depth of 1.5 and 2.5 mm, comparing to the GSI of fibrous plaques 
obtained at 1.5 mm depth. However, at 3.5 mm, the GSI trended to increase 
more in fibro-fatty plaques than in fibrous plaques (152 f 109% vs. 90 i 54%, 
p = 0.07). This resulted in difficulty of discrimination between the fibro-fatty 
)plaque at 3.5 mm and fibrous plaque at 1.5 mm (p = 0.66). Using BSI analysis, 
fibro-fatty plaque was constantly distinguished from fibrous plaque through 
the different depth-settings (p < 0.01). 
g :im f j-jyyyj::atty 
II II 25 31 /I 16 25 26 * pco.01 
mtanee (mm) mtance (ml, 
Conclusions: To accurately classify the plaque characteristic in gray 
IVUS images, the depth of the plaque and the effect of TGC should be 
factored into the evaluation. Radio-frequency analysis appears to be better 
suited for tissue characterization of plaque type than gray-scale interpreta- 
tion. 
1 1088-l 11 1 360’ Thermal Color Mapping of the 
Atherosclerotic Plaque by Means of a Special 
Thermography Catheter and Computer Software 
Leonidas Diamantopoulos, Christodoulos Stefanadis, 
Konstantinos Toutouzas, Charalambos Vlachopoulos, John Demellis, 
Pavlos Toutouzas. Hippokrafion Hospital, Athens Universifl: Afhens, Greece 
Background: We have previously shown (Circulation 1999;99:1965-71) that 
atherosclerotic coronary arteries show temperature (T) heterogeneity, which 
is detectable in vivo. The aim of this study was to obtain a 360” thermal 
mapping of the plaque. 
Methods and Results: We studied 7 patients (pts) with stable angina 
who undetwent elective coronary angioplasty in the right coronary artery 
and IO patients with normal coronary arteries. T meaiurements were made 
with a special thermography catheter that was designed in our laboratory 
(accuracy:0.05 “C, time constant: 300 msec, spatial resolution 0.5 mm). 
The thermal mapping of the lesions was achieved by low-speed retraction 
of the catheter using a modified IVUS retraction system. In each plaque, 
8 linear thermal scans were performed in progressively increasing an- 
gles: 0-45-90-135-180-225-270-315” (angle step 45”). Recordings were fed 
in real time to a PC Pentium computer, equipped with special software 
that was developed for the purpose of the study. Individual temperatures 
were coded to colors based on the Red-Green-Blue (RGB) code (Flashing 
Red for 43°C and Dark Blue for 33”C), and, thus, thermal image of the 
area under measurement was constructed. Stable angina patients had in- 
creased T heterogeneity (figure) whereas T was stable in normal coronary 
arteries. 
Conclusions: The 3609 color-coded thermal mapping of the atherosclero- 
tic plaque demonstrated T heterogeneity in stable angina pts. In contrast, no 
heterogeneity was found in the normal coronary arteries. This method may 
provide important information for 3-dimensional T distribution of coronary 
arteries. 
/ 1088-l 12 ( Detection of Simulated Vulnerable Plaque Using 
a Novel Near Infrared Spectroscopy Catheter 
William E. Charash, Robert A. Lodder, Pedro R. Moreno, K. 
Raman Purushothaman, Julie A. Swain, William N. O’Connor, James 
E. Muller. Gill Heart Insfifufe, Universify of Kent&q Lexington, KY; 
Massachusetts General Hospital, Boston, MA, USA 
Background: A method is needed to identify vulnerable coronary plaques 
in humans. Although it has been demonstrated that near infrared (NIR) 
reflectance spectroscopy can identify vulnerable plaques in autopsy spec- 
imens, clinical utility requires identification through blood via a coronary 
catheter. We constructed a novel NIR catheter, and tested its ability to detect 
a cholesterol target in the rabbit aorta in-vivo, and also through blood in-vitro. 
Methods: NIR light from a tunable laser was transmitted via a 2.5 mm 
fiberoptic catheter. Reflectance was detected at the catheter tip. Spectral 
measurements were obtained at 1730,1745, and 1760 nm. Abdominal aortas 
of two anesthetized rabbits were catheterized. Data were obtained from 
normal aorta, from aorta injected with cholesterol, and from three blinded 
sites with cholesterol or sham injections. Principal component (PC) analysis 
was used. Additionally, the catheter tip was placed in a beaker filled with 
heparinized rabbit blood, and moved away from a cholesterol target in 1 mm 
increments. PC analysis for distance was performed using linear regression 
analysis. 
Results: PC analysis correctly characterized all cholesterol and sham 
injections in the aorta of the rabbit. In the in vitro test, linear regression of 
PC1 versus distance yielded a fit with an P of 0.99, a slope of 1 .OO, and a 
standard error of 0.2 mm, through up to 3 mm of blood. 
Conclusions: A NIR catheter small enough for use in a rabbit aorta has 
been developed. This system can detect cholesterol in the aorta of the living 
rabbit, and can penetrate through 3 mm of blood. These findings support 
continued development of a NIR coronary catheter for human detection of 
vulnerable plaques. 
1088-I 13 Assessment of Lipid Content of Atherosclerotic 
Plaque by Intravascular Ultrasound Using 
Fractal Analysis 
Takafumi Hiro, Takashi Fujii, Shinji Yoshitake, Tetsuya Kawabata, 
Kyounori Yasumoto, Masunori Matsuzaki. Yamaguchi University, Ube, 
Yamaguchi, Japan 
Fractal analysis is a new mathematical model for assessing complexity of 
two-dimensional video-intensity profile. This study investigated the feasibility 
of the fractal analysis in IVUS tissue characterization especially for assessing 
lipid content of atherosclerotic plaque. 
Methods: Ten formalin-fixed noncalcified atherosclerotic plaques from 
human necropsy were imaged in vitro with a 30 MHz IVUS catheter. We first 
selected 19 regions of interest (ROI, 1-2 mm*) from the IVUS plaque images 
to obtain a video-intensity profile of each ROI. To examine the inhomogeneity 
of the profile, an index (fractal index, F.I.) was obtained from the slope of 
the regression line between the mean differences in pixel intensity and the 
logarithm of distance between pixels. The plaque segment corresponded to 
each ROI was also examined histologically by Masson’s Trichrome stain. 
Each segment was first classified as fibrous and fatty areas. Then, we 
measured %fraction of fibro-acellular (Pfb), fibro-cellular (Pfc), fibro-fatty 
(Pff), and nonfibrous lipid core (Plc), within the area of each segment. 
Results: F.I. was significantly greater in fatty area (n = 9) than that in 
fibrous area (n = 10) (0.21 f 0.05 vs. 0.14 & 0.03, p < 0.005). A multiple 
stepwise regression analysis derived a significant correlation as: F.I. = 0.11 Plc 
+ O.08Pff + 0.13 (R = 0.83, adjusted R2 = 0.66, p < 0.0005). Pfb and Pf$ was 
statistically excluded in this multivariate analysis. 
Conclusions: The IVUS video-intensity profile was more inhomogeneous 
in fatty area than that in fibrous area. The multivariate analysis suggested 
that F.I. might reflect lipid content of atherosclerotic plaque. Therefore, tissue 
characterization by fractal analysis using IVUS images may be useful in 
assessing plaque instability in patients with coronary artery disease. 
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ETI . . 1088 114 Hugh Frequency Intravascular Ultrasound 
ldentlfies Atherosclerotic Lipid Lakes With High 
Accuracy 
Francesco Prati, Eloisa Arbustini’ , Antonella Labellarte, Barbara Dal Belle’ , 
Federica Marsico”, Maria Teresa Mallus, Antonio Pagano, Luigi Sommariva, 
Alessandro Boccanelli. Cafh Lab S Giovanni Hospital, Rome; ‘Istituto 
Anatomia Patologica, Pavia; ‘S. Raffaele Hospifal, Miiano, Italy 
Previous intravascular ultrasound (IVUS) studies on atherosclerotic plaque 
characterization were limited by use of low-frequency transducers that did 
not define accurately soft components. The present study tested the effec- 
tiveness of high frequency IVUS transducers in identification of lipid/necrotic 
pools in atherosclerotic plaques. 
Methods: Forty MHz transducers were used for in-vitro IVUS assessment 
of 12 arterial segments (10 coronary arteries and 2 carotids dissected from 
5 different autopsy cases). IVUS acquisition was performed at a 0.5 mm/s 
speed after ligature of the branching points to generate a closed system. 
Lipid necrotic areas were defined by IVUS as large echolucent intra-plaque 
areas surrounded by tissue with higher echodensity. To obtain histopathologic 
sections corresponding to IVUS cross-sections, vessels were divided into 
consecutive 3 mm-long segments using the most distal recorded IVUS image 
as starting reference. Then, samples were fixed with 10% buffered formalin, 
processed for histopathologic study, serially cut and stained with Movat 
penthacrome method. 
Results: On histopathoiogic study, intra-plaque lipid lakes were present 
in 30 of 122 cross-sections (25%) (arrow in figure A). Corresponding IVUS 
cross-sections identified lipid lakes with a sensitivity and specificity of 67% 
and 94% respectively (arrow in figure B). 
Conclusions: High frequency ultrasound transducers enable an accurate 
identification of lipid/necrotic pools leading to a more precise characterization 
of atherosclerotic plaques. 
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843-l Percutaneous Coronary Intervention for Non-ST 
Elevation Myocardial Infarction: A Report From the 
NHLBI Dynamic Registry 
David 0. Williams, Wanlin Yeh, Katherine M. Detre, She@ F. Kelsey, 
Howard Cohen, Michael J. Cowley, Mahdi Al-Bassam, Alice K. Jacobs, 
Martial Bourassa. Dynamic Registry Investigators; Rhode /s/and Hospital 
Brown University School of Medicine, Providence, Rhode /s/and, USA 
Background: The value of an aggressive strategy including catheterization 
and percutaneous coronary intervention (PCI) for patients (pts) with non-ST 
elevation (i.e. non-Q-wave) acute myocardial infarction (AMI) has been ques- 
tioned. 
Purpose: To determine the baseline features, procedural strategies and 
in-hospital outcomes of AMI pts in the 1999 enrollment wave of the Dynamic 
Registry with and without ST-elevation on initial ECG. 
Results: Of 458 AMI pts, 275 (60.0%) had ST-elevation (ST?) and 183 
(40.0%) did not (non-ST?). Non-ST? pts did not differ from ST? pts in age, 
gender, hx diabetes or risk for PCI. Compared to ST? pts, non-ST? pts 
more often had prior CABG (ST?: 2.5% vs. non-STt:16.4%, p < O.OOl), 
prior MI (17.0% vs. 29.4%, p < O.Ol), hx. of CHF (5.9% vs. 14.9%, p < 
O.OOl), multivessel CAD (51.3% vs. 55.8%, p < 0.001) and on average more 
significant lesions (2.3 vs. 3.0, p < 0.01). Attempted lesions in non-ST? pts 
were more often in a vein graft (0.9% vs. 6.6%, p < 0.001) or in the LCX 
(14.4% vs. 32.6%, p i 0.001) and less likely to be a total occlusion (35.2% vs. 
14.9%, p 4 0.001). There was no difference between the groups in the use 
of stents although ST? pts more often received llbllla antagonists (54.9% 
vs. 44.8%, p < 0.05). Non-ST? pts were more likely to achieve TIMI 3 flow 
(90.2% vs. 95.3%, p < 0.05) although final stenosis, angiographic success, 
subsequent MI and CABG rates were similar. In-hospital death was 4.0% for 
ST? pts and 2.7% for non-ST? pts (P > 0.05). 
Conclusions: Despite having more multi-vessel and multi-lesion CAD, hx 
CHF, vein graft lesions attempted and less llbllla ancillary therapy, non-ST? 
pts achieved better angiographic results and similar clinical outcomes as 
ST? pts with PCI. These findings provide further support for the aggressive 
strategy in the management of pts with non-ST? Ml. 
2:15 p.m. 
1843-2 1 Primary Stenting Versus Balloon PTCA for the 
Treatment of Acute Vein Graft Occlusion in 
Myocardial infarction: In-Hospital Results From the 
Brazilian Coronary Interventional Registry (CENIC) 
Luiz Mattos, Amanda Sousa, Cantideo C. Neto, Faust0 Feres, 
Milton Soares, Andre Labrunie, Cleudia Alves, Jamil Saad. Brazilian Society 
of lnfervenfional Cardiology: 520 Paula, Brazil 
Background: There is few data regarding contemporary results of primary 
percutaneous coronary treatment of vein graft occlusion occurring in the first 
hours of AMI. 
Methods: Brazilian Percutaneous Coronary Interventional Registry (CENIC) 
has gathered 39.721 consecutive pts from 1996 to 1998; 4.777 patients un- 
derwent primary coronary procedures in the first 24 hours of AMI. From these 
Ml cohort, we compared the in-hospital outcome of 158 consecutive patients 
with acute vein graft occlusion submitted to routine stenting or primary balloon 
PTCA. The primary coronary device selection was left to operator discretion. 
Results: (table) 
Variables (%) stent (741 PTCA 1841 P 
Mean age 63 * 12 years 63 f 11 years 1.0 
Mean time CABG to AMI 7.1 f 3 years 6.5 * 4 years 0.6 
Anterior Ml/LAD Graft 44 41 0.7 
Triple vessel disease 79 66 0.09 
Baseline EF < 45% 48 68 0.05 
Lesion length > 10 mm 57 64 0.2 
Abciximab usage 6 4 0.5 
Success (TIMI 3) 96 72 0.0001 
Mean stenosis post 11 41 0.0001 
Reinfarction 6.8 5.3 0.5 
Death 6.8 7.1 0.6 
Conclusions: Primary percutaneous treatment of AMI related to acute 
vein graft occlusion is still uncommon in these recent analysis of a large 
national consecutive cohort of patients. In this scenario of adverse angio- 
graphic variables, primary stenting improved luminal diameter plus success 
rate compared to balloon PTCA, but without reducing in-hospital reinfarction 
or death. 
2:30 p.m. 
843-3 Hirudin Significantly Reduces lschemic Events 
Following Coronary Intervention for Acute Coronary 
Syndromes 
Matthew T. Roe, Christopher B. Granger, E. Magnus Ohman, Robert 
M. Califf, Anne Hellkamp, Eric J. Topol, Harvey D. White, Judith Hochman, 
Frans Van de Werf. Duke Clinical Research Institute, Durham, NC; 
C/eve/and Clinic Foundation, C/eve/and, OH, USA 
Background: Potential advantages of direct thrombin inhibitors for use dur- 
ing percutaneous coronary intervention (PCI) include an enhanced anticoag- 
ulant response and improved safety profile compared with heparin. However, 
the relative benefits of the direct thrombin inhibitor hirudin for patients with 
evolving acute coronary syndromes (ACS) undergoing PCI have not been 
well characterized. 
Methods: Patients with ACS enrolled in the GUSTO-lib trial were ran- 
domized to hirudin or heparin. All patients who underwent PCI during blinded 
study drug administration were evaluated. Incremental doses of either drug 
were given during PCI to achieve a target activated clotting time (ACT) of 
300-350 seconds and study drug was to be continued after PCI for a total of 
72 hours. 
Results: Patients treated with hirudin (n = 671) and heparin (n = 733) had 
similar baseline characteristics. Approximately 30% of patients in both groups 
underwent primary angioplasty for acute ST-segment elevation myocardial 
infarction (Ml). The median time to PCI was 9 hours in the hirudin-treated 
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group and 14 hours in the heparin treated group (p = NS). The median 
duration of study drug administration was 74 and 75 hours, respectively. 
30 Dav Outcomes Hirudin Heoarin D-value 
Death (%) 
MI (%) 
Death/MI (%) 
Bleeding (%) 
0.1 0.1 0.95 
1.9 3.7 0.05 
2.1 3.8 0.05 
3.4 2.6 0.75 
Conclusions: Hirudin appears to more effectively reduce ischemic events 
following PCI in patients with ACS compared with heparin and is not associ- 
ated with a significant increase in bleeding events. 
3:00 p.m. 
843-5 Elevated CK-MB Following Coronary Intervention in 
Patients With Acute Coronary Syndromes is 
Associated With a Four-Fold Increase in Mortality: 
Results from the GUSTO-lib and PURSUIT Trials 
Matthew T. Roe, John H. Alexander, Cindy M. Pacchiana, Robert 
A. Harrington, Christopher B. Granger, Robert M. Califf, Eric J. Topol. Duke 
Clinical Research Institute, Durham, NC; Cleveland Clinic Foundation, 
Cleveland, OH, USA 
Background: Multiple studies have demonstrated that elevation of the cre- 
atine kinase MB subfraction (CK-MB) following percutaneous coronary inter- 
vention (PCI) is associated with increased mortality. However, the prognostic 
significance of CK-MB elevation following PCI in patients with acute coronary 
syndromes (ACS) has not been specifically characterized. 
Methods: Patients with ACS without persistent ST-segment elevation 
from the GUSTO-lib and PURSUIT trials who underwent in-hospital PCI 
were evaluated. 6 month death and re-MI (>24 hrs. post-PCI) were evaluated 
based on the presence or absence of CK-MB elevation (23X upper limit of 
normal [ULN] within 24 hrs. after PCI). Patients who had elevated CK or 
CK-MB levels above the ULN within 24 hrs. prior to PCI were excluded. 
Results: CK-MB levels following PCI were recorded in 1819 of 4239 
patients (43%). The frequency of mortality at 6 months was similar in patients 
who did and did not have CK-MB levels recorded after PCI (3.0% vs. 3.2%, 
p = 0.75). After excluding 544 patients with elevated CKfCK-MB prior to PCI, 
outcomes are shown for patients with CK-MB levels measured after PCI. 
N 
Death (%) 
Re-MI (%) 
Death/R+MI (%) 
CK-MB 3 3X ULN No CK-MB? p-V&E 
220 1055 
8.6 2.4 0.001 
4.1 2.0 0.06 
11.4 4.2 0.001 
Conclusions: CK-MB elevation following PCI is associated with an in- 
creased frequency of death and death/re-Ml through 6 months in patients 
with ACS. Further analyses may help determine the longer term significance 
and independent prognostic value of these findings. 
3:15 p.m. 
843-6 Abciximab Improves Microvascular Function After 
Rescue PCI: A TIMI 14 Substudy 
James A. de Lemos, C. Michael Gibson, Elliott M. Antman, Sabina 
A. Murphy, Robert P. Giugliano, David A. Morrow, Kristin C. Schuhwerk, 
Carolyn H. McCabe, Eugene Braunwald. Brigham and Women’s Hospital, 
Boston, MA, USA 
Background: Patients with incomplete ST resolution (STRES) after primary 
PCI are at high risk for left ventricular dysfunction and death, likely due to 
extensive tissue and microvascular injury. We tested the hypothesis that 
adjunctive treatment with abciximab would improve microvascular function 
after PCI, as evidenced by greater STRES. 
Methods: In this retrospective analysis of the TIMI 14 study, we evaluated 
all 92 patients who had interpretable baseline, 90, and 180 minute ECGs and 
who underwent PCI between 90 and 180 minutes after thrombolysis. We 
compared mean STRES from 90 to 180 min (pre- and post-PCI) between 
patients who received abciximab (n = 29) and those who did not (n = 63). 
Results: Mean STRES following PCI was significantly greater in patients 
who received abciximab than in those who received tPA alone (50 -I 48% 
vs 23 i 77%; p = 0.02). In a multivariate model incorporating infarct lo- 
cation, time from symptom onset to PCI, 90 minute TIMI frame count, 90 
minute ST resolution, and residual stenosis post PCI, abciximab remained 
an independent predictor of greater STRES following PCI (p = 0.01). 
Conclusions: In patients who receive early adjunctive (rescue) PCI af- 
ter thrombolytic therapy, abciximab appears to enhance microvascular and 
tissue level reperfusion, as evidenced by improved ST resolution. These find- 
ings extend our previous observations of the specific benefit of abciximab 
on the microcirculation, and suggest a mechanism by which abciximab may 
improve outcomes in patients receiving adjunctive PC1 after thrombolysis. 
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I . 844 1 A Novel Guidance System for Facilitating the Crossrng of Plaque and Chronic Total Occlusions 
Jacques Koolen, Hans Bonnier, Eberhard Grube’ Cafharina Hospital, 
Eindhoven, The Netherlands; ‘Heart Center Siegborg, Siegborg, Germany 
Background: Crossing chronic total occlusions (CTOs) and complex le- 
sions is a complicated, time and material consuming process. A new, novel 
guidewire system that utilizes Optical Coherent Reflectomety (OCR) to guide 
the guidewire through the occlusion was used in a clinical protocol at two 
sites. 
Description of Device: This new technology is based on the variable 
absorption and scattering of near-infrared light by substances such as plaque, 
blood, tissue and thrombus. Algorithms have been devised based on variable 
absorption rates and different scattering coefficients as a light beam of known 
intensity is introduced through the guidewire and illuminates adjacent to the 
tip. 
Procedure: The direction of the tip of the guidewire system is shown on a 
small monitor that is used to maintain the navigation of the guidewire system 
through the chronic occlusion minimizing the possibility of perforating the 
arterial wall. The direction of the guidewire may be changed utilizing a 3.5F 
bi-directional catheter that also yields additional pushability for the guidewire. 
Results: To date, we have performed ten clinical cases (mean age 71 
f 10) under a protocol designed to prove safety and clinical efficacy of 
the IntraLuminal Safe-Steei” Guidewire System. One LCX (75%), one LAD 
(80%) and eight CTOs (five LAD, two RCA, one LCX). All ten stenoses were 
successfully crossed, without complications, using the guidewire system. 
PTCA was performed on all ten patients with eight being stented. 
Conclusions: Our preliminary clinical experience using the Safe-Steer’ 
Guidewire System has shown that this technology is both clinically safe 
and efficacious in guiding the guidewire through both plaque and CTOs. 
This procedure also shows a reduction in the time required to cross these 
stenoses as well as an “early warning system” for detecting the arterial wall 
therefore minimizing the risk of perforation. 
2:15 D.m. 
El 844 2 First United States Experience With a Novel 
Atherectomv and Thrombectomv Device in 
Thromboticiesions in Native Coronary Arteries and 
Saphenous Vein Grafts 
Gregg W. Stone, David Cox, Reginald I. Low, Ray Matthews, Martin 
B. Leon. Washington Hospital Center, Washingfon, DC, USA 
Background: Percutaneous intervention in patients with acute ischemic 
syndromes and saphenous vein grafts results in pen-procedural myocardial 
infarction in up to 30% of patients, most frequently due to macroscopic or mi- 
croscopic distal thromboemboli. A new thrombectomy/atherectomy catheter, 
the EndiCOR X-SIZER”, may improve the early safety profile of intervention 
in these patients by removing friable thrombus and grummous material prior 
to definitive PTCAfstenting. 
Methods: The X-Sizer system consists of a unibody 6F dual lumen 
catheter (9F guide compatible) with a battery driven hollow torque cable at- 
tached to a distal helical cutter. Catheter rotation over any 0.014 inch guide 
wire under saline flush results in extraction atherectomy into a proximal vac- 
uum chamber. A phase I IDE study (X-TRACT) is currently being performed 
in 50 pts at 10 sites to test the safety and efficacy of this device in saphenous 
vein grafts and thrombotic lesions in native coronary vessels. 
Results: To date, the X-SIZER has been used in 14 pts at 4 sites, including 
6 native coronary arteries with thrombus and 8 vein grafts. GP Ilb/llla agents 
were used in only 1 pt (7.1%). The cutter successfully crossed the lesion in 
12 pts (86%). Device related complications consisted of 1 perforation (due to 
a manufacturing defect, since corrected), which was treated conservatively 
without sequelae. Following atherectomy, stents were implanted in all pts. 
No episodes of no/slow reflow or distal thromboemboli were noted. There 
were no in-hospital deaths, MI, or need for CABG or repeat TVR. Specifically, 
there were no elevations in serial CPK and CPK-MB levels (assessed q8 hrs 
JACC February 2000 ABSTRACTS - ACCIS2000 41A 
x 3 post procedure). During 30 day follow-up, 1 pt has had subacute stent 
thrombosis. 
Conclusions: These preliminary data suggest that use of the X-SIZER in 
thrombotic lesions in native coronary arteries and saphenous vein grafts is 
feasible, and has been associated with a low rate of peri-procedural Ml and 
angiographic complications in an otherwise high risk population. Adjudicated 
data from all 50 pts, including angiographic core laboratory analysis, will be 
presented. 
2:30 p.m. 
lIIIILl 844 3 A Novel Device for Removal of Thrombus From Coronary Arteries: The X-SIZER Multicenter 
Trial 
Thomas A. Ischinger. On behalf of the X-SIZER Study Group; Klinikum 
Bogenhausen, Division of Cardiology: Munich, Germany 
Thrombo-occlusive coronary disease continues to be a challenge for inter- 
ventional techniques. The X-SIZER catheter is a novel single use device 
designed to remove thrombus from coronary arteries and SVGs using stan- 
dard catheter techniques, compatible with 8 Fr guides and 0.014 inch wires. 
The clinical trial to date includes 106 pts (age 31-82 years, male 89 (84%) 
at 14 centers. Target vessels were: LAD 31, RCA 40, LCX 12, SVG 23, with 
ref.diameter range 2.0-5.5 mm. Clinical indication was unstable angina in 
54 and acute Ml in 30 pts. Angiographic indication included angio-identified 
or suspected thrombus in 53 pts (15 of them instent occlusions), and instent 
restenosis in 39 pts. The X-SIZER reached target lesion (successful deploy 
ment) in 76% of attempted pts and achieved success (X-SIZER success = 
stenosis reduction and/or 21 TIMI flow grade improvement without MACE) 
in 62% of all attempted cases (and in 81% of successful X-SIZER deploy 
ments), with X-SIZER stand alone success in 2 pts, and total procedural 
success (~30% final stenosis with use of routine adjunct devices, no MACE) 
in 92% of all attempted cases. Mean pre X-SIZER stenosis was 87 f 15%, 
post X-SIZER 61 j, 29%, and final 12 f 17%, MeanTlMl flow grade pre X- 
SIZER was 1.5, post X-SIZER 2.3, final 2.8. CK rise (in 3 cases attributable to 
ongoing Ml) occurred in 5 pts (1 thrombus dislodgement & partial sidebranch 
occlusion, 1 distal embolization, 1 vessel damage) with 2 MACE in total. 
Failures of X-SIZER were mostly due to inability to reach or pass lesions or 
(only early cases) technical deficits. Mean procedural duration was 15.2 min, 
blood loss to vacuum bottle was small (mean 50.9 ml). No other vascular, 
clinical or access site complication have occurred acutely or during FU (2 to 
16 mos) to date. In 26 pts retrieved tissue particles were histologically ex- 
amined and identified as fresh and partially organized thrombus and hyalin 
fragments. In conclusion, the X-SIZER is a novel, simple to use device which 
has demonstrated safety and efficacy for removal of thrombus from native 
coronary arteries, SVGs and stents in selected pts. Further investigation, 
including proliferative restenosis, is necessary. 
2:45 p.m. 
844-4 Recanalization of Total Coronary Occlusions Using 
a the Sonicross Low Frequency Ultrasound 
Catheter 
Louis Cannon, Robert Siegel, Joel Greenberg, Ravi Rao, Ross Prpic, 
Shirley Chan, Jeffrey J. Popma. Brigham and Women’s Hospital, Boston, 
MA, USA 
Background: Coronary occlusion refractory to conventional coronary guide- 
wire crossing remains a clinical challenge, often resulting in chronic ischemia 
despite medical therapy or coronary bypass surgery. A novel: over-the-wire, 
3.0 Fr (tip diameter, 1.2 mm) low-frequency (20 kHz) ultrasound catheter 
powered at 20 Watts has been developed to sonicate the occluded segment 
allowing facilitated guidewire passage. 
Methods: To evaluate the utility of this device in “refractory” total coronary 
occlusions, we used the Sonicross catheter in 14 pts with total occlusion 
(TIMI 0,l flow) in whom there was failure to cross into the distal vessel with 
conventional wires after ~15 minutes of flouroscopy. Baseline quantitative 
angiography was available in 12 patients. 
Results: Either the guidewire or Sonicross catheter crossed the stenosis 
in 10 (71.4%) patients; procedural success (<50% final diameter stenosis 
and no death, infarction, or urgent revascularization) was obtained in 6 
(42.8%) pts; stents were used in all successfully treated patients, resulting 
in a 2.6% final diameter stenosis. No patient died or required emergency 
coronary bypass surgery. In those undergoing quantitative angiography (N = 
12), the Sonicross guidewire use was performed in the right coronary artery 
in 6 pts (50%), circumflex in 3 pts (25%), left anterior descending in 2 pts 
(17%), and left main in 1 pt. The average lesion length was 10.26 mm. 
There were bridging collaterals in 42% and average collateral grade of 1.6. 
Mean angiographic reference diameter was 2.80 mm. Localized coronary 
perforation occurred in two pts and dissection developed in 4 pts. 
Conclusion: The Sonicross catheter is a safe and effective therapy for 
the treatment of “refractory” total occlusions, resulting in recanalization > 
40% of vessels attempted. Longer term restenosis surveillance is ongoing. 
3:00 p.m. 
I 844 5 Helixcision Atherectomy for In-Stent Stenosis: Initial 
In Vivo Experience 
Charles J. Davidson, Gary Gershony, Sidney Lo, Andrew J. Carter, Alan 
C. Yeung, Paul G. Yock, James Passafaro. Northwestern University Medical 
School, Chicago, IL; John Muir Medical Cenfeer, Walnut Creek, CA; Stanford 
University Medical Center, Pa/o Alto, CA; Prolifix Medical, Inc., Sunnyvale, 
CA, USA 
Current therapy for in-stent stenosis is suboptimal. The purpose of this study 
was to determine the efficacy of a new Helixcision atherectomy device for 
treatment of in-stent stenosis in a porcine in viva model. In-stent stenosis 
was created by overstretch injury with a balloon followed by deployment of 
a balloon expandable stent (3.2 mm to 4.0 mm). After 4-6 weeks, animals 
were evaluated for restenosis with angiography and intravascular ultrasound 
(IVUS). 8 lesions were treated in 8 pigs. 
Helixcision utilizes a 4.OF Helixcisor Catheter (Prolifix Medical Inc., Sun- 
nyvale, CA) placed over a 0.014 inch lumen conforming helical guidewire. 
The Helixcisor catheter is rotated at 17,500 rpm with internal aspiration of 
tissue contents. Lumen size is increased by passive mechanical expansion 
of the guidewire coil diameter. Device sizing is accomplished by varying the 
guidewire coil diameter, pitch and length. IVUS minimal lumen area, maxi- 
mal plaque area, vessel area, % area stenosis (plaque area + vessel area) 
were measured pre and post Helixcision at 5 segments and averaged. All 
post-Helixcision IVUS results were accomplished without balloon dilatation. 
Results: 
IVUS Data Pre-Helixcision Post-Helix&ion P 
Minimum Lumen Area (mm2) 4.0 * 1.1 6.8 z!c 1.1 <O.OOl 
Max Plaque Area (mm’) 6.0 zk 1.4 3.5 i 0.1 <O.OOi 
Area Stenosis (%) 60*10 34f5 <O.OOl 
Atherectomy was accomplished within 20 minutes in all lesions. Guidewire 
diameters ranged from 2.5 mm to 4.1 mm. One neointimal flap was observed 
with IVUS post Helix&ion, which was removed with subsequent cuts. There 
was no evidence of distal embolization. 
Conclusion: In this initial experience with Helixcision atherectomy, suc- 
cessful and efficient debulking of in-stent stenosis was accomplished with 
preservation of stent integrity. Additional acute and chronic in viva studies 
are in progress. 
3:15 p.m. 
844-6 Clinical Safety and Efficacy of the PercuSurge 
Guardwire in the Saphenous Vein Graft Angioplasty 
Free of Emboli (SAFE) Study 
Eberhard Grub@, John Webb, Ross Prpic, Satyendra Giri, Ravi Rao, 
Richard E. Kuntz, Lisa Beck, Shirley Chan, Alla Lanina, Leonid Firer, Jeffrey 
J. Popma. Brigham and Women’s Hospital, Boston, MA, USA 
Background: Distal embolization resulting in myocardial necrosis remains a 
significant limitation associated with saphenous vein graft (SVG) angioplasty. 
Methods: To determine whether distal SVG occlusion and aspiration of 
SVG embolic debris reduces the occurrence of complications during SVG 
angioplasty, we used the PercuSurge Guardwire system in 105 patients. 
The Guardwire permits simultaneous distal SVG occlusion and SVG angio- 
plasty followed by removal of embolic debris using a 20 cc, low pressure 
(<I atm) aspiration syringe. 30 day major adverse cardiac events (MACE) 
were defined as the occurrence of death, myocardial infarction [(Ml) defined 
as >3 x normal CK-MB], or revascularization. Angiographic complications 
were defined as transient or sustained abrupt closure (TIMI 0,l flow), distal 
embolization, or no reflow. 
Results: Baseline findings are shown. 
Clinical 
Male Gender 
Diabetes mellitus 
Graft age, years 
In-Hospital MACE 
Death 
MI 
30 dav MACE 
% 
67 yrs 
87.4 
17.5 
8.9 
2.8 
0.9 
2.8 
3.6 
Angiographic 
SVG Reference, mm 
Pre MLD, mm 
Pre % stenosis 
Final MLD 
Final % stenosis 
Distal Embolus 
No reflow 
Anaioaraohic Comuls 
% 
3.39 5 0.71 
1.07 & 0.72 
68.3 + 18.9 
2.80 -c 0.66 
17.1 * 14.0 
3.3 
3.3 
3.3 
MLD = minimum lumen diameter. 
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Any CPK-MB (> 1) elevation occurred in 9.5% of patients. Failure to deploy 
the Guardwire device occurred in ~2.8% of patients. 
Conclusion: The Guardwire is a safe and effective adjunct to prevent 
complications in patients undergoing “high-risk” SVG intervention. 
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1 1107-75 1 Prognostic Influence of Cardiac Troponin I After 
Coronary Angioplasty 
R. Teles, L. Arrieta, J. Ferreira, A. Mesquita, M. Sousa, J. Figueira, 
E. Melo-Gomes, Ft. Seabra-Gomes. Cardiology Departmenf, Santa Cruz 
Hospital, Lisbon, Portugal 
Background: Cardiac troponins (Tn) are valuable tools in unstable angina 
(UA). However, its mid-term prognostic value after coronary angioplasty 
remains controversy. 
Aim: To examine the prognostic influence of Tn I (Tnl) in patients submit- 
ted to an elective coronary intervention procedure. 
Methods: Blood samples for cardiac enzymes and Tnl were collected in 
145 pts before, at 6 and at 12 h after angioplasty. Serum Tnl was determined 
by chemiluminescent immunoassay method (Acces#/Sanofi Pasteur). The 
primary endpoint was determined at F-Up (9 f 3 months) as the compos- 
ite occurrence of death, myocardial infarction, recurrent angina, repeated 
revascularization procedure and angiographic reestenosis. 
Results: At the end of F-Up pts with a least one elevated (>O.l fig/L) 
Tnl determination had a higher event rate compared with those pts whose 
values were always below cut-off value: 38.9% versus 16.2%, p = 0.004, 
Cox-F. test). 
EVENT FREE SURVIVAL AT I-YEAR AFTER CORONARY 
ANGIOFLASTY AOCGRLWG TO CARDIAC TROPONIN I 
cumnldhm RwivnO” *mvMQl mr,pkc-w 
4 t i 
- 
o,o 
TnlNEG 
0 2 4 6 a IO ,2 - ml POS 
Conclusions: These data show that Tnl is an important prognostic marker 
in patients submitted to coronary angioplasty. It should be considered a 
potential useful tool to identify those patients who may be benefit from a 
tighter follow-up. 
1107-76 The Prognostic Value of a Single Creatine 
Phosohokinase Measurement After Percutaneous 
Coronary Interventions 
Abdul M.A. Hasnie, Mamtha Balasubramanian, Robert D. Safian, Cindy 
L. Grines, Aaron D. Berman, James A. Goldstein, William W. O’Neill. 
William Beaumont Hospital, Royal Oak, Michigan, USA 
Objective: This prospective study was undertaken to determine in-hospital 
prognostic significance of single creatine phosphokinase (CPK) measure- 
ment, obtained 8 hours after percutaneous coronary intervention (PCI) in a 
tertiary care referral center. 
Background: Frequent cardiac isoenzyme measurements have been 
used in randomized PCI trials. We tested the prognostic value of a simpler, 
less costly strategy. 
Methods: CPK levels were obtained 8 hours after PCI in 3786 consecutive 
patients, excluding patients with acute myocardial infarction < 24 hours, 
Outcomes were analyzed based on normal CPK level (Group I), 1-2 x 
normal (Group II) and ~2 normal (Group Ill). In hospital major cardiovascular 
events were: death, ventricular arrhythmia (VTNF), stroke (CVA) and urgent 
surgical revascularization (CABG). 
Results: Increase in CPK was independent of age, ejection fraction, di- 
abetes mellitus, hypertension, congestive heart failure, peripheral vascular 
disease, chronic renal insufficiency and prior stroke. Clinical and procedural 
variables associated with elevated CPK value post PCI included: unsta- 
ble/stable angina (p = O.OOl), single or multivessel (p = 0.034) prior CABG 
(p = 0.027) abrupt closure (p < O.OOOl), no reflow (p < O.OOOl), coronary 
perforation (p < 0.001) and intra-aortic balloon pump (p < 0.0001). 
Event 
VTNF 
CVA 
CABG 
Death 
Combined event 
Group-l 
n-3444 (%) 
11 (0.32) 
6 (0.18) 
16 (0.47) 
4(0.12) 
37(1.08) 
Group-II 
n-211 (%) 
4 (1.90) 
1 (0.48) 
2 (0.96) 
6 (2.84) 
12 (5.74) 
Group-Ill 
n-131 (%) 
8 (6.11) 
1 (0.77) 
1 (0.77) 
7 (5.34) 
15 (11.54) 
P-Value 
<0.0001 
0.1590 
0.2840 
10.0001 
-<0.0001 
A multiple logistic regression analysis using a total of 17 baseline de- 
mographic and procedural variables showed that CPK was a significant 
independent predictor of death (p = 0.0001 odds ratio [OR] = 3.75, 95% 
confidence interval [Cl] [I .91-7.371) and combined event (p = 0.002, OR = 
2.07, 95% Cl [I .283.331) respectively. 
Conclusion: A single CPK value 8 hours post PCI can be used to identify 
a patient population for adverse in hospital events. 
I 1107-77 Routine Heparinisation during Coronary Arteriography: Is it Still Indicated? 
Erwin Zegers, Bart Jan Meursing, Freek W.A. Verheugt. Dpts of Cardiology 
Canisius- Wilhelmina Hospital and Heartcenter, University Hospital 
Nijmegen, Nomegen, The Netherlands 
Background: Though not specifically recommended in the 1987 ACC/AHA 
guidelines systematic heparinisation is often used during coronary angiogra- 
phy. But with the introduction of chronic antiplatelet therapy and small-sized 
catheters heparinisation with its inherent risks and poor bioavailibility can be 
questioned. 
Methods: We analysed 6 observational and 9 controlled studies on rou- 
tine heparinisation during diagnostic coronary arteriography (CAG) published 
between 1971 and 1995 including 121,974 patients, Procedural death and 
infarction (Ml) were scored. 
Results: Death occurred in 193 (0.16%) .patients, Ml in 248 (0.20%) 
patients and were divided as follows: 
Death 
MI 
Heparin 
(n=83,085) 
102(0.12%) 
127 (0.15%) 
No heparin 
(n = 38,889) 
91 (0.24%) 
121 (0.31%) 
RR (95% Cl) P 
1.91 (1.43-2.52) 0.0001 
2.03(1.59-2.61) 0.0001 
0 1.0 2.0 3 lleparin wo se hepari” Lmtte, 
Conclusion: Withholding heparin in diagnostic CAG is associated with a 
twofold increase in death and Ml. Routine heparinisation still seems indicated 
in patients undergoing diagnostic GAG. 
1 1107-78 1 Very Low Dose Heparin (30 UUkg) for Routine 
Coronary Angioplasty With Immediate 6F Sheath 
Ablation 
Patrick Godon, Gilles Rioufol, Gerard Finet, Pierre Chirossel, Guy de 
Gevigney, Ricardo Roriz, Xavier Andre-Fouet, Eric Bonnefoy, Michel Ovize, 
Rolland Rossi, Jacques Beaune. Department of Hemodynamics 
Cardiovascular Hospital, Lyon, France 
Background: Platelet inhibition is sought to be the major outcome determi- 
nant for endoarterial procedures, while heparinization seems to have only 
an adjunctive effect. In our institution, we routinely perform (except for acute 
myocardial infarction) femoral access 6F coronary angioplasty (PTCA) with 
unique bolus of 30 Ulikg non fractionned heparin and immediate 6F sheath 
ablation with manual compression, 
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Methods: Between l/1/99 and 8/l/99 all patients referred for PTCA were 
consecutively evaluated. Major adverse cardiac event (MACE), Troponin I el- 
evation, and echographic groin complication were systematically monitored. 
Results: 380 patients (89% of routine activity, 81% male, 63 i 11 years 
old, 76% stenting) were included. The heparin bolus was 2240 + 1120 units 
with a PTCAduration of 25 & 16 min and end procedural clot time of 155 f 88 
sec. Groin compression lasted 7 f 4 min. MACE was 2.6% for a post PTCA in- 
hospital stay of 1.8 f 1.4 days. A 1 -month follow-up detected 1.3% additional 
MACE. Troponin I elevation (~3 x upper level) appeared in 4.7%. Echo- 
graphic groin examination (80% of patients) detected 9% anomalies (8 false 
aneurysms, 19 hematoma) with mean haematoma diameter of 1.4 & 0.9 cm. 
Conclusions: Very low dose heparin for routine 6F PTCA: i) is safe and as 
effective as standard-dose heparinization protocol; ii) dramatically decreases 
groin complications; iii) allows rapid mobilisation and shorter hospitalisation. 
1107-79 Comparative Effects of Low Molecular Weight 
Heparin (With and Without Abciximab) and 
Unfractionated Heparin on Antithrombin Activity 
During Coronary Angioplasty 
Wjlliam H. Matthai, Jr., Dean J. Kereiakes, Cindy L. Grines, Jamie E. Siegel. 
University of Pennsylvania, Philadelphia, USA 
Background: We have shown that antithrombin activity (AT) falls when un- 
fractionated heparin (UFH) is used for anticoagulation during angioplasty and 
through the night of the procedure, sometimes falling to clinically important 
levels. Whether enoxaparin (E), a low molecular weight heparin, will have 
the same effect is unknown. In addition, we hypothesized that the addition of 
abciximab (AB) might reduce activation of coagulation and have independent 
benefit on AT. 
Methods: This study is a substudy of the NICE trials, multicenter, prospec- 
tive registries of angioplasty in which E was used for anticoagulation with 
(NICE 4, n = 81) or without (NICE 1, n = 48) planned use of AB. E was ad- 
ministered as a single weight based intravenous bolus (0.75 mgfkg with AB, 
1 .O mgikg without AB). AT samples were drawn at the start of the procedure 
(before E), within 4 hours of the bolus (to evaluate the change in AT over the 
course of the procedure), and 12 hours after the bolus. Our published data of 
AT during angiopiasty with UFH (n = 250) served as a reference population. 
Results: AT fell over the course of the procedure with both E and UFH 
(7.2 i 14.8% vs 7.4 + 7.8%, p = 0.8). Following the procedure, ATcontinued 
to decline in the population given UFH but stabilized in the E group (4.5 rt 
8.2% vs 0 f 11.8%, p -X 0.001). Much of the decline in AT over the course of 
the angioplasty occurred in those who received AB. Patients given E alone 
had less decline in AT (2.9 k 8.4%) than those given E and AB (9.7 i 17.1%: 
p < 0.05 vs E alone) or than those given UFH (7.4 f 7.8%, p < 0.05 vs E 
alone, p = NS vs E + AB). 
Conclusions: Use of E during angioplasty does not prevent a decline in 
AT over the course of the procedure, but AT does not continue to fall thereafter 
as it does in those in whom UFH is continued. The addition of AB to E does 
not reduce the decline in AT as we initially hypothesized and appears to 
increase the acute fall in AT. Use of E alone had the least acute effect on 
AT. While the clinical importance of the decline in AT in this population is not 
known and may not be the same as in those given UFH, these data raise 
questions regarding the combination of AB and E during angioplasty. 
1107-80 Rapid Platelet Function Assessment Using Two 
Concentrations of Adenosine Diphosphate After 
Clopidogrel Loading Dose in Patients Undergoing 
Cardiac Catheterization 
Wei C. Lau, Eric R. Bates, David G.M. Catville’, Kirk E. Guyer’, Charlene 
J. Neer, Elke G. Marksteinerbs, Dan Zoller. University of Michigan Medical 
Center, Ann Arbor, Michigan; ‘Array Medical Laboratories, Indiana 
Universify, South Bend, Indiana, USA 
Background: Platelet activation is a contributing factor to early thrombotic 
occlusion in patients undergoing percutaneous coronary artery intervention. 
Clopidogrel, an ADP receptor antagonist, has been shown to inhibit platelet 
aggregation within 1 hour of a 375 mg loading dose, with peak effect at 
5 hours, using a 5 PM ADP agonist. This study examined the inhibition of 
platelet aggregation after a 300 mg loading dose of clopidogrel using the 
bedside ICHOR platelet analyser with 5 WM and 20 yM ADP agonists. 
Methods: Twenty patients undergoing cardiac catheterization were ran- 
domized to platelet function analysis using 5 PM (n = IO) or 20 WM (n = 
10) ADP agonist. Platelet aggregation was analyzed at baseline, 2, 4, and 
6 hours after a loading dose of 300 mg of clopidogrel. Data were compared 
using ANOVA with Bonferroni’s correction. 
Results: see figure. 
Conclusion: These data suggest that the 300 mg clopidogrel loading 
dose commonly used with endoluminal stenting does not reach maximal 
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Baseline 2h 4h 6h 
*p < 0.05 VS. 20 KM ,4DP agonist 
platelet inhibition at 5 hours. Earlier treatment or higher loading doses may 
be required to optimize platelet inhibition in the periprocedural period. 
/ 1107 81 Final Report of Six Month Outcomes After Bivalirudin Versus Heparin During Coronary 
Angioplasty: Kaplan-Meier Statistical Analysis 
J.A. Bittl. On behalf of the Bivalirudin Angioplasty Investigators; &a/a Heart 
Insfufe, &ala, FL, USA 
Background: Bivalirudin is a direct thrombin inhibitor under investigation as 
an anticoagulant for use during PTCA. Bivalirudin was evaluated in patients 
undergoing PTCA in 2 large, randomized, double-blind, multicenter studies 
governed by the same protocol. 
Methods: A total of 4312 patients (All Patients) with unstable angina, 
including a pre-stratified subgroup of 741 patients (Post Ml) who had an 
Ml within the prior 2 weeks, between the ages of 29 and 90 years, were 
randomized 1 :I to either bivalirudin or heparin.. Bivalirudin was administered 
by IV bolus (1 .O mg/kg) immediately before PTCA. An infusion of 2.5 mg/kg/h 
was commenced at the same time and continued for 4 hours. An infusion of 
bivalirudin (0.2 mg/kg/h) was then continued for up to an additional 20 hours. 
Heparin was administered to achieve a target ACT of >350 seconds. The 
bivalirudin dose was not titrated to ACT. 
Results: The incidences of any of the following, death, MI, and urgent 
revascularization occurring through 180 days are shown in Table 1. 
Table 1. inadences Clinical Endpoints In Randomized Clinical Trials Occurring through 
180 Days of Follow-up 
Bivalirudin Heoarin 
All Patients n=2161 
Death, MI, Fievascularization 23% 
Death 1 .7% 
MI 5.3% 
Revascularization 20% 
Post MI Patients 
Death, Ml, Revascularization 
Death 
n = 369 
18.7% 
1.6% 
5.4% 
15.2% 
Ml 
Revascularization 
n=2151 
24.7% 
1.2% 
6.1% 
21 .8% 
n = 372 
25.3% 
2.2% 
8.3% 
20.4% 
Conclusion: As compared with heparin treatment, bivalirudin treatment 
was associated with an equivalent rate of ischemic complications in the study 
group as a whole and a lower rate of ischemic complications in patients with 
postinfarction angina. 
[ 1107-82 1 The Impact of Clinical Presentation on the Degree 
of Platelet Inhibition at Baseline and Following 
Glycoprotein Ilb/llla Receptor Blockade in Patients 
Undergoing Percutaneous Coronary Intervention 
Daniel Soffer, Gurkan Taviloglu, Gishel New, Edward Kreps, 
Michael Collins, Sriram lyer, Gary Roubin, Jeffrey Moses, Neil Coplan, 
lssam Moussa. Lenox Hi// Heart and Vascular Institute, New York, NY; USA 
Background: Glycoprotein (GP) Ilb/llla platelet receptor antagonists have 
been shown to improve outcomes in acute coronary syndromes (ACS) and 
percutaneous coronary interventions (PCI). The impact of clinical presen- 
tation on the degree of platelet inhibition (PI) with GPllb/llla inhibitors is 
still controversial. We sought to investigate the extent of variability in PI be- 
tween pts with ACS and pts with stable angina who undergo PCI requiring a 
GPllb/llla inhibitor. 
Methods: We measured PI in 42 pts who underwent PCI and required 
GPllb/llla inhibitor tirofiban (bolus; IO &g/kg, infusion; 0.15 Fg/kg/min) or 
abciximab (bolus; 0.25 mglkg, infusion 0.125 wglkglmin). Pts were classified 
according to the Braunwald unstable angina (UA) classification. Group 1 
included 24 pts with stable or class I UA; Group II included 18 pts with class 
II or Ill UA. PI was measured with .the lchor CBC analyzer (Array Medical), 
using 20 micromole of ADP. All pts received ASA and clopidogrel prior to 
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procedure. Baseline PI was measured prior to GPllb/llla administration and 
at 15 min post bolus. 
Results: Baseline characteristics and risk factors did not differ between 
groups. Gr I had higher PI compared with Gr II at baseline (mean f SE: 26 
+ 4% vs 13 f 4% for Gr I and Gr II respectively, p < 0.05) and at 15 minutes 
following GPllb/llla administration (74 f 3% vs 50 f 5% for Gr I and Gr II 
respectively, p < 0.0001, see fig). In multivariate regression analysis, angina 
class was the only predictor of PI of >70% (p < 0.0005). 
Conclusions: Pts with acute coronary syndromes have lower platelet 
inhibition than pts with stable angina, both at baseline and following GPllb/llla 
blockade. Further studies are needed to establish whether dose adjustment 
is necessary in pts with acute coronary syndromes undergoing coronary 
intervention. 
1107-83 A Prospective Multicenter Study to Determine the 
Optimal Level of Platelet Inhibition With GPllb/llla 
Inhibitors in Patients Undergoing Coronary 
Intervention -The GOLD Study 
Steven Steinhubl, David Talley; Dean Kereiakes, Gregory Braden, 
James Tcheng, Peter Casterella, David Moliterno, Peter Berger, 
Jeff Popma, George Dangas, Richard Gallo, Frank Navetta, David Sane, 
David Holmes, Paul Teirstein, Eric Topol. W/ford Ha// Medical Center, San 
Antonio, TX; Cleveland Clinic Foundation, Cleveland, OH, USA 
Limited data are available regarding the optimal dosing of the GPllb/llla 
inhibitors. Early animal studies with these agents found that 280% receptor 
blockade, which correlated with a decrease in ADP-induced aggregation to 
~20% of baseline, was required in order to prevent thrombus formation in a 
highly thrombogenic environment. Although small studies have demonstrated 
substantial inter-patient variability in response to standard dosing of GPllb/llla 
inhibitors, the clinical significance of this has not previously been evaluated. 
Methods: 500 patients undergoing a percutaneous coronary intervention 
(PCI) with elective GPllb/llla inhibitor use at 13 sites had platelet function 
monitored at baseline, and then 10 min, 1 hr, 8 hr and 24 hours following 
the bolus of a GPllb/llla inhibitor using the Accumetrics Ultegra-RPFA - a 
point-of-care, rapid platelet function assay. Adverse events (death, MI, urgent 
revascularization) following PCI were systematically monitored in all patients. 
Non-Q Ml was defined as a CKMB elevation P 2 x normal. 
Results: 98% of all patients achieved >80% inhibition of platelet function 
immediately following the GPllb/llla antagonist bolus. By 8 hours after the 
bolus, while patients were still receiving an infusion, there was substantial 
variability among patients. Inhibition of 570% of baseline of platelet function 
at 8 hours, seen in 7% of patients, was associated with a significantly higher 
risk of an adverse event compared with those >70% inhibited (32% vs 12%, 
p = 0.02). 
Conclusion: This trial is the first ever to prospectively correlate the degree 
of platelet blockade achieved with standard dosing of GPllb/llla inhibitors with 
clinical outcomes following a PCI, and demonstrates that platelet function, 
as determined by a simple point-of-care instrument, can identify a subgroup 
of patients at significantly higher risk for adverse events. The clinical benefit 
of titrating GPllb/llla inhibitor therapy based on the monitoring of platelet 
blockade requires further evaluation. 
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1 1108-84 1 Stent Underexpansion With Intermediate Inflation 
Pressures 
Dirk Hausmann, Dieter Fischer, Matthias Sturm, Arndt Schaefer, 
Burkhard Hornig, Helmut Drexler. Division of Cardiology and Angiology, 
Hannover Medical School, Hannover, Germany 
Background: Current stent types are frequently implanted with intermediate 
pressures (lo-14 ATM); stent expansion may be not sufficient. 
Methods: Fifty consecutive pts. (35 m, 15 f; age 62 & IO yrs.) underwent 
elective NIR stent implantation (33 LAD, 4 CX, 13 RCA). After predilata- 
tion, semi-compliant balloons (10-14 ATM) were used for stenting. After 
angiographic completion (stenosis < IO%), IVUS was used to measure stent 
lumen at the in- and outflow (% proximal or distal reference) and smallest site 
(% of average reference). Nominal and expected (according to compliance) 
balloon cross-sectional areas were calculated. 
Results: All stents were successfully implanted (no stent thrombosis). 
IVUS showed complete apposition. Stent in- and outflow were only slightly 
underexpanded (87 i 13% and 92 f 14% of reference, Fig.). The smallest 
stent site reached only 73 f 12% of the reference despite significant balloon 
oversizing (nominal, 110 + 21%; expected, 127 + 23%) (Fig.). Small (x7.0 
mm2 CSA) and large vessels showed similar stent expansion (75 & 9 vs. 71 
I!C 14%); however, more oversizing was required for small vessels (122 f 
17 vs. 96 & 17%; p < 0.05). Post-dilatation based on IVUS improved stent 
expansion (65 i 11 vs. 77 i 10%; p < 0.05); higher inflation pressures (11 
f 2 vs. 14 f 2 ATM) diminished ballon/stent ratios. 
Conclusions: Despite adequately (i.e. over-) sized balloons and angio- 
graphic completion, stent expansion remains inadequate with intermediate 
inflation pressures in current stent types, 
1 1108-85 1 Is High Pressure Optimization Necessary in 
Second Generation Stents? Results From the 
IVUS DUET Study 
Andreas Kbnig, Volker Klauss, Evelyn Regar, Johannes Rieber, 
Ulrike Buchmeier, Karl Theisen, Hans U. Stempfle, Harald Mudra’ lDpfs. of 
Cardiology, Klinikum Innenstadt, University of Munich and Stgdtisches 
Klinikum Neuperlach, Munich, Germany 
Background: Presently, there is no consensus with regard to the optimal 
stent implantation pressure in second-generation stents. To assess the stent 
expansion of the ACS .Multi-Link RX DUET stent system (Guidant Corp.), 
we performed quantitative coronary angiography (QCA) and intravascular 
ultrasound (IVUS) after predefined inflation pressures. 
Methods: In 36 pts. with stable angina elective stent implantation (refer- 
ence vessel diameter 3.1 * 0.47 mm; MLD 0.94 i 0.38 mm, lesion length 
12.5 f 4.8 mm) was performed in native coronary arteries. Stent expan- 
sion was assessed by QCA and IVUS (motorized pullback; 0.5 mm/s; 2.9 F; 
30-MHz transducer) after stent delivery at 12 atm. using a balloon to artery 
ratio of 1.1. If predefined QCA-criteria (~10% residual stenosis) and IVUS 
criteria (according to the MUSIC study) of stent expansion were not fulfilled, 
the measurements were repeated after redilatation at 16 atm. With IVUS, 
the reference lumen areas and the proximal and minimal stent area were 
measured. The symmetry index was calculated at the tightest stent site after 
12 atm and 16 atm. Relative changes for each parameter were calculated 
and compared (Mann-Whitney, Cl < 0.05). 
Results: All stents were successfully implanted. Mean diameter stenosis 
(DS) was reduced from 69.8 * 11.3% before intervention to -3.3 f 13.8% 
after 12 atm and further reduced to -7.8 * 12.2% after 16 atm. After 12 
atm., the angiographic criterion of optimal stent expansion was reached in 30 
pts.(83%), whereas only 6 pts. (17%) met the IVUS criteria. After the IVUS 
assessment, 30 pts. underwent a second balloon inflation at 16 atm. This 
IVUS optimization strategy lead to a further gain in stent area from 7.7 f 2.6 
JACC February 2000 ABSTRACTS - ACCIS2000 45A 
mm2 to 8.5 i 2.8 mm* or 13.2 f 19% (p < 0.05). The symmetry index was 
improved from 0.85 after 12 atm. to 0.92 after 16 atm. 
Conclusion: Despite fulfilled angiographic success criteria after MultiLink 
stent implantation at 12 atm in 83% of the patients, IVUS criteria were reached 
in only 17%. Additional balloon inflation at 16 atm could markedly improve 
both, the stent area and stent symmetry index with 78% of the patients 
reaching the IVUS criteria. 
/ 1 f 08-86 1 Intravascular Ultrasound Analysis of the Effect of 
Post-Dilation With Non-Compliant Balloons 
Following Initial High Pressure Stent Implantation 
Using Newer Generation Stent Delivery Systems 
Tejan Patel, Donald E. Cutlip, Christopher J. Cove, Richard M. Pomerantz, 
Frederick S. Ling. University of Rochester, Rochester, New York, USA 
Background: Adjunctive high pressure (>I2 Atm) inflation using noncompli- 
ant balloons to obtain satisfactory stent expansion after initial stent implan- 
tation has become routine because of prior intravascular ultrasound (IVUS) 
studies. Newer generation stent delivery balloons are now capable of high 
pressure inflation potentially obviating the need for adjunctive inflation, al- 
though current stent delivery balloons are semi-compliant. This study uses 
IVUS to assess the effect of adjunctive inflation using non-compliant balloons 
following initial high pressure stent implantation using semicompliant delivery 
balloons. 
Methods: Lesions underwent high pressure stent implantation followed 
by adjunctive inflation using non-compliant balloons at the same maximal 
pressure and of the same balloon diameter as the delivery balloon. IVUS of 
stent minimal cross-sectional area (CSA), minimal luminal diameter (MLD), 
and symmetry index (SI) was measured after high pressure stent implantation 
and again after adjunctive inflation. The results of the first 15 of a planned 
total of 30 lesions are reported below. Stents were implanted using a balloon 
diameter of 3.12 i 0.34 mm at a maximal inflation pressure of 14.9 i 1.6 
Atm. 
IVUS Results: 
Past stem Post Adjunctive P 
Inflation 
CSA (mm’) 6.93 + 1.32 7.60 + 1.82 0.0008 
MLD (mm) 2.84iO.20 2.97 5 0.24 <0.0001 
SI 0.93 + 0.05 0.95 + 0.06 NS 
Conclusion: IVUS data suggest that adjunctive inflation with non-compli- 
ant balloons improves stent expansion despite high pressure stent implanta- 
tion using semi-compliant delivery balloons. Final results will be presented. 
11108-87 ) High-Pressure Stent Implantation is Requested 
Even With Less Rigid Second-Generation Stents 
to Obtain Large Follow-up Lumen Dimensions. An 
Intravascular Ultrasound Study 
Rainer Hoffmann, Philipp Haager, Gregor Kerckhoff, Riidiger Schwarz, 
Andreas Franke, Jijrgen v. Dahl, Peter Hanrath. Universify RWTH Aachen, 
ERG. 
Background: The need for high-pressure stent implantation using second- 
generation stents and the extent of resulting tissue proliferation as compared 
to low-pressure techniques are not resolved. 
Methods: In a prospective, randomized study 109 native lesions were 
assigned to either low pressure (IO atm, n = 54) or high pressure (16-18 
atm, n = 55) implantation of the ACS HP MultiLink stent (15 mm length) 
mounted on a non-compliant balloon. To study lumen dimensions and tissue 
proliferation serial angiographic (QCA) and intravascular ultrasound studies 
(IVUS) were performed after stent implantation and at follow-up (@5.6 rt 1.3 
months). Lumen cross-sectional area (CSA) and stent CSA were measured 
by IVUS at 1 mm increments. lntimal hyperplasia CSA (IH CSA = stent 
CSA-lumen CSA) was calculated. IVUS data are reported as average of the 
total stent length. 
Results: Restenosis rate was 23% for the total study group. IH CSA was 
16% greater in the high-pressure group. 
High-pressure Low-pressure P 
QCA reference diameter (mm) 2.9 * 0.9 2.9 i 0.8 0.394 
QCA acute gain (mm) 1.8 i 0.7 1.5 * 0.7 0.024 
QCA MLD Follow-up (mm) 1.7io.7 1.6ztO.7 0.784 
Stent CSA (mm2) 8.5 i 2.7 7.2 i 1.6 0.011 
Lumen GSA follow-up (mm”) 6.8 zk 2.4 5.6i1.7 0.018 
IH follow-up (mm’) 1.7i 1.2 1.5*0.9 0.488 
Conclusion: High-pressure implantation techniques are requested even 
with the less rigid Mulitlink stent to obtain good stent expansion. At follow-up, 
larger lumen dimensions persist in the high-pressure group while intimal 
hyperplasia is only non-significantly larger. 
III 1108 88 Incomplete Stent Apposition as Determined by 
Post-Procedure Intravascular Ultrasound Does 
Not Effect Clinical Outcome After Elective 
Coronary Stent Placement: A Report From AVID 
and CRUISE 
Akiko Maehara, Joseph C. Apostol, Michael J. Attubato, Charles 
J. Davidson, Anthony C. DeFranco, James B. Hermiller, Robert 
A. laffaldano, Martin B. Leon, Neil J. Weissman, Frederick S. Ling, George 
J. Smith, Paul S. Teirstein, Paul G. Yock, S. Chiu Wong, David M. Zientek, 
Peter J. Fitzgerald, Robert J. Russo. Stanford University, Stanford, CA; 
Scripps C/inic, La Jolla, CA, USA 
Background: AVID (Angiography Versus Intravascular Ultrasound [IVUS]- 
Directed stent placement) and CRUISE (Can Routine Ultrasound influence 
Stent Expansion) are multicenter studies designed to assess the effect of 
IVUS on patient outcome after elective coronary stent placement. 
Methods: To evaluate the effect of stent non-apposition as determined 
by IVUS, on 6-month clinical event rates, IVUS core laboratory and clinical 
outcome data were analyzed for 1081 patients enrolled in AVID (706 patients) 
and CRUISE (375 patients). IVUS imaging was performed after a final result 
was obtained. 
Results: A total of 9.7% (10511081) of stents were not apposed to the 
vessel wall on final IVUS core laboratory evaluation. The overall rate of 
target lesion revascularization for both groups, at 6-months was 8.2%. The 
incidence of stent non-apposition was 6.5% for vessels with a final minimum 
stent area of ~6.0 mm2, 10.2% with a minimum stent area of 6.0-9.0 mm*, 
and 13.7% with a minimum stent area of >9.0 mm2 (chi-square test, p 
= 0.02; test for linear trend, p = 0.004). A comparison of apposition and 
non-apposition groups is presented below. 
Number of patients 
Minimum stent area (mm*) 
Incidence of stent thrombosis 
B-month taroet lesion revascularization 
Non-Apposition 
group 
105 
8.08 + 2.91 
1 .O% 
7.6% 
Apposition 
group P 
976 
7.29 h2.43 0.002 
1 .O% 0.95 
8.3% 0.81 
Conclusion: Non-apposition of stent to vessel wall, as determined by 
post-procedure IVUS imaging, is not associated with an increase in the rate 
of stent thrombosis or target lesion revascularization at 6-months. Non-appo- 
sition is more common in vessels with a minimum stent cross-sectional area 
of >9.0 mm2. 
m 1108 89 Intravascular Ultrasound-Guided Stent Placement Improves Clinical Outcome for Patients With 
High-Grade Lesion Severity: Observations from 
AVID 
Joseph C. Apostol, Michael J. Attubato, Charles J. Davidson, Anthony 
C. DeFranco, Peter J. Fitzgerald, James B. Hermiller, Robert A. laffaldano, 
Martin B. Leon, Neil J. Weissman, Frederick S. Ling, George J. Smith, Paul 
S. Teirstein, S. Chiu Wong, David M. Zientek, Patricia D. Silva, Robert 
J. Russo. Scripps Clinic La Jolla, USA 
Background: AVID (Angiography Versus Intravascular Ultrasound [IVUS]- 
Directed stent placement) is a multicenter, randomized study designed to 
assess the effect of IVUS on clinical outcome after elective coronary stent 
placement in 800 patients. 
Methods: To evaluate the effect of IVUS-directed stent placement in 
vessels with high-grade lesion severity (~70% stenosis by angiography prior 
to stent placement), IPmonth clinical event rates and core lab angiographic 
and IVUS data were analyzed for 228 patients. 
IVUS group Angio group P 
In = 1141 ln=ii4\ 
Stems per patient 
Angio Preprocedure average RVD (mm) 
Preprocedure lesion MLD (mm) 
Preprocedure stenosis (%) 
Final stent MLD (mm) 
Acute gain (mm) 
IVUS Final CSA (mm2) 
Final distal RVD (mm) 
Final CSA stenosis (%) 
1 P-month target lesion revascularization 
12-month major adverse cardiac event 
1.7ztl.O 
3.13 i 0.58 
0.6910.22 
78f6 
2.97 5 0.51 
2.28 dz 0.50 
7.50 i2.81 
3.22 z!c 0.63 
9f19 
3.5% 
10.5% 
1.4 + 0.7 0.01 
3.01 i 0.53 0.15 
0.63 i 0.25 0.04 
7917 0.10 
2.87 zk 0.44 0.13 
2.251k 0.44 0.63 
7.07 zk2.46 0.24 
3.27 + 0.69 0.63 
15Az22 0.04 
14.9% 0.003 
19.3% 0.06 
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Results: (table) Preprocedure lesion severity was independent of refer- 
ence vessel diameter (RVD; rz = 0.01). Acomparison of IVUS and angiogra- 
phy groups is presented below. In the IVUS group, 45% of patients required 
further therapy to fulfill IVUS criteria for optimal stent placement despite an 
adequate angiographic result (~10% stenosis). Indications for further ther- 
apy were: residual stenosis (n = 35) non-apposition (n = 13), and dissection 
(n = 7). Further therapy resulted in a gain of 20 & 14% in cross-sectional area 
(CSA) and 0.33 f 0.23 mm in diameter. Placement of an additional stent was 
required in 12% of patients. 
Conclusion: In vessels with high-grade preprocedure lesion severity, 
n/US-directed stent placement resulted in larger acute stent dimensions and 
a significantly lower 12-month target lesion revascularization rate compared 
to angiography alone. 
I 1108 90 lntracoronary Ultrasound Volumetric Assessment of Stent Expansion and Plaque Redistribution 
After Direct Stenting 
Jacek Legutko, Dariusz Dudek, Pawel Zymek, Krzysztof Zmudka, 
Marcin Wizimirski, Jacek S. Dubiel. Jagiellonian Universifi Krakow, Poland 
Background: lntracoronary ultrasound (ICUS) assessment of stent expan- 
sion is the best predictor of in-stent restenosis. Direct stenting without balloon 
predilatation is a new technique of stent implantation and long term follow up 
is unknown. There is also no data comparing stent expansion and the mech- 
anism of lumen enlargement after direct stenting and stenting with balloon 
predilatation. 
Methods: In vessels > 3 mm in diameter without heavy calcification, we 
assessed 31 lesions before and after direct stenting and 30 lesions before 
and after stenting with optimal predilatation (“optimal” stenting: balloons sized 
by ICUS media - media diameter inflated up to 8 atm). Using automatic 
motorized pullback we analyzed lumen (L), vessel (V) and plaque + media (P 
+ M) cross-sectional areas (CSA) every 1 mm of along the axial stent length 
plus 3 mm long proximal and distal reference segments. The minimal stent 
CSA, minimal stent GSA/mean reference lumen CSA (in-stent ratio), proximal 
stent CSAIproximal reference lumen CSA (prox ratio) were measured as 
ICUS parameters of stent expansion. We also calculated L, V, and P + M 
volumes (vol.) using Simpson’s formula. 
Results: ICUS parameters of stent expansion were similar in both groups. 
An increase in total L vol. and in total V vol. of the stent plus reference sites 
occurred without significant changes in total P vol. (table, value i SD). 
Direct stentina “Ootimal” stentina 0 
Minimal stent CSA (mm?) 8.3zk 1.2 8.1 zk 1.0 NS 
In stent ratio 0.97 * 0.11 0.95 rt 0.13 NS 
Prox ratio 1.16f0.22. 1.08*0.10 NS 
Change in L vol. (mm3) 58.2 i 13.1 (p < O.OOi) 53.0 zk 10.4 (p < 0.001) NS 
Chanae in V vol. (mm3) 55.8 5 18.1 (II < 0.01) 47.2 zt 19.9 CD < 0.01) NS 
Change in P vol. immsj -3.1 zk 4.2 (NS) ’ -5.3 SS.‘i (NS) ’ NS 
Detailed P vol. analysis disclosed a decrease of P vol. in stented region 
in contrast to an increase of P vol. in the reference sites, and this pattern of 
plaque redistribution was identical in both groups. 
Conclusions: In noncalcified, large vessels there is no difference in stent 
expansion between direct stenting and stenting with optimal predilatation. 
Regardless of stent implantation technique, longitudinal plaque redistribu- 
tion and vessel expansion without significant plaque compression are the 
mechanisms of lumen enlargement after stenting. 
I 1108 91 Edge Effect in a Non-Select Stent Population: 
Results from 6-Month IVUS Examination in the 
HIPS Trial 
Neil J. Weissman, Daniel Canos, Harish Rudra, Gary S. Mintz, 
Jean-Francois Tanguay, Jack L. Martin, Aaron V. Kaplan, Robert 
L. Wilensky. Wasbingfon Hospital Center, Washington, DC, USA; Montreal 
Heart Institute, Montreal, Canada 
Background: Stent edge restenosis has been described after brachytherapy, 
but may also occur after stenting without radiation. We therefore determined 
the extent and magnitude of intimal hyperplasia (IH) and vessel remodeling 
along the stent edge in non-select patients (pts) scheduled for 6 month IVUS 
as part of a multicenter trial of heparin infusion prior to stenting (HIPS). 
Methods: Planar measurements 1 mm apart were performed over a 
length of IO mm proximal and distal to the stent at index and follow-up. 
Results: Lumen loss within 3 mm of the stent edge was due primarily to 
intimal proliferation (figure). Beyond 3 mm, negative remodeling contributed 
more to lumen loss. Gender, age, vessel location, index plaque burden, 
hypercholesterolemia, diabetes and tobacco did not predict edge IH. IH 
tended to correlate with the magnitude of deep vessel wall stent penetration 
(p = 0.07). 
DiStancetrOm stent mlrnf mtance vom the stent(mrTl) 
Conclusion: In a nonradiation stent population, lumen loss at the stent 
edge is due primarily to intimal proliferation. These data may be helpful 
assessing the degree of edge effect due to radiation therapy. 
( 1108-92 1 A Prospective, Multicenter Trial of the Safety, 
Feasibility, and Efficacy of Ultrasound Guided 
“Maximal” Stenting to the Media-Adventitial 
Border Final Late Clinical and Angiographic 
Results From the OSTI-2 Study 
Gregg W. Stone, Steven Bailey, David K. Roberts, Tom J. Linnemeier, 
Frederick G. St. Goar, Timothy Sanborn, Peter J. Fitzgerald, Edwin 
L. Alderman, Stefan Kiesz. Washington Hospital Center, Washington, DC, 
USA 
The minimal luminal dia. (MLD) and area (MLA) after stenting are strong 
predictors of freedom from restenosis. Routine balloon oversizing to increase 
stent expansion results in unacceptable rates of dissection and perforation. In 
contrast, IVUS imaging often reveals variable degrees of positive remodeling 
which may permit a selective stent overexpansion strategy, resulting in larger 
lumens and improved late outcomes. 
Methods: 220 unselected consecutive pts (254 lsns) were prospectively 
enrolled in a controlled study at 7 sites. Stents (88% JJIS, 10% Guidant) were 
expanded to the media-adventitial border determined by IVUS. To protect the 
stent edges, a novel focally expanding balloon which grows 0.5 mm larger 
centrally within the stent (the Radiance FACT’“) was used for post dilatation 
at 16 atm. Cinefilms and IVUS tapes were read at independent core labs 
(Stanford). 
Results: High risk lesion features included reference vessel dia. < 3.0 mm 
in 64% and calcification requiring atherectomy in 19%. By QCA, the median 
ref. dia. was 2.89 f 0.51 mm. By IVUS, however, the true reference vessel 
size was 3.90 f 0.62 mm. Stent expansion was performed with mean balloon 
dia. 3.52 f 0.49 mm (balloon/artery ratio 1.27 f 0.21). Final MLD was 2.74 
f 0.50 mm (DS 1.3% i 12.1) and MLA 6.96 f 2.02 mm*. No perforations 
occurred, and core lab dissections were noted at only 2.7% of stent edges; 
only 3 pts (1.4%) required additional stents for dissection. Follow-up was 
98.6% complete at 9.0 f 4.4 months, including late angiography in 64%. 
TVR was required i in 12.4% of pts, and binary restenosis was present in 
25.6% of lesions. By multivariate analysis, the MLD achieved was a powerful 
determinant of freedom from restenosis. Of note, both TVR and restenosis 
rates were similar in vessels < 3.0 mm vs. >3.0 mm diameter (12.7% vs. 
12.0%, p=0.87,and25.9%vs.26.1%, p=O.98). 
Conclusions: Maximal stent expansion may be safely performed with 
IVUS guidance in remodeled vessels using focal balloons typically consid- 
ered oversized. The large resultant lumens may be particularly beneficial 
in ameliorating restenosis in small vessels. Randomized trials vs. standard 
stent technique are warranted. 
JACC February 2000 ABSTRACTS - ACCIS2000 47A 
POSTER 
i 1109 IVUS: Insights Into Methodology and 
Pathogenesis 
Monday, March 13, 2000, 3:00 p.m.-%00 p.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1109-i 15 Validation of IVUS Volumetric Assessment of 
lnstent Neointimal Hyperplasia: A Comparison 
Between Manual and Automated Processing 
Aii H.M. Hassan, Atsushi Takagi, Hiroyuki Okura, Thosaphol Limpijankit, 
Paul G. Yock, Peter J. Fitzgerald. Stanford University Medical Center, 
Stanford, California, USA 
Background: The development of neointimai hyperplasia (NIH) after coro- 
nary stent placement continues to be a limiting factor. To date, IVUS morpho- 
metric analysis of stented segments involves manually selected intrastent 
frames which are compared to the reference. A more objective approach 
is to integrate the complete set of IVUS images covering the entire arterial 
segment, thereby providing volumes within the stent (i.e. lumen volume, LV; 
NIH volume, NIHV; stent volume, SV). So far, this approach has not been val- 
idated. The aim of the present study is to compare an automated approach 
for volumetric IVUS assessment of instent NIH using a contour detection 
algorithm (EchopIque’“: INDEC Systems, CA) to the manual approach using 
Simpspons’ rule. 
Methods: Fifteen patients, who underwent motorized (0.5 or 1.0 mm/set) 
IVUS imaging of instent restenosis, were enrolled in the present analysis. 
Sequential IVUS images of stented segments were analyzed for the as- 
sessment of LV, NIHV and SV by two observers independently utilizing both 
methods (automated vs. manual). Vessels enrolled in the analyses were LAD 
(n = 9), RCA (n = 4) and LCX (n = 2). The following results (mean f SD) 
were obtained: 
Method Seg. Length LV NIHV SV 
Simpson 23.161 11.24 104.8Oi 77.64 111.9111001.92 216.60 zt 157.58 
Echoplaque 23.59i 10.61 112.Oli81.23 117.46 f 112.74 229.45 h 169.23 
0 250 kx 0 400 Xi”1 
Conclusions: Assessment of NIHV LV, and SV using automated con- 
tour detection is comparable to the manual approach. Automated contour 
detection is a time-efficient, objective assessment of target segment volume. 
1109-l 16 Improved Contour Detection for 
Three-Dimensional Intravascular Ultrasound; An 
In-Vivo Validation Study 
Gerhard Koning’ , Jouke Dijkstra’, Clemens von Birgelen3, S&en Melsa3, 
Christian Sieling3, Johan H.C. Reiber’,a. Department of ‘Radiology and 
‘Cardiology, Leiden University Medical Center, The Netherlands; 
3Department of Cardiology, University Hospital Essen, Germany 
Background: IVUS provides real-time high resolution images of the arterial 
wail. By performing a 3D pullback and reconstruction, an advanced assess- 
ment of the vessel, lumen and wall morphology becomes available. To reduce 
the required analysis time and the subjectivity of boundary tracing, automated 
segmentation of the pullback sequence of images is required. 
Methods: We developed a (semi-)automated contour detection approach 
using a combination of transversal and longitudial model- and knowledge- 
guided contour detections, based upon the minimum cost algorithm (MCA). 
In multiple (4 or more) longitudinal cutplanes (LCPs) through the pullback 
stack, the vessel contours are detected simultaneously, allowing mutual guid- 
ance of the detection in difficult areas like behind calcified plaque. Next, the 
lumen contours are detected (and possibly corrected) in these LCP images. 
These vessel and luminal contour points are transformed to the individual 
cross sections, where they guide the vessel and lumen contour detection in 
these transversal images. Using more LCPs helps to reduce the number of 
corrections needed in the transversal images. 
A set of 14 pullback sequences of coronary vessels with obstructive 
coronary artery disease (acquired in-vivo with a mechanical rotating catheter) 
were analyzed using our analytical software and the validated analytical 
software on the Tomtec system. Intervals of on average 60 images were 
used for comparison of the individual vessel and lumen cross-sectional areas 
(CSAs). 
Results: The CSAs detected wilh our system (y) were correlated with 
those of the Tomtec system (x). The vessel and lumen CSAs (mma) correlated 
highly: y = 1.03 x + 0.41, r= 0.995 and y = 0.98 x + 0.01, r = 0.978, respectively, 
N = 877. The average number of vessel and lumen corrections per image 
after LCP contour detections was 0.34 and 0.64, respectively. 
Conclusion: Due to the flexible use of more longitudinal cutplanes and the 
advanced knowledge guided contour detection, the new quantitative IVUS 
analysis package performs well, making the package suitable for clinical 
research studies. 
l----L 1109 117 The Influence of De Novo Atherosclerotic 
Remodeling on Luminal Narrowing Follows a 
Normal Distribution. An Intravascular Ultrasound 
Study 
Gerard Pasterkamp, Allen Jeremias, Aryan Vink, Alan Yeung, 
Peter Fitzgerald, Kiyoshi Hibi, Peter de Jaegere, Cornelius Borst. Heart 
Lung Insfitute, University Medical Center Utrecht, the Netherlands; 
Department of Cardiology Stanford University, San Francisco, USA 
Background: In de novo atherosclerotic disease, luminal narrowing is de- 
termined by both plaque mass and the mode of remodeling. Expansive 
remodeling prevents and constrictive remodeling accelerates luminal nar- 
rowing. It is unknown whether constrictive and expansive remodeling are 
different disease entities or if they are extremities of a normal distribution. 
Aim of the present study was to investigate whether the mode of remodeling 
follows a bimodal or normal distribution. 
Methods: An intracoronay ultrasound pull back maneuver was performed 
in 606 patients (610 lesions) prior to intervention. In each pull back, the lumen 
area (LA), plaque + media area (PA) and vessel area (VA) were measured 
at the lesion site and a proximal and distal reference site. 
For each lesion, the change in VA, PA and LA was calculated by comparing 
the measured values at the lesion site with the values of the reference sites 
(AVA, APA and ALA, respectively). For each lesion, AVA was expressed as 
% of ALA. 
Results: 
(changeotVA/changeln LA)*1001 
Figure: P + E: APA accounts for ALA and part of the plaque is compen- 
sated for by Expansive remodeling. 
C + P: Both AVA (Constrictive remodeling) and APA contribute to ALA. 
C: Constrictive remodeling is responsible for ALA. Plaque area at the 
lesion site is smaller compared with the reference sites 
Median value = -16.5%, indicating that 16.5% and 83.5% of ALA was 
due to AVA and APA, respectively. 
Conclusion: de novo atherosclerotic remodeling is not bimodally dis- 
tributed. This observation supports the idea that expansive and constrictive 
remodeling are the extremities of a normally distributed response to plaque 
formation. 
1 1109-118 1 Intravascular Ultrasound Measurement of Plaque 
Volume: Validation of a Method for Serial 
Regression-Progression Studies 
Khaled M. Ziada, Amrik Shah, Samir R. Kapadia, Timothy D. Crowe, 
Mandish Rai, Ivan Casserly, Steven E. Nissen, E. Murat Tuzcu. The 
C/eve/and Clinic Foundation, Cleveland, OH, USA 
Background: Intravascular ultrasound studies of atherosclerosis regression- 
progression require plaque volume determination at two or more time points. 
However, repeated motorized pullbacks of the same segment often contain 
a different number of frames. 
Methods: Motorized pullbacks over an average vessel length of 33 f 
12 mm were performed at 0.5 mm/set in 20 patients. Plaque area was 
measured by manual planimetry at cross-sections every 1.0 mm. Plaque 
volume was computed using Simpson’s rule. To simulate the effect of varying 
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the number of frames in the pullback, twenty random subsamples of 95% 
of the cross-sections were used to calculate total plaque volume. In each 
subsample, plaque volume was computed by multiplying the average plaque 
area by the actual pullback length. 
Results: The true volume using all data points was compared to the 
volume estimated from each subsample and percent error calculated. The 
percent error in plaque volume was 1.9 f 0.9 (range 0.68-3.5). 
Conclusions: The average error in plaque volume calculation is at most 
3.5% even when there is up to 5% variation in the number of frames between 
pullbacks. Thus small variation in motorized pullbacks does not affect the 
accuracy of plaque volume measurements. 
1 1109-I 19 1 Diet and its Relation to Early Atherosclerosis in 
Teenagers 
Albert Sanchez, Jacques 0. Barth, Ling Zhang. Pacific Health Education 
Center, Bakersfield, California; Prevention Concepts, Inc., Los Angeles, 
California, USA 
Background: Atherosclerosis is known to begin early in life, and it has been 
assumed that the risks of diet and other risks of cardiovascular disease are 
the same at the initial stages of atherosclerosis in youth as they are in adults. 
We tested this assumption in high school students with varying lifestyle and 
ethnic backgrounds. 
Methods: A total of 249 students volunteeredm, 13-18 years old males 
and females, were students from a typical high school, a Hispanic high 
school, and from a high school of a health conscious population (Seventh- 
day Adventists). They were measured for the typical risk factors of age, sex, 
height, weight, blood pressure, and fasting blood cholesterol (total, HDL, 
LDL), triglycerides, glucose, and uric acid. The thickness of the common 
carotid artery wall was measured with ultrasound by the quantitative in- 
tima-media thickness test (QIMT) as a measure of the earliest morphologic 
evidence of atherosclerosis. 
Results: The majority, over 80%, were above the dietary recommen- 
dations for total or saturated fat, and 49% exceeded the recommended 
cholesterol intake. Cholesterol intake was correlated with QIMT (p < 0.005). 
Although the mean serum cholesterol level was 161 mg/dL, there were hyper- 
cholesterolemics according to recommendations for teenagers (37% for total 
cholesterol, 29% for LDL). Also, there was hypertension (11% for systolic, 3% 
for diastolic). BMI correlated directly (p < 0.0029) with total cholesterol, LDL 
cholesterol, total-cholesterol/HDL-cholesterol ratio, triglycerols, uric acid, and 
systolic blood pressure. 
Conclusions: These data support the assumption that diet is important 
in the etiology of atherosclerosis in its beginning stages in teenagers, as it 
is with atherosclerosis in the adult. This knowledge, along with the evidence 
that teenagers are choosing atherogenic diets, provides the basis for fur- 
ther research, and the incentive for health educators to develop strategies 
to reduce atherosclerosis among teenagers in order to prevent later adult 
cardiovascular disease. 
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1 ill O-l 091 Metalloproteinase Inhibition and alpha-v-beta-3 
Receptor Blockade Synergistically Inhibits 
Neointimal Formation and Constrictive 
Remodeling After Balloon Angioplasty in Rats 
Leonid Margolin, llia Fishbein, Shmuel Banai, Gershon Golomb, 
Reuven Reich, Louise S. Perez, S. David Gettz. The Hebrew Universifl: 
Jerusalem, Israel 
Injury-associated release of proteolytic enzymes from smooth muscle and 
foam cells is thought to alter extracellular matrix proteins facilitating cell 
migration, neointima formation, and vessel wall remodeling. Blockage of 
the vitronectin receptor (ol, 8s) with a synthetic RGD peptide has been 
shown to interfere with matrix proteolytic activity and inhibit cell invasion. 
This study tests the effect of metalloproteinase (MMP) inhibition combined 
with vitronectin receptor inhibition on neointimal formation and vascular wall 
remodeling after balloon injury in viva. 
Methods: Male Sabra rats were treated with a competitive, reversible 
MMP inhibitor, Batimastat (BB-94, British Biotech, Pharmaceuticals Ltd., 
Oxford, U.K.) (30 mg/kg, ip), separately and in combination with an avp3 
receptor inhibiting RGD peptide (GIBCO BRL, # 12148-011) (0.1 pmol) 
applied perivascularly within a pleuronic gel to the common carotid artery 
immediately after balloon injury. Animals were sacrificed on day 3, 14, 25 
and 75 (n = 24 each) after balloon. 
Results: Animals treated with BB-94, peptide, or both had markedly 
reduced luminal cross-sectional-area narrowing by neointima (%CSAN-N) 
and intima-to- media area ratio (l/M-R) at all time points except for 3 d 
after balloon injury vs. non-treated, ballooned animals. Constrictive vessel 
wall remodeling, estimated by determining the ratio of the total wall area of 
the ballooned segment to that of adjacent non-injured, reference segment 
(EEA/EEAr), was found in control arteries 75 d after balloon injury but not in 
treated animals. 
Gram (75 cl) %CSAN-N I/M-R EEAfEEAr 
Vehicle 71 * 8% 2.2 i 4 0.67 jI 0.1 
BB-94 21 + 4%** 1.2 * 0.3** 1.12*0.1* 
Peptide 27 l 5%*** 1.3 * 0.5** 1.32 * 0.2”” 
BB-94 + oeotide 10 f 3%*x= 0.4 zt 1*** 1.56 5 0.4*** 
Mean rk SD, *p = 05, -+p = 0.001, ***p = 0.0001 by i-way ANOVA 
Conclusion: Inhibition of MMP activity and vitronectin receptor blockade 
markedly reduces neointimal formation (>80%) and prevents constrictive 
remodeling 2.5 months after balloon injury in rats. Confirmation of the efficacy 
of this strategy in larger animals should be the next step toward testing the 
applicability of this novel approach to the interventional setting. 
1 111 O-1 10 ] Myxoid Tissue in Stent Restenosis May Be a 
Provisional Tissue in Which Active Cell Migration 
and Synthesis of Extracellular Matrix (ECM) 
Occur 
Ick-Mo Chung, Yangsoo Jang, Seung J. Park, Seung-Yun Cho, Seong 
W. Park, Cheol W. Lee, Sang H. Cho, Paraskevi Heldin, Herman K. Gold, 
Stephen M. Schwartz. Ewba Womans Univesitx Seoul, Korea; University of 
Washington, Seattle, WA, USA 
Background: Since we have shown that coronary arterial stent restenotic 
tissue (CASR) has a low cell replication rate, other mechanisms may be 
important for stent restenosis. We did the histological studies of ECM, myxoid 
tissue, and expressions of molecules implicated in cell migration and ECM 
synthesis in CASR comparing to primary coronary atherosclerotic plaques 
(PCAP). 
Methods: Atherectomized samples were obtained from CASR (n = 32, 
28 patients 0.5-23 mo after stenting) and from PCAP (n = 21, 21 patients). 
We used modified Movat staining for ECM analysis and immunocytochem- 
ical staining for the expressions of molecules implicated in cell migration 
(PDGF-B, PDGF receptor B, MMP-I, and MMP-9) and in ECM synthesis 
(hyaluronan synthase (HAS)-1 and TGF-/?I). 
Results: Myxoid tissue in CASR tends to be found decreasingly in time 
afterstenting: 86%vs29%, p < 0.05 (~6 movs ‘6 mo afterstent). There wasa 
general tendency of ECM transition in CASR to change from proteoglycan rich 
to collagen i rich in time after stenting. Comparing to PCAP molecules such as 
PDGF receptor p, MMP-I, and HAS-I tend to be expressed more abundantly, 
especially on the cytoplasm of stellate cells in myxoid tissue, in CASR. 
Conclusion: Myxoid tissue and proteoglycans in CASR may be provi- 
sional tissues in which actid cell migration and synthesis of ECM occur. 
1 111 O-1 11 1 Six-Month Follow-up of Endovascular 
P-Irradiation in Balloon-Injured Pig Coronary 
Arteries 
Mahomed Y. Salame’ , Stefan Verheye’ , Stephen P. Mulkey’ , Ian 
R. Cracker’ , Nicolas A.F. Chronos2, Spencer B. King Ill’, Keith 
A. Robinsot?. ‘Emory University School of Medicine, Atlanta, Georgia: 
2Atlanta Cardiovascular Research Institute, Atlanta, Georgia, USA 
Background: Little is known about the long-term effects of endovascular 
irradiation (ER). We evaluated angiographic (QCA) and histologic effects of 
ER at 6 months after PTCA. 
Methods: Adult mini-pigs received PTCA followed by ER (0, 7, 14, 21, 
or 28 Gy at 2 mm) in LAD and LCX and aspirin daily. Reference (refLD), 
minimum and maximum lumen diameters were measured by QCA at 6 
months, and histopathology performed. 
Results: Non-irradiated control vessels developed a fibrous neointima 
with a % diameter stenosis of 9.7 + 3.4. ER resulted in segmental het- 
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erogeneity of lumen diameter with both greater % stenosis (see table) and 
increased number of vessels with focal enlargement (~25% of refLD; x2: p < 
0.005). Segments with angiographic stenoses consisted of poorly organized 
but stratified mural thrombi and very little neointima, whereas enlarged seg 
ments showed infrequent small mural thrombi, little fibrous neointima and 
medial atrophy. No vessels in control or (low dose) 7 Gy groups had fo- 
cal enlargement. However, 30% of vessels treated with intermediate (14-21 
Gy) and 100% of vessels treated with high dose (30 Gy) had segmental 
enlargement. 
Group A: 0 Gy Group 6: 7 Gy Group C: 14-21 Gy Group D: 28 Gy 
% Stenosis 9.7 * 3.4 39.2i 10.5* 26.1 5 17.4t 34.0 + i.e* 
” Enlarged 225% o/9 013 310 212 
$ < 0.0001; @p = 0.01 Compared to control (A). 
Conclusions: Medium and high dose ER at 6 months in adult Yucatan 
pigs treated only with aspirin is associated with angiographic stenoses histo- 
logically related to mural thrombi rather than neointima, and segmental vessel 
enlargement with medial atrophy. Further study with potent antiplatelet ther- 
apy is needed. 
111 O-1 12 1 Mammalian Suppressor of sgv-l- (MSSl), a 
Putative Transcription Factor and Differentiation 
Related Gene, is Upregulated in Explant Derived 
Compared With Enzyme Dispersed Human Aortic 
Vascular Smooth Muscle Cells In Vitro 
Catherine F. Townsend, Sheila E. Francis, Christopher M. Newman. Section 
of Cardkxvascular Medicine, Diilision of Clinical Sciences NGH7; University 
of Sheffield, UK 
Background: It has previously been reported that human aortic vascular 
smooth muscle cells (VSMCs) cultured by the explant (EX) technique exhibit 
a more differentiated phenotype and faster proliferation rates than cells 
cultured by the enzyme dispersal (ED) technique. We have investigated 
differences in gene expression between the two culture types in an attempt 
to identify genes involved in human VSMC proliferation and/or differentiation. 
Methods: Differential Display Reverse Transcription Polymerase Chain 
Reaction (dd RTPCR) was performed, using 2 Kg total RNA from paired EX 
and ED cultures from the same aorta at passage 2, and one base anchored 
oligo dT primers for reverse transcription, PCR was performed separately 
using eight different arbitrary primers, incorporating 35S. The PCR products 
were then electrophoresed on adjacent lanes of denaturing polyacrylamide 
gels, with appropriate negative controls. Banding patterns were compared, 
and those exhibiting differential expression were reamplified by heat-soak 
PCR. False positives were screened out by dotting reamplified PCR products 
in duplicate onto nylon membranes, which were than hybridised with ‘sP 
labelled cDNA from the two original cultures. Spots which still exhibited 
differential gene expression were cloned and sequenced. Western Blotting 
and immunocytochemistry were performed using a polyclonal antibody to 
human MSSl, to confirm differences in gene expression. 
Results: In total, 63 bands exhibiting differential expression were ex- 
tracted from the dd RTPCR gels. 13 of these were confirmed to be differ- 
entialiy expressed by hybridising with radiolabelled cDNA. After cloning and 
sequencing, one of these gene fragments was found to exhibit extremely high 
homology (98% over 272 bases) to the mRNA for human MSSI. Differential 
expression of MSSI protein in paired EX and ED cultures was confirmed by 
Western Blotting and immunocytochemistry. 
Conclusion: VSMCs cultured by the EX method are highly proliferative 
during early passages, whereas ED VSMCs are relatively quiescent. MSSI 
was found to be upregulated in EX VSMCs, as compared with the ED cells. 
MSSI has been ascribed several functions, including acting as a transcription 
factor, and being upregulated immediately prior to skeletal muscle differen- 
tiation. It is also the 7th subunit of the 26s proteasome, which is involved 
in degradation of ubiquitinated proteins. Although the function of MSSI in 
VSMCs remains to be investigated, it is possible that it is involved in VSMC 
proliferation, and, if so, could be a potential target for therapeutic inhibition 
of VSMC proliferation to prevent restenosis. It is also a potential new marker 
for human VSMC differentiation and/or proliferation in vitro. 
I I IO-1 I8 Successful Non-Viral Gene Transfer Using a 
Novel Thermosensitive Gel Stent Coating 
Iris Haehnel, Ulrike Pfeifer, Christian Seeliger, Eckhard Alt. 1. Med. Klinik, 
Klinikum Rechts der Isar, and De&&es Herzzentrum, Echnische 
Universit& Mijnchen, Germany 
Background: Gene transfer to the arterial wall has been proposed for re- 
duction of restenosis after stent implantation. Catheter-based gene deliv- 
ery mainly employing adenoviral tranfer is limited, however, by procedural 
problems and the prevalence of preexisting immunity to adenovirus. Other 
methods are hampered by low transfection efficiencies. We have developed 
a stent coating on the basis of a water-soluble thermosensitive gel enabling 
the incorporation of DNA plus a non-liposomic transfection enhancer. 
Method: Plasmid-DNA encoding the reporter gene GFP were combined 
with transfection enhancer in the thermosensitive gel, which is fluid at 4°C 
and solid at RT. Sixteen IO mm-multicellular stainless steel stents were 
longitudinally cut, flattened and dipcoated in the liquid coating at 4’C and 
brought to RT for solidification (6 wg DNA/stent). Primary SMC from porcine 
aortas were seeded at a density of 3000 cells/cm2 in WaymouthiHam F12 
growth medium containing 10% FBS. After 12 hours the stents were placed 
onto the cells and incubated at 37°C. Transgene protein expression was 
evaluated after 24 hours by fluorescence microscopy. 
Results: Reporter transgene expression was observed in 28.7 i 5.8% 
in the coated stent treated samples, comparing to a transfection efficiency of 
31.4 rt 6.2% in the conventionally transfected control cells. 
Conclusion: Our results demonstrate the technical feasibility of an effi- 
cient non-viral gene transfer via a DNA-eluting stent coating into vascular 
smooth muscle cells in vitro. To investigate the in-vivo applicability, animal 
studies are currently performed and will be reported. This transfection system 
may hold promise to target in-stent restenosis. 
Ll--- 1110 114 Does Aging Effect Vascular Responses Following Balloon Angioplasty or Stenting? 
Sweta Shroff, Andrew Farb, Renu Virmani. Armed Forces lnsfitute of 
Pathology Washington, DC, USA 
Most coronary interventions are preformed in middle age individuals, but 
animal models examining revascularization therapies typically utilize young 
animals. Few data are available on age-associated vascular changes follow- 
ing balloon angioplasty (BA) or stenting. 
Methods: Stents were placed in iliac arteries of young (4-6 months, n 
= 15) and older (24-26 months, n = 15) NZW rabbits and the contralateral 
iliacs underwent BA. At 3 or 30 days, arteries were processed for light or 
scanning electron microscopy (SEM). Pre-treatment arterial lumen diameters 
were similar among all groups, 
Results: 
Rabbit Cdl lntima Cell lntima lntima % lntimal Cell 
Age Prolifera- Density Thickness Thickness Stenosis Prolifera- 
tion (%) (cell/mm*) (mm) (mm) tion (%) 
3 days 3 days 3 days 30 days 30 days 30 days 
BA Young 202~2.8 4839&1349 0.01010.003 0.1610.01 35.8h3.5 0.410.2 
Old 12.9zt0.7 13691754 0.009iO.001 0.13f0.01 18.4-c3.8 1.3&l .O 
p value p c 0.05 p = 0.07 p=NS p<O.O5 p<O.O05 p=NS 
Stent Young 26.7122 5132&839 0.013&0.002 0.085~0.008 21.511.5 1.2+0.6 
Old 19.2+4.3 19435525 0.021~0.001 0.072f0.009 19.6*0.9 1.4ztO.3 
p value p < 0.18 p < 0.01 p < 0.005 p=NS p=NS p=NS 
BA lead to greater adventitial thickening in young than old animals (0.074 
* 0.007 vs. 0.062 i 0.013 mm, p < 0.05). At 3 days, stenting in older 
animals was associated with increased accumulation of a fibrin-rich hypocel- 
lular intima, which was similar in size to young animals at 30 days. This 
finding suggests older animals exhibit fibrinolytic activity after stenting. Three 
days following stenting or BA, SEM showed no significant age dependent 
differences in percent arterial surface endothelialized. 
Conclusions: Following BA, negative remodeling and a large proliferative 
response caused greater luminal narrowing in young versus old rabbits. Age 
had no effect on restenosis after stenting. These results indicate that when 
using animal models to simulate vascular responses in man, age may be an 
important determinant of outcome. 
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CII 854 1 Single-Session Radiation of Two Coronary Arteries for Prevention of Restenosis in De-Novo Lesions: 
Safety Using a 6 Months Protocol of Clopidogrel 
Sigmund Silber, lngeborg Krischke, Norbert Seidel, Armin Schneider, 
Peter von Rottkay. Dr. Mijller Hospital, Munich, Germany 
One advantage of beta over gamma radiation is the possibility to radiate 
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several coronary arteries in a single session without the risk of overdosing 
adjacent vessels. There is, however, concern that radiating two arteries in 
a single-session could double the risk for late coronary occlusion related to 
the hampered endothelialization. The risk of “delayed acute thrombosis” may 
be even higher when stents have been implanted during brachytherapy. To 
assess the safety and efficacy of single-session beta radiation in patients 
with multi-vessel disease, we performed a prospective evaluation with the 
Novoste’” Beta-Cath system in pats with stable angina, objective signs of 
myocardial ischemia and at least 75% diameter stenoses in two of the major 
coronary arteries. Starting three days before, all pats received ASS (300 mg 
o.d.) and Clopidogrel (75 mg o.d.) for 6 months. Mean pats age was 56 & 7 y 
with a mean LV-EF of 58 f 13%. A total of 36 de-novo lesions were treated in 
these 18 pats with two vessel disease; LAD/RCx/RCA lesions were radiated 
in 39%/33%/28%. For a niean lesion length of 12.4 i 4.4 mm and a reference 
diameter of 3.1 f 0.4 mm, the niean MLD was 1.2 f 0.6 mm before and 
2.7 f 0.3 mm after the intervention. After radiation, stents were implanted in 
89% of the lesions with an average sfent length of 17 f 4.4 mm at 10.4 & 
2.2 bar. The administered dose of the Strontium/Yttrium-SO radiation source 
trains with 12 pellets (30 mm) or 16 pellets (40 mm) was 15 f 2 Gy (14-18) 
with an exposure time of 181 rt 22 s (169-224). No complications ocurred 
during PTCA, radiation or stent implantation. All radiation procedures could 
be finished as planned. Clinical follow-up did not reveal ischemic events, so 
far. 
Conclusions: Beta radiation of two major coronary arteries in a single 
session is feasible and safe. On a prolonged 6 months protocol for clopi- 
dogrel intake, no late coronary occlusions ocurred. The data for MACE and 
angiographically determined restenosis will be presented. 
4:15 p.m. 
854-2 The Effect of Catheter-Based ,&Radiotherapy on 
Coronarv Arterv Remodelina and Plaaue Formation 
After Pe&utan6ous Interven’iions 
Ken Kozuma, Marco A. Costa, Mane1 SabatB, Willem J. van der Giessen, 
Jurgen M.R. Lighharl, Veronique L.M.A. Coen, Pedro Serrano, I. 
Patrick Kay, Alexander J. Wardeh, Peter C. Levendag, Patrick W. Serruys. 
Thoraxcenter and Daniel den Hoed Cancer Center, University Hospital 
Rotterdam, The Netherlands 
Background: Recent reports have shown intracoronaty radiation affects not 
only neointimal formation but vessel remodeling. The aims of this study were 
to quantify the change in lumen volume (LV), total vessel volume (TVV) and 
plaque volume (PV) by means of three-dimensional IVUS analysis and to 
compare the difference between irradiated and non-irradiated segments. In 
the irradiated group, we also compare the balloon angioplasty (BA) with stent 
group. 
Methods: From April/97 to March/99, we successfully treated 96 de novo 
lesions of 90 patients with intervention followed by intracoronaty B-radiation 
or dummy source wire. Of these, 66 patients (72 lesion) have completed 
6-8 month IVUS follow-up (FU). Patients who received multiple stents were 
excluded from this study. IVUS images were acquired by means of ECG-trig- 
gered pullback, and 3-D reconstruction was performed by semi-automated 
edge detection system. BMh g”Sr/soY (n = 38, dose 12-18 Gy) and 32P 
sources (n = 17, dose 28-42 Gy) were used for radiation. 
Results: Sixty-seven lesions (62 patients) were assessed by 3-D volu- 
metric IVUS. Twelve lesions were treated (7 BA and 5 stent) with dummy 
source (placebo group). Thirty-six lesions were treated by BA, and 19 lesions 
by stent in the irradiated group. 
LV, mm3 TW, mm3 PV, mm3 
Post FU Delta Post FU Delta Post FU Delta 
Radiation 233 231 -2 446 481 +35* 214 250 +36* 
Placebo 220 163 -57t 436 419 -17 216 234 +I 8* 
p value NS NS 0.015 NS NS 0.003 NS NS NS 
l i p < 0.001, t p < 0.014, * p < 0.064, Delta = FU - Post-procedure (Post) 
Delta TVV and delta PV were similar between BA and stented patients 
in the irradiated group (+35 versus +35 mm3, and +32 versus +42 mm3, 
respectively). Delta LV was also comparable between both groups (+3 versus 
-12 mm3, respectively, p = NS). 
Conclusion: Radiation appears to stimulate positive vessel remodeling 
after percutaneous intervention with no effect on plaque increase. There was 
no difference in 3-D IVUS parameters between BA and stented patients in 
the irradiated group, suggesting that stent did not play a main role in the 
remodeling process after catheter-based brachytherapy. 
4:30 P.m. 
I 854 3 Geographical Miss: A Cause of Treatment Failure in Radio-Oncology Applied to lntracoronary 
Radiotherapy -- 
Mane1 SabatB, Marco A. Costa, Ken Kozuma, I. Patrick Kay, Willem J. van 
der Giessen, Veronique L.M.A. Coen, Jurgen M.R. Ligthart, Pedro Serrano, 
Peter C. Levendag, Patrick W. Serruys. Thoraxcenter and Daniel den Hoed 
Cancer Center, University Hospital Rotterdam, The Netherlands 
A recognized limitation of endovascular p-radiation therapy is the develop- 
ment of new stenosis at the edges of the irradiated area, which may be 
caused by the combination of low-dose radiation and injuty. We translated 
the radio-oncological concept of “geographical miss” to define those cases 
in which the radiation source did not fully cover the injured area. The aims of 
the study were to determine the incidence and causes of geographical miss 
and evaluate the angiographic impact of this inadequate treatment on the 
outcome of patients treated with intracoronaty B-radiation. 
Methods: We analyzed 55 consecutive patients treated for de novo le- 
sions (n = 39) or recurrent in-stent restenosis (n = 16) with B-radiation after 
percutaneous coronary intervention using 9oSr/goY source, Prescribed dose 
ranged between 12 and 20 Gray at 2 mm from the source axis. By means 
of off-line quantitative coronary angiography (CAASII system), the irradiated 
area (IRA) and both edges (5-mm distal and proximal to the irradiated seg 
ment) were studied prior to, after intervention and at 6-month follow-up. Those 
edges, which were injured during the procedure constituted the geographical 
miss edges. 
Results: After excluding 32 edges due to ostial location (n = 14) or 
overlapping of one of the edges with sidebranches (n = 18), 78 edge areas 
and 55 IRA were finally studied. We found 23 (29.5%) geographical miss 
edges induced by balloon dilatation (n = 14) or additional stent implantation 
(n = 9) outside the IRA. These edges were injured during the intervention 
mainly due to: (1) development of procedural complications which extended 
the treatment beyond the margins of the IRA (unexpected geographical 
miss, n = 9); (2) lack of availability of longer radiation source (>30 mm) in 
the context of patients with diffuse recurrent in-stent restenosis (n = 8); and 
(3) the injured area of prior balloon inflation was not appropriately covered 
by the source (n = 6). Late loss was significantly higher in geographical 
miss edges, as compared to both.IRA and not-injured edges (0.84 & 0.6 
versus 0.16 f 0.4 and 0.09 f 0.4 mm, respectively; p < 0.0001). Similarly, 
restenosis rate was significantly higher in those injured edges (9% within 
IRA, 39% in geographical miss edges, and 0.02% in not injured edges; p 
< 0.001). No difference in the pattern of the late loss between the 3 areas 
were observed in de novolesions as compared to recurrent in-stent restenotic 
lesions. Relative late loss was comparable between geographical miss edges 
located proximally or distally from the IRA (0.31 i 0.2 versus 0.34 f 0.2, 
respectively; p = NS). 
Conclusion: Geographical miss is a novel and frequent phenomenon 
after intracoronaty radiotherapy. It was related to either lesional or procedural 
factors associated with the lack of longer radiation sources. Considering that 
this inappropriate treatment may lead to an untoward angiographic outcome, 
the occurrence of this phenomenon should be avoided. 
4:45 p.m. 
854-4 The Gamma II Trial of Localized Radiation Therapy 
to Inhibit Restenosls After Coronary Stenting 
Martin B. Leon, Paul S. Teirstein, Jeffrey W. Moses, Alexandra J. Lansky, S. 
Chiu Wong, James Willerson, David R. Holmes, Dean Kereiakes, 
Btyan Kluck, James B. Hermiller, Barry S. George, Stephen Ellis, Dilsher 
M. Nawaz, Richard E. Kuntz. Washington Hospital Center, Washington, 
13. C., USA 
Background: A recent multicenter double-blind randomized trial (Gamma 
I) demonstrated a very significant (>50%) reduction in angiographic reste- 
nosis after intetventional treatment of native coronary in-stent restenosis 
(ISR) lesions followed by gamma (Ir-192) coronary radiation therapy (CRT). 
Importantly, a clear dose-response relationship was present using a vari- 
able radiation dosing regimen (mean 13.5 Gy) based upon intravascular 
ultrasound measurements. 
Methods: To determine if a slightly higher fixed dose regimen (14 Gy @2 
mm from the source center) improves simplicity and efficacy of CRT for ISR, 
125 patients with the same inclusion criteria were enrolled in the same 12 
investigational sites for comparison with the CRT and placebo arms of the 
previous Gamma I trial (252 pts). Follow-up includes angiography Q6 mos 
and clinical events 030 days and 9 mos. 
Results: Baseline demographics and lesion characteristics were well 
matched between the Gamma I and II patient cohorts. Mean age was 60 
years, 78% were men, 38% were diabetics, 35% had prior Ml, and 57% 
had FC Ill or IV angina. Lesion length was 20.3 f 11.8 mm and reference 
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vessel size was 2.76 & 0.50 mm. After ISR treatment with combinations 
of balloon PTCA, athero-ablative techniques, and additional stents (at the 
operator’s discretion), final in-stent % diameter stenosis was 17.2 f 17.3% 
and minimal lumen diameter was 2.37 Ii; 0.52 mm. In hospital and 30-day 
clinical events were infrequent (death, Ml, and repeat revascularization was 
1.6% in-hospital and 4% @30 days) and similar to Gamma I patients. 
Conclusions: A slightly higher fixed dose radiation regimen used in the 
Gamma II trial, simplified the application of CRT and was safe with few 
early clinical events. Long-term angiographic and clinical outcomes will be 
presented and compared with similar CRT and placebo patient cohorts from 
Gamma I. 
500 p.m. 
854-5 One Year Follow-Up After intravascular Radiation 
Therapy Following Balloon Angioplasty of Narrowed 
Femoral-Popliteal Arteries. Results of the PARIS 
Feasibility Clinical Trial 
Ron Waksman, John R. Laird, Alexandra J. Lansky, Abdel Brahimi, Larry 
R. White, Claudine T. Jurkovitz, Andrej S. Kosinski, Nancy Murrah, William 
S. Weintraub. For the PAR/S Investigators; Washington Hospital Center. 
Washington, DC; Emory University, Atlanta, GA, USA 
Restenosis is a major limitation of the clinical utility of Percutaneous Trans- 
luminal Angioplasty (PTA) of superficial femoral-popliteal arteries (SFA). The 
feasibility trial of the PARIS (Peripheral Arteries Radiation Investigational 
Study) is a multicenter open label registry. 
Methods: Forty-one patients with claudication were enrolled in the study 
and 6 were excluded (5 due to technical problems in delivering the radiation 
to the PTA site). Mean lesion length was 9.8 f 3.0 cm and mean reference 
vessel diameter was 5.2 & 3.1 mm. Following successful PTA, a segmented 
centering balloon catheter was positioned to cover the PTA site. The patients 
were transported to the radiation oncology suite and treated with a High 
Dose Rate microSelectron Afterioader using 192-lr source with a prescribed 
dose of 14 Gy, 2 mm into the vessel wail. Ankle Brachial Index (ABI) was 
evaluated at 1,6, and 12-month and angiographic follow-up was performed at 
6 month. 
Results: Radiation was delivered successfully to 35/40 patients. There 
were no procedural complications. Exercise and rest ABI were higher at 
one year (0.74 + 0.26; 0.89 f 0.18) compared to the baseline prior to PTA 
(0.55 f 0.28; 0.67 i 0.19) (p < 0.03). Maximum walking time on treadmill 
increased from 3.56 f 2.7 to 4.62 Z!Z 2.7 minutes at 30 days and was 4.04 
i 2.8 minutes at 12 months, P = 0.01. Angiographic binary restenosis at 6 
months was 10% and the clinical restenosis at 12 months was 13.3%. There 
were no perforations, aneurysms or any other adverse events related to the 
radiation, 
Conclusions: Intra-arterial radiation following PTA to SFA lesions using 
high dose rate gamma radiation is feasible and safe. The angiographic and 
clinical improvements are sustained at one year and promise to be a potent 
anti restenotic therapy for the treatment of peripheral arteries. 
5:15 p.m. 
854-6 A New Phosphorus-32 Balloon Catheter Device for 
lntracoronary Brachytherapy - Results From the 
Porcine Stent Model 
J&g Hausleiter, Maurice Buchbinder’ , Brett Trauthen’, Lisa Tam”, Alex Li, 
James Whiting. Cedars-Sinai Medical Center, Los Angeles, CA; ‘Sharp 
Memorial Hospital, San Diego, CA; ‘Radiance Medical Systems, Irvine, CA, 
USA 
Background: lntracoronary radiation devices using ,!I- and v-emitting sources, 
have been shown to reduce neointima formation in porcine models of resteno- 
sis. However, most devices have drawbacks with respect to dose uniformity, 
centering within the coronary artery, personnel exposure or risk of isotope 
leak or spill. We have developed a new radiation delivery catheter system 
using an ultra-thin, B-emitting Psn sheet source, which is encapsulated into 
the balloon material to form a flexible cylindrical radioactive balloon source. 
The feasibility, safety and efficacy of this new balloon device is evaluated in 
a porcine stent model of restenosis. 
Methods: The non-blinded, controlled study protocol included oversized 
coronary stent placement followed by radiation therapy or sham treatment in 
17 LAD arteries. For radiation therapy a dose of 20 Gy at 1 .O mm distance 
from the balloon surface was given using the new P3s balloon system in 9 
arteries. Sham treatment with identical but non-radioactive balloon catheters 
was performed in 8 arteries. Follow-up angiography and histomorphometric 
analysis will be performed after 28 days, 
Results: Radiation treatment with the new P3* balloon device was per- 
formed without complications. One pig in the radiation group died within 24 
hours after the procedure. No leakage of isotope was detected. The radiation 
dose at the chest of the pig was 1 to 1.2 mR/hr, the personnel exposure was 
0.01 mWhr. 
Conclusions: lntracoronary radiation therapy using a new P3a balloon 
catheter device is feasible and safe. The radiation exposure to the catheter- 
ization laboratory personnel is negligible. Final angiographic and histomor- 
phometric analysis will be presented. 
ORAL 
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8:30 a.m. 
El 862 1 Thermosensor Catheter; a Nitinol Shape Memory 
Basket Catheter to Measure Temperature of Vessel 
Wall With Continuous Blood Flow 
Morteza Naghavi, Said Siadaty, James T. Willerson, Ward Casscells. 
University of Texas Housfon, School of Medicine, TX, USA 
We have previously correlated temperature of atherosclerotic plaque with 
histopathological characteristics of vulnerability to rapture. We found that in- 
flamed unstable plaques give off more heat. Others have recently correlated 
plaque temperature with patients’ clinical presentation. In order to monitor 
temperature of vessel wall without occluding blood flow we have developed 
an intravascular thermosensor catheter. Here we report the specifications of 
the catheter along with proof of principle m our canine model of atheroscle- 
rosis. The system comprises a 3F catheter, an ultra-thermometer, and a PC 
for thermographic imaging. An expandable basket is made of 4 hollow nitinol 
wires (ID:O.OOB inch, OD:0.012 inch) with 0.005 inch NTC thermistor built-in 
at the end of a hollow shaft connecting the basket to the ultra-thermometer 
and carrying insulated wires. Having an extra thermister on the shaft of the 
catheter enables monitoring temperature of blood simultaneously. The sys- 
tem has a temperature resolution of 0.005 C and spatial resolution of 0.5 
mm with 0.01 set acquisition time. The blood side of the lead wires and the 
thermistors are coated with thermal insulating material. Upon release from 
a guiding or a delivery catheter, the basket opens, expands and contacts 
the wall to measure its temperature. The number and size of wires m the 
basket can be modified to pass through a guide wire lumen of an angioplasty 
catheter allowing measurement of temperature before and after occlusion of 
blood flow. 
We have, thus far, tested the catheter in 5 atherosclerotic canine pe- 
ripheral and coronary, arteries in vivo. The catheter detected significant 
temperature heterogeneity in areas with lesions and no complications have 
been noted. 
8:45 a.m. 
862-2 Efficacy of Intravascular Ultrasound 
Radio-Frectuencv Signal Analysis in Evaluation of 
Coronary Atherosclerotic Plaques Compared With 
Conventional Video Images 
Nobuyuki Komiyama, Yutaka Yamamoto, Yoshiaki Masuda, Gerald J. ‘Berry, 
Paul G. Yock, Peter J. Fitzgerald. Chiba University Hospital, Chiba, Japan; 
Stanford University School of Medicine, Stanford, CA, USA 
Background: Conventional gray-scale intravascular ultrasound (IVUS) im- 
ages cannot accurately differentiate histologic subtypes of sonolucent coro- 
nary plaques with or without a lipid core. To overcome this limitation, we 
applied radio-frequency (RF) signal analysis to IVUS. 
Methods: Five atherosclerotic human coronary artery specimens were 
harvested at five transplanted hearts and pressure-fixed by formalin. RF sig- 
nals were obtained from 24 regions of interest (ROI) within plaques acquired 
by a 30 MHz catheter-based IVUS system and digitized at 500 MHz in B-bit res- 
olution. The ROls were histologically categorized into 12 preatheroma without 
a lipid core (Core (-)) and 12 atheroma with a lipid core Z!Z a fibrous cap (Core 
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(+)). Integrated backscatter (IB) and parameters of RF envelope probability 
distribution function (mean-to-standard-deviation ratio (MSR), skewness and 
kurtosis) were calculated by off-line analysis of RF from 347 vectors of Core 
(-) and 362 vectors of Core (+). In Core (+), %area of a lipid core (%CoreArea) 
in each ROI was measured in a digitized histologic image by a computerized 
planimeter. On the other side, IVUS video images of all ROls were visually 
classified into two groups with or without a lipid core by 5 interventional cardi- 
ologists blinded to both RF signals and histology. 
Results: 1) Sensitivity and specificity for a lipid core were shown below: 
cut-off value 
Sensitivity (%) 
Specificity (%) 
IS MSR skewness kunosis visual video- 
-54.5 dB 1.80 0.5 -0.35 image analysis 
58.3 63.3 100 100 53.3 
75.0 91.7 91.7 91.7 71.7 
2) % CoreArea was significantly correlated to IB, MSR, skewness and 
kurtosis (r = -0.64, -0.73, 0.78 and 0.63; p < 0.05). 
Conclusion: Compared with IVUS video images, the parameters of RF 
signal analysis can be used for more accurate detection and quantitative 
evaluation of a lipid core, one of major factors of a “vulnerable” coronary 
plaque. 
9:00 a.m. 
862-3 Unstable Coronary Atherosclerotic Plaques: 
lntracoronary Ultrasound Characteristics With In 
Vivo Measurement of Culprit Lesion Temperature 
Konstantinos Toutouzas, Christodoulos Stefanadis, Manolis Vavuranakis, 
Leonidas Diamantopoulos, Eleftherios Tsiamis, Pavlos Toutouzas. 
Hippokra tion Hospital, University of Athens, Greece 
Background: Recent studies have shown positive remodeling to be present 
in the majority of culprit lesions of patients (pts) with acute coronary syn- 
dromes (ACS). Moreover, inflammatory process has been documented in 
these lesions which is associated with increased cellular and matrix ex- 
pression leading to heat production. Therefore, we assessed culprit lesions 
characteristics in pts with stable angina and ACS, and correlated coronary 
arterial remodeling findings with the temperature (T). 
Methods: Twelve coronary lesions of pts with ACS and 13 lesions of 
pts with stable angina were studied. Lumen and external elastic membrane 
(EEM) areas were measured at both target lesion and proximal reference 
sites by intracoronary ultrasound before intervention. The remodeling index 
was defined as the ratio of the EEM area at the lesion to that at the proximal 
site. Positive and negative remodeling were defined as indices of >1.05 and 
cO.95, respectively and plaque area as: EEM area-lumen area at the lesion. 
Additionally, in all pts T was measured at the culprit lesion and at the normal 
vessel wall by a thermography catheter that was developed in our institution 
and the T difference was calculated. 
Table: Pts With Positive Remodeling 
EEM Proximal Area (mm’) 
Plaque Area (mm’) 
EEM Stenosis Area (mm’) 
Remodeling Index 
T difference 
ACS 
14.2 h 3.6 
12.08 zt 4.1 
15.5 i 2.6 
1.17*0.2 
0.22 i 0.17 
Stable Angina 
19.9 i 9.1 
9.97 * 3.2 
19.4 & 8.7 
1.01 i 0.03 
0.03 * 0.03 
p value 
0.07 
0.05 
0.02 
0.02 
0.001 
Results: (Table) Pts of both groups were similar in age, reference vessel 
size, and percent diameter stenosis. Positive remodeling was more frequent 
in pts with ACS (64% vs 23%, p < 0.01). In addition there was a good 
correlation between remodeling index and difference in plaque temperature 
in pts with ACS (r = 0.68, p < 0.001). 
Conclusion: The results of this study show that coronary remodeling is 
greater in culprit lesions of pts with ACS. This is associated with increased T 
probably as a result of cellular and matrix production. These findings provide 
new insights about the involvement of inflammation in the pathogenesis of 
ACS. 
9:15 a.m. 
862-4 Determining the Thermal Heterogeneity of a Model 
Vessel Wall by Pulsed Laser Irradiation: 
A Experimental Attempt to Detect Vulnerability of 
Atherosclerosis 
Takemi Matsui, Tsunenori Arai, Shunichi Sato, Minoru Suzuki, 
Toshiaki Ishizuka, Makoto Kikuchi, Akira Kurita. National Defense Medical 
College, Tokorozawa, Saitama, Japan 
Background: Human atherosclerotic plaques have been shown to display 
thermal heterogeneity with elevated temperature associated with culsters 
of macrophages, suggesting a possible modality for detecting vulnerable 
plaques. The temperature of plaques can not be measured by using conven- 
tional thermistors because of fibrous caps of the intimal surface. 
Methods: We developed a method to determine the thermal heterogene- 
ity of vessel walls using a phantom agar model. Light absorption coefficients 
of the agar vessel wall were adjusted to simulate the coefficients of the ar- 
terial intima, the atheromatous core and the media. The temperature of the 
middle layer in the agar vessel wall (corresponding to the atheromatous core) 
was calculated from the measured temperature changes of the model sur- 
face (corresponding to the arterial intima) under pulsed neodymium yttrium 
aluminum garnet (Nd:YAG) laser irradiation at 3W for 0.1 seconds. The mid- 
dle layer was heated with electric current to simulate temperature elevation 
derived from inflammation, The thermal heterogeneity of the agar vessel wall 
can be obtained by solving the heat transform equation using the upper layer 
thickness, the surface temperature and the boundary temperature at 1 mm 
above the model surface. 
Results: The upper layer thickness, D, can be calculated using the fol- 
lowing working formula: D = 1-0.3ATs + 0.02ATs2, where ATs denotes the 
surface temperature change. There was a significant highly correlation be- 
tween the calculated temperature of the middle layer (the atheromatous core) 
and the measured temperature of the middle layer (r = 0.98, p < 0.0001). 
Conclusion: This new method can provide us to measure plaque heat 
accurately despite fibrous caps coveting atheromatous plaques. 
9:30 a.m. 
862-5 Raman Spectroscopy Provides Characterization of 
Human Atherosclerotic Plaque Composition In Viva 
Sweder W.E. van de Poll, Hendrik P.J. Buschman, Michel J. Visser, J. 
Hajo van Bockel, Arnoud van der Laarse, Albert V.G. Bruschke, Gerwin 
J. Puppels. Leiden University Medical Center, Leiden; Erasmus University 
Rotterdam, The Netherlands 
Background: Raman spectroscopy has shown to provide important diag- 
nostic information on plaque composition in vitro. We tested the applicability 
of Raman spectroscopy in vivo during abdominal aortic surgery. 
Methods: We used a clinical Raman system that delivers 830 nm laser ex- 
citation light through a Raman optical fiber probe. During abdominal aneurys- 
mectomy, performed on a 58 year old man, the tip of the Raman probe was 
positioned perpendicularly onto the opened, diseased aortic wall. Raman 
spectra were then collected in 10 seconds, shining 80-100 mW laser light 
at the aorta. The spectrally examined tissue was then excised for histo- 
logical examination. Spectra were modeled to extract quantitative chemical 
information (Circulation 1998; 97: 878-885). 
Results: We collected Raman spectra with a good signal to noise ratio to 
determine the chemical composition of the atherosclerotic aneurysm (fig). 
I  
Conclusion: Raman spectroscopy can be applied successfully for re- 
mote, in vivo characterization of human atherosclerotic plaque. It can ac- 
curately quantify the amount of proteins, cholesterol and calcium and may 
prove an ideal technique to help identify plaques prone to rupture. 
9:45 a.m. 
1862-6 ] Optical Coherence Tomography of Human Coronary 
Arteries: A New Imaging Modality to Visualize 
Different Components of Plaques 
Guillermo J. Tearney, Ik-Kyung Jang, Dong-Heon Kang, H. Thomas Aretz, 
Stuart L. Houser, Thomas J. Brady, Kelly Schlendorf, Milen Shishkov, Brett 
E. Bouma. Massachusetts General Hospital, Boston, MA, USA 
Background: Optical coherence tomography (OCT) is a catheter-based, 
cross-sectional optical imaging technique with high resolution (10 pm). The 
goal of this investigation was to correlate OCT images of human coronary 
arteries with histology. 
Methods: Cadaveric coronary artery segments (n = 42) were obtained 
from 11 patients: 17 segments contained intimal hyperplasia only (Group A) 
and 25 segments contained atherosclerotic plaques (Group B). OCT images 
were obtained using a 3F or 7F OCT catheter and histologic examination 
was performed. 
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Results: In Group A, the internal elastic lamina was clearly visualized in 
11117 (65%), while the external elastic lamina was identified in lo/17 (59%). 
In Group B, a lipid pool was identified in 15/25 (60%). Fibrous cap thickness 
was measured by OCT (30-450 bm). The correlation between OCT and 
histology was high for measured cap thickness (r = 0.98). 
Conclusion: OCT imaging identified different components of plaques 
with a high correlation to histology. This high resolution imaging technique 
may be used in the future for early detection of vulnerable plaques. 
POSTER 
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L ii 29 75 Acute Renal Failure Requiring Hemodialysis After Percutaneous Coronarv Intervention: In-Hospital 
and One-Year Outcomes 
Luis Gruberg, Roxana Mehran, George Dangas, Gregg W. Stone, Mun 
K. Hong, Gary S. Mintz, Ron Waksman, Ran Kornowski, Alexandra 
J. Lansky, Kenneth M. Kent, August0 D. Pichard, Lowell F. Satler, Martin 
B. Leon. Washington Hospital Center, Washington, D.C., USA 
Background: Acute hemodialysis due to acute renal failure (ARF) is a rare 
but important complication after percutaneous coronary intervention (PCI). 
From a total of 12,054 patients who underwent PCI at our institution, we have 
analyzed the clinical characteristics and outcome of 52 consecutive patients 
(0.4%) who underwent PCI and developed ARF that required emergency 
hemodialysis. 
Results: Mean age was 71 years (range 39-90), 42% were female, 62% 
diabetics (37% insulin treated), 84% had prior renal insufficiency (serum cre- 
atinine ? 1.5 mg/dL, mean 2.7 f 1.5 mg/dL), 60% prior Ml and 48% prior 
CABG. Left ventricular ejection fraction was 35 i 13%. Low-osmolar contrast 
material was used in 94%. Angiographic success rate was 100% and pro- 
cedural success 82%. Patients remained in the hospital after the procedure 
for 15.5 & 10.3 days, with 7.3 f 7.0 days in the intensive care unit. During 
hospitalization mortality rate was 25.5%. At one-year follow up, mortality rate 
was 54.6%, Q-wave Ml 16.7% and major adverse cardiac events (MACE) 
(death, Ml and target lesion revascularization), 61.4% (hierarchial). At dis- 
charge 31% of the patients were on dialysis and at one-year follow-up 23% 
remained on dialysis. 
We conclude: Although the likelihood of ARF that requires emergency 
hemodialysis after PCI is low (0.4%), it is associated with: 1) a prohibitive 
in-hospital and one-year mortality 2) a dramatic increase in hospital resource 
utilization and 3) 23% require permanent hemodialysis therapy. 
l--i 1129 76 Catheter Closure of Patent Foramen Ovale: Single Center Experience With the Cardioseal and the 
New Cardioseal-Starflex Occluder 
Horst Sievert, Ulrike Krumsdorf, Kathrin Horvath, Patrick Keppeter, 
Rainer Schader, Andreas Fach, Hanmut Merle, Hans Spies, Detlef Scherer, 
Roland Enssien, Harald Zeplin. Cardiovascular Center Befbanien CCB, 
Frankfurt, Germany 
Background: Catheter closure of patent foramen ovale (PFO) has been 
proposed to prevent recurrent paradoxical embolism. We used the Cardioseal 
and the Cardioseal-Star-flex ASD occluder in this indication. 
Methods: Transcatheter PFO closure was attempted with a Cardioseal 
(n = 22) or a Cardioseal Starflex (n = 3) occluder in 25 patients. The age 
ranged from 26 to 75 years (mean 49 f 14). 41 embolic events occurred in 
these 25 patients prior to PFO closure. The diameter of the PFO, measured 
with a balloon, ranged from 6 to 17 mm. 
Results: The implantation of the device was successful in all patients. The 
device diameter was 17 mm in 7, 23 mm in 15 and 28 mm in 31 patients. The 
procedure could be performed without general anesthesia in 18125 patients. 
Mean X-ray time was 7.5 i 2.4 min. including balloon sizing of the defect. 
Transoesophageal echocardiogram (TOE) showed a small residual shunt 
in 7 Cardioseal patients which persisted in one patient. No complications 
occurred during the procedure. The advantage of the Starflex occluder was 
a better apposition of the arms to the septum. In one Cardioseal patient an 
asymptomatic left sided thrombus was detected on the device by a routine 
TOE. During follow-up of 1 to 21 months (mean 15.7 + 6.4) no further embolic 
events and no complications occurred. 
Conclusion: PFO closure with the Cardioseal and the Cardioseal-Starflex 
ASD occluder is a safe procedure and prevents further i embolic events. 
/ 1129-77 1 Cost Effectiveness of Digital vs. Analogue 
Archiving of Diagnostic Cardiac Catheterization 
Matthew E. Oetgen, Gishel New, Stephen Baiter, Emily J. Lawrence, 
lssam Moussa, Sriram S. lyer, Michael B. Collins, Jeffrey W. Moses. Lenox 
Hill Heart and Vascular Institute, New York, NL: USA 
Background: The utility of digital technology in the cardiac catheterization 
laboratory can range from hospital wide picture archiving systems to merely 
recording individual cases on compact disc (CD). Whether the conversion 
from analogue to digital technology is cost effective is unknown. Therefore, 
the aim of our study was to determine the difference in direct costs of digital 
versus analogue media, for the storage of diagnostic coronary angiograms. 
Methods: The procedural cost of producing a diagnostic angiogram in a 
digital lab (CD) was compared with the procedural costs in a conventional 
lab (cineangiogram), at our institution. We calculated direct costs for all di- 
agnostic coronary angiograms performed by three physicians, between May 
1998 to February 1999, in these two labs (n = 109). The direct procedu- 
ral costs for each case was determined from five economic variables: the 
length of procedure, contrast media used, angiographic equipment, cost of 
recording media, and x-ray imaging equipment. We also calculated the direct 
procedural costs of these cases excluding the recording media costs. 
Results: The costs are shown in the table below. 
Media 
cost 
Included 
Excluded 
Mean Cost in 
Cine Room ($) 
1102 
1079 
Mean Cost in 
CD Room (5) 
1087 
1080 
P-Value 
<O.OOl 
0.931 
Conclusion: This study shows there is a significant procedural cost 
saving in a catheterization laboratory that uses digital CD’s versus cinean- 
giogram. The cost saving is due to the reduced cost associated with the use of 
CD’s as the recording media for diagnostic coronary angiograms. Transition 
from conventional to digital archiving of catheterizations may offer significant 
cost savings in even low volume, cardiac catheterization laboratories. 
1129-78 Telecommunications System to Support 
Percutaneous Coronary Intervention at a Hospital 
Without Cardiac Surgical Services 
Henry H. Ting, Kirk N. Garratt, Jack T. Cusma, Katherine L. Boutchee, 
Joseph A. Dearani, Douglas L. Wood, David R. Holmes Jr.. Mayo Clinic, 
Rochester, MN, USA 
Background: Percutaneous coronary intervention (PCI) is usually performed 
in hospitals with cardiac surgery services (CSS). With careful patient and 
lesion type selection, urgent cardiac surgery is needed in <I .O% patients in 
the current era. We sought to examine the safety and success of PCI at a 
hospital without on-site CSS. 
Methods: lmmanuel St. Joseph’s Hospital (ISJ), Mankato, MN has a fully 
equipped cardiac catheterization laboratory, but does not possess on-site 
CSS. ISJ is located 85 miles from the nearest tertiary medical center with 
CSS, St. Mary’s Hospital (SMH), Rochester, MN. To facilitate PCI locally, ISJ 
was connected to SMH via a dedicated T3 fiberoptic line having a maximal 
data transfer rate of 45 megabits per second. Digital angiographic images, 
hemodynamic data, intravascular ultrasound images, and video images of 
the ISJ laboratory were transmitted real-time during PCI procedures to SMH 
via the T3 line. 
Results: Elective patients classified as low clinical risk and possessing 
type A and Bl lesion characteristics were eligible for PCI at ISJ. In the first 
5 months, 30 patients underwent PCI at ISJ with consultative support from 
SMH. All 30 patients underwent successful PCI procedures. There were no 
in-hospital complications including death, myocardial infarction, or urgent 
revascularization. One patient developed an expanding hematoma treated 
conservatively and did not require vascular surgical repair. Glycoprotein 
2b/3a inhibitors were used in 26 (87%), intravascular ultrasound in 6 (20%) 
and fractional flow reserve in 4 (13%) of the cases. At 30 days follow-up, 1 
patient underwent surgical revascularization and 1 patient underwent PCI for 
an unrelated vessel. 
Conclusion: Elective PCI can be performed safely and successfully at a 
hospital without on-site CSS utilizing a dedicated, high-resolution telecom- 
munications system to provide consultative support. Further study is needed 
to define the potential of this system to expand PCI to hospitals without 
on-site CSS. 
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I 1129 79 A Randomized Controlled Trial of Groin Shielding During Catheter Ablation and Cardiac 
Catheterization 
Alan Kadish, Annie Palmer, Zachary Yablon, Andi Schaechter, 
Jeffrey Goldberger, George Horvath, Rod Passman, Charles Davidson. 
Northwestern Universit)! Chicago, Illinois, USA 
Groin shielding typically used in selected patients during cardiac catheter- 
ization to decrease gonadal radiation exposure. However, data supporting 
decreased radiation exposure are lacking and concerns regarding peri-shield 
scatter exist. In 47 patients undergoing catheter ablation (n = 15) or cardiac 
catheterization and/or angioplasty (n = 29) patients were randomized to 
groin shielding (n = 24) or no groin shielding (n = 23) during the proce- 
dure. The mean total fluoroscopy time for the procedure was 20.02 f 18.4 
minutes. Mean patient age was 54 + 14 years. There were 32 men. Ra- 
diation exposure was corrected for fluoroscopy time and values below are 
shown millirems per minute (mRem/min) of flourosopy time. There was no 
significant difference in back radiation exposure between patients with and 
without the shield (1127 f 2585 mRem/min) with shield vs. 916 f 1608) 
mRem/min in unshielded patients. Gonadal radiation exposure was low with 
or without shield (1.9 f 3.3 mRem/min), (2.3 f 3.7 mRem/min). Radiation 
exposure on the leg just below the groin shield was also low both with and 
without the shield (6.1 f 1.6 in patients who were unshielded and 3.0 f 10.1 
mRem/min patients with shielding). Radiation exposure just cranial to the 
shield was similar in patients with (1.1 * 2.5 mRem/min) and without (0.6 f 
2.1 mRem/min) groin shielding. 
In summary, although groin shielding does not increase radiation exposure 
due to radiation scatter, there is no systematic decrease in gonadal radiation 
exposure with the use of shielding. Radiation exposure to the gonadal region 
during cardiac catheterization is without shielding. Thus, groin shielding while 
not deleterious, does not confer any clinical benefit. 
1 1129-80 1 Patient Radiation Exposure Related To Complexity 
of Coronary Interventional Procedures 
Jacob Federman, Jack T. Cusma, David R. Holmes. Mayo Clinic, 
Rochester, Minnesota, USA 
Background: Increased complexity of coronary interventional procedures 
(Cl) may lead to increased patient (Pt) X-ray exposure, particularly if multiple 
procedures are required. Our aim was to assess the current Pt radiation 
exposure related to procedural complexity. 
Methods: The radiation exposure of 245 Pts having 253 Cl over an 8 week 
period commencing Dee 98 was monitored using a Pt Exposure Monitoring 
Network (PEMNET) System. Procedures were assessed for complexity re- 
lated to lesion factors (site, severity, number, calcification, thrombus) and 
procedural factors (coronary angioplasty (PTCA), 1” or 2” stent, rotablator 
or complications). Procedures were given an overall grade of 1-3 related to 
their complexity. 
Results: 
Cl 
NO 
FlUOr 
(min) 
Cine 
(min) 
Total Dose 
Rad (R) 
P Value 
All Cl 253 
PTCAalone 26 
Coronaly stents 214 
1 stent 116 
2 stents 72 
?3 stents 26 
I’stenting only 68 
Z’stenting only 117 
Rotablator 26 
Grade 1 70 
Grade 2 127 
Grade 3 56 
21.6+ 14.5 
19.7 i 14.0 
21.3 * 14.4 
17.4 i 12.6 
24.2f 13.8 
31.0 i 17.0 
13.7 * 8.3 
24.6zt 16.1 
31.5zk 16.5 
11.7zt6.5 
20.5 i 10.8 
36.6 f 17.1 
1.2ztO.6 
l.OiO.4 
1.31.0.6 
1.2 ~6 0.6 
1.31kO.6 
1.7&0.6 
1 .o i 0.5 
1.3f0.6 
1.1 it 0.6 
0.9 * 0.4 
1.3 i 0.5 
1.5zto.7 
343.3i216.3 
361.2& 204.2 
339.7 i 221 .l 
274.2 zk 216.6 
392.6 k 187.7* 0.0001 
465.5 4~ 225.2" 0.06 
233.7f 141.5* <0.0001 
376.6 + 246.2 
386.9zk 191.7 
204.4& 115.8 
337.3 & 52.1* 10.0001 
530.4 * 290.9* <0.0001 
Exposure was particularly high for bifurcation lesions (n = 11) and total 
occlusions (n = 39) with radiation dosage being 613.8 + 258.5 (p = 0.001) 
and 469.0 & 308.39 (p = 0.018) respectively. Lesion calcification (n = 19) 
or presence of thrombus (n = 65) did not significantly increase radiation 
exposure. 
Conclusion: Pt radiation exposure is significantly increased in long com- 
plex interventional procedures; close monitoring of fluoroscopy (Fluoro) and 
tine time is critical to prevent potential radiation complications. 
)_I i i 29 81 Scanning-Beam Digital X-Ray System Significantly Reduces X-Ray Exposure for Cardiac 
Angiography 
Michael S. Van Lysel, Matthew R. Wolff, Timothy E. Tanke, Michael 
A. Speidel, Timothy D. Betts, Joseph A. Heanue, Brian P. Wilfley, 
Jerry Pretti. University of Wisconsin, Madison, WI; Cardiac Mariners, Inc., 
Los Gatos, CA, USA 
Background: As fluoroscopically-guided interventional procedures become 
more prevalent and more complex, the high x-ray exposure delivered to both 
the patient and the medical staff is of increasing concern. 
Methods: A prototype scanning-beam digital x-ray (SBDX) system has 
been constructed and is being tested. SBDX uses an electronically scanned 
x-ray source, producing a narrow x-ray beam which scans the patient at up 
to 30 frames/set. Transmitted x-rays are detected by a 5.4~cm x 5.4-cm 
solid-state, direct-conversion, photon-counting device. The goal of SBDX is 
to provide equivalent image quality as conventional image intensifier based 
cardiac angiographic systems at substantially lower x-ray exposure. Ten 
patients were imaged with SBDX after the conclusion of their diagnostic 
examinations on a conventional image intensifier based system. 
Results: Patient entrance exposure with SBDX averaged 7.5 times lower 
than with the conventional system. Models attribute 4x of this reduction to 
the exposure-saving design of the SBDX system. The remainder is attributed 
to limited x-ray output of the prototype x-ray source. Efforts are underway 
to boost both source output and detector efficiency. Increased detector effi- 
ciency will result in further exposure-savings. 
Conclusion: SBDX technology promises to significantly reduce the x-ray 
exposure required for fluoroscopically-guided interventional procedures. 
( 1129-82 1 Revascularization of the Internal Mammary Artery 
Graft: In-Hospital and One-Year Outcomes 
Luis Gruberg, Roxana Mehran, George Dangas, Mun K. Hong, Alexandra 
J. Lansky, Gary S. Mintz, Ron Waksman, Ran Kornowski, Kenneth M. Kent, 
August0 D. Pichard, Lowell F. Satler, Gregg W. Stone, Martin B. Leon. 
Washington Hospifal Center, Washington, D.C., USA 
Background: Due to the increased use of the internal mammary artery (IMA) 
as the conduit of choice for coronary artery bypass surgery (CABG), there is 
a growing need for percutaneous revascularization of this artery. 
Methods: We analyzed the clinical and angiographic characteristics, as 
well as the in-hospital and one-year outcomes of 207 consecutive patients 
who underwent percutaneous revascularization of the IMA. 
Results: Mean age was 64 f 10 years (range 36-91) 69% male, 33% 
diabetics, 60% with prior Ml, and 27% with peripheral vascular disease. Left 
ventricle ejection fraction was 42 f 13%. 63% of the lesions were located at 
the anastomosis site, 30% at the shaft and 7% at the IMA ostium. Procedural 
success was 97% (unable to cross or deliver the device in 3%); By quantitative 
coronary angiography, the reference vessel diameter was 2.1 f 0.6 mm, the 
pre-intervention minimal lumen diameter (MLD) was 0.68 f 0.52 mm, and 
the final MLD was 1.66 f 0.62 mm (p < 0.001 vs. pre-intervention). 
Clinical outcomes: 
Death 
In-Hospital 
1 .O% 
One-Year 
4.3% 
Q-wave myocardial infarction (MI) 
NonQ-waveMI 
Emergent or urgent CABG 
Target lesion revascularization (TLR) 
DeathlMIITLR 
0 0.5% 
11.1% 1 .4% 
1 .O% 0 
5.3% 10.1% 
1.9% 14.5% 
Conclusions: Revascularization of the IMA graft can be performed with 
high procedural success and a low rate of major in-hospital complications. 
At one-year follow-up, clinical event rates are low despite a small vessel size 
of the IMA. 
L--.-l 1129 83 Lack of Correlation Between Angiographic 
Collateral Grading and Myocardial Perfusion and 
Function: Implications for the Assessment of 
Angiogenic Response 
Shmuel Fuchs, Matie Shou, Richard Baffour, Anthony Pierre, Martin 
B. Leon, Stephen E. Epstein, Ran Kornowski. The Cardiovascular Research 
Foundation, Washington Hospital Center, Washington, D.C., USA 
Background: Angiographically apparent collaterals (AAC) have been pro- 
posed to reflect angiogenic response that may enhance myocardial perfusion 
and function in ischemic myocardium. The relationship between AAC with 
quantified myocardial blood flow and regional contractility in chronic ischemic 
myocardium has not been well established. We studied those relationships 
in a pig model of chronic myocardial ischemia. 
JACC February 2000 ABSTRACTS - ACCIS2000 55A 
Methods: Angiographic collateral assessment (visually graded as 0 to 
3) was performed Q4 weeks following ameroid placement around the left 
circumflex artery in pigs (n = 27). Fluorescent microspheres (4 x 1 O6) injected 
into the left atrium were used to quantify regional endocardial, epicardial, and 
transmural myocardial blood flow (MBF) and echocardiography was used to 
assess % regional myocardial thickening (%MT) at rest and stress (pacing 
Q 180 beats/min) in the collateral dependent (LCx artery) region. 
Results: No significant correlation was found between endocardial, epi- 
cardial or transmural MBF and AAC grading (Table). MBF but not AAC 
significantly correlated with % MT @rest according to the formula: 
% MT = 0.06 + 0.42 x MBFtransmuial (r = 0.39, p = 0.047). 
Collateral Grade (#animals) o-1 (12) 2 (8) 3 (14) P 
MBF @test (ml/gm/min) 
Endocardial 0.48 i 0.13 0.49 i 0.12 0.53 + 0.15 0.74 
Epicardial 0.52 i 0.10 0.50 5 0.09 0.53 * 0.10 0.78 
Transmural 0.50f 0.11 0.49 * 0.10 0.53 * 0.12 0.83 
MT (%) 
Rest 24.7 i 5.2 26.6i 15.4 27.6i 13.2 0.77 
Paced 20.0 + 11.0 12.4 i 16.0 12.6 * 11.4 0.35 
Conclusions: Visual angiographic assessment of collateral vessels may 
not correlate with myocardial perfusion and function. Thus, AAC assessment 
should not be considered as a primary endpoint in clinical studies designed 
to enhance myocardial perfusion in ischemic regions. 
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1130-84 Evolving Patterns of Coronary Stenting: Report 
from a Large National Database 
Sameer Mehta, Richard R. Heuser, Salvatore L. Battaglia, April W. Simon, 
Steven D. Culler, Edmund R. Becker. Columbia HCA, Nashville, TN; Emory 
Universify, Atlanta, Georgia, USA 
Background: In recent years, there has been significant evolvement in the 
practice of coronary stenting. Our purpose is to highlight key changes and 
improvements in stent practice in 70 catheterization laboratories over an 
eighteen-month period using the Operational Effectiveness Program (OEP’“) 
reporting system. 
Methods: 21 ,I 66 consecutive stent patients were analyzed for the pe- 
riod July 1997 thru December 1998. Twelve indices of stent activities were 
examined (although all indices are not reported because of space limitations). 
Results: As shown in the table, procedures times and total times have 
dropped 14 and 16 minutes over the study period (p < 0.05). Devices per 
patient have dropped by half a device per patient (p < 0.05). The proportion 
of patients experiencing an abrupt closure or an emergency CABG has been 
cut in half (p < 0.01). Stent success rates, stents per vessel, stents per 
patient, total direct variable costs, and mortality rates have all remained 
stable over the study period. 
Q3-97 Q4-97 Qi-98 Q2-98 (13.98 Q4-98 
Proc Time 82 80 72 70 70 67 
Total Time 
Device/Pat 
Total Cost 
Abrt Closure 
Emrg CABG 
Mortality 
124 123 114 110 109 107 
6.4 6.5 6.1 6.1 6.0 5.9 
$3637 $3940 $3764 $3799 $3690 $3724 
1 .O% 1.2% 1 .O% 0.8% 0.5% 0.4% 
0.7% 0.7% 0.6% 0.5% 0.5% 0.4% 
0.1% 0.2% 0.1% 0.1% 0.1% 0.1% 
Conclusion: Stent use patterns demonstrate significant reductions for 
procedure times and major complications. Monitoring process measures is a 
critical aspect of maintaining and improving cath lab quality. 
m Designs in 966 Stenoses 
1130-85 Randomized Comparison of 4 Different Stent 
Peter B. Sick, Gunar Zindler, Rainer J. Zotz, Hans Krankenberg, Klaus 
W. Diederich, Bernward Lauer, Rainer Hambrecht, Oana Brosteanu’ , 
Gerhard Schuler. University of Leipzig, Heart Center; ’ lnsfifufe for Medical 
Inform&s, Statistics and Epidemiology; Leipzig, Germany 
Background: Primary success rate, incidence of early complications (stem 
loss, myocardial infarctions (Ml), CABG, death, stent thrombosis) and long 
term results may be influenced by stent design. 
Methods: In a prospective randomized trial four different stent designs 
(Micro II, AVE: Sito, Sitomed; Pura vario (PuVa), Devon Medical; Inflow. 
Inflow Dynamics) were compared in 966 treated stenoses of 926 patients 
with respect to primary success rate, incidence of complications and an- 
giographical long term results after 6 months. A total of 1302 stents were 
implanted. The Micro stent arm had to be closed earlier, as stent produc- 
tion was stopped. Increase of %-stenosis and restenosis rate was analyzed 
by quantitative coronary angiography (QCA) after stent implantation and at 
follow up. 
Results: 
treated stenoses 
primary success rate 
stent loss rate 
stent thrombosis 
MI, CABG 
Death 
A% stenosis[median] 
restenosis rate 
Micro Sit0 PuVa Inflow P 
177 259 263 267 
98.9 98.1 96.2 95.5 0.12 
0 0.8 0 1.9 0.04 
0 1.5 1.9 1.1 0.30 
0 0.6 1.1 1.8 0.32 
1.2 0.4 2.6 2.6 0.13 
32.6 28.8 29.9 26.9 0.42 
27.1 30.5 33.8 29.4 0.55 
Conclusion: Stent design seems to have no relevant influence on de- 
velopment of in stent restenosis, primary success rate and periinterventional 
complications like stent thrombosis, Ml and emergency CABG. Stent loss 
rate. however, was significantly lower with the premounted stent system 
(Micro Stent) as compared with hand crimped slotted tube stents. 
1130-86 A Less Favorable Long-Term Clinical Outcome in 
Diabetics Persists Despite Treatment With 
lntracoronary Stents 
Aurea Chaves, Luiz Mattos, lbraim Pinto, Alexandre Abizaid, 
Andrea Abizaid, Faust0 Feres, Marinella Centernero, Luiz Tanajura, 
Angela Paes, Amanda Sousa, J. Eduardo Sousa. lnstifufo Danfe 
Pazzanese de Cardiologia, Slo faulo, Brazil 
Background: There is controversy regarding the results of intracoronary 
stenting in diabetic pts. 
Methods: We analyzed the event-flee survival (freedom from death, Ml or 
any repeat revascularization) following coronary stenting of 1756 consecutive 
pts, comparing diabetics (n = 321) with non-diabetics (n = 1435). Clinical FU 
was obtained in 86% of the pts at 21 & 13 months. Interventions for acute Ml 
(~7 days) were the only exclusion criteria. 
Results: Diabetics were older (61 f 10 vs. 58 i 11 years, p x O.OOl), 
more often female (32 vs. 23%, p = 0.002) and hypertensive (64 vs. 54%, p 
= 0.002). History of smoking was less frequent in diabetic pts (52 vs. 66%, p 
< 0.001). The incidence of unstable angina showed no difference between 
groups (51 vs. 46%). Multivessel disease occurred more often in diabetics 
(31 vs. 22%, p = 0.003), but the frequency of LVEF < 50% was similar (39 vs. 
39%). There was no difference on the incidence of ACC/AHA B2/C lesions 
(63 vs. 58%). Quantitative angiography showed a smaller vessel size (3.10 
h 0.4 vs. 3.17 + 0.4 nun, p = 0.03), final MLD (3.08 i 0.6 vs. 3.17 * 0.4 
mm, p = 0.003) and final % DS (4 f 6 vs. 5 f 12%, p = 0.03) in diabetics. 
Procedural success (95 vs. 97%, p = 0.10) and in-hospital MACE (4.0 vs. 
2.3%, p = 0.11) were similar in both groups. At the long-term FU target lesion 
revascularization was significantly higher among diabetics (19.0 vs. 13.2%, 
p = 0.015). The event-flee survival is presented in the graph. 
-x- NM-Dtabctks * 
1 
*lJhb&x ! 
p < 0,001 Lb% 
I 
months 0 
I w 10 P a m 83 
Conclusion: Coronary stenting in diabetics resulted in equivalent in-hos- 
pital outcome when compared to non-diabetics; however the long-term FU 
was characterized by a higher incidence of death, myocardial infarction and 
repeat revascularization procedures. 
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l---L- 1130 87 Stent Implantation in Proximal Left Anterior Descending Coronary Disease is Associated With 
improved 30-day, 1 and 3-Year Outcomes 
James L. Velianou, Charanjit S. Rihal, Diane E. Grill, David R. Holmes Jr. 
Mayo Clinic, Rochester. MN, USA 
Background: Patients with proximal LAD coronary disease have an in- 
creased morbidity and mortality. The long-term role of stents in this group 
remains poorly defined. 
Methods: We performed an analysis of the Mayo Clinic PTCA registry 
for ail patients (n = 948) who underwent PTCA with stent or PTCA alone for 
treatment of proximal LAD disease, from 1979-98 and compared outcomes 
at 30-days, 1 and 3-years. Patients with AMI were excluded. 
Results: Patients were well matched. The stent group had a higher 
procedural success rate (96.4% vs. 82.6%, p < 0.001). Stent use was 
associated with a significant decrease in adjusted relative risk for MACE of 
0.68 (95% Cl 0.53-0.88). See table for results. 
EndDoint stent In = 280) PTCA alone (n = 668) D 
11130-891 Small Vessel Stenting - Comparison of Modular 
vs Slotted Tube Design. Six Month Results From 
the EXTRA Trial 
Ronald P. Caputo, Alessandro Giambartolomei, Alan Simon?,, Paolo Esente, 
Dean Keriakes, Kalon Ho, Joseph P. Carrozza. St. Joseph’s Hospital, 
Syracuse N. Y: Beth Israel Hospital, Boston, USA 
Background: A slotted tube stent design has been shown to provide superior 
outcomes compared to a coil design, especially in smaller vessels. In order 
to determine the effect of modular stent design, we compared the results 
of stenting vessels < 3.0 mm diameter in patients randomized to either 
Palmaz-Schatz (PS) or the modular XT stent in the EXTRA trial. 
Results: Baseline clinical and angiographic variables were similar be- 
tween groups. Mean reference vessel diameter (2.66 f 0.27 mm vs. 2.66 f 
0.24 mm; p = NS), device success, acute angiographic results and in-hospital 
outcomes were similar. Combined 180 day outcomes are shown. 
x-r PS P 
In= 17RI ,n=,snr 
30-day 
Repeat Procedure % 
CABG % 
Death % 
Freedom from MACE % 
I-year 
Repeat Procedure % 
CABG % 
Death % 
Freedom from MACE % 
3.year 
Repeat Procedure % 
CABG % 
Death % 
Freedom from MACE % 
2.8 5.1 0.27 
1.9 9.2 10.001 
1.6 1.8 0.89 
91.2 82.5 0.004 
15.3 20.3 0.27 
8.2 18.4 co.oo1 
4.6 5.7 0.89 
71.8 59.9 0.004 
26.2 24.3 0.27 
10.8 22.4 10.001 
9.6 8.7 0.89 
57.9 52.7 0.004 
MACE 32 (18%) 19 (11.9%) NS 
Death 5 (2.8%) 2 (11.9%) NS 
Total MI 14 (7.9%) 5 (3.1%) 0.09 
Q MI 9 (5.1%) 0 0.004 
TLR 21 (11.8%) 13 (8.1%) NS 
LosslndexRatio 0.65 ziz 0.45 0.65 + 0.38 NS 
Binary Restenosis 41.3% 32.3% NS 
Conclusions: Angiographic results at 180 days were comparable for 
modular and slotted tube stent designs for vessels < 3.0 mm diameter, 
however, a significantly increased incidence of Q wave Ml was noted within 
the modular stent group. The effect of stent design on clinical outcomes 
following small vessel revascularization warrents further investigation. 
Conclusion: Treatment of unselected, prognostically important proximal 
LAD coronary artery disease with stent versus PTCA alone is associated 
with lower rates of MACE, in particular CABG, at 30-days, and 3-years. 
) 1130-88 ( Divergent Effects of “Discretional” vs “Mandated” 
Stenting on Acute Myocardial Infarction Survival 
in Women 
Lorelei L. Grines, David A. Cox, Eulogio Garcia, James D. Johnston, Mark 
A. Turco, Thomas P. Wharton Jr., John J. Griffin, Joseph McGarvey Jr., 
Dawn Shaddinger, Mariann Graham, Judith A. Boura, William W. O’Neill, 
Gregg Stone, Cindy L. Grines. William Beaumont Hospital, Royal Oak, M/, 
USA 
Background: In trials comparing stents to PTCA, “mandated stenting” due 
to the randomization process did not improve 6 month clinical outcomes for 
women. It is unknown whether these results are seen when operators place 
stents at their discretion. 
Methods: To address this issue, we examined 146 females enrolled in 
PAMI No SOS (stents were used at the operator discretion) and 227 Stent 
PAMI women who were randomized to stent vs PTCA (mandated). 
Results: No differences in recurrent Ml or stroke was observed between 
the groups. When mandated stenting was applied to women, there was no 
reduction in ischemia driven TVR at 6 months (11.4 vs 16.8, p = 0.24) and 
mortality was non significantly higher, Conversely, mortality was significantly 
reduced after discretional stenting (table). 
In-hospital 
Death 
6 Month Death 
Mandated (Stent PAMI) 
PTCA stem 
n=113 n=114 
4.4% 7.0% 
5.3% 9.7% 
Discretional (No SOS) 
PTCA Stent 
n = 75 n = 71 
6.7% 1.4% 
10.7% 1.4%* 
*p = 0.02 
Conclusions: Although “mandated stenting” in women did not improve 
outcomes compared to PTCA, stents placed at the operator discretion re- 
sulted in lower mortality. These data suggest that when the operator is able 
to use his/her judgement, they are able to select women who are unlikely to 
1130-90 Comparison of Intravascular Ultrasound Guided 
‘Stent Like’ Optimal Balloon Angioplasty and 
Stenting: Immediate and One Year Clinical 
Outcomes 
Javed M. Ahmed, Sarah Pollard, Paul N. Silverton, Alex V. Zezulka, M. 
Wazir Baig, John Bowles, David C. Cumberland. Northern General Hospital 
Sheffield, UK 
Backgroulid: Previous reports have shown that optimal stent deployment 
using intravascular ultrasound (h/US) guidance results in favorable long-term 
outcomes. We tested the hypothesis whether in the era of stenting IVUS 
guided ‘stent like’ optimal balloon angioplasty (OBA) would have comparable 
clinical outcomes. 
Methods: We prospectively studied 75 patients: 35 treated with OBA 
and 40 received stents. IVUS was performed at baseline, post intervention 
and @one year follow-up. Balloon size selection under IVUS guidance was 
based on the average of the vessel diameter of the proximal and distal 
reference segments in both groups, OBA result was considered when the 
final lesion lumen cross-sectional area (GSA) by IVUS was more than 80% 
of the reference vessel CSA, residual angiographic stenosis < 30% and 
non-flow limiting dissections. 
Results: Both groups had similar baseline clinical and lesion character- 
istics including QCA reference vessel diameter (3.2 f 0.7 mm vs 3.3 f 0.9 
mm, p = 0.3) and lesion length (9.9 i 4.7 mm vs 10.1 f 4.7 mm, p = 0.8). 
Final IVUS lumen CSA in OBA group was 6.2 rt 1.3 mm2 and in the stent 
group was 7.7 & 1.2 mm2 (p = 0.02). OBA criteria was achieved in 65.7% of 
the patients. 
‘Stent Like’ stsnt P 
OBA 
In-hospital complications (%) 0.2 0.4 NS 
TLR at one ye& (%) 15.0 14.2 NS 
MACE at one year (%) 1.0 1.2 NS 
MACE = death, Q-wave MI, CABG;TLR = target lesion revascularization 
Conclusion: IVUS guided ‘stent like’ optimal BA compared with IVUS 
guided stenting in larger vessels (23 mm) with shorter lesions (<I5 mm) has 
similar rates of TLR and MACE at one year follow-up. 
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/ 1130 91 Influence of Diabetes Mellitus on Initial and Long-Term Outcome of Stented Patients With 
Mult?vessel Coronary Disease 
Joaquin J. Alonso, Juan M. Durin, Federico Gimeno, Benign0 Ramos, 
Juan C. MuRoz, Jo& Bermejo, Emilio Garcia-Morgn, Olga Sanz, 
Javier Paniagua, Francisco FernBndez-AvilBs. Hospital Universifario, 
W/ado/id, Spain 
Background: The objective of this study was to assess the influence of 
diabetes mellitus (DM) on restenosis and long-term prognosis after coronary 
stenting (CS) of pts with multivessel disease. 
Methods: We compared the clinical and angiographic evolution of 94 
multivessel pts with DM versus 489 non-diabetic pts. Diabetics were older 
(64 j; 8 vs 62 f IO yr, p < 0.01) and had more number of diseased vessel 
(2.5 * 0.5 vs 2.3 + 0.5, p < 0.05) and a higher rate of female gender (23 
vs 13%, p < 0.001), hypertension (51 vs 40%, p = 0.01) and previous heart 
failure (14 vs 6%, p < 0.01). No other clinical or angiographic differences 
were found. Clinical follow-up (FU) was completed for 94% of pts at 33 + 18 
months. 
Results: Coronary stenting was the only revascularization method in 
70% of pts, whereas additional ballooning was required in 30% of pts, with- 
out differences between diabetic and non-diabetics. Initial clinical success 
(absence of death, AMI, new revascularization or hospital admission due to 
angina at 30 days) was similar in both groups (87 vs 87%, p = NS). Likewise, 
diabetics and non-diabetics had similar long-term survival (84.5 vs 86.4%, p 
= NS). Nevertheless, diabetics had a higher rate of restenosis and events 
during FU (figures). 
Conclusions: Thus CS provides similar procedural result and initial out- 
come in diabetic and non-diabetic pts with multivessel disease. In terms of 
mortality, late prognosis is also similar. However, events during FU are more 
frequent among diabetics. 
11130-92 1 Autologous Venous and Arterial Graft-Covered 
Stents in Porcine Coronary Arteries: Is 
Hyperplasia a Common Process? 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, 
Dorothea Tsekoura, Lubna Khaldi, Antonios Doufas, 
Konstantinos Tentolouris, Pavlos Toutouzas. Hippokration Hospital, 
University of Athens, Greece 
Background: lntimal cell proliferation after stent implantation plays a role 
in the formation of the neointima. However, limited information exists re- 
garding cell type and cellular proliferation within the arterial wail following 
stem implantation. The aim of this study was to characterize the proliferation 
and cell types using immunohistochemicai and histological methods after 
conventional stent implantation or covered stents by autologous vascular 
grtifts. 
Methods: Fifteen swines were studied (20-25 kg). A 3-4 cm graft was 
harvested from the porcine femoral artery or cephalic vein. These grafts 
were used for coverage of conventional stents. Ten arterial- (AC) and 10 
venous-covered (VC) stents were implanted. Also, IO conventional stents 
were placed, serving as a control group. After 1 month, all stented arterial 
segments were removed, and stained using antibodies against PCNA and 
a-actin. Additional sections were stained with Hematoxylin-Eosin and Elastica 
van Giesson staining. 
Results: Covered stents had a trend to reduce maximal intimal thickness 
(AC:112.2 i 43.6; VC:119.5 ZIY 35.5; control:158.3 f 48.3 km, p < 0.07). 
Abundance of PCNA was expressed in the media and intima of the control 
segments coinciding with a-actin. In AC stents atrophy of the media was 
detected, and PCNA positive cells were detected in the autologous arterial 
graft and in the intimal layer but not in the arterial media. These cells were 
also stained with a-actin. In VC stents, PCNA positive ceils were found in the 
venous graft and in the intimal layer but not in the media. 
VCIAClControl SMA (%) PCNA (%) 
Media 
Graft 
lntima 
30”/90/90 20”/70/80 
40/i o* 4011 o* 
9019Ol90 90/90/90 
However, these positive PCNA cells in the venous graft were not stained 
by a-actin. 
Conclusion: The origin of the proliferating cells seems to differentiate be- 
tween conventional uncovered, AC and VC stents indicating different patho- 
physiologic mechanisms of intimal hyperplasia. 
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1 1131-I 15 / Six Months Follow-Up of Circulating Basic 
Fibroblast Growth Factor in Patients With 
Coronary Artery Disease Undergoing 
Percutaneous Transluminal Coronary 
Angioplasty 
Anastasia A. Katinioti, Emanuel V. Economou, Christodoulos I. Stefanadis, 
Christos P. Pitsavos, Athanasios G. Trikas, Marina G. Toutouza, 
Konstantinos I. Kapetanios, Pavlos K. Toutouzas. Dept. Cardiology Univ. 
Athens, Hippokration Hospital, Athens, Greece 
Background: Basic fibroblast growth factor (bFGF) has recently become of 
major importance because it can induce coronary artery neovascularization. 
Aim of this study was to evaluate the significance of circulating bFGF in 
patients (pts) with coronary artery disease (CAD) undergoing percutaneous 
transluminal coronary angioplasty (PTCA) in a six months follow-up. 
Methods: Twenty nine consecutive pts with CAD referred for an ini- 
tial elective PTCA and obtained primary success (<IO% residual diameter 
stenosis). Twenty CAD pts who underwent elective coronary angiography 
without PTCA (CA) and 20 healthy subjects (HS) served as controls. Pe- 
ripheral blood was sampled on the morning of PTCA or CA and at 24 hours 
(h) after PTCA or CA, as well as 3 months (m) and 6 m after PTCA and 
was evaluated for plasma levels of bFGF (measured by ELISA). In CAD 
pts undergoing PTCA, before the procedure, bFGF plasma levels (2.6 + 
0.8 pgiml) were similar to those of CA pts before the respective procedure 
(2.4 * 0.5 pg/mL) but significanty higher compared to those of HS (0.7 f 
0.2 pg/mL, p < 0.002). Significant positive relation (F-ratio = 0.478, p x 
0.003) was noticed between those levels and the extent of CAD, defined as 
the number of vessels with a >50% diameter stenosis. In PTCA pts, bFGF 
plasma levels gradually decreased to 1.6 f 0.4 pg/mL (p < 0.01) after 24 
h and to 0.9 -f: 0.2 pg/mL (p < O.Ol), after 3 m, in comparison to those 
before PTCA. However, in CA pts, bFGF plasma levels remained, after 24 h, 
similar to those before the procedure (2.5 i 0.5 pg/mL). In PTCA pts, bFGF 
plasma levels rose, although non significantly, to 1.2 f 0.2 pg/mL after 6 m, 
in comparison to those after 3 m. This slight increase was mainly attributed to 
10 PTCA pts who presented excerciseinduced electrocardiographic abnor- 
malities (EIEA), when tested after 6 m, without any other clinical symptom. 
These pts presented, after 6 m, bFGF plasma levels higher, although non 
significantly, than those without EIEA (1.3 f 0.3 vs 1 f 0.2 pg/mL, p = NS). 
Conclusions: bFGF plasma levels are elevated in CAD pts and this may 
reflect an adaptive effort to compensate, probably by inducing coronary artery 
neovascularization, for the reduced coronary circulation. After a primary suc- 
cessful PTCA, bFGF plasma levels gradually decreased to values slightly 
higher than those of HS, since there is no more need for neovascularization 
due to PTCA-mediated coronary revascularization. A slight rebound of bFGF 
plasma levels 6 m after PTCA may be indicative of need for neovascular- 
ization due to progression of CAD. Since elevation of circulating bFGF is 
considered an adaptive mechanism when needs for neovascularization are 
increased, its monitoring may be a useful biochemical indicator for reduction 
of coronary circulation. 
1131-l 16 Induction of Extracellular Matrix Expression in 
the Arterial Wall After the Application of 
Cryotherapy in a Porcine PTCA Model 
Jean-Fran$ois Dotval, Pascale Geoffroy, Martin G. Sirois, 
Jean-Fran$ois Tanguay. Montreal Heart Institute, Montreal, Canada 
Background: The extracellular matrix (ECM) of which collagen is a major 
component, seems to have a role in vascular remodeling and restenosis after 
balloon angioplasty (PTCA). We have shown in previous studies that ctyoap- 
plication post-PTCA, enhances the luminal area and positive remodeling in 
arteries. Therefore, we hypothesized that this technique could modify the 
collagen expression in the arterial wall. 
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Methods: In a porcine model, the femoral arteries underwent a single 
oversized PTCA f cryoapplication. The animals (n = 31) were euthanized at 
various timeframes and the tissues were fixed and red Sirius stained. Each 
segment was illuminated through polarized light. The presence of collagen 
type I (Cl) and Ill (C3) was quantified using a O-4 scoring grade (0 = absence 
of collagen). 
Results: 
lweek 1 month 3 months 6 months 
Cl c3 Cl c3 Cl c3 Cl c3 
PTCA 0.77 1.38 1.07 1.29 1.40 1.60 0.64 1.64 
& 0.17 10.18 *to.13 zt 0.13 zb 0.16 50.16 *to.10 &O.lO 
PTCA+ 1.17 2.17 1.92 2.08 2.10 2.10 1.35 1.90 
CrYO fO.ll * 0.11 4 0.14 f0.14 5 0.18 10.10 zt 0.13 zb 0.12 
P 0.06 0.0001 0.0001 0.0001 0.009 0.02 0.0001 0.1 
Average value with no treatment was 0.67 i 0.19 (Cl) and 1 .OO & 0.12 (C3) 
Conclusion: Cryoapplication increasescollagen I and Ill expression in the 
vessel wall at different timeframes compared to single PTCA alone. There- 
fore, the benefit of cryoapplication in impeding negative vascular remodeling 
appears to be related to ECM modulation post-PTCA injury. 
1131-l 17 Vascular Remodeling Following lntracoronary 
Radiation in the Porcine Model 
Yves Cottin, Balram Bhargava, Yoram Vodovotz, Marc Kollum, 
Han-So0 Kim, Rosanna C. Chan, Ron Waksman. Washington Hospital 
Center, Washington, DC, USA 
Background: lntracoronary Radiation (IR) with doses between lo-25 Gy 
following overstretch balloon injury (BI) has been demonstrated inhibition of 
neointimal proliferation (NP) and arterial constriction in porcine coronaries. 
Methods: To determine the degree of arterial remodeling (AR) following 
IR we evaluated forty-seven juvenile swine (93 coronary arteries) who were 
subjected to BI followed by IR with doses of O-25 Gy of either p or y 
radiation. Two weeks following treatment, the animals were euthanized and 
their arteries subjected to histomorphometric analysis. 
Results: Lower dose of 2.5 Gy was associated with increase in IA. Doses 
between at 7.5-25 Gy were associated with reduction of NF. However, vessel 
area with 25 Gy was smaller than control despite decreased in NP. Medial 
area was unaffected by IR at all doses. 
Luminal lntimal Vessel Adventitial Medial 
Area Area Area Area Area 
(mm’) (IA; mm’) (VA; mm”) (AA; mm*) (MA; mm’) 
Control (n = 12) 4.8 * 0.8 1.1 + 0.3 7.2 f 0.9 2.3 h 0.4 1.4* 0.2 
2.5 Gy(n = 3) 3.5* 1.6 1.4 & 1.0 6.5 zk 1.5 3.3zt1.9 1.3 * 0.7 
5Gy(n=13) 4.5 zt 1.1 0.9 f 0.9 6.7i1.6 2.2 * 1.4 1.2 * 0.5 
7.5 Gy (n = 8) 4.2 It 1.9 0.4 * 0.5* 6.5 + 1.6 3.5 4 1.5 1.3 * 0.4 
15Gy(n=30) 6.0 rt 0.8* 0.2 f 0.1* 7.3 5 0.9 2.1 &0.5X 1.0 i 0.2 
18Gy(n=17) 6.3i l.l* 0.1 f 0.1* 7.9 il.1 2.0 * 0.4* 0.9 i 0.3 
25Gy(n=lO) 4.3 f 1.5 0.2 * 0.4* 5.9 * 1.7* 3.2 i 1.3 l.Of0.3 
*P < 0.05 vs control 
Conclusions: Therapeutic doses of IR reduce IA and AA but do not 
reduce MA. The maximal efficacy of the IR with favorable remodeling and 
maximal decrease of IA is range of 15-18 Gy in this model. 
1 1131-I 18 1 Coronary Artery Endothelial Protection 
Following Local Delivery of 17-Beta Estradiol 
During Balloon Angioplasty: A Potential New 
Pharmacological Approach to Improve 
Long-term Outcome of Angioplasty 
Baskaran Chandrasekar, Stanley Nattel, Jean-Francois Tanguay. Montreal 
Heart Institute, Monfreal, Quebec, Canada 
Background: Endothelial damage occurs following percutaneous translumi- 
nal coronary angioplasty (PTCA). As the endothelium plays a critical role 
in the regulation of structural and functional integrity of coronary arteries, 
restoration of its function is crucial. We studied the effect of locally delivered 
17-beta estradiol (BE) following PTCA on endothelial function. 
Methods and Results: Juvenile farm pigs (8 castrated males, 1 female) 
underwent PTCA of all 3 coronary arteries, following which one artery each 
was randomly assigned to treatment with either 600 &g of BE delivered lo- 
cally (via the InfusaSleeve catheter), vehicle alone, or PTCA only. Cardiac 
catheterization was repeated after 4 weeks. After,selective cannulation of a 
coronary artery, acetylcholine (Ach) was infused in increasing concentrations 
of IO-’ M, 10m6 M, low5 M, and 10m4 M, and angiography was repeated 
after each dose. At 1O-5 M and 10m4 M, arteries treated with PTCA alone 
or vehicle alone demonstrated significant vasoconstriction (p < 0.02, and p 
< 0.0001 respectively), compared to the basal diameter before Ach infusion. 
No vasoconstrictive response to Ach was observed in arteries treated with 
BE. Administration of the endothelium-independent vasodilator nitroglycerin 
dilated the constricted arteries (after 10d4 M Ach, in the PTCA only and vehi- 
cle groups) to their basal diameter. At 4 weeks, immunohistochemistry with 
the lectin Dolichos biflorus agglutinin revealed enhanced reendothelialization 
(p < 0.0005) and immunohistochemistry for endothelial nitric oxide synthase 
(eNOS) demonstrated markedly higher eNOS expression (p < 0.0005) in BE 
treated arteries compared to the other 2 treatment groups. 
Conclusion: Local delivery of BE following PTCA significantly enhances 
reendothelialization and endothelial function, possibly by improving the ex- 
pression of eNOS. Since endothelial dysfunction can promote both resteno- 
sis and coronary spasm, local BE delivery is a promising new approach to 
improving the results after PTCA. 
1 1131-l 19 1 Stent-Based Delivery of Sirolimus for the 
Prevention of Restenosis 
Bruce D. Klugherz, Gerard Llanos’ , Warren Lieuallen’, Greg Kopia’ , 
George Papandreou’ , Pallassana Narayan’ , Tara Levengood, 
Brett Sasseen, Steve Adelmans, Robert Falotico’ , Robert L. Wilensky. 
University of Pennsylvania Health System, Philadelphia, PA; * Wyeth-Ayerst 
Labs, Radnor, PA; ’ Cordis Corporation, Warren, NJ, USA 
Background: Drug-eluting stents represent a promising strategy for local 
vascular therapy. We studied the effects of sirolimus (rapamycin), a cell-cycle 
inhibitor eluted from a polymer-coated stent, on intimal hyperplasia in rabbit 
iliac arteries. 
Methods: Coronary stents were coated with a non-erodable polymer 
incorporating sirolimus and hand-crimped on 3.0 mm angioplasty balloons. 
Via right carotid access, bilateral iliac artery stent implantation was performed 
in New Zealand white rabbits. Animals were randomized to 1 of 4 groups: 
(1) uncoated stent (n = 8); (2) polymer-coated stent (n = 10); (3) low dose 
sirolimus (n = 9); (4) high dose sirolimus (n = IO). Animals were euthanized 
at 28 days. Stented segments were embedded in plastic and analyzed 
morphometrically (IA = intimal area, mms, IT = intimal thickness, microns, % 
AS = % area stenosis, I:M = intimal area/medial area). 
Results: 
Uncoated Coated 
IA 1.20 i 0.07 1.26 * 0.16 
IT 129.50 f 8.34 132.34 & 16.51 
%AS 16.09f 1.12 15.9211.80 
I:M 1.35 * 0.13 1.19~0.18 
*p < 0.01 vs. uncoated,“p < 0.01 vs. coated. 
Lo Sirolimus Hi Sirolimus 
0.92 f 0.14 0.66 i 0.12" 
95.56 zk 14.09 69.14* 12.98* 
11.67* 1.69 8.62 f 1.59" 
1.01 h 0.24 0.54 *0.10*,- 
Conclusion: There was a dose-dependent reduction in intimal hyperpla- 
sia following deployment of the sirolimus-eluting stent in rabbit iliac arteries. 
The polymer coating did not provoke exaggerated intimal formation or local 
inflammation. This study suggests that local vascular therapy for prevent- 
ing restenosis may be accomplished using a polymer-coated stent eluting a 
cell-cycle inhibitor. 
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I 1132 109 Increased Presence of Matrix-Metalloproteinase 3 in Human Coronary Lesions With Positive 
Arterial Remodeling 
Paul Schoenhagen, D. Geoffrey Vince, Khaled Ziada, Tim Crowe, 
Samir Kapadia, Michael Lauer, Steven E. Nissen, E. Murat Tuzcu. The 
Cletieland Clinic Foundation, C/eve/and, Ohio, USA 
Background: Arterial remodeling describes changes in external elastic mem- 
brane (EEM) area in atherosclerosis. Histologic studies have linked matrix- 
metalloproteinases (MMP) to remodeling. We investigated MMP in human 
coronary lesions with positive or negative remodeling. 
Methods: Pre-interventional intravascular ultrasound, images and direc- 
tional atherectomy samples of 25 patients were analyzed. A remodeling ratio 
was calculated as lesional EEM area divided by the proximal reference area. 
Positive and negative remodeling were defined as ratios of >1.05 and cO.95, 
respectively. Using immunostaining, two independent operators classified in- 
tracellular MMP’s 1, 2, 3, 9 as absent to mild vs. moderate to heavy. 
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Results: Positive and negative remodeling was present in 13 and 12 
lesions, respectively. Absent to minimal staining for MMP 1 and MMP 3 was 
evident in 16 and 15 samples, respectively. Moderate to heavy staining for 
MMP 1 and MMP 3 was found in 9 samples each. MMP 2 and 9 were negative 
in all samples. Moderate to heavy staining for MMP 3 was more common 
in lesions with positive than negative remodeling (58% vs. 17%: p = 0.035) 
with no difference in the frequency of moderate to heavy staining for MMP 1 
(30% vs. 41%; p = 0.57). 
Conclusion: In this combined intravascular ultrasound and histologic 
study, increased intracellular MMP 3 was associated with positive arterial 
remodeling. This association suggests a pathophysiologic role of MMP 3 in 
the remodeling process of human coronary atherosclerotic lesions. 
/ 1132-l 10 / Negative Remodeling is an Important 
Determinant of Lumen Compromise in the 
Aortoostial Location: Intravascular Ultrasound 
Analysis of Coronary and Renal Artery 
Atherosclerosis 
George Dangas, Neil J. Weissman, Adrienne Tinana, Nina Goyal, Gary 
S. Mintz, Roxana Mehran, Javed M. Ahmed, Alexandra J. Lansky, John 
R. Laird, Jr., Michael R. Jaff, Ann Greenberg, August0 0. Pichard, Martin 
B. Leon. Washington Hospifai Center, Washington, DC, USA 
We hypothesized that proximity to the aorta would limit the typical positive 
remodeling response of atherosclerotic lesions in both coronary and non- 
coronary arteries. To test this, we studied 44 right coronary artery (RCA) and 
114 renal artery lesions that met the following strict criteria: no significant 
calcium, minimum lumen area within 5 mm of the true aortoostial junction, 
and modest distal reference disease (plaque burden 140%). 
RCA 
Renal 
Arterial area (mm”) 
Lumen area (mm”) 
Plaque area (mm’) 
Plaque burden (%) 
Anerial area (mm”) 
Lumen area (mm”) 
Plaque area (mm*) 
Plaque burden (%) 
Lesion Distal Ref P 
14.5 f 3.8 16.3 i 5.4 0.0248 
3.5 i 1.8 11.3h4.2 <0.0001 
ll.Oi3.7 4.7 i 2.1 <0.0001 
75i12 2817 <0.0001 
12.8 + 11.5 33.2 z!c 13.0 <0.0001 
4.3 + 3.1 26.1 h 9.0 <0.0001 
19.6 zk 4.0 6.8 zk 10.2 <0.0001 
81 fll 22ill <0.0001 
Importantly, 61% of RCA and 96% of renal lesions fit the definition of 
negative remodeling (lesion arterial area <distal reference). This is distinctly 
different from reported series of nonostial coronary lesions in which only 
20-30% exhibit negative remodeling characteristics. 
We conclude: Proximity to the aorta appears to limit positive arterial 
remodeling response of atherosclerotic lesions in both coronary and renal 
arteries. Negative remodeling contributes importantly to lumen compromise 
in this lesion location and may also account for the observed higher restenosis 
frequency. 
/ . 1132 111 Influence of a Change in Gender on Coronary 
Arterial Size. A Longitudinal Intravascular 
Ultrasound Study in Transplant Recipients 
Niall A. Herity, Sidney T. Lo, Michael R. Ward, David P. Lee, Steven 
D. Filardo, Sharon A. Hunt, Paul G. Yock, Peter J. Fitzgerald, Alan 
C. Yeung. Stanford Universitl: Stanford, CA, USA 
Background: Gender differences in coronary artery size, which are inde- 
pendent of body surface area, may explain the unfavorable clinical outcomes 
after coronary surgery and angioplasty in women compared with men. This 
study aimed to examine the relationship between gender and vessel size, by 
measuring temporal changes in coronary arterial vessel area (VA) in hearts 
transplanted across-gender and in hearts transplanted within-gender. 
Methods: In 46 heart transplant recipients, serial intravascular ultrasound 
(IVUS) measurements of the proximal left anterior descending artery (LAD) 
were made immediately post-transplant and at the first annual evaluation 
to assess change over the first post-transplant year. In a separate group of 
49, measurements were made at the first and second annual evaluations 
to assess change over the second post-transplant year. Only disease-free 
segments were considered. 
Results: Baseline LAD VA was similar in men and women. Over the 
first post-transplant year, LAD VA did not change significantly in any group 
(table). However over the second post-transplant year LAD VA increased 
significantly in female hearts transplanted into male recipients and in no 
other group. 
Conclusion: The observed relationship between gender and coronary 
arterial size is likely to be explained by the hormonal and metabolic influences 
of the host environment. 
VA over the first year (n = 46) VA over the second year (n = 49) 
Baseline 1 year P 1 year 2 years P 
F to F 15.41 16.25 0.42 17.29 16.28 0.08 
(3.77) (3.11) (3.17) 
F to M 16.73 17.80 0.15 14.79 
(3.57) (4.36) (2.04) 
M to M 17.15 17.66 0.50 17.41 
(2.91) (2.90) (2.18) 
M to F 16.73 16.58 0.70 16.74 
(3.70) (3.28) (2.01) 
Mean (SD). VA = vessel area in mm’. F = female. M = male. 
(3.73) 
16.56 0.009 
(3.42) 
17.29 0.79 
(2.82) 
17.48 0.74 
(2.63) 
1 1132-l 12 1 Impact of Different Definitions on the 
Interpretation of Coronary Remodeling by 
Intravascular Ultrasound 
Kiyoshi Hibi, Peter J. Fitzgerald, Allen Jeremias, Takeshi Suzuki, 
Yasuhiro Honda, Michael R. Ward, Hiroyuki Okura, Akiko Maehara, Alan 
C. Yeung, Paul G. Yock. Sfanford University Medical Center, Stanford, 
California, USA 
Background: Multiple IVUS studies have demonstrated the importance of 
coronary remodeling, but the actual definitions of remodeling used in these 
studies have differed. The purpose of this investigation was to compare 
the remodeling pattern and predictors of arterial remodeling among the 3 
remodeling definitions most commonly used. 
Methods: 514 lesions in 512 patients with stable or unstable angina un- 
dergoing pre-interventional IVUS in native coronary arteries were studied. 
Vessel area (VA), lumen area (LA), and plaque area (PA) at the lesion site 
(L) and at the proximal (PR) and distal reference site (DR) were measured. 
In method I, positive (pas), intermediate (int), and negative (neg) remodel- 
ing were defined as L-VA/PR-VA of >I .05, ?0.95 and 51.05, and x0.95, 
respectively. In method 2, pos, int, and neg remodeling were considered 
present when L-VA was larger than PR-VA, intermediate between PRVA and 
DR-VA, and smaller than DR-VA, respectively. In method 3, pos and int/neg 
remodeling were defined as L-VA/(average of PR-VA and DR-VA) of >I and 
51, respectively. 
Results: The remodeling distributions were significantly different among 3 
methods (Figure, all P < 0.0001). By multivariate logistic analysis, the clinical 
and IVUS predictors of positive remodeling varied significantly among the 3 
methods (Table). 
Method 1 Method 1 Method 3 
Method 1 
Age 
NS 
Non-talc 
NS 
DR-L4 
<0.0001 
DR.PA 
<0.0001 
L-LA 
NS 
L-PA 
<0.0001 
Method2 NS NS <0.0001 <0.0001 0.0008 <0.0001 
Method 3 0.032 0.023 <0.0001 NS NS <0.0001 
Numbers were P values, NS = not significant. 
Conclusions: This study demonstrates that the definition of remodeling 
chosen has a major impact on the apparent incidence and predictors of 
the remodeling phenomenon. These definition-associated effects should be 
taken into account in evaluating the remodeling pattern by IVUS. 
L-i---l. 1132 113 Lrpoprotein (a): A Predictor of Coronary Artery Remodeling. An Yntravascular Ultrasound Study 
Shigeru Fukuzawa, Shun Ozawa, Juji Sugioka, Kazuhiro Shimada, 
Masayuki Inagaki, Kaoru Tateno, Marehiko Ueda. Funabashi Municipal 
Medical Center, Chiba, Japan 
Background: De novo atherosclerotic remodeling of coronary artery seg- 
ments ranges from compensatory enlargements (CR) to inadequate shrink- 
age (IR). We investigated the hypothesis that serum lipoprotein (a) level may 
influence remodeling patterns. 
Methods: We measured the remodeling by the ratio of total vessel area 
(TVA) at the lesion (L) site to the proximal (P) reference TVA in 88 de 
novo, non-branching, non-ostial lesions on the pre-intervention, 30 MHz 
intravascular ultrasound (IVUS). We also studied serum Lp(a) level and 
coronary risk factors. 
Results: The L-TVA/P-TVA ratio showed a normal distribution (mean 
f SD = 0.92 f 0.18). Lesion with an L-TVA/P-TVA ratio of 21 SD below 
and above the mean were defined as IR (n = 18) and as compensatory 
remodeling (CR) (n = 21) respectively. The IR and CR groups were similar 
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regarding age, sex, diabetes, hypertension, unstable presentation, IVUS 
plaque morphology and calcification. In the CR group, the serum level of 
Lp(a) was higher compared to the IR group, 42.8 f 12.4 mg/dl versus 
18.1 f 14.2 mg/dl (p < 0.05), respectively, while no significant differences 
in remodeling patterns were seen with respect to the serum level of total 
cholesterol or low density lipoprotein. 
Conclusion: The serum level of Lp (a) may influence remodeling patterns 
and may be a good predictor in compensatory vessel enlargement. 
1 1132-l 14 1 The Impact of Remodeling on the Acute Results 
of Saphenous Vein Graft Stent Implantation 
Gary S. Mintz, Myeong-Ki Hong, Mun K. Hong, Chrysoula Pappas, Kenneth 
M. Kent, Martin 8. Leon. Washington Hospital Center, Washington, DC, USA 
We hypothesized that the pattern of SVG lesion remodeling would impact on 
the acute results of stent implantation. Therefore, we categorized remodeling 
in SVG lesions as positive (lesion/mean reference SVG area >I .I, n = 77) 
intermediate (lesion/mean reference SVG area 0.9-l .I, n = 51), and negative 
(lesion/mean reference SVG area cO.9, n = 52) based on pre-intervention 
intravascular ultrasound (IVUS) analysis and compared pre-intervention and 
final IVUS dimensions: 
SVG age <12 mos (%) 
Sent size (mm) 
inflation pressure (atm) 
Mean reference 
SVG area, mm2 
Lumen area, mm* 
Plaque area, mm2 
Lesion 
Pre SVG area, mm* 
Pre lumen area, mm* 
Pre plaque area, mm2 
Arc of calcium (“) 
Final /umen area, m& 
Positive 
0 
3.9 f 0.3 
12.3 + 4.0 
17.3 f 5.5 
10.5 f 3.9 
6.8 rt 2.9 
23.5 5 9.0 
2.9% 1.4 
20.6 -f 8.8 
6+ 18 
9.6& 2.8 
Intermediate 
4 
4.0 i 0.5 
13.0 * 3.6 
17.6 * 5.0 
10.5 zt 2.5 
7.1 * 3.1 
17.6 + 4.9 
2.8 * 1.5 
14.7 i 5.0 
8zk24 
8.6. i 1.8 
Negative P 
12 0.0071 
3.9 + 0.6 0.64 
13.7 + 2.8 0.38 
18.9 i 7.0 0.16 
10.6 f 3.9 0.91 
8.1 zk 4.5 0.12 
13.5 + 5.2 
2.2 h 1.2 
11.2f5.2 
37 + 88 
7.9 i 29 
<0.0001 
0.0163 
<0.0001 
0.0131 
0.0078 
Negative remodeling lesions were more often proximal in location (p = 0.0182). 
We conclude: Remodeling (positive and negative) in SVG lesions is com- 
monly observed and impacts procedural results. Despite similar reference 
dimensions and stenting techniques, final lumen areas depended signifi- 
cantly on pre-intervention remodeling characteristics and were smallest in 
lesions with negative remodeling. 
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870-l Retention of myocardial Injectate After Direct 
Surgical or Catheter-Based Needle Administration 
P. Michael Grossman, Maria Palasis’, James J. Barry’, 
Sanjay Rajagopalan, Robed J. Lederman. University of Michigan Health 
Systems, Ann Arbor, Ml; ‘Boston Scientific Corporation, Nafick, MA, USA 
Background: Direct intramyocardial injection is an attractive strategy for lo- 
cal delivery of protein and gene therapy agents for myocardial and coronary 
artery disease. Little is known about the acute retention of compounds admin- 
istered via percutaneous endomyocardial catheters or via direct epicardial 
injection. 
Methods: Fifteen 4050 kg pigs underwent overlapping myocardial injec- 
tions using a percutaneous endomyocardial catheter (ENDO), an epicardial 
needle via an open. chest (EPI), and epicardial needle post-mortem (POST). 
Multiple distinct 15 p neutron-activated microsphere species were used as 
tracers. Two or three myocardial walls were injected in each animal using 
3 mm 27G needles at varying injectate volumes. Animals were sacrificed 
immediately. Myocardial walls were divided and microspheres quantified. 
Results: Endomyocardial injection was associated with 43 f 15% bead 
retention, compared with 15 f 21% (p .Z 0.01) retention of open-chest 
epicardial injection and 89 & 60% (p i 0.01) for postmortem injection. 
Preliminary data in three animals suggest reducing catheter injectate volume 
from 100 FL to 20 PL may improve bead retention (20 f 32% vs 50 f 58%, 
p = 0.14). 
ENW EP POS, 
Conclusion: (1) Despite direct intramyocardial administration, a signifi- 
cant fraction of injectate is not retained locally. (2) Catheter-based needle 
endomyocardial injection is associated with equivalent or superior injectate 
retention compared with open-chest epicardial injection. (3) Proportionately 
more injectate may be retained at lower volumes. Loss may involve a com- 
bination of channel leakage, venous, and lymphatic return. 
IO:45 a.m. 
870-2 Transendocardial Delivery of Autologous Bone 
Marrow Enhances Collateral Perfusion and Regional 
Function in Pigs With Chronic Experimental 
Myocardial lschemia 
Shmuel Fuchs, Richard Baffour, Marie Shou, Anthony Pierre, Y.F.ihou, Neil 
J. Weissman, Martin B. Leon, Stephen E. Epstein, Ran Kornowski. The 
Cardiovascular Research Foundation, Washington, DC, USA 
Background: The bone marrow (BM) is a natural source of a broad spec- 
trum of cytokines and ceils that are involved in the control of angiogenic 
and inflammatory processes. Angiogenesis involves complex time-critical 
interactions among numerous molecules. We therefore postulated that the 
intramyocardial injection of autologous (A) BM, by taking advantage of the 
natural ability of these cells to secrete many angiogenic factors in a time- 
appropriate manner, would provide an optimal intervention for achieving 
therapeutic angiogenesis in ischemic myocardium. 
Methods: Chronic heart ischemia model was created in 14 SPF York- 
shire pigs by the placement of ameroid constrictors around the proximal left 
circumflex (LCx) coronary artery. Four weeks after implantation, 7 animals 
underwent transendocardial injections of freshly aspirated, heparinized (20 
IUiml) and filtered ABM (2.4 ml per animal, 0.2 ml per injection site x 12 
sites) into the ischemic zone using the Biosense’” transendocardial injection 
catheter. 7 control animals were injected with heparinized saline. At baseline 
and 4 weeks after treatment, all animals underwent 1) rest and pacing (0 180 
b/min) echo to assess regional function, and 2) rest and adenosine stress 
microsphere infusion to assess collateral perfusion. 
Results: Collateral flow, expressed as a ratio of ischemic/normal zone 
perfusion improved in ABM-treated pigs but not in controls Q4 weeks vs 
baseline (ABM: 0.98 f 0.17 vs 0.83 f 0.12 @rest; p = 0.001; 0.89 f 0.18 vs 
0.78 & 0.12 during adenosine, p = 0.025, Controls: 0.92 & 0.10 vs 0.89 f 
0.09 @rest; p = 0.49; 0.78 & 0.11 vs 0.77 i 0.05 during adenosine, p = 0.75). 
Also, regional contractility assessed by echo as % myocardial thickening and 
expressed as % of ischemic/normal zone, increased in ABM-treated pigs but 
not in controls (ABM: 83 f 21 vs 60 f 32 @rest, p = 0.04; 91 f 44 vs 35 f 
43 during pacing, p = 0.056, Controls: 69 f 48 vs 64 f 45 @rest, p = 0.74; 
65 i 56 vs 37 f 56 during pacing, p = 0.23). 
Conclusions: The results indicate that transendocardial injection of ABM 
can augment collateral perfusion and function in ischemic myocardium, find- 
ings suggesting that this approach may.constitute a novel strategy for achiev- 
ing optimal therapeutic angiogenesis. 
II:00 a.m. 
870-S Feasibility of the Percutaneous Coronary Venous 
Approach for Local Drug Delivery to the Myocardium 
Niall A. Herity, Sidney T. Lo, Frederick Oei, David P. Lee, Michael R. Ward, 
Steven D. Filardo, Ali Hassan, Takeshi Suzuki, Paul G. Yock, Alan 
C. Yeung, Peter J. Fitzgerald. Stanford University: Sfanford, CA, USA 
Background: Therapeutic angiogenesis is a promising option for patients 
with refractory angina unsuitable for revascularization, but current deliv- 
ery methods either require open-chest surgery or provide only short-lived, 
transient exposure to growth factors. This study assessed the feasibility of 
percutaneous coronary venous cannulation and selective regional injection 
as a novel approach to local myocardial drug delivery. 
Methods and Results: In 13 anesthetized pigs the coronary sinus was 
cannulated percutaneously and a balloon-tipped catheter was advanced to 
the anterior interventricular vein (AIV) or middle cardiac vein (MCV). During 
balloon occlusion, selective venous injection of radiographic contrast (dia- 
trizoate) caused localized myocardial staining. Videodensitometric analysis 
showed that diatrizoate persisted for at least 30 minutes, with 50% clearance 
over approximately the first 4 minutes (figure). Venous injection of Evans 
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Blue dye showed that localized, regional infiltration was reproducibly ac- 
complished in targeted myocardial regions: the left ventricular apex, anterior 
interventricular septum and anterior wall via the AIV and the inferoposterior 
wall via the MCV. 
100 
Conclusions: The percutaneous coronary venous route is a favorable 
delivery approach for therapeutic angiogenic substances, being reproducibly 
accessible and facilitating selective regional myocardial delivery and persis- 
tence of delivered substances. 
II:15 a.m. 
870-4 Percutaneous Myocardial Revascularization Using a 
Myocardial Channeling Device: First Human 
Experience Using the AngioTrax System 
Fayaz A. Shawl’, Upendra Kaul, Vahid Saadat. Batra Hospital and Medical 
Research Cenfre, New De/hi, India; ’ Washington Adventist Hospital, 
Takoma Park, Maryland, USA 
Background: Percutaneous myocardial revascularization using laser energy 
alleviates angina in inoperable pts with coronary ischemia. However, lasers 
are complex and expensive. We describe the first human experience with a 
mechanical myocardial channeling device. 
Methods and Results: In 7 consecutive inoperable (due to diffuse dis- 
ease) pts (6 men and 1 women, mean age 61 f 7 years) with Class III (n 
= 5) or IV (n = 2) refractory angina, we performed percutaneous myocardial 
revascularization using a 9F percutaneous device that forms channels by 
combined mechanical coring and vacuum tissue extraction (AngioTrax Sys- 
tem). History of prior Ml was present in 4 pts, CABG in 2, 3 vessel CAD in 6, 
2 vessel in 1 and LV ejection fraction of ~25% (mean 47 + 7). An average 
of 9 i- 3 channels (range 5-15) were created in ischemic regions (all had 
thallium perfusion defects in these regions) - inferior wall: 5; anterior: 1; in- 
ferolateral: 1 and posterolateral wall: 1 Endomyocardial tissue was extracted 
as each channel was created. Total procedure time was 31 i 8 min and total 
fluoro time was 12.7 f 5.5 min. Left ventriculography performed before and 
after the procedure demonstrated unchanged or improved wail motion in the 
target region. Histology of core biopsies in all 7 pts demonstrated myocytes 
with focal hypertrophy, myocytolysis, with interstitial scarring in 3, who had 
wall motion abnormalities on left ventriculography. No complications occurred 
(specifically, no CPK-MB elevations) and all pts were discharged within 48 
hours. Follow up exercise thallium perfusion studies will be performed at 1, 
3, and 8 months. Six month follow-up clinical and thallium perfusion data will 
be presented. 
Conclusion: Mechanical percutaneous myocardial revascularization with 
AngioTrax system is safe and feasible and may prove to be an inexpensive 
substitute for laser revascularization. Moreover, left ventricular tissue ob- 
tained may provide diagnostic and therapeutic insights. 
11:30 a.m. 
870-5 Percutaneous In-Situ Coronary Venous 
Arterialization (PICVA) Improves Survival in 
Response to Acute lschemia in the Porcine Model 
Stephen N. Oesterle, Alan C. Yeung, Sidney Lo, Renu Virmani, Richard Van 
Bibber, J. Christopher Flahet-ty, Theodore C. Lamson, Stephen W. Kim, 
John T. Garibotto, Margaret W. Tumas, Josh Makower. Massachusetts 
Genera/ Hospital, Boston, MA; Stanford University Medical Center, Stanford 
CA: Armed Forces Institute of Pathology Washington, D.C.; SNBL USA, 
Inc., Redmond, Washington; TransVascular, Inc., Menlo Park, CA, USA 
Background: We have previously reported on PICVA, a percutaneous tech- 
nique of arterializing a segment of the coronary venous system to retroper- 
fuse an ischemic region of the heart. This is the first study to investigate the 
efficacy of PICVA in an animal model. 
Methods: To model ischemia, a prototype occlusion device was placed 
into the mid Left Anterior Descending Artery (LAD) region in twelve (12) 
50-60 kg Domestic Crossbred Swine. Six (n = 6) of these pigs were simul- 
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taneously treated with an LAD-AIV PICVA procedure and six (n = 6) were 
lefl untreated as a control. The PICVA procedure connecting the proximal 
LAD i to the isolated Anterior Interventricular Vein (AIV) was performed using 
prototype devices developed by TransVascular, Inc. (Menlo Park, CA). Sur- 
vival rate, the site of LAD occlusion, circulating myocardial enzyme levels, 
left ventriculography, EKG, IVUS and angiography were recorded. Measure- 
ments were made at baseline, post-procedure and at 1 week follow-up. All 
surviving animals were sacrificed at one week and the heart and coronary 
vessels were extracted and examined. 
Results: 17% (n = l/6) of the control animals survived to 7 days (five died 
within two hours after LAD occlusion); whereas, 83% (n = 5/6) of the PICVA 
treated animals survived to follow-up at one week. This survival difference 
was statistically significant (p = 0.04) when analyzed using the Fischer Exact 
Test. At follow-up, all surviving PICVA animals (n = 515) had occluded LAD 
vessels, patent LAD-AIV channels and patent AIV grafts with TIMI II (n = 2/5) 
or TIMI III (n = 3/5) flow. Serum levels of Troponin I measured at follow-up 
were 4.7 i 1.3 rig/ml (n = 5) for the PICVA treatment group and 29.7 ngiml 
(n = I) for the single surviving control. One animal (n = l/6) in the treatment 
group died of tamponade, secondan] to a perforation of the Great Cardiac 
Vein (GCV), caused by a defect in one of the prototype devices. Further 
angiographic and IVUS data will be presented. 
Conclusions: PICVA improves survival in the porcine model challenged 
with acute occlusion of the LAD. These data support the potential of the 
PICVA procedure to relieve ischemia in humans. 
11:45 a.m. 
870-6 lntrapericardial Ethanol Delivery Inhibits Neointimal 
Proliferation After Porcine Coronary Overstretch 
Dongming Hou, Alexander E. Marsh, Pamela I. Rogers, Keith L. March. 
lndiana Univ, IN, USA 
Background: Catheter-based approaches to intrapericardial (IPC) delivery 
of therapeutic agents have recently demonstrated to be feasible and well 
tolerated. Previous work has shown that ethanol can dampen cell growth 
signals and inhibit smooth muscle proliferation in restenosis models. This 
study tested the effect of IPC instillation of 30% ethanol on the injury response 
of overstretched porcine coronary arteries. 
Methods: Overstretch injury of porcine coronary arteries (LAD and LCx) 
was performed followed immediately by IPC administration of 30% ethanol 
(E, 10 ml, n = 6) or 0.9% saline as a control (C, 10 ml, n = 6). Animals were 
sacrificed and coronary arteries were perfusion fixed 28 days after balloon 
dilation. Serial sections were evaluated by morphometric analysis. 
Results: Arterial injury indices were no different in the two groups. The 
neointimal and adventitial area were significantly reduced in the ethanol 
group (E, 0.36 i 0.05 mmZ; 1.68 i 0.09 mm”) as compared to the control 
group (C, 0.61 f 0.05 mm*; 2.61 i 0.14 mm’; p < 0.001). The maximal 
intimal and adventitial thickness of the ethanol treated vessels were also 
significantly smaller than saline treated vessels (E, 0.44 f 0.02 and 0.38 i 
0.08 mm vs C, 0.57 f 0.03 and 0.54 i 0.03 mm; p < 0.005). The calculated 
luminal stenosis decreased in the treated group, 16.1%, versus the control 
group, 25.3%. 
Conclusion: IPC delivery of a single-dose of 30% ethanol solution sig- 
nificantly reduces neointimal proliferation in the porcine balloon-overstretch 
model. IPC ethanol delivery may represent a clinically feasible approach to 
reduce restenosis after interventional procedures. 
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1008-l 67 Stenting for Unprotected Left Main Coronary 
Stenosis: Acute and Long-Term Results of the 
First 100 Cases 
Seung-Jung Park, Seong-Wook Park, Cheol Whan Lee, Myeong-Ki Hong, 
Jae-Joong Kim. Department of Medicine, University of U/San, Asan Medical 
Center, Seoul, Korea 
Objectives: The aim of this study was to evaluate the acute and long-term 
results of elective coronary stenting for unprotected left main coronary artery 
(LMCA) stenosis in selected patients with normal left ventricular function. 
Methods and Results: Elective stenting.with (n = 66) or without debulk- 
ing atherectomy (n = 34) was performed in 100 consecutive patients with 
significant LMCA stenosis (men 62, women 37; age 55.3 f 10.2 years) at 
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our institution. Coronary artery lesions were located at the ostium (47%), 
body (15%) and bifurcation sites (38%) of LMCA. Coronary angiography was 
performed at 6-months and clinical evaluation at regular interval. Procedural 
success rate was 99%. Subacute stent thrombosis occurred in 1 patients 
on day 3 after the procedure and treated with repeated intervention. Mean 
follow-up duration was 20.1 * 13.4 months. Four patients died during the 
follow-up (1 in cardiac origin, 3 in non-cardiac origin). Angiographic resteno- 
sis rate (>50% diameter stenosis) was 15.8% (12/76) (11 .I% in debulking 
group vs 18.0% in non-debulking group, p = NS), and target lesion revascu- 
larization rate was 11%. Event-free survival rate (death, myocardial infarc- 
tion, repeat revascularization) was 81.5 f 4.7% at the end of the follow-up 
period. 
Conclusions: Stenting may be a safe and feasible technique for treatment 
of untprotected LMCA stenosis in selected patients, and be associated with 
a favorable long-term clinical outcome. 
12:12 p.m. 
I 1008 168 Intervention of Unprotected Left Main Stenosis 
in High Risk Patients: Acute and Long Term 
Results 
Samin K. Sharma, Annapoorna Kini, David Reich, Tudor Bertea, 
Javed Suleman, Jonathan D. Marmur. Mount Sinai Hospita/, New York, NY 
USA 
Elective stenting of the left main coronary artery (LMCA) with normal left 
ventricular function has been reported to have excellent short and long term 
results, comparable to coronary artery bypass surgery (CABG). Outcome 
of LMCA intervention in patients considered at high risk for CABG due 
to low ejection fraction, comorbid conditions and advanced age, has not 
been published. We report our experience of 72 consecutive patients who 
underwent LMCA intervention, deemed unsuitable for CABG. 
Methods and Results: Mean age was 84 years (range 62-98) 40% fe- 
male and indication for procedure being unstable angina and post Ml in 60%, 
CHF in 25% and both in 15%. Mean LVEF was 32 * 14% (range 11-63%) 
with 42% of patients had LVEF < 25%. Stenosis location was at the ostium in 
25%, in body/distal in 60% and at bifurcation in 15%. All patients underwent 
stenting; 89% after debulking with rotational atherectomy (RA) and 11% had 
stent implantation without debulking. GP Ilb/llla inhibitors were used in 78% 
of cases and elective IABP assistance in 35.5% of cases. Procedural success 
was achieved in all patients without any in-hospital major complications of 
Q-wave MI, CABG or death. Major vascular complications (large hematoma, 
pseudoaneurysm, drop in hemoglobin z 5 gm/L and vascular surgery) oc- 
curred in 3.2%. Mean reference vessel diameter was 3.81 f 0.81 mm with 
MLD pre-procedure 1 .I2 f 0.36 mm, post-debulking 2.11 f 0.26 mm and 
post-procedure 3.67 f 0.52 mm with residual of 8%. Slow flow and minor 
dissection (NHLBI grade < C) occurred in 8% and 13% respectively. Any 
CK-MB elevation occurred in 20.8%, with >5x normal in 2.8%. All patients 
were discharged alive at a mean duration of 6 i 5 days with 30 day MACE 
occurring in 2 patients (3.2%) from non-cardiac cause. At a mean follow-up of 
9 + 3 months there have been 4 additional deaths (2 cardiac, 2 non-cardiac) 
and 5 (8%) clinical restenosis. Freedom from Q-wave MI, repeat intervention 
and death in first 40 patients who have completed at least one year follow-up 
is 82%. Majority (80%) of patients have <Ill CCS class angina. 
Conclusion: Unprotected LMCA stenting with RA in high risk subset of 
patients can be performed with very high procedural success, low in-hospital 
complications and favorable mid term prognosis. The long term follow-up of 
this strategy for left main coronary interventions needs to be determined. 
12:24 p.m. 
I 1008 169 The Use of IVUS-Guided PTCA and Spot 
Stenting for the Treatment of Long Lesions: 
A Comparison to Traditional Stenting 
Joseph De Gregorio, lssam Moussa, Milena Adamian, Yoshio Kobayashi, 
Carlo Di Mario, Jeffrey Moses, Antonio Colombo. Cenfro Cuore Columbus, 
Milan, Italy; Lenox Hill Hospital, New York, USA 
The treatment of long lesions has traditionally yielded unsatisfactory long- 
term results. A prospective registry of consecutive patients were treated 
utilizing the approach of spot stenting (SS) where IVUS guided PTCA was 
performed and short stents were placed only in the segments of a lesion 
where IVUS criteria are not met (CSA of >5.5 mm2 or ~50% of reference 
vessel CSA at the lesion site). These patients were compared to a matched 
group treated during the same time period with the traditional stenting (TS) 
approach where a lesion is covered from proximal normal segment to distal 
normal segment. The SS group (101 patients, 130 lesions) and the TS group 
(143 patients, 168 lesions) had similar baseline clinical and lesion character- 
istics including lesion complexity and reference vessel diameter (2.95 i 0.5 
vs 3.01 i 0.5, p = ns). However, the SS group contained significantly longer 
lesions (27 f IO vs 24 f 9, p = 0.01) and shorter stent lengths (20 f 12 vs 
25 * 13, p = <O.Oi). 
Characteristic SS TS P 
Mean age 
LVEF% 
Multivessel disease, n (%) 
Balloon/artery ratio 
Min lumen diameter pre (mm) 
Final min lumen diameter (mm) 
Acute gain (mm) 
Acute stent thrombosis, n (%) 
Procedural MACE, n (%) 
Restenosis, n (%) 
Target lesion revasc., n (%) 
6 Month MACE, n (%) 
6Ozt 10 
60+11 
72 (72) 
1.23 i 0.2 
0.75 i 0.4 
2.7 f 0.7 
1.94ztO.8 
2(l) 
3 (3.0) 
27 (26) 
25 (20) 
22 (22) 
58flO 
64f13 
94 (67) 
1.21 io.2 
0.89 & 0.4 
3.0 + 0.5 
2.10 IL 0.6 
0 (0) 
5 (3.5) 
63 (36) 
54 (32) 
51 (361 
ns 
<0.05 
ns 
ns 
<0.05 
<0.05 
<0.05 
ns 
ns 
<0.05 
<0.05 
<0.05 - 
(Angiographic follow-up in 81% of SS group and 100% of TS group). 
Conclusions: Despite the use of shorter stent lengths to treat longer 
lesions, the SS group had similar short-term event rates and significantly 
better long-term outcome with lower restenosis rates, TLR and 6 month 
MACE. 
12:36 p.m. 
1008-l 70 Stenting of Long Coronary Lesions: 
A Prospective g-Month Quantitative 
Angiographic Study (STELLA Trial) 
John A. Ormiston, Peter N. Ruygrok, Mark W.I. Webster, Ian T. Meredith, 
Sue Price, Justin P. Ardill, Christopher E. Buller, Donald R. Ricci, 
Charles Chan, Gerard P. Devlin, James T. Stewart, Ian M. Penn. For the 
STELLA Trial Investigators, Green Lane Hospital, Auckland, New Zealand 
Background: Long lesions are often treated by long stent deployment, but 
there is little prospective 6-month angiographic data. 
Methods: This multicenter, prospective, quantitative angiographic (QCA) 
trial of elective long stent deployment enrolled 120 patients with de novo 
native vessel lesions (length > 20 mm, diameter 2 3 mm) to be treated with 1 
or more MultiLink stents (25 and 35 mm). QCA with the CMS-Medis system 
pre- and post-procedure and at 6 months was performed in 93% of patients. 
Clinical follow-up was to 12 months. 
Results: The procedural angiographic success was iOO%, with success- 
ful delivery of MultiLink stents in 98%. The interpolated QCAvessel reference 
diameter was 3.12 f 0.56 mm before stenting. The mean lesion length was 
33.4 (18-99) mm, and the mean length ‘of stent used was 35.8 (25-95) 
mm. Hierarchical major adverse events by 12 months were: death (O%), 
Q-wave myocardial infarction (I%), non-Q-wave myocardial infarction (2%), 
and target vessel revascularization (14%). Restenosis of 150% diameter 
loss occurred in 32%, but there was ~70% diameter loss in only 8%. No 
patient had clinical subacute stent occlusion, but 3 (3%) had suffered a silent 
stent occlusion at 6-month angiography. 
Conclusion: Long MultiLink stenting for long coronary lesions can be 
performed with a high procedural success rate and a low adverse event rate. 
Although restenosis occurred in 32%, severe restenosis was uncommon 
(8%), and the rate of target vessel revascularization by 12 months was low 
(14%). 
12:48p.m. 
1008-l 71 Which is the Best Strategy for Chronic Coronary 
Total Occlusions; Stenting or Debulking or the 
Other? 
Etsuo Tsuchikane, Osamu Katoh’ , Nobuhisa Awata, Tohru Kobayashi. 
Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; 
‘Kyoto Katsura Hospital, Kyoto, Japan 
PTCA of chronic coronary total occlusions (CTO) is associated with an ac- 
ceptable success rate and a favorable long-term angiographic patency by 
primary stenting nowadays. However, massive plaque burden in CT0 some- 
times interferes with optimal lesion dilatation, which results in restenosis. To 
determine the best strategy for CTO, we analyzed angiographic outcomes of 
398 recanalized CT0 (TIMI = 0, occlusive duration 2 3 months) by balloon 
angioplasty alone (POBA) or stenting or debulking strategy (DCA or rota- 
tional atherectomy (RA)) retrospectively. Unsuitable CT0 lesions for stenting 
or debulking were excluded. POBA was performed in 224 lesions, primary 
stenting in 96 lesions, debulking alone in 31 lesions (DCA: 16, RA: 15), and 
debulk-stenting (D-stenting) in 47 lesions (DCA: 1, RA:46). Initial restenosis 
and reocclusion (within 6 months) rates and long-term patency rate at fol- 
low-up angiography 617 * 486 days after the initial PTCA are shown in the 
table. 
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POBA Stenting Debulking D-stenting P value 
Number 224 96 31 47 
RD > 2.5 mm 52.2% 57.3% 61 .3% 55.3% NS 
OLzZOmm 29.0% 24.0% 22.6% 19.1% NS 
Post MLD t 2.0 mm 27.2% 66.7% 51.6% 93.6%” <0.0001 
Initial restenosis 49.6% 43.8% 51 .6% 25.5%” 0.02 
Initial reocclusion 12.1% 4.2% 12.9% 2.1% 0.03 
Lana-term aatencv 93.3% 100% 93.5% 100% 0.02 
* P < 0.05 vs. Stenting (RD- reference diameter, OL: occlusive length, MLD: minimal 
lumen diameter) 
Conclusion: Stenting provides a favorable long-term patency compared 
to POBA or debulking alone. However, stenting alone is not sufficient to 
prevent initial restenosis. Stenting combined with plaque debulking is the 
best strategy for desirable mid- and long-term angiographic outcomes of 
recanalized CTO. 
1 :OO p.m. 
/ 1008 172 Bifurcation Lesions: Two Stents vs. One Stent Immediate and Follow-Up Results 
Takehiro Yamashita, Takahiro Nishida, Milena G. Adamian, Carlo Briguori, 
Marco Vaghetti, Nicola Corvaja, Remo Albiero, Leo Finci, Carlo Di Mario, 
Antonio Colombo, Jonathan M. Tobis. EM0 Centro Gore Columbus, Milan, 
ftalv; University of California, Los Angeles, Los Angeles, California, USA 
Background: In the treatment of bifurcation lesions, limited information is 
available if stent placement into the side branch provides any advantage 
over a simpler strategy of stenting the parent vessel and balloon angioplasty 
of the side branch. 
Methods: A total of 92 patients with true bifurcation lesions (defined as 
a 50% stenosis in both the parent vessel and the contiguous side branch) 
were treated with two strategies: stenting both vessels (bilateral group B, n = 
53) or stenting the parent vessel and balloon angioplasty of the side branch 
(single group S, n = 39). Paired angiograms were analyzed by quantitative 
angiography, and clinical follow-up was obtained. 
Results: 
Bilateral Single p-value 
Post procedure %DS 
parent vessel 6.7 i 9.9% 7.6 zk 12.1% NS 
side branch 7.4 * 10.9% 23.4 + 18.7% <0.0001 
Procedural SUCCESS 91% 95% NS 
In-hospital MACE 9.4% 0% <0.05 
Angiographic restenosis of 
any branch 56% 52% NS 
both vessels 22% 24% 
the parent vessel 11% 14% 
the side branch 22% 14% 
6 M total MACE 43% 33% NS 
%DS, percent diameter stenosis; MACE, major adverse cardiac events = death, myocar- 
dial infarction, coronary artery bypass grafting or repeat percutaneous procedure. 
Conclusion: For the treatment of true bifurcation lesions, a complex strat- 
egy of stenting both vessels provided no advantage in terms of procedural 
success or late outcome. 
1:12 p.m. 
CIa 1008 173 Angiographic Follow-Up of Bifurcated Coronary 
Stent Implantation: Results From a Single 
Center Feasibility Study 
Bernard Chevalier, Bernard Glatt, Philippe Guyon, Thierry Royer. Cenfre 
Cardiologique du Nord, Saint-Denis, France 
Many options have been proposed to cover complete bifurcation lesion with 
coronary stents, using step by step techniques. Bifurcated stent (ES) is 
a theoritical one-step alternative. In the setting of a preliminary feasibility 
study, 20 pts were treated, from 06/98 to 07/99, with a XT Carina Bard* 
on 15 LAD/diagonal, 4 Circumflex/obtuse marginal branch and 1 distal RCA 
bifurcations. Baseline lesion were D type in 19 and C type in 1. Procedure 
was conducted through an 8 F (6) or a 9 F (14) access using a 23 mm long 
Carina. One failure was related to proximal calcification and another one to 
the lack of legs rotation in a calcified bifurcation. These 2 cases were treated 
with stenting in main branch and balloon in side branch. There were 2 nonQ 
Ml (1 related to stent thrombosis at day 9). On-line QCA results (mm): 
RD preMLD postMLD 
Proximal main branch 3.1 + 0.41 0.61 zt 0.35 2.93 f 047 
Distal main branch 2.81 + 0.45 0.63 5 0.32 2.58 z’c 0.46 
Side branch 2.7 + 0.7 0.8 + 0.3 2.5 f 0.81 
Twelve pts had a 7 m. angiographic control with, using off-line QCA, 
residual stenosis from 3 to 44% in proximal main branch, from 17 to 73% in 
distal main branch and from 22 to 93% in side branch. Restenosis (>50%) 
was noted in l/12 in main vessel and in 302 in side vessel among which 
2 were not associated with ischemia. So, TLR was only present in one pt. 
Follow-up on the whole cohort is pending. 
Thus, these results showed a 90% feasibility in large bifurcation lesions 
with encouraging preliminary midterm results. 
1:24 p.m. 
1008-I 74 Treatment of Small Coronary Vessels With 
Complex Lesions 
Carlo Briguori, Takahiro Nishida, Milena Adamian, Carlo Di Mario, 
Antonio Colombo. Centro Cuore Columbus, Milan, ltaly 
Background: The impact of elective stent implantation in small vessels (~3.0 
mm) with complex lesions (B2-C) is still controversed. Restenosis rate in this 
population is high (42% to 53%). 
Methods: We compared the early and late outcome of patients with 
complex coronary lesions in small vessel treated with successful traditional 
coronary angioplasty (Angioplasty Group; n = 80) and with elective stent 
implantation (Stent Group; n = 100). Angioplasty Group and Stent Group 
were comparable for all clinical and angiographic characteristics. All patients 
in the 2 groups had clinical and angiographic follow-up. Major adverse cardiac 
events (MACE) and restenosis rate were evaluated. 
Results: No patients in the 2 groups experienced in-hospital death or by- 
pass surgery. Myocardial infarction occurred in 4 patients in the Angioplasty 
Group, and in 7 patients in the Stent Group (p = 0.28). No patients in either 
the Angioplasty and Stent Group had acute stent thrombosis, whereas sub- 
acute stent thrombosis occurred in only one patients of the Stent Group 
(1.5%). Long-term MACES (20 f 4 month) were not different in the 2 
groups (Angioplasty Group 39% vs. Stent Group 44%, p = 0.49). Target 
lesion revasculatization rate was 35% in the Angioplasty Group and 36% 
in the Stent Group (p = 0.51). Restenosis rate was not statistically differ- 
ent in the 2 groups (Stent Group 4.1% vs. Angioplasty Group 35%, p = 
0.41). 
Conclusion: Elective stent implantation in small coronary vessels with 
complex lesions does not seem to improve both early and late outcome. 
1:36 p.m. 
1008-I 75 Immediate and One-Year Outcome of Coronary 
Stent Implantation in Small Coronary Vessels 
Using 2.5 mm Stents 
Jassim Al Suwaidi, Kirk N. Garratt, Charanjit S. Rihal, Peter B. Berger, 
Malcolm R. Bell, Diane E. Grill, David R. Holmes Jr.. A&y0 Clinic, 
Rochester, MN, USA 
Background: The role of coronary stents in the treatment of patients with 
small vessels is not well defined. 
Objectives: To evaluate the immediate and one-year outcome of coronary 
stents for the treatment of lesions in small coronary arteries. 
Methods: Between Jan 1995 and Aug 1999,108 patients with small coro- 
nary arteries were treated with 2.5 mm stents and 4047 patients with large 
coronary arteries were treated with ~3.0 mm stents. Patients who simulta- 
neously underwent 2.5 mm and ~3.0 mm stents placement were excluded. 
Procedural success, complications, in-hospital and one-year outcomes were 
examined. 
Results: Clinical characteristics, indications for revascularization and the 
number of significantly diseased vessels (~70% diameter stenosis) were 
comparable between the groups. 
Outcomes 2.5 mm stent >3.0 mm stent 0 
Procedural success (%) 
In-hospital events (%) 
Death 
QMI 
CABG 
One year events (%) 
Death 
QMI 
CABG 
TLR 
Severe angina 
MACE 
97.2 
0.9 
0 
0.9 
3.8 3.8 0.62 
0.0 0.2 0.80 
8.4 5.9 0.73 
23.3 13.0 0.02 
33.4 20.2 0.03 
35.4 20.5 o.oi* 
96.7 0.77 
1.5 0.65 
1.0 0.30 
0.7 0.75 
TLR = target lesion revascularization, MACE = Death, MI&TLR; (* After adjustment for 
other covaraites in a Cox model, RR = 1.75, P = 0.02) 
Conclusion: Stenting in small coronary arteries with 2.5-mm stents can 
be achieved with a high success rate and acceptable complication rates, RD: reference diameter, MLD: minimal lumen diameter 
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but may be associated with worse long-term outcome when compared with however, there was significantly less intra-stent neointimal thickening with 
stenting large coronary arteries. ML. 
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I Retrieval Techniques 
1008 176 Current Indications and Results of Stent 
Bernard Chevalier, Bernard Glatt, Philippe Guyon, Thierry Royer, 
Reza Mohammadzadeh, Menif Wajih. Centre Cardiologique du Nerd, 
Saint-Denis, France 
In order to evaluate indications and results of stent retrieval technique (SRT), 
we retrospectively studied a consecutive series of 2959 pts treated with 
PTCA from 01/98 to 08199, by four operators, using 3279 coronary stents, 
with a stenting rate (by pt) of 83.6%. During this time period 178 stents 
(5.5%) could not be placed on the lesion among which 141 (4.3%) have 
been removed in the guiding catheter without dislodgement, 4 (0.1%) were 
immediatly lost after dislodgement without any possible SRT use, 3 (0.1%) 
were proximaly deployed in the coronary artery and 34 (1%) needed a SRT. 
Stents were manually crimped in 38%. Dislodgement occurred during stent 
removal in the guiding catheter in 13, lesion crossing in IO, intracoronary 
advance in 7, and within the guiding in 4. Dislodgement mechanism was 
calcifications in 12, tortuosities in 7, strut damage in 6, handling mistake in 
3, stent entrapment in another stent in 2 and unsatisfactory dilation in 2. 
SRT was performed with a biopsy forceps in 2, a small balloon in 1 and a 
microsnare in 31 cases. Stent status before SRT was: in place on the wire 
29, still on the balloon 2, free 3. SRT site was iliac artery 10, aorta 9, left 
main IO, RCA 3, graft 2. SRT procedure was successful in all pts using a 6F 
sheath in 28 pts, an 8F sheath in 4 pts and a larger sheath in 2 pts. There 
was no SRT-related complication during the inhospital outcome. 
Thus, stent dislodgement became unfrequent (1.2%) with new generation 
products. When it occurs, a SRT can be attempted in 83% of cases with a 
very high success rate in experienced hands. 
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1152-75 Comparison of Serial Intravascular Ultrasound 
Findings of Multi-Link and GFX Stems 
Shiro Ishikawa, Yasushi Asakura, Takahiro Kato, Teruo Okabe, 
Keiko Asakura, Toshiyuki Takahashi, Akio Kawamura, Akiko Yamane, 
Hideo Mitamura, Satoshi Ogawa. Keio Universifx Tokyo, Japan 
Methods: lntrravascular ultrasound (IVUS) findings of Multi-Link stent (ML: 
n = 24) and GFX stent (n = 18) were analyzed, and the late results were 
compared. Vessel area (VA), stent area (SA), and lumen area (LA) were 
measured at the cross section of the smallest LA before (pre) stenting. IVUS 
measurement was performed at the same cross section after (post), and 
at 6 months after stenting (FU). Late recoil of implanted stent (Recoil SA = 
post-LA-FL.-SA), neointimal area (NIA = FU-SA-FU-LA), and ratio of NIA 
to FU_SA (%NIA = NIA x iOO/FU-SA) were calculated. 
Results: There were 4 (17%) angiographic restenosis in ML, and 7 (39%) 
in GFX (p = 0.11). Target lesion revascularization was necessary in 2 (8%) of 
ML and 5 (28%) of GFX implanted lesions (p = 0.09). Quantitative coronary 
angiography showed that reference vessel diameter, % diameter stenosis 
(%DS) before and after stenting, and balloon/reference vessel diameter ratio 
were not different between ML and GFX. Late loss (ML: 0.93 f 0.71, GFX: 
1.6 * 0.9 mm, p < 0.05) was larger and %DS at follow-up (ML: 25.6 + 20.9, 
46.6 f 30.4%, p < 0.05) was smaller in GFX. There were no significant 
differences in pre_VA (ML 16.2 f 3.7, GFX 14.0 * 3.8 mm’), post-LA (ML 
15.2 & 3.9, GFX 16.5 f 4.2 mm’), pre_LA (ML 1.7 f 0.9, GFX 2.1 & 0.9 
mm*), post-LA (ML 7.0 & 1.9, GFX 7.2 f 1.4 mm2), FU_VA (ML 15.0 i 
3.4, GFX 16.0 f 3.7 mms), and Ft..-SA (ML 6.6 f 2.4, GFX 6.9 f 1.3 mm*) 
between ML and GFX. 
Recoil SA (mm’) FU-LA (mm2) NIA (mm’) %NIA 
ML 0.14 i 0.89 4.8 f 1.9 1.7 zk 2.4 29.8 f 17.8’ 
GFX 0.38 f 0.83 4.2 i 2.3 2.8 zk 2.4 46.7 i 28.1 
* p < 0.05 vs. GFX 
Conclusions: Angiographically, ML tended to show lower restenosis rate. 
IVUS findings indicated that stent recoil was minimum with both ML and GFX, 
I 1152 76 Recruitable and Non-Recruitable Collateral Circulation After Successful Recanalization of 
Chronic Total Coronary Occlusions 
Gerald S. Werner, Barbara M. Richartz, Oliver Gastmann, Markus Ferrari, 
Klaus Lang, ‘Hans R. Figulla. Friedrich-Schiller-Universifx Jena, Germany 
Background: Collateral coronary flow (CCF) in total chronic coronary oc- 
clusions (TCO) preserve myocardial viability distal to the occlusion. After 
successful PTCA the remaining collateral function determines late cardiac 
events. This study should evaluate the time course of changes in CCF during 
and after successful PTCA of TCO. 
Patients: 22 patients with a chronic TCO (i.e. at least 4 weeks) were 
studied with an intracoronary Doppler wire. It was advanced through the 
occlusion via an over-the-wire catheter before dilation to record the baseline 
CCF. After stenting of the occlusion, the recruitable CCF was assessed during 
a repeated balloon occlusion of 3 min. This was repeated during a control 
angiogram on the following day. Average peak velocity (APV, absolute value), 
peak velocity integral (PVI), and a collateral flow index (CFI = PVI during 
occlusion/PVl unobstructed) were measured. A CFI bO.30 is considered to 
indicate a sufficient recruitable CCF to prevent ischemia. 
Results: The table shows the data of CCF at baseline, after recanalization 
indicating the recruitable CCFr, and after 24 hours (* p i 0.05). 
CCF baseline 
CCFr 
CCFr next day 
APV (cm/s) 
12.1 * 6.4 
4.4 i 2.3*) 
4.9 f 4.8”) 
PVI (cm) 
9.7 i 5.3 
3.6 i 2.0 
4.3 * 4.1 
CFI 
0.43 zt 0.18 
0.20 5 0.14 
0.15 zt 0.16 
In 36% CCF was completely abolished at the end of PTCA and 24 hours 
later. The non-recruitable CCF was 64% of baseline CCF. A CFI >0.30 was 
observed in only 18% of TCO 24 hours after PTCA. 
Conclusion: CCF is instantaneously influenced by the reopening of a 
TCO. The remaining recruitable CCF is considerably lower than baseline 
CCF. The CFI decreases in the majority of patients and may not be sufficient 
to prevent future ischemic events. 
/ 1152 77 Does Late Arterial Response After Cutting 
Balloon Angioolasty Differ From That of 
Conventional Balloon Angioplasty? A Volumetric 
Intravascular Ultrasound Analysis 
Takeshi Suzuki, Hiroaki Hosokawa, Koichi Yokoya, Takahiko Suzuki. 
Stanford University: Stanford, California, USA; National Toyohashi Higashi 
HospitaS Toyohashi, Japan 
Background: The Cutting Balloon (CB) is a novel dilation device that longitu- 
dinally incises the coronary plaque during balloon dilation. This incision limits 
the degree of arterial trauma associated with balloon dilation, potentially re- 
ducing the late injury response compared with plain old balloon angioplasty 
(POBA). 
Methods: To evaluate whether the late arterial response of CB differs 
from that of POBA, a total of 67 lesions, 33 CB and 34 POBA, was imaged 
at pre-, post-procedure and follow-up. The each area and volume of external 
elastic membrane (EEM), lumen and plaque was measured using Simpson’s 
method. AVolume and Aarea ((Follow-up:Post)/Post*lOO) were calculated. 
Results: The loss of EEM and lumen volume at follow-up in the CB 
group tended to be less than that in the POBA group (AEEM volume; 0.8 
& 10.0% vs -3.3 f 18.2%: p = 0.26, Alumen volume; -0.5 f 20.1% vs 
-6.5 f 22.5%: p = 0.26). There was no significant difference in APlaque 
volume in both groups (3.4 f 17.6% vs 0.5 f 21.8%: p = 0.55). As the figure 
indicates, in mid-lesion, the loss of EEM area at follow-up in the CB group 
was significantly less than that in the POBA group. 
% Change in EEM area 
8 
6 * * a POE.4 
4 
z 
0 
-2 
-4 
9mm 
Proximafl 
MLD 9mm 
b Distal 
Conclusion: These results suggest that the late arterial response of the 
Cutting Balloon may differ from that of plain old balloon angioplasty In the 
CB group, mid-lesion vessel geometry remodeling, is favorable. 
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/ 1152 78 Prognostic Value of Diabetes for Long-Term Event After Percutaneous Coronary Intervention is 
Augmented in Proximal Lefl Anterior Descending 
Artery Lesion 
Hyeon-Cheol Gwon, Sahng Lee, Seung Woo Park, June Soo Kim, 
Duk-Kyung Kim, Sang Hoon Lee, Kyung Pyo Hong, Jeong Euy Park, Jung 
Don Seo, Won Ro Lee. Sun&yunkwari University, Samsung Medical 
Cenfer, Seoul, Korea 
risk factors (graph). On multiple linear regression, HbAlc level (regression 
coefficient 3.16 (0.05 to 6.27)), PTCA (15.14 (2.33 to 27.9)) and vessel 
RD (-11.74 (-22.92 to -0.56)) were independently predictive of diameter 
stenosis at follow-up angiography. However, the goodness of fit of the final 
model was poor (adjusted R2 19%). 
Conclusion: Vessel reference diameter, HbAlc level, PTCA and B:A ratio 
were independent predictors of restenosis in diabetics. Improved periproce- 
dural glycemic control and the avoidance of oversized balloons, in addition 
to stenting, may reduce the restenosis rate in these patients. 
Background: Diabetes has been known as a major risk factor for long term 
prognosis after percutaneous coronary intetvention (PCI). We tested the 
hypothesis that impact of diabetes may be different according to the location 
of target lesion. 
Methods: All patients who were followed up for more than 1 year after 
successful PCI in single lesion of native coronary artery in Samsung Medical 
Center between January 1995 and July 1998 were included. Patients with 
cardiogenic shock and/or left main disease were excluded. Major cardiac 
adverse event (MACE) was defined as death, myocardial infarction, repeated 
PCI, or coronary artery bypass surgery. 
Results: 832 patients out of 875 patients were followed up for 1 year (fol- 
low-up loss 4.9%). 1) 1 year MACE rate was higher in diabetes patients (DM) 
compared with non-diabetes patients (non-DM) (p = 0.024). It was also higher 
in the patients who underwent PCI in proximal left anterior descending seg- 
ment (pLAD) compared with non-pLAD group (p = 0.024). 2) Among pLAD 
group, DM was associated with significantly higher l-year MACE rate (p = 
0.003). On the contrary, there was no signifiaant difference in l-year MACE 
rate between DM and non-DM group among patients whose target lesions 
were not pLAD (p = 0.41). 3) Among MACE in pi-AD group, only the risk of 
repeated PCI lesion was significantly higher in DM group (non-DM 15.6%, DM 
37.8%, p = 0.001). In multivariate analysis, only diabetes was an independent 
risk factor for 1 year MACE rate in pL4D group. 4) Odds ratio between DM 
and non-DM group was 4.0 (95% Cl: 1.4-I 1.4, p = 0.007) for non-stent group 
and 2.1 (95% Cl: 0.8-5.8, p = 0.13) for stent group in plAD group. 
1152-80 The Plasminogen Activator Inhibitor 1 Promotor 
Polymorphism Predicts Late Loss After Coronary 
Stenting 
J.R. Ortlepp, P.W. Radke, A. Killian, S. Merkelbach-Buse, J. vom Dahl, 
P. Hanrath. Medical Clinic 1, University Hospital, Aachen, Germany 
Background: The use of intracoronary stents has improved acute and long- 
term outcome after percutaneous coronary interventions. However instent 
restenosis remains a significant clinical problem. Identification of “high-risk” 
patients would allow selection of individualized appropriate therapeutic ap- 
proaches. Genetic polymorphisms have been previously suggested to be 
associated with instent restenosis. In this study we investigated the influence 
of two recently studied polymorphisms of the DCPI (ACE) gene and the 
ITGA2B (Gllb/llla) gene and of the promotor polymorphism of the plasmino- 
gen activator inhibitor type 1 (PAI-1) gene. 
Methods: 100 consecutive unselected patients with elective coronary 
stent placement and B-month angiographic follow up were recruited. Quan- 
titative coronary angiography and genotyping with PCR and restriction frag- 
ment length polymorphism analysis for the three polymorphisms were per- 
formed in all patients. 
non-pLAD pLAD All 
non-DM 17.4% (493) 20.4% (147) 16.1% (640) 
DM 20.4% (147) 42.2%(45) 25.5% (192) 
All 16.1% (640) 25.5% (192) 19.8% (832) 
p-ValLF2 0.43 0.003 0.024 
* Data presentedas l-year MACE rafe (patients number in the group) 
p-ValUe 
0.41 
0.003 
0.024 
Results: Patients with the PAI- 4Gi4G genotype (n = 24) showed a 
significant (univariate p = 0.03; multivariate p = 0.007) greater late loss (0.71 
mm f 0.13 SE) vs patients with PAI-I genotype 4G/5G or 5G/5G (n = 76) 
(0.38 mm f 0.05). The PAI-I genotype was the only independent predictor 
for late loss in univariate and multivariate analysis. 
Conclusion: Prognostic value of diabetes for long-term event after PCI is 
augmented in proximal left anterior descending artery lesion. Bypass surgery 
using left internal mammary artery can be the better option in this group. 
Conclusion: The promotor polymorphism of the PAI-I gene may be of 
high relevance in the pathophysiological pathway of neointima hyperplasia. 
The 4G/4G genotype may predispose gene carriers to a higher expression 
of plasminogen activator inhibitor 1 after stenting with consecutive more 
proliferation of endothelial and smooth muscel cells and a higher degree of 
neointima hyperplasia. 
I 1152 79 Predictors of Angiographic Restenosis After Coronary Intervention in Patients With Diabetes 
Mellitus 
/ 1152 81 Reversible Perfusion Defects on Thallium-201 SPECT Scintigraphy Early After Coronary 
Stenting Occur Frequently and Do Not Predict 
Late Target Lesion Revascularization 
Peter K. Mazeika, Neeraj Prasad, Sanh Bui, Peter Seidelin, Division of 
Cardiology, The Toronfo Hospital, Toronto, Ontario, Canada 
Background: The identification of risk factors for restenosis in diabetics 
could guide patient selection and allow insight into underlying mechanisms. 
Methods: To pinpoint predictors of restenosis, 75 diabetics (age 60 (10) 
yrs) with 86 treated lesions were studied using a concurrent case-control 
design. All patients had a first, successful, PTCA or stent placement and 
underwent follow-up angiography with analysis using QCA. 
Results: There were 45 patients (53 lesions) with restenosis and 30 
patients (33 lesions) without restenosis. Univariate predictors of angiographic 
restenosls as a binary (graph) or continuous variable were: periprocedural 
HbAlc level; vessel reference diameter (RD); PTCA; postprocedure MLD; 
and larger final balloon size to reference artery diameter (B:A) ratio. Logistic 
regression identified HbAlc level, vessel RD and B:A ratio as independent 
Ronen Jaffe, Simona Ben-Haim, Avi Front, Giora Weisz, Basheer Karkabi, 
Nader Khader, Amnon Merdler, Moshe Y. Flugelman, David A. Halon, Basil 
S. Lewis. Lady Davis Carmel Medical Center and Bruce Rappaport School 
of Medicine, Technion-I/T; Haifa, Israel 
Background: In the pre-stent era, thallium-201 reversible perfusion de- 
fects (RevPd) early after successful coronary balloon angioplasty (PTCA) 
predicted late coronary restenosis. We investigated the frequency and sig- 
nificance of such findings in the current stent era. 
Methods: Single photon emission computed tomography (SPECT)TI-201 
myocard&l scintigraphy (rest and dipyridamole) was used to detect RevPd 
early (12-24 hr) after angiographically successful coronary stenting in 42 pts. 
Late follow-up at 9 (range 3-40) mths sought clinically indicated target lesion 
revascularization (TLR). Findings were compared to 33 pts who underwent 
angiographically successful PTCA without stenting (POBA) during the same 
period. 
Results: Demographic, clinical and pre-procedural angiographic findings 
were similar in both groups. Coronary stenting achieved a larger minimal 
lumen diameter (MLD) than POBA (2.7 f 0.4 vs 2.1 + 0.4 mm, p < 0.001) 
and smaller residual stenosis (4.7 f 11.5 vs 19.8 + 11 .O per cent, p < 0.001). 
The 12-24 hr scan revealed RevPd in 13142 (31%) of stented lesions and 
11133 (33%) of POBA lesions (NS). Early RevPd did not correlate with lesion 
length, MLD or residual stenosis. During follow-up, late TLR was performed 
in l/12 (8%) of stented lesions with early RevPd and in 4/26 (15%) of lesions 
without (NS). In the POBA group, TLR was performed in 2111 (18%) of lesions 
with early RevPd and 3121 (14%) of lesions without (NS). 
Conclusions: This prospective study showed that in era of provisional 
stenting: 1. Early RevPd on 12-24 hr SPECT TI-201 scintigraphy occurred 
in a third of pts both after stenting and POBA, despite the larger MLD and 
lesser residual stenosis achieved by stenting. 2. Incidence of late TLR was 
low in both groups. 3. Late TLR was not predicted by presence or absence 
of early RevPd in either group. 
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I 1152 82 Atherosclerotic Plaque Temperature Before and 
After Angioplasty 
Christodoulos Stefanadis, Leonidas Diamantopoulos, 
Charalambos Vlachopoulos, Eleftherios Tsiamis, John Dernellis, 
Emmanuel Vavuranakis, Costas Stratos, Pavlos Toutouzas. f-tippokration 
Hospital, Athens Medical School, Athens, Greece 
Background: We have shown that plaque temperature (T) is increased in 
acute ischemic syndromes (Circulation 1999; 99: 1965-71) presumably due 
to the intense presence of activated macrophages in the unstable plaques. 
In the present study, we investigated the effect of coronary intervention on 
plaque T. 
Methods: Plaque T was measured with a catheter-based technique that 
was designed and developed in our laboratory (figure) in 35 patients with 
stable angina (SA, 18 pts) and unstable angina (UA, 17 pts) before and after 
angioplasty. The 3 F thermography catheter incorporates a thermistor at its 
distal end (accuracy: 0.05 ‘C, time constant: 300 msec; spatial resolution 0.5 
mm). 
Results: Plaque temperature (difference of maximum plaque T from 
healthy wall T) was greater in the UA pts compared to the SA pts both before 
and after angioplasty (P < 0.001 for bot comparisons). However, there wa 
no difference in the plaque T befor and after angioplasty (SA: befor 0.153 
i 0.123 vs. after 0.147 f 0.106 UA: before 0.788 * 0.337 vs. afte 0.771 i 
0.324, P = NS for both). 
Conclusions: Coronary angioplasty does not alter plaque T. This im- 
plies that the underlying mechanism causing increased plaque T in unstable 
plaques is not affected by changes in plaque structure or blood flow. Thus, 
the hypothesis that activated macrophages are the source of heat production 
is reinforced. 
1152-83 Coronary Flow Reserve as Compared to 
Pressure-Derived Fractional Flow Reserve After 
Successful Recanalization of Chronic Total 
Coronary Occlusions 
Gerald S. Werner, Barbara M. Richartz, Markus Ferrari, Oliver Gastmann, 
Klaus Lang, Hans R. Figulla. Friedrich-Schiller-University: Jena, Germany 
Background: Doppler-derived coronary flow reserve (CFR) and pressure- 
derived fractional flow reserve (FFR) are used to assess the result of PTCA. A 
CFR >2.0 and a FFR 20.75 indicate asufficient PTCA result in nonocclusive 
lesions. The present study evaluated the relevance of these parameters in to- 
tal chronic coronary occlusions (TCO) with a collateral dependent myocardial 
area. 
Methods: Fourteen patients with successful recanalization of a TCO were 
studied by intracoronary Doppler and intracoronary pressure wire simultane- 
ously. Mean duration of TCO was 17 months (4-72). All TCO were treated 
by stenting. CFR and FFR were measured after stent implantation when 
the angiographic result was considered optimal. A bolus of adenosin was 
injected (12 p for fight or 18 lr. for left coronary) and CFR and FFR recorded 
at least three times. In IO patients a control angiogram was done after 24 
hours and the measurement of CFR and FFR was repeated. 
Results: CFR after recanalization of the TCO and stenting of the lesion 
ranged from 1.2 to3.0 (mean 1.9 It 0.5). It was below 2.0 in 50% of patients. 
The FFR ranged from 0.66 to 0.97 (mean 0.83 i 0.10); it was below 0.75 
in only one patient. After 24 hours, CFR remained unchanged (mean 1.9 f 
0.4) as was FFR (mean 0.84 f 0.08). Repeat PTCA in patients with CFR < 
2.0 did not improve the CFR. The value of the CFR was not depedent on 
the extent of global or regional ventricular dysfunction, or on the duration of 
occlusion. 
Conclusion: CFR is dependent on the microvascular function of the 
myocard. The variable myocardial resistance in TCO may impair CFR in a 
large proportion of patients and make it a less valuable tool to assess the 
angioplasty in TCO as compared with FFR. 
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I 1153 116 Short Term Mortality Lower With Clopidogrel Than Ticlodpidine Following Coronary Artery 
Stenting 
Philippe L. L’Allier, Herbert D. Aronow, Fernando A. Cura, Deepak L. Bhatt, 
Abdulhay Albirini, Jakob P. Schneider, Eric J. Topol, Stephen G. Ellis. 
Cleveland Clinic, Cleveland, OH, USA 
Background: Due to its more favorable safety profile, clopidogrel is used 
with increasing frequency in place of ticlopidine after coronary artery stent 
implantation. Randomized trial data (n = 1020) have not shown a difference 
in major adverse clinical events. 
Methods: Between June 1996 and December 1998,2369 patients who 
underwent coronary stent implantation received peri-procedural anti-platelet 
regimens containing clopidogrel (300 mg x 1; and 75 mg PO daily x 30)/ASA 
(325 mg daily) or ticlopidine (500 mg x 1, 250 mg PO BID)/ASA (325 mg 
daily). We compared in-hospital and 30-day outcomes among patients not in 
clinical shock at the time of the procedure. 
Results: Follow-up was 97% complete. There were few important differ- 
ences in baseline characteristics. More than 50% of patients received abcix- 
imab. The in-hospital bleeding complications were not different. The 30-day 
outcomes are summarized below. After multivariate analysis the association 
between clopidogrel and reduced 30-day death persisted (OR 0.231, 95% 
Cl 0.05-0.99). 
30-day Clopidogrel Ticiopidine 
Outcomes n=652 n=i717 
Death 2 (0.3%) 25 (1.5%) 
MI 26 (4.0%) 110 (6.5%) 
Revasc. 9 (1.4%) 27 (1.6%) 
Composite 38 (6.2%) 153 (9.1%) 
P 
0.024 
0.023 
ns 
0.03 
Conclusion: In this registry study, clopidogrel after coronary stenting 
appears to yield more favorable clinical outcomes at 30 days than ticlopidine. 
Whether this difference is due to more potent or rapid platelet inhibiton with 
clopidogrel remains to be elucidated. 
1153-I 17 Thrombotic Stent Occlusion and Associated 
Major Adverse Cardiac Events Beyond the First 2 
Weeks After Coronary Stent Placement. Analysis 
of 3676 Patients With a 4-Week Ticlopidine 
Regimen 
Helmut Schiihlen, Jijrgen Pache, Jarg Hausleiter, Juli Mehilli, 
Josef Dirschinger, Adnan Kastrati, Albert Schsmig. 1. Medizinische K/ink 
rechts der lsar & Deutsches Herzzentrum Technische Universit%, Munich, 
Germany 
Background: The ISAR and STARS trials have demonstrated the bene- 
fit of a ticlopidine regimen after coronary stent placement. As the risk for 
ticlopidine-induced severe neutropenia may be 21% after 2 weeks, there is 
interest to discontinue ticlopidine after 2 weeks. In ISAR and STARS with 
a 4-week regimen, no adverse cardiac events occurred beyond the first 2 
weeks, and nonrandomized trials suggest that the risk for cardiac events is 
low if ticlopidine is discontinued after 2 weeks. However, the size of these 
studies may be too small to specify a risk between 0 and 1%. 
Methods & Results: We analyzed 3676 patients, all with 4 weeks of 
ticlopidine. The overall adverse event rate was 3.4% after 4 weeks; the 
temporal distribution of the events is shown in the graph. The rate for days 
14 to 30 was 0.8%, 17 of these events (0.5%) were stent thromboses or 
cardiac deaths. 
Conclusions: With a 4-week ticlopidine regimen, the risk for major ad- 
verse cardiac events beyond the first 2 weeks is low but not zero. Randomized 
trials are necessary to weigh a presumably higher risk for adverse cardiac 
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events with a Z-week ticlopidine regimen against a lower risk of neutropenia. 
Furthermore, a 4-week regimen might be preferable for clopidogrel with its 
lower risk for neutropenia. 
) 1153-l 18 / The Impact of Oral Antiplatelet Therapy on CK 
Release After Coronary Stent implantation: 
A Comparison Between Ticlopidine and 
Clopidogrel 
lssam Moussa, Eli Traube, Gary Roubin, Antonio Colombo, Sriram lyer, 
Gishel New, Nadim AL-Mubarak, Michael Collins, Edward Kreps, 
Jeffrey Moses. Lenox Hill Cardiac and Vascular institute of New York, NL: 
USA 
Background: Data suggest that ticlopidine administration 3 days prior to 
stenting may reduce post-procedural CK elevation. The purpose of this study 
was to -investigate the differential impact of pre-procedure administration 
(within 24 hrs) of ticlopidine versus Clopidogrel on CK elevation after stenting. 
Methods: All consecutive pts undergoing stent implantation between 
l/l 997 and 12/l 998 were the subject of this analysis. These pts were divided 
into 2 groups: group I - 1405 pts who were pretreated with ticlopidine (250 
mg PO BID); and group II - 1069 pts who were pretreated with 2 300 mg 
loading dose of Clopidogrel. Total CK was systematically determined in all 
pts and MB fraction was determined if total CK was higher than normal (225 
unit). CK elevation was defined as any increase in total CK above normal 
limits with >4% MB. 
Results: Pts treated with clopidogrel were older (64 i 11 yrs vs 62 + 11 
yrs, p = 0.03) and had smaller vessels (2.74 f 0.60 mm vs 2.84 f 0.70, p < 
O.OOOl), but there were no differences in lesion severity, length or complexity. 
The frequency and magnitude of CK release is shown in the table below: 
Ticlopidine Clouidoarel P 
n = i405 nii069 
Any CK Release 113 (8%) 64 (6%) 0.059 
Mean CK release (UI 684 + 663 465 + 364 0.016 
Conclusions: Clopidogrel loading prior to stenting may be an effective 
strategy to achieve rapid and effective platelet inhibition which may attenuate 
the degree of myocardial necrosis following coronary stenting. 
1 1153-l 19 / A Comparison of Clopidogrel to Ticlopidine 
Therapy for the Prevention of Major Adverse 
Cardiac Events at Thirty Days and Six Months 
Following Coronary Stent Implantation 
D.A. Plucinski, Karen Scheltema, Jan Krusmark, Nancy Panchyshyn. 
Cardiovascular Consultants, Ltd., North Memorial Health Center 
(CVC.NMHJ, Minneapolis, Minnesota, USA 
Objective: To compare the efficacy of clopidogrel (CL) to ticlopidine (TI) for 
the prevention of major adverse cardiac events [MACE), including total mor- 
tality (Total Mott), cardiovascular mortality (CV Mod), myocardial infarction 
(Ml), and clinically driven repeat target vessel revascularization (TVR), either 
percutaneous (PCI) or surgical (CABG): and to ascertain event free survival 
(EFS). 
Methods: All patients, including patients undergoing PCI for MI, were 
prospectively enrolled into the CVC.NMH Angioplasty registry from Septem- 
ber 1996 to December 1998. MACE and EFS were determined at thiry days 
and six months after PCI. For patients who underwent stent implantation, 
outcomes for post stent CL were compared to TI. 
Results: The baseline demographic and clinical status of the patients in 
the CL and TI cohorts were comparable with no significant differences. Thirty 
day and six month outcomes are displayed in the following table: 
Total Man 
CV Man 
MI 
Repeat PCI 
CABG 
Total TVR 
Event Free 
30 Day Outcomes 
TI CL 
rid138 n=240 
1 .3% 0.0% p = 0.088 
0.3% 0.0% p = 1 .o 
0.6% 0.8% p = 0.660 
1.3% 0.4% p = 0.333 
0.3% 0.8% p = 0.211 
1 .6% 1.3% p = 1 .o 
97.8% 99.2% p = 0.206 
6 Months Outcomes 
TI CL 
n=1138 n=240 
3.7% 1.7%p=0.113 
1.5% 0.8% p = 0.555 
2.8% 4.6% p = 0.151 
9.6% 10.8% p = 0.552 
4.6% 6.3% p = 0.271 
14.1% 
82.2% 
17.i%p=O.228 
79.2% D = 0.276 
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I 1154 84 Relationship Between the Structure of the Plaque and the Importance of Embolization During 
Carotid Angioplasty 
Serge Kownator, FranGois Luizy, Michel Henry, Max Amor, Bernard Foliguet, 
Zuca’i Chati. Po/yc/inique, Essey-/es-Nancy, France 
Background: Carotid angioplasty (CA) is associated with a higher rate of 
embolization than carotid endarterectomy. A previous ex vivo study found 
a relationship between hypoechoic plaques, high degree of stenosis and 
embolization during CA. The purpose of this study is to investigate in vivo 
the importance and the nature of embolization during CA and to establish 2 
correlation with the structure of the plaque and the importance of the stenosis. 
Method: 20 patients were selected for CA. Ultrasound examination were 
performed in the first place on an ATL HDI 5000 device. All the frames were 
recorded on HDI lab and SVHS videotape. The images were computerized 
and standardized following Nicola’ides’ method, in order to define the median 
density value (MDV) of the plaque. Low MDV is correlated with hypoechoic 
lesions, high MDV with hyperechoic. Degree of stenosis is evaluated by 
measuring the peak systolic velocity on duplex scan. CA and stenting has 
been performed under cerebral protection completed through a protection 
balloon (PercuSurge system). Debris were collected by aspiration and flush- 
ing before deflation of the protection balloon. After filtration and fixation they 
were analyzed by microscopy and electron microscopy. 
Results: Size of the debris take place between 50 p and 2.5 mm. They are 
made of recent thrombi, ancient thrombi, lipoid masses or acellular material 
such as fibrous particles, calcified particles. Low MDVs (i.e. hypoechoic 
plaques) are related with a greater number of panicles but a smaller size. 
High MDVs (i.e. hyperechoic plaques) are associated with a bigger size of 
particles, but a lower number of debris. We do not find any relationship 
between the degree of stenosis and the number or particles. 
Conclusion: Whatever the structure of the plaque, CA brings exposure 
to the risk of embolism Hypoechoic lesions provide a great number of small 
debris, hyperechoic lesions, a smaller number of larger particles. To avoid 
cerebral embolization, protection seams to be an effective technique. 
1154-85 Probucol and Brachytherapy as a Combined 
Strategy to Prevent Restenosis After Angioplasty 
of the Lower Limb Arteries (PTA): A Valid Model to 
Prevent Restenosis After PTCA? 
August0 Gallino, Felix Mahler, Kurt Jager, Ernst Schneider. Divisions of 
Vascular Medicine Bellinzona, Bern; Base/; Zurich, Switzerland 
In the femoro-popliteal arteries restenosis occurs with an incidence of -40%. 
Among the large number of strategies tested for the prevention of resteno- 
sis only a few seem to maintain their potential value: the antioxidant drug 
Probucol (P) and intravascular brachytherapy (B). Aim of our prospective 
randomized multicenter trial involving the major Swiss angiology centres, 
is to determine the impact of P and 5 or both in reducing restenosis after 
femoro-popliteal PTA when compared to 2 standard regimen with Aspirin 
alone (A). The study consists of the following four treatment arms of 80 
randomized patients each: 
A alone (100 mgid) A+B 
A i P (1 g/d, d -30 i 180 d) A+B+P 
The prescribed gamma-radiation dose is 16 Gy to a 2 mm radial distance 
from a non-centred 6Fr closed endlumen catheter. 
Follow-up examinations immediately post, 3 and 6 mts after PTA include 
assessment of the key lesion by duplex-US defining restenosis as ~50% 
reduction of luminal diameter (major endpoint). A total of 166 pts (81 pts 
receiving B) have been randomized with a drop out rate of 11%. Thusfare 
no major side effects have occurred. The long multicenter experience of the 
participating centres and the expected number of eligible pts should allow to 
determine the efficacy of two of the rnost promising treatments for prevention 
of restenosis and may serve as a model for studies in pts undergoing PTCA. 
Conclusions: MAE and EFS at thirty days and six months following stent 
implantation are similar in patients treated with TI and CL with no significant 
differences. 
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1154-86 Radial Approach for Selective Carotid 
Angiography 
Young-sup Yoon, Won Heum Shim, Kyung-Jin Park, Seung-Yun Cho. 
Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, 
Korea 
Background: Carotid and coronary artery occlusive diseases frequently 
coexist. Currently, diagnostic and interventional coronary procedures are 
increasingly performed by the radial approach. In this regard, the radial ap- 
proach can be beneficial for the evaluation of carotid system during coronary 
angiography. This approach can also be useful for follow-up angiography 
after carotid stenting. We assessed the feasibility and safety of selective 
carotid angiography by transradial route at cardiac cath lab. 
Methods: Selective carotid angiography was performed in 90 consecutive 
patients through the right radial artery at cardiac oath lab. Data for patients 
were collected prospectively as “intention to use” the radial artery after 
confirming positive Alien’s test. There were 68 males and 22 females. Mean 
age was 62 f 8. The indications were follow-up angiography after carotid 
stenting in 22 cases and detailed assessment of carotid artery stenosis in 68 
cases at the same setting of coronary angiography. We used 4F/5F Simmons 
catheter for the initial 19 cases and 4F multipurpose (125 cm-long) catheter 
for the latter 71 cases. Hydrophilic guidewire (0.035 inch, 260 cm-long) was 
used to facilitate the manipulation of the catheter or to engage carotid arteries. 
Procedure time (after sheath insertion to catheter removal), fluoroscopy time 
and amount of dye used were measured. Patients were discharged on the 
same day unless follow-on intervention was performed. 
Results: Radial artery cannulation was successful in all cases. Selective 
angiography was successfully performed for 179 carotid arteries of 90 pa- 
tients (success rate 99%). All the angiograms were of diagnostic quality. In 
one patient we failed in engaging the left carotid artery due to spasm of the 
radial artery and severe tortuosity of the fight subclavian artery. In the latter 
70 cases, procedure time and fluoroscopy time was 8.3 f 4.1 minute and 
3.2 f 1.5 min, respectively. Average amount of dye used was 23.8 f 7.6 
ml. There were no neurologic complications or clinically significant access 
site complications such as radial artery perforation, aneurym, fistula or hand 
ischemia. 
Conclusion: Transradial angiography of both carotid arteries can be 
performed safely and effectively with high procedural success rate and no 
significant complications at cardiac oath lab. Considering short procedure 
time and small amount of dye used, this procedure will find wider applica- 
tions such as the assessment of carotid system during transradial coronary 
angiography or follow-up angiography after carotid artery stenting. 
1154-87 A New Protection Filter Device to Prevent Distal 
Embolization in Peripheral Interventions - First 
Results in Renal and Carotid Arteries 
Ulrich Gerckens, Ralf Mueller, Sabine Soblik, Thomas Wollweber, 
Eberhard Grube. Department of Cardio/ogy/Angio/ogy Heart-Center 
Siegburg, Siegburg, Germany 
Background: Percutaneous interventions of renal and carotid arteries are 
now frequently performed. However, they carry a high risk of distal em- 
bolization. The AngioGuard’” Emboli Capture system provides a method of 
containing and retrieving loose plaque material without distal vessel occlu- 
sion. We evaluated the effectiveness and safety of the system in renal and 
carotid artery interventions. 
Device description: The AngioGuard’” Capture Guidewire system con- 
sists of a 0.014 PTCA wire with an expandable filter basket at the distal end. 
After crossing the target lesion the basket is expanded and the intervention 
can be performed in a standard manner. Plaque debris is captured within the 
distal basket and can be extracted using the AngioGuard’” Guidewire. The 
filter membrane allows a normal blood-flow during the procedure. 
Method: To evaluate the efficacy and safety of this new protection device 
we used the AngioGuard’” system in 8 patients with 11 lesions (renal stenosis 
n = 6, carotid stenosis n = 5). In all lesions angioplasty with additional stent 
implantation was performed. 
Results: In all patients the system could be safely placed, expanded 
and extracted. We observed no in-hospital major events related to the 
AngioGuard’” device. In renal arteries the success rate was 100%. Macro- 
scopic debris could be retrieved in every case. In one case, a large plaque 
particle contained in the filter caused side branch occlusion. Normal flow was 
reestablished after the plaque was extracted using the basket filter. 
The AngioGuard’” Capture Guidewire was able to cross all carotid lesions, 
also highgrade and ulcerative lesions, and could be passed even through 
tortourous vessels. Common practice with wall stent implantation could be 
performed. Debris was extracted in 4/5 carotid interventions. In one case 
visible obstruction caused by loosened material within the filter deminished 
distal flow. A large atheromatous plaque could be safely retrieved and normal 
flow was reestablished thereafter. 
Conclusion: The AngioGuard” Emboli Capture system can be easily 
and safely used in renal and carotid arteries. It is effective in retrieving 
debris material which potentially could cause clinically important distal vessel 
occlusion. 
1 1154-88 1 Factors influencing and Predicting 
Post-Intervention Renal Function Outcome on 
lschmic Nephropathy 
Robin Yue, Mark Wholey, Zhanbin Feng, Tyrone J. Collins, J. 
Stephen Jenkins, Stephen R. Ramee, Christopher J. White. Ochsner 
Medical Foundation, New Orleans, Louisiana; Pittsburgh Vascular Institute, 
Pittsburgh, Pennsylvania, USA 
Background: Progressive renal artery stenosis can cause ischemic nephropa- 
thy. Percutaneous revascularization has high success rate and low complica- 
tion rate. Clinical predictors for improvment or stabilization of renal function 
(ISRF) are uncertain. 
Methods: Successful renal artery intervention was obtained in 131 pa- 
tients between 1994 and 1998. Renal function was determined at baseline, 
572 hours post-procedure and at >6 months of follow-up. Univariate and 
multivariate analysis of variables were used to analyze clinical outcomes at 
~6 months post-intervention. Renal function improvement or deterioration 
was defined as greater than 0.2 mg/dl change in serum creatinine (Cr). 
Results: Univariate and multivariate analysis revealed that baseline Cr 
(BCr) 5 2.0 mg/dl (p < 0.04) and ISRF at 572 hours post procedure (p 
< 0.0001) correlated with stable renal function at ?6 mos follow-up. In 
contrast, BCr ? 2.0 mg/dl and post-procedure 5 72 hours serum creatinine 
deterioration were with worsening outcome 6 mos later. In 14 out of 31 (45%) 
patients with BCr 2 2.0 mgidl had a worsening outcome. 
BCr > 2.0 mg/dl 
ECr 5 2.0 mg/dl 
Worse 5 72 hrs Cr 
ISRF 5 72 hrs Cr 
Pt # 
31 
100 
21 
110 
?6 mm 
Better/same Worse p-V&le 
17 (55%) 14 (45%) 0.0116 
78 (78%) 22 (22%) 0.0116 
8 (38%) 13 (62%) 0.0001 
87 (79%) 23 (21%) 0.0001 
Conclusion: Baseline and ~72 hours post-procedure renal function are 
independent predictors of more than 6 mos renal function. 
I 1154 89 Late Clinical Outcomes After Renal Artery Stenting in Patients With Renal Insufficiency and 
Uncontrolled Hypertension 
George Dangas, John R. Laird, Roxana Mehran, Luis Gruberg, Javed 
M. Ahmed, Ajith Purush, Chryssoula K. Pappas, Petros Okubagzi, 
Michael Astatkie, Ahn Bui, Bryan Curry, Nancy McCarthy, Martin B. Leon. 
Cardiovascular Research Foundation, Washington, DC, USA 
Background: Renal artery stenosis can led to uncontrolled hypertension 
(HTN) and chronic renal insufficiency (CRI). Endovascular stent implanta- 
tion is a commonly employed method of renal artery revascularization for 
atherosclerotic ostial renal artery narrowing. 
Methods: We studied the outcome of renal stenting for uncontrolled HTN 
in patients with CRI (baseline creatinine > 2 mg/dl, n = 63) versus No CR/ 
(n = 56). One-year follow-up was obtained by a dedicated Data Coordinating 
Center. Overall, 43% of patients had diabetes, 52% prior myocardial infarc- 
tion, 50% prior coronary bypass surgery, and 48% prior coronary angioplasty. 
Patients with CRI were older: 72 f 8 versus 69 i 8 years, p = 0.04; other 
baseline demographics were similar. 
Results: Procedural success was 100%. Post procedure, 9% of patients 
with CRI required temporary hemodialysis, but none required permanent 
dialysis. Long-term functional and clinical results are shown: 
CRI NO CRI P 
Temporary Dialysis 9% 0 0.03 
Acute renal failure 11% 5% 0.12 
acreatinine, mgfdl -0.1 h 0.8 0.1 f0.4 NS 
ASyst:Diast. BP -21 * 14x; 8 * 9* -24 IL 20; 7 zt 10” NS; NS 
l-year Death; Q-MI 16%; 1.6% 7%; 0 NS; NS 
*Significant decrease from baseline (p < 0.05, paired t-test). Ml = myocardial infarction. 
Syst:Diast. BP = systolic/diastolic blood pressure (mmHg). 
No patient required repeat renal artery intervention. 
Conclusion: Renal artery stenting is safe and improves BP control without 
worsening renal dysfunction in patients with CRI. Despite these results, 
late mortality is high due to the presence of advanced atherosclerosis and 
significant cardiac comorbidity. 
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I 1154 90 Renal Artery Stenosis interventions Guided by Intravascular Ultrasound and Pressure Gradient 
Measurements 
Michael Haude, Dirk Welge, Dietrich Baumgatt, Clemens von Birgelen, 
Holger Eggebrecht, Andreas Kribben, Thomas Philipp, Raimund Erbel. 
Cardiology Department and Department for Nephrology and Hypertension, 
University-GHS Essen, Germany 
Background: Percutaneous transluminal angioplasty (PTA) and stenting are 
accepted techniques for the treatment of renal artery stenosis to preserve 
renal function and to control hypertension. In order to maintain an optimal 
interventional result we measured luminal enlargement by quantitative an- 
giography (QA), intravascular ultrasound (IVUS) and translesion pressure 
gradients (Ap mean). 
Methods: In 35 patients (pts) with 45 renal artery stenoses QA (CMS, 
Medis), IVUS (3.0 F Vision Five-64 F/X, Endosonics) and Ap mean mea- 
surements (0.014 inch Wave Wire, Endosonics) were performed before PTA, 
afler PTA, after stent implantation and at six month. 
Results: The maximum balloon diameter for PTA was 6.2 + 0.8 mm 
compared to 6.4 i 0.7 mm for stent implantation. 
Before PTA After PTA After Stent At 6 months 
QA MLD [mm] 2.2 i 0.9 5.7 i 1.8# 6.7 5 0.7#+ 6.0 + 1.6” 
QA MCA [mm*] 3.8f 1.9 25.5 * 8.7# 33.9 i 5.8#+ 29.3 i 7.7’ 
IVUS MLD [mm] 1?3+1.1 4.7 f 1.9# 6.4 i 0.9#+ 5.8 i 1.4* 
IVUS MCA [mm21 2.8 i 1.7 17.9 h 6.6# 32.8 f 4.8#+ 26.9 i 6.1* 
Ap mean [mm Hg] 55 i 19 23 zk 20# 5 i 3#+ 5 zt 21 
MLD = Minimal luminal diameter, MCA = minimal cross-sectional area, #: 
p < 0.001 versus pre PTA, +: p < 0.05 versus after PTA, 0: n. s. versus after 
stent, *: p < 0.05 versus after stent. There was no restenosis at 6 month. 
Serum creatinine was 1.4 I 0.5 mg/dL before intervention and 1.3 f 0.4 
mg/dl at six month. Mean blood pressure decreased from 178/97 to 156/88 
mm Hg (p < 0.01). 
Conclusion: Guidance of renal artery stenosis intervention by QA, IVUS 
and Ap mean provides the best interventional short- and long-term results. 
IVUS better reflects luminal enlargement compared to QA. 
/ Stenting 
1154 91 Long-Term Outcome Following Carotid Artery 
Fayaz A. Shawl, Fernando Lapetina, Waleed Y. Kadro, Stephanie Cornell, 
Kathryn G. Dougherty. Washington Adventist Hosptial, kkoma Park, 
Maryland. USA 
Background: Although recent studies have suggested that carotid stenting 
(CS) can be performed with a low periprocedural complication rate, the 
long-term benefit from CS has not been evaluated. 
Methods: We prospectively followed 91 patients (with 97 vessels) under- 
going carotid stenting from 8/95 to 8198. 
Results: The mean age of the patients 72 -I 9 yrs (73% were male). Thirty 
nine percent had no history of a neurological event or symptoms and 68% 
were NASCET eligible. Bilateral disease was present in 36% with contralat- 
erai occlusion in 8%. There were ipsilateral prior CEA in 9%. Periprocedural 
death, major stroke and minor stroke was 3.3%, 0% and 3.3%, respectively 
for the first year of the study and 3.3%, O%, 0% for the last year. 
3 Year Event-Free Survival 
Event 
All “euro deaths & 
stroke 
All “euro deaths 8 
ipsilateral stroke 
Inclusive of 
periprocedural events 
90.7 * 3% 
90.7 i 3% 
Exclusion of 
periprocedural events 
93.6 zt 3.5% 
92.6 i 3.2% 
Conclusion: Periprocedural outcomes improved over the time course of 
the study. The risk of long-term neurological events following carotid artery 
stenting is small. These data suggest that carotid stenting is durable and 
effective in reducing the risk of Stroke or neurological death. 
I 1154 92 Is Combined Intervention a Safe Alternative to 
Staged Intervention in Patients With Coronary 
Artery Disease and Renal Artery Stenosis? 
Krishnamoorthy Vivekananthan, Aditya Samal, Vijay Chillakumari, J. 
Stephen Jenkins, Tyrone J. Collins, Christopher J. White, Stephen 
R. Ramee. Ochsner C/inic, New Orleans, Louisiana, USA 
Background: Significant renal artery stenosis is present in as high as 30% of 
patients with CAD. The safety and cost effectiveness of combined interven- 
tion in a single procedure versus staged intervention has not been adequately 
evaluated. We performed this study to evaluate the above hypothesis. 
Methods: Our study population consisted of a total of 79 patients (40 
males, 39 females). Group I consisted of 45 consecutive patients who under- 
went combined coronary (single or multivessel) and renal artery (unilateral 
or bilateral) interventions as a single procedure. We assessed the baseline 
patient characteristics, duration of hospitalization (LOS), procedural succes 
(PS) (residual diameter stenosis x50%, with TIMI Ill flow) and in-hospital 
outcomes in these patients. A parallel group of 34 patients (Group II) who 
underwent renal and coronary intervention as staged procedure were sim- 
ilarly assessed and the composite outcomes of both the procedures were 
compared. 
Results: 
Combined Staged 
Age (YN 7119 69 i 8 
Hypertension, % 92 94 
Diabetes, % 36 32 
Dyslipidemia, % 57 63 
Smoking, % 42 43 
Indication (for either coronary/renal intervention) 
Stable angina, % 34 50 
Unstable angina, % 36 34 
Myocardial 
Infarction, % 9 9 
Heart Failure, % 21 16 
Hvoertenslon. % 93 93 
P-value 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Combined 
In = A51 
Staged 
In = 341 
P-value 
Mean LOS, days 
PS, % 
SBP -Baseline (mm/Hg) 
SBP - 1 month (mm/Hg) 
DBP - Baseline (mm/Hg) 
DBP - 1 month (mmVHg) 
Target Vessel Revasc, % 
211 5*3 NS 
98 97 NS 
167129 177*30 NS 
148 + 17 144120 NS 
84+14 90&14 NS 
71110 79ilO co.03 
0 3 NS 
There were no myocardial infarctions, need for surgical revascularization, 
or dialysis among both the groups. One patient died in the combined group 
due to sustained ventricular fibrillation during hospital stay, and in the staged 
group one patient died of advanced heart failure. 
Conclusions: 1) Combined coronary and renal intervention is a safe 
alternative to staged intervention, and can be performed with a high success 
rate and few complications. 2) In addition, the shorter hospitalization period 
makes combined intervention more cost-effective than staged intervention. 
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1 1155-I 09 1 Red Light Therapy Does Not Prevent 
Restenosis: Angiographic Results of the Pilot 
Phase of CLASS Trial 
Bernard Chevalier, Upendra Kaul, Balbir Singh, Stephen W. Lee, 
Bernard Glatt, Philippe Guyon, Linda Lam, Thierry Royer. On behalf of 
CLASS investigators; Centre Cardiologique du Nerd, Sainf-Denis, France; 
5afr.a Hospital New Delhi, India 
Evidence of intimal hyperplasia prevention by cold red laser illumination 
(CRL), after balloon and stent, in animals was already published. On this 
basis, a pilot randomized study was organized in 4 centers to validate a 
statistical hypothesis before the launching of a large mullticenter trial. Pts 
CRL Control 
N pts 30 17 
pre RD (mm) 3.11 Yk 0.7 3.05 f 0.62 
pre MLD (mm) 0.88 * 0.39 0.77 zt 0.39 
post MLD (mm) 2.65 zt 0.68 2.81 zt 0.65 
Fup MLD (mm) 1.89 zt 0.82 1.87 & 0.98 
Net gain (mm) 1 + 0.8 1.19iO.86 
Loss index 0.42 zk 0.47 0.36 5 0.41 
RD. reference diameter, MLD: minimal lumen diameter 
P 
NS 
NS 
NS 
NS 
NS 
NS 
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were randomized on a 2:l basis between cold laser (red: 650 nm wave- 
length) illumination (2 times 60 sec./IO mWatt power) using dedicated 
rapid exchange balloon catheter after achievement of angioplasty or con- 
ventional angioplasty technique. Baseline and procedural data were similar 
in both groups, particularly restenotic lesion and stenting rates. There was 
no CRL-related clinical event in this group. Corelab angiographic analysis 
was done (acute and at systematic (100%) follow-up angiography) (see 
table). 
Thus, at this level of power, CRLdoes not prevent angiographic restenosis 
in human beings. A new pilot phase study is in progress using higher power. 
Erl 1155 110 Sulindac Reduces lntimal Hyperplasia After 
Femoral Artery Endothelial Denudation in 
Apolipoprotein E Knockout Mice 
Merce Roque, Ernane D. Reis, Juan J. Badimon, Hayes Dansky, John 
T. Fallon, Steven Shiff, Edward A. Fisher. Mount Sinai School of Medicine, 
and Rockefeller University: New York, New York, USA 
Background: Endothelial dysfunction and inflammation are central to the 
development and progression of atherosclerosis. The nonsteroidal antiin- 
flammatory Sulindac can inhibit cyclooxygenase-2 (COX-Z), which is induced 
predominantly at inflammatory sites. Sulindac also has been associated with 
inhibition of cell proliferation and induction of apoptosis. We studied the effect 
of Sulindac on intimal hyperplasia after femoral artery endothelial denuda- 
tion in apoE-knockout (apoE KO) mice, a model that mimics the response to 
injury of human atherosclerotic vessels. 
Methods: Thirty apoE KO mice underwent femoral artery denudation 
by three passages of a 0.25-mm angioplasty guidewire. Mice were fed a 
Western diet (WD) from 1 week before injury to 4 weeks after, either alone, or 
supplemented with Sulindac (300mg/kg of food/day) or aspirin (300 mg/kg 
of food/day). Arterial specimens were harvested 28 days after injury and 
histologic and morphometric analyses performed. 
Results: Total cholesterol levels were comparable in the three treatment 
groups, averaging 1,704 f 310 mg/dL. Twenty-eight days after endothelial 
denudation, exuberant lesions, composed of smooth muscle cells, choles- 
terol crystals, and macrophages, were found in specimens from apoE KO 
mice fed a WD, with an intimal-to-medial (l/M) ratio of 1.6 i 0.2, and luminal 
narrowing of 49 + 6%. Sulindac reduced the I/M ratio significantly, 0.8 f 
0.1 (p < O.Oi), as well as the percentage of luminal narrowing, 28 ;t 6% 
(p c 0.05). Aspirin did not change the intimal response significantly when 
compared to WD alone. Macrophage infiltration tended to be reduced in the 
intimal lesions of Sulindac-treated mice (2.6 i 1.3%) versus WD alone (6.8 
f 3.1%). 
Conclusions: Sulindac decreased the proliferative response to arterial 
injury in the apoE KO murine model of atherosclerosis. The results suggest 
Sulindac could have a potential application in preventing progression and 
complications of human atherosclerotic disease, such as restenosis following 
coronary angioplasty. 
1155-l 11 Evaluation of the Effect of Oversizing on 
Vascular Injury, Thrombogenicity and Neointimal 
Hyperplasia Using the Magic Wailstent’” in a 
Porcine Coronary Model 
Ivan De Scheerder, Monika Szilard, Yanming Huang, Qiang Bei Ping, 
Xiaoshun Liu, Erik Verbeken, Frans Van de Werf. University Hospitals, 
Leuven, Belgium 
Background: Oversizing of self-expandable coronary stents results in a 
continuous pressure on the stented vessel wall and has been considered as 
a continuous stimulator for neointimal growth. 
Methods: Magic Wallstents (Schneider, Bulach) with a length of 24 mm 
were randomly implanted with either an oversizing of f50% (n = 28), or an 
oversizing of *I 00% (n = 28) in two coronaries of 28 crossbred pigs (weight 
20-25 kg). The pigs underwent a control angiogram and were subsequently 
sacrificed at day 3 (n = 4) day 7 (n = 4) day 14 (n = 6), day 42 (n = 10) and 
day 84 (n = 4). Quantitative coronary analysis before, immediately after stent 
implantation and before sacrifice was performed using the semi-automated 
Polytron lOOO@ system. Morphometry was performed using a computerized 
morphometric program. 
Results: Histopathology showed significantly more perivasculitis in the 
high oversizing group (1.08 f 0.17 vs. 0.92 f 0.18, p < 0.02). Morphometry 
showed a similar lumen area at day 3 and 7. At day 14 the lumen area 
in the high oversizing group was significantly smaller compared to the low 
oversizing group (4.70 i 0.56 vs. 5.70 j, 0.64 mm’, p = 0.016). At day 42 
and 84, however, this difference became insignificant. 
Neointimal hyperplasia was also significantly more pronounced at day 14 
in the high oversizing group (1.94 & 0.64 vs. 1.04 f 0.66, p < 0.037). At 
later follow-up neointimal hyperplasia remained increased at a non-significant 
level in the high oversizing group. 
Conclusion: This study suggests that high oversizing results in an early 
neointimal overresponse, most probably induced by the higher vessel stretch, 
resulting in more perivasculitis and subsequently more neointimal hyperpla- 
sia. At longer follow-up, however, this continuous vessel overstretching did 
not result in a significantly more pronounced neointimal hyperplasia. 
1155-i 12 Estrogen-Induced Vasprotection is Estrogen 
Receptor Dependent: Evidence From the Balloon 
Injured Rat Carotid Artery Model 
Tatsuhiko Mori, Stephen Bakir, Yiu Fai Chen, Suzanne Oparil. University of 
Alabama at Birmingham, USA 
Previous studies carried out in mice with deletion of either c1 or p isoform of the 
estrogen receptor (ER,, ER,!I) have demonstrated vasprotective responses 
to exogenous estrogen indential to those seen in wild type mice. These 
findings indicate that the vascular injury response in this model, which is 
produced by repetitive passage of angioplasty wire or plastic filaments in the 
mouse carotid artery, is not dependent on either isoform of the ER alone. 
Possible explanations include: (1) redundancy of function, such that both 
ER isoforms must be blocked in order to inhibit the estrogen effect; (2) 
participation of a novel ER isoform; (3) a nongenomic effect of estrogen. 
This study tested the hypothesis that the vasoprotective effect of estrogen 
in the rat carotid artery is mediated by ER. Balloon injured intact female 
Sprague-Dawley rats (Int) were randomly divided into four groups and were 
treated with either the non selective ER antagonist lCl182,780 (ICl;O.5, 1.5 
or 5 mg/kg/day, S.C.) or vehicle (V) beginning before and continued for 14 
days after balloon injury of the right common carotid artery. Ovariectomized 
rats (OVS) were treated with either 17p-estradiol (E2) (20 &kg/day, SC.) 
or V according to a similar protocol. Two weeks after balloon injury, rats 
were killed and carotid arteries were evaluated for neointima formation using 
morphometric analysis. Results (mean f SE) in graph: A) Int B) Int + 0.5 C) 
ICI15 D) Int + 5.0 E) OVX F) OVX + E2 G) OVX + ICI50 + E2. ICI 182,780 
increased neointima formation in balloon injured carotid arteries of Int. and 
,inhibited the effects of exogenous E2 in OVS in a dose-dependent fashion. 
2 r Intima/Media Ratios 
*p-amvaovx+E2 
These data provide strong evidence that estrogenmediated vasoprotec- 
tion in this model is an ER-dependent phenomenon, perhaps depending on 
inhibition of multiple ER isoforms. 
1 1155-l 13 1 T-Lymphocytes in Initial Coronary Lesions are 
Associated With the Development of Clinical 
Restenosis in Patients With Unstable Angina 
Martijn Meuwissen, Steven A.J. Chamuleau, Jan J. Piek, Karel T. Koch, 
Allard C. van der Wal, Anton E. Becker. Academic Medical Center, 
University of Amsterdam, Amsterdam, the Netherlands 
Background: Literature suggests a positive association between macrophage 
infiltration in atherosclerotic plaques and the incidence of angiographic re- 
stenosis after coronary atherectomy for unstable angina. 
Methods: A total of 84 patients with unstable angina, according to Braun- 
wald’s classification, underwent directional coronary atherectomy (DCA) for 
culprit lesions. Cryostat sections of atherosclerotic plaques were immunohis- 
tochemically stained with the monoclonal antibodies, ol-actin (smooth muscle 
cells; SMC), CD-68 (macrophages; MAC) and CD-3 (T-lymphocytes; T-cells). 
The extent of atherosclerotic inflammation of the initial lesion was determined 
by MAC and T-cells, planimetrically quantified as the percentage immunopos- 
itive tissue area of the total tissue area (MAC) or counted per mm2 (T-cells). 
Patients were followed for one year for development of clinical restenosis, 
defined as recurrence of stable or unstable angina related to renarrowing 
(diameter stenosis P 50%) of the initial treated lesion. 
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Results: Clinical restenosis developed in 18 patients (28%). Immunopos- 
itive MAC and SMC areas were not different in patients with or without re- 
stenosis. However, numbers of T-lymphocytes were significantly increased 
in patients who developed clinical restenosis. The table shows initial plaque 
inflammation in patients with clinical restenosis. 
% MAC T-cells/mm2 % SMC 
No &&stenosis (n = 46) 21.8f 15.0 14.6i11.8 24.0 i14.8 
Restenosis (n = 18) 21.1 i 14.8 25.0 3~ 12.7" 25.3 + 15.3 
“p = 0.003 compared to group without Restenosis 
Conclusion: Rather than macrophages, large amounts of T-lymphocytes 
in initial plaques are associated with the development of clinical restenosis 
after directional coronary atherectomy. This suggests a regulatory role for 
T-lymphocytes in the process of restenosis. 
I 1155 114 How Does Brachytherapy Affect Coronary Artery 
Vasa Vasorum and Vessel Wall 
Neovascularization After Angioplasty? 
Three-Dimensional Analysis by Microsopic 
Computed Tomography 
Birgit Kantor, Ron Waksman’ , Yves Cottin’, Marc Kollum’ , 
Yoram Vodovotz’ , Erik L. Riman, David R. Holmes Jr., Robert S. Schwartz. 
Mayo Clinic and Foundation, Rochester, .MN 55905; ’ Washington Hospital 
Center, Washington DC, 20010, USA 
Background: A fine network of vasa vasorum (w) provides oxygen and 
nutrients to the outer layers of the arterial wall. These adventitial capillaries 
proliferate in both atherosclerotic arteries and in neointimal proliferation af- 
ter angioplasty. lntracoronary radiation reduces neointima formation through 
poorly understood mechanisms. The impact of brachytherapy on neovascu- 
larization is unknown. This study assessed the spatial density and distribution 
of w in normal, injured and radiated porcine coronary arteries 28 days after 
balioon-angioplasty. 
Methods: Following balloon-injury, ten coronary artery segments were 
randomized to receive intracoronary radiation therapy (15 Gy; n = 5) or to 
be injured, but unradiated controls (n = 5). Micro-CT, a novel high resolution 
imaging technique was used to obtain microscopic 3-D images of coronary 
vasa vasorum (voxel size 40 pm). 
Radiated Coronafy Artery 
Results: Normal coronary arteries showed a typical well-organized pat- 
tern of 1st and 2nd order vasa vasorum. In balloon-injured control segments, 
adventitial capillary density was increased and disorganized compared to 
normal segments (3.2 f 0.2/mm2 vs 1.9 i 0.1/mm2, p < 0.001). Radi- 
ated segments showed significantly decreased vasa vasorum density (2.2 & 
0.4/mm*, p < 0.01) 28 days after balloon injury compared to injured untreated 
controls. 
Conclusions: 1. Normal coronary arteries contain a well-organized three- 
dimensional network of vasa vasorum, which proliferates in an disorganized 
manner after angioplasty. 2. lntracoronaty radiation causes significant de- 
crease in spatial vasa vasorum distribution 28 days after balloon injury. 3. 
Brachytherapy may have an antiangiogenic effect on arterial adventitia, which 
may relate to its apparent efficacy in reducing neointimal thickening. 
~43 lntegrin Receptor Blockade Reduces 
Restenosis and Macrophage Infiltration With a 
Reduction in Cellular Adhesion Molecule 
Expression Following Balloon Angioplasty in the 
Atherosclerotic Rebbit 
Gregory G. Bishop, John A. McPherson, John Sanders, 
Sean Hesselbacher, Michael J. Feldman, Lawrence W. Gimple, Eric 
R. Powers, Shaker A. Mousa, As Ian J. Sarembock. University of Virginia, 
Charlottesville, VA; DuPont Pharmaceutical Company Wilmington, DE, USA 
01”,& integrin receptors are up-regulated in atherosclerotic arteries and play 
a key role in smooth muscle cell (SMC) and possibly inflammatory cell 
migration. We hypothesized that following balloon angioplasty (BA) of ath- 
erosclerotic arteries, inhibition of the o~“BQ receptor by XTI99, a non-peptide 
selective CL”& integrin inhibitor would reduce restenosis. 
Methods: Following induction of focal atherosclerosis, NZW rabbits un- 
derwent femoral BA and received XT1 99 (2.5 mg/kg IV bolus plus 2.5 mg/kg/d 
IV) (n = 19) or vehicle (n = 20) for 14 days. 
Results: At 28 days after BA, by histomorphometric analysis the XT199 
treated group had a significantly larger lumen (0.75 f 0.26 vs. 0.57 + 0.20 
mm2, p = 0.03) and smaller intimal area (0.49 * 0.18 vs. 0.68 f 0.25 
mm2, p = 0.01). Vessel size and adaptive remodeling at 28 days were 
not different in the two treatment graups. lmmunohistochemical analysis of 
arteries harvested at 28 days after BA showed no effect on intima-media 
SMC content but a 50% reduction in macrophage cell density in the XT1 99 
versus vehicle treatment group (716 i 452 vs. 1458 i 989 cells/mm’, p < 
0.006). Peripheral monocyte count was not altered by XT199. At the site of 
angioplasty, femoral arteries from the XT1 99 group had reduced intima-media 
ICAM-I expression at 3 days post BA followed by a reduction in VCAM-1 
and macrophage infiltration at 7 days, with no affect on MCP-1 expression. 
Quantitative angiography confirmed a 30 to 40% reduction in restenosis 
after c+Bs receptor blockade as measured by a decrease in minimal luminal 
diameter (MLD), AMLDc,,,~ so t0 p8 d) and late lumen loss index. 
Conclusion: Following BA, in the focally atherosclerotic rabbit, specific 
Al”,& receptor blockade for 14 days significantly reduced restenosis, lim- 
ited intramural macrophage infiltration, and was associated with a reduction 
cellular adhesion molecule expression. 
ORAL 
/ 878 Risk Factors for Adverse Outcomes of 
Percutaneous Coronary Intervention 
Tuesday, March 14, 2000, 2:00 p.m.-3:30 p.m. 
Anaheim Convention Center, Lecture Hail Al 
2:00 p.m. 
878-l Angioplasty in Women: A Re-Look Into Their Clinical 
Success and Complications 
Patrick C.H. Ang, Richard W. Harper, Ian T. Meredith. Center for Heart & 
Chest Research, Monash Medical Center, Monash University, Melbourne, 
Australia 
Background: Past studies have shown that women undergoing percuta- 
neous coronary revascularization (PCR) have a lower success rate and 
higher incidence of procedure-related complications than men. It is possible 
that recent improvements in PCR such as the widespread use of stenting and 
more aggressive antiplatelet regimes may have abolished or lessened these 
differences. The purpose of this study was io analyze the baseline character- 
istics and compare the procedural results and the incidence of complications 
in women undergoing PCR in the modern era with men. 
Methods: Of 2584 patients who underwent PTCA from February 1994 to 
March 1999,723 were females 1861 were males. Their short-term procedural 
success and complication rates were compared. 
Results: Women were older with a mean age of 64.5 f 11 .I vs 58.9 jr 
11.3 years, p < 0.001). At presentation, females had a higher incidence of 
hypecension (60% vs 43%), diabetes (18% vs 14%) and obesity (41% vs 
33%) but a lower incidence of smoking (30% vs 59%) and left ventricular 
dysfunction (36% vs46%, p values <: 0.05). Acute coronary syndromes were 
more common in women (54% vs48%, p < 0.01). Females had more single 
vessel disease (62% vs 50%, p < 0.01) and ostial lesions (9.2% vs 6.7%, 
p = 0.01). The veSsel length, size and type were similar in both groups. 
The stent rates per person (60% vs 58%) and the combination therapy of 
aspirin and ticlopidine after angioplasty (88% vs 87%) were similar. The 
angiographic and clinical success rates were comparable (93% vs 94% and 
90% vs 90% respectively). The incidence of death, stroke, Q and non-Q 
myocardial infarction were similar in both groups (1.0% vs 1.2%, 0.1% vs 
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0.3%, 0.7% vs 0.4% and 4.1% vs 3.0% respectively) but women had a higher 
incidence of repeat angioplasty (2.5% vs 1.2%, p = 0.02) and emergency 
bypass surgery (2.9% “s 1.4%, p = 0.01) during the same admission and a 
higher incidence of local vascular complications (3.9% vs 1.7%, p < 0.01). 
These differences remained after correcting for baseline characteristics. 
Conclusion: In the modern era, PCR in women now has a similar an- 
giographic and clinical success rates as in men but the need for repeat 
revascularization during the index admission is higher and there is a higher 
incidence of local vascular complication. These differences could not be 
accounted for by differences in baseline characteristics. 
2:15 p.m. 
El 878 2 Influence of Gender on In-Hospital Outcomes of Patients Undergoing Primary Percutaneous 
Transluminal Coronary Angioplasty for Acute 
Myocardial Infarction: New York State Experience 
Babak A. Vakili, David L. Brown. Albert Einstein College of 
Medicine/Montefiore Medical Center, Bronx, New York, USA 
Background: Female gender has been found to be an independent risk 
factor for mortality from acute myocardial infarction (Ml), possibly due to 
undertreatment of women with repetfusion therapies. We sought to determine 
if gender influenced outcome in a cohort of acute Ml patients, all of whom 
underwent primary percutaneous transluminal coronary angioplasty (PTCA). 
Methods: Using the 1995 New York State Angioplasty Database, we 
compared the in-hospital mortality of men and women undergoing primary 
PTCA for a first Ml within 24 hours of symptom onset. 
Results: A total of 1044 patients undergoing primary PTCA for acute 
Ml were identified, of whom 727 (70%) were males and 317 (30%) were 
female. The mean age was 59 years in men and 65 years in women (p < 
0.005). Significantly more women were 270 years of age (42% vs. 23%, p 
< 0.005). Diabetes was present in 14% of men and 19% of women (p = 
0.04). Hypertension was diagnosed in 44% of men and 59% of women (p < 
0.005). Shock was present at the time of PTCA in 3% of men compared to 
7% of women (p < 0.005). Intra-aortic balloon counterpulsation was required 
in 7% of men and 12% of women (p = 0.02). Triple vessel coronary disease 
was present in 15% of men compared to 12% of women (p = NS). Left main 
disease was demonstrated in 0.7% of men and 1.6% of women (p = NS). 
In-hospital mortality was 2.3% in men and 7.9% in women (p < 0.005). After 
multivariate analysis to correct for differences in baseline characteristics, 
female gender remained associated with significantly increased in-hospital 
mortality (OR 2.2, 95% Cl 1.1-4.5, p = 0.025). 
Conclusion: Women undergoing primary PTCA for acute Ml present 
with higher risk characteristics than men. However, after correction for differ- 
ences in baseline characteristics, women have significantly higher in-hospital 
mortality. 
2:30 p.m. 
III 878 3 Diabetes Mellitus is Associated With an Increased 
Risk of In-Hospital Death Following Elective 
Percutaneous Coronary Intervention: An Analysis of 
18,309 Patients 
Steven P. Marso, Lee V. Giorgi, Warren L. Johnson, Steven B. Laster, 
Kenneth C. Huber, James O’Keefe, Barry D. Rutherford. Mid America Heart 
Insfifute, Saint Luke’s Hospital, Kansas City Missouri, USA 
Background: Patients (Pts) with diabetes mellitus have been shown to 
have increased rates of restenosis, myocardial infarction and late mortality 
following percutaneous coronary intervention (PCI). It is unclear whether 
diabetics also have an increased short-term death following PCI. 
Methods: We evaluated in-hospital mortality in consecutive pts who un- 
derwent elective PCI from June 1980 through December 1998. A multi-vari- 
able logistic regression model was developed for the diabetic cohort for 
in-hospital mortality. 
Results: 18,309 pts underwent PCI during study period: 14827 non-dia- 
betics and 3482 diabetics. In-hospital mortality was 1 .O% and 2.0% for the 
non-diabetic and diabetic cohorts respectively, p < 0.001. Independent multi- 
variable predictors of in-hospital mortality for the diabetic cohort included the 
following: Age (Relative Risk (RR) 1.02; p < O.OOl), ejection fraction (RR 
1.02; p < O.OOl), serum creatinine (RR 1.17; p = 0.002) and hypertension 
(RR 1.31; p < 0.041). 
Conclusion: When compared with non-diabetics, pts with diabetes have 
a two-fold increase in short-term mortality following elective PCI. 
2:45 o.m. 
I 878 4 One Year Follow-up After Primary Coronary Interventions for Acute Myocardial Infarction in 
Diabetic Patients: STENT PAMI Trial Results 
Luiz Mattos, Cindy Grines, J. Eduardo Sousa, Gregg Stone, Marie 
C. Morice, Judith Boura, David Cox, Eulogio Garcia, William O’Neill, 
Mariann Graham, Brian Firth. lnsfitufe Dante Pazzanese of Cardiology, Sao 
Paula, Brazil; William Beaumont Hospital, Royal Oak, Michigan, USA 
Background: The multinational STENT PAMI trial randomized 900 pts with 
~12 hours of AMI at 62 centers, either to coronary stenting or primary PTCA. 
The 6 months ischemia driven TVR rote was reduced when a routine stenting 
strategy was applied (7.7 vs. 17%, p = 0.0001). However, the extension of 
this benefits to diabetic pts treated in AMI is not clear. 
Methods: We compared the combined occurrence of major clinical events 
at 1 year, between diabetic and non-diabetic pts randomized to heparin 
coated stent or balloon PTCA during AMI. 
Results: One year cumulative follow-up was obtained in 893 patients. 
Non-Diabetics (N = 758) Diabetics (N = 135) 
stent PTCA P stent PTCA P 
Baseline (%) 
N= 
Anterior MI 
TIM1 3 post 
Stenosis post 
6 months (%) 
lschemic TVR 
Restenosis 
Stenosis f-up 
1 year (%) 
Reinfarction 
Death 
Stroke 
lschemic TVR 
Combined 
377 
40 
89 
20 f 9 
17 0.001 8 16 0.18 
36 0.001 40 40 0.94 
47 rt 22 0.001 46 + 21 54 zt 23 0.09 
3.2 2.4 
6 3 
0.5 0.3 
10 21 
17 25 - 
44 0.26 
93 0.10 
29* IO 0.000 7 
0.49 1.4 3 0.60 
0.05 4 5 1.0 
0.62 0 1.6 0.50 
0.001 15 21 0.42 
0.005 20 30 0.21 
72 63 
42 41 
91 90.5 
lQzk7 28 zk 9 
0.96 
1.0 
0.0001 
Conclusions: At 1 year follow-up, non-diabetic stent pts had higher rate 
of death although the ischemia driven TVR and overall rate of combined 
events were lower for coronary stenting vs. balloon PTCA. For diabetics, 
routine stenting did not reduce the major complications of AMI and neither 
the need for further revascularization procedures driven by the presence of 
ischemic evidences. 
3:00 p.m. 
878-5 The Impact of Diabetes Mellitus on In-Hospital 
Clinical Outcomes Post Angioplasty 
S. Chiu Wong, Stylianos Papadakos, Carl Rosenberg, Gregory Gustafson. 
The New York Hospital Medical Center of Queens, Flushing, New York, USA 
Background: Diabetes mellitus (DM) is associated with worse long-term 
clinical outcomes post PTCA. Whether pts with DM also experience worse 
in-hospital clinical outcomes post PTCA less clear. 
Methods: Using the 1995 NYS Angioplasty Database, we compared 
acute clinical events in pts with DM (treated with insulin or oral hypoglycemics) 
to non-DM pts. 
Results: 
Pt Characteristics 
Age (yrs)/%Male 
%SmokelHypertension 
%Hx*MI/CHF 
%Multi -vessel disease 
%Hx stroke/CABG 
%Creatinine > 2.5 mg/dl 
%Dialysis/Shock 
Non-DM 
(N = 16,366) (N ::72) 
P value 
61172 63158 Both < 0.0001 
27157 19172 Both < 0.0001 
50/3.9 51/9.9 NSk0.0001 
42 54 <0.0001 
2112 4118 Both < 0.0001 
0.9 3.4 <0.0001 
O.UO.7 1.710.7 <O.OOOi/NS 
In-Hospital Events 
%DeathlCABGIQ-MI 0.77I1.5IO.32 1.42/i .3/0.25 0.0002iNSiNS 
%Dialysis/LOS#(days) O.OU5.5 0.55l6.4 Both 4 0.0001 
* = History of, # = length of stay 
Multi-variant regression analysis revealed age, female, history of DM (OR 
= 1.58, 95% Cl = 1 .I-2.3, P = O.Oi), Ml, prior CABG, dialysis and multi-vessel 
disease as well as pts with Ml, CHF, or shock on admission were independent 
predictors for in-hospital mortality. 
We conclude: 1) Compared with non-DM pts, DM pts had more adverse 
co-morbid conditions and were more likely to require dialysis with a longer 
length of stay post PTCA. 2) Pts with DM not only have a worse long-term 
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prognosis, but DM itself is an independent predictor for in-hospital mortality 
post PTCA. 
3:15 p.m. 
El 878 6 The Detrimental impact of Chronic Renal 
insufficiency and Diabetes Mellitus on Late 
Prognosis After Percutaneous Coronary 
Interventions 
Roxana Mehran, George Dangas, Luis Gruberg, Alexanda J. Lansky, 
Petros Okubagzi, Michael Astatkie, Ajith Purush, Kartick Desai, 
Frank Kiipper, Hassan Faraj, Kenneth M. Kent, Gregg W. Stone, Martin 
B. Leon. Cardiovascular Research Foundation Washington, DC, USA 
Background: The interaction of diabetes mellitus (D) and chronic renal 
insufficiency (RI, defined as serum creatinine >2.0 mgidl or dialysis) on 
prognosis after percutaneous coronary intervention (PCI) is unknown. 
Methods: We studied the effects of D and RI on late mortality, non-fatal 
myocardial infarction (Ml) and target lesion revascularization (TLR) in 7,640 
consecutive patients who underwent PCI. Patient grouping: (i) -D, -RI n = 
5278; (ii) +D, -RI n = 1681; (iii) -D, +RI n = 371; (iv) +D, +RI n = 300. Events 
were source documented and adjudicated by a dedicated Data Coordinating 
Center. 
Results: A significant additive effect of these two co-morbid conditions 
was noted with respect to short and long-term clinical outcomes: 
Outcomes 4, -RI +D, -RI -D, +RI +D, +RI P 
Procedural success 94.6% 97.5% 96.6% 98.3% NS 
n-day Death or MI 
l-year Death or MI 
1 -year TLR 
1 .6% 2.4% 3.6% 6.3% 0.0001 
4.2% 7.8% 14.9% 25.9% 0.0001 
16.8% 22.1% 16.4% 17.9%% NS 
Post-procedure CKMB enzyme elevation >3x normal occurred in 20%, 
18%, 21% and 25% of patients respectively (p = 0.006). 
Conclusions: The combination of D and RI confer additive and disastrous 
post-procedural prognosis in patients undergoing PCI, despite non-significant 
impact of long-term TLR. Thus, in patients with both co-morbid conditions, the 
options of medical therapy or bypass surgery should be considered strongly. 
If PCI is performed in patients with both D and RI, meticulous post:procedural 
scrutiny and medical management is warranted. 
ORAL 
m Gene Therapy: New Approaches to 
Restenosis and Angiogenesis 
Tuesday, March 14, 2000, 2:00 p.m.-3:30 p.m. 
Anaheim Convention Center, Lecture Hall A2 
2:00 p.m. 
879-I Results of a Phase I Open Label Dose Escalation 
Study of lntracoronary and Intravenous Basic 
Fibroblast Growth Factor (rFGF-2) in Patients (Pts) 
With Severe lschemic Heart Disease: 6 Months 
Follow-Up 
R.J. Laham’, N.A. Chronos*, M. Leimbach3, J.D. Pearlman’, R. Pettigrew’, 
V. Diisiziar?, J. Udelson5, M.J. Whitehouse6, M. PikeG, C. Yoshizawas, 
M. Simons’ ‘Beth-Israel Deaconess Medical Center, Boston, MA; “Atlanta 
Cardiovasc. Res. Inst., Atlanta, GA; 3Emory University, Atlanta, GA: 4~/H, 
Bethesda, MD; 5New England Medical Center, Boston, MA: “Chiron Corp., 
Emeryville, CA, USA 
Background: rFGF-2 is a heparin-binding growth factor capable of inducing 
functionally significant angiogenesis in animal models of chronic ischemia. 
Methods: This Phase I open label dose escalation study was designed 
to evaluate the safety, tolerability, PK and preliminary efficacy of intracoro- 
nary (IC) and intravenous (IV) rFGF-2 administered as a single 20 minute 
infusion in pts with ischemic heart disease not amenable to treatment with 
CABG or PTCA. Doses (fig/kg) studied IC ranged from 0.33-48, and IV from 
18-36. Efficacy was assessed using treadmill exercise testing (ETT), stress 
nuclear perfusion, magnetic resonance imaging (MRI) and Seattle Angina 
Questionnaire (SAQ) at baseline, 1 (except SAQ), 2 and 6 months. 
Results: 66 pts were enrolled in the study. The mean age was 60.6 
f 9.6 years with 95% males. 83% of pts had previous CABG, 48% had 
prior PTCA. Four pts died during the study (cardiac death in 3), 4 pts had 
myocardial infarction, and one patient had a malignancy. There were no 
clinically significant hemodynamic effects and no significant renal toxicity. 
Values for the following parameters (mean f SD.) pooled for all dose 
groups on all patients with measurements for the specified time points are: 
Baseline 1 month 2 months 6 months P value 
ET-T (set) 5161161 569 * 150 650 f 148 658i137 <0.001 
RPP (x1000) 18.6 + 6.7 17.7 + 5.6 18.5 i 6.0 21.6 i 6.5 <0.04 
SAQIEC 49.2 f 18.9 64.4 zt 21.8 71.2 i 24.1 <0.001 
SAQIAF 42.1 + 27.4 68.7 zt 27.5 63.7 i 29.7 <O.OOl 
MRlTWM% 21.3 * 8.9 24.3 2~ 9.5 26.2 1 9.7 28.6 ik 8.6 <O.OOl 
MWlschemia % 14.9 5 5.5 9.0 * 4.3 5.9 5 4.8 5.4 + 4.9 <O.OOl 
Nuclear/lschemia 8.3 + 7.0 7.3 zt 6.2 8.3 i 7.0 7.9 zt 6.1 0.12 
P value: 6 months compared to baseline, RPP: rate pressure product, EC: exercise ca- 
pacity, AF: angina frequency MRiTWM: target wall motion, MWischemia: ischemic area 
by MRI: NuclearNschemia: stress minus rest perfusion reversibility score 
Conclusion: A single IC or IV dose of rFGF-2 was well tolerated over a 
wide range of doses. Preliminary efficacy results in this open label, uncon- 
trolled study showed increased exercise tolerance, improved quality of life by 
SAQ, improved target wall motion, a reduction of rest ischemic area by MRI, 
and a similar degree of stress ischemia at a higher stress workload by nuclear 
imaging. A Phase II double blind placebo controlled study of intracoronary 
rFGF-2 is ongoing. 
2:15 km. 
ELI 879 2 Catheter-Based Transendocardial Injection of Adenoviral VEGFI~~ Offers Eauivalent Gene Deliverv .-. 
and Protein Expression Cornbared to a 
Surgical-Based Transepicardial Injection Approach 
Ran Kornowski, Shmuel Fuchs, Yoram Vodovotz, Michael A. Flynn’, David 
A. Gordon’, Anthony Pierre, Matie Shou, lmre Kovesd?, Joan A. Keiser’ , 
Martin B. Leon, Stephen E. Epstein. The Cardiovascular Research 
Foundation, Washington Hospital Center, Washington DC; ’ The 
Department of Cardiovascular Therapeutics, Parke-Davis Pharmacological 
Research, Ann Arbor, Ml; “GenVec, Inc., Rockville, MD, USA 
Background: Angiogenesis has been induced by direct injection of growth 
factors into ischemic myocardium during open-heart surgery. Catheter-based 
transendocardial injection of genes encoding angiogenic factors may provide 
equivalent benefit without the need of open chest thoracotomy. 
Methods: We have used a new guidance system (Biosense-Webstei”) 
for transendocardial injection by utilizing electromagnetic fields and catheter- 
tip sensors to locate the catheter position in space and reconstruct 3 dimen- 
sional left ventricular (LV) maps. The guidance system has been coupled to 
a retractable 27G needle for LV transendocardial injection. Ten (IO) animals 
underwent transendocardial catheter-based injection and 6 animals were 
injected transepicardially via open chest thoracotomy (n = 6) with the gene 
encoding vascular endothelial growth factor-l 21 (Ad. VEGFI 21 .lO; 1 x IO’O 
viral particles per site x 6 sites/animal) and sacrificed @24 hours. Injection 
sites were identified with UV light by co-injection of fluorescent beads. 
Results: 59160 (98.3%) transendocardial injection sites were identified 
vs 36/36 (100%) of transepicardial surgical injections. The transfection 
sites were discrete and manifested significant VEGFIPl production in 57/59 
sites (96.6%) using the catheter approach and in 36136 sites (100%) using 
the surgical approach. Ad. VEGF121.10 injected sites showed high levels 
of VEGFlp, production which was of similar magnitude whether injected 
transendocardially (880.4 f 412.2 pg VEGFlzl/mg protein) or transepicar- 
dially (838.3 * 270.0 pg VEGF&mg protein), (P = 0.62). 
Conclusion: The catheter-based transendocardial injection system offers 
an equivalent gene delivery efficiency and protein expression compared to 
the surgical-based transepicardial angiogenic gene delivery. Thus, this less 
invasive catheter-based system may have clear advantages compared to 
surgical-based transepicardial injection approach. 
2:30 p.m. 
879-3 Unique Kinetics and Hemodynamics of Vascular 
Endothelial Growth Factor (rhVEGF) Following 
lntracoronary and Intravenous Infusion in Humans 
Stephen M. Eppler’ , Edward R. McCluskey’, Timothy D. Henry, 
Michael Simons, Frank J. Giordano, Thomas F. Zioncheck’. ‘Genentech, S. 
San Francisco, CA, USA 
Background: Recombinant human vascular endothelial growth factor 
(rhVEGF) is a angiogenic factor that has been shown to improve myocardial 
blood flow and function in animal models of myocardial ischemla. VEGF 
binds to both high affinity signaling receptors and low affinity, high capac- 
ity heparan sulfate proteoglycans. Binding to these receptors, which have 
previously been shown to be upregulated under ischemic conditions, may 
influence VEGF disposition in vivo. Phase I clinical trials in patients with coro- 
nary artery disease investigated the safety, tolerability and pharmacokinetics 
74A ABSTRACTS - ACCISZOOO JACC February 2000 
(PK) of rhVEGF following two IO-minute intracoronary (IC) infusions (la) or 
multiple intravenous (IV) infusions (lb). Here we report the first description of 
rhVEGF PK in humans and the resulting changes in blood pressure. 
Results: The PK and hypotensive effects were dependent on rhVEGF 
infusion rate over the dose range studied (5 to 100 ng/kg/min). Systemic 
exposure following IC administration of 50 ng/kgfmin was low (plasma Cmax 
= 660 pg/mL) and returned to baseline levels by 30 minutes. Following IV 
infusion for 1, 2, or 4 hours at 50 ng/kg/min, the Cmax was 1230, 1540, and 
2640 pg/mL, respectively. VEGF levels decreased in a biphasic manner with 
an initial half-life ranging from 2-8 minutes and a terminal half-life ranging 
from 29 to 77 minutes. The plasma half-life increased with increasing dose, 
suggesting a saturable tissue uptake mechanism. The volume of distribution 
ranged from 2 to 15-fold greater than plasma volume, suggesting sequestra- 
tion of VEGF on endothelial receptors. Transient decreases in mean arterial 
pressure (MAP) were infusion rate dependent and ranged from 3 to 21 mmHg 
below baseline following rhVEGF IC infusion. The maximally tolerated infu- 
sion rate was 50 ng/kg/min for IC and IV routes. The maximal decrease 
in MAP occurred within 10 minutes followed by a return to baseline by 90 
minutes. Evidence for a tachyphylactic response was noted following the 
second IC infusion and by the return of MAP to near baseline levels during 
prolonged IV infusion (1-4 hours). 
Conclusion: VEGF is rapidly cleared from the systemic circulation via a 
specific and saturable tissue uptake process. A 20-minute IC infusion and 
a 4-hour IV infusion at 50 ngikgimin was hemodynamically tolerable and 
resulted in average VEGF plasma levels that were approximately 20 and 
80-fold greater than baseline levels, respectively. The characterization of 
VEGF PK and hemodynamics will be critical in optimizing the dose, route, 
and regimen for future clinical investigation. 
2:45 p.m. 
879-4 Reduction in Stress Myocardial lschemia by Basic 
Fibroblast Growth Factor (rFGF-2) in Severe 
lschemic Heart Disease 
J.E. Udelson’, V. Dilsizian’, R.J. Laham3, N.A. Chronos4, J. Vansant5, 
M.J. Whitehouses, M. Pikes, C. Yoshizawas, M. Simons3. ‘Tufts-New 
England Med Ctr, Boston MA; ‘NHLBYNIH, Bethesda MD; 3Beth 
Israel-Deaconess Med Ctr; Boston MA; 4Atlanta Cardiol. Res. Inst., Atlanta, 
GA.; ‘Emory University Atlanta GA; 6Chiron Cop, Emeryville CA, USA 
Background: While significant angiogenesis has been observed with rFGF-2 
in animal models, the effect on myocardial perfusion in humans is unknown. 
Methods: In a Phase I open label, uncontrolled, dose escalation study of 
an intracoronary or intravenous infusion of rFGF-2 in pts with severe ischemic 
heart disease, serial SPECT imaging was performed at baseline and at 1, 2, 
and 6 months using stress Tc-99m sestamibi and rest thallium-201. Images 
were evaluated by 2 observers blinded to patient and test sequence (dis- 
played randomly) using semiquantitative scoring of stress and rest perfusion 
in a 20 segment model (0 = normal, 4 = severe defect). 
Results: Of 66 pts enrolled, 51 pts had SPECT evidence of stress-induced 
ischemia at baseline. Changes in summed reversibility score (SRS, ischemia) 
and summed stress score (SSS, total abnormality at stress) in the ischemic 
segments compared to baseline in these 51 pts, for pooled dose groups are: 
1 Month 2 Months 6 Months 
SRS -3.0 * 3.2* -2.9 f 4.2* -3.8 * 4.0* 
sss -2.9 * 3.6' -2.8 * 3.P -3.1 + 4.2* 
*P < 0.001 
In 37 pts with evidence of rest hypoperfusion without severe infarction 
(mild/moderate rest thallium-201 defect), there was an apparent improvement 
in rest perfusion: 
1 Month 2 Months 6 Months 
Rest score -1.4f2.1* -1.2 zk 2.3* -0.7 * 2.1 
*P < 0. 005 
Conclusion: These preliminary efficacy data suggest that a single infu- 
sion of rFGF-2 reduces the magnitude of stress-induced myocardial ischemia 
for up to 6 months as assessed by nuclear imaging. 
1879-5 1 
3:00 p.m. 
Regional lntramyocardial Vascular Endothelial 
Growth Factor (VEGF) Gene Transfer and 
Expression Using a Fluoroscopically Guided 
Catheter-Based Technique 
Timothy A. Sanborn, Neil R. Hackett, Leonard Y. Lee, Irene Blanco, 
Norman Tarazona, Ezra Deutsch, Todd K. Rosengart, Ronald G. Crystal. 
Weill Medical College of Cornell University: New York, N,: USA 
Background: Preliminary reports indicate the feasibility of catheter-based 
plasmid and adenoviral mediated marker gene (B galactosidase) transfer and 
expression in porcine myocardium using both fluoroscopic and electrome- 
chanical mapping techniques. 
Objective: The present study was designed to test the feasibility of 
regional intramyocardial expression of the gene for the angiogenic growth 
factor (AdevVEGF121 .lO) using a percutaneous fluoroscopically guided leff 
ventricular catheter system. 
Methods: Using a coaxial 9F aligning and 6F endocardial delivery catheter 
system, 10 injections (1 x IO” pu/iOO @I of AdavVEGF121.10) were ad- 
ministered to either the anterolateral or posterolateral regions of porcine 
myocardium under biplane fluoroscopy. At 2448 hours, animals were sac- 
rificed for measurement of VEGF activity in 16 regions of the heart (apex to 
base; anterior, lateral, posterior and septal walls). 
Results: In the first series of animals (N = 3) in which injections were dis- 
persed over the left ventricular free wall, VEGF activity ranged from 50-200 
pglmg protein in the targeted regions. In the second group of animals (n 
= 3) in which VEGF administration was localized to the posterolateral area 
from mid ventricle to apex, VEGF activity was 1,272 f 365 pg/mg protein 
in the targeted areas as compared to 272 i 92 pg/mg protein in non tar- 
geted regions (p < 0.001). No arrhythmias, perforations or hemodynamic 
compromise odcurred. 
Conclusion: The feasibility of fluoroscopically guided, endocardial, 
catheter-based gene transfer and expression of an angiogenic agent (Adov 
VEGF121.10) has been demonstrated. Localized administration of this agent 
with a percutaneous approach can achieve VEGF levels of similar magni- 
tude to the direct surgical epicardial application. This technique may provide 
clinical benefit for patients who are not candidates for conventional bypass 
surgery or angioplasty. 
3:15 p.m. 
879-6 Low Event Rates in Patients With Viable 
Underperfused Myocardium Who are Not Eligible 
(VUNE) for Revascularization: A VIVA Substudy 
William L. Greene, Edward R. McCluskey. The V/VA Investigators; 
Genentech, Inc., South San Francisco, CA, USA 
Background: Patients who have viable underperfused myocardium but are 
not considered eligible for PTCA or CABG are thought to have high rates 
of morbidity and mortality and to be “end stage”. They have recently been 
targets of novel revascularization strategies such as transmyocardial revas- 
cularization (TMR). Claims of success with these therapies are difficult to 
evaluate because intervention studies in this population are often uncon- 
trolled. TMR trials report up to 10% 30-day mortality (up to 18% at one 
year) in these patients. The VIVA trial assessed rates of adverse events in a 
prospectively defined, placebo controlled cohort of VUNE patients. 
Methods: Patients were eligible if they were willing: to participate in a 
clinical trial, had stable angina and a significant reversible defect by nuclear 
perfusion studies, but were not optimal candidates for PTCA or CABG. 
rhVEGF protein (Genentech, Inc.) was administered by two IO-minute IC 
infusions followed by three 4 hour IV infusions and compared with placebo. 
The primary efficacy endpoint of improved treadmill exercise time compared 
to placebo was not reached, so results for the entire cohort are combined for 
outcomes analysis at 120 clays. 
Results: Baseline demographics: mean age was 60; 59% had a prior MI, 
86% prior CABG, 58% prior PTCA; 63% had Class Ill-IV angina, and 31% 
had CHF. At follow-up, 52% had Class Ill-IV angina and 29% had CHF. 
120 day outcomes Placebo VEGF All Patients 
(n = 63) (n = 115) (n = 178) 
Death 2 0 2 (1%) 
MI 0 0 0 (0%) 
Any Hospitalization 5 9 14 (8%) 
New or worsened CHF sxs. 3 8 11 (6%) 
Worsened angina (~1 class) 4 3 7 (4%) 
Mean change in angina class -0.62 -0.89 -0.79 
Conclusions: Contrary to common perception, “end stage” VUNE pa- 
tients in clinical trials do not have extremely high short to medium term 
mortality and morbidity. In this study, there were few deaths and little devel- 
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opment or worsening of CHF. Patients’ angina symptoms improved signifi- 
cantly (perhaps due to being enrolled in a clinical trial). Intervention studies 
in VUNE patients should employ a control group to avoid erroneous claims 
of clinicai success and possible patient harms from exposure to unwarranted 
therapeutic maneuvers. 
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EII 1175 75 Minor Myocardial Damage is Not Associated With 
an Increase of Cardiovascular Events During 
Follow-Up After Angioplasty With High Rates of 
Stenting and GPllbllla-Antagonist Application 
B. Mark, Ft. Zahn, K. Donges, B. Fraiture, B. Frilling, F. Fischer, D. Nagel’, 
D. Seiler’ , J. Senges. Herzzenfrum Ludwigshafen; ‘Insfifut fiir Klinische 
Chemie, Klinikum Lodwigshafen, Germany 
Background: After percutaneous transluminal coronary angioplasty (PTCA) 
5-30% of the patients (pts.) show a minor myocardial damage (“infarctlet”) 
diagnosed by an elevation of cardiac markerenzymes without a new ST-ele- 
vation or new Q-waves. Little is known about the prognostic value of these 
infarctlets particular-y in the era of stenting and GPllbllla-antagonists. 
Methods: Since October 1997, 619 pts. who underwent PTCA for stable 
or unstable angina were included in a prospective registry. Pts. with an acute 
myocardial infarction in the past 48 hours or a perinterventional infarction 
were excluded. Total-CK, CK-MB and troponin T were measured before 
intervention, 1 to 2 hours and 8 to 24 hours after intervention. Clinical and 
procedural data were documented. Follow-up data were obtained after 6 
months. 
Results: 48% of pts. underwent the procedure for a stable and 52% for 
an unstable angina. A stent was implanted in 48%. 21% were treated with a 
GPIIbilla-antagonist. An elevation of total-CK over the upper limit of normal 
was found in IO%, whereas CK-MB was elevated in 36% and troponin T 
in 16%. After 6 months pts. showed the following rates of MACE [= major 
adverse cardiovascular events: unstable angina (UA), myocardial infarction 
(Ml), Revascularisation by PTCA/CABG, death]: 
” = 619 pts. all MACE UA 
lnfarcflet 12% 3% 
no infarctlet 12% 2% 
MI Revascular. Death 
1% 6% 2% 
1% 8% 1% 
Pts. with and without infarctlet had no significant difference in the rates of 
MACE during this follow-up periode. 
Conclusion: In pts. treated with PTCA combined with high rates of stent 
implantation and application of GPllbllla-antagonist, the occurrence of an 
infarctlet was not associated with an increase in the rate of MACE during a 
follow-up period of 6 months. In these pts. MACE were found almost half as 
often (12%) than reported in previous studies (20%). 
1175-76 The Deleterious Prognostic Impact of Cardiac 
Tropnin I Re-Elevation Following Percutaneous 
Coronary Intervention in Patients With Acute 
Coronary Syndromes 
Shmuei Fuchs, Ran Kornowski, Roxana Mehran, Lowell F. Satler, Mun 
K. Hong, Steve Slack, Gregg W. Stone, Martin 8. Leon. The Cardiovascular 
Research Foundation, Washington Hospital Center, Washington, DC, USA 
Background: In patients undergoing percutaneous coronary intervention 
(PCI) with normal baseline cardiac enzymes, Troponin I (Tnl) elevation may 
be associated with adverse clinical outcomes. However, the prognostic im- 
portance of cardiac Tn-I re-elevation in high-risk patients with acute coronary 
syndrome (ACS) as reflected by elevated admission Tn-I levels has not been 
determined. 
Methods: We studied 133 consecutive patients (68% males) with non-ST 
elevation ACS (62% non-Q wave Ml) and elevated admission Tnl (>0.15 
rig/ml) levels who underwent PCI ? 48 hrs from admission. Tnl levels were 
routinely measured Q 6 and 18-24 hrs after the PCI and patients were dis- 
tinguished according to the presence or absence of Tnl re-elevation (>xl or 
<xl admission levels). In-hospital and cumulative &month clinical outcomes 
were compared between the 2 groups. 
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Results: Patients with Tnl re-elevation (n = 52) were slightly older (68 i 
12 vs 64 & 13 years) but otherwise had similar baseline characteristics, clin- 
ical presentation and angiographic success (overall 97%). Tnl re-elevation 
group had significantly higher in-hospital and 6 months death rate Ml and 
target lesion revascularization (TLR) were similar between groups (Table). 
By multivariate analysis, Tnl re-elevation (OR 8.9, 95% Cl 1.9-41.7, p = 
0.005) and diabetes mellitus (OR 8.6, 95% Cl 1.6-45.9, p = 0.01) were the 
strongest independent predictors for increased 6-months cumulative mor- 
tality. 
Tnl Re-Elevation (# pts) 
In-Hospital 
Death/Q-Ml (%) 
6 months follow-up 
DeathlMlmLR (%) 
Event Free Survival (%) 
No (al) 
o/o 
4.2/4.3/17.4 
64.7 
Yes (52) 
11.110 
23.9/13.5/16.7 
65.2 
P Value 
0.00311 .o 
0.001/0.12/0.92 
0.014 
Conclusion: Tnl re-elevation following PCI is associated with substantial 
increased mortality and overall cardiac events at follow-up. Thus, adjunctive 
pharmacotherapy aimed to reduce subsequent cardiac enzymes elevation 
may become mandatory among high-risk ACS patients who undergo early 
PCI. 
/ 1175-77 1 Prognostic Value of Recurrent Episodes of CK-MB 
Elevation Following Repeated Catheter-Based 
Coronary Interventions 
Ran Kornowski, Shmuel Fuchs, Roxana Mehran, Lowell F. Satler, August0 
D. Pichard, Kenneth M. Kent, Steve Slack, Mun K. Hong, Gregg W. Stone, 
Martin B. Leon. Washington Hospital Center, Washington, DC, USA 
Background: Creatine kinase-MB (CK-MB) elevation after percutaneous 
coronary intervention (PCI) has been associated with an adverse prognostic 
risk. The impact of recurrent episodes of CK-MB rise following repeated PCls 
has not been shown. 
Methods: We studied 767 consecutive pts (age 64 i 11 yrs, 69% male) 
who underwent 2 consecutive PCls on 2 separate hospitalizations (mean 
interval 121 f 210 days). Patients were stratified to 4 groups according to 
number of episodes of any (>4 ngiml) post PCI CK-MB rise (none, once 
[current or previous procedure] or twice, N = 403, 107, 153 and 104 pts, 
respectively). In hospital clinical outcomes (death, Q-MI, and repeat revas- 
cularization) and @up to one-year follow up were obtained. 
Results: Recurrent episodes of CK-MB elevation were associated with 
(1) increased in-hospital mortality, (2) increased cumulative mortality and Q 
wave Ml rates and lower overall cumulative cardiac event-free survival at 
one year (Table). 
CK-MB Elevation NOW3 Prior Current Twice P 
[#Patients\ (403) (1531 (1071 11041 
In-hospital 
Death/Q-Ml (%) o/o.2 010 1.911.9 3.8/l .9 0.000310.05 
One-year cardiac events 
Death/Q-wave Ml (%) 4.310.8 4.311 .o 5914.9 18.9B.O 0.0003/0.005 
Event-free survival (%) 88.8 86.8 80.5 66.8 <0.0001 
By multivariate analysis, recurrent episodes of CK-MB elevation was the 
strongest independent predictor for cumulative mortality (OR 3.4, 95% Cl 
1.6-7.1, P = 0.001) or any adverse cardiac events (OR 2.6, 95% Cl 1.6-4.3, 
P = 0.0002) at one year. 
Conclusions: Repeated episodes of peri-procedural CK-MB elevation 
are associated with incremental cumulative adverse prognostic risk including 
mortality and Q wave MI. Thus, prior records of peri-procedural CK-MB rise 
should be obtained and procedural measures aimed at reducing subsequent 
CK-MB ‘leak’ may become warranted among patients with a prior history of 
PCI related CK-MB elevation. 
(1 AngioJet@ Rheolytic’” Thrombectomy: 
An Important Tool for Percutaneous Coronary 
Interventions in High Risk Patients; VeGAS II Trial 
S. Dohad, T.M. Parris, C. Setum, M. Cohen, D.J. McCormick. Hahnemann 
University Hospital, Philadelphia, PA, USA 
Background: lntracoronary thrombus during percutaneous coronary inter- 
vention is associated with poor outcome. We evaluated procedural success 
(PS) and outcome in patients with large thrombus burden using AngioJet 
rheolytic thrombectomy (ART). 
Methods: Patients from randomized trial (VEGAS II) assigned to ART 
(A), urokinase (U), and patients in the thrombolysis exclusion registry of 
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VEGAS II (R), from 21 centers were evaluated for outcome. QCA and TIMI 
(T) flow measurements were performed by angiographic core lab. Endpoints 
were analyzed on an intent-to-treat basis and adjudicated by an independent 
clinical endpoints committee. Major adverse cardiac events (MACE) included 
death, Q-wave MI, non-Q wave MI (CKMB > 3 time normal), CABG, target 
lesion revascularization, CVA, stent thrombosis at 30 days, and failure to 
achieve: post-procedure diameter stenosis (DS) < 50%, T Ill flow, or ~20% 
change in DS. 
Results: 454 patients (105 R, 180 A, 169 U), mean age 63 + 12 years, 
78% male, were evaluated, with similar baseline demographics and lesion 
characteristics (except trombus burden) between groups. Pre-procedure 
mean LVEF was 47%, minimum luminal diameter was 0.83 mm, lesion 
length was 15.67 mm. Interventions were performed on 48% native coronary 
lesions and 52% saphenous vein grafts. 75% were B2/C lesions, 99% with 
thrombus. In the A and R groups, T Ill flow was achieved in 75% post-ART 
alone (MLD 1.6 mm), and in 88% at the end of the procedure (MLD 2.6 mm, 
21.6% with residual thrombus, 73% stents). 
ps* NO LOS TBR* % MACE MACE MACE 
reflow * in hosoital 30 davs 1 vear 
PI=105 76%* 14.4%* 4.1* 63.4% 20.0%* 24.0%X 31%* 
A=180 88.3%* 7.8%’ 2.5* 91.0% 13.9%* 15.1%” 28%* 
U=169 72.2% 11.1% 3.5* 83.6% 30.6%* 32.5%* 44%* 
Key: a P c 0.01; * LOS = length of stay, PS = proceduresuccess (DS < 50%, T III flow, no 
death, urgent CABG, Q wave MI prior to discharge): TBR = thrombus burden reduction. 
Conclusion: ART is a superior strategy for patients undergoing high risk 
percutaneous coronary interventions with large thrombus burdens. 
1175-79 The strategy for side branch during intervention 
of target lesion 
Teruo Okabe, Yasushi Asakura, Shiro Ishikawa, Keiko Asakura, 
Toshiyuki Takahashi, Akio Kawamura, Hideo Mitamura, Satoshi Ogawa. 
Keio Universifi: Tokyo, Japan 
We evaluated whether the intervention for side branche lesions (SB) at the 
target lesions (TL) was effective on initial and late results during the same 
procedure for the latters, by way of the quantitative coronaty angioplasty 
WA). 
Methods: The study population consists of 432 patients whose TL had SB 
more than 1 .O mm of the refference diameter (RD), and were followed up by 
the angiography. The groups that had already SB before the procedure were 
sub-devided into group I which were treated by PTCA and group II which 
were not. The groups that had new lesions at the ostium of side brances 
during the procedure for TL were sub-devided into group Ill which treated 
by PTCA and group IV which were not. The group V had no SB before and 
through procedures, as control group. As QCA measurements, RD of both 
TL and SB, and %DS were measured at initial and follow-up time. 
Result: The RD of both TL and SB before the procedure did not affect 
the results of SB. The favourable %DS immediately after the procedure in 
group I became worse at follow-up. There were no different of %DS in group 
II and Ill between after the procedure and at follow-up. However, in group IV, 
%DS after the procedure improved significantly at follow-up. The %DS of SB 
at follow-up were affetcted by whether or nbt TL would become restenotic 
(restenosis (+); 39.2 f 2.5%, restenosis (-); 32.9 f 1.7%) (p < 0.05). 
side branch lesions f+) new lesions control 
group I (n = 45) ll(n=57) lll(n=31) IV(fl=59) V(n=240) 
%DS atter procedures 34.7 + 3.8 51.9 i 1.4 33.5 k 4.4 76.3 i 2.6* 18.9 I 1.2 
%DS at follow-up 46.9S2.9# 49.453.5 46.6i5.0 47.2f3.9 22.1 il.6 
#p < 0.05 vs. after procedures *p c 0.05 vs. at follow-up 
Conclusion: This study indicated that initial results of intervention for side 
branch lesions did not reflect the late results of side branches. Moreover, it 
was suggested that the late results of side branches might be affected by the 
late results of target lesions. 
1 II 75-80 1 Cutting Balloon for Treatment of In-Stent 
Restenosis: Is it More Effective Than 
Conventional PTCA? 
E. Schmidt, B. Lauer, S. Stellbring, H. Ambrosch, K.-W. Diederich, 
R. Hambrecht, H. Krankenberg, A. Kuhn, P. Sick, R. Zotz, G. Schuler. Hearf 
Center, Univ. of Leipzig, Germany 
Background: In the era of stenting the optimal treatment of an instent 
restenosis has become a growing problem. Conventional PTCA alone does 
not yield satisfactory long-term results. Therefore we examined whether 
cutting balloon (CB) treatment leads to better results compared to PTCA 
(P). Angioplasty with a CB is thought to produce lesser tissue trauma and 
therefore may lead to less intima proliferation. 
Methods: In a controlled matched paired follow-up study we compared 
the primary and long-term-results of 60 patients (pat) with in-stent restenosis 
who were treated either with cutting balloon or PTCA. Thirty pairs of patients 
were matched according to target lesion, degree and length of stenosis. 
Coronary angiograms were analyzed bei quantitative coronary angiography 
(QCA) after primary treatment and after six months. 
Results: The degree of stenosis (DS) before treatment showed no signif- 
icant difference (70.6 f 74.0% (CB) vs 70.8 & 13.3% (P)). Primary outcome 
after the procedure was similar in both groups (27.4 & 9.6% (CB) vs 26.9 i 
8.9% (P)). After six months (30 pat) the DS was not different (44.2 f 23.1% 
(CB) vs 47.5 f 21.9% (P)) between the two groups (p = 0.57). Net gain was 
similar for both procedures (26.4 & 21.9% (CB) vs 23.2 i 19.7% (P), p = 
0.73). Out of 30 controls target lesion revascularisation was necessary after 
CB in 6 patients and after PTCA in 5 patients. 
Conclusion: The treatment of in-stent-restenosis with a cutting balloon 
does not seem to yield better long-term results compared to conventional 
PTCA. 
[ 1175-81 ( Prospectively Randomized Evaluation of Regular 
Physical Exercise Versus PTCA/Stent in Stable 
Coronary Artery Disease 
Claudia Walther, Nina Schoene, Anamaria Wolf, Doris Burck, Jiang-Tao Yu, 
Peter Sick, Rainer Hambrecht, Gerhard Schuler. University of Leipzig, Heart 
Center, Department of Cardiology, Leipzig, Germany 
Background: Aim of this study is to evaluate the effects of regular physical 
exercise training in comparison to an interventional approach (PTCA and 
stent implantation) as primary therapy in patients with symptomatic but stable 
coronary artery disease (CAD). 
Methods: 42 male patients (pts) with coronaty artery stenosis (amenable 
for PTCA/stent implantation) with evidence of local ischemia as assessed by 
radionuclide scintigraphy were prospectively randomized to either a training 
group (T) (n = 22) or an intervention group (INT) (n = 20). Pts of the T 
group exercised daily for 20 minutes at 70% of their peak oxygen uptake 
(V02max) on a bicycle ergometer whereas pts in INT underwent PTCA with 
stent implantation. At the beginning and after 6 months patients underwent 
a symptom-limited bicycle ergospirometty. 
Results: After 6 months pts in T and INT demonstrated a significant 
improvement in clinical status (CCS-class) (from 1.4 f 0.6 to 0.7 f 0.6 and 
from 1.3 & 0.6 to 0.8 f 0.7, respectively). Compared to INT, pts in T showed 
a significant increase in functional work capacity and peak oxygen uptake by 
25% (from 134 + 20 to 167 i- 24 [watts], p < 0.05 vs. INT) and by 18% (from 
23.1 f 3.2 to 27.2 f 4.2 [mUkg/min], p < 0.05 vs. INT), respectively. 
Conclusion: Daily physical exercise training seems to be a feasible 
alternative to PTCA/Stent. Both therapies are equally effective regarding the 
mid-term clinical status of patients with symptomatic CAD. The significantly 
higher improvement in functional work capacity after training may result in a 
better quality of life for the patients. 
) 1175-82 ) Gradual Computerized Inflation During Coronary 
Angioplasty Reduces by Half the Need for 
Stenting and Revascularization 
A. Teddy Weiss, lony Katz, Morris Mosseri, Chaim Lotan, Hisham Nassar, 
Yoseph Rozenman, Mervyn S. Gotsman. Hadassah Universjty Hospital, 
Jerusalem, lsrael 
We developed CAPSID (computerized automatic pressure sensor and inflator 
device) for gradual-inflation of the balloon to reduce traumatic dilatation 
of coronary stenosis, the major cause for early and late complications of 
coronary angioplasty. CAPSID was applied by intermittent, slow (over 20 
inches) incremental pressure rise inflations, followed by rapid deflations and 
reperfusion (183 lesions) or by a continuous, single slow gradual inflation 
over 120 set (91 lesions). This study summarizes our experience in these 
274 lesions, dilated gradually by this device - and compared the results 
to those obtained in a similar consecutive patient group (278 lesions) who 
underwent standard angioplasty, at the same time period, on days when the 
device was unavailable. Baseline characteristics were similar. The need for 
provisional stenting was significantly less in the CAPSID group - 12% vs 25% 
and the rieed for i-year target lesion revascularization (TLR) was halved 16 
vs 36% in the standard group (p < 0.05). TLR was significantly reduced by 
CAPSID in subsets of patients with higher risk for restenosis: diabetes, 11% 
vs 27% and in proximal LAD lesion: 12% vs 23% (p < 0.05). 
Conclusions: Gradual computerized inflation by CAPSID halved the 
need for provisional stenting and the need for TLR, by minimizing the trauma 
applied on the vessel wall. 
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/ 1175 88 Does the Pattern of Arterial Remodeling Impact 
Vessel Behavior Following Balloon Angioplasty? 
A Serial Intravascular Ultrasound Study 
Hiroyuki Okura, Shinichi Shimodozono, Motoya Hayase, Paul G. Yock, 
Peter J. Fitzgerald. Stanford University Medical Center, Stanford, CA, USA 
To characterize the impact of pre-intervention arterial remodeling on subse- 
quent vessel behavior following balloon angioplasty (BA), serial IVUS anal- 
ysis was performed in 93 coronary lesions. IVUS imaging was performed 
before and after BA in all lesions, and repeated at 6 M follow-up in 37 le- 
sions. External elastic membrane (EEM) and lumen area were measured. 
Plaque + media (P + M) area was calculated as the difference between EEM 
and lumen area. The pattern of remodeling was classified as follows: (1) pos- 
itive remodeling (PR) as EEM area-lesion > EEM area-proximal reference, 
(2) intermediate remodeling (IR) as EEM area-proximal reference > EEM 
CSA-lesion P EEM CSA-distal reference, (3) negative remodeling (NR) as 
EEM area-lesion c EEM area-distal reference. Serial changes in EEM, P + 
M, and lumen were compared. 
Results: PR, IR, and NR were present in 29 (31%) 35 (38%), and 29 
(31%) of 93 lesions, respectively. Although acute lumen gain was similar, 
lesions with PR showed a smaller AEEM and larger AP + M area than those 
with NR (both, p < 0.05). During 6 M follow-up, lesions with PR showed a 
smaller AEEM area compared to those with NR (p < 0.05). However, AP 
+ M area was similar among the three groups. As a result, late loss was 
significantly larger in those with PR (p < 0.05). 
Ml occurring after revascularization of the target vessel was not considered 
LST. 
Results: Definite LST occurred in 8 patients (47-l 45 days post-stenting), 
with possible LST in an additional 11 (34-269 days post-stenting). The 
cumulative incidence of LST is shown below. The 95% Cl for the rate of LST 
at 180 days was 0.4-2.2/1000 for definite and 1.6-4.3/1000 for possible LST. 
Conclusion: Ml with stent thromboses beyond 30 days after elective 
stenting of native coronary arteries (without the use of brachytherapy) occurs 
rarely (I-311 000 at 180 days). 
L-A 1176 85 Aggressive Stent Dilatation Results in Lower Restenosis Despite Greater Late Loss 
Yoshio Kobayashi, Joseph De Gregorio, Nobuyuki Kobayashi’ , Carlo Di 
Mario’, Antonio Colombo’ Lenox Hill Hospital, New York, Ply USA; ’ Centro 
Cuare Columbus, Milan, My 
Background: There is a concern if aggressive stent dilatation (negative 
residual stenosis) causes excessive late loss and results in restenosis. 
Methods: Between April 1993 and July 1997, 1,306 lesions with 13 
mm reference vessel diameter underwent successful stenting. Lesions were 
divided according to the final % diameter stenosis achieved after stenting; 
1) Group with a positive residual stenosis (n = 835) defined according to the 
presence of a final % stenosis 2 0 and <30%, 2) Group with a negative 
residual stenosis (n = 471, final % stenosis < 0%). 
Results: 
PR IR NR 
Positive Neoative P 
AEEM area (post-6 M) 
AP + M area (post-6 M) 
Alumen area (post-6 M) 
* p < 0.05 “s NR 
-0.2* 1.5 1.8 
1.4 2.4 1.4 
-1.5* -0.9 0.4 
Conclusions: The pattern of arterial remodeling affects both mechanism 
of acute gain and late loss following BA. Lesions with PR appear to have 
less capacity to compensate further to plaque growth following BA and thus 
show proportionally larger late loss despite the similar acute gain. This may in 
part explain the less favorable outcomes of the positively remodeled lesions 
following coronary interventions. 
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/ 1176 84 The Incidence of Late Stent Thrombosis Without the Use of Brachytherapy 
Kaion K.L. Ho, Donald E. Cutlip, David J. Cohen, Manish S. Chauhan, Alyce 
S. Lanoue, Christine M. Rizzitano, Janine M. Schmidt, Shiu K. Ho, Richard 
E. Kuntz. Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, Massachusetts, USA 
Background: Acute thrombosis within the 1 st 30 days after stent implantation 
is well-described. Recent angioscopic studies and anecdotal reports suggest 
that endothelialization of stents may be incomplete at 30 days, leading to 
subsequent late stent thrombosis (LST) with acute myocardial infarction (Ml), 
especially after use of intracoronary brachytherapy. 
Methods: The incidence of LST (at r30 days post-stenting) was exam- 
ined in 6535 patients who underwent elective stenting of a native coronary 
artery (without the use of brachytherapy) in 7 FDA-sanctioned clinical trials 
and who were free of stent thrombosis at 30 days, The median duration of fol- 
low-up was 284 days. Definite LST was defined as an acute Ml attributable to 
the stented vessel with angiographic evidence of thrombus or total occlusion 
at the original stent. Possible LST was defined as an acute Ml attributable to 
the stented vessel in the absence of an identifiable “culprit” lesion elsewhere. 
Multiple stems (%) 
Stent thrombosis (%) 
Reference (mm) 
Lesion length (mm) 
Pm-MLD (mm) 
Final MLD (mm) 
Final % stenosis 
F/U MLD (mm) 
Restenosis (%) 
Acute gain (mm) 
Late loss (mm) 
Loss index 
30 
1.1 
3.47 It 0.40 
12.0 f 7.4 
0.94 i 0.58 
3.21 i 0.47 
8.7 f 6.3 
2.21 l 1.06 
23.5 
2.27 i 0.66 
1 .Oi + 0.98 
29 
0.6 
3.37 zk 0.33 
10.6 & 6.1 
0.92 + 0.53 
3.60 i 0.44 
-6.9 +. 5.0 
2.39 i 0.92 
16.2 
2.69 z+ 0.61 
1.25 + 0.88 
NS 
NS 
co.01 
<O.Ol 
NS 
<O.Ol 
<O.Ol 
0.01 
<O.Ol 
<O.Ol 
<O.Ol 
0.47 i 0.51 0.48 * 0.34 NS 
MLD: minimum lumen diameter, F/U: follow-up 
Follow-up angiography was performed in 925 of the 1,288 lesions (72%) 
eligible for follow-up. 
Conclusion: Aggressive stent dilatation results in lower restenosis de- 
spite greater late loss because of similar loss index. 
L-L. 1176 86 Influence of the Presence and Type of Diabetes Mellrtus on the Initial and Long-Term Outcome 
After Coronary Stenting 
Joaquin J. Alonso, Juan M. Duran, Federico Gimeno, Benign0 Ramos, Juan 
C. Murioz, Luis de la Fuente, Ana Serrador, Javier Paniagua, lciar Gomez, 
Francisco Fernandez-Aviles. Hospital Universitario, Valladolid, Spain 
Background: Data regarding the evolution after coronary stenting (CS) of 
insulin-dependent diabetes mellitus (IDDM) and non-IDDM patients are scant 
and controversial. 
Methods: To assess the initial and long-term efficacy of CS in diabetics 
we compared the evolution of 35 IDDM patients (pts) with the outcome of 92 
non-IDDM pts and a control group of 856 nondiabetic stented pts of a series 
of 983 consecutive pts treated with CS. Patients with IDDM were more often 
female (40%) and had a higher rate of previous heart failure (14%) and lower 
reference diameter (p < 0.05, compared with non-IDDM and non-diabetic 
pts). Hypertension was more frequent in non-IDDM pts than in the other two 
groups (52% vs 46% vs 37%, p < 0.05). Clinical follow-up was completed for 
94% of pts (3.1 i 1.4 years, range: 1.865). 
Results: Clinical success at one month (angiographic success without 
major events) was similar among the three groups (IDDM: 93%, non-IDDM: 
94%, non-diabetic: 94%). Angiographic restenosis rate was significantly 
higher in IDDM pts. Major adverse cardiac events (death, re-PTCA, CABG 
or admission for myocardial infarction or unstable angina) (MACE) during 
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follow-up were significantly higher among diabetics, without differences be- procedures 11.4%, for single vessel/multiple stenting 13.0%, and for multi- 
tween IDDM and non IDDM-pts (figures) ple-vessel stenting 24.3%. 
Conclusions: Thus: 1) initial outcome of diabetics is similar to that of 
nondiabetic pts but angiographic restenosis occurs more often in IDDM pts; 
2) diabetics have a worse clinical long-term evolution without differences 
related to the type of diabetes. 
At late follow-up, 11 pts died (2.5%), 46 pts had repeat PTCA (10.5%), 
and 11 pts underwent CABG (2.5%). 
Conclusion: These data indicate that the GFX stent can be deployed 
successfully in a set of patients with complex clinical and anatomic features 
with low in-hospital event rates and excellent long-term TLR rates, particularly 
in patients receiving single stents < 30 mm. 
1 1176-87 1 Balloon Angioplasty Versus Stenting in Diabetic 
Patients With Coronary Atherosclerosis 
Peter K. Mazeika, Neeraj Prasad, Sanh Bui, Peter Seidelin. Division of 
Cardiology; The Toronto Hospita/, Toronto, Ontario, Canada 
Background: Although coronary stenting reduces angiographic restenosis 
in diabetic patients, its impacton clinical outcome remains undefined. 
Methods: The Angioplasty v Stenting in Diabetics with Angina (ASDA) 
study compared the clinical effectiveness of these treatments using a obser- 
vational historically prospective cohort design. Over 30 months, 176 of 433 
diabetics who underwent an intervention, met the inclusion criteria and were 
enrolled. The 88 patients in each group had similar baseline characteristics 
and were followed up 22 (8) months later. Assuming an alpha error of 0.05 
and a treatment difference of 1.75, a sample size of 176 gave a power of 
80%. 
Results: Post-procedure MLD was greater with stent placement (2.97 
(0.44) ~2.24 (0.53) mm; p < 0.001). Event-free survival for the composite 
primary endpoint (death, MI, repeat revascularization, clinical restenosis) 
favoured stenting (hazard ratio 1.57; 95%CI, 0.95-2.58; p = 0.08; graph). A 
similar trend was seen for the composite secondary endpoint of TVR and 
clinical restenosis (hazard ratio 1.72; 95%CI, 0.99-2.99; p = 0.05). After 
adjusting for covariates using Cox regression analysis, the results for both 
primaty (hazard ratio 1.62; 95%CI, 0.97-2.69; p = 0.06) and secondary 
(hazard ratio 1.64; 95%CI, 0.94-2.86; p = 0.08) endpoints changed only 
slightly. There was no significant interaction between mode of intervention 
and severity of CAD. 
0.00 c 0 260 460 ,i,-~,~o,,,~ e&o r&o IzzdO 
Conclusion: A strong and consistent trend favoured stenting for both 
endpoints, and persisted after adjusting for covariates. Diabetics requiring 
coronary revascularization who are not surgical candidates should be con- 
sidered for stent placement rather than PTCA. 
EIII 1176 88 Acute and Long-Term Outcomes for a New Generation Stent: Exoerience in 441 Patients With 
the Medtronic AVE GkX Stent 
Michael J. Giocondo, Steven P. Marso, Kenneth C. Huber, Lee V. Giorgi, 
Steven P. Laster, Barry D. Rutherford. Mid America Heart Institute, Saint 
Luke’s Hospital, Kansas Cifi: Missouri, USA 
Background: The acute and long-term outcome for patients (pts) receiving 
the Medtronic AVE GFX (GFX).stent have not previously been documented 
for a large, complex group of pts. 
Methods: Using a computerized database and chat-l review, we identi- 
fied 441 consecutive pts undergoing elective GFX stenting and evaluated 
in-hospital and long-term clinical outcomes. Mean follow-up was of 9.5 - 4.5 
months. 
Results: Mean age was 64.8 f 12.0 yrs, 174 pts (39.4%) were ~70 
yrs, 116 pts were female (26.3%), mean LVEF was 47.7 & 12.6%, 163 pts 
(37.0%) had multi-vessel disease, 134 pts (30.4%) had unstable angina, 32 
pts had diabetes (7.3%), 14 pts had serum creatinine > 2.0 mg/dL (3.2%), 
198 pts (44.9%) had previous PTCA, 86 pts (19.5%) had previous CABG, 
and 32 pts (7.3%) had an acute Ml < 24 hours. Procedural success was 
achieved in 424 pts (96.1%), 4 in-hospital deaths occurred (0.9%), 2 pts had 
an acute Ml (0.5%), 11 pts (2.5%) required repeat PTCA, in-hospital MACE 
(death, acute MI, em-CA&G, and re-PTCA) was 17 (3.9%), and acute stent 
thrombosis rate was 6 (1.4%). 
Target lesion revascularization (TLR) rate at follow-up was 57/426 (13.4%). 
For stent diameter 3.0, 3.5, and 4.0 mm, TLR was 16.7, 8.3, and 4.9% re- 
spectively (resp). For stent lengths O-12, 13-24, 25-36, and >37 mm, TLR 
was 7.5, 12.5, 13.6, and 13.2% resp. TLR rate for LAD, RCA, LCX, and SVG 
were 8.7, 7.2, 9.7, and 13.0% resp. TLR rate for single-vessel/single-stent 
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1176 89 Minor Myocardial Injury With Primary Coronary 
Joerg Herrmann, Clemens von Birgelen, Michael Haude, Dirk Welge, 
Axel Schmermund, Dietrich Baumgatt, Stefan Sack, Raimund Erbel. 
University of Essen, Essen, Germany 
Background: Especially new device percutaneous coronary intervention 
can be associated with a post-procedural serum marker elevation, consid- 
ered to indicate an underlying myocardial injury. However, the incidence of 
these myocardial “infarctlets” after primary stenting in comparison to balloon 
angioplasty is not well known. 
Methods: 596 consecutive patients (pts) undergoing balloon angioplasty 
(BA, n = 136), primary stenting (Stent, n = 89), or coronary stenting because 
of a dissection (40.7%) or a suboptimal result (59.3%) after BA (BA + Stent, 
n = 371) had blood samples taken before as well as 6, 12, and 24 hours 
after the coronary intervention. Serum marker analysis was done by enzyme 
activity assay for creatine kinase (CK, normal range IO-80 IU/I) and by a 
rapid bedside test for cardiac troponin T (cTnT, threshold 0.1 rig/ml). Normal 
range values at baseline were obligatory for study inclusion. 
Results: With primary stenting serum marker elevation tended to be less 
frequent than with conventional strategy but was still more frequent than with 
balloon angioplasty. 
(n 236) 
stent 
(n = 89) 
Positive cTnT test 7.4% */** 20.2%’ 
CK 1.5-3x nml 4.4% 7.9% 
CK >3x nml 0.7% 2.2% 
Peak CK [IU/I] 51 *54*/= 67zk& 
*p < 0.001; *“p < 0.001; pp = 0.02; =p < 0.001 
BA + Stent 
(n =371) 
24.5%‘* 
8.9% 
3.5% 
76 zk 145” 
Conclusion: Stenting with or without predilatation is associated with a 
higher incidence of serum marker elevation than PTCA. More extensive 
squeezing of coronary lesions with consecutive distal microembolization 
could explain the higher rate of myocardial injuy seen with coronary stenting. 
1176-90 Comparison of Self-Expanding Wallstents and 
Balloon-Expandable Palmaz-Schatz Stents During 
Long-Term Follow-Up: Serial Volumetric Analyses 
With lntracoronary Ultrasound Regarding Relative 
Changes of Coronary Morphology 
Andreas Kbnig, Volker Klauss, Evelyn Regar, Johannes Rieber, 
Karl Theisen, Harald Mudra’ Dpts of Cardio/ogK Klinikum Innenstadt, 
University of Munich and ‘St~dtisches Klinikum Neuperlach, Germany 
Background: The self-expanding Wallstent (WS) and the balloon-expand- 
able Palmaz-Schatz Stent (PSS) represent different mechanical and dynam- 
ical stent designs. In recent studies we observed a significant late stent 
expansion after WS implantation and neither expansion nor compression of 
PSS during long-term follow-up. We performed serial measurements with in- 
tracoronay ultrasound (ICUS) to investigate the impact of the different stent 
designs on the coronary wall morphology during long-term. 
Methods: ICUS was performed in stent segments and reference seg- 
ments of 50 pts. (25 WS/25 PSS) with a standardized, motorized pullback 
ws 
h=251 
PSS P 
(n=251 
Stent segments 
AStA% 
ALA% 
AVA % 
APA % 
NA mm* 
Reference segments 
ALA % 
AVA % 
APA % 
27.7zk 23.7 
-13.6i22.5 
11.?3* 15.4 
3.2 5 21.2 
4.23 zt2.07 
-3.3f21.6 
2.6 f 15.1 
11.6 zk 29.4 
0.2 i- 10.9 1 
-20.1 & 24.3 NS 
2.0 ck 15.8 * 
5.2 * 27.9 NS 
2.22zt 2.22 = 
-3.8 5 16.5 NS 
-0.7-t 18.0 NS 
13.0 * 48.3 NS 
mean value * SD; “p = ~0.0001 
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system (0.5 mm/set, 2.9 F; 30 MHz transducer). Vessel area (VA), stent area 
(StA), lumen area (LA), neointimal area (NA = StA-LA) and plaque area (PA 
= VA-StA) were measured in steps of 1 .O mm. Relative changes for each 
parameter in both stents designs were calculated and tested for significancy 
(Mann-Whitney, Cl e 0.05). 
Results: (see table) 
Conclusion: We observed a significant difference of AVA in WS probably 
due to late stent expansion while lumen loss was not significantly different 
between both stent designs. Neointimal ingrowth was significantly higher in 
WS. APA and ALA were not significantly different in stent and reference 
segments. The late stent expansion of WS did not lead to unfavourable 
reference response compared to PSS. 
1176-91 Autologous Vascular Graft-Covered Stents: Effect 
on Endothelialization, lntimal Hyperplasia and 
Vascular Injury in Porcine Coronary Arteries 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, 
Lubna Khaldi, Konstantinos Tentolouris, Antonios Doufas, 
Andreas Michaelides, Pavlos Toutouzas. Hippokration Hospital, University 
of Athens, Greece 
Covered stents have been proposed to eliminate current problems of stent- 
ing. The aim of this experimental study was to compare stents covered by 
autologous arterial or venous grafts with conventional uncovered stents. 
Methods: The study was performed in 19 swines (20-26 kg). The arterial 
graft was harvested from the iemoral artery and the venous graft from the 
cephalic vein. Both grafts were stabilized on the external surface of Multilink’” 
stents by the application of 3 sutures (Prolene 7-O) at each end. Fourteen 
arterial-covered stems (AC), 14 venous-covered stents (VC) and IO uncov- 
ered Multilink’” stents, serving as control group, were implanted. The animals 
were sacrificed between a period of 7 days-2 months. The luminal area cov- 
ered by endothelial cells (EC) was quantified by computer-assisted digital 
planimetry. The vascular injury score was assigned: IO: intact internal elastic 
lamina (IEL); II: fragmentation of IEL; 12: stent penetration into the media: 
13: fragmentation of external elastic lamina. 
Results: The injury score was less in AC and VC (the majority: II) 
compared to the control group (the majority: 13, p < 0.001). The maximal 
intimal thickness (MIT) and the EC were similar between AC and VC. The 
uncovered stems had less EC. 
GrouD VA LA MIT EC 
(“4 
AC 40.4 h 4.2 24.8& 1.4 116.7 * 47.8 81*12 
VC 41.2 i 2.3 23.9 i 1.6 119.5 * 34.7 84114 
COiltrOl 40.9 * 3.1 21.5% 1.5 150.2 i 46.8 55* 14 
p value NS NS 0.07 <0.05 
VA: Vessel area (pm’), LA: Luminal area (pm’), MIT: Maximal intimal thickness (urn). 
Conclusions: Our results demonstrate that implantation of covered stents 
autologous vascular grafts graft results in accelerated endothelialization less 
vascular injury and has a trend fo reduce the neointimal hyperplasia. 
1176-92 Long-Term Clinical Outcome After Endoluminal 
Reconstruction of Diffusely Degenerated 
Saphenous Vein Grafts With Less-Shortening 
Wallstents 
RBmi P. Choussat, Alexander J. Black, Irene Bossi, Thierty Joseph, 
Jean Fajadet, Jean Marco. Clinique Pasteur, Toulouse, France 
Background: The optimal treatment strategy for patients (pts) with diffusely 
degenerated saphenous vein gratis (SVG) is controversial. “Endoluminal re- 
construction” by stent implantation is one proposed strategy however there 
is little data regarding long-term clinical outcome. We report the follow-up re- 
sults in patients undergoing endoluminal reconstruction using self-expanding 
Wallstents in diffusely degenerated SVG. 
Methods: Between May 1995 and September 1998,6534 consecutive pts 
underwent angioplasty in our institution: 126 (115 males, median age 69 i 6 
years (y)) with old SVG (mean age: 12 & 2 y) diffusely degenerated stenosed 
or occluded (mean lesion length: 27 & 12 mm, range 8-80) were treated 
electively with implantation of one or multiple (total 197) less-shortening 
Wallstents. Mean length of the Wallstent per graft was 44.5 f 16.7 mm. 
Results: Before discharge, 13 pts (10.3%) sustained at least one ma- 
jor cardio-vascular event: 4 deaths (3.2%), 11 myocardial infarctions (MI) 
(8.7%), 3 repeat revascularizations (target vessel = 1, non-target vessel = 2, 
2.4%). Surviving patients were followed for 22 5 11 months: 13 pts (11 .I%) 
died, 11 (9.4%) sustained a MI, 37 underwent angioplasty (31.6%), and 4 
(3.4%) underwent bypass surgery. The estimated 3-year event-free survival 
rates (freedom from death, and freedom from death/Ml/target vessel revas- 
cularization) were (mean ZIZ SEE) 81.1 & 7.8% and 40.7 i 18.5% respec- 
tively. 
Conclusions: The long-term clinical outcome of pts undergoing the treat- 
ment strategy of “endoluminal reconstruction” in diffusely degenerated SVG 
is relatively poor, mainly because of a high incidence of death, Ml and the 
very strong need for repeat angioplasty. It is unlikely that percutaneous 
intervention alone will provide a satisfactory or definite answer for these pts. 
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lzIzLIl 1177 111 Preclinical Safety of Transatrial Access to the 
Normal Pericardial Space for Local Cardiac Drug 
Delivery During Aspirin Use and Pulmonary 
Hypertension 
Todd C. Pulerwitz, Sergio Waxman, Katharine A. Rowe, William C. Quist, 
lzabella Lipinska, Richard L. Verrier. Beth /me/ Deaconess Medical Center, 
Harvard Medical School, Boston, MA, USA 
Background: We have previously demonstrated the feasibility of transatrial 
intrapericardial access in large animals as an approach for local cardiac 
drug delivery. Since aspirin use and pulmonary hypertension are prevalent in 
cardiac patients who could potentially benefit from this procedure, we tested 
in additional animals whether it can be safely performed in these settings. 
Methods: Transatrial access was performed in 10 anesthetized pigs. An 
8 Fr multipurpose catheter was fluoroscopically placed via a femoral vein 
against the right atrial appendage, and a 0.038 inch infusion wire was ad- 
vanced over a 0.014 inch guidewire transatrially into the pericardial space. 
Pericardial fluid was aspirated and the catheters removed after 5 min. Six 
of the animals received oral aspirin (162 mg) on the day before and the 
morning of the procedure. Arachidonic acid testing confirmed 100% block- 
age of platelet aggregation by aspirin. Following transatrial access, the pigs 
recovered and were sacrificed at 24 hrs. In the 4 remaining pigs, pulmonary 
hypertension was induced by injecting repeated 5 ml (250 mg) doses of 106 
pm glass beads directly into the pulmonary artery. Mean pulmonary artery 
pressure was elevated from 12.7 i 1.8 to 25.7 & 0.3 mm Hg and sustained 
for 245 min, after which transatrial access was performed. Pulmonary hy- 
pertension was sustained for an additional 30 min and the animals were 
sacrificed. 
Results: Pericardial access was successfully accomplished in all ani- 
mals within 3 min following guide positioning and no hemodynamic or ECG 
changes were observed. In the aspirin group, initial pericardial fluid hemat- 
ocrit wasO.1 i- 0.1% and 1.9 + 1 .l% at 24 hrs (NS) (Values = Means f SEM). 
In the pulmonary hypertension group, initial pericardial fluid hematocrit was 
1.0 f 0.5% and 4.3 i 0.8% at 30 min (NS). There were no complications 
such as tamponade in either group. Histopathologic analysis in both groups 
revealed a small thrombus and localized inflammation at the site of puncture. 
Conclusions: Neither aspirin use nor pulmonary hypertension are asso- 
ciated with significant bleeding into the pericardial space following transatrial 
pericardial access and do not preclude the use of this technique for local 
cardiac delivery, of angiogenic and antiarrhythmic agents or gene therapy. 
1177-l 12 Catheter-Based Ultrasound With Urokinase 
Enhances Thrombolysis and Improves TIMI 
Flow: In Vivo Studies 
Joseph Mitchel, Dadong Li, Tod Alberghini, Francis J. Kiernan, 
Satyendra Giri. Hartford Hospital, Hartford, CT; Covance, Berkeley, CA, 
USA 
Background: Catheter-based ultrasound (US) energy has been shown to 
enhance the effect of urokinase (UK) on TIMI flow in a porcine model. This 
study was performed in two parts: first, to further examine the effects of 
UK + US on TIMI flow, thrombolysis and distal embolization in a porcine 
model. Second, in order to evaluate a new multielement US catheter (EKOS, 
Bothell, WA) in a thrombus model which responds to lyric agents in a manner 
similar to humans (canine), time to recanalization and residual thrombus 
were measured against conventional lytic infusion using a standard sidehole 
infusion catheter. 
Methods: Bilateral iliac arteries underwent endothelial injury (5 cm), fol- 
lowed by ligation. Thrombin was added and autologous blood was incubated 
to allow clot formation and vessel adherence. In the porcine model, l’23 was 
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added for nuclear detection of distal embolization and quantitation of throm- 
bolysis. The treatment time in the porcine studies occurred over a 30 minute 
interval. In both studies the UK dose used was 250,000 units except for the 
high dose UK (750,000 units). 
a potential accelerated thrombolysis device for treating thrombo-embolic 
stroke. 
Results: 
Porcine studies: 
Treatment n % lysis # TIMI 3 segments #distal emboli 
U.S+UK 6 25 * 7.15 6 1 
UK 6 10 * 7.63* 1" 1 
UK (high dose) 5 14 * 5.03 2 1 
us 8 10 z!z 6.08# 1 1 
Control 3 6.6 i 3.8* 0* 1 
Methods: Measured segments of externally created thrombus were in- 
jected bilaterally in canine common carotid arteries and trapped against an 
occlusive coil positioned at the OS of the internal carotid arteries (n = 11 
animals). Prototype ultrasound drug infusion catheters. (EKOS, Bothell, WA) 
were advanced bilaterally to the proximal margins of each thrombus. Uroki- 
nase (125,000 IU in 10 ml) was infused simultaneously through each catheter 
for 30 minutes. Ultrasound (Freq = 2.1 MHz, Power = 0.45 W) was activated 
on one side (test) vs. drug only (control). Blood flow was monitored in each 
vessel. 
Canine studies: # of Segments at TIMI 2 or 3 
Results: The percentage of blood reflow (post-therapy flow/pre-occlusion 
flow) afler 30 minutes of treatment was greater in the ultrasound treated 
vessels, 36.0% i 28.9, vs. urokinase only treated vessels, 14.4% f 16.5 (p 
< 0.035). 
Treatment 20 min 
US+UK 4w 
UK 015 
*P < 0.05; ‘P = 0.058 
40 min 
515* 
215 
60 min 
5/5* 
415 
Residual clot % 
27.8i 25.4* 
72.6 zt 41 
Conclusion: In a porcine model, a significant difference in TIMI flow 
and thrombolysis was seen in segments treated with US + UK vs controls 
and the same dose of UK. In a canine model, US + UK resulted in faster 
recanalization time with more complete thrombus removal than conventional 
side hole infusion alone. 
US + Drug Drug 
Pre Occl Post TX %f+?flOW Pre Occl Post TX %Reflcw 
98.7 A 53.0 28.7 h25.2 36.0* 28.9 112.3 zk 26.4 17.9 Lt22.6 14.4 h 16.5 
mllmin mllmin mllmin mllmin 
Conclusion: Ultrasound enhancement of low dose urokinase is effective 
in re-establishing flow in occluded canine carotid arteries as compared to 
urokinase alone. These results reflect earlier fermoral artery studies, indicat- 
ing that the enhancement can be applied using a small ultrasound transducer 
designed for cerebral vascular access. 
1177-l 13 Endoluminal Ultrasound Enhances Local Drug 
Delivery Efficiency 
Dongming Hou’ , Michael A. Reidyz, Keith L. March’. ‘Indiana Univ., 
Indianapolis, IN; ‘Unk, of Washington, Seattle, WA, USA 
1177-I 15 Electromechanical Characterization of Treatment 
Response to Laser Myocardial Revascularization 
Guided by Left Ventricular Mapping 
Background: Local drug deliivery (LD) to modulate restenosis has attracted 
much interest. However, the general utility of this approach has been limited 
by low efficiency in essentially all LD catheters. Since acoustic energy is 
known to alter cell membrane permeability, we hypothesized that ultrasound 
exposure might enhance local delivety of compounds into vessel wall cells in 
viva. This study was designed to determine whether catheter-based applica- 
tion of endoluminal ultrasound enhanced the distribution of compounds into 
the artery wall. 
Methods: Rabbit carotid arteries (n = 38) were bilaterally denuded of 
endothelium with a balloon catheter. An ultrasound field generating catheter 
(EKOS Corp., Bothell, WA) was positioned in each vessel and vessels were 
ligated distally. Goat IgG (25 mg/ml) was infused into each vessel through the 
ultrasound catheter. One vessel in each animal was exposed to a field of 1.2 
MPa peak acoustic pressure at 1.3 MHz for IO minutes, while the contralat- 
era1 (control) vessel received no ultrasound exposure. Vessels were per- 
fusion-fixed immediately after treatment. Serial sections (5-6ivessel) were 
evaluated by immunohistochemical staining and circumferential staining was 
quantitated for each layer (intima, superficial and deep media, and adventitia) 
by a grading system of O-4 quartiles of stained vascular circumference. 
Ran Kornowski, Shmuel Fuchs, Anthony Pierre, Mun K. Hong, Martin 
8. Leon. The Cardiovascular Research Foundation, Washington, DC, USA 
Background: The Biosense” system has been used for 3D electromechan- 
ical (EM) mapping of the left ventricle (LV) and identification of ischemic 
target zones for direct myocardial revascularization (DMR). Since recent 
experiences have shown considerable alterations in voltage potentials and 
mechanical activity in ischemic endocardial regions, we sought to character- 
ize the EM response to DMR in patients undergoing repeat LVEM mapping 
Q6 mos following laser DMR. 
Methods: EM mapping was performed immediately before and Q6 mos 
after laser DMR in 54 patients (42 men, age 62 & 11 yrs) treated with 26 
i 9 laser channels. LV maps were projected into 16 segments model and 
unipolar voltage amplitudes (UpV) and local endocardial shortening (LS) data 
were submitted to a central core laboratory for a standardized processing, 
interpretation and matched analysis. Segments (n = 864) were distinguished 
by the number of annotated laser channels per mapped segment (none, 
l-5, 6-10, ~10 channels per segment, n = 477, 267, 87, and 33 segments 
respectively). 
Results: The control and ultrasound groups consisted of 104 and 115 
vessel segments respectively. Ultrasound treated vessels (U, n = 20) were 
found to exhibit a significant increase in the average absolute grade of IgG 
distribution by 26.5% in the intima, 64.1% in the superficial media, 74.6% in 
the deep media and 86.4% in the adventitia in comparison with the control 
vessels (C, n = 18). Exposure to endovascular ultrasound also resulted in a 
higher frequency of segments with greater than 50% circumferential staining 
(grade ? 3) in each of the vessel layers than found in control. Specifically, this 
frequency was 82.6% (U) vs. 55.8% (C) in the intima; 32.2% (U) vs. 10.6% 
(C) in the superficial media; 19.1% (U) vs. 6.7% (C) in the deep media; and 
31.3% (U) vs. 13.5% (C) in the adventitia. 
Results: On average, the % of endocardial surface area treated was 25 
i 12% with a mean channel density of 1 .O & 0.4 channels/cm2. The UpV 
showed slight but significant (p < 0.05) reduction (by -1 mV) in voltage 
amplitudes @6 months compared to baseline without an apparent effect of 
DMR or the number of laser channels placed on this finding (Figure). By 
contrast, improved LS was noted from baseline to 6 mos in DMR treated 
segments but not in segments not treated by DMR (8.7%, 25.5%, and 40.8% 
relative increase in LS Q6 mos in l-5, 6-10, and >I0 channels/segment 
group, p < 0.01 vs 2% change in non-treated segments, p = 0.42, Figure). 
Conclusion: These results demonstrate that ultrasound exposure signif- 
icantly enhances the IgG distribution into all layers of the rabbit artery wall by 
increasing penetration into the deeper artery wall in a manner that results in 
a more circumferential delivery. This suggests that the addition of ultrasound 
might provide a feasible therapeutic adjunct to promote local drug delivery 
consistency and consequent efficacy. 
1177-I 14 Ultrasound Accelerated Thrombolysis in a 
Canine Carotid Model of Thrombo-Embolic 
Stroke 
Stanley L. Barnwell, Dusan Pavcnik, Russell L. Tucker, Joseph Eskridge, 
Wolfgang Janas. Oregon Health Sciences University: Portland, OR; 
Washington State University: Pullman, WA: University of Washington; EKOS 
Corporafion, Bothell, WA, USA 
Conclusion: At 6 mos following LV guided laser DMR, repeat LVEM 
mapping document 1) a small (-1 mV) but significant global decrease in 
voltage amplitudes, and 2) significant improvements in LS in laser treated 
areas which seem to correlate well with the number of laser channels per 
treated segment. 
Purpose: To evaluate a new 2.5 Fr ultrasound drug delivery catheter as 
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piiJ Nonfluoroscopic Electromechanical Mapping 
to Assess Myocardial Viability 
Tuesday, March 14, 2000,4:00 p.m.-5:OO p.m. 
Anaheim Convention Center, Lecture Hall A2 
Conclusion: NOGA volumes have a systematic error compared to MRI, 
but still correlate well. Volumes decrease with subsampling, but good corre- 
lation (r > 0.83) is preserved down to n = 10 points. The basis for the offsets 
merits further investigation. 
4:00 p.m. 
888-l Hibernating Myocardium Diagnosed With 
Nonfluoroscopic Electromechanical (NOGA’“) 
Mapping: A Comparison With Dobutamine Stress 
Echocardiography 
/ 
4:30 p.m. 
888 8 NOGAe Mapping of the Endocardial Surface 
Subtended by Chronic Total Occlusions With and 
Without Collateral Circulation 
Mark Reisman, Jeffrey Westcott, John Petersen, Verna Harms, Chiu Wong. 
Swedish Medical Center, Seattle WA; Queens Hospital, Flushing, NY; USA 
Glenn Van Langenhove, Peter C. Smits, Jaap N. Hamburger, 
Pedro Serrano, Patrick W. Serruys. Thoraxcentre Rotterdam, The 
Netherlands 
Background: To date no study has determined the endocardial voltage 
of myocardium subtended by vessels with chronic total occlusions which 
have either the presence or absence of collateral flow. This study assesses 
myocardial voltage in myocardium subtended by chronic total occlusions. 
Introduction: Nonfluoroscopic electromechanical mapping with the NOGA’” 
system has been introduced as a new technique for the assessment of 
hibernating but viable myocardium in patients with coronary artery disease. 
We compared the mapping results with low and high dose dobutamine stress 
echocardiography (DSE). 
Methods: NOGA three dimensional mapping was performed on 15 pa- 
tients with either left anterior descending or circumflex total occlusions identi- 
fied during angiography. Collateral circulation and wall motion were assessed 
during angiography. 
Methods: DSE was performed prior to the mapping procedure. 12 differ- 
ent segments were analyzed by an operator blinded for the mapping results. 
Segments were evaluated at rest (dyskinetic = -1, akinetic = 0, severe hy- 
pokinetic = 1, mild hypo P 2, normal = 4) during low dose (unchanged = 0, 
improvement = 1) and high dose dobutamine (same as at rest). These results 
were than compared to the average local linear shortening (LLS, %) and the 
unipolar voltages (UP, mV) of the same 12 segments obtained during the 
NOGA-” procedure. 
Results: 7/15 patients had normal wall motion in the affected area as 
judged by LVgram, 7/15 had moderate to severe hypokinesis and l/15 was 
akinetic in the affected wall. Collateral circulation was present in 517 with 
normal wall motion, 3/7 with hypokinetic wall motion and l/i with akinetic 
wall motion. As shown in the table below both poor wall motion and lack of 
collaterals were associated with lower endocardial voltage. 
Results: In 15 patients, 156 (of 180, 87%) segments were compared. 
The results are shown in the table. 
No Collaterals 
Collaterals 
p value 
Voltage * SD 
10.1 * 4.3 mv 
13.6 * 4.2 mv 
<O.Oi 
Poor Wall Motion 
Normal Wall Motio 
p value 
Voltage & SD 
9.3 5 3.2 rn” 
15.5 * 3.3 mv 
<O.OOl 
Comparison 
UP-DSE at rest 
UP-Low dose DSE 
UP-High dose DSE 
LLS-DSE at rest 
LLS-Low dose DSE 
LLS-High dose DSE 
Pearson Correlation 
0.33 
0.31 
0.21 
0.25 
0.35 
0.26 
p-V&IS 
<0.0005 
<0.0005 
0.01 
0.002 
<0.0005 
0.001 
Conclusions: This study demonstrates the impact of collaterals to zones 
subtended by chronic total occlusions and demonstrates significant differ- 
ences in the magnitude of endocardial voltages in zones with and without 
collaterals and with poor or normal wall motion. Whether these voltages 
can be used to predict functional recovery in the hypokinetic zones will be 
important when considering therapeutic strategies. 
Average UP for patients with or without improvement during low dose 
DSE was 10.2 mV & 5.7 and 6.9 mV f 3.1 respectively (p = 0.004); average 
LLS was 7.3% i 7.5 (improvement) versus 1.4 * 9.2% (no improvement) (p 
= 0.005). ROC curves showed cut-off values for viability of UPV = 9.0 mV 
(sens 56%, spec 81%, p < 0.0001) and LLS = 6.8% (sens 56%, spec 92%, 
p cc 0.0001). 
4:45 p.m. 
888-4 Endocardial Electromechanical Mapping to Assess 
Myocardial Viability: A Comparative ROC Analysis 
With Radionuclide Perfusion Imaging 
Conclusion: Nonfluoroscopic electromechanical mapping data (LLS and 
UP) are significantly correlated with low and high dose DSE, suggesting 
their value in the detection of viable and ischemic myocardial tissue. UPV 
of 9.0 mV and LLS of 6.8% are highly significant cut-off values for viable 
myocardium. 
Ran Kornowski, Shmuel Fuchs, Robert C. Hendel, Matthew Pietrusewics, 
Robert 0. Bonow, Martin 8. Leon. Washington Hospital Center, 
Washington, DC; Northwestern University Medical Center, Chicago, IL, USA 
m 
4:15 p.m. 
888 2 Correspondence of BIOSENSE-Guided Endocardial 
Catheter Maps With MRI: Influence of Number of 
Locations Sampled 
Background: Recent experiences using a non-fluoroscopic 3 dimensional 
(D) left ventricular (LV) mapping system (Biosense’“) showed considerable 
alterations in voltage potentials and mechanical activity detected in endocar- 
dial zones with severe myocardial ischemia or infarction. This study exam- 
ined the sensitivity and specificity cutoffs for detecting myocardial viability 
using SPECT nuclear perfusion imaging as a ‘gold standard’ modality for 
comparison. 
Justin D. Pearlman, Yun Wu, Mike Simons, Donald S. Bairn, Roger 
J. Laham. BIDMC/Harvard Me&a/ School, Boston, Massachusetts, USA 
Background: Biosense NOGA electromechanical triangulation guidance 
system allows accurate localization for left ventricular mapping and targeted 
therapy. Eletromagnetic triangulation allows generation of endocardial sur- 
face maps from acquired points, We developed methods relating BIOSENSE 
NOGA points to 4D MRI (beating volume images). We analyzed the overall 
agreement and influence of the number of sample points. 
Methods: A 12 segment comparative analysis model was used in 61 
patients (732 segments) having reversible and/or fixed myocardial perfusion 
abnormalities on SPECT imaging. Rest unipolar voltage potentials (UpV) and 
local endocardial shortening (LS) values were compared to rest and rest-4 
hrs redistribution 201TI perfusion defect score (0 = nl, 1 = mild, 2 = mod, 3 = 
severe, 4 = no uptake). To calculate the sensitivity and specificity of mapping 
measurements for predicting viable tissue, receiver-operating characteristic 
(ROC) curves were plotted. 
Methods: IO patients had MRI sequential breath-hold turboFLASH tine 
imaging at continguous 5 mm sections from apex to base, using 1.5 T 
Siemens Vision MRI. The same patients had NOGA maps with >I 00 points 
distributed over the endocardium. Volumes were assessed by NOGA algo- 
rithm (NA), convex hull fit (CH), Simpson’s rule integration, trapezoid rule, 
and spline, for all points and for random subselections. Distributed random 
subsampling from MRI was obtained for n = 5-20, 25, 50, 100, 200, 400. 
Results: NA and CH correlate well (r = 0.99) but with systematic offset: 
CH = 0.68NA + 8.8 cm3 (p < 0.001). CH vs. MRI volumes by trapezoid rule 
correlate fairly well (r = 0.81) but with a larger systematic offset: MRI = 0.67 
CH + 71 cm3 (p < 0.01). Subsampling MRI as low as 10 distributed points 
correlates with full MRI r > 0.83. 1 _ Specrficity 
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Results: ROC curves showed higher sensitivity and specificity for UpV 
compared to LS value to detect myocardial viability (Figures). UpV cutoff of 
~7.4 mV had sensitivity and specificity of 71% and 78% for detecting viable 
tissue (i.e. perfusion score 52 @rest) with odds and likelihood ratios of 8.7 
and 3.2, respectively. LS cutoff of ~4.8% had sensitivity and specificity of 
63% and 65% for detecting viable tissue. The upper and lower UpV cutoffs 
to predict myocardial viability with 90% sensitivity and 90% specificity were 
12.0 and 5.4 mV, respectively. 
Conclusions: 1) LV electromechanical mapping can identify viable my- 
ocardium using pre-specified cutoff values, 2) UpV amplitude is a better 
marker for viable myocardium compared to LS value at rest. 
ORAL 
I 896 Coronary Brachytherapy II 
Wednesday, March 15, 2000, 8:30 a.m.-lo:00 a.m. 
Anaheim Convention Center, Lecture Hall Al 
8:30 a.m. 
I 896 1 Compassionate Use of lntracoronary Gamma Radiation Therapy for Patients With Refractory 
k&tent Restenosis 
Ron Waksman, Balram Bhargava, Nancy McCarthy, R. Larry White, Lowell 
F. Satler, Roxana Mehran, Kenneth M. Kent, August0 D. Pichard, Martin 
0. Leon. Washington Hospital Center, Washington DC, USA 
Background: Clinical trials utilizing intracoronary gamma radiation in-patients 
with In Stent Restenosis (ISR) demonstrated reduction in the recurrence rate 
of restenosis. However, large population of patients with ISR does not meet 
the inclusion exclusion criteria of these clinical protocols. Compassionate 
Use Radiation Endovascular (CURE) is a FDA approved open label registry 
in 100 patients with ISR who had at least 2 episodes of restenosis at the 
target lesion and are not considered good candidates for CABG or medical 
therapy. 
Methods: Patients were eligible to participate in CURE if approved by all 
members of a committee that includes cardiac surgeon, radiation oncologist, 
general and intetventional cardiologist. Patients with ISR in up to 2 lesions 
in native coronaries and vein grafts with lesion length ~80 mm are included. 
The angioplasty procedure utilizes balloon, laser, rotational atherectomy, or 
additional stents. After the intervention a ribbon with different trains of 192lr 
seeds is inserted to a closed lumen catheter and covers the treated segment. 
The radiation doses are 14 or 15 Gy at to 2 mm. Clinical and angiographic 
follow-up are performed at 6 and 24 months. 
Results: To date 68 patients were enrolled into CURE. Baseline demo- 
graphics detected 74% of patients had prior CABG, 65% had prior Ml and 
40% had diabetes. The first 23 patients who completed 6 months follow-up 
had target lesion and vessel revascularization of 3 (13%) and 5123 (22.7%) 
respectively. One patient had cardiac death and one had late thrombosis with 
myocardial infarction. 
Conclusion: lntracoronary gamma radiation proves to be an attractive 
therapeutic modality (78% free from major cardiac events) for complex com- 
passionate patients who did not respond to conventional standard of care 
therapy. 
8:45 a.m. 
L-l 896 2 Gamma Radiation vs. Placebo in Focal vs. Diffuse In-Stent Restenosis: The Length Makes the 
Difference! 
9:15 a.m. 
Roxana Mehran, Alexandra J. Lansky, Ron Waksman. Washington Hospital 
Center, Washington, DC, USA 
896-4 Economic Assessment of Gamma-Brachytherapy for 
Treatment of InStent Restenosis: Results From the 
Randomized GAMMA-l Trial 
Angiographic pattern (diffuse vs. focal) of in-stent restenosis (ISR) is a well 
recognized risk factor for recurrence after treatment of ISR. Gamma radiation 
reduces angiographic and clinical restenosis in patients with ISR, howeverthe 
impact of gamma radiation on diffuse vs. focal ISR is not well established. 
We compared clinical and angiographic outcomes of patients with diffuse 
ISR (lesion length [LL] > 15 mm) vs. focal ISR (LL 5 15 mm) enrolled in 
the Washington Radiation for In-stent Restenosis Trial (WRIST). OF the 124 
patients with available QCA and 6 month follow-up enrolled in WRIST, 44 
had focal ISR, and 80 diffuse ISR. Clinical and angiographic results at Gmos 
are shown (table). 
David J. Cohen, Martin B. Leon, Paul Teirstein, Roberta Cosgrove, Mary 
A. Jones, Ronna H. Berezin, Kalon K.L. Ho, Donald E. Cutlip, Richard 
E. Kuntz. Beth lsrael Deaconess Medical Center, Boston, Massachusetts, 
USA 
Background: Recent studies have demonstrated that intracoronary brachyther 
apy can reduce angiographic and clinical restenosis in patients undergoing 
percutaneous coronary intervention for treatment of in-stent restenosis. How- 
ever, brachytherapy involves considerable expense due to the additional 
equipment, procedural time, and physician services required, and the overall 
cost-effectiveness (C/E) is unknown. 
Conclusions: Angiographic and clinical outcomes of patients with ISR Methods: We prospectively measured medical resource utilization and 
treated with placebo after percutaneous intervention remains high even in cost for patients with in-stent restenosis randomized to radiation therapy (RT, 
focal lesions. Brachytherapy with lg*lr results in significant reduction of an- n = 131) or conventional therapy (CT, n = 121) as part of the GAMMA-I 
giographic RS (06 mos) in diffuse andfocal lesions, However lesion length trial. Catheterization laboratory costs were based on measured resource 
remains an important risk factor for recurrence despite radiation therapy. utilization and 1999 unit costs, while all other costs were estimated from 
Diffuse 
Placebo n=3&3 
Binary RS (in-lesion)(%) 73.5 
Binary RS (in-sfenr) (%) 67.6 
Target vessel revascularization (%) 78.9 
Target lesion revascularization (%) 76.3 
1g21r ” = 42 
Binary RS (in-/esion)(%) 30.8 
Binary RS (in-sfenf) (%) 28.2 
Target vessel revascularization (%) 26.2 
Target lesion revascularization (%)) 14.3 
FOCZII 
n=23 
38.9 
38.9 
56.5 
47.8 
n=21 
5.3 
0.0 
28.6 
14.3 
P 
0.015 
0.046 
0.063 
0.023 
0.043 
0.011 
NS 
NS 
Further optimization of dosimetry is warranted for these challenging lesion 
subsets. 
9:00 a.m. 
896-3 Six-Month Angiographic Results of Single 32P 
Radioactive P-Emitting Stents With an Initial Activity 
Level Up to 21 PCi Implanted in Patients With CAD 
Remo Albiero, Milena Adamian, Takahiro Nishida, Antonio Amato, 
Nicola Corvaja, Marco Vaghetti, Carlo Di Mario, Antonio Colombo. Centro 
Cuore Columbus, Milan, Italy 
Background: We have previously reported a high restenosis rate in the 
reference segments at the edges of 32P radioactive p-emitting stents with an 
initial activity level up to 12 &i in patients (pts) with CAD, possibly due to a 
low activity level of radiation at the stent edges combined with an aggressive 
approach to stenting. The aim of this study was to evaluate whether a higher 
stent activity level of 12-21 &i combined with a non-aggressive implantation 
strategy could solve the problem of edge restenosis. 
Methods: From Ott ‘97 till Feb ‘99 a single 3sP radioactive B-emitting 
.slotted tubular stent (15 mm long) was implanted in 98 lesions (les) in 83 
pts. Seventy-three pts (86 les, 88%) underwent a 6-month FU angiogram, 
and were included in this study. The 86 les were divided in 4 groups: Grl 
= 0.753 pCi, Gr2 = 3-6 pCi, Gr3 = 6-12 &I, and Gr4 = 12-21 PCi. The 
Palmaz-Schatz stent was implanted in Grl and the BX lsostent in Gr2-Gr4. In 
most of the les in Gr3 and Gr4 a non-aggressive stent implantation approach 
was used. 
Results are shown in the table. 
0.7-3 uCi >6 icCi 6-12 &I 12-21 iLCi P 
Lesions Grl,n=15 Gr2,n=23 Gr3,n=lB Gr4,n=32 
Ref. Diam. mm 3.07hO.63 3.11 k0.33 3.15hOo.35 3.17i0.47 NS 
Balloon-to:Artery ratio 
MLD pre, mm 
MLD post stent, mm 
MLD FU, mm 
lntralesion Restenosis, 
% DS ? 50, ” (“h) 
- Only Intra-Stat, n (%) 
-Total Occlusion, n (%) 
- Edge Restenosis, n (%) 
1.24i0.19 
1 .oo i 0.39 
3.20 2r 0.52 
1.85 + 1.0 
6 (40) 
2(13) 
0 
4 (27) 
1.19+0.11 
0.84 zt 0.32 
3.16 i 0.39 
2.02 i 0.91 
8 (35) 
0 
0 
8 (35) 
1.11 50.10 
0.79 i 0.52 
3.00 * 0.41 
1.84* 1.1 
7 (44) 
1.14zt0.14 NS 
0.90 zk 0.50 NS 
3.04 i 0.50 NS 
2.28 + 0.87 NS 
8 (25) NS 
0 NS 
0 NS 
8 (25) NS 
Conclusions: In patients with CAD, 32P radioactive B-emitting stents 
with a high initial stent activity level of 12-21 &I, mostly implanted using a 
non-aggressive approach, did not solve the problem of edge restenosis. 
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hospital charges and cost-center specific cost-to-charge ratios. We estimated 
that the coronary brachytherapy system would cost $2500 per patient. 
Results: Compared with CT, RT increased procedure duration by an 
average of 33 minutes and increased overall initial hospital costs by $3900 
per patient ($13,534 vs. $9,933, p < 0.001). Over the one-year follow-up 
period, RT reduced the need for repeat target-vessel revascularization by 
42% (24.4 vs. 42.1%, p = 0.003) and reduced follow-up medical care costs 
by more than $2000 per patient ($11,219 vs. $13,244, p = 0.12). As a result, 
overall one year medical care costs were only $1900 higher in the RT group 
($32,447 vs. $30,554, p = 0.02). Exclusion of events related to late stent 
thrombosis (n = 8) increased the follow-up cost savings with RT to more than 
$3100 per patient ($10,124 vs. $13,244, p = 0.04). Under these conditions, 
the net one-year cost difference fell to $750 ($31,404 vs. $30,643, p = NS) 
and the incremental cost-effectiveness ratio for RT remained ~$10,000 per 
repeat revasculariration avoided in 96% of bootstrap simulations. 
lowing injury. Radioactive stents (RS) as a platform are easy and practical to 
use compared with other IR modalities. Beta-emitting RS have shown some 
efficacy at reducing restenosis in the stent but are reported to have excessive 
restenosis at the edges, possibly due to low radiation doses at these seg- 
ments. Herein, we present a novel concept for producing a gamma-emitting 
RS in an attempt to overcome these problems. 
Conclusions: Coronary brachytherapy for treatment of in-stent resteno- 
sis improves late clinical outcomes and reduces follow-up treatment costs by 
$2000-$2800 per patient. The C/E of this technology thus appears reason- 
able compared with other accepted interventional techniques (e.g., stenting, 
ReoPro, etc.). 
Methods and Results: I. Three stainless steel bovine serum albumin 
(BSA)-coated and three control steel coupons were treated with anti-BSA. 
The coupons were then either incubated with biotinylated secondary antibody 
coupled to alkaline phosphatase and subjected to calorimetric analysis, or 
incubated with biotinylated antibody horseradish peroxidase and subjected 
to enhanced chemiluminescence analysis. Both methods showed specific 
binding of the anti-BSA to BSA-coated coupons. 2. Five BAS-coated and five 
control-coated Multilink stents (Guidant, Santa Clara, CA) were incubated 
with 125~I-anti-BSA. The BSA-coated stents exhibited an 13-fold greater 
radioactivity as compared to controls, with activities in the range of 0.16-0.31 
&i (Table). 
stent type Activity pci 
Control-coated (n = 5) 0.017 rt 0.009 
BSA-coated (n = 5) 0.23 + 0.06 P < 0.001 
9:30 a.m. 
896-5 The Effect of p-Radiation Therapy on Stented 
Coronary Segments and Adjacent Stent Edges: 
A B-Dimensional IVUS Interpretation 
Marco A. Costa, Ken Kozuma, Mane1 Sabate, Willem J. van der Giessen, 
Pedro Serrano, Veronique L.M.A. Coen, I. Patrick Kay, Jurgen 
MR. Lighhart, Alexander J. Wardeh, Peter C. Levendag, Patrick 
W. Serruys. Thoraxcenter and Daniel den Hoed Cancer Center, University 
Hospital Rotterdam, The Nerheriands 
Conclusions: Labeled compounds may be targeted to coated stents 
to render them radioactive in vitro. This concept should allow for numerous 
variations in dose as well as isotope, and may be extended to in vivo targeted 
immuno-radiotherapy by injecting labeled compounds intravenously. 
ORAL 
Background: The “edge effect” has been reported after both conventional 
and radioactive stents. Catheter-based o-radiotherapy has shown to have a 
beneficial effect on both vessel remodeling and plaque growth after balloon 
angioplasty. The aims of this study were: 1) to determine the influence of 
B-radiotherapy in patients (pts) treated with conventional stenting on ves- 
sel remodeling and plaque growth (inside [NIH] and outside the stent), 2) 
to evaluate the effect of catheter-based brachytherapy on remodeling pro- 
cess and plaque growth at the edges of the stented segment by means of 
3-dimensional IVUS volumetric assessment. 
I 897 In-Stent Restenosis 
Wednesday, March 1.5, 2000, 8:30 a.m.-l 0:OO a.m. 
Anaheim Convention Center, Lecture Hall A2 
8130 a.m. 
Methods: The study population consists of 41 patients successfully 
treated with single stent (length 518 mm) implantation associated (n = 18, 
RAD group) or not (n = 23, control) with intracoronary /J-radiation using either 
gOSr/goY or 32P sources. IVUS images were acquired by means of ECG-trig- 
gered pullback immediately after the procedure and at 6-8 follow-up (FU) in 
all patients. Three-dimensional reconstruction and volumetric quantification 
of total vessel (TVV), overall plaque (PV), NIH and plaque volume outside 
(PVout) the stent were performed by means of a semi-automated edge de- 
tection system. Coronary segments covered with stent as well as the edges 
(5-mm distal and proximal to the stent) were analyzed. 
897-i Predictors of Recurrent In-Stent Restenosis 
Following Mechanical Treatment by Angioplasty or 
Rotational Atherectomv: Results From an 
Angiographically Cont;olled Prospective Trial 
(ARTIST Study) 
Juergen vom Dahl, Philipp K. Haager, Thorsten Reineke, Ulrich Dietz, 
Sigmund Silber, E. Niccoli, H.J. Buettner, Francois Schiele, Martin Thomas, 
F. Commeau, T. Ramsdale, Ernest0 Garcia, Heinrich G. Klues. On Behalf Of 
The ARTIST Investigators; University Hospital, RWTH Aachen, Germany 
Results: The lengths of the analyzed segments were similar between 
both groups. In the RAD group, TVV (292 vs. 316 mm3, p = 0.002), overall 
PV and outside the stem PV (151 vs. 180 mm3 and 151 vs. 172 mm3, 
respectively, p i 0.001) increased at FU as compared to post-procedure. 
Background: Diffuse in-stent restenosis (ISR) with high recurrence rates 
remains a challenging problem for which the best mechanical treatment 
is not clear. We sought to evaluate clinical and angiographic predictors of 
recurrent restenosis from an angiographically controlled prospective study 
(ARTIST study). 
Stented Segment 
mm3 ATVV APV APVout NIH 
RAD 23.4 28.7 172.3 7.1 
CClntr0l 1.1 23.5 131.2 23.1 
p value 0.002 NS 0.03 <O.OOl 
Delta (A) = FU- post- procedure IVUS measurements 
Edges 
ATVV APV 
1.3 4.1 
-7.4 1.8 
0.004 NS 
ALV 
-3.8 
-8.5 
0.05 
Methods and Results: Angiographic follow-up with quantitative coronary 
angiographic analysis is available in 259/269 eligible patients randomized to 
either balloon angioplasty (PTCA) or rotational atherectomy (ROTA) for dif- 
fuse ISR (IO-50 mm length). A logistic regression analysis was performed 
for restenosis (>50% diameter stenosis (DS) at follow-up) as the depen- 
dent variable using univariate and multivariate models with 15 clinical and 
angiographic variables. 
Conclusion: Compared to control, irradiation pts had less lumen loss in 
the stent edges. mainly due to the beneficial effect of p-radiation on vessel 
remodeling. Plaque growth was not decreased by radiation in both analyzed 
segments, although the RAD group had less NlH formation compared to 
control. Our results further suggest that radiation may stimulate vessel en- 
largement after stenting. The clinical implication of this effect remains to be 
clarified, since tubular stents are not able to further expand after deployment 
and stent malapposition may occur at FU. 
Variable 
Diabetes (0 = no) 
T (0 = PTCA, 1 = ROTA) 
Lesion length (mm) 
% DS T pre 
MLD Dost T 
Univariate model Multivariate model 
Odds ratio P Odds ratio P 
1.67 0.09 1.44 0.30 
1.75 0.03 1.64 0.10 
1.09 0.0003 I .oa 0.001 
1.05 0.0001 1.06 0.0008 
0.41 0.02 0.8 0.65 
MLD = minimal luminal diameter; T = treatment of ISR 
9:45 a.m. 
EJ 896 6 A Novel Gamma Emitting Radioactive Stent 
Constructed by Targeted Radioimmunotherapy 
Morris Mosseri, Yoram Vodovotz, Zvi Symon, Rosanna Chan, Rui Lu, 
Ron Waksman. Washington Hospital Center, Washington, DC, USA 
Conclusions: In this angiographically controlled prospective study base- 
line lesion length defined as length of first in-stent restenosis (>50% DS) and 
baseline diameter were the most powerful predictors of recurrent restenosis 
after mechanical treatment. This indicates that the in-stent tissue volumen at 
first ISR seems to be the most important predictor of angiographic long-term 
outcome. 
Background: lntracoronary radiation (IR) reduces neointima formation fol- 
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/ 897-2 1 In-Stent Restenosis: An Inflammatory Response 
Harish Ft. Chandra, John A. Fry, Carol O’Neill, Nivedita Choudhary, William 
W. C’Neill. William Beaumont Hospital, Royal Oak, Michigan, USA 
Background: In-stent restenosis has been associated with lesion morphol- 
ogy as well as procedural and clinical variables. Potential mechanisms in- 
clude, elastic recoil, intimal thickening, arterial thickening and remodeling. 
Recent studies have proposed inflammation as a contributing factor. 
Methods: We conducted a case-control study to evaluate the association 
between in-stent restenosis and serum levels of C-reactive protein (CRP), 
fibrinogen and Chlamydia pneumoniae titres (CPlgG). Blood tests and clini- 
cal information were obtained on 67 patients (number of lesions = 70) who 
underwent repeat coronary angiography due to chest pain within 35 to 442 
days (mean = 136 days) of intra-coronary stent placement. Coronary an- 
giograms were reviewed to obtain procedural details. Cases (n = 30, 250% 
diameter stenosis) were compared with controls (n = 40, ~50% diameter 
stenosis). 
Results: Mean age of the study population was 62 f 12 yrs and 63% were 
males. Cases were not different from the controls in terms of age, gender, 
diabetes, hypertension, hyperlipidemia, current smoking, congestive heart 
failure, prior myocardial infarction, and bypass surgery (p = NS). Procedural 
variables were similar in both groups in terms of indication for stenting, target 
vessel, denovo lesion, lesion length, pre and post MLD, balloon to artery 
ratio, maximum balloon pressure, number of stents, total length of stents, 
and residual stenosis (p = NS). The cases had siginificantly higher levels of 
CRP (1.65 mg/dl vs. 0.5 mgidl, p = 0.05) and fibrinogen (346 mgidl vs. 293 
mg/dl, p = 0.05). The distribution of CPlgG titres was found to be similar in 
both groups (p = NS). 
lnflammatotv Markers No In-stent Restenosis In-stent Restenosis D Value 
(n = 40) (fl=30) 
C-Reactive Protein, mean * SD 0.5 * 0.58 mg/dl 1.65 -i: 2.95 mg/dl 0.05 
Fibrinogen, mean + SD 293 5 69 mg/dl 346 4~ 137 mgkll 0.05 
CPlgG 
~1:64, n (%) 32 (82%) 22 (76%) 0.92 
el:128, n (%) 30 (77%) 22 (76%) 0.35 
?1?512, n (%) 22 (56%) 13 (45%) 0.92 
>1:1024. n (%) 13 (33%) 10 (34%) 0.53 
Conclusion: Elevated levels of inflammatory markers were found to be 
strongly associated with in-stent restenosis while seropositivity to C pneu- 
moniae was not. There is a need to further study the role of inflammation in 
the pathogenesis of in-stent restenosis. 
9:00 a.m. 
1 897-3 1 A Potential New Indication for Thienopyridine 
ADPReceptor Antagonists: InStent Restenosis 
Debabrata Mukherjee, Joel P. Reginelli, Derek P. Chew, Jakob P. Schneider, 
Russell Raymond, Patrick L. Whitlow, Irving France, Eric J. Topol, Stephen 
G. Ellis. Cleveland Clinic Foundation, C/eve/and, Ohio, USA 
Background: Thienopyridine ADP-receptor antagonists are not routinely 
used after PCI for in-stent restenosis. We determined the effect of adjunc- 
tive use of ADP antagonists (ticlopidine or clopidogrel) after percutaneous 
intervention (PCI) for treatment of in-stent restenosis. 
Methods: 263 patients with in-stent restenosis underwent PCI at the 
Cleveland Clinic between 02/96 and 12/98. Patients treated with DCA, Laser, 
additional stents and brachytherapy were excluded. 205 of these patients re- 
ceived ADP antagonist for 2-4 weeks after PCI and 58 were treated without 
ADP antagonists. The baseline characteristics and mode of treatment for 
these patients are summarized in the Table. The groups were similar with 
respect to age, gender, elevated lipids, diabetes, LV function, number of 
vessels involved. history of prior CABG and unstable symptoms at pre- 
Aoe 
ADP antagonist (n = 205) 
62* 11.2 
No ADP antagonist (n = 58) 
62.7 i 10.4 
Miles 
Unstable symptoms 
Hypertension 
Diabetes 
LVEF 
Current smoker 
Sallon Angioplasty 
Rotablation 
MI (Q and Non-Q) 
Revascularization 
Death (Total) 
* p < 0.001,~ p < 0.01 
76% 
12.8% 
63.4% 
26.4% 
60% 
14.2% 
84% 
16% 
1 .4% 
14.1% 
4.3% 
75.8% 
12.1% 
46.5%* 
27.5% 
62% 
13.8% 
88% 
12% 
8.6%5 
23.2%§ 
5.1% 
sentation. There were more hypertensives in the ADP antagonist treated 
group. 
Results: (table) At 1 year there was a significantly lower revascularization 
and lower incidence of MI in the ADP antagonist treated group. 
Conclusions: For management of in-stent restenosis adjunctive use of 
ADP antagonists (ticlopidine or clopidogrel) significantly improves clinical 
outcomes at I year with reduction in myocardial infarction and revasculariza- 
tion. 
9:15 a.m. 
I 897 4 Association of In-Stent &stenosis With Hvpersensitivitv Reactions to Nickel and 
M’b;lybdenum - 
Ralf Kbster, Dieter Vieluf, Margret Kiehn, Martin Sommerauer, 
Stephan Baldus, Jan Klhler, Thomas Meinertz, Christian W. Hamm. 
Universify Hospital Eppendotf Hamburg; Kerckhoff Heart Center, Bad 
Nauheim, Germany 
In-stent restenosis may be triggered by allergic reactions to nickel, chromate, 
manganese or molybdenum which are components of stainless steel stents. 
The aim of this study was to investigate the incidence of allergic reactions to 
stainless steel components in patients with in-stent restenosis. 
In 131 patients (63 f 9 years) with 171 stainless steel stents (33 Pal- 
maz-Schatz, 70 AVE, 68 other types) coronary angiography was performed 
6.1 f 2.7 months after stent implantation. The percentage diameter stenosis 
within the stent was measured by quantitative coronary angiography. All pa- 
tients underwent epicutaneous patch tests using Finn chamber technology 
for nickel-II-sulfate 2.5% and 5%, potassiumdichromate 0.5%, molybdenum- 
V-chloride 0.5%, manganese 0.5% and 316L stainless steel platelets. Results 
of the patch tests were evaluated by independent investigators after 48 h, 72 
h and if necessary after 96 h of contact with the potential allergen. 
Quantitative coronary angiography revealed in-stent restenoses (150% 
diameter stenosis) in 89 pts; 42 pts had no restenosis. In the group withouf 
restenosis there was no patient with an allergic reaction. Allpts with positive 
patch tests (n = 9) were in the group with restenosis. In this group the overall 
incidence of positive reactions was significantly higher compared to that in the 
control group (10% vs O%, p < 0.05). In 3 pts we observed positive reactions; 
to molybdenum and in 6 pts (3 male, 3 female) to nickel. However, none of 
the pts with hypersensitivity reaction to the standardized test solutions had a 
positive reaction to the 316L stainless steel platelets. 
Conclusions: Patients with in-stent restenosis had a higher incidence of 
positive patch test reactions to nickel than those without restenosis. These 
results from this small group of patients suggest that allergic reactions to 
nickel may trigger in-stent restenosis. 
9:30 a.m. 
897-5 Does “Stent-on-Stent” for In-Stent Restenosis 
Exaggerate lntimal Hyperplasia? A Volumetric 
Intravascular Ultrasound Analysis 
Gary S. Mintz, Balram Barghava, Roxana Mehran, Ron Waksman, 
Mihaela Folescu, Alexandra J. Lansky, August0 D. Pichard, Martin B. Leon. 
Washington Hospital Center, Washington, DC, USA 
In-stent restenosis may be treated with additional stent implantation. To as- 
sess the efficacy of this approach, we used serial (post-intervention and 
follow-up) volumetric intravascular ultrasound (IVUS, using motorized pull- 
back) to study 98 pts enrolled in WRIST, a randomized placebo-controlled 
trial of Ir-I 92 gamma irradiation to treat in-stent restenosis. 31 pts had addi- 
tional stents placed prior to radiation, Stent, lumen, and intimal hyperplasia 
(IH = stent-lumen) areas were measured every 1 mm of in-stent restenosis 
length. IH area was averaged, minimum lumen area (MLA) was measured, 
and differences were compared. Post-intervention lumen dimensions were 
similar in pts with and without additional stents. Pts with subacute or late 
stent thrombosis were excluded. 
Follow-uo @6 months New stsnt No new stent 13 
Ir-192 
A mean IH area (mm*) 0.3 -t 0.9 0.1 * 2.0 0.77 
A MLA (mm2) -0.7 * 0.12 -0.6 AT 1.9 0.92 
Placebo 
A mean IH area imm2) 2.4 i 1.4 1.5 * 1.8 0.0963 
A MLA(mm*) ’ -2.7 h 1.2 -1.6 i 2.0 0.0584 
In-stent restenosis is the result of exaggerated neointimal hypeplasia. The 
initial stimulus for this exaggerated neointimal hyperplasia (which resulted in 
the Is* episode of in-stent restenosis) appears to be retriggered by additional 
stent implantation (causing greater increase in Amean IH and a greater 
decrease in MLA). However, this is neutralized by gamma irradiation. 
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We conclude: Serial volumetric IVUS analysis shows that the “stent-on- Conclusion: In-hospital and long-term complications in patients under- 
stent” technique for treating in-stent restenosis leads to increased subse- going PCA for restenotic CEA lesions are low. Percutaneous treatment of 
quent IH formation without adjunctive radiation therapy. these lesions may be a viable alternative to redo CEA. 
9:45 a.m. 
El 897 6 Treatment of In-Stent Restenosis. Shall We Balloon or Stent the Stent? A Prospective Single Center 
Randomized Study 
Thiery LefBvre, Abdeljabbar Benslimane, Rajendra Kumar Premchand, 
Yves Louvard: Pierre Dumas, Christophe Loubeyre, Niels Guillard, 
Jean-Franqois PiBchaud, Marie-Claude Morice. lnsfitut Cardiovasculaire 
Paris Sud, Mass& France 
Background: In-stent restenosis remains the Achilles’ heel of coronary stent- 
ing In a prospective obsetvational registry, we found that stenting the stent 
(sandwich steni) was associated with a lower rate of target vessel revascu- 
larization (TVR) than balloon PTCA, Laser or Rotablator in coronary arteries 
23 mm. 
Methods: A randomized study was designed to compare balloon PTCA 
vs sandwich stent in patients with ischemia-driven in-stent restenosis in 
coronary arteries ~3 mm in diameter. Patients were assigned to sandwich 
stent or balloon PTCA with provisional stenting in cases of unsatisfactory 
angiographic results (stenosis ~30% by QCA after balloon PTCA). A 7-month 
follow-up was set-up with treadmill stress test or thallium scan, coronary 
angiogram in cases of ischemia and subsequent TVR. 
Results: ‘I-month follow-up was completed in the first 57 pts (69 restenotic 
lesions) included from April 1998 to January 1999. Both groups were com- 
parable (37 lesions in the balloon group and 32 in the stent group). Patients 
had a mean age of 61 j, If years, 73% male. Repeat PTCA was performed 
5.4 i 3.7 months after the first procedure. The restenotic artery was the RCA 
n 45% of cases: LAD in 33% and the Circ. in 22%. Reference diameter was 
3.2 & 0.3 mm and length of the previous stent 18 & 6 mm. Restenosis was 
focal in 46% of cases, diffuse in 32% and proliferative in 22%. Angiographic 
success was obtained in all cases. Cross-over to stent was performed in 
19% of cases in the balloon group. In-hospital major cardiac events (SAT 
with rePTCA and non-Q-wave Ml) occurred in 1 pt in the balloon group: 
1.8%). At -/-month follow-up, TVR was performed in 19% of cases in the 
stent group vs 32% in the balloon group (p = NS). No other event occurred 
at follow-up. 
Conclusion: The preliminary results of this randomized study suggest 
that rePTCA or restenting for in-stent restenosis is safe. The use of sandwich 
stent could be a better option than balloon PTCA with provisional stenting. 
Final data will be presented during the meeting. 
ORAL 
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Anaheim Convention Center, Room 207A 
8:30 a.m. 
1898-l 1 Long-Term Outcomes of Percutaneous Carotid 
Artery Revascularization (PCA) for 
Post-Endarterectomy (CEA) Restenosis 
Walter A. Tan, Chester Ft. Jarmolowski, Gustav Eles, Michael H. Wholey, 
John S. Bechtel, Mark H. Wholey. Pittsburgh Vascular Instifufe, 
UPMC-Shadyside, Piffsburgh, PA, USA 
Background: Up to 20% of patients develop restenosis after CEA. Redo 
CEA is accompanied by higher complication rates, and PCA is a potentially 
suitable alternative. However, long-term outcomes in this population have 
not been documented. 
Methods: Seventy consecutive patients who underwent PCA between 
January 1996 to June 1999 for restenotic post-CEA lesions were extracted 
from the Pittsburgh Vascular Institute Carotid Interventional Registry. The 
mean follow-up was 14.3 months, with a 6-month follow-up rate of 94.5%. 
Angiograms were evaluated based on NASCETcriteria (distal internal carotid 
artery as reference segment) using standardized core laboratory methods. 
The mean age was 73 years, 51% were male, and 36% had diabetes, and 
20% had a prior Ml. Sixty-eight percent had asymptomatic presentation, and 
19% had prior stroke. The mean stenosis pre-procedure was 89% visually 
(64% by electronic calipers), and 0% post (8%). 
Results: Periprocedural complications included 1 (1.4%) major stroke and 
no deaths. There were 2 technical failures without complications. Long-term 
all-cause mortality was 2.9% (2 patients at 14 and 17 months postprocedu- 
rally), and no new neurologic events. 
8:45 a.m. 
898-2 Protected Carotid Stenting With the PercuSurge 
Guardwire: Results From a Multi Speciality Study 
Group 
Patrick L. Whitlow, Pedro Lylyk, Hugo Londero, Juan Parodi, 
Claudio Schonholz, Jose Milei. C/eve/and Clinic Foundafion, C/eve/and, 
Ohio, USA; Buenos Aires, Argentina 
Background: Although carotid stenting has been used successfully to treat 
patients with symptomatic or asymptomatic severe extracranial carotid artery 
stenosis, embolic complications remain a concern. Stroke has been reported 
in 2-8% of cases. Emboli protection devices might improve the safety of 
carotid stenting. 
Methods: The PercuSurge Guardwire is a temporary occlusion balloon 
on a wire which can be steered distal to the carotid stenosis and inflated, 
providing protection prior to and during balloon dilation and stenting. Trapped 
material is removed by a monorail aspiration device and the PercuSurge 
balloon is deflated. 
Results: A registry of 50 pts undergoing protected carotid stenting is 
underway by this multi-specialty group including cardiologists, a neuroradi- 
ologist, a vascular surgeon and an interventional radiologist. In our study, 
40 cases have been completed to date. 45% of lesions were ulcerated and 
11% had visible thrombi prior to treatment. 50% of patients had ipsilateral 
ischemic symptoms within 3 months of stenting. Two pts had contralateral 
100% occlusion, 1 pt had contralateral subtotal occlusion, and a 4th pt had 
80% stenosis of the contralateral carotid before the target vessel was treated. 
Mean total occlusion time was 15.2 f 5.7 min for the entire procedure. No 
patient had minor or major stroke or death during the procedure or within 
30 days. Two cases were associated with transient focal neurologic deficits 
which resolved immediately with balloon deflation. Particulate matter was 
visible in all aspiration samples, and Coulter counter analysis documented 
380 i 164 particles/case. Particle size ranged up to 1.6 mm, but the majority 
of particulate debris was 50-100 microns. Treatment of the remaining 10 pts 
in this protocol will be finished within the next month, and complete data on 
the 50 pt cohort will be presented. 
Conclusions: 1). Protected carotid stenting with the PercuSurge Emboli 
Containment and Aspiration System is feasible and safe. 2). The system is 
effective in the hands of multiple physicians involved in invasive procedures 
from all related subspecialities. 3). Emboli appear universal with carotid 
stenting, and emboli protection systems will be required to minimize ischemic 
complications. 
9:00 a.m. 
898-3 Outcome of Carotid Stenting in Symptomatic 
Octogenarians and Won-Octogenarians 
Fayaz A. Shawl, Waleed Y. Kadro, Fernando Lapetina, Robert Tobar, 
Stephanie Cornell, Kathryn G. Dougherty. Washington Adventist Hospital, 
Takoma Park, Mary/and, USA 
Background and Methods: With the increase in life span, more octogenari- 
ans are presenting with carotid stenosis. Most carotid endatterectomy (CEA) 
trials (NASCET and ACAS) have excluded these pts. Pts undergoing carotid 
stenting (CS) at our institution were stratified to 180 yrs and 180 yrs in order 
to assess the impact of age on clinical and in-hospital outcomes. 
Results: From 8/95 to 8199 270 pts (307 procedures) underwent CS (~80 
yrs = 194, 280 yrs = 76 [including 3 pts >90]). Summarized below are the 
characteristics of the two groups. 
CS in pts stratified by age (yrs) 
Age < 80 Age > 80 
cn = 1941 ln =761 
p value 
Age (yrs) Male (%) 
Prior CABGiPTCA (%) 
Contralateral occlusion (%) 
Bilateral occlusion >70% (%) 
Prior CEA (%) 
Diabetes (%) 
Severe COPD (%) 
Refused for CEA (%) 
Procedural success (%) 
Complications at 30 days 
Death (%) 
Minor CVA (%) 
Maior CVA (%I 
66/57 
73 
7 
20 
7 
27 
20 
10 
99 
0 
2.5 
85159 p < 0.001 
74 p ~0.528 
12 p = 0.1890 
13 p = 0.1720 
a p=o.518 
72 p < 0.001 
25 p = 0.29 
89 p < 0.001 
100 p = 0.97 
0 
1.3 
0 
p=1.0 
p =0.465 
PZO.519 
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Conclusion: Despite a higher incidence of refusal for CEA because of 
associated comorbidities, octogenarians have similar procedural success 
and complications as non-octogenarians. Therefore, advanced age should 
not exclude ots from CS. 
9:15 a.m. 
898-4 Initial Experience of Glycoprotein Ilb/llla Inhibition 
With Abciximab During Carotid Stenting: A Safe 
Adjunctive Therapy - 
Samir R. Kapadia, Christopher T. Bajzer, Khaled M. Ziada, Mitchell J. Silver, 
Fernando A. Cura, Philippe L. CAllier, Jay S. Yadav. The Cleveland Clinic 
Foundation, Cleveland, Ohio, USA 
Background: Abciximab has been shown to decrease periprocedural is- 
chemic complications after coronary intervention. However, the adjunctive 
use of abciximab in carotid stenting has not been studied. We sought to 
determine the safety of abciximab in carotid stenting. 
Methods: Carotid stenting with adjunctive abciximab was performed m 70 
consecutive between April 98 and May 99. Only patients determined to be at 
high surgical risk by a vascular surgeon were candidates for carotid stenting. 
All patients received abciximab bolus (0.25 mg/kg) prior to crossing the lesion 
with guide wire, followed by 0.125 mcg/kg/min infusion. Infusion was discon- 
tinued at the end of the procedure. Heparin bolus of 51) units/kg was given 
and ACTwas maintained between 250300. All patients received aspirin (325 
mg/day) and clopidogrel (75 mg/day) for 4 weeks. Independent neurologic as- 
sessment was performed pre and post intervention in all patients. 
Results: Most of the patients (52, 75%) were men with a mean age of 
70 jr 10 years. Forty-nine (70%) patients were symptomatic: 14 (20%) had 
strokes and 35 (50%) had TIAs. Significant cardiac comorbidities included 
severe left ventricular dysfunction in 11 (16%), unstable angina in 27 (39%) 
and aortic stenosis in IO (14%) patients. Intracranial hemorrhage occurred in 
1 patient. This patient was discharged after procedure and presented 6 days 
after the intervention with subacute intracranial bleeding and had favorable 
outcome. Minor groin bleeding, not requiring blood transfusion occurred in 2 
patients and 2 patients had pseudoaneurysm. There were no periprocedural 
strokes or stent thromboses. 
Conclusion: Adjunctive use of abciximab for carotid stenting is asso- 
ciated with low risk of intracranial hemorrhage Potent glycoprotein Ilb/llla 
inhibition may reduce periprocedural adverse events in high-risk patients 
without increasing bleeding complications. 
9:30 a.m. 
[898-5 Treatment of Atherosclerotic Vertebral Artery 
Disease by Endoluminal Stenting: Results From a 
US Multicenter Registry 
Suresh P. Jain, Stephen R. Ramee, Christopher J. White, J. 
Stephen Jenkins, Tyrone J. Collins, Gary S. Roubin, Sriram S. lyer, Larry 
S. Dean, Kimberly Kretzer, Jay S. Yadav, Samir Kapadia, John R. Laird, 
Gary Ansel, Mark H. Wholey. Ochsner Clinic, New Orleans, LA, USA 
Atherosclerotic vertebral artery occlusive disease has been treated surgically 
with limited success. Balloon angioplasty of vertebral artery is fraught with 
suboptimal results due to elastic recoil and intimal dissection. A US multi- 
center registry was formed to evaluate the safety, acute clinical success and 
long term outcome of endoluminal stenting (ES) in treating pts with vertebral 
artery (VA) stenosis. Fifty four pts (mean age 63 yrs, Females = 8) who 
underwent ES of VA (symptomatic = 43, asymptomatic critical stenosis = 
II) between October 1995July 1999 have been enrolled in the registry, A 
total of 62 VA (right = 37, left = 25) were treated with balloon expandable 
stents (n = 69) with the majority receiving medium size Palmaz stents. Post 
stenting pts received either ticlopidine (250 mg twice a day) or clopidrogel 
(75 mg once a day) for 2-4 weeks in combination with aspirin (325 mg daily). 
Quantitative angiography was performed using an automated edge detection 
technique or electronic calipers. 
Results: 53/54 (98%) achieved procedural success defined as ~20% 
diameter stenosis without any major neurological event, emergency surgery 
or death. 
Baseline Post stent P value 
MLD (mm) 1.18iO.50 4.57 * 1.07 co.ooo1 
Diameter stenosis (%) 74.96 f 9.32 3.1911 <0.0001 
Acute aain (mm) 3.39 * 1 
Three pts (5.5%) developed restenosis with recurrent symptoms during 
follow up (444 * 353 days) and were successfully treated with balloon 
angioplasty. Two pts died from cardiac failure. 
Conclusions: Endoluminal stenting of vertebral artery is associated with 
excellent technical and procedural success without any major complications. 
A low rate of restenosis and symptom recurrence makes it a better choice 
over traditional surgical revascularization. 
9:45 a.m. 
1 898-6 1 Carotid Stenting in Symptomatic Versus 
Asymptomatic Patients. Acute and Long-Term 
Clinical Outcomes 
George Dangas, John Ft. Laird, Roxana Mehran, Neil J. Weissman, Lowell 
F. Satler, Alexandra J. Lansky, Emily M. Parsons, Lee H. Monsein, Gary 
S. Mintz, Martin B. Leon. Washington Hospital Centec Washington, DC, 
USA 
Background: Acute surgical complications correlate with the patient’s neu- 
rological status before carotid endarterectomy (CEA). However, the impact 
of this factor on the outcome of carotid artery stenting (CAS) has not been 
established. 
Methods: We evaluated the acute and late clinical outcome after CAS in 
194 consecutive patients. Independent neurologic evaluation was performed 
pre- and post-GAS. Patients with neurological symptoms within 4 months of 
CAS were deemed symptomatic (SX, n = 45 patients, 47 CAS), otherwise as 
asymptomatic (ASX, n = 149 patients, 158 CAS). 
Results: Baseline clinical characteristics were similar between the two 
groups. Intravascular ultrasound imaging before stenting identified lower plaque 
burden in ASX vs SX patients both at the lesion (81 & 9% vs. 87 * 6%, p = 
0.03) and at the distal reference site (26 i 12% vs. 32 f 8%, p = 0.09). 
Neurological history and clinical outcomes: 
Prior major ipsilateral stroke 
Prior minor ipsilateral stroke 
Prior transient ischemic attack (TIA) 
in-hospital TIA 
In-hospital minor ipsilateral stroke 
In-hospital major ipsilateral stroke 
Any in-hospital ipsilateral stroke 
One-year follow-up (f/u) TIA 
One-year flu minor ipsilateral stroke 
One-vear flu major iosilateral stroke 
ASX 
10.1% 
19.6% 
25.9% 
1.9% 
4.4% 
1.9% 
6.3% 
3.2% 
0 
0 
sx 
10.6% 
36.2% 
80.9% 
8.5% 
0 
2.1% 
2.1% 
0 
6.1% 
0 
P 
0.94 
0.01 
0.001 
0.05 
0.35 
0.84 
0.30 
0.66 
0.06 
Conclusions: SX patients have marginally fewer acute complications 
and higher late minor strokes. Careful case selection is required in CAS 
of ASX patients and improved adjunctive pharmacological therapy may be 
beneficial after GAS of SX patients. 
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1 1197-Z ) ACClAHA Guidelines for Coronary Angiography: 
Analysis of Patients With Non Significant 
Coronary Artery Disease 
Meredith K. Evans, Michael J. Cowley, Evelyne Goudreau, Walter Malloy, 
On Topaz, George Vetrovec. Medical College of !/irginia Campus of Virginia 
Commonwealth lJniversi@ Richmond, Virginia, USA 
To assess the relevance of the clinical decisions to perform coronary angiog- 
raphy (CA) which fails to identify significant coronary artery disease (CAD), 
the recently published ACCiAHA guidelines were retrospectively applied to 
176 patients undergoing CA who had no or non significant (~50% stenosis) 
CAD (neg-CA). Chart reviews were performed in all patients with neg CA in 
1998. Pts with valvular, myopathy and transplant indications were excluded. 
All 176 pts with CA for suspected CAD were classified according to ACC/AHA 
guidelines by one primary reviewer. The mean age was 51.8 i 7 (SEM); 102 
were female (58%). Symptoms vs classes are as shown below: 
N Class %Positive 
I IIA IIB Ill NuclearScan 
Stable Anoina 68 1 17 49 1 53 
Unstable .&gina 
(78%) 
54 35 19 - - 32 i59%j 
Non Spec Chest Pain 24 16 8 14 (58%) 
Post Revasc lschemia 27 6 9 12 - 9 (33%) 
Acute MI 3 3 - - 
Total 176 42 45 80 9 106 (61%) 
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In summay: neg CA was performed for Class IIA (established indications) 
or above indications in 48%, Class IIB (consensus agreement) or above in 
90% and in only 5% for Class III (not useful) indications. Nuclear scans 
were positive in 61% comprising the most frequent underlying factor in CA 
performance. 
I 1197 76 Regional and Gender Differences in the Access to 
Early Percutaneous Coronary intervention for 
Non&T-Segment Elevation Acute Coronary 
Syndromes: Experience From the PURSUIT Trial 
With Glycoprotein Ilb-llla Inhibitor Eptifibatide 
(INTEGRILIN@) 
Todd J. Lorenz, Sally Greenberg, Michael M. Kitt. COR Therapeutics, Inc., 
South San Francisco, California, USA 
Background: PURSUIT was a randomized, double-blind trial of a GP Ilb-llla 
inhibitor eptifibatide (INTEGRILIN~) for the management of patients with 
non-ST-segment elevation acute coronary syndromes (ACS). A total of 
10,948 patients in North America (United States and Canada), Western 
Europe, Eastern Europe, and Latin America were randomized to receive ei- 
ther eptifibatide or placebo. The use and timing of diagnostic catheterization 
and PCI was left to the discretion of individual investigators, 
Purpose: To investigate the use of percutaneous coronay interventions 
(PCI) within the first 72 hours (median duration of study drug infusion) in 
different geographic regions or the overall population, as well as for men and 
women, 
Methods: Data on the use of early PCI were collected from the case 
report forms. 
Results: Early PCI was used most often in North America, with consis- 
tency between men and women. This was not the case in the rest of the 
world, where far fewer patients underwent PCI and men were more likely to 
undergo the intervention than women. 
Overall coculation 
North 
America 
24.5% 
W&era 
Europe 
7.2% 
EaStera 
Europe 
2.0% 
Latin 
America 
4.0% 
Men 25.6% 7.6% 2.6% 5.2% 
Women 22.4% 6.5% 1.4% 2.0% 
Conclusion: For North American patients with non-ST-segment elevation 
ACS, PCI is a commonly employed procedure in both men and women. In 
contrast, these procedures are not readily accessible to Western European. 
Eastern European, and Latin American patients, particularly women. Differ- 
ences in availability of early PCI may have contributed to the regional/gender 
variability in outcomes observed in the main study. 
/ 1197-77 / Transcranial Doppler Detection of Microemboli 
During Left Heart Catheterization 
Florence Leclercq, Saad Kassnasrallah, Jean-Baptiste Cesari, 
Jean-Marc Davy, Robert Grolleau R.. Cardiology and Neurology 
Departments, University of Montpellier, France 
Background: The occurrence of microemboli during invasive procedures 
such as cardiac angiography is well documented but relationship with patients 
(pts) characteristics and catheterization procedure remains unclear. 
Methods: Fifty-one consecutive pts (38 men, 15 women) who referred 
for diagnostic coronary angiography were included in the study. Clinical data 
regarding age, cardiovascular risk factors, histoy of cardiac or cerebral 
disease were collected. Left heart catheterization was performed via the 
transfemoral retrograde route in all pts. Angioplasty was performed during 
the same procedure in 16 pts. Transcranial Doppler (TCD) examination of the 
right and/or the left middle cerebral artery was performed from 20 minutes 
before the start of the catheterization procedure until 10 minutes after its end. 
Microembolic signals (MES) were counted manually during and after (off-line 
analysis) of the procedure. 
Results: No neurologic event occurred with a mean follow-up of IO 
months. MES were never observed before or after the procedure. MES were 
detected in all but 2 pts (mean 17 i 12 per patient) during the procedure. 
They were observed mainly during left ventriculography (38%) and contrast 
injection in coronary arteries (55%), suggesting its gaseous origin. There 
was not statistically significant association between the number of MES and 
patient age or risk factors (p = 0.3), left ventricular ejection fraction (p = 0.5), 
aspirin therapy (p = 0.32), duration of catheterization or angioplasty procedure 
(p = 0.6). There was a trend between absence of ischemic cardiopathy and 
number of MES (36 pts; p = 0.06) 
Conclusion: Despite frequent detection of microemboli with TCD during 
left heart catheterization, there was no association between MES and pa- 
tient/procedure characteristics and majority of MES seems to have gaseous 
origin. Because air embolism may be harmful, attempt to reduce its occur- 
rence may be useful. 
I 1197 78 Post-Interventional Chest Pain - Coronary 
Stretching or Myocardial Injury? 
Joerg Herrmann, Allen Jeremias, Michael Haude, Axel Schmermund, 
Raimund Erbel. University of Essen, Essen, Germany 
Background: Chest pain (CP) after successful percutaneous coronary in- 
tervention mainly regarded as a stretching effect of coronary arteries, but 
has not been related to new markers of ischemia. Therefore, we investigated 
the relationship between post-interventional CP and the incidence of serum 
marker elevation. 
Methods: In 180 consecutive patients (pts) undergoing balloon angio- 
plasty (BA, n = 44), coronary stenting (Stent, n = 120), or rotational atherec- 
tomy/excime laser coronary angioplasty (RA/ELCA, n = 16) a validated ques- 
tionnaire was used to evaluate the occurrence of CP within 24 hours after the 
coronary procedure. Serum marker analysis was done before, as well as 6, 
12, and 24 hours after coronary intervention using a rapid bedside troponin 
T test (threshold 0.1 rig/ml) for the detection of a cardiac troponin T (cTnT) 
release and a standard enzymatic assay (normal range IO-80 IU/I) for the 
quantification of creatine kinase (CK). Only patients with normal range values 
at baseline were included in this study. 
Results: The overall incidence of post-interventional CP was 42%, be- 
ing significantly higher after RA/ELCA (75%) and Stent (4%, p < 0.01 vs. 
RAIELCA) than after BA (25%, p < 0.05 vs. Stent, p < 0.001 vs. RA/ELCA). 
A significant correlation was found for CP and both cTnT (r = 0.338, p < 
0.001) and CK (r = 0.413, p x 0.001). 
Positive cTnT test 
CK 1.5-3x nml 
CK > 3x nml 
Peak CK [ItJill 
(n 26) 
52.6% 
10.5% 
7.9% 
1171213 
no CP 
(n = 104) 
14.4% 
5.8% 
1 .O% 
46 & 37 
p-value 
p < 0.001 
p = 0.26 
p = 0.02 
p < 0.001 
Conclusion: Post-procedural chest pain seems to be related not only to 
stretching but also to myocardial ischemic injury in a considerable number of 
patients. 
1197-79 Rotational Atherectonmy for Chronic Total 
Coronary Occlusions: Acute Results and 
Predictors of Target Vessel Revascularization 
Annapoorna Kini, David Reich, Tudor Bertea, Javed Suleman, 
Cristina Mitre, Jonathan D. Marmur, Samin K. Sharma. Mount Sinai 
Hospital, New York, New York, USA 
Balloon angioplasty of chronic total coronary occlusion (CTCO) has lower 
initial success and high subsequent restenosis. Recent reports have shown 
a lower target vessel revascularization (TVR) rate after stenting of CTCO 
compared to balloon angioplasty. However, stenting may not be appropri- 
ate in all CTCO due to lesion characteristics like long length, calcification, 
small vessels, ostial location and angulation. Rotational atherectomy (RA) 
by decreasing the plaque mass and changing lesion compliance may be 
appropriate for the interventional treatment of CTCO and may facilitate stent 
deployment (if needed). 
Results: We describe the acute results, in-hosptial outcome and need for 
TVR after RA of CTCO in 201 consecutive lesions in 200 patients which were 
initially crossed by the guide wire. Clinical characteristics: mean age 64 i IO 
yrs, mean duration of CTCO 82 + 48 days, multivessel disease 26%, LAD 
50%, reference vessel diameter 2.65 f 0.74 mm. Procedural characteristics: 
mean burr-to-artery ratio 0.74 rt 0.12, mean maximal burr size 2.0 f 0.3 mm, 
and post dilatation balloon size 3.2 * 0.8 mm. Stent was deployed in 38% 
of cases without any delivery failure. Procedural success was achieved in 
99.5% of cases with post procedural minimal luminal diameter of 2.32 f 0.42 
mm and residual stenosis of 12 & 10%. There were two cases of wire/burr 
perforation but no therapy was required. There were no cases of Q-wave 
MI, CABG, or death. Vascular complications occurred in 1 .I% and CK-MB 
elevation > 3x control occurred in 5%. Subsequent follow-up at a mean of 11 
i 4 months, revealed TVR of 20%: 24% after RA and 13% after RA + stent (p 
= 0.04). Multivariate predictors of TVR were diabetes mellitus (OR 3.02; 95% 
Cl 1.12-4.08), lesion length (OR 2.00 for each IO mm), reference vessel 
(OR 2.65; 95% Cl 1.35-3.95) and post-procedure MLD (OR 2.12; 95% Cl 
1.56-2.56). Also on follow-up, 7 patients required CABG, 3 presented with 
non-Q-wave Ml and 3 patients died. 
Conclusion: RA in the treatment of CTCO is safe and effective and has 
a relatively low TVR rate in comparison to historic controls. RA followed 
by stent implantation in suitable lesions may further decrease the need for 
88A ABSTRACTS - ACCISZOOO JACC February 2000 
repeat intervention, perhaps by achieving a large post-procedure MLD. Thus, 
a randomized trial comparing rotational atherectomy with stenting vs. stenting 
alone in the treatment of CTCO in large vessels (>2.75 mm) is warranted. 
1197-80 Prolonged QT Interval and QT Dispersion Induced 
by Coronary Rotational Atherectomy 
Hamo Tomoda, Naoto Aoki. Tokai University: and Yamato Seiwa Hospital, 
Kanagawa, Japan 
Background: Although coronary rotational atherectomy (RA) is widely ap- 
plied to clinical cases with calcified and/or long lesions, the incidence of slow 
flow and creatine kinase elevation, including oven myocardial infarction, is 
higher than in percutaneous transluminal coronary angioplasty (PTCA) or 
stenting. Thus, the aim of this study was to evaluate myocardial perfusion 
disturbances induced by RA using conventional electrocardiograms (ECGs). 
Methods: Twelve patients who underwent RA (group 1) and 12 other pa- 
tients who underwent PTCA (group 2) for a single target lesion were studied. 
There was no significant difference in clinical characteristics between the two 
groups. Standard 12-lead ECGs were recorded before and throughout the 
interventions. QT interval was measured from the onset of the QRS complex 
to the end of the T wave. QT dispersion was defined as the difference be- 
tween the maximum and minimum values of QT intervals. QT interval and , 
QT dispersion were corrected for heart rate (QTc and QTc dispersion). 
Results: Electrocardiographic measurements are summarized in the Ta- 
ble. In group 1, maximum and minimum QTc intervals and QTc dispersion 
were prolonged in all patients during RA. Maximal ECG changes occurred 
after the first passage of the RA device through the lesions, and these im- 
proved rapidly on a beat-to-beat basis after the cessation of RA. There was a 
single case with non-sustained ventricular tachycardia at the peak of the pro- 
longed QT. In contrast, group 2 showed insignificant decreases in maximum 
and minimum QTc and an insignificant increase in QTc dispersion. 
Group 1 Group 2 
Baseline RA P Baseline PTCA p 
QTc maximum (ms) 449 jl28 551 + 67 <O.OOOl 429zk24 423*21 NS 
QTc minimum (me) 406zt25 467162 <0.005 384i27 371h27 NS 
QTc dispersion (ma) 43i14 84i20 <0.0001 45i13 52il3 NS 
Conclusion: Markedly prolonged QTc interval and QTc dispersion appear 
to be sensitive markers for myocardial microcirculatory disturbances induced 
by RA. 
1197-81 Relationship of Number of Septal Branches 
Injected and Creatinine Kinase Area Under the 
Curve in Nonsurgical Septal Reduction Therapy 
for Hypertrophic Obstructive Cardiomyopathy 
Oscar M. Aguilar, Denise Meyer, Robert E. Fromm, William H. Spencer III. 
Baylor College of Medicine, Houston, Texas, USA 
Background: Non surgical septal reduction therapy (NSSRT) injecting al- 
cohol into septal perforator branches for hypertrophic obstructive cardiomy 
opathy (HOCM) has been used succesfully. We investigated the relationship 
between the number of septal branches injected with alcohol and myocardial 
injury by creatinine kinase (CK) area under the curve (AUC). 
Methods: In 104 patients undergoing NSSRT, we measured the CK at 
baseline and during the first 36 hours after the procedure. The baseline and 
follow up (6-28 weeks) left ventricular outflow (LVOT) gradient was also 
measured. Baseline clinical data and the relationship between the number of 
septal branches injected and CK-AUC were analyzed 
Results: The mean age was 49.5 t&16), 59 patients were males (57%) 
92 (88%) non smokers, 9 had hypertension (9%), 5 had hypercholesterolemia 
(5%), 8 were diabetics (8%) and 7 had coronary artery disease (7%). The 
mean baseline LVOT gradient was 60.2 mmHg (f32). Fifty six percent had 
I septal branch injected, 39 had 2, 3 had 3 and 2 had 4 septal branches 
injected respectively. Seventeen patients had pacemaker (PM) prior to the 
procedure. 
At follow up, the mean LVOT gradient was 12.1 mmHg (fig), for a 
decrease of 48.1 mmHg (529) which represents a decrease of 80%. PM 
insertion was required in 17 patients (19.5%), 7 (6.7%) required implantable 
defibrillator insertion after the procedure and 2 patients died (1.9%). Non 
parametric test for trend showed a statistically significant relationship be- 
tween the number of branches injected and the CK area under the curve 
(AUC), p < 0.001. 
Conclusions: NSSRT succesfully reduces the LVOT gradient in this 
patient population with low morbidity and mortality. Myocardial injury as 
measured by CK-AUC was related to the number of septal branches injected. 
We correlated the CK-AUC and the change in the LVOT gradient, 
. 
L--l 1197 82 Should Ethanol Septal Reduction be Performed on Young Patients With Symptomatic HOCM? 
Nasser Lakkis, Sherif Nagueh, Donna Killip, William Spencer. Bay/or 
College of Medicine, Houston, TX, USA 
Ethanol septal reduction is a recently introduced therapeutic option to relieve 
symptoms in patients with HOCM. This percutaneous technique involves 
the instillation of ethanol to the septal branches supplying the bulging septal 
muscle resulting in immediate relief ofthe obstruction along with symptomatic 
improvement. This treatment could potentially result in myocardial scarring, 
complete heart block and electrical instability. Thirty-one patients younger 
than 40 years have been referred to our center to be treated for refractory 
symptomatic HOCM. The procedure was performed successfully in all except 
two patients: one due to anatomical reasons where different kinds of wires 
could not be advanced, and the second patient had a few small septal 
branches which reduced the gradient only partially and the patient continued 
to be symptomatic requiring myomectomy. The average number of vessels 
ablated was 1.6 f 0.7. The mean increase in creatine kinase was 1524 f 398 
units. All patients had complete symptomatic improvement except for two. 
The mean resting gradient was 54 + 34 mmHg. It decreased to 6 f 13 mm Hg 
at 6 months (p < 0.01). The dobutamine-provoked gradient decreased from 
97 i 9 mmHg at baseline to 57 f 43 mmHg at 6 months (p < 0.01). The mean 
septal thickness decreased from 2.4 cm to 1.3 cm at 6 months (p < 0.01). 
Only one patient required a permanent pacemaker placement for complete 
heart block. The mean exercise time increased from 285 f 90 seconds 
to 411 i 54 seconds (p = 0.03). None of the patients had any arrhythmic 
documented events over the period of follow-up. In conclusion, ethanol septal 
reduction is an excellent option for young patients with symptomatic HOCM. 
1197-83 High Homocysteine Concentration is a Risk 
Factor for Major Adverse Cardiovascular Events 
and Angiographic Restenosis After Coronary 
Intervention 
Anjan Gupta, Gary Zander, Donald H. Schmidt. Sinai Samaritan Medical 
Center, Milwaukee, Wisconsin, USA 
Background: High homocysteine concentration is an independent risk factor 
for coronary atherosclerotic disease, but its role in causing major adverse car- 
diovascular events and angiographic restenosis after coronary interventions 
is unknown. 
Methods: Fasting plasma homocysteine levels were measured in 80 
patients (56 men, 24 women, mean age 64.4 i 12.8 years) using high per- 
formance liquid chromatographic technique before percutaneous coronary 
intervention. We then prospectively followed these patients over a course of 
10.2 f 2.3 months.’ 
Results: Twenty-five of the 80 patients (30%) had a major cardiovascular 
event (death, acute myocardial infarction, or repeat revascularization), and 
30 of the 80 patients (37%) had angiographic restenosis > 50% at the site of 
previous intervention. Those who experienced major adverse cardiovascular 
events had mean homocysteine concentrations that were significantly higher 
than those who did not have an adverse event (15.4 + 5.6 vs. 10.4 f 4.8 
~moles/L, p < 0.01). Multivariate analysis showed that a high homocysteine 
concentration was an independent risk factor for angiographic restenosis 
(OR 3.6, CI1.2-5, p < 0.01) and for major adverse cardiovascular events 
(OR4.5, C12.3-6.8, p < 0.01) after a coronary intervention. 
Conclusion: High homocysteine concentrations are an independent risk 
factor for major adverse cardiovascular events and angiographic restenosis 
after coronary intervention. Since B-vitamins lower plasma homocysteine 
levels, further studies should evaluate their benefit in reducing the incidence 
of restenosis after coronary interventions. 
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1198-l 15 Stent Therapy Improves the In-Hospital Outcome 
After Coronary Intervention in Males but not in 
Females 
Ziad A. Abbud, Leonard M. Schwartz. fJniversi(y of Toronto, Toronto, 
Ontario, Canada 
Background: lntracoronay stent deployment has been shown to improve 
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the short and long term outcome after percutaneous transluminal coronary 
angioplasty (PTCA). The female gender, however, is consistently under-rep- 
resented in the available data studying the outcome after coronary stent 
therapy. 
Methods: To compare the effect of stent therapy on short-term outcome 
between males and females, we reviewed 5,379 cases that were performed 
at the Toronto General Hospital between April 1994 and December 1998. 
Results: There were 3,978 males and 1,401 females. Stenting occurred 
in 56.7% of males and in 55.9% of females. In univariate analysis, the 
in-hospital outcome after PTCA was significantly improved by stenting in 
males but not in females. 
Fetll&S Males 
PTCA stent P PTCA stent P 
Acute Reacclusion 4.7% 3.1% 0.122 2.4% 1.5% 0.043 
MI 2.4% 4.0% 0.131 2.5% 2.2% 0.524 
CABG 1.3% 1.4% 1.000 1.7% 0.7% 0.006 
Death 0.5% 0.8% 0.739 0.9% 0.2% 0.003 
MACE 3.9% 5.4% 0.206 4.5% 2.8% 0.005 
Ml: Myocardial Infarction, CABG: Coronary Artery Bypass Graft Surgery MACE: Major 
Adverse Cardiac Events. 
Similarly,, in multivariate analysis adjusting for age, hypertension, dia- 
betes mellitus, hypercholesterolemia, tobacco use, and number of diseased 
vessels, stenting in males, significantly reduced the risk for acute reocclu- 
sion [OR = 1.65, 95% Cl (1.03, 2.65)], coronary artery bypass graft surgery 
[OR = 2.42, 95% Cl (1.29, 4.54)], death [OR = 3.35, 95% Cl (1.16, 10.06)], 
and major adverse cardiac events [OR = 1.49, 95% Cl (1.05, 2.12)], while 
consistently not affecting the outcome in females. 
Conclusion: While stenting in this series improved the immediate out- 
come after PTCA in males, it appears to offer no advantage in females. 
Randomized clinical trials to study the benefit of stent therapy in females are 
needed. 
/ 1198-l 16 / Predictive Factors of Direct Stenting Failure in a 
Single Center Experience of 1,500 Patients 
Bernard Chevalier, Thieny Royer, Philippe Guyon, Bernard Glatt. Centre 
Cardiologique du Norcl, Saint-Denis, France 
De novo coronary stenting has been validated in some coronary lesions by 
several randomized studies. In this setting, we used, from 10195 to 08/99, 
direct stent implantation (DSI) without prior dilatation technique in 1500 pts 
excluding age z 70, onset of (related to the target artery) angina or MI 
> 3 months, TIMI 0 occlusion. Clinical indication were almost exclusively 
acute syndromes: unstable angina 52%, recent Ml 24%, acute MI 14% and 
stable angina in 10%. Lesions were simple in 61% and complex in 39%. 
Additional balloon inflation was used in 21% and additional stenting in 4%. 
Technical success (defined as a successful deployment of the stent on the 
target lesion) was 95%. All direct stenting failures were successfully treated 
with conventional technique, Predictive factors of DSI failure, using univariate 
analysis were respectively in the order of less importance: pre-PTCA MLD, 
circumflex location, distal location, use of GFX AVE*stent, calcified vessel 
and age > 70 y. Multivariate analysis identifies circumflex location as the 
best predictive factors of failure. Stent loss rate was 0.2%. There were 6 
cases of partial failure to deploy the stent with residual stenosis from 31% to 
42%. Clinical success was 97.6%, inhospital MACE rate was 2.2% and stent 
thrombosis was 0.6%. 
Thus, DSI is feasible in selected coronary lesions and its success is 
dependent on anatomic conditions and delivery device quality. 
/ 1198 117 Clinical and Angiographic Follow-up of a New Biodegradable Coronary Stent (Igaki-Tamai 
Stent) 
Takafumi Tsuji, Hideo Tamai, Keiji Igaki’, Eisho Kyo, Kunlhiko Kosuga, 
Akiyoshi Kawashima, Shigeo Matsui, Tatsuhiko Hata, Hidenori Komori, 
Seiichiro Motohara, Hiromu Uehata. Shiga Medical Center for Adults, 
Moriyama; ‘Igaki Medical Planning Co. Ltd., Japan 
Background: High molecular weight poly-l-lactic acid (PLLA) stent is re- 
ported to be the most biocompatible among biodegradable polymer stents. 
We analyzed our experience of this stent in human coronary arteries. 
Methods: The Igaki-Tamai stent is made of PLLA monopolymer with 0.17 
mm thickness, and has a zigzag helical coil design with self-expanding ability. 
Forty-one lesions in 33 patients electively underwent the stent implantation 
for coronary artery stenoses. There were 29 males, and the mean age was 
60 i 13 yrs. All target lesions were AHAiACC type 6 and C. Coronary 
angiography was performed before, immediately after, 1 day, 3 months and 6 
months after the procedure. Serial changes of MLD and %DS were assessed 
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by quantitative coronary angiography. Restenosis was defined as %DS ? 
50% at follow-up. 
Results: The reference vessel diameter was 2.85 f 0.34 mm and the 
lesion length was 13.4 + 5.9 mm. The %DS decreased from 64% before 
stenting to 12% after stenting. All PLLA stents were successfully implanted. 
Subacute thrombosis occurred in one lesion (2.4%) which had been treated 
with inadequate heparinization because of gastorrhagia. No other MI, CABG 
or death developed within the follow-up period. The interim follow-up results 
are shown in the table. 
3 months 6 months 
&stenosis rate 
TLR rate 
13% (4/30) 19% (4/21) 
10% f3/30) 19% (4/21) 
Conclusions: Our preliminary experience suggests the feasibility, safety, 
and perhaps the efficacy of the Igaki-Tamai biodegradable stent in humans. 
Six months final outcome will be presented. 
1198-l 18 Is the Angiographic Guidance Sufficient for 
Optimal Stent Deployment in Ostial Stenoses? 
Insight From IVUS 
Milena Adamian, Cario Di Mario, Takahiro Nishida, Carlo Briguori. 
Bernard Reimers, Marco Vaghetti, Nicola Corvaja, Remo Albiero, 
Antonio Colombo. Centro Cuore Columbus, Milan, ltaly 
Precise positioning of stents in ostial lesions under fluoroscopic guidance is 
difficult because of the poor stent visibility and angiographic foreshortening 
or overlapping. The adequacy of stent deployment in ostial stenoses was 
evaluated with intravascular ultrasound (IVUS) in 86 consecutive patients 
(90 native de novo lesions). 
Methods: The stent position relative to vessel ostium was defined as: 
“optimal” (within *I mm to ostium; 39 lesions); “too proximal” (>I mm 
protrusion from the ostium with range from 1.5 to 7.0 mm; 32 lesions) and 
“too distal” (> 1 mm distal to the ostium, range from 1.5 to 4.5 mm; 19 lesions). 
Lesions were located in: RCA 18%, LAD 46%, LCX IO%, branch-ostial 19%. 
All deployed stents were balloon-expandable with PSI 54 used in 46 lesions 
(50%). Angiographic follow-up was obtained in 86% of eligible patients 6.8 
i 2.0 months after stenting. 
Results: There were no statistically significant differences in clinical char- 
acteristics among the 3 groups. 
Ootimal Too Proximal Too distal 
RVD (pie/final), mm’ 3.3 + 0.5/3.4 * 0.4 3.1 + o.tY3.4 * 0.4 3.1 * 0.3/3.3 * 0.5 
MLD (pm/final), mm* 1.1 f 0.7/3.3 i 0.6 1 .O i 0.613.3 f 0.5 0.9 zk 0.5/3.2 i 0.7 
B/V Ratio* 1 .ll f 0.30 1.19 * 0.21 1.16zkO.16 
Acute Gain, mm* 2.27 iO.73 2.29 it.78 2.19 & 0.85 
Late Loss, mm* 0.94 * 0.83 1.10 * 0.95 0.93 * 0.99 
Loss Index* 0.45 zk 0.42 0.67 zk 0.82 0.42 f 0.33 
Fin stem CSA, mms* 9.83 + 2.66 9.70 * 2.39 9.5 * 3.37 
Fin vessel CSA, mm*’ 17.43 * 4.76 17.33zt 4.40 17.25i 5.36 
RestenosisTTLR, %* 25125 22/20.7 19118.7 
* p = NS; RVD = reference vessel diameter; MLD = minimal lumen diameter: TLR = target 
lesion revascularization; CSA = cross-sectional area 
Conclusions: With modern stems and angiographic guidance precise 
stent positioning can be achieved in most cases with a trend to moderate 
stent protrusion. Suboptimal (too proximal or too distal) stent position within 
the small range observed does not predict an increased risk of restenosis. 
1198-I 19 Rotational Atherectomy, 
Excimerlaser-Angioplasty or Balloon 
Angioplasty for Therapy of In-Stent-Restenosis? 
Bernward Lauer, Eike Schmidt, Heiko Ambrosch, Silke Steinbrink, Klaus 
W. Diederich, Rainer Hambrecht, Hans Krankenberg, Andreas Kuhn, 
Peter Sick, Rainer Zotz, Gerhard Schuler. University of Leipzig-Heart 
Center, Germany 
Background: Optimal treatment of restenosis after stent implantation re- 
mains to be determined. Tissue debulking with rotational atherectomy (PTRA) 
or excimer-laserangioplasty (ELCA) may be more efficious than conventional 
balloon angioplasty (PTCA) alone. Therefore, the present study evaluates 
the acute and long-term results after PTRA, ELCA or PTCA for in-stent 
restenosis. 
Methods: 682 lesions (L) in 576 patients with in-stent restenosis were 
treated with PTRA (190 L), ELCA (191 L) or PTCA (301 L), respectively. After 
PTRA or ELCA, additional PTCA was performed to achieve optimal acute 
procedural results. Coronary angiogramms were analyzed by quantitative 
angiography @CA). 
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Results: QCA data are given in the table 
Acute intervention Long-term results 
n MLD at MLD after MLDafter n MLD at follow- 
baseline &bulking intervention up (6 months) 
PTRA 190 0.64 + 0.45 1.83 * 0.47 2.71 zt 0.53t 161 1.62 3~ 0.89* 
ELCA 191 0.86 rk 0.44 1.83 i 0.48 2.89 * 0.75+ 159 1.35 f 0.93 
PTCA 301 0.81 & 0.73 2.51 zt 0.64 229 1.53 f 0.87 
MLD: minimal lumen diameter (mm), t: p < 0.05 vs PTCA, *: p < 0.05 for PTRA vs ELCA 
Conclusions: PTRA and ELCA for in-stent restenosis result in significant 
ablation of restenotic tissue. Acute gain with PTRA and ELCA is better than 
with PTCA alone. However, in the present study, MLD after 6 months is 
significantly greater only afler PTRA compared to ELCA. 
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L-.-z-- 1199 84 Total Platelet Volume is an Independent Predictor 
for Mortality Reduction in Patients Treated With 
Abciximab 
Mark G. Treuth, John C. Isaac, Katherine Wolski, Neal S. Kleiman. Baylor 
College of Medicine, Houston, TX; Delmarva Heart, SalisburL: MD; 
Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: We investigated the relationship between total platelet volume 
and the effect of abciximab on mortality. 
Methods: Calculation of total platelet volume was performed using platelet 
volume prior to percutaneous coronary intervention and multiplying it by es- 
timated blood volume. Estimated blood volume was calculated using the 
following formulas: [weight (kg) x 411 + 1530 for males, and [weight (kg) 
x 47.21 + 846 for females. Patients (n = 8555) enrolled in EPIC, EPILOG, 
EPISTENT, and CAPTURE were analyzed for death at 6 months. Platelet 
volume was dichotomized into high vs low (upper 20th vs. lower 80th per- 
centile). A Cox Proportional Hazard model was used to control for significant 
differences in baseline characteristics. 
Results: Abciximab treatment resulted in a reduction of the hazard for 
mortality in patients with high platelet volumes (unadjusted hazard ratio = 
0.368; 95% Cl = 0.176-0.771). At baseline, there were significant differences 
with respect to the number of patients with CHF, PVD, hypertension, or age. 
When controlling for these factors, there was still a significant benefit from 
treatment with abciximab in patients with high platelet volumes (adjusted 
hazard ratio = 0.384; 95% Cl = 0.180-0.821). 
Conclusion: The risk of death was significantly reduced when patients 
with high platelet volumes were treated with abciximab. Even after controlling 
for differences in baseline characteristics, platelet volume predicts a subpop 
ulation of patients that have a mortality benefit when treated with abciximab 
during angioplasty. 
11199-85 ( Abciximab Administration During Angioplasty in 
Acute Coronary Syndromes 
Battistina Castiglioni, Mauro Boscarini, Vruyr Balian, Raffaella Vaninetti, 
Sergio Repetto. Invasive Cardiology Department of Cardiology, Ospedale di 
Circolo, Varese, Italy 
Background: Abciximab is now a spreading treatment of complicated per- 
cutaneous transluminal coronary angioplasty (PTCA) and acute coronary 
syndromes. To reduce bleeding complication, we are now using the only bo- 
Ius administration with the aim of evaluate efficacy of abciximab administered 
with conventional way of treatment (bolus + venous infusion) and with the 
only bolus administration. 
Method: From 1996 to 1999 143 consecutive patients with acute coronary 
sindrom have been treated with abciximab during PTCA, 56 (39%) with 
bolus and infusion, 87 (61%) with the only bolus. Clinical and angiographic 
characteristic, technical data and results are reported in the table. 
Conclusion: Abciximab is a good way of treatment in PTCA during 
acute coronary sindromes. With the only bolus administration we obtain an 
important antiplatelet aggregation and a reduced bleeding risck. 
Treated vessels 
LAD 
LCX 
RCA 
IA 
LM 
SVG 
Stenting 
Indications for abciximab 
No-reflow 
Thrombus 
Dissection 
TIMI 3 
30 days follow-up 
Exitus 
Subacute occlusion 
RI?-PTCA 
Bleeding complications 
BOIUS Bolus + Infusion 
44 (51%) 28 (50%) 
16 (18%) 7 (13%) 
21 (24%) 17 (30%) 
4 (4%) 0 
0 1’(2%) 
3 (3%) 3 (5%) 
81 (93%) 54 (96%) 
63 (72%) 27 (48%) 
20 (23%) 20 (36%) 
4 (5%) 9 (16%) 
86 (99%) 55 (98%) 
0 1 (2%) 
2 (2%) 1 (2%) 
1 (1%) 1 (2%) 
2 (2%) 4 (7%) 
I 1199 86 Influence of Thrombus on the Outcome of Coronary Interventions in the Current Era 
Mandeep Singh, Henry H. Ting, Nelson A. Araujo, Guy S. Reeder, John 
F. Bresnahan, Ryan J. Lennon, David R. Holmes Jr.. Mayo C/ink, 
Rochester, MN, USA 
Background: Thrombus is associated with increased risk of complications 
during percutaneous coronary interventions (PCI). We sought to determine 
the influence of pre-existing thrombus in the current era on the acute and 
intermediate-term outcomes of PCI. 
Methods: 3914 patients who underwent PCI at Mayo Clinic between 
1996 and 99 were identified from the prospective database and divided into 
those with (n = 1508) and without (n = 2406) angiographic thrombus prior 
to treatment. Baseline, angiographic data, in-hospital outcomes and post- 
discharge outcomes of patients with successful procedure (~50% residual 
stenosis with no in-hospital death, MI, TVR and combined end points) were 
compared. 
Results: The group with thrombus was more likely to present with acute 
Ml (35% vs 3.1%), cardiogenic shock (9% vs 1.4%) and prior Ml (74.5% vs 
39.9%) before PCl.(each P 4 0.01). 
Event 
*In-hospital-Death 
-Death/Ml 
- Composite end points 
Odds ratio (95% Cl.) 
2.09 (1.11-3.96) 
1.79 (1.37-2.34) 
2.4 (1.93-2.98) 
P 
0.02 
<O.OOl 
<O.OOl 
*Post-discharge 
- Death 
- Death/Ml 
- Comoosite end ooints 
Risk ratio (95% C.I.) P 
0.99 (0.72-l .351 0.94 
I .21 {0.94-i .54j 0.14 
0.92 10.86-l .19) 0.92 
In the multivariate analysis after adjusting for all the significant variables, 
thrombus Was a predictor of in-hospital death, MI, and composite end points. 
In post-discharge survival there was no influence of thrombus on adverse 
events. 
Conclusion: Patients with pre-existing thrombus have lower procedural 
success and higher in-hospital complications. After adjusting for variables 
in patients with a successful procedure, pre-existing thrombus before PCI 
was not an independent predictor of adverse outcome following hospital 
discharge in the present era. 
l---z-! . Ii 99 87 An Algorithm Based on Clinical and Angiographic 
Criterra for Selecting a Glycoprotein llblllla 
Inhibitor During Percutaneous Coronary 
Intervention 
Annapoorna Kini, Chacko I. Nebu, Elie Banbahji, David Reich, 
Tudor Bertea, Samin K. Sharma. Mount Sinai Hospital, New York, NK USA 
The GP Ilb/llla inhibitors (GPI) during percutaneous coronary intervention 
(PCI) can reduce periprocedural CK-MB release and major adverse cardiac 
events (MACE) of acute/subacute closure, Q-wave MI and emergent bypass 
surgery. In the absence of randomized trials directly comparing the available 
GPI [abciximab (A), tirofiban (T) and eptafibatide (E)], the decision to use a 
particular agent depends on a case by case analysis of riswbenefit vs. cost. 
To define the most appropriate GPI use, a practice guideline for selecting a 
particular agent based on clinical and angiographic variables was formulated: 
A in high risk subsets (type C, complex, thrombotic or calcified lesions, post 
Ml, diabetes mellitus), T or E in moderate risk subsets (type B, IO-20 mm 
lesion length, vein graft, prior A use, stable or crescendo angina), and no 
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GPI in low risk lesions (type A, restenotic, small vessel, thrombocytopenia, 
bleeding disorders). 
Methods: To analyze the impact of these guidelines, we studied 919 
consecutive patients undergoing PCI with baseline normal CK-MB. GPI were 
used in 73.2% (A in 46.1%; Tin 16.1% and E in 11%). Crossover to emergent 
bailout use of abciximab for significant procedural complications was required 
in 2.0% after no GPI, 4% after T and 2% after E (p = NS). 
Results: 
No GPI 
(n = 246) 
30 day MACE (%) 2.0 
Any CK-MB f (%) 13.0 
1-3 x normal (%) 12.6 
3-5 x normal (%) 0.4 
>5 x normal (%) 0 
Vascular complications (%) 0.8 
p = NS for all categories and groups 
Conclusion: A strategy based on clinical guidelines for use of GPI during 
PCI was associated with similar incidence of CK-MB elevation and 30 day 
MACE. Thus, in the absence of a head-to-head comparison, the decision 
to use a particular GP llbillla inhibitor (A, T or E), based on a clinical and 
angiographic algorithm, can be expected to result in similar outcome and 
may be justified from the cost-effective point of view. 
/ 1199-88 1 Observed Protective Effect of Glycoprotein Ilb/llla 
Antagonists Against In-Hospital Death Stratified 
by Patient Risk 
Frederic S. Resnic, Lucila Olmo-Machado, Gavin J. Blake, Andrew Selwyn, 
Daniel I. Simon, Jeffrey J. Popma. Brigham and Women’s Hospital, Boston, 
MA, USA 
Background: Randomized trials suggested an early mortality benefit of ly- 
coprotein Ilb/llla antagonists (Ilb/llla) used at the time of percutaneous coro- 
nary interventions (PCI). However, the benefit observed in clinical practice 
is known to vary based on underlying risk factors. Accordingly, we sought 
to clarify the relationship of the benefit of adjunctive Ilb/llla antagonists with 
identifiable patient risk factors. 
Methods: We prospectively collected data on 37 clinical and procedu- 
ral variables for 2,804 consecutive cases from l/97 through 2/99, including 
patients presenting with acute myocardial infarction, cardiogenic shock, and 
those who undenvent same stay coronary artery bypass surgery. The dataset 
included 996 patients who received llb/llla at the time of PCI. Risk score mod- 
els were developed from the beta coefficients of a multiple logistic regression 
model. Models were constructed from a random subset of 1877 cases and 
validated on the remaining 927 cases. 
Results: There were 19 deaths in the llbillla treated patients (1.91%) 
and 43 deaths in the non-llb/llla group (2.38%; Odds Ratio = 0.80 p = 0.42). 
Aftar controlling for independent predictors of in-hospital death (including: 
age, gender, occluded vessel, type 82 or C lesion, presenting AMI, conges- 
tive heart failure and left main lesion), the use of Ilb/llla antagonists was 
associated with a trend toward reduced risk of in-hospital death (Odds Ratio 
= 0.504, p = 0.074). This mortality benefit was concentrated in those patients 
presenting with acute myocardial infarction, congestive heart failure, or two 
or more additional clinical risk factors. Observed mortality versus risk score 
stratified by use of Ilb/llla antagonists is shown. 
Conclusion: After controlling for known predictors of risk, the use of 
llbillla antagonists as an adjunct to PCI is associated with a trend toward 
a 50% reduction in the odds of in-hospital mortality. This benefit appears 
concentrated in those patients with identifiable increased pre-procedural 
risk. Further study is warranted to refine the identification of patients most 
likely to benefit from these agents. 
I 1199 89 The Impact of Abciximab on Mortality After Multivessel PCI: A Striking Effect in Diabetics 
Deepak L. Bhatt, A. Michael Lincoff, James E. Tcheng, Robert M. Califf, 
Philippe L. CAllier, Steven P. Marso, Katherine E. Wolski, Dean 
J. Kereiakes, Eric J. Topol. C/eve/and Clinic, C/eve/and, Ohio, USA 
Background: Patients with multivessel disease, especially diabetics, are 
often referred for coronary artery bypass surgery as an outgrowth of the BARI 
randomized trial. We sought to determine whether abciximab at the time of 
multivessel percutaneous coronary intervention (PCI) would favorably alter 
1 -year death and MI. 
Methods: Data from the EPIC, EPILOG, and EPISTENT trials were 
pooled. The i-year death and Ml rates for patients undergoing multivessel 
intervention randomized to either placebo or abciximab were compared. 
Results: In the overall cohort, the l-year mortality rate was 3.1% for pa- 
tients receiving placebo versus 2.0% for patients randomized to abciximab, 
p = 0.010. In the 612 patients undergoing multivessel PCI, the rate of death 
or Ml at 1 year was decreased by abciximab use from 15.5% to 8.5%, p = 
0.006, from 14.2% to 85% in the 439 non-diabetic patients undergoing mul- 
tivessel PCI, p = 0.053, and from 18.7% to 8.3% in the 173 diabetic patients 
undergoing multivessel PCI, p = 0.044. Similarly, in the patients undergoing 
multivessel PCI, abciximab decreased the mortality from 5.0% to 2.3%, p = 
0.070; specifically, in the non-diabetic patients mortality was reduced from 
3.9% to 2.8%, p = 0.548, while in the diabetic patients undergoing multivessel 
PCI, abciximab decreased the mortality from 7.7% to 0.9%, p = 0.018. 
Conclusion: Abciximab substantially reduces the risk of death or Ml in 
patients undergoing multivessel intervention, The mortality reduction at 1 
year is particularly striking in diabetic patients, 
I 1199 90 Abciximab and Enoxaparin Administration During Elective High-Risk PTCA in Patients With More 
Than 3 Days of Ticlopidine Pretreatment 
Dariusz Dudek, Stanislaw Banus, Pawel Zymek, Jacek Legutko, 
Lukasz Rzeszutko, Marianna Janion, Krzysztof Zmudka, Jacek S. Dubiel. 
Cardiology Department, Jagiellonian University, Krakow, Poland 
Background: Low molecular weight heparins have been suggested to re- 
duce acute coronary events during and after PTCA in comparison to un- 
fractionated heparin (UFH), whereas platelet Ilb/llla blockade with abciximab 
substantially improves the outcome. On the other hand ticlopidine therapy 
several days prior to PTCA is also associated with a reduced risk of proce- 
dural non-Q-wave myocardial infarction (Ml). 
Methods: To assess the eff icacy and safety of combined abciximab-enoxa- 
parin versus enoxaparin (Enox) administration during PTCA of complex (82 
or C) lesions, we randomized patients (n = 162) to 3 groups: UFH (n = 50) 
adjusted to ACT > 300 set, Enox (n = 58) enoxaparin (iv 1 mg/kg) and Re- 
oEnox (n = 54) receiving enoxaparin (iv 0.75 mgikg) followed by abciximab 
(iv bolus 0.25 mg/kg and 0.125 kgikgimin 12 h infusion). Importantly, all 
patients were pretreated for 3 days with aspirin and ticlopidine (250 mg bid) 
prior to elective PTCA. Serial CK, CK-MB (0, 8, 16, 24, 48 h) and cardiac 
troponin TnT and Tnl (0, 24, 48 h) were obtained after PTCA. 
Results: There were no major cardiac events (death, large MI [CK-MB < 
5x], rePTCA, CABG) in any group, but biochemical markers were distinct: 
Stenting rate 
Non-Q MI, CK-MB > 3 x 
TnT positive 
TnT positive 
Bleeding majoriminor 
*( UFH “s ReoEnox 
UFH EnOX ReClEnlX P 
68% 59% 72% NS 
16% 6.9% 5.5% p = 0.07* 
18% 11% 11% NS 
60% 50% 44% p = 0.07” 
014% O/l 0% O/l 1% NS 
Conclusions: Despite standard therapies (aspirin + UFH + ticlopidine), 
there remains a relatively high occurrence of peri-PTCA myocardial damage. 
The use of enoxaparin reduced the number of ischemic events and the 
combination of enoxaparin and abciximab appears safe, however there was 
no additional benefit of abciximab against myocardial damage in pts with 
ticlopidine pretreatment and application of enoxaparin during PTCA. 
1199-91 Abciximab Thrombocytopenia: Clinical Correlates 
and Outcomes 
Dean J. Kereiakes, Scott D. Berkowitz, A. Michael Lincoff, James 
E. Tcheng, Katherine Wolski, Roben M. Califf, Eric J. Topol. The Lindner 
Center, Cincinnati, Ohio, USA 
Thrombocytopenia (TP) is infrequently associated with abciximab (AB) ther- 
apy, but was shown in the EPIC trial to contribute to hemorrhagic risk and to be 
associated with adverse outcomes. To further define clinical predictors of and 
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outcomes in patients with TP following AB, we pooled and analyzed the data 
from EPIC, EPILOG and EPISTENT placebo (PL) controlled randomized tri- 
als of AB therapy in 7290 pts undergoing percutaneous coronary intervention, 
While AB bolus + infusion was similar in the 3 trials, in EPIC, heparin ad- 
ministration was not weight-adjusted and higher total doses of heparin were 
administered. TP (plt count < 100 x log/L) occurred in 178 (2.4%) pts and 
was more frequent (multivariable analysis) in EPIC (p < 0.001) and in older 
(265 yrs; p < O.OOl), lighter weight (<90 kg; p < 0.027) pts, those with lower 
baseline platelet counts (1150 x log/L; p < 0.001) and pts who received AB 
therapy (p 4 0.002). Clinical outcomes to 30 days in pts with/without TP by 
AB treatment are shown (“p < 0.001; tP = NS TP vs. Non-TP): 
N 
TP (AB) TP (PL) TP (Total) Non-TP 
139 39 178 7112 
Major Non CABG Bleeding Events (%) 13.4 22.2 15.3” 2.7 
Minor Non-CABG Bleeding Events (%) 16.4 11.1 15.3* 6.6 
Transfusion (%) 43.2 82.1 51.7* 4.7 
Death 6.5 15.4 6.4* 0.6 
Ml 3.6 0 5.6+ 2.8 
Uraent Revasc 0.7 2.9 3.0+ 1.2 
Conclusion: Age, weight, baseline platelet count, AB therapy and ,non- 
weight adjusted heparin are associated with AB-TP. TP is associated with 
increased bleeding risk and transfusion requirement. Among TP pts, those 
who received prophylactic AB have improved survival. 
1199-92 Abciximab-Enoxaparin Interaction During 
Percutaneous Coronarv Intervention: Results of 
the NICE 1 and 4 Trials- 
Dean J. Kereiakes, Cindy Grines, Edward Fry, Lawrence Barr, 
William Matthai, Thomas M. Broderick, Rose Lengerich, Marc Cohen, 
Paolo Esente. The Lindner Research Center, Cincinnati, Ohio, USA 
Low molecular weight heparin (LMWH) is used both for prevention and 
therapy of deep venous thrombosis and ischemic complications of acute 
coronary syndromes. Its adjunctive role during percutaneous coronary inter- 
vention (PCI) is unknown. 
Methods: As part of two multicenter, open-label trials to evaluate safety of 
0.75 mgIkg IV enoxaparin (EN) administered concomitantly with abciximab 
(AB) (NICE-4) or EN 1.0 mg/kg without concomitant AB (NICE-I) to pa- 
tients undergoing PCI, indices of coagulation (anti-Xa, anti-lla activity) were 
measured. 
Results: The interaction of AB and EN as reflected by measured levels 
(mean f SD) of anti-Xa vs. time from each trial (figure) is shown. NICE 4 
samples were obtained at baseline, post-EN, post-AB, 4, 8, 12 hrs. Anti-lla 
concentrations followed a similar pattern. 
Conclusion: These data suggest an AB-EN interaction that enhances 
antithrombotic effect of EN. The mechanisms and safety of this interaction 
are being evaluated. 
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L--l-- 1200 109 Theoretical Evaluation of the Influence of Aortic Pressure and Zero-Flow Pressure on Myocardial 
Fractional Flow Reserve 
Maria Siebes, Jos A.E. Spaan, M. Meuwissen, J.J. Piek. Dept.. ofCardio/- 
ogy and Medical Physics, University of Amsterdam, The Netherlands 
Background: Myocardial fractional flow reserve (FFR) is a measure of the 
functional significance of a stenosis which is assumed to be independent 
of heart performance at the time of measurement, and has a cut-off value 
of 0.75 as the decisive threshold for coronary intervention, The theoretical 
model underlying FFR was evaluated on how variations in the zero-flow 
pressure (Pzf) and aortic pressure (Pao) propagate into FFR. 
Methods:The stenosed coronary circulation was modeled as a flow- 
dependent stenosis resistance in series with a downstream myocardial re- 
sistance that was low and constant over the physiological pressure range, 
thus modeling maximum vasodilation. Lesion severity was varied from 20 
to 80% diameter stenosis (DS) in a 3 mm coronary vessel. Mean Pao was 
varied from 70-130 mmHg and distal perfusion pressure (Pd) was calculated 
with and without inclusion of Pzf = 10 mmHg. Parameters of the stenosis 
resistance were chosen based on their geometry, using well-established fluid 
dynamic principles. 
Results: Overall, FFR decreased hyperbolically with increasing aortic 
pressure. With inclusion of Pzf, the decline of FFR was larger over the same 
range of Pao. These effects were larger with increasing stenosis severity. An 
example for an intermediate lesion is given below: 
DS Pzf Pa0 Pd Q FFR 
60% 
mmHg mmHg mmHg mllmin = PdlPao 
0 70-l 30 49.8-82.6 124.6-206.4 0.71-0.63 
10 70-l 30 53.7-83.5 109.3-l 93.7 0.77-0.68 
Conclusions: Only with Pzf = 0 and a flow-independent stenosis resis- 
tance is FFR independent of Pao. Inclusion of a realistic nonlinear stenosis 
resistance and a non-zero Pzf results in FFR being dependent on cardiac 
conditions unrelated to stenosis severity. In the worst case for the above 
example, a decrease in Pzf and increase in Pao causes FFR to change by 
0.14 (0.77-0.63), which is a considerable fraction of the decision margin 
between 0.75 and 1 .O and can result in crossing the established threshold 
value of 0.75. This theoretical analysis suggests that additional controlled 
experiments are needed to further study these effects. 
/ 1200 110 A Novel Method to Simultaneously Measure Fractional Flow Reserve and Coronary Flow 
Reserve 
Luis Gruberg, Gary S. Mintz, Neil J. Weissman, Evgeny Shalman’ , 
Chen Barak’ , Elhanan Dgani’, August0 D. Pichard, Ben Berogan, Martin 
B. Leon. Washington Hospital Center, Washington, DC, USA; ‘Florence 
Medical, Kfar Saba, Israel 
Background: Coronary flow reserve (CFR) and fractional flow reserve of the 
myocardium (FFR,,,) can be useful to assess not only the functional sever- 
ity of coronary artery stenoses, but also the prognosis after intervention. 
Unfortunately both methods have inherent limitations and require different 
guide wires and subsequent hyperemic measurements. Obtaining both mea- 
surements simultaneously, with a single guidewire, may provide important 
information regarding the precise hemodynamic characterization of the epi- 
cardial stenosis (FFR,,) and of the distal microcirculation (CFR). 
Methods: The SmartFlow’” intravascular processor (SFIP’“) is a medical 
grade personal computer based device which together with unique algorithms 
provide immediate FFR,,, and CFR calculations based on intravascular 
pressure measurements using the PressureWire’” (Radi Medical Systems, 
Uppsala, Sweden). 
Results: In 11 consecutive patients, pre- and post-stenotic coronary 
pressure measurements were obtained at rest and during maximal hyperemia 
induced with an intracoronary bolus injection of 36-48 pg of adenosine. 
Quantitative coronary analysis (QCA) using automated edge detection was 
performed after the procedure at the Core Laboratory. 
FFRmyo Radi FFR,,,,,o SFIP’” 
0.80 f 0.14 0.85 * 0.05 
%DS = percent diameter stenosis 
CFR-SFIPT” 
1.81 I!z 0.59 
%DS by QCA 
50.4* 15 
We conclude: Simultaneous measurements of transstenotic FFR,,, and 
CFR with the SFIP’” may simplify the process of obtaining accurate stenosis 
hemodynamics, and may have potential clinical advantages. With a single 
guidewire and pharmacologic vasodilation we can now accurately assess 
translesion physiology and target vessel microcirculatory phenomena. 
/ 1200 111 Time Course of Coronary Flow Reserve Recovery in Infarct-Related and Remote Vascular 
Areas Following Acute Myocardial Infarction 
Matthijs Bax, Robbert J. De Winter, Carl E. Schotborgh, Karel T Koch, Jan 
J. Piek. Acad. Med. Center, Dept. of Cardiol., Amsterdam, The Netherlands 
Background: Several studies have indicated the pivotal role of adequate 
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flow restoration in acute myocardial infarction (AMI). However, there are 
limited data on coronary flow dynamics in the infarct (IRA) related and the 
non-infarct (non-IRA) related arteries following AMI. 
i-I 1200 113 Mechanisms of Systolic Flow Reversal in Internal Mammary Artery Grafts 
Methods: We prospectively studied 57 patients treated with primary 
PTCA for anterior AMI. Coronary flow velocity reserve (CFR), defined as 
the ratio of hyperemic and baseline average peak flow velocity (APV), was 
measured, using a Doppler guide wire, directly after successful PTCA and at 
1 week (n = 34) and 6 months (n = 21) follow up. 
Iku Toda, Masakazu Teragaki, Kenei Shimada, Yuji Sakanoue, 
Makoto Hirose, Hiroyuki Yamagishi, Minoru Yoshiyama, Kaname Akioka, 
Kazuhide Takeuchi, Junichi Yoshikawa, Toshihiko Shibata, 
Shigefumi Suehiro. Osaka City University Medical School, Osaka, Japan 
Results: CFR of IRA improved at 6 months follow up due to a decrease 
in baseline APV (p = 0.11) and in particular an increase in hyperemic APV 
(p i 0.05), while the CFR improvement in non-IRA was particularly due to a 
decrease in baseline APV (p 5 0.05). (See table) 
Background: The internal mammary artery (IMA) graft is generally used for 
coronary artery bypass grafting, since it remains patent for a long period 
of time. However, the hemodynamics of IMA grafts have not been clearly 
determined. 
CFR baseline APV hyperaemic APV 
IRA noa-IRA IRA n0n-IRA IRA non-IRA 
PTCA 1.7 (f0.4) 2.4 (hO.6) 21 (h8.9) 17 (G.5) 34 (514) 40 (f13) 
1 week 1.9 (*0.4)* 2.8 (10.5)” 22 (17.4) 18 (dc6.0) 40 (113) 48 (f14)t 
6 months 2.7 (fO.S)* 3.5 (~kO.5)~ 16 (18.3) 13 (15.9)t 45 (&23)f 45 (*18) 
All data as mean (GO). APV in cm/s. ‘p 5 0.001 vs PTCA; rp ( 0.05 vs PTCA 
Objective: We investigated the hemodynamics of the IMA grafts anasto- 
mosed to the left anterior descending coronary artery (LAD) using a Doppler 
guide wire. 
Methods: The subjects were 48 patients who underwent successful LAD 
bypass using IMA grafts (38 men and IO women, mean age: 64 i 7 years). 
During postoperative coronary angiography, a Doppler guide wire was used 
to measure the time-averaged peak velocity (APV) in the distal IMA graft and 
that in the LAD distal to the anastomosis (distal LAD). 
Conclusions: Coronary flow reserve recovery shows a similar trend 
in both the infarct-related and the remote vascular areas, although this 
may be due to different underlying mechanisms, The alterations in baseline 
APV indicates disturbed autoregulation in remote normally perfused areas 
following the acute phase of myocarciial infarction. 
1200-112 Intravascular Estimation of Volumetric Blood 
Flow From Doppler Powers Using a Doppler 
Guide Wire 
Lazar Mandinov, Andre Linka, Rolf Jenni. Echocardiographx Division of 
Cardiology University Hospital Zurich, Switzerland 
Results: Baseline systolic flow reversal (FR) was confirmed in 71% 
(34/48) of the subjects. The postoperative vessel diameter and APV in the 
IMA were significantly greater in patients without FR than in those with FR 
(2.13 f 0.25 vs 1.81 f 0.42 mm; p < 0.05, 32.0 & 10.4 vs 23.1 * 12.9 
cm/s; p < 0.05, respectively). There were no significant differences in APV 
and coronary flow reserve of the distal LAD between the patients with and 
without FR (21.6 i 7.6 vs 26.0 * 10.5 cm/s; p = NS, 2.23 f 0.72 vs 1.80 
i 0.30; p = NS, respectively). The % diameter stenosis of the proximal LAD 
lesion was significantly more severe in patients without FR than in those 
with FR (86.0 + 17.1 vs 67.8 * 18.5%; p < 0.005). We believe that blood 
flows backwards through the IMA graft when a pressure gradient is created 
between the LAD and the IMA graft due to a time difference in pulse wave 
propagation between the coronary artery and the IMA. 
Background: Measurement of coronary blood flow in patients requires tra- 
ditionally determination of blood flow velocity by Doppler ultrasound and 
vessel cross-section area by quantitative coronary angiography. Average 
peak velocity alone is widely used for evaluation of coronary blood flow and 
flow reserve, however, changes in velocity profile and vessel area are not 
taken into account. We studied the ability of a new method for calculation of 
volumetric blood flow by Doppler powers using Doppler flow wire. 
Conclusion: Systolic FR is observed in approximately two-thirds of pa- 
tients with a patent IMA graft. FR is present in IMA grafts when the amount 
of blood flowing through the grafts is low and the % diameter stenosis of the 
proximal LAD is mild. 
/1200-114/ 
Method: An in vitro pulsatile flow model with serially connected silicon 
tubes of known lumen diameters (2.0, 2.5 and 3.0 mm) and changing blood 
flow (range 10 to 110 ml/min) was employed. A 0.014 inch Doppler Flow 
Wire was coupled to acommercially available Doppler system (FloMap, Car- 
diometrics). The following power-based parameters were calculated on line 
by the Doppler system: Ml = first Doppler moment, MO = zeroth Doppler 
moment: Ml/MO = mean flow velocity. Two different groups of sample vol- 
umes (different gate depths) were used to evaluate the effect of scattering 
and attenuation on Doppler power: 1) sample volumes, lying in the vessel 
(proximal gates), and 2) those, intersecting the vessel lumen (distal gates). 
Power-based parameters obtained at the distal gates were corrected for scat- 
tering and attenuation by the data obtained at the proximal gates, Corrected 
power-based parameters were than used for calculation of vessel cross-sec- 
tion area and mean blood flow velocity. Finally, an absolute volumetric flow 
in each tube and in 7 different flow rates was calculated and compared to 
time collected flow. 
Can the Results of lntracoronary Doppler Flow 
Velocity Measurements and of Quantitative 
Coronary Angiography Predict Less Major 
Adverse Cardiac Events After Stenting 
Compared to PTCA According to the DEBATE 
Trial? 
Michael Haude, Dietrich Baumgart, Dirk Welge, Christoph Altmann, 
Heinrich Wieneke, Holger Eggebrecht, Olaf Oldenburg, J&g Herrmann, 
Claus Neurohr, Raimund Erbel. Cardiology Department, University GH 
Essen, Essen, Germany 
Background: The D.E.B.A.T.E trial identified a distal coronary flow velocity 
reserve (CVRd) of >2.5 and a residual diameter stenosis of ~35% after 
balloon angioplasty (PTCA) to be predictive for good long-term outcome with 
a low incidence (16%) of major adverse cardiac events (MACE). A similar 
approach after additional stent implantation has not been described. 
Results: Volumetric flow calculated by the power-based method was 
compared to the real (time collected) flow through the system. The calculated 
flow 52.6 & 28 ml/min did not significantly differ from the real flow 52.7 f 31 
ml/min The mean paired difference between the two flows was 0.05 ml/min, 
p = 0.97. 
Methods: Sequential measurements of minimal luminal diameter (MLD), 
percent diameter stenosis (%stenosis), baseline and hyperemic (after 18 
bg adenosine) coronary flow velocity distal to the target lesion and in a 
non-stenotic reference artery were performed before and after predilatation, 
after stenting and after six months in 99 patients (pts) with single vessel 
coronary artery disease, Additionally, CVRd was calculated as the ratio of 
hyperemic and baseline velocity, and relative CVR (CVRrel) as the ratio 
of CVRd and CVR in the reference artery. Cut-off criteria were derived 
from Receiver-Operator-Curve analysis. Positive (PPV) and negative (NPV) 
predictive values are reported. 
Results: At six months 16 of 99 patients (16%) developed MACE (no 
death, 4 myocardial infarctions, 12 target vessel revascularisations). 
20 40 60 80 loo tae 
Real blood ilow (m&&~+) 
Conclusion: Volumetric blood flow (ml/min) can be measured from 
Doppler powers, using Doppler flow wire. This method can improve markedly 
further application of Doppler guide wire for measurement of coronary volu- 
metric flow and flow reserve for physiologic and clinical purposes. 
Parameter 
MLD 
% stenosis 
CVRd 
CVRrel 
cut-off Value 
2.65 mm 
11% 
2.7 
0.88 
Sensitivity 
72% 
83% 
83% 
78% 
Specificity 
79% 
61% 
75% 
84% 
PPV 
43% 
32% 
43% 
52% 
NPV 
93% 
94% 
95% 
94% 
Conclusion: Best long-term outcome after stenting with a MACE rate of 
only 2% is predicted by a MLD > 2.65 mm and a CVRrel > 0.88, documenting 
a better outcome as after PTCA in the DEBATE trial. 
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907-l Impact of Coronary Debulking Prior to Stenting 
Versus Conventional Stenting on Early Outcome: 
Initial IVUS Findings 
Kiyoshi Hibi, Tadanori Aizawa, Yasuhiro Honda, Yasushi Asakura, 
Shozo Tanaka, Takashi Uchiyama, Tetsuo Matsubara, Cynthia E. Handen, 
Paul G. Yock, Hideo Tamai, Peter J. Fitzgerald. Sfanford University: 
Stanford, CA, USA; Cardiovascular Insfifufe, Tokyo, Japan 
Background: Previous IVUS studies have shown a strong relationship be- 
tween neointimal hyperplasia after stent implantation and the amount of 
pre-existing plaque burden. The purpose of the &bulking and ztenting in 
Restenosis Elimination (DESIRE) trial was to compare DCA prior to stent 
implantation (DCAfS) to stent implantation alone (SA). 
Methods: To date, 175 patients out of 400 target enrollment have been 
randomly assigned to DCA/S or to SA. Pre- and post-interventional IVUS 
studies have been fully analyzed in 37 patients (DCAIS: 16, SA: 21). IVUS 
images were obtained using a motorized pullback speed of 0.5 mmisec, and 
measurements made of vessel area (VA) and lumen area (LA). 
Results: There were no significant differences in the pre-interventional 
IVUS characteristics between the DCAIS group and the SA group with regard 
to vessel size (VA at the proximal and distal reference site: 17.1 f 3.1 vs. 
18.0 f 5.0 mm2, P = 0.57 and 12.8 f 3.8 vs. 12.1 f 4.0 mm2, P = 0.67, 
respectively) and lesion characteristics (VA: 14.5 f 3.8 vs. 14.4 i 3.3 mm*, 
P = 0.95 and LA: 1.44 f 0.55 vs. 1.47 f 0.44 mm*, P = 0.83). The maximum 
inflation pressure for stent deployment was 9.5 f 2.0 atm for the DCAfS 
group and 10.5 f 2.7 atm for the SA group (P = 0.30). However, the acute LA 
gain was largerjn patients who underwent DCAIS compared to those who 
underwent SA (7.2 f 2.1 vs. 5.7 i 1.5 mm*, P = 0.02), resulting in a larger 
minimal LA after the procedure (8.6 & 2.3 vs. 7.2 5 2.6 mm*, P = 0.03). VA at 
the minimal LA tended to be larger for DCAfS group compared to SA group 
(17.8 i 4.2 vs. 15.3 A 3.6 mm2, P = 0.07). 
Conclusions: The present study demonstrates that DCA/stent results 
in larger acute lumen and vessel dimensions compared with stent alone. 
Debulking prior to stenting may be an important adjunct to stenting lesions 
with large plaque burden. 
IO:45 a.m. 
I 907 2 Normal lntimal Thickness is an Age Dependent 
Phenomenon: An Intravascular Ultrasound Studv in 
Asymptomatic Individuals 
Samir R. Kapadia, Khaled M. Ziada, Oussama M. Wazni, Eralp Tutar, 
Mandish Rai, Ivan Casserly, Suzanne R. Lutton, Steven E. Nissen, E. 
Murat Tuzcu. The C/eve/and Clinic Foundation, Cleveland, OH, USA 
Background: Although normal values for intimal thickness by intravascular 
ultrasound are commonly used, no in viva data have documented whether 
age adjustment of measurements is necessary. 
Methods: We performed intravascular ultrasound within 1.470 coronary 
segments in 260 recipients 31 f 28 days after cardiac transplantation (donor 
age 33 i 13 years). All sites with atherosclerosis defined as maximal intimal 
thickness (ITmax) >0.5 mm were excluded. In each CASS segment without 
atherosclerosis, ITmax, lumen area, EEM area, and percent intimal area 
were measured. For each patient, the average ITmax was calculated. 
Results: The arterial wall was monolayered (ITmax = 0) more frequently 
in younger individuals (table). The mean and median intimal thickness in- 
creased with age (table). In a multivariate model, age was the only determi- 
nant of intimal thickness (odds ratio 1.2). 
Aae n ITmax = 0 Ava ITmax Median Iranoe) I I  
40 47 18 (38%) 0.07 * 0.07 0.05 (0.0-0.28) 
20-30 66 12 (18%) 0.10 * 0.08 0.09 (0.0-0.29) 
30-40 57 8 (14%) 0.15zk0.10 0.14 (0.0-0.39) 
40-50 58 5 (8%) 0.18 zk 0.1’2 0.16 (0.0-0.49) 
>50 33 1 (3%) 0.20 i 0.12 0.21 fO.&0.47) 
1907-3 1 Restenosis Following Minimally Traumatic 
Rotational Atherectomy is Associated With Higher 
Residual Plaque Burden-IVUS Results From the R&R 
Study 
Gregory A. Braden, Teresa Young, Wendy Love. Wake Forest University 
School of Medicine, Winsfon-Salem, North Carolina, USA 
Restenosis following balloon angioplasty and directional atherectomy has 
been associated with higher residual plaque burden (PB), however, the 
relationship of PB to restenosis following rotational atherectomy (RA) has 
not been evaluated. Pre, post and follow-up IVUS imaging was compared in 
the subset of the 100 patients in the R&R Study, a series of patients treated 
with a careful stepped burr technique followed by 1 atm oversized balloon 
to minimize vessel wall trauma. Angiographic restenosis occurred in 27% 
of these lesions. For the group, lumen area increased from RA by plaque 
removal while late lumen loss occurred secondary to neointimal proliferation 
(vascular remodeling did not occur). Compared to new restenosis lesions, 
those which restenosed had both larger lumens and substantially higher 
plaque areas. 
PreRA 
Post RA 
FU 
POST RA 
Restenosis 
No &stenosis 
LA 
1.75 zt 0.85 
4.4 + o.i* 
4.0 i 0.1* 
4.5 * 0.1 
5.25 5 0.8* 
PA 
9.6 i 0.3 
7.3 * 0.2* 
8.4 + 0.4* 
7.2 i 0.3 
8.7 + 0.8” 
VA mm2 
11.3 5 0.3 
11.7 * 0.3 
12.5 f 0.4 
* p < 0.01 
11.6 z’c 0.6 
14.0 * 8’ 
Conclusion: Minimal traumatic rotational atherectomy increases lumen 
size by plaque area removal, and late lumen loss is largely a proliferative 
process. Lesion restenosis is associated with larger lumens initially and larger 
residual plaque burdens. 
II:15 a.m. 
907-4 Intravascular Ultrasound Study of Residual 
Dissection Following Percutaneous Coronary 
Intervention 
Takahiro Nishida, Carlo Briguori, Milena Adamian, Nicola Corvaja, 
Marco Vaghetti, Vaios Tzifos, Remo Albiero, Carlo Di Mario, 
Antonio Colombo. Centro Cuore Columbus, Milan, Italy 
Background: The aim of the present study is to investigate severity of Resid- 
ual Dissection (RD) on their outcomes following percutaneous interventions 
with unrestricted stent usage. 
Methods: Minimal lumen area (MLA) at RD, area stenosis at RD, depth 
of vessel wall injury and axial length of RD were studied with intravascular 
ultrasound (IVUS) on 125 consecutive lesions accompanied by RD in 97 
patients. Patients of acute myocardial infarction (Ml), lesions treated with 
radioactive stents and in-stent restenotic lesions were excluded. 
Results: The ACC/AHA type 82 and C lesion accounted for 119 lesions 
(95%). Stents were used in 82 lesions (66%) and angiographic success 
was achieved in all lesions. None of the lesion required repeat intervention 
during the hospital stay. No acute or subacute stent thrombosis occurred. 
In-hospital major adverse cardiac events (death, emergency coronary bypass 
surgery, Q-wave Ml or non-Q-wave Ml) occurred in 9 patients (9.3%). Type 
A dissection was found in 8 lesions (6.4%), type B in 102 (82%), type C in 14 
(11%) and type D in 1 (0.8%). In all lesions, MLA at RD was 6.5 f 3.1 mm, 
area stenosis at RD was 50 f 13% and axial length of RD was 9.6 f 9.0 mm. 
RD reached media in 92 lesions (74%). Angiographic follow-up was achieved 
in 94 lesions (75%) and restenosis was found in 27 lesions (29%). None of 
the above variable significantly correlated with the occurrence of in-hospital 
major adverse cardiac events. In lesions which developed restenosis, MLA 
at RD was smaller (5.1 f 2.1 mm” vs 6.5 7t 2.9 mm2, p = 0.022) and area 
stenosis at RD was larger (55 f 14% vs 48 + 13%, p = 0.045) compared 
to lesions without restenosis. The depth of RD and axial length of RD were 
similar between lesions with or without restenosis. 
Conclusions: 1) Most of RD was type B and frequently reached media. 
2) For short-term outcomes, area stenosis at RD ~50% and 510 mm length 
of RD would be acceptable. 3) To minimize restenosis rate, area stenosis at 
RD site is an important variable and should be minimized. 
Conclusion: The normal value for coronary intimal thickness increases 
with age. Accordingly, the definition of abnormal intimal thickness in clinical 
trials must be adjusted for patient age. 
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L-2 907 5 increased In-Stent Restenosis in Diabetes is the Combination of Small Vessel Size and Exaggerated 
lntimal Hyperplasia 
Gary S. Mintz, Roxana Mehran, Alexandra J. Lansky, Donald Harrington, 
Borjanka Leiboff, Kenneth M. Kent, Martin 6. Leon. Washington Hospital 
Center, Washington, DC, USA 
To understand the reasons for increased in-stent restenosis in diabetic (DM) 
pts, we analyzed procedural variables, intravascular ultrasound (IVUS) find- 
ings, and target lesion revascularization (TLR @ 1 yr) in 2853 lesions in 2242 
pts according to DM status or treatment (Rx): nonDM, oral Rx, or insulin 
dependence (IDDM): 
nonDM Oral Rx IDDM a 
8alloon size (mm) 3.5 zk 0.6 3.5 l!c 0.5 3.4 h 0.6 0.07 
Inflation pressure (atm) 151-3 1613 1654 0.18 
Reference lumen (mm*) 8.5 zk 2.7 8.3 i 2.7 7.9 f 2.6 0.013 
Final lumen (mm*) 7.6 5 5.7 7.4 + 2.4 7.0 zt 2.4 0.0064 
Despite similar procedural variables (balloon sizes & inflation pressures), 
final lumen dimensions were smaller in DM pts, especially /DDM pk. The 
overall mean IVUS final lumen area was 7.5 mm’. Therefore, we assessed 
TLR according to DM status and IVUS final lumen area larger or smaller than 
7.5 mms : 
We conclude: Increased in-stent restenosis in diabetic pts is multifac- 
torial. Smaller reference size and noncompliant lesion characteristics result 
in smaller final lumen areas upon which is superimposed an exaggerated 
neointimai response (higher TLR than non diabetic pts with the same lumen 
CSA). As a result lesions with a final lumen area ~7.5 mm2 in IDDM pts, 
have strikingly high TLR (31%). 
1 907-6 1 Extent of Neointima Predicts Subsequent Neointimal 
Proliferation in In-Stent Restenosis: A Volumetric 
Intravascular Ultrasound Study 
Hiroyuki Okura, Thosaphol Limpijankit, Atsushi Takagi, David P. Lee, 
Yasuhiro Honda, Paul 6. Yock, Peter J. Fitzgerald. Stanford University 
Medical Center, Stanfo(d, CA, USA 
Background: Pre-intervention plaque burden has been shown to impact the 
neointimal (NI) proliferation following de novo stent implantation. However, it 
is unknown whether plaque burden and thus the amount of NI accumulation 
at the time of in-stent restenosis (ISR) impact subsequent NI proliferation 
following treatments of ISR. 
Methods: To clarify the relationship between the amount of preexisting 
in-stent neointima as well as plaque burden outside the stent and subsequent 
NI proliferation, serial (pre, post, and 6M) volumetric intravascular ultrasound 
analysis was performed in a total of 37 ISR lesions from the Stanford Core 
Laboratory database. Plaque and NI volume were calculated using Simpson’s 
method. 
Results: In-stent NI volume decreased significantly after interventions 
(rotational atherectomy, laser angioplasty, stent, and/or balloon angioplasty) 
to treat ISR (112.9 & 100.0 to 65.9 f 64.2 mm3, p < O.Oi), but increased 
significantly during 6M follow-up (138.0 f 109.2 mm3, p c 0.01). NI volume at 
6M correlated well with plaque volume outside the stent prior to interventions 
(r = 0.76). In addition, NI volume index normalized by the stent length at 6M 
correlated well with both pre-intervention and post-intervention NI volume 
indexes (6M vs pre: r = 0.80, 6M vs post: r = 0.54). 
Conclusions: Recurrent in-stent neointimal proliferation following catheter 
interventions to treat ISR is strongly influenced by both the amount of plaque 
volume outside the stent and initial NI volume prior to intervention despite the 
amount of neointimal removal by various devices. Adjunctive therapy (phar- 
macological, gene, or radiation) may be necessary to impact this biological 
component of ISR 
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